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Abstract  
The aim of this thesis was to measure inequalities in the burden of vaccine-preventable 
disease and vaccine uptake amongst older individuals in England, using primary care 
electronic health records (EHR) linked to hospitalisation and deprivation data. Social factors 
previously associated with vaccination amongst older individuals in Europe were first 
determined by conducting a comprehensive systematic review. Methods were developed to 
identify and investigate the recording of these factors in the linked UK EHR data. These 
methods were then applied in two cohort studies, focussing on herpes zoster (a common 
debilitating condition in older populations), to identify the social determinants of (a) zoster 
incidence in the decade before zoster vaccine introduction, 2003-2013 and (b) uptake of 
zoster vaccination in 2013-15 (the first two years after vaccine introduction).  
The methodological study showed that, among 591,037 individuals aged ≥65 years, 
completeness of recording of individual social factors varied from 1.6-80%. The ethnic 
distribution, and prevalence of deprivation, living alone, living as a couple and care home 
residence, were all comparable with data from the 2011 English Census.  
In the first cohort study of 862,470 older individuals, those at higher risk of zoster in the pre-
vaccination era included females, those in care homes, those of White ethnicity and non-
immigrants, with increased zoster incidence in these groups ranging from 10-100%. Known 
clinical risk factors for zoster (co-morbidities and immunosuppressive treatment) explained 
little of these increased risks. In the second cohort study of 35,333 individuals, social factors 
associated with lower uptake of zoster vaccination included: care home residence (adjusted 
odds ratio (aOR):0.64 (95% confidence interval: 0.57-0.73)), living alone (aOR:0.85 (0.81-
0.90)), and being of non-White ethnicity (for example: Black ethnicity versus White ethnicity: 
aOR:0.61 (0.49-0.75)). Uptake decreased by increasing deprivation: aOR (most deprived 
areas versus most affluent): 0.69 (0.64-0.75). Lower uptake was also seen amongst females 
in the older catch-up group.  
The findings from this thesis should help inform specific interventions to mitigate zoster 
vaccine inequalities, including amongst doubly disadvantaged groups (with higher zoster 
burden and lower vaccine uptake) such as care home residents. The methods developed 
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can also be used to examine other health inequalities in older UK populations.  Future 
linkages to other data sources, such as the Census, would further enhance the availability of 
information for studies of the social determinants of health.  
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Background section 
 
This thesis utilises routinely collected primary care electronic health care records linked to 
hospitalisation and deprivation data to ascertain inequalities in burden of vaccine-
preventable disease and vaccine uptake amongst older individuals in England. The focus of 
the thesis is on herpes zoster and it describes the disparities for zoster burden and zoster 
vaccine uptake.  
The background section for this thesis has two chapters:  
Chapter 1 gives a general outline of health inequalities and their impact on older individuals.  
It also summarises the biology and epidemiology of herpes zoster. The existing knowledge 
of the association of social factors with herpes zoster disease burden and vaccination is also 
discussed, highlighting the gaps in our understanding which provided the rationale for this 
PhD research. The end of the chapter describes the aims and objectives, and the overall 
structure of this thesis. 
Chapter 2 presents a systematic review and meta-analysis of the association of social 
factors with vaccine uptake amongst older individuals. 
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 Chapter 1. Background 
1.1 Health inequalities and their social determinants 
1.1.1 Definition  
Health inequalities can be defined as systematic differences in health amongst different 
population groups.1 These inequalities may arise due to genetic or biological variations (for 
example, women have uterine problems but men do not) or from autonomous choices (such 
as choosing an unhealthy lifestyle), or they may be socially produced and therefore unfair 
and modifiable (for example, if access to a particular treatment varies between different 
income groups).1-3 Health inequalities, as illustrated in the last example, which are unjust, 
avoidable, and amenable to interventions result in health inequities, a term that has an 
ethical and moral basis.3-5  However, in the public health context, the terms health inequity 
and inequality are often used interchangeably and  are considered to be synonymous, as the 
element of unfairness is implicit in both terminologies.3 In this thesis, in which the focus is on 
investigating socially generated differences in health, the term health inequalities is used for 
the most part, except when describing studies that have specifically used the term health 
inequities.    
The World Health Organisation’s (WHO) Commission on Social Determinants of Health 
(CSDH) in 2010 proposed a conceptual framework describing the inter-relationships  
between the social determinants of health inequities (Figure 1-1).4 On the left of the figure 
(Figure 1-1) are structural determinants: socioeconomic and political contexts (such as 
public policies and societal values) that stratify society into a set of socioeconomic positions 
based on an individual’s income, occupation, education, gender and ethnicity. These 
structural determinants of health inequities operate through a set of intermediary 
determinants, comprising  individuals’ material circumstances (such as housing and 
employment conditions, ability of buy food), biological/behavioural factors (such as 
substance misuse, physical exercise) and psychosocial factors (such as relationships and 
social support).4 The resulting health inequities can further disadvantage individuals who are 
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already socially disadvantaged, for example by affecting their income or employment (as 
shown by the reverse arrow in the Figure 1-1). The actions required to mitigate health 
inequities should ideally act on both structural and intermediary factors to have a larger 
impact.4  
 
Figure 1-1 Conceptual framework of social determinants of health* 
* Reproduced from4 
 
1.1.2 Health inequalities and older individuals 
A population group particularly vulnerable to health inequalities is older individuals.6 The 
number of older individuals is growing rapidly world-wide due to increases in life expectancy,  
and the proportion of individuals aged ≥60 years is expected to nearly double, from ~12% in 
2012 to 22% in 2050.7, 8 In the European Union, the number of individuals aged ≥65 years is 
predicted to increase by 53%, from ~19% in 2014 to ~29% by 2080.9 However, this increase 
in life expectancy does not necessarily translate into an increase in healthy life expectancy, 
a term that takes into account both mortality and morbidity and provides a comprehensive 
measure of disability-free years, with implications for a country’s health and social care 
expenditure.10, 11 Healthy life expectancy acquires significance as older individuals are at 
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increased risk of disability not only because of a higher prevalence of chronic conditions but 
because they are also predisposed to higher mortality and morbidity due to infectious 
diseases.11, 12 This increased susceptibility to infectious diseases is due to the age-related 
decline in immune function (immunosenescence) and may also result from the detrimental 
effect of chronic conditions and their treatments on immune functions.12  
Health inequalities in  general have been described for both life expectancy and healthy life 
expectancy amongst older individuals.13  A 2015 systematic review reported the association 
of socio-demographic factors such as gender, ethnicity, level of education, socioeconomic 
class and behavioural factors with disparities in both mortality and disability i.e. healthy life 
expectancy amongst older individuals.14 In England,  gender and socio-economic 
differentials (social class, education, wealth and income) have been found to be associated 
with both life expectancy and healthy life expectancy amongst individuals aged ≥50 years.13 
Psycho-social factors such as living alone are also known to be associated with higher 
morbidity and mortality amongst older individuals.15 Studies have shown that the burden of 
certain infectious diseases have a socio-economic gradient making older individuals from 
disadvantaged social strata more prone to infections, resulting in inequalities of infections-
related mortality and morbidity.16-19 
1.1.3 Reducing health inequalities 
Achieving health equality remains a challenging global ambition for governing bodies and 
health care providers. Reducing health inequalities is an ethical and social obligation. In the 
UK, promoting equality and reducing inequality in health remains a statutory requirement 
enshrined under two separate laws: Health and Social Care Act 2012 and Equality Act 
2010.20, 21 It is also acknowledged as one of the people’s rights as set out in the National 
Health Service (NHS) constitution, an absolute objective set by the UK Department of Health 
and other national bodies, and it is a common theme in the area of health improvement for 
public health.22-28  
An important action to reduce health inequalities amongst the older individuals is to first 
identify their social determinants and then plan specific interventions. In fact, one of the 
WHO’s CSDH recommendations to tackle health inequalities was to set up global and 
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national surveillance systems to measure these inequalities, and also monitor the equality 
impact of any interventions.5 This also includes promoting universal healthy ageing by 
reducing disabilities resulting from both chronic and infectious diseases. For the latter, a key 
intervention to reduce morbidity and mortality in all age groups (including older individuals), 
is vaccination.29, 30 Vaccines administered to older individuals include seasonal influenza 
vaccine and pneumococcal vaccine for pneumonia. More recently, a vaccine targeting zoster 
amongst older individuals was introduced.  
1.2  Herpes zoster 
1.2.1 Aetiology  
Herpes zoster or shingles is a neurocutaneous disease, which occurs due to reactivation of 
latent varicella-zoster virus, a double-stranded DNA human herpesvirus. Chicken pox or 
varicella is a common childhood infection that occurs due to primary infection with varicella-
zoster virus. Following this primary infection, the virus remains dormant in the host’s nerve 
cells.31 The reactivation of the dormant virus in form of zoster occurs due to waning of virus-
specific immunity and the virus then migrates along the nerve cell to reach the skin, giving 
rise to its characteristic clinical features, as detailed below.31, 32 
1.2.2 Clinical characteristics of zoster 
Zoster is characterised by a painful unilateral vesicular rash in the affected dermatome.33 
Patients might also experience pain or sensitive skin in the affected area 2-3 days prior to 
the rash.32, 33 The symptoms generally last for ~2-4 weeks. In some cases, the pain persists 
leading to the commonest complication of zoster: post-herpetic neuralgia (PHN), which 
occurs in ~5-30% of individuals with zoster.34, 35 The pain of PHN may be associated with 
long-term morbidity and can significantly affect quality of life.32, 36 Other less common but 
serious complications of zoster include stroke, encephalitis, visual impairment following 
ophthalmic zoster, secondary infections of the rash and other neuro-muscular conditions.32, 
37 
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1.2.3 Zoster disease burden and risk factors 
The lifetime risk of zoster is ~10%-30% in the general population with the overall zoster 
incidence rate ranging from 3-5/1000 person-years.32, 35, 38. Individuals may also experience 
more than one episode of zoster, the risk of recurrence varying from 1% to 6%.31, 35 The risk 
of zoster increases sharply after the age of 50 years with nearly 1 in 2 people experiencing 
zoster by the age of 85 years;  the age-specific zoster incidence varying from 6-8/1000 
person-years (aged 60 years) to 8-12/1000 person-years (aged 80 years).31, 32, 35  
The quality of life and ability to perform activities of daily living amongst older individuals 
could be adversely affected by the pain associated with acute zoster, and for some frail 
individuals it may also lead to permanent loss of independent living.39, 40 The risk of zoster-
related complications and their severity, zoster-related hospitalisations and deaths also 
increases amongst the older age groups, giving rise to a much higher disease burden.35, 41 
For example, both the risk of PHN and severity of PHN symptoms increases with age.35, 42 
The higher morbidity resulting from zoster and its complications amongst older individuals is 
also associated with considerable healthcare costs.41, 43 During 2004-2013 the average 
annual hospitalisation costs in England for individuals aged ≥60 years was estimated to be 
10 million (95% confidence interval (CI): 9.8-10.4) based on 2013-2014 national tariff.43  
As stated in Section 1.1.2, increasing age is associated with higher zoster burden due to an 
age-related decline in immune functions: immunosenescence.12, 32, 44, 45 Zoster-specific 
immunity is also hypothesized to be related to the age at which chickenpox is acquired, as 
individuals acquiring chickenpox later in life may have immunity lasting to older age and thus 
lower risk of zoster.44, 45  
Conditions that compromise immune function are major risk factors for zoster. For example, 
higher risk of zoster is observed in patients with severe immunosuppression due to 
conditions such as leukaemia, lymphoma, HIV infection, bone marrow transplant and 
immunosuppressive therapies such as chemotherapy, radiotherapy and steroids.44-46 In a 
large matched UK case-control study, some autoimmune conditions such as inflammatory 
bowel disease, rheumatoid arthritis and systemic lupus erythematosus, and chronic 
conditions associated with moderate immunosuppression such as asthma, chronic 
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obstructive pulmonary disease, chronic renal disease and diabetes, were also identified to 
be associated with increased zoster risk.44  
The association of socio-demographic factors with zoster incidence is described in Section 
1.3.2. 
1.2.4 Diagnosis and treatment of zoster  
A clinical diagnosis of zoster, based on its typical clinical features (Section 1.2.2), is usually 
accurate.47 The most common differential diagnosis of zoster includes recurrent herpes 
simplex virus infection.46, 48 Laboratory confirmation is usually obtained by detecting the viral 
DNA using polymerase chain reaction, which offers rapid confirmation with high sensitivity 
and specificity.48, 49 This is seldom done for diagnostic purposes, except for atypical 
presentation of zoster, for example amongst immunocompromised individuals.47 Other 
diagnostic tests include serological testing for VZV virus antibodies and antigens but they 
have lower sensitivity and specificity compared to the polymerase chain reaction test.48, 49  
Studies that have looked at the accuracy of the clinical diagnosis have shown high positive 
predictive values.50, 51 A Dutch study compared the clinical diagnosis in primary care with 
serological testing amongst older immunocompetent individuals.50 Of the total 260 zoster 
cases diagnosed clinically, 236 cases were serologically confirmed, giving a positive 
predictive value of 91%.50 The authors acknowledged that the positive predictive value might 
have been even higher had a more sensitive confirmatory test such as a polymerase chain 
reaction test been used.50 In an earlier German study conducted in a dermatology clinic, 
which utilised a polymerase chain reaction test as the reference test to confirm the clinical 
diagnosis, all 65 clinically diagnosed cases of zoster were confirmed, giving a positive 
predictive value of the clinical diagnosis as 100%.51 
An important challenge in treating zoster is early initiation of antiviral therapy. Treatment with 
oral antiviral agents, if initiated within 72 hours of the onset of rash, may reduce the duration 
of symptoms.52, 53 However, it is known that most patients do not present to their doctor in 
time to benefit from the treatment.47 The effectiveness of antiviral therapy, as perceived by 
the patients, is also reported to be low.39 A 2014 Cochrane review also found the effect of 
antiviral treatment in preventing PHN, an important zoster complication, to be inconclusive.54 
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Due to the limitations of current therapeutic options, zoster prevention becomes central to 
minimise its burden amongst older individuals.  
1.2.5 Prevention of zoster: zoster vaccine 
In view of the impact that zoster has on older people and the limitations of available   
treatment (Section 1.2.4), zoster prevention becomes important. The Joint Vaccine Working 
Group of the European Union, which provided vaccination guidelines for individuals aged 
≥60 years, recommended zoster vaccination to reduce morbidity and promote healthy 
ageing in 2009.55 At present, two types of zoster vaccines are available: a live zoster vaccine 
(Zostavax®) and an inactive zoster subunit vaccine (Shingrix®).56, 57  The inactive vaccine, 
approved by the US Food and Drug Administration in October 2017 and also by the US 
Advisory Committee on Immunization Practices, is not yet approved for use in the UK.56, 58  
In UK only the live zoster vaccine (Zostavax®) is currently available.59, 60  The efficacy of 
Zostavax® to reduce the incidence of zoster and PHN was reported as 51.3% (95% CI: 
44.2%-57.6%) and 66.5% (95% CI: 47.5%-79.2%), respectively.61 This was later confirmed 
in the post-licensure vaccine effectiveness studies.62, 63  A 2016 Cochrane review, which 
combined 13 studies on both live (N=10) and inactive zoster vaccines (N=3), also concluded 
vaccination to be effective amongst older individuals: the risk ratio for zoster incidence 
amongst the vaccine recipients (reference group: placebo) was 0.49 (95% CI: 0.43-0.56).64  
In order to reduce the zoster disease burden amongst older individuals and based on 
clinical, epidemiological and vaccine-effectiveness data, in 2010 the UK Joint Committee on 
Vaccination and Immunisation recommended a single-dose zoster vaccination programme 
for older individuals.59, 65, 66 The national zoster vaccination programme was introduced in 
September 2013, which targeted people aged 70 years (the routine/ main target cohort) and 
a catch-up programme for older individuals up to the age of 79 years.59, 67, 68 The eligibility for 
the vaccine was determined based on the an individual’s age on 1st of September of the 
year, for example in 2013, individuals aged 70 years on 01/09/2013 were targeted as a part 
of the routine cohort (Table 1-1).68 The vaccine was also sequentially rolled out to the catch-
up cohort as follows: individuals aged 79 years on 01/09/2013, those aged 78 years and 79 
years on 01/09/2014 for the year 2014-2015, and to those aged 78 years on 01/09/2015 for 
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the year 2015-2016.68-70 Moreover, in 2015-2016, there were three additional cohorts 
consisting of individuals who had missed vaccination in the previous two years and were 
aged <80 years (Table 1-1); in contrast there were no additional cohorts in 2014-2015 due to 
vaccine shortages.70, 71  
Based on the UK Green Book guidance- the zoster vaccine, which is a live vaccine, is 
contraindicated in individuals with immunosuppressive conditions. These include 
lymphoproliferative disorders (e.g. acute and chronic leukaemias, lymphomas), cellular 
immune deficiency, immunosuppression due to HIV infection, individuals on 
immunosuppressive treatment with high dose of corticosteroids, biological and non-
biological immune-modulating treatments, cancer chemotherapy and radiotherapy.60 
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Table 1-1 Eligibility for zoster vaccine in the first three years of the UK national programme 
Year: zoster vaccination programme  Age-based eligibility for zoster vaccine 
Routine cohort Catch-up cohort Additional cohorts 
1/09/2013 to 
31/08/2014 
Number of cohorts  1 1 None 
Age on 01/09/2013 (DOB) 70 years (DOB: 2/9/1942-1/9/1943) 79 years (DOB: 2/9/1933-1/9/1934) - 
1/09/2014 to 
31/08/2015 
Number of cohorts  1 2 None 
Age on 01/09/2014 (DOB) 
 
70 years (DOB: 2/9/1943-1/9/1944) 79 years (DOB: 2/9/1934-1/9/1935) 
78 years (DOB: 2/9/1935-1/9/1936) 
- 
1/09/2015 to 
31/08/2016 
Number of cohorts  1 1 3* 
Age on 01/09/2015 (DOB) 70 years (DOB: 2/9/1944-1/9/1945) 78 years (DOB: 2/9/1936-1/9/1937) 71 years (DOB: 2/9/1943-1/9/1944) 
72 years (DOB: 2/9/1942-1/9/1943) 
79 years (DOB: 2/9/1935-1/9/1936) 
DOB date of birth 
* Included individuals who missed vaccination in 2013/2014 and 2014/2015 and remained eligible till 80 years of age 
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1.2.6 Zoster vaccine uptake in England 
In England, the zoster vaccination programme was rolled out via general practice with GPs 
encouraged to administer zoster vaccine at the same as time as the seasonal influenza 
vaccine.72 A national zoster vaccine uptake surveillance was also established, the data for 
which is derived from the aggregated coverage data at the general practice-level using 
automated extraction methods.68 Amongst the routine cohort, the annual uptake of 61.8% 
during the first year of introduction (2013-2014) was reduced to 59% and 54.9% during 
2014-2015 and 2015-2016, respectively.68-70 The annual uptake during 2013-2014 for the 
catch-up cohort (for individuals aged 79 years on 01/09/2013) was 59.6%, which also 
declined to 58.5% in 2014-2015.68, 69 This decline in the uptake also persisted for the catch-
up cohort aged 78 years, with uptake reduced from 57.8% (2014-2015) to 55.5% during 
2015-2016.69, 70  Thus, the national data for annual zoster vaccine uptake in England has 
shown a gradual decline in uptake amongst both the routine and the catch-up cohorts in the 
first three years of its introduction. Some of the reasons identified for the decrease in zoster 
uptake over these three years of vaccine introduction included decreasing public awareness 
about the vaccination programme and inefficient GP reminder-recall systems for identifying 
and calling eligible individuals for zoster vaccination during a busy seasonal influenza 
vaccination season.70  
In each year of the first three years after zoster vaccine was introduced, the majority of 
vaccine uptake occurred by the end of January (Figure 1-2), which also marks the end of 
surveillance period for seasonal influenza vaccine.68-70 This was not a surprising finding for 
two reasons. Firstly, seasonal influenza vaccine and zoster vaccine can be given 
simultaneously and GPs were encouraged to co-administer these vaccines.60, 72 Secondly, 
the eligibility for zoster vaccine is determined by an individual’s age in September, which 
also marks the start of  seasonal influenza vaccination season, and thus co-administrating 
the two vaccines also becomes logistically convenient from the programme implementation 
point of view.60, 73 Some US studies have also reported a higher uptake of zoster vaccine 
amongst those who had received seasonal influenza vaccine.74, 75  
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Figure 1-2 Monthly cumulative zoster vaccine coverage for routine cohorts (2013-
2016)* 
*Reproduced from70  
 
1.3 Health inequalities and socio-demographic factors of zoster 
disease burden and zoster vaccine uptake 
1.3.1 Socio-demographic factors 
To achieve the overall goal of reducing health inequalities and to meet the requirements of 
equality laws in the UK (Section 1.1.3), the planning and implementation of any health 
intervention including vaccination programmes have to be effective and equitable.20, 21 Thus 
to achieve an equitable zoster vaccination programme and determine its effect on disease 
burden, it is important to identify the socio-demographic factors associated with both zoster 
disease burden and zoster vaccine uptake in England. Identification of these factors is 
essential as it will subsequently help in monitoring any inequalities in specific socio-
demographic groups and aid in planning actions to reduce these inequalities. In the following 
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two sections (Sections 1.3.2 and 1.3.3) socio-demographic factors associated with both 
zoster incidence and vaccination are discussed 
1.3.2 Socio-demographic factors associated with zoster disease burden  
The association of age with risk of zoster was discussed in Section 1.2.3. Other socio-
demographic factors are detailed here. The risk of zoster is reported to be higher amongst 
females.44, 45 This female preponderance of the disease could be due to a yet unknown 
genetic predisposition to the disease and/or a reflection of healthcare seeking behaviour.45 
Ethnicity is also associated with zoster: individuals of non-White ethnicity have a lower risk 
of developing zoster.45, 76, 77 The protective effect of non-White ethnicity could be due to 
genetic factors or due to spending childhood in tropical countries where the average age at 
varicella infection is later than that observed in temperate countries; the reasons for this are 
unclear but may reflect the effect of environmental temperatures on VZV transmission.78 The 
lower zoster risk amongst individuals of non-White ethnicity may also be contributed by 
immune-boosting due to repeated contacts with chickenpox amongst children in extended 
families.45 However, the evidence for the association of zoster disease burden with other 
social factors such as immigration, marital status (a possible proxy for social support) and 
socio-economic status including education has been largely inconclusive.32, 44, 45, 76, 79, 80  
The association of socio-demographic factors with zoster disease burden could be mediated 
in part by coexisting co-morbidities. Some socio-demographic groups might be predisposed 
to certain co-morbidities; these conditions and/or their treatments (Section 1.2.3) in turn 
may increase an individual’s risk of zoster by their effect on cell-mediated immunity.44 In a 
large matched UK case-control study some of these conditions (as described in Section 
1.2.3) and therapies were identified to be associated with zoster.46 In this study, these 
associations were still present after adjusting for socio-economic status but the independent 
association of socio-economic status with zoster incidence was not reported.46 
In England, zoster is not a notifiable infection. In 2017, the impact of zoster vaccination 
programme on the incidence of zoster was reported but apart from age and gender, no other 
socio-demographic factors were evaluated.81 
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1.3.3 Socio-demographic factors associated with zoster vaccine uptake 
Similar to the zoster disease burden, the association of socio-demographic factors with the 
uptake of zoster vaccine in Europe is not well described. In England, the data for the 
national zoster vaccine uptake surveillance provides information only on two social factors: 
gender and ethnicity.68 A 2017 UK study utilised these national data and reported the 
association of zoster vaccination for the year 2014-2015, amongst individuals aged 70 
years, with ethnicity and additionally with deprivation.82 The zoster vaccine uptake was 
reported to be lower amongst those from the most deprived areas (reference group: least 
deprived) and those of Mixed (White and Black African) ethnicity (reference group: White-
British).82 However, in this study only 35.6% of the individuals with vaccine coverage data 
had ethnicity data available and the remainder were excluded from the study.82 Moreover, 
these results have to be interpreted with some caution as no individual-based data were 
available in the study and thus ethnicity and vaccination data were allocated to the 
individuals in a manner to ensure that the number vaccinated in each ethnicity stratum 
matched the aggregated coverage data for that general practice; also the area-level 
deprivation data was based on the location of the general practice rather than the 
individual.82 A Dutch study, in which free zoster vaccine (zoster vaccine is not offered 
routinely in the Netherlands) was provided concurrently with seasonal influenza vaccine 
found lower zoster vaccine uptake amongst those with higher education level but found no 
association of age or gender with uptake.83 
Further data for the association of socio-demographic factors with zoster vaccination are 
available from other high-income countries from the non-European region such as the US, 
where the zoster vaccination was approved for use in 2006.84 These US studies have 
reported higher uptake amongst females, those of non-Hispanic White ethnicity, married 
individuals and those with higher education and income levels.74, 75, 85, 86 Similarly, in Alberta, 
Canada, where zoster vaccination is not a part of public funded immunisation programme, 
uptake was reportedly higher amongst females and those from higher income levels.87 
However, it is plausible that these findings may not be generalizable to the publicly funded 
health system in the UK. Also, zoster vaccine uptake has been low in the US (31.1% and 
34.2% in 2014 and 2015, respectively) amongst individuals aged ≥65 years.88, 89 
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Another important social factor which may be associated with zoster vaccination is religion. 
The zoster vaccine (Zostavax®) consists of porcine gelatine which may compromise its 
acceptability amongst Muslim and Jewish religions.90 However, so far the association of 
zoster vaccine uptake with religion has not been assessed in the UK. 
1.3.4  “Double” inequalities 
It is feasible that individuals from specific social groups with a higher burden of zoster may 
also have lower zoster vaccine uptake. This differential distribution of both burden and 
vaccine uptake in specific groups may make these individuals “doubly disadvantaged” by 
having a much higher zoster disease burden after the zoster vaccination programme is in 
place. 
Identifying socio-demographic groups with not only burden or vaccination inequalities but 
also the “doubly disadvantaged” individuals amongst older individuals is therefore essential 
for planning preventative strategies to mitigate inequalities of zoster burden and to promote 
healthy ageing.   
1.4  Electronic health records 
This thesis utilised routinely collected anonymised primary care electronic health records 
(EHR) linked to hospitalisation and deprivation data (detailed in Chapter 3) to ascertain 
inequalities in zoster burden and zoster vaccine uptake amongst older individuals in 
England. The utility of these data to ascertain ethnicity-associated health inequalities  in 
chronic disease burden have been examined.91 My PhD thesis explored to what extent these 
large linked primary care EHR can provide information on socio-demographic factors 
including ethnicity associated with zoster disease burden and zoster vaccine uptake to 
supplement/enhance existing surveillance methods. As further discussed in Chapter 3, the 
advantages of using these linked datasets include their very large size allowing for longer 
follow-up time, the data are population-based that are collected prospectively and using 
these data also allow more efficient use of limited resources. Using EHR also provides an 
additional advantage of automating the monitoring processes to generate an ongoing cycle 
of assessment, intervention and re-evaluation.  
35 
 
 
1.5 Thesis rationale, aims and objectives 
1.5.1 Thesis rationale 
Infection-related mortality and morbidity, which are more likely amongst disadvantaged 
social groups, can be targeted by effective vaccination to promote healthy ageing and health 
equality.16, 29, 55 Equitable healthy ageing can also help to minimise the negative impact of 
population ageing on a country’s healthcare expenditure. Therefore, tackling inequalities in 
burden and vaccination of zoster, an infectious disease associated with significant impact on 
older individuals, becomes an important component to address overall health inequalities in 
this group. To accomplish this aim it is vital to first assess the magnitude of these 
inequalities, if any, which will subsequently inform the design of any appropriate 
interventions.  
1.5.2 Aims and objectives 
The overarching aim of this PhD was to ascertain inequalities in vaccine-preventable 
disease burden and vaccine uptake using routinely collected EHR and contribute towards 
achieving the goal of health equality and healthy ageing amongst older individuals. 
Specific objectives were as follows: 
Objective 1: To summarise and critically appraise the existing studies of the social 
determinants of vaccine uptake by reviewing the literature systematically. 
Objective 2: To develop methodology for ascertainment of socio-demographic factors 
(including those identified from objective 1) and assess their availability in linked electronic 
health records. 
These methods were then applied in objectives 3 and 4 as follows: 
Objective 3: To describe the association of socio-demographic factors with zoster disease 
incidence in England, by applying the methodology developed in objective 2. 
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Objective 4: To describe the association of socio-demographic factors with zoster vaccine 
uptake in England, utilising the methods developed under objective 2. The thesis objectives 
along with the studies designed to meet these objectives are outlined in Table 1-2. 
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Table 1-2 Objectives of the thesis 
Objectives: primary Study 
design 
Study 
population 
Exposures Outcome(s) Effect 
measure 
Location in 
thesis 
1. To summarise and 
critically appraise the 
existing studies of the social 
determinants of vaccine 
uptake by reviewing the 
literature systematically 
Systematic 
review and 
meta-analysis 
Older individuals 
from Europe 
Socio-demographic 
factors 
Vaccine uptake Odds ratios, rate 
ratios 
Chapter 2 
2. To develop methodology 
for ascertainment of socio-
demographic factors and 
assess their availability in 
the electronic health records 
Cross-
sectional 
study 
Individuals aged 
≥65 years in 
England 
Socio-demographic 
factors including those 
identified from 
Objective 1 
For all exposures: 
1. Completeness of recording 
2. Representativeness  
3. Additional information gained by 
data linkages  
4. Timeliness of recording of 
exposures deemed as time-
varying 
Not applicable 
(descriptive 
study) 
Chapter 6 
3. To describe the 
association of socio-
demographic factors with 
zoster disease incidence in 
England 
 
Cohort study 
 
Individuals aged 
≥65 years in 
England with no 
prior history of 
zoster 
As above   First episode of zoster during the 
follow-up 
Incidence rate 
ratios 
Chapter 7 
4. To describe the 
association of socio-
demographic factors with 
zoster vaccine uptake in 
England 
Cohort study Individuals 
eligible for zoster 
vaccine 
As above  
 
 
 
Zoster vaccine uptake during 
follow-up 
Odds ratios Chapter 8 
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1.6 Structure of thesis 
The structure of this thesis is based on the ‘research paper’ style format, including four 
research papers that are either published or submitted for publication and presented as 
chapters. The thesis comprises of nine chapters, which describe the Background, 
Methodology, Results and Discussion sections.  
The overall rationale including the study questions, aims and objectives of the thesis are 
presented in this chapter. Table 1-2 summarises all the objectives of this thesis.  
Chapter 2 presents the published systematic review and meta-analysis describing the social 
determinants of vaccine uptake amongst older individuals (objective 1). 
Chapter 3 describes the EHR datasets utilised in the thesis and how three different study 
populations were defined to meet the thesis objectives 2-4.  
Chapter 4 defines how the main exposures of interest, socio-demographic factors, were 
identified in the EHR. 
Chapter 5 describes the ascertainment of the main outcomes in the EHR and how other 
variables of interest were identified.  
Chapter 6 presents the published research paper describing the methodology for 
ascertaining and assessing the recording of socio-demographic factors in the EHR 
(objective 2).  
Chapter 7 presents the published research paper describing the association of socio-
demographic factors with zoster disease incidence amongst older individuals in England 
(objective 3).  
Chapter 8 also presents a research paper (submitted for publication) investigating zoster 
vaccination inequalities amongst older individuals in England (objective 4). 
The final Chapter 9 summarises the overall study findings, an overview of strengths and 
limitations of the thesis, implications for public health and future research. 
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 Chapter 2. Social determinants of vaccine uptake 
amongst older individuals in Europe: systematic 
review  
This chapter forms the second part of the background section of this thesis and reports the 
work carried out to fulfil the first objective: to summarise and critically appraise the existing 
studies of the social determinants of vaccine uptake by reviewing the literature 
systematically. The details of this work, published in the journal Vaccine in 2017 (and herein 
referred to as “published review paper”), are provided in the next section. The 
supplementary material to the published review paper are presented in Section 2.3. As this 
published review paper identified studies available until 24/02/2016, I updated the review on 
01/11/2017 to identify new studies available from 25/02/2016 until 31/10/2017. The findings 
from the update are described in Section 2.4. 
2.1 Introduction to paper 1 
This paper presents a systematic review of the association between socio-demographic 
factors and vaccine uptake amongst individuals aged ≥60 years, using meta-analyses to 
provide summary effect estimates when appropriate. The paper summarises data from 47 
papers describing 44 studies from Europe identified from searches of Medline and Embase 
databases from inception to 24/02/2016. Living alone was identified as an important factor 
associated with lower vaccine uptake in this older age group. Other socio-demographic 
factors associated with lower uptake included not being married, being an immigrant, lower 
education, lower income and living in deprived areas.   
The search strategy, conceptual framework, study selection criteria, quality assessment 
criteria, the flow chart of the studies included in the review, summary of the studies and 
details of quality assessment referred to as supplementary material in the paper are 
presented in Section 2.3.  
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2.2 Paper 1: Lower vaccine uptake amongst older individuals living 
alone: A systematic review and meta-analysis of social determinants of 
vaccine uptake  
Review
Lower vaccine uptake amongst older individuals living alone: A
systematic review and meta-analysis of social determinants of vaccine
uptake
Anu Jain a,⇑, A.J. van Hoek a,b, Delia Boccia a, Sara L. Thomas a
a Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
b Immunisation, Hepatitis and Blood Safety Department, Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK
a r t i c l e i n f o
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Meta-analysis
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a b s t r a c t
Introduction: Vaccination is a key intervention to reduce infectious disease mortality and morbidity
amongst older individuals. Identifying social factors for vaccine uptake enables targeted interventions
to reduce health inequalities.
Objective: To systematically appraise and quantify social factors associated with vaccine uptake amongst
individuals aged 60 years from Europe.
Methods: We searched Medline and Embase from inception to 24/02/2016. The association of vaccine
uptake was examined for social factors relevant at an individual level, to provide insight into individuals’
environment and enable development of targeted interventions by healthcare providers to deliver equi-
table healthcare. Factors included: living alone, marital status, education, income, vaccination costs, area-
level deprivation, social class, urban versus rural residence, immigration status and religion. Between-
study heterogeneity for each factor was identified using I2-statistics and Q-statistics, and investigated
by stratification and meta-regression analysis. Meta-analysis was conducted, when appropriate, using
fixed- or random-effects models.
Results: From 11,754 titles, 35 eligible studies were identified (uptake of: seasonal influenza vaccine (SIV)
only (n = 27) or including pneumococcal vaccine (PV) (n = 5); herpes zoster vaccine (n = 1); pandemic
influenza vaccine (n = 1); PV only (n = 1)). Higher SIV uptake was reported for individuals not living alone
(summary odds ratios (OR) = 1.39 (95% confidence interval (CI): 1.16–1.68). Lower SIV uptake was
observed in immigrants and in more deprived areas: summary OR = 0.57 (95%CI: 0.47–0.68) and risk
ratio = 0.93 (95%CI: 0.92–0.94) respectively. Higher SIV uptake was associated with higher income
(OR = 1.26 (95%CI: 1.08–1.47)) and higher education (OR = 1.05 (95%CI: 1–1.11)) in adequately adjusted
studies. Between-study heterogeneity did not appear to result from variation in categorisation of social
factors, but for education was partly explained by varying vaccination costs (meta-regression analysis
p = <0.0001); individuals with higher education had higher vaccine uptake in countries without free vac-
cination.
Conclusions: Quantification of associations between social factors and lower vaccine uptake, and notably
living alone (an overlooked factor in vaccination programmes), should enable health professionals target
specific social groups to tackle vaccine-related inequalities.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Vaccination is an important intervention to prevent infections
amongst older individuals, who have increased susceptibility to
infections and often experience more severe outcomes [1–3]. A
successful vaccination programme depends not only on vaccine
effectiveness and well-organized programme delivery but also on
high vaccination uptake [3]. Inequalities in vaccine uptake
amongst older individuals could be related to social factors: the
social circumstances of living and working [4–6]. Determining
the association between social factors and vaccine uptake helps
to quantify any vaccination inequalities in specific population
groups and assists health care providers in planning targeted inter-
ventions and making any necessary changes to vaccination pro-
grammes. The social factors affecting vaccine uptake may vary
with age and with the type of vaccine [4–7]. A 2011 systematic
review summarised the association of social determinants of
health with uptake of a single vaccine (seasonal influenza (SIV))
for older individuals (aged 65 years), without quantitative syn-
thesis [6]. This previous study found conflicting associations of fac-
tors such as education, marital status, ethnicity, socio-economic
level and place of residence, without undertaking a comprehensive
assessment of between-study heterogeneity [6].
The social factors associated with SIV uptake may be different
from other vaccines used for older adults such as pneumococcal
and herpes zoster vaccines that are not administered annually.
The objective of this review was to systematically appraise and
quantify the association of social factors with uptake of vaccines
amongst individuals aged 60 years from Europe including a
detailed between-study heterogeneity assessment when neces-
sary. It was anticipated that the studies from the European region
may be more homogenous compared to those from low-income
settings, making data synthesis more feasible.
2. Methods
2.1. Search strategy
This review formed part of a larger search for studies exploring
social determinants of vaccine uptake in Europe for all age groups.
The wider search ensured that studies spanning different age
groups, including subgroups of older individuals, were not
potentially missed. The data sources comprised Medline and
Embase, searched from inception to 24/02/2016. Search terms (text
words and subject headings) were drawn up for four search con-
cepts: social factors, the European region [8], vaccination and
uptake. The search included articles, letters and conference
abstracts published in English. Additionally, reviews of vaccine
uptake (worldwide from the last five years) were searched to iden-
tify further European studies. The detailed search strategy is pro-
vided in Appendix-1. Reference lists of all eligible studies and
reviews were also searched.
To identify social factors associated with vaccine uptake, we
adapted the conceptual framework developed by the World Health
Organisation’s Commission on Social Determinants of Health
(Appendix-2) [7] for tackling health inequalities globally. This
framework provides a comprehensive approach for identifying
complex relationships between social factors and inequality, and
how to plan and implement interventions. We sought evidence
for social factors relevant at an individual level or provided insight
into individuals’ environment that could assist healthcare provi-
ders to target specific social groups for equitable healthcare deliv-
ery. The following factors were identified as possible determinants
of vaccine uptake: country of birth, religion, urban/rural residence,
marital status, living arrangements (living with others versus liv-
ing alone), and socio-economic position (education, income (indi-
vidual or household), type of health insurance, area-level socio-
economic status (SES), social class/occupation). For the purposes
of this review, we did not examine factors that were possible medi-
ators of the main factors of interest: knowledge, attitude and
beliefs, access to healthcare and health status/co-morbidities
(Appendix-2).
The titles and abstracts of the records retrieved were screened
for full text assessment based on a priori inclusion criteria (Appen-
dix 3). Studies reporting the effect of one or more social factor of
interest on vaccine uptake amongst individuals aged 60 years
from Europe [8] were potentially eligible. The outcome was any
routine vaccination programme and/or one-off vaccination such
as pandemic mass vaccinations or catch-up vaccinations; travel
or occupational health vaccinations were excluded. Eligible study
designs comprised cross-sectional, ecological, case-control or
cohort studies. We further restricted to studies that quantified
the relationship between social factors of interest with vaccine
uptake by either reporting relative risks or providing raw data
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for their calculation; studies presenting the results of hypothesis
testing without reporting effect measures were described narra-
tively. Multiple papers describing the same study population were
included once. The abstracts of the records that appeared to meet
these screening criteria were selected for a full text review.
The eligibility criteria were applied by one reviewer (AJ) to the
titles/abstracts identified, for full-text assessment. A random sam-
ple (10%) of titles considered ineligible were screened indepen-
dently by two other reviewers (ST and AJVH) (no disagreements
were observed). Of the total records identified for full text review,
the eligibility for 10% of the records for which eligibility was ini-
tially unclear was resolved by discussion (ST, AJ and AJVH).
2.2. Data extraction
Data were extracted by one reviewer (AJ). Information was
extracted for: author, study characteristics (year, country, design,
size, participants) vaccine types, social factors, effect estimates
and confounders used for adjusted effect estimates.
2.3. Quality assessment
Quality assessment was performed by one reviewer (AJ) includ-
ing detailed discussions with the second reviewer (ST), using the
Cochrane approach for risk of bias adapted for observational data
[9,10]. Risk of bias (categorised as low, high or unclear risk) was
assessed for the following five domains: selection bias, missing
data, misclassification of vaccination status, misclassification of
social factors (including consideration of timeliness for time-
varying social factors - marital status, living alone, rural/urban res-
idence, area-level SES, income and insurance status), and con-
founding bias. Details of the bias assessment are provided in the
Appendix-4.
2.4. Data analysis
Forest plots of effect estimates (odds ratios (OR) or risk/rate
ratios (RR)) were generated for each social factor, stratified by vac-
cine type. Raw data were used to calculate ORs if effect estimates
were unavailable. The effect estimates from the most appropriate
model (ideally, controlling for confounding and not adjusted for
mediating variables) were used when available, otherwise the
unadjusted estimate was used. For social factors with more than
two categories, reported estimates for the highest or lowest cate-
gory were selected. To address varying choice of baseline exposure
group in different studies, effect estimates for a comparable base-
line were re-calculated when possible using raw data; if the expo-
sure variable was binary, the effect estimates were reversed for
studies that used a different baseline. Similarly, effect estimates
for non-uptake of vaccination were reversed to obtain estimates
for vaccine uptake. Studies were described narratively if such com-
parisons were impossible or if estimates from probit or linear prob-
ability models were presented.
Between-study heterogeneity was explored using I2-statistics
and the Cochrane Q-statistic [11]. When the I2-statistic was
50% fixed effects meta-analyses [11] were conducted. When
between-study heterogeneity (I2 > 50%) was identified for a partic-
ular factor, a random effects meta-analysis was conducted if effect
estimates were all broadly in the same direction, but was not
attempted when effect estimates were in opposing directions as
the summary estimate was considered uninformative [11].
Between-study heterogeneity was explored as follows: stratify-
ing by vaccine type (influenza vs other vaccine uptake), different
effect measures (OR or RR), re-categorising exposures with >2 cat-
egories (when feasible) to maximise homogeneity of exposure def-
initions; restricting analyses to studies reporting adequately
adjusted estimates (Appendix 4), and stratifying results by
whether the vaccine was available free-of-charge in the country
(to see whether costs of vaccination modified effect estimates).
Meta-regression analysis was conducted to further investigate
heterogeneity for social factors with at least 10 studies, assessing:
vaccine type (influenza vs other vaccine uptake); OR/RR as effect
estimates; heterogeneity in the categories chosen for the social fac-
tor; confounding bias; whether the vaccine was available free-of-
charge; and any over-adjustment of effect estimates (inclusion of
hypothesized mediating variables in multivariable models).
Data were analysed using Stata 14 software package (StataCorp
LP, College Station, TX, USA).
3. Results
A total of 11,754 titles were identified, of which 479 titles
(including one title identified from references) were evaluated
for full text review (Appendix-5) resulting in 35 eligible studies
conducted between 1997 and 2015 (Appendix-6). Most were
cross-sectional with five cohort studies and one case-control study.
Three studies reported data for more than one European country
[12–14], with the remaining 32 studies conducted in 11 countries
(Table 1), Spain being the most frequent (n = 11) followed by the
UK (n = 5). The studies ascertained uptake of SIV (n = 27), pneumo-
coccal vaccine (PV) (n = 1), both SIV and PV (n = 5), SIV and pan-
demic influenza vaccine (n = 1), and SIV and herpes zoster
vaccine (n = 1).
Amongst studies providing effect estimates education was the
most frequent social factor investigated (n = 14), followed by living
alone (n = 13), and country of birth (n = 11). The least studied fac-
tors were health insurance (n = 3) and religion (n = 1) (Table 1).
Two studies reported effect estimates for some social factors but
only statistical evidence (without effect estimates) for country of
birth [15] and for private medical insurance [16] (Appendix-7).
Nine additional studies [17–25] (Appendix-7) that did not provide
effect estimates were summarised narratively.
3.1. Quality assessment
As shown in Table 2 and Appendix-8, studies had low risk of
bias for outcome and exposure measurement but confounding bias
was common. The confounding bias mostly resulted from lack of
adjustment for at least one other social factor (Appendix-4) in mul-
tivariable models.
3.2. Social factors of vaccine uptake
3.2.1. Living alone
Of the nine studies considered for meta-analysis, six classified
living alone as a binary variable, and for the other three [26–28]
studies ‘‘living as a couple” was compared to living alone. Although
results were heterogeneous, studies consistently showed increased
uptake amongst those not living alone, with an overall 25% and
53% increase for SIV uptake after restricting analysis to adequately
adjusted studies and stratifying by vaccine cost respectively
(Fig. 1). Re-analysis of living arrangements as a binary variable
(Fig. 1) did not reduce heterogeneity.
Two studies [29,30] categorised living arrangements differently.
One (comparing smaller versus larger households) reported
increased uptake amongst individuals from large households
[29], whereas the other (living with children versus not living with
children) [30] reported lower vaccine uptake amongst those living
with children. The studies that used probit or linear regression
models found negative associations between vaccine uptake and
housing density [31] and those living with children [14]. The single
A. Jain et al. / Vaccine 35 (2017) 2315–2328 2317
45
Table 1
Summary of studies reporting associations of social determinants with vaccine uptake (N = 35).
First author Country Study period Sample size Study population Vaccine Social determinants and their association with vaccine uptake
SES (A)a Incob SCc COBd Edue LAf RSg Relih Resi HIj
Cross-sectional studies
1 Abramson
[32]
Israel 1997 626 People aged 65 years with a telephone and registered at the
Jerusalem community centre
SIV N*d N* ;* N*
2 Aguilar [56] Spain 2010–2011 104,427 Computerised vaccination records for all non-institutionalised
individuals 65 years covered by Navarre Health Service
SIV ;* N*
3 Barrett & Mc
Hugh [33,47]
RoI October 2009–
February 2011
3,510 Community residents aged 65 years from The Irish
Longitudinal Study on Ageing (TILDA)
SIV ; ; "
4 Bodekar [15] Germany March–June 2014 825 Respondents (aged 60 years) to a nationwide telephone survey SIV N
5 Bohmer [37] Germany July 2008–June
2009
8,458 Respondents (aged 60 years) to a national telephone health
survey
SIV N* N
6 Burns [57] UK 2001–2002 444 Adults aged 65 years interviewed at public places around
Birmingham
SIV ;* "*
7 Carreno-
Ibanez [58]
Spain March–June 2014 76,782 Individual records from the primary care electronic records for
people aged 60 years with chronic bronchitis or emphysema
from the Autonomous Community of Madrid
PV ;
8 Chiatti
[26,48,59]
Italy December 2004–
September 2005
25,183 (3,738
with COPD)
People (aged 65 years) from the ‘‘Healthstatus of the
population and use of health services in Italy” survey (ISTAT 8)
and a secondary analysis of individuals who self-reported a
diagnosis of COPD
SIV N* "* N* N* ;*
9 Christenson
[34]
Sweden December 2000–
May 2001
7,631 Responders (aged 65 years) of a postal survey sent to people
registered with the Stockholm County Council Population
Register
SIV &
PV
" ;
10 Crawford [12] UK and RoI 2004 2,033 Community residents (aged 65 years) surveyed as a part of
‘‘Healthy Aging Research Programme”
SIV N* N* N* N*
11 Damiani [35] Italy September 1999–
June 2000
24,564 Respondents (aged 65–89 years) to the Italian national survey SIV "* N* N* ;*
12 de Souto [42] France May–July 2011 6,275 Residents from 175 nursing homes in the Midi-Pyrenees region SIV &
PV
SIV:
N*;
PV ;*
13 Jimenez-
Garcia [60]
Spain 2003 6,134 Non-institutionalised participants (aged 65 years) in the
Spanish National Health survey
SIV N*
14 Jimenez-
Garcia [61]
Spain June 2006–June
2007
7,835 Non-institutionalised respondents (aged 65 years) to the
Spanish National Health survey
SIV ;*
15 Jimenez-
Garcia [62]
Spain November 2004–
June 2005
1,629 Respondents (aged 65 years) to the ‘‘Madrid City Health
Survey: ESCM 0500
SIV N*
16 Jimenez-
Garcia [63]
Spain July 2011–June
2012
5,725 Non-institutionalised respondents (aged 60 years) to the
Spanish National Health Survey
SIV ;*
17 Jimenez-
Garcia [64]
Spain 2012–2013 1,307,165 Records of people aged 60 years registered with the public
health system of the Autonomous Community of Madrid
SIV ;*
18 Kroneman
[29]
Sweden April–May 2004 &
March–April 2005
612 Respondents (aged 65 years) to a national telephone survey SIV N*
19 Landi [13] 11
countries^
2001–2003 3,878 Participants from urban areas aged 65 years from 11 European
countries that took part in the ‘‘Aged in Home Care (ADHOC)
project” of EU
SIV "* "*
20 Mamelund
[36]
Norway November 2008 354 Non-institutionalised participants aged 65 years of a national
telephone survey
SIV N N N
21 Nexoe [65] Denmark September 1996 &
February 1997
1,204 Respondents to postal questionnaires aged 65 years identified
from the Civil Registration System
SIV "*
22 Opstelten
[45]
Netherlands 1999 666 Respondents to a postal questionnaire, aged 65 years and
registered with 4 general practices in Amersfoort town
SIV and
PV
;*
23 Opstelten
[49]
Netherlands September 2007 1,221 Respondents to postal questionnaire, aged 65 years and
registered with 3 general practices in Amersfoort town
HZ &
SIV
;*
24 Pena-Rey [50] Spain January 2000 1,111 Participants (aged 65 years) in a women’s social and health SIV "* N ;* N*
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Table 1 (continued)
First author Country Study period Sample size Study population Vaccine Social determinants and their association with vaccine uptake
SES (A)a Incob SCc COBd Edue LAf RSg Relih Resi HIj
survey in Galicia
25 Sarria-
Santamera
[16]
Spain 1997 1,148 Non-institutionalised participants (aged 65 years) in the
Spanish National Health survey (ENS)
SIV N N
26 Schmitz [14] 15
countries
2004 & 2006 8,891 Respondents aged 65 years from the first and the second wave
of the Survey of Health, Ageing and Retirement in Europe
(SHARE)
SIV "*a ;* a f "* a s
27 Shahrabani
[31]
Israel 1999–2000 4,083 Respondents (aged 60 years) to the Health Survey of the
Central Bureau of Statistics
SIV ;* a e N* a ;* a g ;* a
28 Sintes [28] Spain May 2005–January
2007
1,702 Non-institutionalised patients aged 65 years admitted with
community acquired pneumonia to 3 acute general hospitals in
Catalonia and Galicia
SIV &
PV
SIV:
N,
PV: "
SIV:
N,
PV:;
"* N
29 Wershof
Schwartz [43]
Israel 2008–2009 136,944 Individuals aged 65 years and registered with Maccabi
Healthcare Services
SIV &
PV
;* ;* "*
Casecontrol study
30 Van Essen
[46]
TN 1993–1994 181 Respondents (aged 65 years) to a postal questionnaire,
registered with seven family practices situated in a suburban
area
SIV N* N*
Cohort studies
31 Breeze [41] UK 1997–2000 29,731 People aged >74 years with available flu vaccination records
registered with general practices in the UK taking part in the
‘‘Trial of Assessment and Management of Older People in the
Community Study”
SIV N* N* N*
32 Mangtani
[27]
UK 2000 5,572 People aged >74 years from the ‘‘Trial of Assessment and
Management of Older People in the Community”
SIV N* N* " ; "*
33 Martinez-Baz
[30]
Spain 2010–2011 64,245 Individual records of non-institutionalised people aged
65 years and previously vaccinated in 2009–2010 Navarre
SIV ;* ;*h N*
34 Sammon [44] UK August 2009–June
2010
353,921 Individuals aged 65 years in clinical risk groups and registered
with a practice contributing to the General Practice Research
Database at the beginning of the H1N1 vaccination campaign
SIV &
PIV
SIV:
N*b;
PIV:;* b
35 Shah [66] UK June 2008–
January 2009
387,568 Individual records of community and care (nursing and
residential) home residents aged 65–104 years and registered
with a practice contributing to The Health Improvement
Network primary care database
SIV ;*
Total number
of studies (%)
5 (14%) 10
(29%)
5
(14%)
11
(31%)
14
(40%)
13
(37%)
9 (26% 1
(3%)
9
(26%)
3
(9%)
SES(A) – socio-economic status area a most deprived versus least deprived (reference group) except for bSammon et al. (3rd quintile: reference group).
Inco – income b Highest income level versus lowest income level (reference group).
SC – social class c Lowest social class versus highest social class (reference group).
COB – country of birth d Immigrants versus native (reference group) (dAbramson et al.: others versus those from Asia/Africa (reference group), aprobit marginal probabilities eShahrabani et al. individuals from USSR (after 1990)
versus native (reference group)).
Edu – education e Highest education level versus lowest education level (reference group).
LA – living arrangements f Not living alone versus living alone/smaller household size (reference group); fSchmitz et al. number of children in household (ordinal variable); gShahrabani et al. housing density (ordinal variable);
hMartinez-Baz et al. living with children aged <15 years versus not living with children aged <15 years (reference group).
RS – relationship status g Not married versus married (reference group); sSchmitz et al. no partner (reference group).
Reli – Religion h Not religious versus religious (reference group).
Res – Residence i Urban versus rural area (reference group).
HI – health insurance j Private insurance versus no private insurance (reference group).
SIV seasonal influenza vaccine PIV pandemic influenza vaccine PV pneumococcal vaccine HZ herpes zoster vaccine.
N – not associated with vaccine uptake. *adjusted estimates ; lower vaccine uptake " higher vaccine uptake.
RoI – Republic of Ireland, COPD – Chronic Obstructive Pulmonary Disease.
^11 countries Czech Republic, Denmark, Finland, France, Germany, Iceland, Italy, The Netherlands, Norway, Sweden, UK.
15 countries Austria, Belgium, Czech Republic , Denmark, France, Germany, Greece, Ireland, Italy, The Netherlands, Poland, Spain, Sweden, Switzerland & Israel.
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Table 2
Quality assessment of the studies included in the review.
Study 
type & 
Ref.
Social determinants and bias 
SB OM 
Area SES Income  Social class COB  Educaon Living alone Marital status Religion Residence Insurance 
Cross-
seconal EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD 
[32] L L                   L L U L L U       L L U L L U             
[56] L L                   L L L                         U L L       
[33, 47] H L       H H H             L H L                         H H L 
[15] H L                         L H L                               
[37] H L       L L U             L H U                               
[57] L L             L L L             L L L                         
[58] L L                   L H L                                     
[26, 48, 
59] U L L L L L L L       L L L L L L L L L                   
[34] L L                         L H L       L H L                   
[12] H L             L L U             L L U L L U       L L U       
[35] U L       L L L L L L       L L L       L L L                   
[42] H L                                                 L L L       
[60] U L                   L H L                                     
[61] U L                   L H L                                     
[62] U L                   L H U                                     
[63] U L                   L H L                                     
[64] L L                   L H L                                     
[29] U L                               L H U                         
[13] U L       L L L                   L L L                         
[36] H L       L H H             L H L L H L                         
[65] H L                               L H L                         
[45] H L                                                       L H L 
[49] H L                         L H L                               
[50] L L       L L L             L H L       L L L       L L L       
[16] L L       L H L             L H L                               
[14] U L                         L L U L L U L L U                   
[31] U L                   L L U L L U L L U L L U                   
[28] U L             L H L       L H L L H L* L             L H L       
[43] L L H L L             L L L                         L L L       
Cohort 
[41] U L L L L L L L                                     L L L       
[27] L L L L L L L L                   L H L L H L       L L L       
[30] U L                   L L U       U L U             U L U       
[44] U L U H U                                                       
[66] U L U H L                                                       
Case-
control 
[46] L L                               L L L                   L L L 
Ref. – reference, SES – socioeconomic status, COB – country of birth, SB – selection bias, OM – outcome misclassification, EM – exposure misclassification, CB – confounding
bias, MD – missing data, L – low risk of bias, U – unclear risk of bias, H – high risk of bias.
Red cell with letter H signifies high risk of bias.
Green cell with letter L signifies low risk of bias.
Yellow cell with letter U signifies unclear risk.
*Low risk of bias for pneumococcal vaccine.
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Seasonal influenza
van Essen (The Netherlands)
Nexoe (Denmark)
Mangtani (UK)
Burns (UK)
Landi (multinational )
Crawford (UK and RoI)
Chiatti (Italy)
Sintes (Spain)
Mamelund (Norway)
Subtotal  (I-squared = 82.7%, p =< 0.0001)
Pneumococcal
Sintes (Spain)
Author
1993
1996-1997
2000
2001-2002
2001-2003
2004
2004-2005
2005-2007
2008
2005-2007
Study period
1.79 (0.40, 9.09)
1.59 (1.03, 2.48)
1.70 (1.51, 1.90)
2.25 (1.35, 3.73)
1.28 (1.11, 1.49)
1.14 (0.83, 1.67)
1.07 (0.98, 1.17)
1.51 (1.09, 2.13)
1.21 (0.79, 1.86)
1.39 (1.16, 1.68)
1.71 (1.20, 2.46)
*
Odds-ratio (95% CI)Living arrangement: all studies (baseline: living alone)
Chiatti (Italy)
Sintes (Spain)
Landi (multinational )
Seasonal influenza
Burns (UK)
van Essen (The Netherlands)
Crawford (UK and RoI)
Subtotal  (I-squared = 65.3%, p = 0.021)
Pneumococcal
2004-2005
2005-2007
2001-2003
2001-2002
1993
2004
1.07 (0.98, 1.17)
1.71 (1.20, 2.46)
1.28 (1.11, 1.49)
2.25 (1.35, 3.73)
1.79 (0.40, 9.09)
1.14 (0.83, 1.67)
1.25 (1.03, 1.51)*
Seasonal influenza: free
van Essen (The Netherlands)
Nexoe (Denmark)
Mangtani (UK)
Burns (UK)
Chiatti (Italy)
Sintes (Spain)
Subtotal  (I-squared = 89.1%, p =<0.0001)
Seasonal influenza: paid
Mamelund (Norway)
Pneumococcal: free
Sintes (Spain)
1993
1996-1997
2000
2001-2002
2004-2005
2005-2007
2008
2005-2007
1.79 (0.40, 9.09)
1.59 (1.03, 2.48)
1.70 (1.51, 1.90)
2.25 (1.35, 3.73)
1.07 (0.98, 1.17)
1.51 (1.09, 2.13)
1.53 (1.15, 2.04)
1.21 (0.79, 1.86)
1.71 (1.20, 2.46)
*
Seasonal influenza
van Essen (The Netherlands)
Nexoe (Denmark)
Mangtani (UK)
Burns (UK)
Landi (multinational)
Crawford (UK and RoI)
Chiatti (Italy)
Sintes (Spain)
Mamelund (Norway)
Subtotal  (I-squared = 91.4%, p =< 0.0001)
Pneumococcal
Sintes (Spain)
1993
1996-1997
2000
2001-2002
2001-2003
2004
2004-2005
2005-2007
2008
2005-2007
1.79 (0.40, 9.09)
1.59 (1.03, 2.48)
1.57 (1.41, 1.74)
2.25 (1.35, 3.73)
1.28 (1.11, 1.49)
1.14 (0.83, 1.67)
0.93 (0.88, 0.99)
1.44 (1.07, 1.93)
1.21 (0.79, 1.86)
1.10 (1.05, 1.15)
1.69 (1.26, 2.26)
Living arrangement: adjusted studies (baseline: living alone)
Living arrangement: studies cost stratified^(baseline: living alone)
Living arrangement: analyzed as binary variable (baseline: living alone)
Seasonal influenza
Abramson (Israel)
Damiani (Italy)
Mangtani (UK)
Pena-Rey (Spain)
Christenson (Sweden)
Crawford (UK and RoI)
Chiatti (Italy)
Subtotal  (I-squared = 74.0%, p = 0.001)
Pneumococcal
Christenson (Sweden)
1997
1999-2000
2000
2000
2000-2001
2004
2004-2005
2000-2001
0.47 (0.28, 0.78)
0.82 (0.74, 0.91)
0.54 (0.44, 0.67)
0.69 (0.50, 0.95)
0.76 (0.69, 0.84)
1.30 (0.80, 2.10)
0.82 (0.76, 0.89)
0.73 (0.66, 0.80)
Marital status: all studies (baseline: married)
Marital status
Seasonal influenza
Abramson (Israel)
Damiani (Italy)
Pena-Rey (Spain)
Crawford (UK and RoI)
Chiatti (Italy)
Subtotal  (I-squared = 56.1%, p = 0.06)
1997
1999-2000
2000
2004
2004-2005
0.47 (0.28, 0.78)
0.82 (0.74, 0.91)
0.69 (0.50, 0.95)
1.30 (0.80, 2.10)
0.82 (0.76, 0.89)
Marital status: adjusted studies (baseline: married)
Marital status: studies cost stratified~ (baseline: married)
Seasonal influenza: free
Abramson (Israel)
Damiani (Italy)
Mangtani (UK)
Pena-Rey (Spain)
Chiatti (Italy)
Subtotal  (I-squared = 78.4%, p = 0.001)
Seasonal influenza: paid
Christenson (Sweden)
Pneumococcal: Paid
Christenson (Sweden)
1997
1999-2000
2000
2000
2004-2005
2000-2001
2000-2001
0.47 (0.28, 0.78)
0.82 (0.74, 0.91)
0.54 (0.44, 0.67)
0.69 (0.50, 0.95)
0.82 (0.76, 0.89)
0.70 (0.60, 0.83)
0.76 (0.69, 0.84)
0.73 (0.66, 0.80)
*
*NOTE: Weights are from random effects analysis
RoI Republic of Ireland
^ 2 multinational studies excluded
~ 1 multinational study excluded
Seasonal influenza
Abramson (Israel)
Damiani (Italy)
Pena-Rey (Spain)
Mangtani (UK)
Christenson (Sweden)
Crawford (UK and RoI)
Chiatti (Italy)
Subtotal  (I-squared = 94.8%, p =< 0.0001)
Pneumococcal
Christenson (Sweden)
1997
1999-2000
2000
2000
2000-2001
2004
2004-2005
2000-2001
0.47 (0.28, 0.78)
1.02 (0.97, 1.07)
0.69 (0.50, 0.95)
0.60 (0.54, 0.67)
0.76 (0.69, 0.84)
0.61 (0.50, 0.75)
0.82 (0.76, 0.89)
0.73 (0.66, 0.80)
Not favours vaccine uptake  Favours vaccine uptake 
1.2 1.5 2.5 9.5
Marital status: analyzed as binary variable (baseline: married)
Fig. 1. Effect of living arrangements and marital status on vaccine uptake.
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UK study that did not provide effect measures, found no associa-
tion between living arrangements (categorised as a seven-level
variable) and SIV uptake amongst patients admitted to a geriatric
ward [20] (Appendix-7).
3.2.2 Marital status
Four of the seven studies considered in the meta-analysis cate-
gorised marital status as a binary variable, for the remaining three
studies single status was compared to being married. After stratifi-
cation by vaccine type, 18–53% lower vaccine uptake was observed
amongst unmarried individuals in all studies except one [12] with
notable between-study heterogeneity (I2 = 74%, Fig. 1). Reclassify-
ing marital status in three studies as a binary variable (unmarried
versus married) did not reduce the between-study heterogeneity
(Fig. 1). Heterogeneity was reduced but still appreciable after
restricting analyses to adequately adjusted SIV uptake studies.
Results were more homogeneous after stratifying by vaccine cost;
in countries in which SIV was free-of-charge, overall uptake
amongst unmarried individuals was 30% lower compared to mar-
ried individuals (Fig. 1), echoing findings for living arrangements
(Fig. 1). The studies that used linear probability [14] or probit mod-
els [31] also found higher SIV uptake amongst married individuals
or those with a partner, as did one of the three Spanish studies that
did not provide effect measures (uptake 47.8% vs 53%) [21]; the
other two Spanish studies found no evidence for an association
between marital status and SIV uptake [16,18] (Appendix-7).
3.2.3. Education
Twelve studies were considered for meta-analysis (Fig. 2). There
was no consistent effect of higher education on vaccine uptake
after stratification by vaccine-type (I2 > 80%). Results were little
changed after re-categorising education in seven studies as a bin-
ary variable (education up to ages 12–15 years and >15 years)
[16,26,32–36] (Fig. 2). Restricting analysis to adequately adjusted
studies resulted in a consistent direction of effect (Fig. 2) with a
summary estimate of 5% higher uptake amongst those with the
highest education level.
Interestingly, stratification by vaccination cost [32,34,35,37–40]
showed marked differences. In countries where the vaccine was
provided free-of-charge there was no overall effect of education.
In contrast, in countries where a payment for vaccination was nec-
essary, higher education was associated with an overall 67%
increased odds of SIV uptake. (Fig. 2). A reverse effect (20%
decreased odds of uptake) was seen in the single Irish study, where
vaccine administration payments are means tested [39,40].
Two studies excluded from meta-analysis reported marginal
probabilities: one found no evidence of an association of education
level with SIV uptake [31] and the other (including fifteen coun-
tries) found low education level associated with lower SIV vaccina-
tion (linear probability model coefficient = 0.034) [14]. Four
further studies did not provide effect estimates: a Greek study
[24] showed higher uptake amongst those with at least primary
education whilst three Spanish studies [18,21,22] reported no evi-
dence of effect of education on SIV uptake (Appendix-7).
3.2.4. Household/individual income
The eight studies that reported ORs for income and SIV uptake
showed no consistent effect (Fig. 2). Amongst the two studies
[27,41] reporting RRs, there was no overall effect of income on
SIV uptake (Fig. 2).
Despite remaining heterogeneity, results were more consistent
after restricting to studies with adequate adjustment for confound-
ing, with an overall 26% increased odds of SIV uptake amongst
those with higher income, consistent with that observed for the
effect of education (Fig. 2). Unlike the findings for education, in
stratified analyses an overall 14% higher odds of SIV uptake
amongst those with higher income was observed in countries
offering free-of-charge vaccination [37,40] (Fig. 2). However, in a
single Irish study [33] where vaccination payment was means
tested [40], the effect of higher incomewas similar to that of higher
education: those with higher income had lower odds of SIV uptake
(Fig. 2). It was not possible to re-classify income status as a binary
variable for comparison across studies, and the exploration of
heterogeneity for this aspect was therefore not undertaken.
Four studies did not provide effect estimates for the association
of income with vaccine uptake (Appendix-7). A second Irish study
found uptake of both SIV and PV to be higher (p < 0.001) amongst
individuals entitled to free vaccine (possessors of a medical card)
compared to those who paid for vaccination [17]. Higher SIV cov-
erage was reported for individuals with lower income in urban
areas of Turkey where the vaccination was not available free-of-
charge [19]. In contrast, two Spanish studies found no evidence
of an association between income and SIV uptake [18,21].
3.2.5. Urban or rural area of residence
Eight of the nine studies (SIV n = 6, SIV and PV n = 3) with effect
estimates reported the association of vaccine uptake with the loca-
tion of individuals’ own homes (urban or rural), whilst one French
study [42] investigated the location of individuals’ nursing homes
(Fig. 3). No consistent direction of effect was observed for studies
reporting ORs for the association of SIV uptake with residence.
However, the studies that presented RRs for SIV uptake and ORs
for PV uptake found an overall 11% and 15% increase in uptake
respectively amongst urban residents (Fig. 3).
The location of nursing homes had no effect on SIV uptake, but
(in contrast to individuals living independently) a lower uptake of
PV was observed in residents in urban versus rural nursing homes
(Fig. 3).
Between-study heterogeneity for SIV uptake could not be
explained by restricting the analysis to adjusted ORs (Fig. 3) and
all studies except one [12] offered free vaccination. Again, it was
not feasible to re-categorise this exposure as binary variable.
A UK study that did not provide effect measures found no asso-
ciation between location of general practices and SIV uptake [23].
3.2.6. Area-level SES
Five UK studies reported the association of area-level SES with
vaccine uptake (SIV alone n = 3, SIV and pandemic influenza
n = 1, SIV and PV n = 1, Fig. 3). All but one study reported RRs
[43]. The reference group for one study [44] was the third quintile
of deprivation in contrast to the other four studies (the baseline
group being the least deprived area).
The results were similar to the effect of household income
(Fig. 2), with risk of SIV uptake modestly (7–11%) lower amongst
those living in most deprived areas. This effect was seen consis-
tently irrespective of vaccine type or measure of effect (Fig. 3) or
using a different baseline group. All studies were from countries
providing free-of-charge vaccination and it was not feasible to
re-categorise this exposure.
3.2.7. Private medical insurance
Two [45,46] of the three studies considered in meta-analysis
categorised insurance as a binary variable; one study [47] used a
four-level variable (Appendix-6). The latter study compared indi-
viduals with private medical insurance to those without insurance
as baseline. After stratification by vaccine types (Fig. 3), overall SIV
uptake was 67%more likely amongst individuals with private med-
ical insurance, but uptake of both SIV and PV was 62% lower
(Fig. 3). One study [46] provided adequately adjusted estimates;
all but one study [47] were conducted in countries that provided
vaccine free-of-charge (Fig. 3). SIV uptake was 72% higher amongst
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Fig. 2. Effect of education and income on vaccine uptake.
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Fig. 3. Effect of residence, area level socio-economic status and medical insurance on vaccine uptake.
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Social class
~Cost stratified studies not presented as all study 
countries offered free-of-charge vaccine
RoI Republic of Ireland *Weights are from random 
effects analysis
^ one multinational study excluded
Seasonal influenza
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Wershof (Israel)
Aguilar (Spain)
Martinez-Baz (Spain)
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Subtotal  (I-squared = 97.6%, p =<0.0001)
Pneumococcal
Wershof (Israel)
Carreno-Ibanez (Spain)
Subtotal  (I-squared = 96.7%, p =<0.0001)
2003
2004-2005
2006-2007
2008-2009
2010-2011
2010-2011
2011-2012
2012-2013
2008-2009
2010
0.85 (0.35, 2.06)
0.96 (0.43, 2.04)
0.34 (0.19, 0.59)
0.82 (0.80, 0.84)
0.40 (0.36, 0.45)
0.55 (0.45, 0.67)
0.60 (0.32, 0.99)
0.60 (0.57, 0.62)
0.58 (0.46, 0.73)
0.88 (0.86, 0.90)
0.60 (0.52, 0.68)
0.73 (0.50, 1.06)
*
*
Country of birth analyzed as binary variable (baseline: native)
Seasonal influenza
Wershof (Israel)
Aguilar (Spain)
Martinez-Baz (Spain)
Subtotal  (I-squared = 98.1%, p =<0.0001)
Pneumococcal
Wershof (Israel)
2008-2009
2010-2011
2010-2011
2008-2009
0.74 (0.71, 0.77)
0.40 (0.36, 0.45)
0.55 (0.45, 0.67)
0.55 (0.35, 0.85)
0.73 (0.70, 0.77)
*
Country of birth: adjusted studies (baseline: native)
Seasonal influenza
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Wershof (Israel)
Aguilar (Spain)
Martinez-Baz (Spain)
Jimenez-Garcia (Spain)
Jimenez-Garcia (Spain)
Subtotal  (I-squared = 94.8%, p =<0.0001)
Pneumococcal
Wershof (Israel)
Carreno-Ibanez (Spain)
Subtotal  (I-squared = 86.3%, p = 0.007)
Author
2003
2004-2005
2006-2007
2008-2009
2010-2011
2010-2011
2011-2012
2012-2013
2008-2009
2010
Study period
0.85 (0.35, 2.06)
0.96 (0.43, 2.04)
0.34 (0.19, 0.59)
0.74 (0.71, 0.77)
0.40 (0.36, 0.45)
0.55 (0.45, 0.67)
0.60 (0.32, 0.99)
0.60 (0.57, 0.62)
0.57 (0.47, 0.68)
0.73 (0.70, 0.77)
0.60 (0.52, 0.68)
0.67 (0.55, 0.81)
Odds-ratio (95% CI)
*
*
Country of birth: all studies (baseline: native)~
Seasonal influenza
Damiani (Italy)
Burns (UK)
Crawford (UK and RoI)
Chiatti (Italy)
Sintes (Spain)
Pneumococcal
Sintes (Spain)
1999-2000
2001-2002
2004
2004-2005
2005-2007
2005-2007
0.94 (0.81, 1.08)
0.68 (0.51, 0.92)
0.95 (0.70, 1.20)
1.21 (1.11, 1.33)
1.01 (0.77, 1.35)
1.40 (1.07, 1.84)
Social class: all studies (baseline: highest class )
Subtotal  (I-squared = 80.2%, p =<0.0001)
Seasonal influenza
Damiani (Italy)
Burns (UK)
Crawford (UK and RoI)
Chiatti (Italy)
1999-2000
2001-2002
2004
2004-2005
0.94 (0.81, 1.08)
0.68 (0.51, 0.92)
0.95 (0.70, 1.20)
1.21 (1.11, 1.33)
Social class adjusted studies (baseline: highest class)
Subtotal  (I-squared = 85%, p =<0.0001)
Seasonal influenza
Damiani (Italy)
Burns (UK)
Chiatti (Italy)
Sintes (Spain)
Pneumococcal
Sintes (Spain)
1999-2000
2001-2002
2004-2005
2005-2007
2005-2007
0.94 (0.81, 1.08)
0.68 (0.51, 0.92)
1.21 (1.11, 1.33)
1.01 (0.77, 1.35)
1.40 (1.07, 1.84)
Not favours vaccine uptake  Favours vaccine uptake 
1.15 .5 2.5
Social class cost stratified studies (baseline: highest class)^
Subtotal  (I-squared = 84.5%, p =<0.0001)
Fig. 4. Effect of country of birth and social class on vaccine uptake.
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those with private medical insurance was observed in the Irish
study [47] where vaccination charges were means tested [40].
A Spanish study [16] that did not provide effect measures
reported no evidence of association of private medical insurance
with SIV uptake (Appendix-7).
3.2.8. Country of birth
Nine studies, all except one conducted in Spain, were consid-
ered for meta-analysis (Fig. 4). Overall, there was lower uptake of
vaccination amongst immigrants irrespective of vaccine type, with
uptake 43% and 33% lower for SIV and PV vaccines respectively
(Fig. 4). The summary effect estimate was near-identical after
restricting SIV studies to those with adequate adjustment of con-
founding, and after reclassifying country of birth in one study
[43] as a binary variable (Fig. 4). Stratification based on vaccine
costs was not required as all included countries offered free
vaccinations.
Two studies from Israel with effect estimates were excluded
frommeta-analysis, one [32] used a different definition for country
of birth (those born in Asia or Africa versus elsewhere) and the sec-
ond used marginal probabilities to investigate immigration status;
neither found an association with SIV uptake [31]. Two further
studies did not provide effect estimates: an Israeli study [25] found
statistical evidence for lower uptake of both SIV and PV amongst
Russian speakers compared to Arabic speakers, whilst a German
study found no evidence for lower SIV uptake amongst immigrants
[15].
3.2.9. Social class/occupation
Five studies (SIV: n = 4, SIV and PV: n = 1) provided effect esti-
mates for the association of social class with vaccine uptake
(Fig. 4). There was no consistent effect seen for SIV uptake
(I2 = 80.2%), but the single study of PV uptake (from Spain)
reported higher uptake amongst individuals from the lowest social
class [28].
Between-study heterogeneity could not be explained after
restricting to studies with adequate adjustment for confounding
or stratifying by vaccine costs (Fig. 4), and this exposure could
not be consistently re-categorised as a binary variable across stud-
ies to further explore between-study heterogeneity.
3.2.10. Religion
The one study that provided effect estimates [32], found no
strong evidence for an association with SIV uptake (religious ver-
sus not religious: OR = 1.71 (95%CI:0.96–3.03)) Another study (no
effect estimates provided) [25] reported an association of SIV
uptake with place of residence that varied with individuals’ reli-
gion: amongst Jewish individuals higher uptake was noted in rural
areas compared to urban areas (p < 0.04) whilst the association
was reversed amongst Muslim individuals(with higher uptake in
urban (80%) compared to rural areas (76%) (Appendix-7).
3.3. Meta-regression
There were sufficient studies (n = 12) to further examine the
reasons for heterogeneity for the association of education with
SIV uptake [15,16,28,32–37,48–50].
Multivariable meta-regression analyses included vaccination
cost (free versus paid), confounding bias (low or high risk of bias)
and ‘over-adjustment’ (studies that included in multivariable anal-
yses variables hypothesized to be on the causal pathway between
education and vaccine uptake). There was strong evidence
(p < 0.0001) that the association of education with vaccine uptake
varied with vaccination costs: in studies from countries (Sweden
and Norway) where the population had to pay for vaccination,
the ORs were 1.93 times the ORs reported from countries where
vaccines were available free-of-charge for some (e.g. Ireland) or
all (e.g. Spain) of the population. There was some evidence
(p = 0.05) that between-study heterogeneity could be explained
by risk of confounding bias, but little evidence that it was
explained by ‘over-adjustment’ (p = 0.2). All education studies
reported ORs and investigated SIV vaccine uptake, and thus the
type of effect estimate and vaccines were not examined.
Each study categorised education differently making it infeasible
to examine this the meta-regression model. Analyses were
repeated after excluding the study reporting both SIV and zoster
uptake (n = 11), revealing similar results, but the effect
‘over-adjustment’ could not be investigated in the reduced model
due to collinearity.
4. Discussion
To our knowledge, this is first review to quantify systematically
the effect of a wide range of social factors on vaccine uptake
amongst older individuals in Europe. Not living alone, an important
social factor for this population group, was associated with higher
SIV (39%) and PV (71%) uptake. Marital status, which is likely to be
highly correlated with living alone, also showed lower uptake of
both SIV and PV amongst unmarried individuals in all except one
study. Other characteristics associated with lower vaccine uptake
included being an immigrant (43% and 33% lower uptake for SIV
and PV respectively), and lower area-level deprivation (7% lower
uptake for SIV), highlighting that vaccination inequalities continue
to exist despite availability of free vaccines. The direction of effect
for all these factors remained even after restricting the analyses to
studies with low risk of confounding bias.
No consistent direction of effect was observed for education.
However, restricting analyses to adequately adjusted studies
showed a small (5%) overall increase of SIV uptake with higher
education. The effect of income also initially appeared heteroge-
neous, but amongst adequately adjusted studies that measured
ORs (and excluding the single study in which vaccines were not
universally supplied free-of-charge), the effect of higher income
was consistent with that of higher education. These findings con-
cur with those from a study of individuals aged 50 years from
13 European countries, which reported lower utilisation of a range
of preventative services, including SIV uptake, amongst those with
lower income and education [51]. In contrast, there was no evi-
dence of an effect of income for the two studies measuring RRs.
This could in part be explained by ORs having more extreme values
than RRs when the outcome is common [52]. Stratification by vac-
cine costs revealed contrasting results for education and income:
unlike education, income-related inequalities persisted, with
higher uptake amongst those with higher income in countries
offering free-of-charge vaccination. Contrarily in Ireland (where
vaccination payment are means-tested) [40], both lower income
and lower education were associated with higher uptake.
Overall there was no consistent effect of social class on vaccine
uptake; between-study heterogeneity could have resulted from
differences in the definition used for this exposure, although data
were not available to explore this further. The role of urban resi-
dence with vaccine uptake was also variable; although summary
estimates for two SIV studies (measuring RRs) and for two PV stud-
ies (measuring ORs) indicated higher uptake in urban areas, most
of the SIV studies showed inconsistent direction of effects for
urban residence.
Some important determinants such as religion and access to pri-
vate medical insurance were not consistently included across stud-
ies from different countries. Given increasingly diverse populations
and differences in provision of healthcare across Europe, these
determinants could be important end-points for future studies.
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Living alone was identified as an important factor associated
with lower vaccine uptake in this review and may be an indicator
for social isolation [53]. Living alone has emerged as an important
determinant of health in older populations. For example, in a 2010
systematic review, lack of social relationships was associated with
a 50% increase in mortality, comparable to the increased risk
resulting from smoking or obesity [54]. Similarly, a 2015 meta-
analysis [53] found that living alone was associated with 32%
higher mortality (OR 1.32, 95%CI 1.14–1.53). In 2013, approxi-
mately 13% of households in the European Union comprised indi-
viduals aged 65 years living alone [55]. With an increasingly
ageing population, the numbers living alone are likely to rise,
increasing the importance of preventative measures such as vacci-
nations. Interestingly in our review, living with children or increas-
ing housing density in some studies was associated with lower SIV
uptake, suggesting that not living alone also may have different
effects on vaccine uptake depending upon household composition.
Our analysis is an important update (with nineteen additional
studies) of the previous 2011 systematic review by Nagata et al.,
which assessed only SIV uptake amongst older individuals [6].
Our review extends the scope to all vaccines given routinely to
older individuals, has provided the results of quantitative synthe-
ses, and has carried out extensive investigation of between-study
heterogeneity. Our review also included religion as a social factor,
incorporates studies prior to 2011 that were not presented in this
earlier review [6], and provides more detailed analyses of social
factors such as country of birth, individual components of socio-
economic position, marital status and living alone.
Our review has several strengths. A comprehensive search strat-
egy was utilised to identify pertinent social determinants of SIV
and other vaccine uptake amongst older populations. Stringent cri-
teria for quality assessment were followed. Meta-analyses to
obtain summary estimates, and detailed exploration of the causes
of between-study heterogeneity using a priori stratification criteria
and meta-regression, allowed insight into the complex relation-
ships between various social determinants and vaccine uptake in
different countries.
Our review also has some limitations. A number of the studies
included in the review had high risk of confounding bias, and
restricting analyses to studies presenting adequately adjusted
effect estimates led to a reduced number of studies in these anal-
yses. Our use of stratification revealed some causes of between-
study heterogeneity. Meta-regression analysis, to further explore
the causes for heterogeneity for factors other than education was
not feasible due to insufficient numbers of studies. The multivari-
able meta-regression analyses for the effect of education indicated
that both vaccine costs and confounding bias independently
explained some of the heterogeneity in results. In this review the
effect of social isolation or loneliness on vaccine uptake was not
examined; individuals living alone may have strong social net-
works. The relationship between social isolation and vaccine
uptake can perhaps be explored in future research. In addition,
we hypothesized correlations between some social factors based
on our conceptual framework, but it is possible that other complex
inter-relationships between these factors may exist. Finally, we
included only studies published in English language, which could
have excluded some relevant data.
5. Conclusion
This is the first systematic review that quantifies the association
of living alone, an important social factor for older individuals,
with lower vaccine uptake. This, along with quantification of other
factors such as immigration status, deprivation and education
level, will help to target older individuals for interventions to mit-
igate vaccination inequalities. This review has also highlighted the
limitations of existing studies in terms of study quality and
between-study heterogeneity. As the role of social factors becomes
increasingly recognised for equitable healthcare delivery, the find-
ings of this review should provide guidance to healthcare providers
for addressing vaccination inequality amongst older individuals.
Our review should also help researchers to design future studies
of higher quality with potentially more standardised definitions
of social factors.
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2.3 Supplementary material to the published paper 1 
Appendix 1 Search Strategy  
Database(s): Ovid MEDLINE(R) 1946 to February Week 3 2016 
# Searches 
1 exp Immunization Programs/ 
2 exp Vaccines/ 
3 exp Immunization/ 
4 1 or 2 or 3 
5 (IMMUNI#ATION* or VACCIN* or IMMUNIS* or IMMUNIZ* or UNDER-IMMUNIS* or UNDERIMMUNIS* or UNDER-
IMMUNIZ* or UNDERIMMUNIZ* or NON-IMMUNIS* or NONIMMUNIS* or NON-IMMUNIZ* or NONIMMUNIZ* or 
UNDER-VACCINAT* or UNDERVACCINAT* or NON-VACCINA* or NONVACCINA*).ti,ab. 
6 decision making/ or choice behavior/ or exp refusal to participate/ 
7 exp "Patient Acceptance of Health Care"/ 
8 6 or 7 
9 (ACCEPT* or AGREE* or BARRIER* or CHOOSE* or CHOSE or CHOICE* or COMPLIAN* or COVER* or 
DECISION* or DELAY* or DROPOUT* or DROP*-OUT* or HESITAN* or INCOMPLETE or INDECISION* or 
POSTPONE* or RECEIVE* or RECEIPT or REFUS* or RELUCTAN* or TIMELY or UPTAKE or UP-TO-DATE or 
UPTODATE or USAGE or UTILI#ATION or NON-COMPLIAN* or NONCOMPLIAN* or UNDER-UTILI#ATION or 
UNDERUTILI#ATION).ti,ab. 
10 4 and 8 
11 ((IMMUNI#ATION* or VACCIN* or IMMUNIS* or IMMUNIZ* or UNDER-IMMUNIS* or UNDERIMMUNIS* or UNDER-
IMMUNIZ* or UNDERIMMUNIZ* or NON-IMMUNIS* or NONIMMUNIS* or NON-IMMUNIZ* or NONIMMUNIZ* or 
UNDER-VACCINAT* or UNDERVACCINAT* or NON-VACCINA* or NONVACCINA*) adj10 (ACCEPT* or AGREE* or 
BARRIER* or CHOOSE* or CHOSE or CHOICE* or COMPLIAN* or COVER* or DECISION* or DELAY* or 
DROPOUT* or DROP*-OUT* or HESITAN* or INCOMPLETE or INDECISION* or POSTPONE* or RECEIVE* or 
RECEIPT or REFUS* or RELUCTAN* or TIMELY or UPTAKE or UP-TO-DATE or UPTODATE or USAGE or 
UTILI#ATION or NON-COMPLIAN* or NONCOMPLIAN* or UNDER-UTILI#ATION or UNDERUTILI#ATION)).ti,ab. 
12 10 or 11 
13 (AGEISM or (AGE adj3 DISCRIMINAT*)).ti,ab. 
14 DEMOGRAPH*.ti,ab. 
15 (EDUCAT* or LITERACY or LITERATE or ILLITERACY or ILLITERATE or LEARN*).ti,ab. 
16 (ETHNICITY or ETHNIC or TRADITION* or (TRAVELLER* adj3 COMMUNIT*) or COMMUNIT*).ti,ab. 
17 ((FAMILY adj3 SIZE) or (BIRTH adj3 (ORDER* or INTERVAL*)) or PARITY or (MATERNAL adj3 AGE*) or 
(MOTHER* adj3 AGE*) or MARITAL or MARRIAGE* or MARRIED).ti,ab. 
18 (INEQUALIT* or INEQUIT* or EQUIT* or EQUALIT* or DISCRIMINAT* or DISPARIT*).ti,ab. 
19 (OCCUPATION* or JOB* or EMPLOY* or UNEMPLOY* or PROFESSION*).ti,ab. 
20 (LIVING adj3 CONDITION*).ti,ab. 
21 (MIGRATION or IMMIGRANT* or RELOCAT* or SETTLER* or REFUGEE* or DISPLACE* or ASYLUM*).ti,ab. 
22 (MARGINALI* or MINORIT*).ti,ab. 
23 (RESOURCEPOOR or RESOURCE-POOR or POOR or POVERTY or IMPOVERISHED or INCOME or WAGE or 
WAGES or AFFLUEN* or WEALTH* or FEE or FEES or COST* or AFFORD* or INSURANCE or INSURED or 
((MEDICAL or PRESCRIPTION* or HOSPITAL or DOCTOR* or USER or CONSULT* or (VACCIN* adj3 
ADMINIST*)) adj3 (FEE or FEES or CHARGE* or COST* or EXPENSE* or FUND*))).ti,ab. 
24 (RACIAL or RACE).ti,ab. 
25 (RELIGION* or RELIGIOUS or FAITH or ANTHROPOSOPHY or BUDDHIS* or CHRISTIAN* or CATHOLIC* or 
PROTESTANT* or (JEHOVAH* adj WITNESS*) or MUSLIM* or ISLAM* or HINDU* or JEWS or JEW or 
JUDAISM).ti,ab. 
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26 (RURAL or VILLAGE*).ti,ab. 
27 (((GENDER or SEX*) adj3 (BIAS or DIFFEREN* or DISCRIMINAT*)) or SEXIS*).ti,ab. 
28 (SLUM* or HOMELESS*).ti,ab. 
29 (ANTI?VACCI* or ANTIVACCI* or ANTI-VACCI* or ANXIET* or ANXIOUS* or AWARE* or BEHAVIO?R or 
BEHAVIO?RAL or BELIEF* or BIAS* or CAUTIO* or CONCERN* or CONFIDEN* or CRITICIS* or DILEMMA* or 
DISBELIEF* or DISTRUST* or DOUBT* or EXPERIENCE* or FEAR* or KNOWLEDG* or LEARN* or 
MISUNDERSTAND* or MIS-UNDERSTAND* or MISCONCEPTION* or MIS-CONCEPTION* or MISTRUST* or MIS-
TRUST* or MORALITY or MOTIVAT* or OPPOSITION* or PEER or PERCEPTION* or PRECONCEPTION* or 
PREJUDICE* or RUMO?R or RUMO?RS or SCARE* or SCEPTIC* or SOCIAL* or TRUST or UNCERTAIN* or 
UNDERSTAND* or UNWILLING* or WILLING*).ti,ab. 
30 (((SOCIO-ECONOMIC or SOCIOECONOMIC) adj3 (FACTOR* or DETERMINANT* or DIFFERENCE*)) or (LIVING 
adj3 STANDARD*) or LIFESTYLE or LIFE-STYLE or SOCIO-DEMOGRAPH* or SOCIODEMOGRAPH* or 
DEPRIV*).ti,ab. 
31 ((AREA* adj3 RESIDEN*) or ((BUILD-UP or BUILDUP or BUILT-UP or BUILTUP) adj3 AREA*) or CITY or CITIES or 
INNERCIT* or INNER-CIT* or TOWN* or URBAN*).ti,ab. 
32 (DIS-ADVANTAGE* or DISADVANTAGE* or UNDER-PRIVILEGE* or UNDERPRIVILEGE* or VULNERAB*).ti,ab. 
33 ((HEALTH or HEALTH-CARE or HEALTHCARE) adj3 (ACCESS* or AVAILAB*)).ti,ab. 
34 ((HEALTH or HEALTH-CARE or HEALTHCARE or HEALTH-STATUS or HEALTHSTATUS) adj3 DISPARIT*).ti,ab. 
35 (CROSS-CULTUR* or CROSSCULTUR* or CULTURAL or ETHNOLOGY).ti,ab. 
36 or/13-35 
37 exp Sociology/ 
38 exp Social Behavior/ 
39 exp Vulnerable Populations/ 
40 exp cross-cultural comparison/ 
41 exp Cultural Characteristics/ 
42 exp cultural diversity/ 
43 exp Cultural Evolution/ 
44 exp Ethnology/ 
45 exp Religion/ 
46 exp Homeless Persons/ 
47 exp Health Services Accessibility/ 
48 exp Healthcare Disparities/ 
49 exp "Fees and Charges"/ 
50 exp Attitude to Health/ or exp Attitude to Death/ 
51 population characteristics/ or exp demography/ or exp "social determinants of health"/ or exp population/ or exp 
socioeconomic factors/ 
52 exp Population Groups/ 
53 education/ or exp health education/ 
54 exp Medically Uninsured/ 
55 exp cost of illness/ 
56 exp life style/ or exp morals/ 
57 exp Parity/ 
58 exp Maternal Age/ 
59 or/37-58 
60 36 or 59 
59 
 
61 exp Albania/ 
62 (Albania or Albanian or Albanians).ti,ab. 
63 exp Andorra/ 
64 (Andorra or Andorran or Andorrans).ti,ab. 
65 exp Armenia/ 
66 (Armenia or Armenian or Armenians).ti,ab. 
67 exp Austria/ 
68 (Austria or Austrian or Austrians).ti,ab. 
69 exp Azerbaijan/ 
70 Azerbaijan*.ti,ab. 
71 exp Belgium/ 
72 (Belgium or Belgian*).ti,ab. 
73 exp Bosnia-Herzegovina/ 
74 (Bosnia*-Her#egovin* or "Bosnia* AND Her#egovin*" or BOSNIA* or HER#EGOVIN*).ti,ab. 
75 exp Bulgaria/ 
76 (Bulgaria or Bulgarian or Bulgarians).ti,ab. 
77 exp Croatia/ 
78 (Croatia or Croatian or Croatians).ti,ab. 
79 exp Cyprus/ 
80 (Cyprus or Cypriot or Cypriots).ti,ab. 
81 exp Czechoslovakia/ 
82 exp Czech Republic/ 
83 (Czech Republic or Czechoslovakia or Czech or Czechs).ti,ab. 
84 exp Denmark/ 
85 (denmark or faeroe islands or Danish).ti,ab. 
86 exp Estonia/ 
87 (Estonia or Estonian or Estonians).ti,ab. 
88 exp Europe/ 
89 EUROPE*.ti,ab. 
90 exp Finland/ 
91 (Finland or Finnish).ti,ab. 
92 exp France/ 
93 (France or French).ti,ab. 
94 exp "Georgia (Republic)"/ 
95 ("REPUBLIC OF GEORGIA" or Georgian or Georgians).ti,ab. 
96 exp "Macedonia (Republic)"/ 
97 (Germany or German or Germans).ti,ab. 
98 exp "Republic of Belarus"/ 
99 ("republic of belarus" or belarus or byelarus or belorussia or Belarusian or Belarusians).ti,ab. 
100 exp Germany/ 
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101 (Germany or German or Germans).ti,ab. 
102 exp Great Britain/ 
103 (great britain or GBR or united kingdom or UK or northern ireland or scotland or channel islands or "isle of man" or 
British or Scottish or (wales not new south wales) or (england not new england)).ti,ab. 
104 exp Greece/ 
105 (Greece or Greek or Greeks).ti,ab. 
106 exp Hungary/ 
107 (Hungary or Hungarian or Hungarians).ti,ab. 
108 exp Iceland/ 
109 (Iceland or Icelandic).ti,ab. 
110 exp Ireland/ 
111 (eire or ireland or "republic of Ireland" or Irish).ti,ab. 
112 exp Israel/ 
113 (Israel or Israeli or Israelis).ti,ab. 
114 exp Italy/ 
115 (Italy or Italian or Italians).ti,ab. 
116 exp Kazakhstan/ 
117 (kazakh or kazakhs or kazakhstan or kazakhstani).ti,ab. 
118 exp Kyrgyzstan/ 
119 (kirgizstan or kyrgyz republic or kirghizia or kirghiz or kyrgyzstan or Kyrgyzstani).ti,ab. 
120 exp Latvia/ 
121 (Latvia or Latvian or Latvians).ti,ab. 
122 exp Liechtenstein/ 
123 (liechtenstein or leichtenstein).ti,ab. 
124 exp Lithuania/ 
125 (Lithuania or Lithuanian or Lithuanians).ti,ab. 
126 exp Luxembourg/ 
127 (luxembourg* or luxemburg* or luxemborg).ti,ab. 
128 exp Malta/ 
129 (Malta or Maltese).ti,ab. 
130 exp Moldova/ 
131 (Moldavia or "Moldavian s.s.r." or Moldova or "Moldavian ssr" or "Republic of Moldova" or Moldovan or 
Moldovans).ti,ab. 
132 exp Monaco/ 
133 (Monaco or Monegasque).ti,ab. 
134 exp Montenegro/ 
135 (Montenegro or Montenegrin or Montenegrins).ti,ab. 
136 exp Netherlands/ 
137 (netherlands or holland or Dutch).ti,ab. 
138 exp Norway/ 
139 (Norway or Norwegian or Norwegians).ti,ab. 
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140 exp Poland/ 
141 (Poland or (Polish adj3 (population or patient* or people))).ti,ab. 
142 exp Portugal/ 
143 (Portugal or Portuguese).ti,ab. 
144 exp Romania/ 
145 (Romania or Romanian or Romanians).ti,ab. 
146 exp Russia/ 
147 exp USSR/ 
148 (Russia or Russian Federation or Russian or Russians).ti,ab. 
149 exp San Marino/ 
150 (San Marino or Sammarinese).ti,ab. 
151 exp Scandinavia/ 
152 (Scandinavia or Scandinavian).ti,ab. 
153 exp Serbia/ 
154 (Serbia or Serbian or Serbians).ti,ab. 
155 exp Slovakia/ 
156 (slovakia or slovak republic or Slovakian or Slovakians or Slovak or Slovaks).ti,ab. 
157 exp Slovenia/ 
158 (Slovenia or Slovenian or Slovenians).ti,ab. 
159 exp Spain/ 
160 (spain or balearic islands or canary islands or Spanish).ti,ab. 
161 exp Sweden/ 
162 (Sweden or Swedish).ti,ab. 
163 exp Switzerland/ 
164 (Switzerland or Swiss).ti,ab. 
165 exp Tajikistan/ 
166 (tadjikistan or tadzhik or tadzhikistan or tajikistan).ti,ab. 
167 exp Turkey/ 
168 (turkey or Turkish).ti,ab. 
169 exp Turkmenistan/ 
170 (turkmen or turkmenistan or Turkmens).ti,ab. 
171 exp Ukraine/ 
172 (Ukraine or Ukrainian or Ukrainians).ti,ab. 
173 exp Uzbekistan/ 
174 (uzbekistan or uzbek or Uzbeks).ti,ab. 
175 exp Yugoslavia/ 
176 (Yugoslavia or Yugoslav or Yugoslavs or Yugoslavian or Yugoslavians).ti,ab. 
177 or/61-176 
178 12 and 60 and 177 
179 exp animals/ 
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180 exp humans/ 
181 179 not (179 and 180) 
182 exp case reports/ 
183 178 not 181 not 182 
184 limit 183 to english language 
185 exp Immunization Programs/ 
186 exp Vaccines/ 
187 exp Immunization/ 
188 185 or 186 or 187 
189 (IMMUNI#ATION* or VACCIN* or IMMUNIS* or IMMUNIZ* or UNDER-IMMUNIS* or UNDERIMMUNIS* or UNDER-
IMMUNIZ* or UNDERIMMUNIZ* or NON-IMMUNIS* or NONIMMUNIS* or NON-IMMUNIZ* or NONIMMUNIZ* or 
UNDER-VACCINAT* or UNDERVACCINAT* or NON-VACCINA* or NONVACCINA*).ti,ab. 
190 decision making/ or choice behavior/ or exp refusal to participate/ 
191 exp "Patient Acceptance of Health Care"/ 
192 190 or 191 
193 (ACCEPT* or AGREE* or BARRIER* or CHOOSE* or CHOSE or CHOICE* or COMPLIAN* or COVER* or 
DECISION* or DELAY* or DROPOUT* or DROP*-OUT* or HESITAN* or INCOMPLETE or INDECISION* or 
POSTPONE* or RECEIVE* or RECEIPT or REFUS* or RELUCTAN* or TIMELY or UPTAKE or UP-TO-DATE or 
UPTODATE or USAGE or UTILI#ATION or NON-COMPLIAN* or NONCOMPLIAN* or UNDER-UTILI#ATION or 
UNDERUTILI#ATION).ti,ab. 
194 188 and 192 
195 ((IMMUNI#ATION* or VACCIN* or IMMUNIS* or IMMUNIZ* or UNDER-IMMUNIS* or UNDERIMMUNIS* or UNDER-
IMMUNIZ* or UNDERIMMUNIZ* or NON-IMMUNIS* or NONIMMUNIS* or NON-IMMUNIZ* or NONIMMUNIZ* or 
UNDER-VACCINAT* or UNDERVACCINAT* or NON-VACCINA* or NONVACCINA*) adj10 (ACCEPT* or AGREE* or 
BARRIER* or CHOOSE* or CHOSE or CHOICE* or COMPLIAN* or COVER* or DECISION* or DELAY* or 
DROPOUT* or DROP*-OUT* or HESITAN* or INCOMPLETE or INDECISION* or POSTPONE* or RECEIVE* or 
RECEIPT or REFUS* or RELUCTAN* or TIMELY or UPTAKE or UP-TO-DATE or UPTODATE or USAGE or 
UTILI#ATION or NON-COMPLIAN* or NONCOMPLIAN* or UNDER-UTILI#ATION or UNDERUTILI#ATION)).ti,ab. 
196 194 or 195 
197 (AGEISM or (AGE adj3 DISCRIMINAT*)).ti,ab. 
198 DEMOGRAPH*.ti,ab. 
199 (EDUCAT* or LITERACY or LITERATE or ILLITERACY or ILLITERATE or LEARN*).ti,ab. 
200 (ETHNICITY or ETHNIC or TRADITION* or (TRAVELLER* adj3 COMMUNIT*) or COMMUNIT*).ti,ab. 
201 ((FAMILY adj3 SIZE) or (BIRTH adj3 (ORDER* or INTERVAL*)) or PARITY or (MATERNAL adj3 AGE*) or 
(MOTHER* adj3 AGE*) or MARITAL or MARRIAGE* or MARRIED).ti,ab. 
202 (INEQUALIT* or INEQUIT* or EQUIT* or EQUALIT* or DISCRIMINAT* or DISPARIT*).ti,ab. 
203 (OCCUPATION* or JOB* or EMPLOY* or UNEMPLOY* or PROFESSION*).ti,ab. 
204 (LIVING adj3 CONDITION*).ti,ab. 
205 (MIGRATION or IMMIGRANT* or RELOCAT* or SETTLER* or REFUGEE* or DISPLACE* or ASYLUM*).ti,ab. 
206 (MARGINALI* or MINORIT*).ti,ab. 
207 (RESOURCEPOOR or RESOURCE-POOR or POOR or POVERTY or IMPOVERISHED or INCOME or WAGE or 
WAGES or AFFLUEN* or WEALTH* or FEE or FEES or COST* or AFFORD* or INSURANCE or INSURED or 
((MEDICAL or PRESCRIPTION* or HOSPITAL or DOCTOR* or USER or CONSULT* or (VACCIN* adj3 
ADMINIST*)) adj3 (FEE or FEES or CHARGE* or COST* or EXPENSE* or FUND*))).ti,ab. 
208 (RACIAL or RACE).ti,ab. 
209 (RELIGION* or RELIGIOUS or FAITH or ANTHROPOSOPHY or BUDDHIS* or CHRISTIAN* or CATHOLIC* or 
PROTESTANT* or (JEHOVAH* adj WITNESS*) or MUSLIM* or ISLAM* or HINDU* or JEWS or JEW or 
JUDAISM).ti,ab. 
210 (RURAL or VILLAGE*).ti,ab. 
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211 (((GENDER or SEX*) adj3 (BIAS or DIFFEREN* or DISCRIMINAT*)) or SEXIS*).ti,ab. 
212 (SLUM* or HOMELESS*).ti,ab. 
213 (ANTI?VACCI* or ANTIVACCI* or ANTI-VACCI* or ANXIET* or ANXIOUS* or AWARE* or BEHAVIO?R or 
BEHAVIO?RAL or BELIEF* or BIAS* or CAUTIO* or CONCERN* or CONFIDEN* or CRITICIS* or DILEMMA* or 
DISBELIEF* or DISTRUST* or DOUBT* or EXPERIENCE* or FEAR* or KNOWLEDG* or LEARN* or 
MISUNDERSTAND* or MIS-UNDERSTAND* or MISCONCEPTION* or MIS-CONCEPTION* or MISTRUST* or MIS-
TRUST* or MORALITY or MOTIVAT* or OPPOSITION* or PEER or PERCEPTION* or PRECONCEPTION* or 
PREJUDICE* or RUMO?R or RUMO?RS or SCARE* or SCEPTIC* or SOCIAL* or TRUST or UNCERTAIN* or 
UNDERSTAND* or UNWILLING* or WILLING*).ti,ab. 
214 (((SOCIO-ECONOMIC or SOCIOECONOMIC) adj3 (FACTOR* or DETERMINANT* or DIFFERENCE*)) or (LIVING 
adj3 STANDARD*) or LIFESTYLE or LIFE-STYLE or SOCIO-DEMOGRAPH* or SOCIODEMOGRAPH* or 
DEPRIV*).ti,ab. 
215 ((AREA* adj3 RESIDEN*) or ((BUILD-UP or BUILDUP or BUILT-UP or BUILTUP) adj3 AREA*) or CITY or CITIES or 
INNERCIT* or INNER-CIT* or TOWN* or URBAN*).ti,ab. 
216 (DIS-ADVANTAGE* or DISADVANTAGE* or UNDER-PRIVILEGE* or UNDERPRIVILEGE* or VULNERAB*).ti,ab. 
217 ((HEALTH or HEALTH-CARE or HEALTHCARE) adj3 (ACCESS* or AVAILAB*)).ti,ab. 
218 ((HEALTH or HEALTH-CARE or HEALTHCARE or HEALTH-STATUS or HEALTHSTATUS) adj3 DISPARIT*).ti,ab. 
219 (CROSS-CULTUR* or CROSSCULTUR* or CULTURAL or ETHNOLOGY).ti,ab. 
220 or/197-219 
221 exp Sociology/ 
222 exp Social Behavior/ 
223 exp Vulnerable Populations/ 
224 exp cross-cultural comparison/ 
225 exp Cultural Characteristics/ 
226 exp cultural diversity/ 
227 exp Cultural Evolution/ 
228 exp Ethnology/ 
229 exp Religion/ 
230 exp Homeless Persons/ 
231 exp Health Services Accessibility/ 
232 exp Healthcare Disparities/ 
233 exp "Fees and Charges"/ 
234 exp Attitude to Health/ or exp Attitude to Death/ 
235 population characteristics/ or exp demography/ or exp "social determinants of health"/ or exp population/ or exp 
socioeconomic factors/ 
236 exp Population Groups/ 
237 education/ or exp health education/ 
238 exp Medically Uninsured/ 
239 exp cost of illness/ 
240 exp life style/ or exp morals/ 
241 exp Parity/ 
242 exp Maternal Age/ 
243 or/221-242 
244 220 or 243 
245 review.pt. 
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246 196 and 244 and 245 
247 exp animals/ 
248 exp human/ 
249 247 not (247 and 248) 
250 246 not 249 
251 limit 250 to english language 
252 limit 251 to last 5 years 
253 252 not 184 
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Appendix 2 Conceptual framework for the systematic review.  
The data for main factors were extracted (Red arrows show variables hypothesized as highly 
correlated) 
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Appendix 3 Study selection criteria 
 Inclusion criteria 
Population Individuals from Europe aged ≥60 years from either 
community and/or hospital settings 
Intervention/ exposure Social factors of interest were: country of birth, religion, 
urban/rural residence, marital status, living arrangements 
(living with others versus living alone), education, income 
(individual or household), type of health insurance, area-level 
socio-economic status and social class/occupation 
Comparison Unvaccinated individuals 
Outcome Vaccine uptake (initiation or completion for routine vaccination 
and vaccination in pandemics, mass vaccinations, catch-up 
vaccinations) 
Study design Observational analytical studies including cross-sectional, 
ecological, case-control or cohort studies that measured 
exposure and outcome of interest in the study population and 
used statistical analyses. Letters and conference abstracts 
reporting quantitative data were included 
Publications Published on any date, language: English 
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Appendix 4 Details of bias assessment 
In the selection bias assessment, response or follow-up rate (depending on the study design) 
had to be ≥70% to be classified a low risk of bias. If >30% data were missing, the study was 
considered to be at high risk of missing data bias. Vaccination status ascertained using 
records were considered at low risk of bias. For the purposes of this review self-reported 
vaccination was considered at low risk of bias.[67-69]  
Variables that do not change over time, such as country of birth, religion, and (for this older 
study population) education and occupation were considered unlikely to be misreported by 
participants. However, the time-varying factors (such as marital status, living alone, place of 
residence, area-level SES, income and insurance) ascertained more than five years before 
the outcome were considered at high risk of bias for exposure misclassification. 
For adequate adjustment for confounding all effect estimates needed to be adjusted for 
gender and at least one other main social factor (Appendix-2) to which the exposure of 
interest was not deemed to be strongly correlated. For example, effect estimates for the 
association between marital status and vaccine uptake were considered at high risk of 
confounding bias if they were only adjusted living arrangements (living alone/with others) 
and gender, as the former was likely to be strongly correlated with marital status. 
References: 
[67] Skull SA, Andrews RM, Byrnes GB, Kelly HA, Nolan TM, Brown GV, et al. Validity of 
self-reported influenza and pneumococcal vaccination status among a cohort of hospitalized 
elderly inpatients. Vaccine. 2007;25:4775-83. 
[68] Rolnick SJ, Parker ED, Nordin JD, Hedblom BD, Wei F, Kerby T, et al. Self-report 
compared to electronic medical record across eight adult vaccines: Do results vary by 
demographic factors? Vaccine. 2013;31:3928-35. 
[69] Williams WW. Surveillance of Vaccination Coverage Among Adult Populations—United 
States, 2014. MMWR Surveillance Summaries. 2016;65(No.SS-1):1-36. 
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Appendix 5 Flow chart of studies included and excluded in the review 
 
 
 
SIV seasonal influenza vaccine 
 
 
Appendix 6 Summary of the studies included in the review 
First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Cross-sectional studies   
Abramson[32] 
2000  
COB 
Education 
Relationship status 
Religion 
SIV  COB (2)  Gender, country of birth, marital status, education, religiosity, 
chronic disease, exercise, physician visit in 3 months, knowledge 
and attitude questions 
Asia (excluding Israel)/ Africa  
 
1 (AOR) 
Others  1.61 (0.83-3.10)e 
Education (2)  
0-8 years 1 (AOR) 
9+ years 1.04 (0.98-1.10) 
Relationship status (2) 
 
 
Unmarried 0.47 (0.28-0.78)*(AOR) 
Married 1 
Religion (2)  
Religious 1 (AOR) 
Not religious 1.71 (0.96-3.03) 
Aguilar[56] 2012 COB 
Location: residence 
SIV  COB(2) 
 
 Age, gender, major chronic conditions, outpatient visits in the 
previous year, country of birth, area of residence, level of 
dependence, Hospitalisation in the previous year 
Native  
 
1 (AOR) 
Immigrants 
 
0.40 (0.36–0.45) 
Location: residence (2)  
Urban (>10,000 people) 1.00 (0.98–1.03) (AOR) 
Rural (any other) 1 
Barrett & Mc 
Hugh[33, 47] 
2011 & 2015 
Education 
Health insurance 
Income/ wealth 
 
SIV Education (3)  Unadjusted 
Complete primary education and  only primary education ‘primary/ none’ 1 (Raw data) 
Completed a junior certificate, or leaving certificate or 
equivalent ‘secondary’ 
0.84 (0.71-1.00) 
Completed a diploma, first degree or higher degree ‘tertiary or higher’ 0.80 (0.66-0.97) 
Health insurance (4)  
No additional cover (no medical card or private insurance) 1 (Raw data) 
Medical Card only 4.41 (3.07-6.33) 
Dual cover (medical card and private insurance) 4.63 (3.20-6.70) 
Private Health Insurance only  1.72 (1.19-2.48) 
Income/ wealth (4) 
 
 
Low 1 (Raw data) 
2nd quartile 0.73 (0.53-1.00) 
3rd quartile 0.72 (0.53-1.00) 
Highest 0.46 (0.34-0.63) 
Bodekar[15] 2015 Education SIV Education (3)  Unadjusted 
Low (9 years or less of school education) 1 (UOR) 
Middle (at least 10 years of school education) 0.71 (0.47–1.08) 
High (University entrance exam) 0.72 (0.49–1.06) 
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First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Bohmer[37]    
2011 
Education 
Income/ wealth 
 
SIV Education (3)  Unadjusted 
Low (ISCED level 1&2) 1 (UOR) 
Medium (ISCED level 3&4) 0.96 (0.86–1.07) 
High (ISCED level 5&6) 0.88 (0.77–1.02) 
Income/ wealth  Age, sex, residence (Western Federal States & Eastern Federal 
States), household income and belonging to target groups, 
education 
Low (<70% of the median of the study sample) 1 (AOR) 
Medium (70-120% of the median of the study) sample 1.30 (1.10–1.53) 
High (>120% of the median of the study sample) 1.19 (1.00–1.41) 
Burns[57]  2005 Living arrangement  
Social class 
 
SIV Living arrangement (2)  Age, sex, living arrangements, household occupation status, 
transport to GP, chronic disease, smoking, alcohol consumption, 
seen national advertising campaign and explanation by GP 
regarding usefulness of vaccine and its side effects. 
Living with others 2.25 (1.35–3.73) (AOR) 
Living alone 1 
Social class (2)  
Professional (National statistics social economic classifications system 
NSSECS I & II) 
1* (AOR) 
Non-professional (National Statistics Social Economic Classifications System 
NSSECS III -V) 
0.68 (0.51-0.92) 
Carreno-Ibanez 
[58] 2015 
 
COB PV COB(2) 
 
 Unadjusted 
Native  
 
1 (UOR) 
Immigrants  0.60 (0.52-0.68)*~ 
 
Chiatti[26, 48, 59]  
2010 & 2011 Education 
Income/ wealth 
Living arrangement 
Relationship status 
Social class 
SIV Education (4)  Gender, age group, family social class, education, chronic diseases, 
self-reported health, GP visit in last 30 days No title 1 (AOR) 
Primary school degree 1.01 (0.94–1.10) 
Intermediate degree 0.96 (0.87–1.06) 
High school, bachelor or higher 1.11 (0.99–1.25) 
Income/ wealth (4)  Gender, education, self-reported wealth, smoking status, marital 
status, GP visits in last 30 days, other chronic diseases, self-rated 
health status 
Low 1 (AOR) 
Medium-low 1.37 (0.79–2.36) 
Medium-high 1.28 (0.93–1.78) 
High 1.09 (0.79–1.52) 
Living arrangements (4)  Gender, age, education level (ordinal), self-reported household 
wealth (ordinal), marital status, informal and formal help, household 
size, smoking &  respondent type 
Single person 1 (AOR)γ 
Couple 1.07(0.98-1.17) 
 3-5 persons 0.84(0.76-0.92) 
 More than 6 persons 0.84(0.67-1.05) 
 Relationship status (2)  
Married 1 
Not married 0.82 (0.76 - 0.89) (AOR) γ 
Social class (4)  Gender, age group, family social class, education, chronic diseases, 
self-reported health, GP visit in last 30 days 
Skilled and unskilled working 
class 
1.21 (1.11–1.33) 
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First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Self-employed persons 1.18 (1.07–1.31) 
White collar and small employers 1.01 (0.92–1.12) 
Managers, professionals and entrepreneurs. 1 
Christenson[34] 
2002 
Education 
Relationship status 
 
SIV & PV SIV  Unadjusted 
Education (4)  
Elementary school 1 (Raw data) 
Junior secondary school 1.37 (1.20-1.56) 
Upper secondary school 1.44 (1.23-1.67) 
University/college 1.67 (1.45-1.92) 
Relationship status (2)  
Married/living with partner 1 (Raw data) 
Widowed/living alone 0.76 (0.69-0.84) 
PV  
Education (4)  
Elementary school 1 (Raw Data) 
Junior secondary school 1.32 (1.17-1.50) 
Upper secondary school 1.38 (1.19-1.59) 
University/college 1.44 (1.26-1.63) 
Relationship status (2)  
Married/living with partner 1 (Raw data) 
Widowed/living alone 0.73 (0.66-0.80) 
Crawford[12] 
2011 
Living arrangements 
Relationship status 
Location: residence 
Social class 
 
SIV Living arrangements (2)  Adjusted for gender, age, marital status, living status, social class, 
home location, geographical location Lives with others 1.14 (0.83-1.67)* (AOR) 
Lives alone 1 
Location: residence (2)  
Urban 1.15 (0.91-1.43)* (AOR) 
Rural 1 
Relationship status (3) 
 
 
Married 1 (AOR) 
Single 1.3 (0.8–2.1) 
Widowed 1.5 (1.1–2.3) 
Social class (2)  
Higher 1 (AOR) 
Lower 0.95 (0.7–1.2) 
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First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Damiani[35]  
2007 
Education  
Income/ wealth 
Relationship status 
Social class 
 
SIV Education (4)  Age, gender, education, region of residence, self-assessed health 
status, chronic medical conditions, occupation class, smoking, 
marital status, self-assessed household income 
University degree  1.05 (0.87-1.28)* AOR 
Upper secondary education - 
Lower secondary education  - 
Without any qualification 1 
Income/ wealth (2)  
Very good/good  1.12 (1.06-1.19)*(AOR) 
Poor/Very poor 1 
Relationship status (4)  
Married 1 (AOR) 
Divorced/separated 1.12 (0.92–1.36) 
Widowed  0.83 (0.77–0.88) 
Single 0.82 (0.74–0.91) 
Social class (5)  
Middle class  1 (AOR) 
Medium employer class  1.08 (0.93–1.24) 
Upper worker class  1.02 (0.89–1.17) 
Worker class 1.03 (0.90–1.18) 
Unemployed class 0.94 (0.81–1.08) 
de Souto[42]  
2014 
Nursing home location SIV & PV SIV  Ownership, location, physicians/100 beds, physician training, living 
in special care, prescription re-examination, individual healthcare 
project, informatics system, age, sex, length of stay in the nursing 
home, disability in activities of daily living, number of medications, 
body mass index, number of diseases, diabetes, chronic pulmonary 
disease, heart failure, myocardial infarction, peripheral vascular 
disease, moderate–severe renal failure, dementia, hospitalisation in 
the last 12 months, disorientation regarding space and time (defined 
by a physician), pressure ulcers, and psychiatric diseases (other 
than depression). 
Location: nursing home (4)  
Rural (<2000 inhabitants) 1 (AOR) 
Low-urban  (inhabitants  ≥2000 - <10,000) 1.09 (0.67–1.78) 
Intermediate-urban (inhabitants ≥10,000- <100,000) 0.90 (0.54–1.50) 
High-urban (inhabitants ≥ 100,000) 0.93 (0.51–1.71) 
PV  
Location: nursing home (4)  
Rural (<2000 inhabitants) 1 
Low-urban  (inhabitants  ≥2000 - <10,000) 2.35 (1.00–5.50) 
Intermediate-urban (inhabitants ≥10,000- <100,000) 0.56 (0.23–1.40) 
High-urban (inhabitants ≥ 100,000) 0.10 (0.03–0.31) 
Jimenez-
Garcia[60] 2006 
COB SIV  COB(2)  Age, gender, nationality and chronic conditions 
Native  
 
1 (AOR) 
Immigrants  0.85 (0.35-2.06) 
Jimenez-
Garcia[61] 2008  
COB SIV  COB(2) 
 
 Age, gender, nationality and chronic conditions 
Native  
 
1 (AOR) 
Immigrants  0.34 (0.19-0.59) 
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First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Jimenez-
Garcia[62] 2008  
COB SIV  COB(2) 
 
 Gender, age, health care worker (yes/no), nationality and co-
morbidity  
Native  
 
1 (AOR) 
Economic immigrant (excluding people from EU, Canada and USA)  0.96 (0.43-2.04)* 
Jimenez-
Garcia[63] 2014  
COB SIV  COB(2) 
 
 Age, sex, presence of chronic disease, health care worker (yes/no) 
and nationality 
Native  
 
1 (AOR) 
Immigrants  0.60 (0.32-0.99) 
Jimenez-
Garcia[64] 2014 
COB SIV  COB(2) 
 
 Age, sex, country of origin, number of previous flu vaccinations 
received, uptake of 2009 pandemic vaccine  and presence of 
chronic condition 
Native  
 
1 (AOR) 
Immigrants  0.60 (0.57-0.62)* 
Kroneman[29]  
2007 
Living arrangements  Living arrangements (2)e  Household size, gender, age, health professional opinion, health 
care system characteristics  Household size: larger 1.38 (1-1.90) e (AOR) 
Household size: smaller 1 
Landi[13] 2005 Income/ wealth 
Living arrangements 
SIV Income/ wealth (2)  Age, gender, living arrangements, economic status, compromised 
activities of daily living function, depression, impaired cognitive 
performance, malnutrition, comorbidities   
Has economic problems 1 
No economic problems 1.72 (1.35-2.22)*(AOR) 
Living arrangements (2)  
Living alone 1 (AOR) 
Lives with informal caregiver 
 
1.28 (1.11-1.49)* 
Mamelund[36] 
2011 
Income/ wealth 
Education 
Living arrangements 
SIV Education (4)  Unadjusted 
18+years 1.63 (0.85-3.10) (Raw data) 
17years 1.70 (0.87-3.30) 
13years 1.43 (0.79-2.57) 
10years 1 
Income/ wealth (1000 Norwegian Krone) (4)  
600+  0.84 (0.33-2.11) (Raw data) 
400–599 1.06 (0.47-2.36) 
200–399 1.04 (0.48-2.25) 
0–199 1 
Living arrangements (2)  
2 person household  1.21 (0.79-1.86 (Raw data) 
One person household 1 
Nexoe[65]  1999 Living arrangements SIV Living arrangements (2)  Adjusted for age, perceived barriers to vaccine, perceived benefits, 
perceived severity, living in a nursing home or sheltered housing, 
living together with another person, advised by GP, vaccinated in 
previous influenza seasons, living in Copenhagen. 
 
 
 
 
 
 
 
 
 
Living with someone 1.59 (1.03-2.48) (AOR) 
Not living with someone 1 
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First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
 
Opstelten [45] 
2001 
Health insurance SIV and PV SIV & PV  Age, insurance, factors for perceived health, barriers, severity and  
Health insurance (2)    
Private insurance 0.38 (0.21-0.67)α 
No private insurance 1 
Opstelten [49] 
2009 
Education HZ & SIV HZ & SIV  Education, diabetes, factors for perceived  barriers, severity, 
doctor’s recommendation and compliance with recommendation  Education (2)  
High education (not defined) 0.63 (0.40-0.91)α (AOR) 
Low education (not defined) 1 
Pena-Rey[50]  
2004 
Income/ wealth 
Education 
Relationship status 
Location: residence 
SIV Education (2)  Unadjusted 
<Primary 1 (Raw data) 
≥Primary 1.02 (0.79-1.32) 
Income/ wealth (2)  Age, income, size of place of residence, marital status, health self-
perception, visit with a physician last 2 years, tetanus vaccination, 
caregiver (of children ,old people or sick people) 
≤ €6010 1 (AOR) 
> €6010 1.39 (1.01–1.90) 
Location: residence (3)  
Urban: >20,000 people 0.81 (0.58-1.11)* (AOR) 
Intermediate: 5000-20,000 people - 
Rural: <5000 people 1 
Relationship status (2)  
Not married 0.69 (0.50-0.95)*(AOR) 
Married 1 
Sarria-
Santamera[16]  
2003 
Education 
Income/ wealth 
 
 
SIV Education(2)  Unadjusted 
Finished education ≤ 15 years old  1 (Raw data) 
Finished education>15 years old 0.83 (0.59-1.16) 
Income/ wealth (3)  
<€360.6 1 (Raw data) 
€360.6-601 1.21 (0.89-1.64) 
>€601 1.25 (0.90-1.73) 
Schmitz[14]  
2011 
Education 
Living arrangement 
Relationship status 
 
SIV  Linear regression coefficientβ 
(standard error) 
Age, chronic disease, self-assessed health, has partner, number of 
children in household, sex, education, current cognitive abilities 
(verbal fluency and recall), health behaviour (measured using 
alcohol intake, smoking, visit to dentist, eye exam, physical activity) 
and physician quality index  
Education  
Education International Standard Classification of Education level between 0-2 - 0.034 (0.012) (Adjusted) 
Living arrangements  
Number of children in household -0.024 (0.013) (Adjusted) 
Relationship status   
Spouse in household 0.047 (0.011) (Adjusted) 
74
 
 
First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Shahrabani[31] 
2006 
COB 
Education 
Living arrangement 
Relationship status 
SIV  Probit marginal probabilities e Gender, chronic illness, hospitalisation, smoking, health 
management organisation, housing density, marital status, country 
of birth, education, Kibbutz membership COB(7)e   
Israeli-born Jews 1 (Adjusted) 
Asia-Africa 60-64 years: 0.019 
75+years : -0.169 
 
Europe-America 60-64 years: 0.055 
75+ years: -0.108 
USSR (before 1990) 60-64 years: -0.011 
75+ years: -0.226 
USSR (after 1990) 60-64 years: -0.195 
75+ years: -0.436 
Other (after 1990) 60-64 years: -0.117 
75+ years: -0.111 
Arabs 60-64 years: -0.035 
75+ years: -0.116 
Education (3)  
Years of schooling 0–8 1 (Adjusted) 
Years of schooling 9–12 60-64 years: -0.003 
75+ years: 0.084 
Years of schooling 13+ 60-64 years: -0.001 
75+years: 0.030 
Living arrangements  
Housing density (number of persons/ room ≤1.0-1.5+) 60-64 years:  -0.064 (Adjusted) 
75+ years: -0.046 
Relationship status (3)  
Married 60-64 years: 0.108 (Adjusted) 
75+ years: 0.130 
Not married 1 
Sintes[28]   
2011 
Social class 
Education 
Living arrangement 
Location: residence 
SIV & PV SIV  Unadjusted 
Education (2)  
Primary or less 1 (UOR) 
Secondary or more 0.87 (0.68–1.12) 
Living arrangements (4)  Age, sex, risk of pneumonia, type of household, number of 
physician visits last year 
Alone 1 (AOR) 
Partner (without children) 1.51 (1.09–2.13) 
Children 1.22 (0.87–1.72) 
Others 0.93 (0.56–1.56) 
Location: residence (2)  Unadjusted 
Rural (<10 000 inhabitants) 1 (UOR) 
Urban 1.08 (0.81–1.45) 
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First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Social class (2)  Unadjusted 
According to the last job as unqualified or manual workers (classes iva, ivb, V) 
 
1.01 (0.77–1.35) (UOR) 
Others (classes I–III) 1 
PV   
Education (2)  Unadjusted 
Primary or less 1 (UOR) 
Secondary or more 0.69 (0.55–0.89) 
Living arrangements (4)  Age, sex, risk of pneumonia, social class, education, type of 
household, number of physician visits last year, influenza 
vaccination in last season 
Alone 1 (AOR) 
Partner (without children) 1.71 (1.20–2.46) 
Children 1.30 (0.91–1.88) 
Others 1.08 (0.62–1.91) 
Location: residence (2)  Unadjusted 
Rural (<10 000 inhabitants) 1 (UOR) 
Urban 1.03 (0.78–1.38) 
Social class  Unadjusted 
According to the last job as unqualified or manual workers (classes IVa, IVb, V) 
 
1.40 (1.07–1.84)  (UOR) 
Others (classes I–III) 1 
Wershof 
Schwartz[43]  
2013 
Area SES 
COB 
Location: residence 
SIV & PV SIV  Age, gender, rural residency, socio-economic status, region of 
origin, years since immigration, Holocaust survivorship, number of 
chronic medical conditions, number of primary care visits in the past 
5 years,  primary physician's region of origin and gender 
Area SES (4)  
Low 0.72 (0.68–0.77) (AOR) 
Low–mid 0.74 (0.71–0.77) 
Mid-high 0.82 (0.79–0.85) 
High 1 
 COB(4) 
 
 
Israel 1 (AOR) 
Former soviet union 0.74 (0.71–0.77) 
Western 1.13 (1.05–1.22) 
Middle east 1.13 (1.07–1.19) 
Location: residence (2)  
Rural 1* (AOR) 
Urban 1.14 (1.11-1.18) 
PV  
Area SES  
Low 0.79 (0.74–0.84) (AOR) 
Low–mid 0.79 (0.76–0.83) 
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First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Mid-high 0.84 (0.81–0.87) 
High 1 
 COB(4) 
 
 
Israel 1 (AOR) 
Former soviet union 0.73 (0.70–0.77) 
Western 0.91 (0.84–0.98) 
Middle east 1.21 (1.15–1.28) 
Location: residence (2)  
Rural 1* (AOR) 
Urban 1.15 (1.11-1.19) 
Case control study   
van Essen[46] 
1997 
Health insurance 
Living arrangement 
 
SIV Health insurance (2)  Adjusted for gender, age groups, insurance, family characteristics, 
perceived health, perceived threat of influenza, perceived benefits 
and costs 
Social  1 
Private 0.91 ( 0.21 to 5)α 
Living arrangement (2)  
Not living alone 1.79 (0.40-9.09)* α (AOR) 
Living alone 1 
Cohort studies 
 
 
    
Breeze[41] 2004 Area SES 
Income/ wealth 
Location: residence 
SIV  Risk ratios (95%CI) Adjusted for year, gender, current age, Carstairs deprivation score, 
Individual socioeconomic position and population density Area SES (5)  
Carstairs’ deprivation index  
Least deprived 
 
1 (ARR) 
Second quintile 1.05 (0.97-1.13)  
Mid quintile 1.03 (0.94-1.13) 
Fourth quintile 0.99 (0.83-1.18)  
Most deprived 0.85 (0.70-1.05) 
Income/ wealth (3)  
Owner occupier with central heating 0.97 (0.90-1.04)* (ARR) 
Owner-occupier without central heating, renter with central heating, renter 
without central heating 
- 
Supported housing 1 
Location: residence  
Urban density indicator <250 persons/km2 1 (ARR) 
Urban density indicator 250–1000 persons/km2 0.99 (0.83-1.17) 
Urban density indicator 1000–2500 persons/km2 1.10 (0.94-1.30) 
Urban density indicator urban (>2500 persons/km2) 1.14 (0.95-1.36)  
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First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Mangtani[27] 
2005  
Area SES 
Income/ wealth 
Living arrangement 
Location: residence  
Relationship status 
 
SIV  Risk ratios (95% CI)  
Area SES (5)  Age, gender, practice factors, personal socio-economic position, 
area SES, location: residence Carstairs’ deprivation index 
 Least deprived 1 δ (ARR) 
Second quintile 0.97 (0.91-1.03) 
Mid quintile 0.92 (0.86-0.99) 
Fourth quintile 1.02 (0.94-1.11) 
Most deprived 0.91 (0.79- 1.04)  
Income/ wealth (5)  Age, gender, practice factors, personal socio-economic position, 
area SES, location: residence 
Owner occupied with central heating 0.97 (0.90-1.04)*δ (ARR) 
Owner-occupier without central heating - 
Renter with central heating - 
Renter without central heating - 
Supported housing 1 
Living arrangements (5)  Unadjusted 
Alone 1 (Raw data) 
With spouse only 1.70 (1.51-1.90) 
With spouse and others 1.61 (1.18-2.20) 
With son/daughter 1.06 (0.84-1.34) 
With other 1.22 (0.95-1.56) 
Location: residence (4)  Age, gender, practice factors, personal socio-economic position, 
area SES, location: residence 
Rural <250 persons/km2 1 δ (ARR) 
250–1000 persons/km2 0.94 (0.85-1.03) 
1000–2500 persons/km2 0.95 (0.86-1.04) 
Urban (>2500 persons/km2) 1.10 (1.01-1.21) 
Relationship status (3)  Unadjusted 
Married/ cohabiting 1 (Raw data) 
Widowed/divorced/separated 0.61 (0.55-0.68) 
Single 0.54 (0.44-0.67) 
Martinez-Baz[30] 
2012 
COB 
Living arrangement 
Location: residence 
SIV  COB (2)  Age groups, gender, residence, country of origin, outpatient visits in 
the previous 12 months, major chronic conditions, diagnosis of any 
major chronic condition in the previous 12 months, hospitalization in 
the previous 12 months, high level of dependence, living with 
children <15 years 
Native 1 
Immigrant 0.55 (0.45–0.67) (AOR) 
Living arrangements (2)  
Not living with children aged <15 years 1 
Living with children aged <15 years 0.85 (0.77–0.94) (AOR) 
Location: residence (2)  
Rural 1 
Urban 0.99 (0.94–1.04) 
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First Author 
publication date 
SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used for the SD) 
Effect estimates of vaccine uptake 
(estimates are odds ratios (95% 
confidence interval) unless 
specified 
Effect estimates adjusted for the following confounders 
Sammon[44] 
2012 
Area SES 
 
SIV & PIV  Rate ratios (95% CI) Sex, patient SES quintile, body mass index, alcohol consumption, 
smoking status, history of Guillain Barré syndrome, total number of 
underlying health conditions (1,2,>2), practice region 
SIV  
Area SES (5)  
Townsend score or the area indices of multiple deprivation  
Least deprived 
 
1.05 (1.02-1.08) (ARR) 
Second quintile 1.03 (1.00-1.07)  
Mid quintile 1 
Fourth quintile 0.97 (0.94-1.00)  
Most deprived 0.97 (0.94-1.00)  
Unknown 0.88 (0.81-0.95)  
PIV  
Area SES (5)  
Townsend score or the area indices of multiple deprivation  
Least deprived 1.04 (0.98-1.10) (ARR) 
Second quintile 1.05 (1.00-1.09)  
Mid quintile 1 
Fourth quintile 0.92 (0.88-0.97)  
Most deprived 0.86 (0.79-0.93)  
Unknown 0.85 (0.75-0.96) 
Shah[66]  2012 
 
Area SES SIV Area SES (5) Risk ratios (95% CI) Age and sex 
Index of Multiple Deprivation (IMD) 2007  
Least deprived 1 (ARR)ϵ 
Second quintile 0.99 (0.98–0.99) 
Mid quintile 0.97 (0.96–0.97) 
Fourth quintile 0.95 (0.94–0.96) 
Most deprived 0.93 (0.92–0.94) 
SD social determinants SIV seasonal influenza vaccine COB country of birth PV pneumococcal vaccine HZ herpes zoster SES socio-economic status CI confidence interval PIV pandemic influenza vaccine AOR adjusted odds ratio UOR unadjusted 
odds ratio ISCED International Standard Classification of Education ARR adjusted risk/rate ratios e not in meta-analysis *baseline changed ~ effect estimates for males used for meta-analysis as sample size bigger α OR for refusing vaccination 
were reversed to get estimates for acceptance β Estimates from weighting scheme C  γ effect estimates from model 2  δ effect estimates from model 3 ϵ effect estimates from model 2 
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Appendix 7 Summary of studies not providing effect estimates 
First author Country  Vaccine/s Study period Sample size Study population Vaccine uptake measures 
 
All were cross-sectional studies 
 
     
Bedford[17] Ireland Seasonal flu and 
pneumococcal 
vaccine  
Sept. 1998- 
Jan. 1999 
450 Records of patients aged ≥65 years from two 
rural general practices, with a medical 
condition that predisposes to pneumococcal 
disease were invited for both vaccines 
Medical card holders in one practice were more likely than non-holders in the same practice 
to have accepted either vaccine (p>0.001). 
de Andres[18] Spain Seasonal influenza 2003 6134 Data for people aged ≥65 years drawn from 
the 2003 Spanish Health Survey 
No evidence of difference in vaccination coverage reported based on education, monthly 
household income and relationship status.  
de Lataillade[19] Data for Turkey 
extracted 
(Multinational 
study) 
Seasonal influenza Feb.2006-
March 2006 
Not reported for 
participants aged 
≥65  
 Respondents (aged ≥65 years) to a 
population survey of non-institutionalized 
people from an urban area 
Lower income was associated with higher coverage for Turkish elderly respondents 
Gosney[20] UK Seasonal influenza Jan.-
Feb.1998 
649 All inpatients (aged 75-79 years) interview 
respondents from eight hospitals in 
Merseyside (Care of the Elderly wards)   
 No difference in living arrangements when comparing the vaccinated to the non-vaccinated 
groups. 
Jimenez[21] Spain Seasonal influenza 1997 Not reported for 
elderly  
Elderly respondents (aged ≥64 years) to a 
nation-wide study  
 Educated <16 years versus those with higher (university and non-university) education: 
proportional coverage 52.6% (95% CI: 49.1-56.1) and 53.1% (95%CI: 39.1-67.1%) 
respectively 
Monthly income €600 versus €1200: coverage 51.3% (95%CI: 47.5-55.1%) and 49.7% 
(95%CI: 42.7-56.7%) respectively.  
Married versus not married 53.4% (95% CI: 49.7-57.1%) and 47.8% (95%CI: 43.0-52.6%) 
respectively 
Jimenez-Garcia[22] Spain Seasonal influenza 2007 5507 Older non-institutionalised participants (aged 
≥60 years) in the 2007 "Madrid Regional 
Health Survey" and the 2007 Spanish National 
Health, from 13/17 Spanish autonomous 
communities.   
Amongst those aged ≥ 65 years: 
Madrid 
Education (≤primary versus ≥secondary coverage 66.3% (64.2–68.4) versus 61.3% (57.2–
65.3) 
Rest of Spain 
Education (≤primary versus ≥secondary)  
coverage 66.3% (63.7–68.9) versus 65.3% (59.1–71.5) 
Nicholson[23] UK Seasonal influenza 1985-86 244  Survey of general practitioners in Trent 
regarding seasonal influenza vaccination 
programme 
No significant difference in vaccination rates of urban and rural practices 
Noula[24] Greece Seasonal influenza Not reported 235 Community dwelling individuals aged ≥65 
years 
 Higher education level was associated with being vaccinated (p=0.028) 
Shemesh[25]  Israel Seasonal influenza 
and pneumococcal 
vaccine 
2002 1422 Community-dwelling respondents (aged ≥60 
years) respondents to a survey conducted at  
a physical activity-oriented health fair 
 
 
 
Seasonal influenza: Russian speakers versus Hebrew and Arabic speakers had lower 
coverage (p < 0.001).  
Amongst the Jewish population, residence in rural settings had higher coverage (71%) versus 
residence in urban areas (62%), p < 0.04).  
Pneumococcal vaccine: The highest coverage was reported by Arabic speakers (57.6%), 
while Russian speakers had the lowest (12.1%) coverage 
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First author Country  Vaccine/s Study period Sample size Study population Vaccine uptake measures 
Studies also included in the review 
Bodekar[15] Germany  Seasonal influenza March-June 
2014 
825 Respondents aged ≥60 years from a 
nationwide telephone survey  
Immigration status was not associated with SIV uptake 
Sarria-Santamera[16] Spain Seasonal influenza 1997 1148 Non-institutionalised participants (aged ≥65 
years) to the Spanish National Health survey 
(ENS) 
No differences were found by availability of private health insurance or marital status on 
vaccine uptake 
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Appendix 8 Quality assessment of the studies included in the review 
First author Selection bias  Outcome 
misclassification 
SD 
number 
examined 
Which SD Exposure bias  Confounding bias Missing data bias Overadjustment 
Abramson[32] 
 
Low risk: 
rr78.7% 
Low risk : self-
reported SIV 
vaccination in latest 
SIV season 
4 COB Education 
Religion 
Relationship 
status 
All 4 SD (exposure data self-reported): low risk All 4 SD: low risk as adjusted for gender, country of 
birth, marital status, education, religiosity, chronic 
disease, exercise, physician visit in 3 months, 
knowledge and attitude questions 
Unclear risk: N/R High risk as 
adjusted for 
chronic conditions 
Aguilar [56] Low risk: all 
pop 
Low risk: data from 
recent records 
2   COB COB (data from records): low risk COB & location of residence: low risk as  adjusted 
for age, gender, major chronic conditions, country of 
birth, area of residence, level of dependence, 
outpatient visits and hospitalisation in the previous 
year 
Low risk: no missing 
data reported 
High risk as 
adjusted for 
chronic conditions 
  Location of 
residence 
Location: residence (data from records (date not 
reported): unclear risk 
  
Barrett  & Mc hugh [33, 
47] 
High risk : rr 
62% overall for 
the study 
Low risk: self-
reported ‘have you 
ever had a flu shot’ 
3   Education Education (self-reported): low risk as education is 
unlikely to change in this older age group at time of 
vaccination 
All 3 SD: high risk as  unadjusted effect estimates Low risk for education: 
low risk as only 0.1% 
had missing data 
Low risk as 
unadjusted 
Income/ wealth Income/ wealth (self-reported): high risk as wealth 
could change over time and could be different at the 
time of vaccination 
High risk for income: as 
~45% had data missing 
Health 
insurance 
Health insurance (self-reported): high risk as 
insurance status could change over time 
Low risk for insurance: 
no missing data 
reported 
Bodeker[15] High risk: 
16.2% rr 
Low risk : self-
reported SIV 
vaccine in last 
season 
1  Education Education (self-reported): low risk Education: high risk as  unadjusted estimates  Low risk : overall only 
1.6% study population 
had missing data for 
education 
Low risk 
Bohmer [37] High risk : 21% 
rr 
Low risk:  self-
reported SIV 
vaccination in either 
or both of 2 seasons 
2007-2009 
depending on when 
individuals were 
interviewed 
2  Education Education & income/wealth (self-reported): low risk Education: high risk as  unadjusted effect estimates Unclear risk: not 
reported 
Low risk as 
unadjusted 
Income/ wealth Income/ wealth (self-reported): low risk Income/ wealth: low risk adjusted for age, gender, 
residence (Western federal states & Eastern federal 
states), household income and belonging to target 
groups, education 
High risk as 
adjusted for 
chronic conditions 
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misclassification 
SD 
number 
examined 
Which SD Exposure bias  Confounding bias Missing data bias Overadjustment 
Burns[57] Low : 70% 
response rate 
Low risk: self-
reported  SIV 
vaccination in last 
12 months 
2   Social class 
living 
arrangements 
Social class & living arrangements (self-reported): 
low risk 
Social class & living arrangements: low risk as 
adjusted for age, gender, living arrangements, social 
class, transport to GP, chronic disease, smoking, 
alcohol consumption and other factors 
Low for both: <4% had 
missing data overall 
High risk as 
adjusted for 
chronic conditions 
Carreno-ibanez [58] Low risk: all 
registered 
patients 
included 
Low risk :  PV 
vaccination from 
records 
1  COB COB (records): low risk COB: high risk as  unadjusted estimates  Low risk : <1% missing 
data 
Low risk 
Chiatti [26, 48, 59] Unclear risk : 
N/R 
Low risk:  self-
reported SIV 
vaccination in last 
12 months 
5   Education All 5 SD (self-reported): low risk Education: low risk adjusted for gender, age group, 
family social class,  chronic diseases, self-reported 
health, GP visit in last 30 days 
Low risk for all: overall 
only 1.7% had missing 
data 
High risk as 
adjusted for 
chronic conditions 
Income/ wealth Income/ wealth: low risk adjusted for gender, 
education, self-reported wealth, smoking status, 
marital status, GP visits in last 30 days, other chronic 
diseases, self-rated health status 
Family social 
class 
Family social class: low risk adjusted for gender, age 
group,education, chronic diseases, self-reported 
health, gp visit in last 30 days 
Relationship 
status 
Relationship status: low risk as adjusted for gender, 
age, education level (ordinal), self-reported income/ 
wealth (ordinal), relationship status, informal and 
formal help, household size, smoking &  respondent 
type 
Low risk 
Living 
arrangements 
Living arrangements: low risk adjusted for gender, 
age, education level (ordinal), self-reported income/ 
wealth (ordinal), marital status, informal and formal 
help, household size, smoking &  respondent type 
Christenson [34]  low risk :  rr 
78%  
Low risk:  self-
reported recent SIV/ 
PV vaccine 
2  Education 
Relationship 
status 
Education & relationship status  (self-reported): low 
risk 
Education & relationship status: high risk as 
unadjusted 
Low risk : data for 
education and 
pneumococcal 
vaccination missing for 
~3% & marital status for 
<2% for both vaccines 
Low risk as 
unadjusted 
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misclassification 
SD 
number 
examined 
Which SD Exposure bias  Confounding bias Missing data bias Overadjustment 
Crawford [12] High risk : rr 
68%  
Low risk: self-
reported SIV 
vaccination in 
previous winter  
4  Social class 
Living 
arrangements 
Relationship 
status 
Location of 
residence 
All 4 SD (self-reported): low risk All 4 SD: low risk as adjusted for gender, age, 
marital status, living arrangements, social class, 
location of residence, geographical location 
Unclear risk: not 
reported 
Low risk  
Damiani [35] Unclear risk: 
not reported 
Low risk: self-
reported SIV 
vaccinated in past 
12 months 
4 Income/ wealth 
Social class 
Education 
Relationship 
status 
All 4 SD (self-reported): low risk All 4 SD: low risk as  adjusted for age, gender, 
education, region of residence, self-assessed health 
status, chronic medical conditions, social class, 
smoking, relationship status, income/ wealth 
Low risk: no missing 
data reported 
High risk 
De souto[42]. High risk: rr 
57% 
Low risk: data for 
SIV vaccination from 
records  
1  Location of  
nursing home 
Location of the nursing home (online questionnaire 
completed by nursing home administrative staff 
staff): low risk 
Low risk as adjusted for age, gender, nursing home 
ownership, location, chronic diseases, physician 
factors and other patient factors including 
medications 
Low risk: 3%  High risk 
Jimenez-garcia[60] Unclear risk: 
overall rr 
67.02%  age 
specific rr not 
available 
unclear risk 
Low risk: self-
reported SIV 
vaccination in latest 
campaign 
1 COB COB (self-reported): low risk High risk as model did not include any level 1 
variable (adjusted for age, gender and chronic 
condition) 
Low risk: no missing 
data reported 
High risk 
Jimenez-garcia[61] Unclear risk: 
overall  rr 65% 
age specific rr 
not available 
unclear risk 
Low risk: self-
reported SIV 
vaccination in latest 
campaign 
1 COB COB (self-reported): low risk High risk as model  did not include any level 1 
variable (adjusted for age, gender and chronic 
condition) 
Low risk: no missing 
data reported 
High risk 
Jimenez-garcia [62] Unclear risk: 
40% overall 
response rate 
overall rr, age 
specific rr not 
available 
Low risk: self-
reported SIV 
vaccination in latest 
campaign 
1 COB COB (self-reported): low risk High risk as model did not include any level 1 
variable  (adjusted for gender, age-groups, health 
care workers and co-morbidity) 
Unclear risk: not 
reported 
High risk 
Jimenez-garcia[64] Low risk: data 
for all 
registered 
individuals 
were used 
Low risk: data for  
SIV vaccine from 
records 
1 COB COB (data from records): low risk High risk as model did not include any level 1 
variable (adjusted for age-groups, gender, number of 
previous flu vaccine received, uptake of 2009 
pandemic vaccine  and presence of chronic 
condition that is an indication for vaccination) 
Low risk: no missing 
data reported 
High risk 
Jimenez-garcia[63] Unclear risk: 
61% overall rr 
age specific rr 
not available  
Low risk: self-
reported SIV 
vaccination in latest 
campaign 
1 COB COB (self-reported): low risk High risk as model did not include any level 1 
variable (adjusted for age, gender and presence of 
chronic disease)  
Low risk: no missing 
data reported 
High risk 
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Which SD Exposure bias  Confounding bias Missing data bias Overadjustment 
Kroneman[29] Unclear risk : 
rr not reported 
Low risk : self-
reported SIV 
vaccine in last 
season 
1 Living 
arrangements 
Living arrangements (self-reported): low risk High risk as unadjusted for any level 1 variable 
(adjusted for gender, age, health professional 
opinion, health care system characteristics including 
out of pocket payment) 
Unclear risk: missing 
data not reported 
Low risk 
Landi[13]  Unclear risk as 
rr was variable 
across 
countries from 
43%-100% 
Low risk : self-
reported SIV 
vaccination status in 
last 2 years 
2 Income/ wealth, 
living 
arrangements 
Both SD (self-reported): low risk Both SD: low risk as adjusted for age, gender, living 
arrangements, income/ wealth, compromised 
activities of daily living function, depression, impaired 
cognitive performance, malnutrition, comorbidities   
Low risk: no missing 
data reported 
High risk 
Mamelund[36] High risk:  rr 
68.9% 
Low risk: self-
reported recent SIV 
vaccination  
3 Education All 3 SD (self-reported): low risk All 3 SD: high risk as unadjusted Education & living 
arrangements: low risk 
for missing data 
Low risk 
Living 
arrangements 
Income/ wealth   income: high risk ~34% 
had missing data   
Nexoe[65] High risk : rr 
58% 
Low risk: self-
reported recent SIV 
vaccination  
1 Living 
arrangements 
Living arrangements (self-reported): low risk High risk as model unadjusted for gender or any 
other level 1 variable (adjusted for age, perceived 
barriers to vaccine, perceived benefits, perceived 
severity, living in a nursing home or sheltered 
housing, advice by GP, vaccinated in previous 
influenza seasons, living in Copenhagen) 
Low risk 18% missing 
data 
High risk 
Opstelten[45] High risk: rr 
69% 
Low risk: from 
recent records SIV 
& PV vaccination 
1 Health 
insurance 
Health insurance from recent records: low risk  High risk as adjusted for age, factors for perceived 
health, barriers, severity and cues to actions 
Low risk: 19% missing 
data 
High risk 
Opstelten[49]  High risk: rr 
69% 
Low risk : recent 
records of SIV & hzv 
uptake 
1 Education Education (self-reported): low risk High risk as  unadjusted for gender or any other level 
1 variable (adjusted for diabetes, factors for 
perceived  barriers, severity and cues to actions)  
Low risk : missing data 
for 18% 
High risk 
Pena-rey[50] Low risk : rr 
75.2%  
Low risk: self-
reported SIV 
vaccine in last 
season  
4  Income/ wealth All 4 SD (self-reported): low risk Income, relationship status & location of residence: 
low risk as adjusted for age, income, location: 
residence, relationship status, health self-perception, 
visit with a physician last 2 years, tetanus 
vaccination, caregiver status 
Low risk: missing data 
for income 19%, no 
missing data for 
residence, and 
education and only one 
person had marital 
status missing 
High risk 
  
  
  
Relationship 
status 
Location of 
residence 
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First author Selection bias  Outcome 
misclassification 
SD 
number 
examined 
Which SD Exposure bias  Confounding bias Missing data bias Overadjustment 
Education Education: high risk as unadjusted  Low risk 
Sarria-santamera[16] Low risk : rr 
85% 
Low risk : self-
reported SIV 
vaccination in last 
season  
2  Education 
income/ wealth 
Both SD (self-reported): low risk Education & income: high risk as unadjusted Low risk: no missing 
data reported 
Low risk 
Schmitz[14] Unclear risk : 
rr 62% overall, 
age specific rr 
not available 
Low risk :  self-
reported SIV 
vaccination in the 
previous year  
3  Education 
relationship 
status living 
arrangements 
All 3 SD (self-reported): low risk All 3 SD: low risk as model adjusted for age, gender, 
education, living arrangements, health behaviour, 
relationship status, self-assessed health cognition, 
physician quality index 
Unclear risk: missing 
data not reported 
High risk 
Shahrabani[31] Unclear risk: rr 
not reported 
Low risk : self-
reported SIV 
vaccine in last 12 
months  
4 Education COB 
relationship 
status living 
arrangements 
All 4 SD (self-reported): low risk All 4 SD: low risk as  adjusted for gender, living 
arrangement, relationship status, country of birth, 
education, chronic illness, hospitalisation, smoking, 
health management organisation,  kibbutz members 
Unclear risk: missing 
data not reported 
High risk 
Sintes[28] Unclear risk : 
rr not reported 
Low risk: records of 
SIV & PV uptake 
  
  
  
  
4 Education All 4 SD education, social class, living arrangements, 
location: residence  (self-reported): low risk 
Education, social class and location: residence: high 
risk as unadjusted 
Low risk: missing data 
~20% 
Low risk 
Social class 
Location of 
residence 
Living 
arrangements 
(SIV) 
Living arrangements (SIV): high risk as unadjusted 
for any other level 1 variable (adjusted for age, 
gender, risk of pneumonia, number of physician 
visits last year) 
High risk 
Living 
arrangements 
(PV) 
Living arrangements (PV): low risk as adjusted for 
age, gender, social class, education, risk of 
pneumonia, number of physician visits last year, 
influenza vaccination in last season 
Wershof schwartz[43] Low risk; : took 
all patients 
enrolled with a 
healthcare 
service 
Low risk : from 
recent records for 
both SIV & PV 
vaccinations  
3  COB COB (from records): low risk All 3 SD: low risk as adjusted for age, gender, 
residence location, area socio-economic status, 
country of birth, number of chronic medical diseases 
and physician factors 
Low risk: ~20%  missing 
data 
High risk 
Area SES  SES data was from records >10 years before the 
study period: high risk 
Location 
ofresidence 
Location of residence during study years from 
records: low risk 
 Cohort       
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First author Selection bias  Outcome 
misclassification 
SD 
number 
examined 
Which SD Exposure bias  Confounding bias Missing data bias Overadjustment 
Breeze[41] Unclear risk : 
follow-up rate 
not reported 
Low risk: medical 
records for SIV 
vaccination 
 3   area SES Area SES (recent records): low risk All 3 SD: low risk as adjusted for year, gender, 
current age, area SES, income and location: 
residence  
Low risk: 12% missing 
data 
Low risk 
Income/ wealth Income/ wealth (interview self-reported): low risk 
Location of 
residence 
Location of residence  (area of residence assessed 
at study start): low risk 
Mangtani[27] Low risk: low 
risk as 72.6% 
follow up  
Low risk: medical 
records for SIV 
vaccination 
5  Area SES All 5 SD (self-reported and recent records): low risk Area SES, income/ wealth, location: residence: low 
risk as adjusted for age, gender, practice factors, 
income/ wealth, area SES, location: residence 
Low risk: 16.1% missing 
data 
Low risk 
Income/ wealth 
Area of 
residence 
Relationship 
status 
Relationship status: high risk as unadjusted 
Living 
arrangements 
Living arrangements: high risk as unadjusted 
Martinez-baz[30] Unclear risk : 
follow-up rate 
not reported 
Low risk: medical 
records for 
continued 
adherence for SIV 
vaccination 
 3 : COB COB (from records): low risk All 3 SD: low risk as adjusted for age, gender, 
location: residence, COB,  living arrangements, 
chronic conditions, hospitalisation in previous 12 
months and dependence 
Unclear risk: missing 
data not reported 
High risk 
Living 
arrangements 
Living arrangements & location: residence (from 
records date not reported): unclear risk   
Location: 
residence 
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First author Selection bias  Outcome 
misclassification 
SD 
number 
examined 
Which SD Exposure bias  Confounding bias Missing data bias Overadjustment 
Sammon[44] Unclear risk: 
follow-up rate 
not reported 
Low risk: records for 
SIV and PIV uptake 
1 : Area SES Area SES (from records date not reported): unclear 
risk 
Area SES: high risk as unadjusted for any level 1 
variable (adjusted for gender, body mass index, 
alcohol consumption, smoking status, history of 
Guillain Barré syndrome, total number of underlying 
health conditions (1,2,>2) and practice region) 
Unclear risk: missing 
data for ≥65 year-old not 
reported  
Low risk 
Shah[66] Unclear risk: 
follow-up rate 
not reported 
Low risk: records 
SIV vaccination  
1  Area SES Area SES (from records date not reported): unclear 
risk 
Area SES: high risk as unadjusted for any level 1 
variable (adjusted for age and gender) 
Low risk: SD data 
available for all 
individuals 
Low risk 
 Case control       
 
        
Van essen[46] Low risk:: rr  
77% -91% 
Low risk: recent 
records for SIV 
uptake  
2  Health 
insurance 
Health insurance (noted from recent records) & living 
arrangements (self-reported): low risk 
Both SD: low risk as adjusted for gender, age 
groups, health insurance, living arrangements, 
perceived health, perceived threat of influenza, 
perceived benefits and costs 
Low risk:  missing data 
for 22.7%  
High risk 
Living 
arrangements 
SD social determinants COB country of birth N/R not reported SIV seasonal influenza vaccine COB country of birth PV pneumococcal vaccine HZ herpes zoster SES socio-economic status rr response rate 
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2.4 Literature review update: 2017 
The search for the review was updated on 1/11/2017 using the same methodology as 
described in the published paper (Section 2.2). The details are described below. 
2.4.1  Updated review: results  
Nine additional studies, published between 25/02/2016 and 31/10/2017, were identified in 
the updated search (and herein referred to as “2017-updated search/review”).82, 92-99 Eight 
studies were cross-sectional82, 92-95, 97-99 and one was a cohort study.96 The studies reported 
the association of socio-demographic factors with seasonal influenza vaccine uptake 
(n=6),92, 93, 95-97, 99 uptake of zoster vaccine (n=1),82  pneumococcal vaccine uptake (n=1),94 
and uptake of both seasonal influenza and pneumococcal vaccine (n=1)98 (Table 2-1). The 
socio-demographic factors of interest reported in these studies included education (n=5),93, 
94, 97-99 living arrangements (n=4),92-94, 97 marital status (n=4),93, 94, 98, 99 area of residence 
(n=4),92, 97-99 individual or household income (n=4),92, 97-99 area-level socio-economic status 
(n=2),82, 96 and country of birth (n=1).95 The studies included data from Spain (n=2),93, 94 
France (n=2),92, 96 Poland (n=2),97, 98 UK (n=1),82 Denmark (n=1)99 and Italy (n=1).95 Of the 
nine studies identified in the 2017-updated review, four studies were hospital based.93, 94, 97, 
98 An overview of the studies is provided in Table 2-1 in the same format as the published 
review paper. The details of these nine additional studies are provided in Appendix 1. 
2.4.1.1 Quality assessment of the additional studies  
Consistent with the published review paper, the studies included in the 2017-updated review 
had low risk of exposure and outcome misclassification (Table 2-2 and Appendix 2) and high 
risk of confounding bias, mainly due to the unavailability of adjusted estimates in the studies. 
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Table 2-1 Updated literature review: Summary of additional studies published between 25/02/2016-31/10/2017 (N=9) 
SES(A) area-level socio-economic status Inco income COB country of birth Edu education LA living arrangements MS marital status Res residence SIV seasonal influenza vaccine N=study reported no 
association with vaccine uptake *adequately adjusted estimates based on confounding bias assessment # from the model unadjusted for chronic disease ↑ higher vaccine uptake reported ↓lower vaccine uptake 
reported PV pneumococcal vaccine HZ herpes zoster vaccine  
1 most deprived (area-level) versus least deprived (reference)  2 Highest versus lowest income level (reference) 3 Immigrants versus native (reference) 4 Highest versus lowest education level (reference) 5 Not 
living alone versus living alone (reference) 6 Single versus married (reference) 7 Urban versus rural area (reference) ^ baseline 2nd and 3rd quartile 
       Social determinants associated with vaccine uptake 
 Author Country Study period Sample 
size 
Study population Vaccine SES 
(A)1 
Inco2 COB3 Edu4 LA5 MS6 Res7 
 Cross-sectional studies           
1 Bocquier92  France April-
September 
2008 
7,088 Respondents (aged ≥65 years) of French National survey on 
health and disability (people with disabilities were over-represented 
using a sampling co-efficient) 
SIV  N*#   ↑*#  N*# 
2 Dominguez93  Spain November 
2013-May 
2014 
1,038 Individuals aged ≥65 years, admitted via emergency departments 
to 19 different city hospitals in 7 regions for causes other than 
respiratory illnesses  
SIV    N N ↓  
3 Dominguez94  Spain September 
2013-
September 
2014 
916 Individuals aged ≥65 years, admitted via emergency departments 
to 19 different city hospitals in 7 regions for causes other than 
respiratory illnesses 
PV    ↓ N N  
4 Fabiani95  Italy 2012-2013 27,003 Respondents, aged ≥65 years, of a multi-purpose survey 
conducted to gather information about health service utilisation 
amongst Italian residents 
SIV   ↓*     
5 Ganczak97  Poland November 
2015- April 
2016 
230 Consecutive patients aged ≥65 years admitted to municipal 
hospital in city of Szczecin 
SIV  N  N N  ↑ 
6 Gorska-
Ciebiada98  
Poland 2013 219 Patients aged ≥65 years with type 2 diabetes diagnosed at least a 
year previously and attending the medicine and diabetes outpatient 
clinics in a university hospital 
SIV & PV  SIV:↑ 
PV: N  
 N  N SIV:↑ 
PV: N  
7 Hellfritzsch99  Denmark February 2016 4,237 Individuals aged 65-79 years who participated in the 2006 public 
health survey conducted by Centre for Public Health, Denmark 
SIV  N  N  N N 
8 Ward82  UK 2014-2015 178,808 Individuals aged 70 years on 01/09/2014 eligible for zoster 
vaccination between 1 Sept 2014-31 Aug 2015 and with available 
ethnicity data, extracted from GP records in England 
HZ ↓       
 Cohort study           
9 Gallini96  France 2007-2009 5,269 Individuals aged ≥65 years selected from the French Health 
Insurance database containing claims for a 1/97th random sample 
of the French population. 
SIV N^       
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Table 2-2 Quality assessment of the additional studies identified between 25/02/2016-31/10/2017 
 
 
 
 
 
 
 
 
 
Ref. reference SB selection bias OM outcome misclassification SES socioeconomic status EM exposure misclassification CB confounding bias MD missing data COB country of birth L low risk of bias U unclear 
risk of bias H high risk of bias 
 
 
 
Social determinants and bias 
Study type & 
Ref. SB OM Area SES Income  COB  Education Living alone Marital status Residence 
Cross-
sectional 
  
EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD EM CB MD 
Bocquier92  
L L    L L L       L L L    L L L 
Dominguez93  
U L          L H L L H U L H U    
Dominguez94  
U L          L H L L H L L H L    
Fabiani95  
L L       L L L             
Ganczak97  
L L    L H L    L H L L H L    L H L 
Gorska-
Ciebiada98 
U L    L H L    L H L    L H L L H L 
Hellfritzsch99  
U L    L H H    L H L    L H L L H L 
Ward82  
L L L H L                   
Cohort 
                       
Gallini96 
L L U H L                   
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2.4.1.2 Association of social factors with vaccine uptake 
A) Living arrangements  
Four additional studies were identified in the 2017-updated search, which reported the 
association of living arrangement with vaccine uptake.92-94, 97 Meta-analysis was repeated for 
previously identified studies with the addition of the studies identified in the 2017-updated 
search (Figure 2-1). Irrespective of the vaccine type and the measure of effect, all studies 
except one,97 showed a consistent direction of effect, similar to the published review paper, 
with higher uptake of vaccine amongst individuals who were not living alone. As with the 
previous analysis, there was considerable between-study heterogeneity. The results 
remained unchanged when the analysis was restricted to the same five adequately adjusted 
studies as in the published review, the summary odds for seasonal influenza vaccine uptake 
were 25% higher amongst those not living alone compared to those living alone. When the 
studies were stratified by vaccine costs, the findings were again similar to the published 
review paper: the summary odds of seasonal influenza and pneumococcal vaccine uptake 
were 50% and 42% higher, respectively amongst individuals not living alone in countries 
where vaccines were available free-of-charge. In countries where seasonal influenza 
vaccination was paid for, no consistent effect of living arrangements on vaccine uptake was 
observed in the two studies (including one study97 identified from the 2017-update). 
To summarise, living alone was consistently associated with lower vaccine uptake in all 
except one study, similar to the findings from the published review. 
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Figure 2-1 Association of living arrangements on vaccine uptake: including studies 
identified on updating the review   
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B) Marital status 
The results of meta-analysis after including the four additional studies identified in the 2017-
updated search are shown in the Figure 2-2.93, 94, 98, 99 Inclusion of these additional studies 
did not change the findings for the uptake of seasonal influenza vaccine from the published 
review paper, the direction of effect remained that of lower uptake amongst unmarried 
individuals, with strong evidence of between-study heterogeneity. There was no evidence of 
between-study heterogeneity (I-squared=0.0%) for the three pneumococcal vaccine uptake 
studies (including the two recent studies94, 98 identified in the 2017-updated search), with the 
summary estimate of 26% lower uptake amongst unmarried individuals. These observations 
reflected the findings of the association of living arrangements (discussed under (A) above). 
The findings of lower (17%-27%) summary odds for vaccine uptake amongst unmarried 
individuals after stratifying the studies based on vaccination costs and vaccine types, were 
similar to those reported in the published review paper.  
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Figure 2-2 Association of marital status on vaccine uptake: including studies 
identified on updating the review  
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C) Education 
The results of meta-analysis after including the five additional studies identified in the 2017-
updated review are shown in Figure 2-3.93, 94, 97-99 Again the findings from the published 
review paper remained unchanged with overall 5% higher odds of uptake amongst those 
with higher education level when the analysis was restricted to the same three adequately 
adjusted studies. The uptake of both pneumococcal and seasonal influenza vaccine was 
higher, by 43% and 68% respectively, amongst individuals with a higher level of education in 
countries where vaccines were paid for (Figure 2-3), echoing the results of the published 
review paper. The inclusion of three recent studies93, 94, 99 also strengthened the findings of 
the published review for the countries where vaccines were available free-of-charge: there 
was no association (summary odds ratio: 1.02 (95%CI: 0.97-1.06) of seasonal influenza 
vaccine uptake with education level, while the summary odds of pneumococcal vaccine 
uptake were 32% lower amongst those with the highest education level.  
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Figure 2-3 Association of education level with vaccine uptake: including studies 
identified on updating the review 
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D) Household/individual income 
As described previously, meta-analysis was repeated after including the four additional 
studies identified in the 2017-updated search which reported the association of income with 
vaccine uptake,92, 97-99 (Figure 2-4). Again, the inclusion of these additional studies did not 
change the findings from the published review; there was no consistent effect from the 
studies reporting odds ratios for the association of income with seasonal influenza vaccine 
uptake. Similar to the findings from the published review, there was no evidence for an 
overall association (summary risk ratio- 0.99 (95%CI: 0.95-1.04) of income with seasonal 
influenza vaccine uptake after adding a third study to the two studies that reported effect 
estimates as risk ratios (Figure 2-4). The higher summary odds for seasonal influenza 
vaccine uptake amongst those with higher income when the analysis was restricted to the 
adequately adjusted studies and where vaccine was available free-of charge, of 26% and 
13% respectively (Figure 2-4), remained unchanged from the findings of the published 
review paper.  In countries where the seasonal influenza vaccine was paid for, the inclusion 
of two97, 98 additional studies to the previously identified single study, showed no consistent 
effect of income on seasonal influenza vaccine uptake.   
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Figure 2-4 Association of income on vaccine uptake: including studies identified on 
updating the review 
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E) Urban or rural area of residence 
The results of meta-analysis for the effect of area of residence on vaccine uptake, after 
including the four additional studies identified in the 2017-updated search, 92, 97-99 are shown 
in Figure 2-5. As found previously, no consistent effect was observed for the studies 
reporting odds ratio for the association of an individual’s residence with seasonal influenza 
vaccine uptake after including three additional studies.97-99  Amongst the three studies 
reporting a risk ratio (including one recent study from France 92 and the two previously 
described  UK studies100, 101) for the association of individual’s residence with seasonal 
influenza vaccine uptake, no consistent effect of residence on vaccine uptake was observed 
(Figure 2-5). This latter finding was in contrast from that of the published review where the 
summary estimate from the two UK studies:100, 101 showed 11% higher uptake amongst 
urban residents (summary risk ratio 1.11, 95%CI: 1.02-1.20). The higher (15%) summary 
odds for pneumococcal vaccine uptake amongst individuals residing in urban area after 
including one additional study,98 as described in the published review, remained unchanged. 
Similarly no change was observed after the 2017update when analyses were restricted to 
the adequately adjusted studies and to the countries where vaccines were available free-of-
charge. (Figure 2-5). The 2017-updated review provided additional information from two 
Polish studies where vaccinations were not free; 97, 98 the odds of uptake of both seasonal 
influenza and pneumococcal vaccines were higher (more than twice) amongst urban 
residents in these studies.    
101 
 
 
Figure 2-5 Association of residence with vaccine uptake: including studies identified 
on updating the review  
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F) Area-level socio-economic status 
Two studies identified from the 2017-updated search reported the association of area-level 
socio-economic status with the uptake of seasonal influenza96 and zoster vaccine.82 The 
findings of the meta-analysis from the published review remained unchanged following the 
inclusion of these two additional studies (Figure 2-6); the risk of seasonal influenza uptake 
remained modestly lower (7-11%) amongst individuals from most deprived areas.  Additional 
information was available for the association of area-level socio-economic status with zoster 
vaccine uptake from the 2017-updated review, the odds for zoster vaccine were lower (0.66 
(95%CI: 0.64-0.68)) amongst individuals from the most deprived areas as compared to the 
baseline group of least deprived areas,82 keeping with the finding for other vaccine types 
from the published review. The reference group for the study reporting the uptake of 
seasonal influenza vaccine identified in the 2017-updated review, was the second and third 
quartile of deprivation; the reported adjusted risk ratio amongst those from the lowest 
quartile of deprivation was 1.00 (0.96-1.04) and amongst those from the highest quartile of 
deprivation was 1.02 (0.97- 1.06), respectively.96   
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Figure 2-6 Association of area-level socio-economic status with vaccine uptake: 
including studies identified on updating the review 
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G) Country of birth 
As described previously for other social factors, the meta-analysis was repeated after 
including one additional study identified in the 2017-updated review (Figure 2-7).95 The 
findings from the published review remained unchanged, the summary odds of uptake were 
40% and 33% lower amongst immigrants for both seasonal influenza and pneumococcal 
vaccines, respectively (Figure 2-7). Similar to the published review there was a strong 
evidence of between-study heterogeneity.  
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Figure 2-7 Association of country of birth with vaccine uptake: including studies 
identified on updating the review 
2.5 Chapter summary 
A systematic review and meta-analysis of the socio-demographic factors associated with 
vaccine uptake amongst older individuals was conducted to meet the first objective of this 
thesis. The factors associated with lower vaccine uptake included living alone, being not 
married, being an immigrant, individuals with lower-level of education, lower income, 
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residence in rural areas and area with higher level of deprivation. The findings were 
presented as a published paper. The review was updated in November 2017 and nine 
additional studies that identified were included with the studies from the published review 
paper and the meta-analyses were repeated, which corroborated the findings of the 
published review paper. One difference was the inclusion of a single extra study from 
France, that unlike the two UK studies from the published review (which showed slightly 
higher uptake in urban areas), reported no difference in uptake between urban and rural 
areas. 
In the next chapter (Chapter 3), the details of the electronic health data utilised in this thesis 
are provided and in Chapter 4 I will describe how the socio-demographic factors identified in 
this review were determined in the electronic data.  
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Methods section 
 
The methods section for this thesis has three chapters:  
Chapter 3 describes the different electronic datasets used for the analyses in this thesis. It 
also presents the methods used to select the study populations from these data for the three 
observational studies conducted to meet objectives 2-4 of this thesis.  
Chapter 4 describes the methods used to identify the social factors of interest in the 
electronic data that were identified from the findings of the systematic review (Chapter 2).  
Chapter 5 presents the methods used to ascertain the outcome variables in these data, 
namely herpes zoster and zoster vaccine uptake, as well as all other covariates used in 
analyses. 
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 Chapter 3. Data sources: Electronic Health Records 
3.1 Introduction 
Health care provided by the National Health Service  (NHS) in the UK is delivered free at 
point-of-care.102 The general practice forms the main component of primary care delivered 
by the NHS, and offer diagnostic, preventative and therapeutic services to the UK 
population. More than 98% of individuals in England are registered with a general 
practitioner (GP) and nearly 80% of patient contact in the NHS occurs via general practice; 
the GP consultation rate during 2013-2014 was ~5 per person-year.103-105  
General practice, considered to be the most digitalised part of the NHS, began using 
computers for patients’ records in the 1980s and by the middle of the 2000 decade nearly all 
practices were using  EHR at point-of-care.106, 107 In 2004, a pay-for-performance scheme 
(the Quality and Outcomes Framework (QOF)) was introduced for general practices in 
England.108 Under this scheme, GPs are financially incentivised based on their 
performances against a set of QOF parameters, which are defined annually. General 
practice EHR are also indispensable when claiming for QOF payments.106    
Data from NHS hospitals in England are also available in form of a data warehouse: the 
Hospital Episode Statistics (HES), managed by NHS Digital.109 These data are recorded by 
healthcare providers for patient care and payment purposes.109 There are different types of 
data in HES and these include all admitted patient care data, data for attendances in 
outpatient departments and accident and emergency (A&E) attendances data.109 The HES 
data are discussed further in Section 3.3. 
Routinely collected electronic medical data such as those described above provide an 
invaluable data resource for research. Compared to research based on data collected 
specifically for research purposes, EHR-based research typically offers a quicker, more 
efficient and less expensive alternative.110 It generally allows larger sample sizes, longer 
follow-up and assessment for numerous outcomes including rare conditions.110 In England 
where all residents have access to primary and hospital-based health care that is 
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computerised, the results of EHR-based research are more likely to be generalizable than 
specific research population. It is also feasible to link primary care EHR with other data 
sources such as hospitalisation data, disease registries and death registration data, which 
makes these an attractive research option.111, 112  It is therefore not surprising that in this era 
of financial constraints, EHR are increasingly utilised for health research and many research 
groups now specialise in conducting research using EHR.110 
However, there are caveats to using EHR data for research. The primary purpose of these 
data is patient care and not research. Therefore, researchers should consider the 
completeness and validity of the EHR data. This also includes changes in EHR data over 
time, for example with changes in clinical, diagnostic and QOF criteria.111 In the following 
sections, the main electronic health datasets used in this thesis are described, including 
primary care data, hospitalisation data and deprivation data. 
3.2 Primary care EHR: The Clinical Practice Research Datalink 
The primary care electronic health data utilised in this thesis were the anonymised 
longitudinal UK primary care data provided by the Clinical Practice Research Datalink 
(CPRD), known as CPRD GOLD.113 The CPRD was initiated in 1987, and provides one of 
the world’s largest repository of primary care data for research, which has been used in 
more than 1000 peer-reviewed publications.113, 114 CPRD GOLD (herein referred to as CPRD 
data) covers ~7% of the UK population and is representative of the UK population in terms 
of gender, age and ethnicity.114 The CPRD software system extracts de-identified patient 
information (Figure 3-1) from consenting general practices monthly. Patient-identifiable data 
such as the patient’s name, full date of birth, address, and NHS number are not extracted 
and to maintain patient confidentiality, CPRD provides only the year of birth for adult 
patients.114, 115  As outlined in Section 3.2.3, CPRD primary care data are also linked to 
other data such as hospital or deprivation data. These anonymised data are subsequently 
made available to researchers.115 
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Figure 3-1 Data extraction and linkages by Clinical Practice Research Datalink* 
*adapted from115  
3.2.1 CPRD data collection and format 
As mentioned in Section 3.2, the data available in CPRD are collected in general practices, 
as a part of routine clinical care and therefore the frequency of these records is dependent 
on a patient’s medical circumstances.114 Much of the information in EHR is captured using 
structured and coded data; free-text being used if required.107 Previously, selected 
anonymised free text data could be purchased by researchers, however changes in the 
information governance of CPRD means that these data were no longer available after 
March 2016 [Personal communications via email with the CPRD Knowledge Centre]. The 
majority of the information (e.g. clinical, administrative and lifestyle data) is recorded using 
Read codes (Read Version 2) and other specialist codes (described below), while therapies 
are recorded using Gemscript codes.107, 114, 116 The aim of coded data entry is to help ensure 
that recordings are largely consistent, speedy, and retrievable for audit or payment 
purposes.107 The information received by practices from a range of referral services,  
EHR from GP 
CPRD 
De-identified EHR 
from GP 
+ 
Pseudonym ID 
+ 
De-identified other 
data 
Anonymised data 
Other data e.g. 
hospitalisation data, 
deprivation data 
De-identified data Patient 
identifiable 
information 
Trusted Third 
Party (NHS 
Digital): data 
linkages 
Pseudonym ID or 
encrypted identifier 
for data linkages 
Researchers 
EHR Electronic health records; GP general practices; 
CPRD Clinical Practice Research datalink. 
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Gemscript/ Product code 
Entity type 
Read/ Medical codes 
Patient demographics (e.g. year of 
birth, gender, family number, marital 
status), whether the patient met 
CPRD’s quality criteria and details of 
registration with general practice 
Details of the general practice (e.g. 
region, date when the practice 
achieved CPRD’s quality criteria) 
Details of general practice staff (e.g. 
gender, role) 
Date, duration and place of 
consultation 
Coded medical history, diagnoses 
including relevant dates 
Additional information for clinical 
events and includes information 
recorded as entity type code for e.g. 
entity type code 132 gives information 
about residence and living alone, entity 
type code 98 gives information about 
next of kin for elderly patients 
Data about referral to other services 
from primary care 
Details of immunisations (e.g. date, 
type, status (advised, given, refused)) 
Investigations performed 
Prescribing information from the 
general practice e.g. total quantity 
prescribed, duration of prescription, 
codes for British National Formulary 
Patient file 
Practice file 
Staff file 
Consultation file 
Clinical file 
Additional Clinical 
Details file 
Referral file 
Immunisation file 
Test file 
Therapy file 
CPRD data files Main contents Codes in the files 
Up to eight data fields 
Consultation type 
Immstype codes & status  
Figure 3-2 Clinical Practice Research Datalink: data structure and contents 
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including patient-related correspondence, may be also recorded using coded data.114 CPRD 
also generates unique codes for the Read and the Gemscript codes called medical codes 
and product codes respectively, that are available to the researchers.  
The information captured in the CPRD is formatted in ten different data files (Figure 3-2). 
These files provide information about the patient, the general practice and its staff, medical 
and preventative care provided to the patient, investigations, details of referral and 
correspondence with specialist care and also include the treatments provided.  
A patient’s demographic details, an overall indicator of whether their data are of acceptable 
quality (further described in Section 3.2.2, below), and their registration details with the 
practice such as their current registration date and the date they left the practice, are 
available in the Patient file (Figure 3-2). It also includes information (the family number) to 
identify other individuals registered with the practice sharing the same address as the 
patient.  The Practice file includes unique practice identifiers for all practices in the database 
and provides details about the region where the general practice is located, the date when 
the data were last collected from the practice (the last collection date) and the up to standard 
date (UTS date: discussed in Section 3.2.2). 
The Read codes and corresponding medical codes are present in the Clinical, Referral, Test 
and Immunisation files while the Gemscript/product codes are available in the Therapy files. 
In addition to the medical codes, the immunisation files also provide information about of the 
type of vaccine administered (e.g. seasonal influenza, zoster) and the status of immunisation 
i.e. whether the vaccination was advised, refused or given. Additional clinical information 
and test results (for e.g., a patient’s weight or blood pressure results) are also available in 
the form of entity type codes, which capture additional structured coded data i.e. data 
recorded in a format that can be identified by the GP computer systems. This entity type field 
is available in the Clinical, Additional Clinical Details and Test files. Each entity type field 
may additionally have up to eight data fields (Figure 3-2) depending upon the type of data 
file, that gives additional information regarding that entity.  
With the exception of the Patient, Practice, Staff and Additional Clinical Details files, all 
CPRD data files provide two date fields associated with ‘events’ (for example- recording of 
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symptoms and signs, diagnoses, tests, prescriptions):  (i) the event date, which is the date 
the event occurred as recorded by the GP and (ii) the system date, the date when the event 
was recorded on the GP computer system. 
The details of all medical and product codes are provided by CPRD in the form of medical 
and product dictionaries, which can be searched using the supplied Browser Tool function 
(the Medical Browser  tool for medical codes and the Product Browser tool for medications 
or product codes) to create various code lists for research studies. Similarly, CPRD also 
provides detailed information for all entity type codes present in the data. 
3.2.2 CPRD data quality 
The validity and reliability of the results of an EHR-based research depend upon the quality 
of data in terms of both completeness and validity. The introduction of QOF in 2004, which 
remunerated the GPs for their performance against pre-specified targets, played an 
important part in improving the quality of some aspects of primary care health records.107  
Secondly, CPRD also provides data quality checks at both the patient and the general 
practice level.114, 117 Patients meeting CPRD’s quality criteria are identified in the Patient file 
by an ‘acceptable’ flag, which gives an indication about the continuity of their follow-up and 
the quality of their captured data.114, 117 Some of the criteria for labelling patients as 
‘unacceptable’ include invalid recording of: gender, year of birth, current or first registration 
date, transfer out date; age >115 years, and temporary registration.114, 117 It is recommended 
that patients who do not meet the CPRD’s acceptability criteria should not be included in 
research projects. 
At the practice level, the date when a practice meets the CPRD quality assurance criteria is 
indicated by the UTS date in the Practice file. The quality of the data from the practice is 
judged on (1) data continuity and (2) any unexpected gaps in the death rate for the 
practice.114 As with the patient acceptability flag, it is recommended to include the practice 
data for research purposes only after the UTS date. 
The validity of the diagnoses recorded in CPRD has been examined in numerous studies.114, 
117 A 2010 systematic review summarised the findings and the quality of validation studies 
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for 183 diagnoses recorded in CPRD and reported a high positive predictive value (median 
value of 89% (range 24-100%)) for the diagnoses in these data.118 However, this review also 
found that most validation studies did not report the negative predictive value, specificity and 
sensitivity for the diagnoses.118 Although overall there is a good comparability of disease 
rates for a range of diseases estimated using the CPRD with rates from external sources, an 
overestimation of incidence rates have been observed within these data during the 
immediate post-registration period for patients.118, 119 This overestimation in rates soon after 
patient registration may result from either a patient with new onset of symptoms seeking to 
register with a new GP, or during these earlier visits to the GP a patient’s past medical 
conditions are recorded with the date of the visit, thus being misclassified as  ongoing or 
present conditions.119 Excluding the period immediately following a patient’s registration for 
six months (for acute conditions) to one year (for chronic conditions) has been shown to 
minimise this misclassification.119   
3.2.3 CPRD: data linkages 
General practices in England, subject to their consent, can have their data linked with other 
datasets at an individual-level. All patients registered with the consenting practices are 
included for the linkages, unless they opt out. 114 By 2015, linked data were available for up 
to 75% of the English practices (~57% of all UK practices).114, 120 Some of the other datasets 
available for linkages include deprivation data, hospitalisation data, disease registries and 
death registration data.120 The linkages with these data, which require access to patient 
identifiable information, are conducted by a trusted third party (NHS Digital).115 The trusted 
third party provides CPRD with an encrypted linker key, which is common to both primary 
care records and the linkage data  (Figure 3-1).120 For this thesis, CPRD data linked to 
admitted patient HES data and deprivation (IMD data) were utilised. These two linked data 
sources are described in the next two sections: Sections 3.3 and 3.4. 
3.3 Hospital Episode Statistics 
As introduced in Section 3.1, HES includes different types of data such as admitted patient 
care data, A&E attendances and outpatient appointments data.109 In this thesis, the Admitted 
Patient Care data, which includes administrative and clinical details for all patients admitted 
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in the NHS hospitals in England, were utilised. Unlike other data in HES, the Admitted 
Patient Care data records full diagnostic information. CPRD provides linkages with Admitted 
Patient Care HES data from 1997 onwards as the NHS number, a patient identifier required 
for data linkages, was introduced in 1997.120 Depending upon the linkage period covered, 
CPRD provides different sets/ versions of HES data linked to CPRD patients. For example, 
in this thesis HES version 10 (covering the Admitted Patient Care data for the period: 
01/04/1997-31/03/2014) and version 13 (covering the Admitted Patient Care for the period: 
01/04/1997-29/02/2016) were utilised.  Primarily, HES data are used for clinical care and 
also allow the healthcare providers to be paid for their activities.109 Additionally, these data 
have non-clinical or secondary uses; they are utilised for the commissioning of health 
services, planning for future healthcare and research by numerous bodies such as the 
Department of Health, NHS, local commissioning groups, commercial and national 
organisations.109 
3.3.1 Data collection and format  
The hospital data are collated by a single data repository, the Secondary Uses Service 
(SUS) maintained by NHS digital, which extracts this information as a database (HES) and 
also supplies information to the healthcare commissioners for payment purposes.109 The 
SUS takes extracts from the data submitted by the healthcare providers at predetermined 
intervals and sends it to HES. The HES extracts are available every month, which are 
cumulative. For example at the start of the financial year the April extract will include data for 
only one month, but in month 4 the extract will include cumulative data from April-July.109 
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Figure 3-3 Hospital Episode Statistics: data structure 
 
In HES, the period of hospitalisation between admission and discharge is known as a ‘spell’. 
Each hospital spell in turn comprises  of one or several consultant episodes (Figure 3-3), 
each episode being defined as a period of continuous care from one consultant at a single 
hospital.109 As mentioned earlier in Section 3.3, HES Admitted Patient Care data consists of 
individual-level data about clinical diagnoses and hospital procedures during 
hospitalisation.109 It also includes basic demographic details for the patient (age group, sex, 
ethnicity, geographical location) and a HES generated patient identifier. Each HES episode 
has an episode start date, one primary diagnosis and may have up to 19 secondary 
diagnosis and up to 24 procedures recorded.121 The primary diagnosis for the first episode 
typically indicates the reason for hospital admission.121 The codes used for recording the 
clinical diagnoses and procedures are the World Health Organization’s 10th revision of 
International Classification of Diseases and Related Health Problems (ICD-10) and the 4th 
revision of the Office of Population Censuses and Surveys: Classification of Interventions 
and Procedures (OPCS-4), respectively.122 
CPRD supplies the HES data as text tab delimited files with different types of data content. 
The HES data files used in this thesis are shown in Figure 3-4; these included the Patient, 
Hospitalisation, Episodes, Diagnoses and Procedures files. 
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Figure 3-4 Hospital Episode Statistics: data format and contents 
 
3.3.2 HES data quality 
The data captured from the NHS hospitals by the SUS is audited against set standards for 
validity and completeness.123 Before these data can be made available in the HES data 
warehouse, NHS Digital  removes patient-related sensitive data, carries out data cleaning 
including removal of duplicate records, performing routine and ad hoc quality checks, and 
publishing data quality reports.123 The accuracy of diagnoses and procedures coding in data 
submitted for payment were audited in 2012-2013 and a mean error rate of 11%-16% was 
found .124 The majority of the errors were reported for secondary diagnoses coding  due to 
poor capture of co-morbidities data.124 However, since the introduction Payment by Results 
(2004) whereby the hospitals are remunerated based on the coding data, the accuracy of 
the coding information continues to improve in more recent data.125, 126  
 
Patient 
Hospitalisations 
Episodes 
Diagnoses 
Procedures 
Basic patient details including 
ethnicity* 
Details of hospitalisation including 
admission and discharge dates, source 
of admission (e.g. usual place of 
residence, care home) 
Details of episodes, episode start date, 
ethnicity~ 
Details of diagnoses including primary 
diagnosis, ICD-10 codes, episode start 
date 
Details of procedures including OPCS 
codes, episode start date 
HES data files 
used in the thesis Contents 
*HES version 10 
~HES version 13 
ICD International Classification of Diseases 
OPCS Office of Population Censuses and Surveys 
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3.4 Deprivation data 
Patients’ and/or general practices’ postcodes in CPRD databases can be linked by a trusted 
third party (NHS Digital) with a small area-based measure of relative deprivation called the 
English Index of Multiple Deprivation (IMD), a proxy marker for socio-economic status.127 
The IMD is defined at a Lower Layer Super Output Area (LSOA): an area with an average 
population of 1500 people.128 This index is a composite score of 38 indicators derived from 
seven domains, which measure different aspects of deprivation including income, 
employment, education and skills, health and disability, crime, housing and living 
environment.129 The actual IMD scores are not provided to researchers using CPRD to avoid 
the risk of identification of LSOA and patients’ area of residence. Instead, all LSOA in 
England are ranked based on their area-level IMD score and are divided into equal groups 
or quantiles (generally quintiles), which are available to the researchers. Quintile one 
represents the least deprived and quintile five represents the most deprived quintile.129  
There are four English IMD datasets (2004, 2007, 2010 and 2015) available for linkage.120 
To mitigate the risk of deductive disclosure of an individual’s area of residence, CPRD 
provides linkage with only one these datasets for any one study.120 
3.5 Identifying the study populations  
In Chapters 6, 7 and 8, the three observational studies conducted to ascertain the recording 
of social factors amongst older individuals in linked electronic health data and then the 
application of these methods to examine the socio-demographic determinants of zoster 
burden and uptake of zoster vaccine are described, respectively. In this section an overview 
of how the study populations for these three studies were selected from the linked electronic 
data is provided. 
3.5.1 Identifying the study population for the cross-sectional study to 
ascertain socio-demographic factors and assess their recording in the 
electronic health record data (objective 2) 
The CPRD data used for this study was from the January 2015 release, linked to version 10 
of the HES data and the 2010 English IMD data. To assess both completeness and 
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timeliness of recording of the social factor data, an index date of 01/01/2013 (the start of the 
year in which zoster vaccination was introduced in England) was chosen.68 The study 
population was required to be aged ≥65 years on 01/01/2013. As only year of birth was 
available in these data (Section 3.2), the common convention of using the mid-year (1st 
July) to assign study participants’ day and month of birth was followed. To ensure data 
quality, both the individuals and the practices included in the study were required to meet the 
quality requisites set by the CPRD i.e. individuals were required to be acceptable for 
research (Section 3.2.2). Participants were required to be active (alive and registered with a 
CPRD practice that was UTS) on the index date (01/01/2013).  Active registration on the 
index date was determined by ensuring patients’ start dates (the later of their current 
registration date with the practice or the UTS date for the practice) fell before the index date 
and their end dates (the earliest of their transfer out date, date of death or practice’s last 
collection date) were after the index date. This led to the inclusion of 591,037 patients from 
389 general practices.  
3.5.2 Identifying the study population for the cohort study to describe the 
socio-demographic factors associated with zoster disease incidence in 
England (objective 3)  
This cohort study spanned a period of ten years (01/09/2003-31/08/2013) prior to the 
introduction of zoster vaccine in England on 01/09/2013.68 The CPRD data utilised for this 
study was from the January 2016 release, linked to HES data version 10 and 2007 English 
IMD data (the latter approximately at the midpoint of the study period). The participants were 
required to have no prior history of zoster, and to be alive and currently registered with a 
CPRD practice in England. As described previously (Section 3.2.2), to ensure data quality, 
only participants categorised as ‘acceptable’ by the CPRD, were included in the study.  
Follow-up for each individual started on the latest of: their 65th birthday, one year after their 
current registration date, the UTS date for the practice or the study start date (01/09/2003) 
(Figure 3-5).  As discussed in Section 3.2.2, a period of one year was added to the current 
registration date to avoid overestimation of zoster incidence in the immediate post-
registration period as a patient’s past zoster history might be misreported as an ongoing or a 
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presenting complaint.119 The end of follow-up was defined as the earliest of: the patient’s 
transfer out date from the practice, their death date, the date of zoster, the last collection 
date from the practice or the end of the study (31/08/2013) (Figure 3-5). Patients were 
required to have a minimum follow-up of one day. 
 
Figure 3-5 Cohort study ascertaining the socio-demographic factors associated with 
zoster disease incidence: study follow-up period 
 
Two approaches were used to identify and exclude individuals with previous zoster history 
using CPRD data linked to HES: (1) Patients with a code for zoster or PHN (Appendix 3) 
prior to the start of follow-up were excluded (2) Individuals for whom the first zoster code 
was that for PHN during the follow-up period were also excluded (Figure 3-6). Both medical 
codes and ICD-10 codes130 were utilised to identify individuals with zoster and PHN 
(Appendix 3). 
Follow-up starts at the 
latest of: 
1. Age ≥65 years 
2. One year after current 
registration date  
3. Up to standard date of the 
practice  
4. Start of study 
(01/09/2003) 
  
 
Follow-up ends at the 
earliest of: 
1. Transfer out date 
2. Death date 
3. Last collection date from 
practice 
4. Zoster date 
5. End of study 
(31/08/2013) 
Individuals with no previous history of zoster  
Study period: 01/09/2003-31/08/2013 (10 years) 
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Figure 3-6 Identifying individuals’ previous history of zoster or post-herpetic 
neuralgia 
 
The number of patients meeting the above defined eligibility criteria was 931,830 from 385 
practices in England. Of these participants, 69,360 (7.4%) individuals were excluded due to 
a prior history of zoster (Figure 3-7). 
 
 
Figure 3-7 Cohort study ascertaining the socio-demographic factors associated with 
zoster disease incidence: study participant flow chart 
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the study 
Zoster code Patient 1 
Start follow-up 
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the study 
Patient 2 PHN code 
Start follow-up 
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excluded from 
the study 
PHN Post-herpetic neuralgia 
Patients aged ≥65 years during study period 01/09/2003-31/08/2013 registered with a CPRD 
practice and meeting the CPRD’s data quality criteria N=931,830 
  
Total patients included in the study N=862,470 
Patients with zoster or PHN code prior to start of follow-up or 
with a first zoster code during follow up recorded as PHN 
N=69,360 
CPRD Clinical Practice Research Datalink 
PHN post-herpetic neuralgia  
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3.5.3 Identifying the study population for the cohort study to describe the 
socio-demographic factors associated with zoster vaccine uptake in 
England (objective 4) 
The CPRD data utilised for this study was from the January 2017 release, linked to HES 
data version 13 and the 2015 English IMD data. This cohort study spanned the first two 
years following the introduction of zoster vaccine in England, from 01/09/2013 until 
31/08/2015.68 Follow-up started on 01/09/2013 (start of national programme) and all 
participants were required to be “acceptable” (Section 3.2.2), alive and currently registered 
with a UTS CPRD practice in England on this date. Follow-up ended at the earliest of: the 
patient’s transfer out date, death date, the date data were last collected from the practice or 
the end of the study (31/08/2015) (Figure 3-8). To allow sufficient time for the individuals to 
be invited for vaccination and the possibility of co-administration of zoster vaccine with 
seasonal influenza vaccine amongst the older population, the study participants  were 
required to have a minimum follow-up of 5 months (September 1st  until the end of January 
2013), which coincided with the main part of the seasonal influenza vaccination campaign.131  
As zoster vaccine was available to a limited extent (privately at first followed by availability 
on the NHS based on GP’s discretion) prior to the introduction of the national programme, 
any individuals with a zoster vaccine code prior to 01/09/2013 were also excluded from the 
study.132, 133 
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Figure 3-8 Cohort study ascertaining the socio-demographic factors associated with 
zoster vaccine uptake: study follow-up period 
 
3.5.3.1 Identifying individuals eligible for zoster vaccination  
In England zoster vaccine is offered routinely to individuals aged 70 years on 1st of 
September of the corresponding vaccination year, with a catch-up amongst older individuals 
as detailed in Section 1.2.5 and Table 1-1. For this study, which spanned a two-year period 
(2013-2015), the routine cohort eligible for vaccination comprised of individuals born 
between 02/9/1942-1/9/1943 for the first vaccination year (2013-2014) and those born  
02/9/1943-1/9/1944 for the second vaccination year (2014-2015) (Table 1-1). As discussed 
previously, to maintain patient confidentiality, only year of birth is available for adults in 
CPRD data. This posed a problem in how to identify an individual’s age-based eligibility for 
zoster vaccine during the study period. The common convention of assigning individuals with 
a nominal birth of 1st July would misclassify some individuals’ eligibility. For example, during 
the 2013-2014 vaccination year, individuals born between 02/09/1942-01/09/1943 and aged 
70 years on 01/09/2013 were eligible for vaccination as a part of the routine cohort. The 
assigned date of birth for those born between 02/09/1942-31/12/1942 would be 01/07/1942, 
therefore misclassifying all these individuals as ineligible as their CPRD age on 01/09/2013 
would be 71 years (Figure 3-9). On the other hand, individuals born between 01/01/1943-
01/09/1943, with an assigned date of birth as 01/07/1943 and aged 70 years on 01/09/2013 
Follow-up starts on 
01/09/2013 (start of the 
national vaccination 
programme) 
  
Follow-up ends 
Earliest of: 
1. Transfer out date 
2. Death date 
3. Last collection date from 
the practice 
4. End of study 
(31/08/2015) 
Individuals eligible for zoster vaccination 
Study period: 01/09/2013-31/08/2015 (2 years) 
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would be correctly identified as eligible. The remaining group of individuals, those born 
between 02/09/1943-31/12/1943 with an assigned date of birth of 01/07/1943 would be 
incorrectly identified as eligible (Figure 3-9). Importantly, the inclusion of this latter group 
could bias the effect estimates for vaccine uptake for the socio-demographic factors of 
interest because the unvaccinated group would comprise a mixture of individuals with 
possibly differing socio-demographic factors: a) those eligible for vaccination who chose not 
to be vaccinated and b) those ineligible on the grounds of age (Figure 3-9).  
To address this, all individuals born in 1943 (or 1934 for the catch-up cohort), who would 
have been eligible for the vaccine in 2013/14 (if born between January-August) or in 2014/15 
(if born between September-December) were selected to investigate vaccine uptake for the 
2-year study period (Figures 3-9 and 3-10). The study population therefore comprised 
individuals born in 1943 (the routine cohort, Figure 3-9) and in 1934 (the catch-up cohort, 
Figure 3-10). 
3.5.3.2 Excluding patients with immunosuppressive conditions and treatments 
As zoster vaccine contains the live attenuated virus, the UK Green book provides guidance 
about contraindications to its administration amongst individuals with certain 
immunosuppressive conditions and treatment (Section 1.2.5).60 To ascertain eligibility for 
zoster vaccination, individuals with the following conditions and treatments were identified 
and excluded at the start of follow-up. These conditions included: leukaemia, lymphoma, 
myeloma, other plasma cell dyscrasias, stem cell transplant, bone marrow transplant, solid 
organ transplants, Human Immunodeficiency Virus infection and cellular immune 
deficiency.60 The immunosuppressive treatments (Section 1.2.5) comprised: biological 
therapies, other immunosuppressive agents such as tacrolimus, disease modifying anti-
rheumatic drugs such as ciclosporin, specific doses for some of these: azathioprine, 
methotrexate, 6-mercaptopurine, steroids; cancer chemotherapy and radiotherapy.60 
The details of how these immunosuppressive conditions and treatment were identified in the 
linked CPRD data are provided in Chapter 5 (Section 5.5).
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Figure 3-9 Individuals included in the zoster vaccine uptake cohort study during 2013-2015 based on year of birth in Clinical Practice 
Research Datalink: routine cohort  
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Figure 3-10 Individuals included in the zoster vaccine uptake cohort study during 2013-2015 based on year of birth in Clinical Practice 
Research Datalink: catch-up cohort 
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3.6 Data management 
Data were analysed using Stata®14 software (StataCorp, College Station, TX, USA). 
In Chapters 4 and 5 details of how I identified the exposure and outcome variables in these 
data including the other covariates used in the analyses, are provided.  
I first generated the patient denominator files for the different studies from the Patient and 
Practice files in CPRD data to identify eligible individuals for each study. The patient list thus 
created was used to identify their records in all the remaining CPRD data files.  
Information for the variables of interest was extracted using code lists, which were generated 
using both text terms and hierarchical searches of the relevant Read codes applied to the 
CPRD’s Medical Browser tool. Similarly, for drugs and therapeutic agents, a list of product 
codes was generated using the CPRD’s Product Browser tool (Section 3.2.1). In addition to 
code lists, information was also captured from the Patient file, Consultation file (using 
consultation type codes) and the structured coded data in these records (entity type codes). 
Information as to when data were recorded was extracted using event dates and system 
dates (Section 3.2.1). As discussed in Section 3.2.1, the Additional Clinical Details files 
does not have dates showing when any entity type code was recorded. However, it is 
feasible to link the Clinical details file with the Additional Clinical Details file using the specific 
identifier present in both files. This allows an event date which is present in the Clinical file to 
be associated with an entity type code recorded in the Additional Clinical Details file 
(Section 3.2.1). I brought together the information from these different sources using 
specific algorithms where necessary (as described in the relevant sections of Chapter 4 for 
socio-demographic factors of interest, and of Chapter 5 for the outcome of interest and 
other variables used in analyses).  
In HES, code lists were generated to identify ICD-10 codes for the conditions of interest. 
Similarly, OPCS code lists were created to identify procedures (for example, bone marrow 
transplants) performed in hospital. The list of patients eligible for inclusion in the study was 
merged with the Patient, Hospitalisation, Episodes and Diagnoses files in the HES data. The 
resultant file comprising eligible patients’ hospitalisation records was subsequently used to 
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identify the ICD-10 codes of interest from the ICD-10 code lists generated. The Procedures 
file was used to select the OPCS codes of interest from the OPCS code lists. 
3.7 Ethics 
All data were anonymised prior to receipt by the candidate.  
Objective 2: Approval for this study was obtained from the Independent Scientific Advisory 
Committee of the Medicines and Healthcare products Regulatory Agency Database 
Research (Ref: 15_253). The study was also approved by the Observational Research 
Ethics Committee of the London School of Hygiene and Tropical Medicine (reference: 
10524). 
Objectives 3 and 4: The protocol for this research was approved by the Independent 
Scientific Advisory Committee of the Medicines and Healthcare products Regulatory Agency 
Database Research (protocol number 16_168).  The study was also approved by the 
Observational Research Ethics Committee of the London School of Hygiene and Tropical 
Medicine (Reference: 11910). 
3.8 Chapter summary 
This thesis utilised CPRD data, one of the world’s largest repository of routinely collected 
primary care electronic health data, linked to hospitalisation data (HES) and deprivation data 
(IMD) from England. These quality-assured primary care data are generally representative 
and cover ~7% of the UK population.  
In this chapter I described the nature of the data sources and how I selected the study 
population for the three different observational studies from the linked CPRD data, 
conducted to meet objectives 2, 3 and 4 of this thesis. 
In the next chapter (Chapter 4), I describe the methods I used to identify the socio-
demographic factors of interest (exposure variables), including age, gender, ethnicity and 
the relevant socio-demographic factors identified from the systematic review (Chapter 2) in 
these linked data.  
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 Chapter 4. Defining social factors in electronic 
health records 
In this chapter (the second of the three methods chapters in this thesis), I describe the 
following- (1) the rationale for selecting the socio-demographic factors considered for further 
investigation, (2) the electronic data sources used to identify these factors, (3) identification 
of socio-demographic factors in linked electronic data and (4) how data algorithms were 
developed and categorisation for each factor was carried out. The results of analyses to 
assess the completeness, timeliness and representativeness of recording for these socio-
demographic variables in the electronic health data are described under the Results section 
(Chapter 6). 
4.1  Rationale for selecting the socio-demographic factors  
The factors examined were chosen if they were considered relevant at an individual level, 
informed by my systematic review (Chapter 2) that was based on the WHO CSDH’s 
conceptual framework (Section 1.1.1) (Figure 1-1), and if they were potentially  available in 
the linked CPRD data.4  
Apart from age and gender, the seven socio-demographic factors of interest included: 
ethnicity, immigration status, religion, living arrangements (including two closely-related 
variables: living alone and cohabitation (living as a couple)),134 marital (relationship) status, 
residence and deprivation (the latter available as linked data). Of these factors, immigration 
status, living arrangements, residence, marital status and area-level deprivation were 
identified as important determinants of vaccine uptake from the findings of my systematic 
review (Chapter 2). The review also highlighted the lack of availability of studies examining 
the association of religion with vaccine uptake. Also, as discussed earlier (Section 1.3.3), 
the zoster vaccine used in the UK includes porcine components which may compromise its 
acceptability amongst some religious groups. Therefore religion was included as one of the 
factors examined in this thesis. Place of residence, which was examined as a binary variable 
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in the systematic review (as urban versus rural area of residence), was examined in greater 
detail, as described later (Section 4.4). Ethnicity was included because of its association 
with both zoster disease burden and zoster vaccine uptake, as previously described 
(Sections 1.3.2 and 1.3.3) and to allow comparisons of this thesis’ findings with the 
analyses of zoster vaccine uptake that had been carried out using the national data, which 
included ethnicity (Section 1.3.3).82 The additional rationale for including specific socio-
demographic factors in the analyses conducted to meet Objectives 2-4 are described in 
Chapters 6-8. 
4.2 Electronic health data for ascertainment of socio-demographic 
factors 
As discussed in Chapter 3, the electronic health data utilised for analyses comprised CPRD, 
HES and IMD data. Information for socio-demographic factors was extracted from all three 
sources, as described below. 
4.2.1 CPRD data 
The data structure of CPRD was detailed in Section 3.2. Information about the socio-
demographic factors of interest was gathered from different data files (Section 3.2.1) 
available in this primary care database. Information was obtained from (1) coded data 
available in different data files and (2) using more targeted information in specific data fields 
within these files (Figure 4-1). To extract information recorded as coded data, specific code 
lists (Section 4.3) were generated for each factor, while information from the specific data 
fields in the Patient files was extracted using specific criteria (Section 4.4).  
Code lists comprised medical, entity type and consultation type codes. Medical codes were 
utilised to gather information for specific socio-demographic factors from the Clinical, 
Immunisation, Referral and Test files (Figure 4-1). Entity type codes available in the 
Additional Clinical Details files and the place where the consultation with the GP took place 
(consultation type codes) was taken from the Consultation files. 
Targeted information from specific data fields available in the Patient file (Figure 4-1) 
included gender, year of birth, marital status and family number. Family number, as 
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described previously in Section 3.2.1, is a practice-specific data field based on a patient’s 
address.135 This number may help to identify individuals registered with the same practice 
who may be sharing a household. Apart from the same households, family number may also 
represent patients with the same address from institutions such as long-term hospital care 
(e.g. neuro-disability), sheltered accommodation, prisons or even under some circumstances 
a block of flats.136 This field is generated by the general practice software when a patient 
registers with a GP or moves address but it is unclear as to how often the family number 
field is updated with changes in address [Personal communications via email CPRD 
Knowledge Centre]. Family number was used to provide information for the following social 
factors: residence, living arrangements (cohabitation and living alone) and marital status 
(Figure 4-1), further details are provided in Section 4.3. 
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Figure 4-1 Information for socio-demographic factors from Clinical Practice Research Datalink data
133 
 
4.2.2 HES data 
The data structure of HES was described in Section 3.3. The data for socio-demographic 
factors were gathered from the Patient, Hospitalisation and Episodes files of HES (Figure 4-
2). The basic demographic (ethnicity) information about individuals was obtained from the 
Patient and Episodes file (Section 4.3.3). Information was also accrued from the source of 
admission codes in the Hospitalisation file. (Figure 4-2). 
4.2.3 IMD data 
As described in Section 3.4, CPRD provides information on patient- and general practice-
level deprivation data as linked datasets. Further details on how the IMD data were 
categorised for use in the analyses are provided in Section 4.5.  
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Figure 4-2. Information on socio-demographic factors from Hospital Episode Statistics data
Patient 
Hospitalisations 
Episodes 
Basic patient details including ethnicity 
Details of hospitalisation including 
admission and discharge dates, source 
of admission (e.g. usual place of 
residence, care home) 
Details of episodes, episode start date, 
ethnicity 
HES data files Contents 
*HES version 10 
~HES version 13 
Socio-demographic factors Information from the 
files 
Ethnicity* 
Ethnicity~ 
Source of admission 
codes 
Ethnicity 
Residence 
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4.3 Identification of socio-demographic factors in linked electronic 
data 
Code lists were generated and applied to the different data files of the linked CPRD data to 
identify socio-demographic factors of interest (Figures 4-1 and 4-2; details are given in the 
following sections). Further information was also obtained from data held within the Patient 
file of CPRD. 
The code lists of CPRD medical codes for socio-demographic factors except ethnicity were 
developed by Prof. Sara Thomas. I went through these medical codes to assess if I 
concurred with these codes and any differences were resolved by discussion. Ethnicity 
codes for both CPRD and HES data were those used previously by Mathur et al. and 
recommended for use under QOF.137 I identified other types of codes (entity type codes and 
consultation type codes) for social factors of interest from the Additional Clinical Details file 
and the Consultation files of CPRD (Figure 4-1). I also identified relevant socio-demographic 
factor codes available in the Patient file of HES data (Figure 4-2). The code lists generated 
for use in the different data sources were then combined to generate final code lists for each 
factor after discussions amongst Prof. Sara Thomas, Dr AJ van Hoek and myself. The 
details of the development of code lists for specific socio-demographic factors is described in 
the following sections.  
As mentioned in Section 4.2.1, four data fields: year of birth, gender, marital status and 
family number, available in the Patient file of CPRD data (Figure 4-1) were also utilised to 
gather information for socio-demographic factors. Information from the family number field 
was obtained as described below. 
Information from family number available in the Patient file of CPRD 
As mentioned briefly in Section 4.2.1, family number is a general practice-specific data field 
based on a patient’s address.135 As family number is not a unique entity across all general 
practices in CPRD, I created a unique identifier by combining both the practice identification 
number and the family number. This unique number was subsequently used to identify 
individuals sharing the same family number (i.e. likely to be from the same household) within 
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the same practice. This allowed identification of study participants who shared the same 
family number (and with other individuals in the general practice who were not part of the 
study population) (Figure 4-3).  
 
Figure 4-3 Identifying individuals sharing a family number in general practices 
 
Family number was utilised to provide information for residence, living arrangements 
(cohabitation and living alone) and marital status for the cross-sectional study (objective 2) 
and the two cohort studies (objectives 3 and 4). For the cross-sectional study, individuals 
sharing same household as the study patients were required to be actively registered on the 
index date of interest (01/01/2013) and their age was also ascertained on this date. For the 
two cohort studies, individuals sharing the same household had to be actively registered with 
the practice at the start of follow-up of the study participant and their age (which was 
required for the development of algorithms to extract relevant information and is discussed 
for each specific factor below) was also determined on this date. 
 
General practice 1 General practice 2 
Key: 
Other patients in the practice 
Study patient in the practice 
Study patient sharing family number with other patient in the same practice 
Study patient sharing family number with another study patient in the same practice 
Putative household 
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 I will now describe how the code lists for specific socio-demographic factors were 
developed and how the information from the Patient file including family number was utilised 
to identify specific factors in the linked data. 
 
4.3.1 Age 
Age was estimated from year of birth available in the Patient file (Figure 4-1) by the common 
convention of using the 1st of July (mid-year) to assign study participants’ day and month of 
birth.  
4.3.2 Gender 
The categorisation of gender available in the Patient file is discussed in Section 4.4.  
4.3.3 Ethnicity 
As mentioned in Section 4.3 above, the codes used for identifying ethnicity from the linked 
CPRD data (Figures 4-1 and 4-2) were those used by Mathur et al.137 The code list is 
provided in Appendix 4 and consisted of 183 codes. The medical codes were sought in the 
Clinical, Referral, Test and Immunisation files of the CPRD dataset (Figure 4-4). In the HES 
data, information on ethnicity was captured from the Patient file (HES version 10) or the 
Episodes file (HES version 13). The site for ethnicity codes in the HES data changed over 
time and I found that it was available in the Episodes file of HES version 13 unlike the HES 
version 10 where this information was available in the Patient file. The implications of this 
finding for extracting ethnicity information from HES are described further in Section 4.4.   
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Figure 4-4  Ascertainment of socio-demographic factors in linked Clinical Practice Research Datalink
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4.3.4 Immigration status 
I identified immigration status using both country of birth codes and specific immigration 
codes. Unlike ethnicity, information for immigration status was available only from the CPRD 
data and not from the HES data (Figure 4-4). Initially 240 medical codes were identified for 
country of birth and immigration status; records with these codes were accrued from the 
Clinical, Referral, Test and Immunisation files of the dataset. However, when the initial 
analysis indicated that these codes did not capture the full extent of immigration status (as 
outlined in Chapter 6), the code list was expanded to additionally include language codes to 
identify individuals born in non-English speaking countries. This broader definition was used 
to maximise the use of available data because from 2008-2011 GPs were incentivised to 
record the first language spoken for all registered patients.138, 139 This decision led to 
inclusion of an additional 225 medical codes. So, in total 465 codes were used for the 
broader definition of immigration status (including country of birth, immigration status and 
language codes) (Appendix 5).   
4.3.5 Religion 
As with immigration status, information on patients’ religion was also only available in the 
CPRD data (Figure 4-4). A code list consisting of 110 medical codes for religion (Appendix 
6) was used to extract relevant information from the Clinical, Referral, Test and 
Immunisation files of the dataset (Figure 4-4).  
4.3.6 Residence 
CPRD does not provide information on whether practices or patients are situated in urban or 
rural areas.  However, information was sought on the type of residence for the older study 
populations, such as whether they lived independently, in sheltered housing, or resided in 
care homes. Care homes included both (i) nursing homes that provide nursing care and (ii) 
residential homes providing only personal care to their residents.140 Homelessness was also 
a potential variable of interest.  Codelists were drawn up to identify all these factors as 
detailed below. 
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Information from CPRD data 
(a) Information from medical, entity type and consultation type codes in CPRD 
Information from the Clinical, Immunisation, Referral and Test files was extracted using 204 
medical codes (Figure 4-4) for place of residence and homelessness (Appendix 7). The 
code list comprised of codes such as- ‘seen in own home’, ‘residential care’, ‘sheltered 
housing’ and ‘homeless’. Additional information on place of residence was obtained from the 
Consultation file and the Additional Clinical Details file.  Two consultation type codes in the 
Consultation file were used: consultation type code 30 (nursing home visit) and 31 
(residential home visit) (Figure 4-4). The entity type code 132 from the Additional Clinical 
details files provided information on care home residence, residence in the patient’s own 
home, sheltered accommodation and other places of residence. 
(b) Information from the family number (Patient file of CPRD) 
Family number was utilised by Shah et al.  as one of the criteria used to define care home 
residence, using data from the Health Improvement Network (THIN) (another UK primary 
care database comprising of some general practices contributing data to both CPRD and 
THIN).141 This study included individuals aged ≥65 years from 326 general practices from 
England and Wales; all these practices had to provide data at least up to March 2008.141 
Care home residence was defined by the presence of a Read code for living in a care home, 
or at least two of the following three criteria: (i) ≥4 individuals aged ≥65 years residing in one 
household, identified using family number, but excluding households where the majority of 
individuals were aged <65 years; (ii) a specially commissioned postcode linkage to an area 
with a care home; (iii) a record of a consultation in care home.141 Although no explanations 
were provided as to why these criteria were utilised, the age and gender distribution of care 
home residents identified by this methodology were comparable to the distributions from a 
national survey and from census data.141  
In the UK, ~94% of care home residents are aged ≥65 years.142 The average nursing home 
size (~47 beds) is larger than the average residential home size (~18 places), and ~40% of 
residential homes provide <10 beds.140 I used this information on the size of care home 
(ranging from <10- 47 beds), the age of care home residents (majority being ≥65 years of 
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age) , and the methodology of Shah et al.,141 to develop two independent criteria to define 
care home residence. Criterion 1 was based on the family number definition used by Shah et 
al. and was as follows:141 a household with >3 individuals aged ≥65 years was defined as a 
care home if the total count of these older individual was greater than the number of 
individuals aged <65 years in the same household.  For Criterion 2, to further allow capture 
of information if the care homes included individuals aged 51-64 years, households with >3 
individuals aged ≥65 years and ≤3 individuals aged ≤50 years were defined as care homes 
(Figure 4-5). 
 
*Based on141 
 
Figure 4-5 Criteria for defining care home residence using family number 
 
Information from HES data  
The codes for source of admission in the Hospitalisations file of the HES data, which provide 
information about patient’s location immediately prior to hospital admission, were also used 
to derive information about an individual’s place of residence. The code list utilised is shown 
in Table 4-1 and comprised codes for place of residence such as prison, care home and 
hospice.  
Family number: criteria for defining care home residence 
Criterion 1*  
In a household: 
A. Number of individuals 
aged ≥65 years is >3  
And 
B. Number of individuals 
aged ≥65 years is more 
than those aged <65 years 
Criterion 2  
In a household: 
A. Number of individuals 
aged ≥65 years is >3  
And 
B. Number of individuals 
aged <50 years is ≤3  
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Table 4-1 Source of Admission codes in the Hospital Episodes Statistics data used to 
derive place of residence information 
Code* Description Information 
extracted for 
residence# 
30  Repatriation from high security psychiatric hospital (1999-00 to 2006-07) Residence: other 
39  Penal establishment (court and police station excluded from 1999-2000) Residence: other 
48  High security psychiatric hospital, Scotland (1999-00 to 2006-07) Residence: other 
49  NHS other hospital provider: high security psychiatric accommodation in 
an NHS hospital provider (NHS trust) 
Residence: other 
50  NHS other hospital provider: medium secure unit (1999-00 to 2006-07) Residence: other 
54  NHS run nursing home, residential care home or group home Care home residence 
65  Local authority Part 3 residential accommodation: where care is provided 
(from 1996-97) 
Sheltered 
accommodation 
66  Local authority foster care, but not in Part 3 residential accommodation: 
where care is provided (from 1996-97) 
Residence: other 
69  Local authority home or care (1989-90 to 1995-96) Care home residence 
85  Non-NHS (other than Local Authority) run residential care home (from 
1996-97) 
Care home residence 
86  Non-NHS (other than Local Authority) run nursing home (from 1996-97 to 
2006-07) 
Care home residence 
88  Non-NHS (other than Local Authority) run hospice Residence: other 
* Source of admission codes # Categorisation are outlined in Section 4.4.4 
 
Information from place of residence such as such as living in a household, care home 
residence or sheltered accommodation was also extended to rule out that a patient was 
homeless. 
The categorisation of the residence variable after information from all sources was combined 
is described in Section 4.4.4. 
4.3.7 Living arrangements: cohabitation 
Information from CPRD data 
(a) Information from medical codes in CPRD 
The medical code list for cohabitation comprised 86 codes and included codes such as 
‘cohabiting’ and ‘spouse unwell’ (Appendix 8). The list was used to identify information 
recorded in the Clinical, Immunisation, Referral and Test files (Figure 4-4). 
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(b) Information from the family number (Patient file of CPRD) 
Further information on cohabitation was accrued from the family number field of the Patient 
file. The criteria used to identify cohabitation status from the family number were based on 
two previous studies conducted using the THIN database.143, 144 In the older study, 
conducted between 2005-2008 amongst individuals aged ≥60 years, the criteria for 
identifying cohabitation were based on an analysis of  national survey data.144 In this study, 
individuals aged ≥60 years residing with a member of the opposite sex with an age gap of 
≤10 years, and with an age gap between the couple and any other younger member of the 
household of >15 years, were identified as a cohabiting couple.144 In the second study, 
conducted between 2003-2013, cohabitees were identified as a two adult household (to 
avoid counting care homes or a block of flats), irrespective of gender, with age gap of ≤15 
years.143 These authors excluded household with two adults where the age difference was 
>15 years to avoid counting individuals residing with their children or individuals who had 
parents living with them.143  
For this thesis, the criteria from the two studies described above,143, 144 were adapted to 
identify cohabitation status from the family number as follows. Two adults (at least one aged 
≥65 years) living in a household size of two or three, irrespective of gender, were considered 
as a cohabiting couple if their age difference was ≤15 years (to avoid counting offspring); if 
there was another occupant, the age difference between the couple and the third occupant 
was required to be >15 years to capture either living with children or an elderly parent. 
Further information for cohabitation was also obtained from the other two closely related 
social factors: living alone and marital status (described further in Section 4.4). 
4.3.8 Marital status 
Information from CPRD data 
(a) Information from medical and entity type codes in CPRD 
The medical code list for marital status consisted of 152 codes (Appendix 9). Entity type 
code 98 from the Additional Clinical Details files (Figure 4-4), which provided information on 
‘next of kin- spouse’ was also used to extract information.  
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(b) Information from the Patient file of CPRD  
Further information for marital status was also gathered from the two data fields present in 
the Patient files of the CPRD data (Figure 4-1): marital status and family number. The 
information obtained from the marital status data field in the Patient file (Figure 4-1) was 
used to supplement data obtained from the marital status code list. The categorisation of this 
variable in the Patient file is supplied by CPRD and provides information about whether an 
individual was single, engaged, married or in civil partnership, separated, widowed or 
divorced (Table 4-2). The ‘stable relationship’ field was not utilised to extract marital status 
data as this field was deemed too non-specific to provide further information about the 
relationship status of an individual. 
Table 4-2 Extraction of marital status information from the Patient file of Clinical 
Practice Research Datalink 
Marital status field in Patient files Information extracted for marital status 
variable 
Single Single  
Married Married/ civil partnership 
Remarried Married/ civil partnership 
Civil partnership Married/ civil partnership 
Co-habiting Partner uncategorised 
Stable relationship Not used as does not provide information on 
marital status  
Engaged Single 
Widowed Widowed 
Divorced Divorced 
Separated Separated 
 
Individuals who were cohabiting (Section 4.3.7) were also assigned the marital status of- 
‘Partner uncategorised’ (categorisation of marital status is discussed in Section 4.4.4) due 
to limited information about marital status available from cohabitation status. 
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4.3.9 Living arrangements: living alone 
Information from CPRD data 
(a) Information from medical and entity type codes in CPRD 
The code lists for living alone status (as a binary yes/no variable) comprised both medical 
codes and entity type codes. The medical code list comprised 91 codes (Appendix 10) and 
included codes such as ‘lives alone’ and ‘lives with relatives’ (the latter providing evidence 
for not living alone). Entity type code 132, available from the Additional Clinical Details file 
(Section 4.2.1) was also used to provide information on living alone (Figure 4-4). 
(b) Information from the family number (Patient file of CPRD) 
Further information on not living alone was also accrued from the family number field of the 
Patient file. Study participants were described as not living alone if their family number was 
shared by one or more individuals (household size ≥2). 
 Additionally, indirect information on not living alone was also obtained from other social 
factors: place of residence, cohabitation and marital status (Figure 4-4) as described in 
Section 4.4.3. 
4.4 Data algorithms and categorisation of socio-demographic factors 
In this section, I describe:  
 variation of some socio-demographic factors over time 
 how the information about socio-demographic factors, depending upon their 
variability over time, was assimilated from different data sources (as described in 
Section 4.3) using data algorithms and how indirect information was obtained from 
other social factors ;   
 categorisation of factors; and 
  how variables that varied with time were managed for specific studies conducted as 
a part of this thesis. 
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4.4.1 Effect of time on socio-demographic factors 
Certain socio-demographic factors such as ethnicity and immigration status which do not 
change with time, and factors such as religion which are unlikely to change over time, were 
assumed as time-invariant variables. For example, if a person had their ethnicity recorded 
20 years ago, it was assumed to hold true for the present time. On the other hand, a 
recording made 20 years ago about individuals’ marital status might not necessarily reflect 
their current marital status. Therefore, marital status, place of residence and living 
arrangements, which were more likely to change with the passage of time, were classified as 
time-varying factors in this thesis.  
4.4.2 Determining the date of recording of socio-demographic factors 
For the time-varying social factors- residence, living arrangements and marital status, it was 
important to determine the date when the factor was recorded in the health data.  
Determining dates of recording of time-varying factors in CPRD data 
As described previously in Sections 3.2.1 and 3.6, all CPRD data files (with a few 
exceptions- namely the Patient, Practice and Additional Clinical Details files) provide two 
different date fields associated with any recordings made. These include an event date (the 
date the event occurred, as recorded by the GP) and a system date (the date when the 
event was recorded on the GP computer system). The event date was used to determine 
when a socio-demographic factor was captured in these data.  If the event date was 
unavailable, the system date was utilised. For information extracted from the Patient files (as 
described in Section 4.3), both the event date and system date were unavailable to indicate 
when the data for the given factor was recorded. For such records, patients’ current 
registration date (the date when a patient’s current registration began with the general 
practice, Section 3.2.1), which is available in the Patient file, was used as a conservative 
estimate of the date of recording the socio-demographic factor. The dates for recording of 
entity codes in the Additional Clinical Details file, as described in  Section 3.6, were 
ascertained after linking this file to the Clinical file and using the event date field present in 
the Clinical file. 
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Determining dates of recordings in HES data 
For information extracted from the Hospitalisation file in HES data, the hospital admission 
date was utilised as the date of recording of the factor; for data extracted from the remaining 
HES files, the episode start date (as described in Section 3.3.1) was used. 
The issue of when factors were recorded in these data (timeliness of recording) is further 
discussed in Chapter 6 where timeliness of recording of time-varying factors was 
considered as a quality criterion in terms of ascertaining these factors from EHR.  
4.4.3 Developing data algorithms 
An individual may have single or multiple records of a socio-demographic factor of interest in 
their EHR. Multiple records can be made on either the same event date or on different event 
dates. When an individual had multiple records for a factor with the same event date, if the 
information was discordant or contradictory, those records were excluded. For example, if an 
individual had two records on a single event date, with one record coding this individual as 
an immigrant and another record coding this same individual as a non-immigrant, both these 
records for the patient for that event date were excluded from any further analysis. 
In the following sections, I describe how information for both time-invariant and time-varying 
factors for a given patient were further processed.  
(I) Data algorithm for assimilation of information for time-invariant factors 
As discussed in Section 4.3.1, information on ethnicity was assimilated from both CPRD 
and HES data (Figure 4-4). If a patient had no ethnicity information from CPRD data but had 
this information available in their HES data (if version 10), no algorithms were required to 
extract ethnicity information as the information from the HES Patient file was supplied as a 
single record. Information from individuals with multiple records of ethnicity in CPRD data 
which did not have discordant information on same event date, was extracted using an 
algorithm developed by Mathur et al. 91  According to this algorithm, when an individual had 
multiple ethnicity coded records in CPRD data, the code which was most common was 
utilised to assign ethnicity. If all ethnicity codes were equally common then the most recent 
code was used to assign ethnicity. However, for HES version 13, I found that ethnicity 
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information was recorded in the Episodes file and not (as in HES version 10) in the Patient 
file (Figure 4-2).  As a result, there could be more than one ethnicity-coded record for a 
patient in the HES version 13 data. I adapted the above described algorithm (Figure 4-6) to 
extract ethnicity information, using the same principle of first utilising the most common code 
followed by most recent code if all codes were equally common. 
Unlike ethnicity, information for religion and immigration status was only available from 
CPRD data (Figure 4-4). The algorithm described above for determining ethnicity from 
multiple records per patient, using the most common code or most recent code if codes were 
equally common (Figure 4-6), was also utilised to gather information for these two factors.
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Figure 4-6 Algorithm for ascertainment of time-invariant social factors (ethnicity, immigration status and religion) in linked Clinical Practice 
Research Datalink data* 
* Based on91 
Code available in CPRD data 
Single record with the code 
Yes 
Code available in HES data No 
Multiple records with code 
Code used for analyses 
Equally common codes Most common code 
Most recent code used for analyses Most common code used for 
analyses 
CPRD Clinical Practice Research Datalink HES Hospital Episode Statistics 
No 
Two conflicting codes on the same 
day Yes 
Discard both 
records 
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(II) Data algorithm for assimilation of information for time-varying factors 
II a) Information from family number 
Information for time-varying factors, namely marital status, place of residence and living 
arrangements (as described in previous Section 4.3), was gathered from different sources 
using CPRD and HES data (Figure 4-4). Information for these variables was also accrued 
from the family number in the Patient files (Section 4.3). However, as it was unclear as to 
how often the family number field is updated (Section 4.2.1) with changes in patient’s 
address [Personal communications via email with the CPRD Knowledge Centre]; information 
for marital status, residence and living arrangements extracted from this field was used only 
when data for these factors for a given patient were unavailable from other data sources in 
CPRD or HES (Figure 4-7). 
 
 
Figure 4-7 Using information for marital status, living arrangements and residence 
extracted from family number in linked Clinical Practice Research Datalink data 
 
II b) Indirect information about a social factor from other closely related social factors 
Indirect information was also obtained for a time-varying social factor from information for 
another social factors (Figure 4-4) in the following manner.  Ascertainment of marital status 
Code* available in CPRD or/and HES data 
* for marital status, residence or living arrangements  
CPRD Clinical Practice Research Datalink 
HES Hospital Episode Statistics 
Yes 
Code* used for analyses 
No 
Use information* if available from family 
number 
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also provided indirect information for cohabitation, as shown in the Table 4-3 and Figure 4-4. 
Individuals with codes for being married, in a civil partnership or in a stable relationship were 
assumed to be cohabiting, and individuals who were cohabiting were assumed to be not 
living alone. Individuals with a residence code for living in a care home or residential home, 
in a hospice, psychiatric unit or  prison were also assumed to be not living alone (Table 4-4 
and Figure 4-4). Similarly individuals with codes for residing in households, care homes, 
sheltered accommodation or other places of residence were assumed not to be homeless. 
Table 4-3 Extracting information from closely related time-varying social factors: 
marital status, cohabitation and living alone 
Marital status code Information for cohabitation  Information for living alone variable 
Married Cohabiting Not living alone 
Remarried Cohabiting Not living alone 
Civil partnership Cohabiting Not living alone 
Co-habiting Cohabiting Not living alone 
Stable relationship Cohabiting Not living alone 
 
Table 4-4 Extracting information from closely related time-varying social factors: 
residence and living alone 
Residence code Information for Living alone variable 
 Residence in care home, residential home or hospice Not living alone 
 Residence in prison Not living alone 
 Residence in high security psychiatric hospital or medium secure 
units 
Not living alone 
 
4.4.4 Categorisation of social factors 
The categorisation of both time-invariant and time-varying factors was guided by the 
categorisation used for these variables in the 2011 English Census data and the availability 
of data in EHR.134, 145-151 The categorisation used in the Census was utilised in this thesis to 
enable assessment of the representativeness of the recorded socio-demographic factors in 
the linked EHR by comparing these recordings with the 2011 English Census; this 
comparison is described further in Chapter 6. In the following section I describe how these 
factors were categorised. 
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Age 
Age in years was categorised into age-groups (described further in Chapters 6-8). 
Gender 
Gender was a binary (male/female) variable. 
Ethnicity 
The ethnicity data were categorised into five categories: White, South Asian, Black, Others 
and Mixed. 
Immigration status 
In the 2011 English Census data, country of birth had four main categories: (a) Europe 
including the United Kingdom, (b) Africa, Middle East and Asia, (c) The Americas and the 
Caribbean and (d) Antarctica, Oceania and other.152 I anticipated that the data from the EHR 
would provide less detailed information about immigration status and therefore categorised 
this factor as a binary variable: immigrant and not an immigrant. It was still feasible to 
compare the recording of immigration status with the 2011 English Census data, which could 
also be categorised as a binary variable.152  
Religion 
Religion was categorised into eight categories: Buddhists, Christians, Hindus, Jews, 
Muslims, Sikhs, Others and no religion (atheists). 
Residence 
Place of residence was grouped into four categories: household, care home including 
residential homes, sheltered accommodation and `other places of residence’. The latter 
consisted of places of residence not included in the first three residence categories: for 
example- prisons and hospices. Information obtained about care home residence was also 
considered as a binary variable in its own right as it was assumed that a GP was more likely 
to record care home residence than other places of residence such as household, perhaps 
due to differences in healthcare requirements – this is further discussed in Chapter 6. 
Homelessness was also categorised as a binary variable. 
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Living arrangements: cohabitation and living alone 
Cohabitation and living alone were both categorised as binary (yes/no) variables. 
Marital status 
Marital status had seven categories: single (including engaged), married/in a civil 
partnership, widow/er, divorced, separated, partner-other, and partner-uncategorised. The 
partner-other category included the following three groups: common-law husband, common-
law wife and common-law partnership. The partner-uncategorised category included non-
specific codes such as ‘relationship problem’s, ‘cohabitation’, ‘partner unemployed’ and 
‘partner stops working’ (the entire list of codes included in the partner uncategorised 
category are presented in Appendix 11). I considered that some of these non-specific codes 
could be used by GPs for individuals who were previously categorised with a more specific 
code such as married, common-law husband or engaged. A decision tree was generated for 
individuals categorised as partner-uncategorised to gather more specific information from 
earlier codes, if available. If an individual had an earlier code for being married, engaged or 
a partner-other category, their marital status was categorised as per their earlier code 
(Figure 4-8). However if individuals’ previous marital status was widowed, divorced or 
separated, I decided to keep the marital status as partner-uncategorised, as these 
individuals might have a different current relationship status (Figure 4-8). No changes were 
made if the individual’s previous marital category was also partner-uncategorised (Figure 4-
8).  
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Figure 4-8 Decision tree for categorisation of marital status: partner uncategorised 
 
4.4.5 Ascertainment of socio-demographic factors for the cross-sectional 
and cohort studies 
This section outlines how date of recording was used to ascertain socio-demographic factors 
for the cross-sectional study carried out for objective 2 (the investigation of completeness, 
timeliness and representativeness of recording of socio-demographic factors in the linked 
Is the marital 
status for the 
patient: partner- 
uncategorised? If 
yes check the 
earlier marital 
codes 
Previous code is 
engaged 
Previous code is 
married/ civil 
partnership 
Previous code is 
widowed 
Previous code is 
divorced 
Previous code is 
separated 
Previous code is 
partner- other 
Previous code is 
partner- 
uncategorised 
Decision: keep  as 
previous engaged 
Decision: keep as 
previous married/ civil 
partnership 
Decision: keep as 
partner- uncategorised 
Decision: keep as 
partner- uncategorised 
Decision: keep as 
partner- uncategorised 
Decision: keep as 
previous partner- other 
Decision: keep as 
partner- uncategorised 
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EHR) and for two cohort studies carried out for objectives 3 and 4 (to assess inequalities in 
the burden of zoster and uptake of zoster vaccine amongst older individuals).  
Time-invariant factors: ethnicity, religion and immigration status 
Codes for factors considered as time-invariant (Section 4.4.1) were considered for analyses 
irrespective of the date of recording.  
Time-varying factors: marital status, living arrangements and place of residence 
For the cross-sectional study (Section 3.5.1, objective 2), the latest code of a time-varying 
social factor in the period immediately before or on the index date of interest (01/01/2013) 
was used for the analysis.  
For the two cohort studies (Sections 3.5.2 and 3.5.3, objectives 3 and 4), information for 
time-varying social factors, with the exception of care home residence (explanation to 
follow), for a given patient was carried forwards or backwards depending upon the 
availability of the code in relation to the study period. This is illustrated in the Figures 4-9, 4-
10 and 4-11. If a single code for a given factor was available before the start of follow-up, the 
information from the code was carried forward for the duration of the study (Figure 4-9). 
Similarly, if a code was available only after the end of follow-up of the study, the information 
was carried backwards for the study period (Figure 4-10). If multiple codes were available 
(Figure 4-11), the information from a code was carried forwards up until the appearance of 
another code. 
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Figure 4-9 Utilising information for time-varying factors (except care home residence) available only before the start of follow-up of cohort study 
 
Figure 4-10 Utilising information for time-varying factors (except care home residence) available only after the end of follow-up of cohort study 
A. Information available from the data 
Start of follow-up End of follow-up 
Code: living alone  
B. Assumptions made  
Start of follow-up End of follow-up 
Code: living alone  
Living alone 
Key A: an example of information available in linked data; B: how information was utilised in this thesis 
A. Information available from the data 
Start of follow-up End of follow-up 
Code: living alone  
B. Assumptions made  
Start of follow-up End of follow-up 
Code: living alone  
Living alone 
Key A: an example of information available in linked data; B: how information was utilised in this thesis 
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Figure 4-11 Utilising information for time-varying factors (except care home residence) available before and during follow-up of cohort study 
A. Information available from the data 
Start of follow-up End of follow-up 
Code: living alone  Code: not living alone  
Start of follow-up End of follow-up 
Code: living alone 
B. Assumptions made  
Not living alone Living alone 
Code: not living alone  
Key A: an example of information available in linked data; B: how information was utilised in this thesis 
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For individuals residing in care homes, I assumed that a GP was more likely to record their 
place of residence compared to the residence of other older individuals, due to differing 
health needs of this social group. Therefore carrying a care home code information 
backwards i.e. assuming that a patient was residing in a care home in the period preceding 
the care home code, as was conducted for other time-varying factors,  could have an 
increased risk of misclassification. So in the period preceding the appearance of a care 
home code, individuals were considered as not residing in a care home (Figure 4-12) and in 
the period after the code, they were assumed to be living in a care home until the 
appearance of another code indicating different residential circumstances.   
Further details about ascertainment of these factors in the specific cohort studies are 
presented in Chapters 7 and 8. 
 
Figure 4-12 Utilising information for care home residence from linked data for cohort 
study. 
 
4.5 Index of Multiple Deprivation: Patient- and practice-level 
As detailed in Section 3.4, the IMD quintiles used in analyses were available at a LSOA 
level for both the location of the general practice and for the patient’s residence. Quintile 1 
A. Care home residence information available from the data 
Start of follow-
up 
End of follow-
up 
Code: care home 
residence 
Start of follow-
up 
End of follow-
up 
B. Assumptions made for care home residence 
Code: care home 
residence 
Not in care 
home 
Care home 
resident 
Key A: an example of information available in linked data; B: how information was utilised in this thesis 
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represented the least deprived area and quintile 5 indicated the most deprived area.129   
Practice-level IMD quintiles were used if patient-level data were unavailable. The details 
about the proportion of patients with missing IMD status for whom the practice-level IMD 
data were used are provided in Chapters 7 and 8. As CPRD provides linkage with only one 
of the IMD datasets for any one study to maintain patient confidentiality,120 the 2010 IMD 
data were used for the cross-sectional study (objective 2) while the 2007 and 2015 IMD 
data were used for the zoster burden and zoster vaccine uptake cohort studies (objectives 
3 and 4), respectively. 
4.6 Chapter summary 
In this chapter, I have described the methods used to ascertain and categorise the socio-
demographic factors of interest in the linked EHR. In the next chapter, I continue to discuss 
the methodology employed in this thesis, and describe how the outcome variables and other 
covariates used in the analyses of zoster burden and zoster vaccine uptake were 
ascertained in the electronic data. 
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 Chapter 5. Defining outcomes and other variables 
of interest in electronic health records 
5.1 Introduction 
This is the third and the final chapter for the Methods section of this thesis. In this chapter, I 
describe the ascertainment of the outcomes of interest in the linked data for objectives 3 
and 4, namely incident zoster and receipt of zoster vaccination, as well as other covariates 
used in the analyses. 
5.2 Outcome variables 
As mentioned earlier (Section 1.5), two observational studies were conducted to meet 
objectives 3 and 4: to examine the socio-demographic determinants of the burden of 
incident zoster and of zoster vaccine uptake amongst older UK individuals, respectively. 
5.2.1 Defining zoster incidence in the linked data 
To meet the third objective, a 10-year cohort study (2003-2013), covering the period prior to 
zoster vaccine introduction in the UK, was conducted to ascertain the association of socio-
demographic factors with a first episode of zoster. The identification of the study population 
in these linked data was described previously (Section 3.5.2). It consisted of individuals 
aged ≥ 65 years who were alive and currently registered with a CPRD practice in England. 
As the objective of this study was to determine the incidence of a first zoster episode during 
follow-up (i.e. a first code for a zoster diagnosis during the study period) it was not 
necessary to generate multiple zoster episodes during the follow-up period and individuals 
with a history of zoster prior to the start of follow-up had to be excluded. The generation of 
the zoster code list and the method of excluding individuals with past zoster was detailed in 
Section 3.5.2 when describing the study population, and a brief overview is presented here.  
Both CPRD and HES data (Admitted Patient Care data, Section 3.3) were examined to 
identify a diagnosis of zoster as patients with zoster can present in general practice or 
directly to a hospital. This entailed using medical codes (CPRD data) and ICD-10 codes 
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(HES data) for zoster and PHN (the code list is available in Appendix 3). In CPRD data, the 
Clinical and Referral data files (described in Section 3.2.1) were utilised to identify these 
individuals. In HES data, the diagnosis of zoster or PHN was identified  using relevant ICD-
10 codes recorded in either the primary or secondary diagnosis fields (Section 3.3.1) of the 
Diagnoses data file (Figure 3-4) from any hospitalisation episode.   
After identifying patients with relevant zoster codes, I ascertained the date of recording of 
the zoster diagnosis using the event date field in CPRD (described in Section 3.2.1) and the 
episode start date in HES data (described in Section 3.3.1). Individuals with missing dates 
for zoster diagnoses were excluded from the zoster incidence study as it was impossible to 
ascertain whether zoster occurred prior to or during the study period. Zoster-coded records 
of study participants from CPRD and/or HES were appended together. To identify and 
exclude patients with a prior history of zoster (as detailed in the Section 3.5.2), individuals 
who had a code for zoster or PHN recorded prior to the start of follow-up were excluded 
(Figure 3-6). Similarly, individuals who had their first code for zoster as PHN (a sequela of 
zoster) during the follow-up period (Figure 3-6) were also excluded. For the remaining 
participants, the earliest date of a zoster code recorded during the study period in the 
appended CPRD and HES dataset was used to identify the first zoster code and this was 
used as a date of the outcome (incident zoster).  
The incidence of first episode of zoster during follow-up was ascertained using a Poisson 
regression model and was determined by dividing the number of individuals with a first 
zoster code (the numerator) by the person-time at risk of developing zoster (the 
denominator). The details of the statistical analysis, and the results of this analysis: 
ascertaining the socio-demographic determinants of zoster incidence in this study 
population, are presented in Chapter 7 in form of a published paper. 
5.2.2 Defining zoster vaccine uptake in CPRD 
For the fourth objective of this thesis a cohort study, spanning a two-year period (2013-2015) 
following the introduction of zoster vaccine in the UK, was conducted to examine the 
association of socio-demographic factors with zoster vaccine uptake. The study population 
(identified as described in Section 3.5.3) comprised individuals currently registered with a 
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CPRD practice in England and eligible for zoster vaccination during the study period 
(01/09/2013-31/08/2015). Below, a description of how I identified zoster vaccine uptake 
during the study period is provided.  
The CPRD data were examined to determine zoster vaccination for the participants during 
the study period as the NHS zoster vaccination programme is delivered through general 
practice and not via hospitals. Zoster vaccination was determined from five different data 
files in CPRD data. These included using product codes in the Therapy files, immstype 
vaccine codes in the Immunisation file and medical codes in the Clinical, Referral and Test 
files (codes provided by Prof. Sara Thomas, Appendix 12). In the Immunisation file an 
additional ‘status’ field exists (as described in Section 3.2.1, Figure 3-2) which also provides 
information on the status of vaccination: i.e. whether the vaccine was advised, refused or 
given. Similarly, medical codes for declining, not consenting or not attending for zoster 
vaccination were also identified (Appendix 12). The records for individuals with relevant 
zoster vaccination codes from these five different data files were first appended. I then 
excluded from the study individuals with conflicting information on zoster vaccine uptake on 
same date; i.e. participants with the simultaneous recoding of a zoster vaccination code and 
a refusal/declining/not attending/not consenting code on a given date. 
An individual might have multiple records for zoster vaccination recorded on the same day or 
on different days in the same and/or different data files. For a participant with multiple 
vaccination records on different dates but in the same data file, I used the earliest record. In 
order to integrate information from individuals with multiple vaccination codes recorded on 
different event dates in different data files, I developed an algorithm (Figure 5-1) to 
determine when these individuals were vaccinated during the study period. In this algorithm, 
the Therapy files were given the highest priority as the presence of a product code in this file 
indicated that a prescription was actually issued by the GP.113 The second priority was given 
to the Immunisation files that provided information about both the vaccine type (zoster) and 
additional information on whether the vaccine was advised, refused or given (the ‘status’ 
field). Finally, medical codes from the Clinical, Referral or Test files were used. After 
excluding individuals with conflicting vaccination information on a given date (Figure 5-1), 
receipt of zoster vaccination during the study period was first ascertained by the presence of  
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Figure 5-1 Algorithm for determining zoster vaccination status in Clinical Practice Research Datalink 
Patients with presence of a product code for zoster vaccine in the Therapy file 
Vaccinated 
Patients without zoster vaccine code in the Therapy file but with an 
immunisation type code for zoster vaccine and the status field was `given’ 
Patients with conflicting codes on the same date i.e. if zoster vaccine codes 
and codes for refusal/declining/did not attend/no consent co-exited 
Patients without zoster vaccination information from the Therapy and 
Immunisation files but with zoster vaccination medical codes in the Clinical, 
Referral or Test files 
Vaccinated 
Vaccinated 
Patients excluded from the study 
Patients without any conflicting zoster vaccination codes on the same date 
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a relevant code in the Therapy file, as described in the algorithm. For patients without 
vaccination information from the Therapy file, the Immunisation file was then examined for 
the relevant immunisation type codes with the immunisation status field recorded as `given’ 
to assign vaccination status. Finally, the Clinical, Referral or Test file records of the 
remaining participants were examined for the presence of specific zoster vaccine medical 
codes (Figure 5-1) to categorise individuals as vaccinated. 
The association of socio-demographic factors with zoster vaccine uptake was assessed 
using a logistic regression model. The reasons why a logistic regression model was used for 
these analyses and the results are discussed in Chapter 8 in form of a research paper 
(submitted for publication). 
5.3 Other covariates 
In the two analyses for objectives 3 and 4, conducted to ascertain the association between 
socio-demographic factors and outcome of interest (zoster disease burden and zoster 
vaccine uptake respectively), the reasons why other covariates needed to be considered, 
follow. Firstly, in the zoster disease burden analyses, certain chronic conditions and 
immunosuppressive conditions/therapies that are risk factors for zoster were considered as 
a priori potential mediators of the relationship between socio-demographic factors and zoster 
disease incidence. Secondly, in the zoster vaccine uptake analyses, the study population 
consisted of individuals eligible to receive this live vaccine (Section 3.5.3). In order to 
identify eligible participants, individuals with certain immunosuppressive conditions or taking 
immunosuppressive therapies, which are contraindications for zoster vaccine administration 
had to be identified and excluded from the study. Additional covariates for the vaccine 
uptake analysis comprised a past history of zoster and administration of seasonal influenza 
vaccine. In Chapters 7 and 8, the rationale for using these covariates in these two analyses 
is further discussed. In this section, I provide the details of how these variables were 
determined in the linked electronic health data. 
The immunosuppressive conditions and therapies which are contraindications to zoster 
vaccine administration were identified based on the UK Green Book guidance.60 Chronic 
conditions that increase the risk of zoster were identified from a previous UK study.46 The 
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covariates were identified using medical codes in CPRD (Section 3.2), and using ICD-10 
codes in HES Admitted Patient care data (Section 3.3). For some hospital-based 
procedures (described in the relevant sections below), OPCS codes (Section 3.3.1) were 
also utilised to identify certain immunosuppressive conditions in HES data. The code lists 
were provided by Prof. Sara Thomas. I examined the entire records of the patients for the 
presence of these codes at any point prior to the end of follow-up. The only exceptions to 
this were the two covariates utilised in the zoster vaccine uptake analyses: (a) for past 
history of zoster, I looked for the relevant code present at any point before the start of follow-
up, and (b) for seasonal influenza vaccine uptake- I ascertained relevant codes during the 
zoster vaccine uptake study period (2013-2015). Individuals with chronic conditions 
(described in Section 5.3.1 below) were considered to have the condition from the date of 
the first recording of the code in either the CPRD or HES dataset; if codes for chronic 
conditions were identified in both CPRD and HES data, the earliest date of recording was 
used. For immunosuppressive conditions and therapies, I devised algorithms and criteria to 
ascertain periods of immunosuppression during the study period (details to follow in 
Sections 5.3.2 and 5.3.3). Following the common convention when routinely collected 
health data are utilised for research, individuals without a relevant code were assumed not 
to have that condition or treatment. Further details for these covariates are provided below in 
Sections 5.3.1-5.3.5.  
5.3.1 Chronic conditions  
The chronic conditions that increase the risk of zoster were identified from a previous study 
and included: rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel 
disease, chronic obstructive pulmonary disease, asthma, chronic kidney disease and 
diabetes.46 Both CPRD (Clinical, Referral and Test files) and HES data were used to identify 
these conditions using medical codes and ICD-10 codes, respectively (Appendix 13).  
5.3.2 Immunosuppressive conditions  
Based on the UK Green Book guidance, the following immunosuppressive conditions, in 
which zoster vaccination is contraindicated, were identified: haematopoietic and lymphoid 
tissue malignancies, human Immunodeficiency virus (HIV) infection, other cellular immune 
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deficiency and solid organ transplant.60 The details of how these conditions were identified in 
CPRD (Clinical, Referral and Test files) and hospitalisation data, and the criteria used for 
determining the duration of immunosuppression are provided below. 
A) Haematopoietic and lymphoid tissue malignancies including haematopoietic 
stem cell transplant 
This included leukaemia, lymphoma, myeloma, other plasma cell dyscrasias and 
haematopoietic stem cell transplant.60 Individuals with these conditions were identified using 
both medical codes and ICD-10 codes (Appendix 14) in CPRD and HES data. OPCS codes 
(to identify procedures carried out during hospitalisation, Section 3.3.1) were also used to 
identify haematopoietic stem cell transplant in the Procedures file of HES data. The list of 
OPCS codes used is provided in the Appendix 14. Following each diagnostic or procedure 
record, individuals with any of these conditions were considered to be immunosuppressed 
for a period of 24 months.46, 60 
B) HIV, other cellular immune deficiency and solid organ transplant 
Individuals with these conditions were identified in both the CPRD and HES data, using 
medical and ICD-10 code lists (Appendix 15), respectively. The OPCS code list was also 
used to identify individuals with solid organ transplants (Appendix 15). Individuals with 
cellular immune deficiency (e.g. Di George syndrome, Wiskott - Aldrich syndrome), with HIV 
infection or with a solid organ transplant were considered to be immunosuppressed from the 
date of the first appearance of the code, as these are life-long conditions. 
5.3.3 Immunosuppressive medications 
As described for the immunosuppressive conditions, the UK Green Book also provides 
criteria for certain immunosuppressive treatments during which the administration of zoster 
vaccine is contraindicated.60 These immunosuppressive treatments (Table 5-1) included 
chemotherapy, radiotherapy, specific high doses of oral or injectable corticosteroids and 
other immunosuppressive agents (thiopurine medications, Disease Modifying Anti-rheumatic 
Drugs (DMARDs), non-biological immune modulating agents and biological therapies). The 
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details of how I identified these medications in the linked CPRD data and criteria used for 
defining the duration of immunosuppression are provided below.   
A) Immunosuppressive chemotherapy and radiotherapy 
As for other conditions described in previous sections, individuals undergoing 
immunosuppressive chemotherapy and/or radiotherapy were identified in the Clinical, 
Referral and Test files of CPRD using medical codes (Appendix 16); and using ICD-10 
codes and OPCS codes (Appendix 16) in HES data. Study participants with these codes 
were considered to be immunosuppressed for a period of three months before the first 
documented prescription in the general practice, as these therapies are initiated in hospital. 
Individuals on these medications were also categorised as immunosuppressed for one year 
after each record instead of the recommended duration 6 months in the UK Green Book to 
account for potential recording delays in GP data for any hospital-based treatments .60 
Table 5-1 Immunosuppressive medications: defining dose criteria and period of 
immunosuppression 
Immunosuppressive 
medications 
Immunosuppressive 
dose 
Duration of 
immunosuppression 
prior to first 
documented script* 
Duration of 
immunosuppression 
after every script 
Corticosteroids >40 mg/daily for >7 
days or >20mg/ daily 
for >14 days 
3 months 3 months 
Methotrexate >3.57 mg/day or 
>25mg per week 
3 months 3 months 
Azathioprine ≥50mg/daily#  3 months 3 months 
6-mercaptopurine  ≥45mg/daily#   3 months 3 months 
Other 
immunosuppressants 
such as tacrolimus, 
sirolimus 
Any dose 3 months 3 months 
Other DMARDs  such 
as ciclosporin, 
mycophenolate, 
leflunomide  
Any dose 3 months 3 months 
Biological therapy, 
chemotherapy and 
radiotherapy 
Any dose 3 months 12 months 
* these treatments might be initiated in hospital prior to the first documented record in primary care # UK Green 
Book and British Society of Gastroenterology guidance (as described in the text)  DMARD disease modifying anti-
rheumatic drugs 
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B) High dose corticosteroids and other immunosuppressive therapies 
Individuals on immunosuppressive treatment were identified using code lists (product codes) 
from the Therapy files of CPRD (Appendix 17). I classified the product codes in these code 
lists into specific therapeutic categories to apply the specific immunosuppressive dose 
criteria (Table 5-1). The immunosuppressive dose of corticosteroids was defined as >40mg 
of prednisolone/day for >7 days or >20mg of prednisolone/day for >14 days; for 
methotrexate, doses of >25mg/week were considered immunosuppressive (Table 5-1).60 
The immunosuppressive doses for azathioprine and 6-mercaptopurine were defined as 
≥50mg/day and 45mg/day respectively, based on the recommendations from the UK Green 
Book and the British Society of Gastroenterology. 60, 153 Other immune-modulating drugs 
such as tacrolimus, ciclosporin, etc. were considered to be immunosuppressive irrespective 
of the doses used. As with chemotherapy and radiotherapy, patients on these therapies 
were considered to be immunosuppressed for a period 3 months prior to the first 
documented script in primary care based on assumption that the therapy was typically 
initiated in a hospital setting (Table 5-1). Patients on any dose of biological therapy (e.g. 
anti-tumour necrosis factor agents such as alemtuzumab, ofatumumab and rituximab) were 
considered to be immunosuppressed for one year after each prescription.60 For the 
remaining medications, patients were considered to be immunosuppressed for a period of 3 
months following each prescription (Table 5-1).60  
5.3.3.1 Data management to obtain information for immunosuppressive medications 
from the therapy files in CPRD  
Apart from the product codes and generic drug codes, the Therapy file in CPRD data also 
includes data fields which provide additional information about a given prescription. These 
data field can be used to estimate the dose and duration for each prescription which are 
unavailable in CPRD data.46 These data fields include: 
(i) Product name: provides the name of the product including the dose (for example 
prednisolone tablets 5 mg) 
(ii) Text identifier: This field provides information from the free text associated with 
the record in form of numeric values, which are interpreted by CPRD. A value of 
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0 indicates there is no free text available for that record. This field consists of 
actual prescribing information i.e. how many tablets are to be taken by the 
patient, for example, “take one daily”. This data provides information on numeric 
daily dose, as described below under (iii).  
(iii) Numeric daily dose: This data field provides information about the numeric daily 
dose of each drug, which describes the total number of doses of the prescribed 
product to be taken by a patient per day. CPRD uses an algorithm based on 
information obtained from text identifier (described in (ii), above) to provide 
information in this field. To illustrate this with an example, if the free text 
associated with a record was “one tablet twice a day”, the numeric daily dose 
provided for that record will be 2. 
(iv) Total quantity: the total quantity of the prescribed product for that prescription as 
entered by the GP. 
(v) Other fields: these include the number of treatment days and the number of 
product packs prescribed for a particular prescription.  
The information on the number of treatment days and the numeric daily dose was 
required to apply the dose and duration criteria for defining the immunosuppressive 
phase of specific therapies. However, the data for numeric daily dose and number of 
treatment days were missing for ~>30% of the prescriptions for oral corticosteroids and 
other immunosuppressive medications (Appendix 18). I modified a technique called `hot 
decking’ which was developed by Forbes et al for cleaning the prescription data for 
immunosuppressive agents and imputing the missing values for numeric daily dose.46 In 
this technique, the missing values for the numeric daily dose are replaced by the median 
numeric daily dose of the chosen group of records. These groups of records could be 
from the same patient (intra-patient) or from different patients (inter-patients) sharing 
common characteristics such as the same age group, gender, and drug dosage. These 
records are selected based on an algorithm in which missing values for the numeric 
daily dose are first replaced by the median values from intra-patient observations; if 
these were unavailable the median values from records of patients sharing common 
characteristics are utilised (inter-patient values)  (Figure 5-2).46 I adapted this algorithm 
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in two ways. Firstly, changes in the information governance policies of CPRD [personal 
communication via email CPRD Knowledge Team] led to unavailability of the data for 
free text (described in (ii) above) when the numeric value of the text identifier was 
≥100,000 . This had implications for the data management. Secondly, to reflect temporal 
changes in prescribing and to capture prescribing practices of practice staff members, I 
used two additional criteria (in addition to age-groups, gender and dosage) to define 
groups of patients sharing the same characterises and use their median values for 
numeric daily doses from these inter-patient observations. These additional criteria 
included observations with prescriptions issued within two years of each other (a 2-year 
calendar period) and prescriptions issued by same member of staff (using the staff 
identifier available in the Therapy file) (Figure 5-2). Applying this adapted algorithm, the 
missing numeric daily doses were sequentially replaced by the median numeric daily 
dose value from the chosen stratum, as detailed in Figure 5-2.  
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Figure 5-2 Algorithm# for imputing missing values of numeric daily dose 
# Modified from46 
Missing data for NDD in the Therapy file records 
Use median NDD of records for same patient, same dose in mg and same 
quantity 
NDD still missing: Use median NDD of records for same patient, same dose 
in mg and same quantity group* 
NDD still missing: Use median NDD of records for same patient and same dose in mg 
NDD still missing: Use median NDD of records for same 5-year age-groups, gender, 
dose in mg, quantity, staff identification number and 2-year calendar period 
NDD still missing: Use median NDD of records for same 5-year age-groups, gender, 
dose in mg, quantity and staff identification number 
NDD still missing: Use median NDD of records for same 5-year age-groups, gender, 
dose in mg and quantity 
NDD still missing: Use median NDD of records for same 5-year age-groups, gender, 
dose in mg, quantity group*, staff identification number and 2-year calendar period 
NDD still missing: Use median NDD of records for same 5-year age-groups, gender, 
dose in mg, quantity group* and staff identification number  
NDD still missing: Use median NDD of records for same 5-year age-groups, gender, 
dose in mg and quantity group* 
NDD numeric daily dose: number of tablets/day *binary variable (low/high): cut off was the 
median quantity (56 tablets for oral corticosteroids and 28 tablets for other immunosuppressant 
drugs) 
Intra-patient 
observations 
Inter-patient 
observations 
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5.3.4 Seasonal influenza vaccine uptake 
For the zoster vaccine uptake study (objective 4), I also examined the co-administration of 
zoster vaccine with seasonal influenza vaccine, as GPs were encouraged to administer zoster 
vaccine at the same as time as seasonal influenza vaccine (Section 1.2.6),72  although zoster 
vaccine could continue to be administered outside the seasonal influenza season. Seasonal 
influenza vaccine uptake was identified during the influenza vaccination campaign season 
(September-March)73 of the corresponding years of the zoster vaccine uptake study (2013/14 
and 2014/15). Similar to zoster vaccine, the uptake of seasonal influenza vaccine was 
identified in the CPRD data by utilising specific product codes in the Therapy file, immunisation 
type codes in the Immunisation file and medical codes in the Clinical, Referral and Test files 
(Appendix 19). The information for seasonal influenza vaccine code was first extracted using 
the Therapy file (as described for zoster vaccine uptake in Section 5.2.2). The Immunisation 
file, for individuals with no vaccination information from the Therapy file, was examined for the 
presence of specific immunisation type codes and the status field had to be `given’ (Section 
3.2.1) to categorise these individuals as vaccinated for seasonal influenza. Amongst 
individuals without seasonal influenza immunisation information in either the Therapy or 
Immunisation files, the vaccination status was determined based on information obtained from 
the presence of specific medical codes from the Clinical, Referral and Test files. 
5.3.5 Past history of zoster 
To examine whether the association of zoster vaccine uptake with social factors varied with 
prior history of zoster (as a potential partial mediator for some social factors such as 
ethnicity, as discussed in Chapter 8), 154, 155 individuals with a prior zoster history were 
identified as described in Section 3.5.2. 
5.4 Chapter summary 
This final chapter of the Methods section has detailed the data algorithms that I developed 
and/or adapted and applied to the linked electronic health data to ascertain the two outcome 
variables of interest for objectives 3 and 4 of the thesis, namely incident zoster and zoster 
vaccine uptake, respectively. The definitions and data algorithms to identify the key 
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covariates in the analyses for objectives 3 and 4, comprising selected chronic conditions 
and immunosuppressive conditions/therapies, have also been outlined.  
The next chapter (Chapter 6) is the first of the three chapters comprising the Results section 
of the thesis and presents the findings of the cross-sectional study conducted to meet the 
second objective (Section 1.5.2): to develop methodology for the ascertainment of socio-
demographic factors in linked electronic health records, and to assess their availability in 
these data. 
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Results section 
 
The Results section of this thesis has three chapters: Chapters 6-8, which present the 
findings of the three observational studies to meet objectives 2-4 of this thesis (1.5.2). 
Chapter 6 presents the finding of the cross-sectional study (the first observational study) 
conducted to investigate the completeness, timeliness and representativeness of recording 
of socio-demographic factors of interest in the linked CPRD data (objective 2). 
Chapter 7 presents the findings from the cohort study (the second observational study), 
which describe the association of socio-demographic factors with zoster disease incidence 
in England using the methodology developed and presented in Chapter 6. 
Chapter 8 presents the findings of the third observational study: a cohort study that 
investigated zoster vaccination inequalities amongst older individuals in England by 
determining the socio-demographic factors associated with zoster vaccine uptake. 
All these three chapters are presented in a journal article format with brief abstract, 
background, methods, results, discussion and overall conclusion sections. Any additional 
results or discussions follow the journal article in the relevant chapter. 
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 Chapter 6. Quality and completeness of recording 
of social factors in linked electronic health records: 
a cross-sectional study 
6.1 Introduction 
This chapter forms the first of the three chapters included in the Results section of this 
thesis. It reports the findings of the cross-sectional study conducted to meet the second 
objective of this thesis: to assess the methodology for ascertainment of socio-demographic 
factors (including those identified from the systematic review (chapter 2)) and assess their 
availability in the linked electronic health records. The details of this work, published in the 
journal PLOS ONE, are presented in the next section. 
The detailed methodology for determining the socio-demographic factors of interest was 
presented previously (Chapter 4). The paper presented in this current chapter reports the 
results of the analyses to assess among 59,1037 older individuals the completeness of 
recording of socio-demographic factors, including: the extent to which linked data improved 
completeness; timeliness of recording for factors that might change with time (such as 
marital status, living arrangements or residence); and the representativeness of the results 
compared with data from the English 2011 Census. The paper is followed by supplementary 
material for the published paper (Section 6.3); further discussion on how immigration status 
was determined in these data and the implications of this (Section 6.4), and how data from 
the family number variable were utilised (Section 6.5). 
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6.2 Paper 2: Identifying social factors amongst older individuals in 
linked electronic health records: An assessment in a population 
based study 
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Identifying social factors amongst older
individuals in linked electronic health records:
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L. Thomas1
1 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London,
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Abstract
Identification and quantification of health inequities amongst specific social groups is a pre-
requisite for designing targeted healthcare interventions. This study investigated the record-
ing of social factors in linked electronic health records (EHR) of individuals aged65 years,
to assess the potential of these data to identify the social determinants of disease burden
and uptake of healthcare interventions. Methodology was developed for ascertaining social
factors recorded on or before a pre-specified index date (01/01/2013) using primary care
data from Clinical Practice Research Datalink (CPRD) linked to hospitalisation and depriva-
tion data in a cross-sectional study. Social factors included: religion, ethnicity, immigration
status, small area-level deprivation, place of residence (including communal establishments
such as care homes), marital status and living arrangements (e.g. living alone, cohabita-
tion). Each social factor was examined for: completeness of recording including improve-
ments in completeness by using other linked EHR, timeliness of recording for factors that
might change over time and their representativeness (compared with English 2011 Census
data when available). Data for 591,037 individuals from 389 practices from England were
analysed. The completeness of recording varied from 1.6% for immigration status to ~80%
for ethnicity. Linkages provided the deprivation data (available for 82% individuals) and
improved completeness of ethnicity recording from 55% to 79% (when hospitalisation data
were added). Data for ethnicity, deprivation, living arrangements and care home residence
were comparable to the Census data. For time-varying variables such as residence and liv-
ing alone, ~60% and ~35% respectively of those with available data, had this information
recorded within the last 5 years of the index date. This work provides methods to identify
social factors in EHR relevant to older individuals and shows that factors such as ethnicity,
deprivation, not living alone, cohabitation and care home residence can be ascertained
using these data. Applying these methodologies to routinely collected data could improve
surveillance programmes and allow assessment of health equity in specific healthcare
studies.
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Introduction
Health inequity is defined as unjust differences in health status amongst different social
groups, and may be explained by the distribution of social determinants of health.[1] Health
inequities not only exist between countries, but are apparent within a country.[2] In the UK,
reducing health inequities is a statutory requirement and is a common theme in the area of
health improvement in the Public Health Outcome Framework.[3–6] In order to attain health
equity, it is vital that the disadvantaged individuals are identified to quantify the problem and
formulate targeted public health interventions. Increase in life expectancy has led to an aging
population, and globally the proportion of individuals aged60 years is projected to nearly
double by 2050 from ~12% in 2013.[7, 8]The higher prevalence of chronic diseases in this age
group is associated with greater disability and requirement for long-term care, necessitating
changes in health and social care delivery.[9, 10] The effect of ageing on future health expendi-
ture will depend on health expectancy: a measure that takes both life expectancy and disability
into account.[11, 12] A 2015 systematic review reported associations of social factors such as
gender, ethnicity, and socioeconomic position (including education) with inequalities in
healthy life expectancy amongst older individuals.[13] Similarly, amongst individuals aged 50–
65 years, social class, education, wealth and income were found to be associated with all three
indicators of health expectancies: disability-free, illness-free and healthy life expectancy.[9]
Living alone is also known to be associated with higher morbidity and mortality.[14] Uptake
of preventative measures such as vaccination amongst older individuals has been shown to be
lower amongst immigrants, individuals of certain ethnicities, and those living alone.[15, 16]
One of the recommendations by the World Health Organisation’s (WHO) Commission on
Social Determinants of Health (CSDH) in 2008 was setting of global and national equity sur-
veillance systems to monitor health inequities routinely.[17] Surveillance programmes in the
UK lack detailed information about social factors.[18] However, these factors potentially could
be ascertained using routinely collected electronic health records (EHR). This provides an
opportunity to utilise routinely collected data to improve surveillance programmes and to
assess health inequities in specific studies.
The Clinical Practice Research Datalink (CPRD) is the world’s largest primary care data-
base, comprising anonymised patient information from ~7% of the UK population and includ-
ing >79 million person-years of follow-up cumulatively.[19, 20] These EHR comprise not
only data relating to primary care consultations, but also records of referrals to and feedback
from secondary care.[21] Data in CPRD are representative of the UK population and are qual-
ity assured at both patient and general practice level.[20, 21] In England, linkage of the CPRD
data at the individual level (from ~75% of English practices that consent to linkages) is avail-
able for hospitalisation data (Hospital Episode Statistics, HES)[22] and deprivation data (e.g.
quintiles of Index of Multiple deprivation (IMD) score).[21, 23] For deprivation data, the link-
age is made at the lower layer super output areas (LSOA) level, which covers a population of
1000–3000.[23] The completeness and quality of recording of one social factor in the CPRD,
namely ethnicity, have been assessed by Mathur et al using data up to 2012 and focusing chiefly
on the time during which GPs were financially incentivised to record the ethnicity of newly
registered patients.[24] This study showed that in linked CPRD-HES data, completeness of
recording reached 90% in newly registered patients. However, this analysis did not include
assessment of recording specifically for older patients in CPRD, and was not extended to
examine completeness after incentivisation was withdrawn in 2011.[25] In the UK, EHR have
also been utilised to study cohabitation and care home residence,[26–28] but these studies did
not provide information on timeliness or representativeness of recording of these factors and
did not utilise linked hospitalisation data. To our knowledge, simultaneous investigation of the
Identifying social factors amongst older individuals in electronic health records
PLOS ONE | https://doi.org/10.1371/journal.pone.0189038 November 30, 2017 2 / 17
MHRA database research (details at www.cprd.
com/isac). The authors did not have any special
access privileges to the data.
Funding: The research was funded by the National
Institute for Health Research Health Protection
Research Unit (NIHR HPRU) in Immunisation at
the London School of Hygiene and Tropical
Medicine in partnership with Public Health England
(PHE). The views expressed are those of the
authors and not necessarily those of the NHS, the
NIHR, the Department of Health or PHE. LS is
supported by a senior clinical fellowship from
Wellcome Trust [098504/Z/12/Z] RM is supported
by a Sir Henry Wellcome Postdoctoral Fellowship
from the Wellcome Trust [201375/Z/16/Z]. AJvH,
JLW and SLT are supported by National Institute
for Health Research (HPRU-2012-10096). AJ PhD
studentship was funded by National Institute for
Health Research (HPRU-2012-10096).
Competing interests: The authors have declared
that no competing interests exist.
180
quality and completeness of recording in CPRD of the social determinants of disease burden
or healthcare usage in older populations have not yet been undertaken.
This study aimed to investigate the utility of the CPRD and linked databases in ascertaining
social factors that are potential determinants of disease burden and inequitable healthcare
interventions targeted towards older individuals, to discuss challenges associated with using
routinely collected data and to supplement and enhance existing surveillance methods with
the overarching goal of informing interventions to reduce health inequities.
Methods
Data source and study date
This was a cross-sectional study using CPRD data linked to HES data and deprivation data
(IMD 2010) in England. It investigated the historical recording of social factors among indi-
viduals aged65 years, actively registered with a CPRD practice on a randomly chosen index
date (1st January 2013), to allow assessment of both completeness and timeliness of recording
of social factor data. Active registration on 01/01/2013 was determined by ensuring that
patients’ start dates (the later of their registration date with the practice or the date the practice
reached CPRD-defined quality criteria[21]) fell before the index date and their end dates (the
earliest of their transfer out date, date of death or practice last collection date) were after the
index date.
CPRD data are supplied in ten different files,[19] of which eight (patient, practice, clinical,
consultation, additional clinical details, immunisation, referral and test files) were used for this
study (S1 Table). These files include information about patients’ demography, lifestyle factors,
clinical details, feedback from secondary care, therapy and laboratory results, stored in form of
medical, therapy and other codes used by the GP practice staff.[21]
Social factors examined
In this study, social factors relevant at an individual level and informed by the conceptual
framework of the WHO’s CSDH,[1] were examined in CPRD and included: religion, ethnicity,
immigration status, deprivation based on LSOA of each individual’s residence,[23] living
arrangements (living alone and cohabitation), residence (place of residence and homelessness)
and marital status.
Lists of medical codes (S2 Table) for each factor were compiled by searching the CPRD’s
Read code dictionary [21] for specific and broader text terms (using wild card searches)
encompassing all social factors of interest. This was an iterative process that subsequently
included a hierarchical search of the Read codes identified. The number of codes identified for
these factors ranged from 86–465 (S2 Table). Further information (S1 Table) was accrued
from other sources within the dataset as follows: the consultation files provided codes (‘consul-
tation type’) on where the consultation took place and thus patients’ residence (for example in
a care home), while the patient files provided information regarding patients’ marital status
and their family number.[29] The latter variable can identify individuals sharing the same
household and therefore can be used to get information for living arrangements (living alone,
cohabitation), marital status and care home status. Similarly, the additional clinical details files
provided coded information (‘entity type’) about residence, living alone and marital status.
The linked hospitalisation data from HES provided additional information for ethnicity and
residence, whilst the deprivation data provided deprivation scores for individuals’ LSOA as
IMD quintile. The multiple code lists thus generated were discussed amongst the three of the
authors (AJ, SLT and AJvH). These code lists were then utilised to systematically search for the
Read codes in the clinical, immunisation, referral and test files. Additional information was
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sought from consultation type and entity types in the consultation and additional clinical
details files respectively and also from the patient file and from linked HES and deprivation
data. Some factors also provided information about another social factors: for example an indi-
vidual coded as living alone was deemed not to be cohabiting, whereas an individual residing
in a care home was considered not to be living alone.
The following example illustrates how information for social factors was assimilated. Type
of residence (whether a patient lived in their own home, in sheltered accommodation, or in a
care home) can be recorded in numerous way in both CPRD and HES. In CPRD, this informa-
tion can be determined using the medical codes within multiple files as described above, using
the entity type 132 for residence in the additional clinical details file, from the consultation file
(e.g. “nursing-home visit”) and from the family number (as described below); residence data
are also potentially available in HES by using information about individual’s location prior to
hospital admission.
Exposure variables definition and categorisation
The code lists for the social factors of interest (religion, ethnicity, living arrangements (includ-
ing living alone and cohabitation), immigration status, deprivation, residence (including place
of residence and homelessness) and marital status) are presented in S2 Table. Ethnicity codes
were those recommended for use by the Quality and Outcomes Framework, as used by Mathur
et al.[24] Family number was used to derive additional information by modifying approaches
used in previous studies,[27, 28, 30] as follows. Two adults, living in a household size of two or
three, were identified as cohabiting (adults living in a couple) if the age difference between the
couple was15 years and age difference between the other household occupants and those liv-
ing in a couple was >15 years. Couples identified as cohabiting were also allocated ‘partner-
uncategorised’ category for marital status. Individuals from household size of two or more
were identified as not living alone. Based on previous studies [26, 31, 32] care home was
defined as a household with>3 individuals aged65 years and if their total count was more
than individuals aged <65 years. In sensitivity analyses households with>3 individuals aged
65 years and3 individual aged50 years were defined as a care home.
Religion was categorised into eight categories (Buddhists, Christians, Hindus, Jews, Mus-
lims, Sikhs, Others and no religion (atheists)) to ensure comparability with Census data.[33]
We hypothesised that certain minority religions might be more likely to be coded by GPs, and
explored this by categorising one religion (Muslim) as a binary (yes/no) variable. Ethnicity was
categorised in five groups: White, South Asian, Black, Others and Mixed as per the UK 2011
Census.[34]
Living alone and cohabitation were coded as binary variables (yes/no). Immigration status,
a binary variable (immigrant/ not immigrant) was defined using: i) country of birth informa-
tion and (to increase completeness of ascertainment) ii) codes for the first language spoken (S2
Table).
Place of residence had four categories: living in a care home, sheltered accommodation,
other places of residence (e.g. prison, hospice, hostel, welfare home) and living in a household.
Care home status was also considered as a binary (yes/no) variable, on the assumption that
being in a care home might be more completely recorded by GPs than other places of resi-
dence (e.g living in a household). Homelessness was also a binary variable.
Relationship status was characterised by using following seven categories: single, married/
civil partnership, widow/er, divorced, separated, partner-other (e.g. common-law husband/
wife) and partner (uncategorised). As the last category was non-specific, an algorithm was
developed to obtain more specific marital status information. If the ‘partner uncategorised’
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status was preceded by any of the following three categories: 1) Single/engaged 2) Married/
civil partnership and 3) Partner-other category, the ‘partner uncategorised’ category was
updated to that of the earlier observation.
Deprivation status is a composite score of 38 indicators for seven domains of deprivation
(income, health and disability, employment, education and training, housing, living environ-
ment and crime).[23] These indices are available at the small area level (LSOA) as quintiles:
quintile one representing the least deprived to quintile five representing the most deprived.[23]
Analysis
For the purposes of recording, the social factors that were likely to change with time (e.g. mari-
tal status, living alone status) were treated as time-varying exposure variables whereas ethnic-
ity, religion and immigration status were deemed to be time-invariant.
In CPRD the event date (the date the event occurred as recorded by the GP) was used to
ascertain when the factor was recorded in relation to the index date. If the event date was miss-
ing then the system date (the date when the event was recorded on the GP system) was used
for these observations.[19] For information extracted from the patient files (such as marital
status, family number), which does not include event dates, a conservative estimate of the date
of recording was taken, using the date the patient registered with the practice[19], and the hos-
pital admission date was utilised for HES data.[22]
All mentions of each factor of interest were identified within a patient’s linked records.
Observations providing discordant information for a factor on the same date for a patient
were excluded and the social factor recorded nearest the index date was used.
As family number provided information for social factors indirectly, and the date of record-
ing this variable was unclear, information from family number was used only when data for a
particular social factor were unavailable from other sources in CPRD or HES for that patient.
For each social factor, the following information was analysed:
(a) Completeness of recording and contribution from linkages. Completeness was
described as the percentage of total patients who had data available: i) within CPRD and ii)
within CPRD linked to HES, to investigate the extent to which use of the linked data increased
completeness. For time-varying variables, completeness was determined in the period before
or on the index date (taking the value nearest the index date). However, for time-invariant var-
iables such as country of birth, ethnicity and religion, completeness of recording included both
the period before and after the index date. For ethnicity, we further investigated completeness
of recording by GPs over time by plotting completeness against year of registration with the
general practice. We also assessed the contribution of family number by looking at complete-
ness with and without family number data.
(b) Representativeness. The representativeness of the recorded data was investigated by
comparing the distribution of each social factor amongst those with non-missing data with the
distribution recorded in the 2011 Census (data from England for individuals aged65 years).
When applicable, we also considered the binary version of multi-category variables (i.e. care
home status instead of the four-category variable for residence, and Muslim religion). For all
binary variables, (immigration status, care home status, Muslim religion, homelessness, living
alone, and cohabitation status) we assessed representativeness assuming that those without a
code did not have the attribute, and thus compared the distribution of each factor among the
entire study population to the Census data.
(c) Timeliness. For the time-varying factors, the duration between index date and the
record nearest to the index date was calculated. Factors recorded more than five years before
the index date were not considered timely.
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Ethics approval
All data were anonymised prior to receipt by the authors. Approval for this study was obtained
from the Independent Scientific Advisory Committee of the Medicines and Healthcare prod-
ucts Regulatory Agency (Ref: 15_253) and the Research Ethics Committee of the London
School of Hygiene and Tropical Medicine (reference:10524). The original Independent Scien-
tific Advisory Committee protocol was made available to the reviewers of this paper.
Data were analysed using Stata-14 software (StataCorp, College Station, TX, USA).
Results
The study population comprised 591,037 patients from 389 GP practices in England. More
than half of the study participants (55%) were females, and 53% were aged between 65–74
years at the index date, with ~14% aged85 years. The median age for women was 75.5 years
(interquartile range (IQR): 69.5–82.5 years) whilst for men it was 73.5 years (IQR: 68.5–79.5
years). Information for one or more time-invariant social factors was available for~92% (n =
541,197) of the study population, while 75% (n = 444,827) had data for one or more time-vary-
ing social factors. Overall, ~98% (n = 578,410) had information for one or more social factors.
Further details of the overall pattern of completeness is given in S3 Table; only 45 patients
(<0.01%) had data for all seven social factors included in this study while ~21% (n = 123,450)
had information for three social factors: ethnicity, IMD and living alone. The system date was
used to replace missing event date for only 0.4% (n = 2,219) of the study population (S4
Table). The maximum number (n = 456; <0.1%) of patients were excluded due to discordant
information recorded on the same date (S4 Table) were for the factor: living alone.
Completeness of recording for individual social factors, and contribution
from linkages
Completeness of recording for all social factors was better for females and amongst the oldest
individuals (aged85 years) for all factors except for religion, immigration status and IMD
score (Table 1). Of the seven social factors ascertained, recording for deprivation data and eth-
nicity were the most complete, at ~82% (n = 486,426) and ~80% (n = 469,557) respectively
(Table 1). The recording of ethnicity over time showed an increase in completeness in the year
2006 (when incentivisation was introduced) with a slight downward trend in 2011 and 2012
(Fig 1).
The most incompletely recorded social factor was immigration status which available for
only 4,187 (0.7%, data not shown) of the study population when country of birth codes were
used alone. However, the additional use of ‘first language’ codes with country of birth codes
more than doubled the information, to 1.6% (n = 9,713) of the study population (Table 1).
Religion was the second most poorly recorded factor, available for only 2.6% (n = 15,449) of
study individuals (Table 1). Data on place of residence was recorded for 10.3% of the popula-
tion, whereas living alone (yes/no) and marital status were recorded for nearly a third of the
study population (29.2% and 27.2%, respectively).
The contribution of data from linked datasets to completeness of recording was particularly
important for ethnicity, which showed a ~45% improvement (increasing from ~55% to ~80%,
Table 1) after including linked hospitalisation data, and for IMD data (which was only avail-
able as linked data). For other social factors, there was hardly any evidence of improvement in
completeness of recording from the linked data compared to using CPRD alone (Table 1).
The utilisation of family number in providing information for individuals who had no data
for living alone, cohabitation, care home residence and marital status in either CPRD or HES
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showed that there was much higher completeness of recoding for living alone (70% versus
29%), cohabitation (60% versus 22%) and marital status (60% versus 27%) when information
from family number was included (S3 Table, S4 Table and S5 Table). In contrast, family num-
ber contributed little to the completeness of recording of care home residence (11% versus
10%), irrespective of definitions used (S4 Table).
Table 1. Proportion of individuals with information on social factors available in Clinical Practice Research Datalink and Hospital Episodes Statis-
tics: Age, sex and database distribution (N = 591037).
Study
population
stratified (N)
Codes available for social factors in CPRD and linked data: proportion* (95% confidence interval)
Marital
status
codes
Living arrangements Residence Religion
codes
Ethnicity
codes
IMD Immigration
status codes
Cohabitation
(yes/no) codes
Living alone
(yes/no)
codes
Place of
residence
codes
Homeless
(yes/no)
codes
Age groups in
years (N)
65–69 (183382) 26.10% 21.50% 26.60% 4.60% 4.60% 2.40% 76.90% 82.50% 1.60%
(25.9–
26.3)
(21.4–21.7) (26.4–26.8) (4.5–4.6) (4.5–4.7) (2.3–2.5) (76.7–77.1) (82.3–
82.7)
(1.5–1.7)
70–74 (131552) 25.90% 21% 26.60% 5.70% 5.70% 2.70% 80% 82.60% 1.80%
(25.7–
26.2)
(20.8–21.2) (26.4–26.9) (5.6–5.9) (5.6–5.9) (2.6–2.8) (79.8–80.2) (82.4–
82.8)
(1.8–1.9)
75–79 (109628) 27.10% 21.40% 27.80% 8.20% 8.20% 2.90% 80.10% 82.30% 1.80%
(26.8–
27.3)
(21.1–21.6) (27.5–28) (8.1–8.4) (8.1–8.4) (2.8–3) (79.8–80.3) (82–
82.5)
(1.7–1.9)
80–84 (84473) 28.70% 21.80% 30.30% 13.10% 13.20% 2.70% 81.10% 82% 1.60%
(28.4–29) (21.5–22) (30–30.6) (12.9–13.4) (12.9–13.4) (2.5–2.8) (80.9–81.4) (81.8–
82.3)
(1.5–1.7)
85–89 (51278) 30.80% 24.30% 37.70% 25.20% 25.30% 2.60% 82.40% 82% 1.40%
(30.4–
31.2)
(23.9–24.6) (37.3–38.1) (24.8–25.6) (24.9–25.7) (2.5–2.8) (82.1–82.7) (81.6–
82.3)
(1.3–1.5)
90 (30724) 29.50% 23.40% 43.90% 38.20% 38.30% 2.50% 80.70% 81.60% 0.97%
(29–30) (22.9–23.9) (43.3–44.4) (37.7–38.7) (37.8–38.9) (2.3–2.7) (80.2–81.1) (81.1–
82)
(0.9–1.1)
Gender (N)#
Males (264752) 22.80% 19.60% 24.40% 8.20% 8.30% 2.50% 79.30% 82.30% 1.50%
(22.6–23) (19.5–19.8) (24.3–24.6) (8.1–8.3) (8.2–8.4) (2.5–2.6) (79.2–79.5) (82.2–
82.5)
(1.5–1.6)
Females
(326283)
30.80% 23.50% 33.10% 11.90% 11.90% 2.70% 79.60% 82.30% 1.70%
(30.6–31) (23.4–23.6) (32.9–33.2) (11.8–12) (11.8–12.1) (2.6–2.7) (79.4–79.7) (82.2–
82.4)
(1.7–1.8)
Database (N)
CPRD database
only (591037)
27.20% 21.80% 29% 10% 10.10% 2.60% 55.40% 1.6%
(27.1–
27.3)
(21.6–21.9) (28.9–29.2) (10.0–10.1) (10.0–10.1) (2.6–2.7) (55.3–55.5) (1.6–1.7)
CPRD & Linked
data (591037)
29.20% 10.30% 10.30% 79.40% 82.30%
(29.1–29.3) (10.2–10.3) (10.2–10.4) (79.3–79.5) (82.2–
82.4)
* row percentages IMD index of multiple deprivation CPRD Clinical Practice Research Datalink
# 2 individuals had indeterminate gender
https://doi.org/10.1371/journal.pone.0189038.t001
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Representativeness
Amongst those with ethnicity data available, (Table 2), White ethnicity was recorded for the
majority (~95%) and the ethnic composition of the study population was comparable to the
English Census data[34] (Fig 2). In contrast, amongst the small number of individuals with
available data on religion, 85% (n = 13,074) were recorded as Christians (Table 2), with an
over-representation of the minority religion categories in CPRD (Table 2) compared to Census
data[33], for example Muslim (3.1% in CPRD versus 1.3% in the Census), Hindu (2.5% versus
0.8%), Jewish (1.6% versus 0.7%) and Sikh (1.1% versus 0.4%). When Muslim religion was
considered as a binary variable, using the entire study population as the denominator and
assuming those without a code were non-Muslim, there was appreciable under-recording of
Muslim status (n = 481, 0.1%) compared to English Census (1.3%).[33]
Similarly, among those with data on immigrant status, there was marked over-representa-
tion of immigrants (n = 7,866, ~81% of the total) among those with recorded data (Table 2),
but under-representation when immigrant status was considered as a binary variable (1.3% of
the total study population (Fig 3) compared to 9.9% non-UK born individuals in the English
Census).[35]
For living arrangements, amongst those with available data, the proportion of individuals
recorded as living in a household (~50%, Table 2) was under-reported in CPRD compared to
English Census data (in which ~96% of people aged65 years were recorded as living in
household) and living in a care home was over-reported (~48%) compared to Census (3.2%).
[36, 37] However, once care home residence was categorised as a binary yes/no variable, repre-
sentativeness improved markedly; in the total study population, 4.9% of individuals were cate-
gorised care home residents compared to 3.2% in the English Census data (Fig 3).[37]
The data from EHR for marital status amongst those with non-missing data were also not
comparable to the Census data, [38–40] with 68% being recorded as married or in a civil part-
nership, compared to 55.9% in the Census data. Data were comparable for the sub-categories
of: ‘single’ (4.5% versus 5.5% in the Census) and ‘separated’ (1.3% versus 1.2%), but there were
Fig 1. Patients with ethnicity records in Clinical Practice Research Datalink and Hospital Episode
Statistics over time. Abbreviations: CPRD Clinical Practice Research Datalink HES Hospital Episode
Statistics.
https://doi.org/10.1371/journal.pone.0189038.g001
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small number of individuals in both these sub-categories, making it difficult to draw any
conclusions.
The number of individuals with a code indicating that they were homeless was also very
small, representing just 0.02% (n = 92) of total study population. There were no corresponding
data in the 2011 Census, but data for statutory homelessness and homelessness prevention and
Table 2. Social factors in Clinical Practice Research Datalink: Recording and categorisation.
Social factors recorded* and their categorisation
(N = Total number with information available)
CPRD only N (%)* CPRD & linked data N (%)*
Marital status
(N = 160812)
Single 7291 (4.5%) No further information from linked
dataMarried/Civil 108921 (67.7%)
Widow/er 30459 (18.9%)
Divorced 7446 (4.6%)
Separated 2100 (1.3%)
Partner uncategorised/
other#
4595 (2.9%)
Living arrangements: Cohabitation (N = 128573) No 14666 (11.4%) No further information from linked
dataYes 113907 (88.6%)
Living arrangements: living alone
CPRD (N = 171625); CPRD & linked data
(N = 172590)
No 165914 (96.7%) 166896 (96.7%)
Yes 5711 (3.3%) 5694 (3.3%)
Residence: place
CPRD (N = 59263); CPRD & linked data (N = 60638)
Care home 28318 (47.8%) 28876 (47.6%)
Sheltered 1001 (1.7%) 1272 (2.1%)
Household 29371 (49.5%) 29296 (48.3%)
Others 573 (1%) 1194 (2%)
Residence: homelessness
CPRD (N = 59435); CPRD & linked data (N = 60809)
No 59342 (99.8%) 60717 (99.8%)
Yes 93 (0.2%) 92 (0.2%)
Religion
(N = 15449)
Christian 13074 (84.6%) No further information from linked
dataBuddhist 40 (0.3%)
Hindu 389 (2.5%)
Jewish 249 (1.6%)
Muslim 481 (3.1%)
Sikh 169 (1.1%)
Other 31 (0.2%)
No religion 1016 (6.6%)
Ethnicity
CPRD (N = 327420); CPRD & linked data
(N = 469557)
White 311466 (95.1%) 449668 (95.7%)
South Asian 7688 (2.4%) 9316 (2%)
Black 4686 (1.4%) 5483 (1.2%)
Other 2727 (0.8%) 4045 (0.9%)
Mixed 853 (0.3%) 1045 (0.2%)
Index of Multiple Deprivation (N = 486426) Least deprived No information from
CPRD
119826 (24.6%)
2 126957 (26.1%)
3 101068 (20.8%)
4 81978 (16.9%)
Most deprived 56597 (11.6%)
Immigration status (N = 9713) Not immigrant 1847 (19%) No further information from linked
dataImmigrant 7866 (81%)
* Total study population = 591037 CPRD Clinical Practice Research Datalink IMD
# Due to very small numbers in ‘Partner: other’ category the data are combined with ‘Partner: uncategorised’
https://doi.org/10.1371/journal.pone.0189038.t002
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relief data (2013) from local authorities in England for individuals aged65 years showed that
the proportion of homeless individuals accepted for assistance was 0.01%,[41] providing a
minimum estimate of the true proportion of homeless individuals (as not all would have been
accepted for assistance).
Amongst those with available data, individuals categorised as those not living alone and as
cohabiting were both over-represented in the data (96.7% and 88.6% respectively, Table 2).
When considered as a binary variable using the entire study population as denominator, these
factors were under-represented (28% and 19% respectively) compared to the Census data
(68.5% and 58.6%, respectively).[39, 40] However, when information from family number was
added, the percentage of those not living alone (68.9%) or cohabiting (52.2%) were fairly com-
parable (68.5% and 58.6% respectively) to the Census data (Fig 3).[39, 40]
For deprivation (Table 2), the data showed a slightly lower proportion of study population
from the two most deprived quintiles of IMD status, suggesting that older patients in the prac-
tices consenting for linkage with deprivation data tended to be from more affluent areas. This
is in contrast to a previous study which suggested that overall, including patients of all ages,
those in linked CPRD IMD data are comparable to the UK population.[42]
Timeliness
The recording of time-varying social factors in relation to the index date varied considerably
(Fig 4). Amongst those who had information available, 34.7% of individuals had data on
whether they lived alone recorded within 5 years of the index date if data from family number
Fig 2. Comparing ethnicity recording (denominator: Those with available data) in electronic health
records with English Census 2011. Abbreviations: CPRD Clinical Practice Research Datalink HES Hospital
Episode Statistics.
https://doi.org/10.1371/journal.pone.0189038.g002
Fig 3. Comparing recording of immigration status, care home residence, not living alone,
cohabitation and religion in electronic health records and English Census 2011. Abbreviations CPRD
Clinical Practice Research Datalink HES Hospital Episode Statistics FN family number.
https://doi.org/10.1371/journal.pone.0189038.g003
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was not included, but this decreased to about 20% if family number data were also considered
(Fig 4 and S1 Fig). The equivalent percentages for marital status, without and with family num-
ber data were 19.5% and 13.5%, respectively. (Fig 4 and S2 Fig). Little difference (58.8% versus
59.5%) was observed for recording of residence within this defined period for analyses includ-
ing and excluding family number (Fig 4 and S1 Fig).
The equivalent figures for timeliness when the entire study population (n = 591037) was
considered, varied from 3.7% for cohabitation status to 14.2% for living alone data (including
use of family number, S3 Fig).
Discussion and conclusions
This study presents the methodology for ascertaining social factors utilising one of the largest
collections of primary care EHR in the world. This involved drawing up detailed code lists, uti-
lising multiple files within CPRD and in the linked hospitalisation data to maximise ascertain-
ment, and devising algorithms to time-update variables and to deal with discordant recording.
Wide variation in the completeness of recording of social factors was noted, ranging from
1.6% for immigration status to ~82% for deprivation. Overall, the completeness for recording
was better amongst females and older individuals, perhaps reflecting a higher consultation
rates amongst this demographic group.[43]
The influence of GP incentivisation on completeness of recording of social factors was evi-
dent in the recording of ethnicity, an important factor for describing disease burden and for
ascertaining health inequities. In 2006 GPs were incentivised to record ethnicity for all newly
registered patients[44] and in year 2008 this was extended for all registered patients including
the recording of first language spoken.[45] However, this incentivisation was withdrawn on 31
March 2011[25] and we found signs of a downward trend in ethnicity recording from 2011
onwards. The ethnicity data from the present study were available for 79% of the study popula-
tion and when compared to Census data, were found to be representative of the English popu-
lation. These results are comparable to an earlier study that reported ethnicity recording in
CPRD and linked data for all age groups combined, which found completeness of recoding to
be ~78% and ethnicity composition comparable to UK Census.[24]
Fig 4. Timeliness of recording of living alone, cohabitation, marital status and place of residence.
*data from family number analysis excluded
https://doi.org/10.1371/journal.pone.0189038.g004
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Immigration status and religion were poorly recorded in these data, and living arrange-
ments were also sub-optimally recorded. Among those with data, a higher than expected pro-
portion were of minority religion, immigrant status or living in a care home, suggesting that
GPs are more likely to record these specific social characteristics. When these factors were con-
sidered as binary variables (present or absent) in the entire study population, comparison with
Census data suggested that care home status may indeed be well recorded. This is perhaps not
surprising, as these individuals may be fragile and have higher healthcare needs, necessitating
more attendances and interventions. In contrast, being of Muslim religion or an immigrant
appeared to be under-recorded. However, our use of “first language” codes may have preferen-
tially captured immigrants from specific countries, whilst under-ascertaining English-speaking
individuals born in countries such as the Republic of Ireland, North America, Australasia and
the Caribbean, who comprised of ~34% of non-UK born individuals in the 2011 Census.[35]
This under-ascertainment may be exacerbated for individuals who moved to the UK many
decades previously. Thus, CPRD data may be better for capturing recent arrivals to the UK
who are not native English speakers. Homelessness was also under-recorded in these datasets,
representing just 0.02% (n = 92) of total study population. Although the proportion of home-
less individuals registered with GP has increased (63% in 2002 to 90% in 2014), the poor
recording of homelessness status in these data is likely to reflect difficulties encountered by
homeless individuals in accessing GP services.[46, 47]
Our findings show that completeness of recording was enhanced by use of multiple sources
within datasets, as well as use of linked data. Living in a care home was recorded by GPs in
the clinical, referral and test files, consultation data, additional clinical details and could be
inferred from the family number, with additional information provided in the hospital data.
Similarly, living arrangements such as cohabitation and living alone, the latter an important
indicator of morbidity and mortality,[14, 48] were well captured for the study population
(~60% and 70%, respectively) when Read code and family number data from CPRD and HES
data were combined. Other studies have utilised family number to identify care home resi-
dence[26] and cohabitation status.[27, 28, 49] We found that addition of data from family
number improved completeness and representativeness of recording of whether a patient lived
alone or cohabited, but at the potential expense of timeliness of recording and misclassifica-
tion. The family number variable is generated by the general practice software when a patient
registers with a GP or moves address, assigning the same number to individuals with the same
address (Personal communications via email CPRD Knowledge Centre). As the date of updat-
ing family number is not captured directly, we took the patient’s registration date as a conser-
vative estimate of when these data were recorded. Patients can move in or out of households
and this information may not be captured by the practice, and patients sharing households
may be registered at different practices, so that cohabitation status and living alone may be
wrongly assigned. For this reason, we used family number to supplement information only
when it was unavailable from other sources.
Other social characteristics of patients may have been misclassified in these routinely col-
lected medical records–either due to mis-recording or because patients’ status changed over
time and this was not updated. Even factors considered time-invariant in this study may not nec-
essarily have been so; for example, individuals may change their religion. A further point is that
the codes used for determining social factors in general practice have not been validated except
for ethnicity.[50] We could not examine other social factors that may be associated with uptake
of healthcare interventions and health inequities but that were not recorded in these data, such
as education, income, housing, social class, social relationships and cultural beliefs.[1, 51]
The significance of determining social factors in assessing the quality of healthcare and
value-based payments to healthcare providers have been recognised, for example in a 2017
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report published in the United States.[51, 52] A rise in multi-morbidity and frailty amongst
older individuals due to population ageing will also increase the need for assessing social fac-
tors for delivering equitable healthcare. The CPRD database is used internationally for a wide
range of public health studies, and HES includes nation-wide data used extensively for
National Health Service (NHS) based research in the UK. Our methods will be thus of interest
to researchers using these data. The underlying methods of this study could also be adapted for
use in other UK primary care databases. The broader methodological approach utilised in this
study such as to investigate the timeliness and the representativeness of these factors in elec-
tronic health data by comparing to a national standard such as Census data should be general-
izable to other countries with EHR. Our study shows that linked general practice data can be
used to ascertain individuals’ ethnicity, deprivation status, care home residence, and whether
they live alone. However, other factors such as religion and immigration status are incom-
pletely captured and as mentioned earlier some relevant social characteristics are not recorded
in these data. Improvement in completeness and quality of recording of these factors could be
achieved by GP incentivisation and use of unambiguous codes. The effect of GP incentivisa-
tion was evident in the recording of ethnicity in CPRD which increased from ~30% in the
period prior to incentivisation to>80% during the period of incentivisation.[24] A similar
approach could be used for other social factors that are currently poorly captured in these
data. Increasing health care providers’ awareness about the role of social factors in disease bur-
den and uptake of interventions should also help to improve recording of these factors. Link-
ages of general practice records with other population based data such as the Census could
also greatly enhance the availability of information on social factors.
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6.3 Supplementary material to the published paper 2 
S1 Table- Sources of information for social factors in linked Clinical Practice Research Datalink 
Social factors CPRD data files HES Deprivation 
data 
Patient file Patient file 
(family 
number) 
Consultation file Clinical file Additional 
clinical details 
Immunisation file Referral file Test file 
Religion - - - Medcodes - Medcodes Medcodes Medcodes - - 
Ethnicity - - - Medcodes - Medcodes Medcodes Medcodes Ethnos 
variable 
- 
Immigration status - - - Medcodes - Medcodes Medcodes Medcodes - - 
IMD - - - - - - - - - Yes 
Type of residence 
including 
homelessness 
- Yes Consultation 
Type:30 & 31 
Medcodes Entity Type: 
132 
Medcodes Medcodes Medcodes  Admisorc 
variable 
- 
Living alone/ 
cohabitation 
Derived 
from 
marital 
status 
Yes Consultation 
Type:30 & 31 
Medcodes Entity Type:  
132  
Medcodes Medcodes Medcodes Admisorc 
variable 
- 
Marital status Marital 
status 
Yes - Medcodes Entity Type:  
98 
Medcodes Medcodes Medcodes - - 
CPRD Clinical Practice Research Datalink HES Hospital Episodes Statistics IMD index of multiple deprivation  
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S2 Table- Code lists for social factors 
Codelists are available in this thesis as Appendices 4-10.  
S3 Table- Pattern of completeness for social factor recording (N=591,037(100%)). 
Social factors Source: CPRD & HES 
Number of patients with 
complete information N 
(%) 
Source: CPRD and 
HES (including 
family number) 
Number of patients 
with complete 
information N (%) 
All eight social factors 
Living arrangements: living alone (yes/no)  
Living arrangements: cohabitation (yes/no)  
Marital status 
Residence: place  
Ethnicity 
IMD  
Immigration status 
Religion 
45 (0.01%) 53 (0.01%) 
Six social factors (excluding religion and immigration status) 
Living arrangements: living alone (yes/no)  
Living arrangements: cohabitation (yes/no)  
Marital status 
Residence: place  
Ethnicity 
IMD  
13042 (2.2%) 22477 (3.8%) 
Five social factors (additionally excluding residence) 
Living arrangements: living alone (yes/no)  
Living arrangements: cohabitation (yes/no)  
Marital status 
Ethnicity 
IMD  
81583 (13.8%) 222600 (37.7%) 
Four social factors (additionally excluding marital status) 
Living arrangements: living alone (yes/no)  
Living arrangements: cohabitation (yes/no)  
Ethnicity 
IMD  
84974 (14.4%) 246609 (41.7%) 
Three social factors (additionally excluding cohabitation) 
Living arrangements: living alone (yes/no)  
Ethnicity 
IMD  
123450 (20.9%) 290912 (49.2%) 
CPRD Clinical Practice Research Datalink HES Hospital Episodes Statistics IMD index of multiple deprivation 
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S4 Table- Time varying social factors and data source: discordant information on the same date and missing event dates (total study population 
591,037(100%)). 
Social factors and source of their information Number of patients (%) 
with information on social 
factor prior to dropping 
discordant information 
recorded on same date 
Number of patients (%) 
excluded due to 
discordant information 
recorded on same date 
Number of patients (%) 
with information on social 
factor after dropping 
discordant information 
recorded on same date 
Missing event date 
replaced with system 
date#  
Number of patients 
(%) 
Living arrangements Living alone (yes/no) (CPRD & HES) 173046 (29.3%) 456 (0.1%) 172590 (29.2%) 1812 (0.3%) 
Living alone (yes/no) (CPRD only) 172085 (29.1%) 460 (0.1%) 171625 (29%) 1812 (0.3%) 
Living alone (yes/no) (CPRD, HES & FN) 413694 (70%) 456 (0.1%) 413238 (69.9%) 1812 (0.3%) 
Cohabitation (yes/no) (CPRD & HES) 128641 (21.8%) 68 (0.01%) 128573 (21.8%) 1916 (0.3%) 
Cohabitation (yes/no) (CPRD only) 128641 (21.8%) 68 (0.01%) 128573 (21.8%) 1916 (0.3%) 
Cohabitation (yes/no) (CPRD, HES & FN) 356870 (60.4%) 68 (0.01%) 356802 (60.4%) 1916 (0.3%) 
Marital status Marital status (CPRD only) 160963 (27.2%) 151 (0.03%) 160812 (27.2%) 2061 (0.3%) 
Marital status (CPRD, HES & FN) 351432 (59.5%) 151 (0.03%) 351281 (59.4%) 2061 (0.3%) 
Residence Residence: place (CPRD & HES) 60811 (10.3%) 173 (0.03%) 60638 (10.3%) 61 (0.01%) 
Residence: place (CPRD only) 59437 (10.1%) 174 (0.03%) 59263 (10%) 61 (0.01%) 
Residence: place (CPRD, HES & FN)~ 65140 (11%) 173 (0.03%) 64967 (11%) 61 (0.01%) 
Residence: place (CPRD, HES & FN)* 64876 (11%) 173 (0.03%) 64703 (10.9%) 61 (0.01%) 
Residence: homelessness  (CPRD & 
HES) 
60813 (10.3%) 4 (<0.001%) 60809 (10.3%) 64 (0.01%) 
Residence: homelessness  (CPRD) 59439 (10.1%) 4 (<0.001%) 59435 (10.1%) 64 (0.01%) 
CPRD Clinical Practice Research Datalink HES Hospital Episodes Statistics FN Family number 
# Overall, event date was missing for 2219 (0.4%) patients 
~ 1st criteria for care home residence using family number: households with ≥3 individuals aged ≥65 years who were in the majority compared to those aged <65 years 
*2nd criteria for care home residence using family number: households with ≥3 individuals aged ≥65 years, ≤3 individuals aged ≤50 years and those aged ≥65 years were in the majority 
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S5 Table- Additional information obtained from using family number 
Social factors  Information from CPRD 
(including family number) &, 
HES (number of patients with 
data available) 
Total study population 
591,037 (100%) 
Information from CPRD 
(excluding family number)& HES  
Total study population 
591,037(100%) 
Frequency (%) Missing 
data 
Frequency (%) Missing 
data 
Living alone  
 
No 407544 (69%) 177799 
(30.1%) 
166896 (28.2%) 418447 
(70.8%) 
Yes 5694 (1%)  5694 (1%)  
Cohabitation            No 48445 (8.2%) 234235 
(39.6%) 
14666 (2.5%) 462464 
(78.2%) 
Yes 308357 (52.2%)  113907 (19.3%)  
Residence: place  Care home 33205 (5.6%) 526070 
(89%) 
28876 (4.9%) 530399 
(89.7%) 
Sheltered 1272 (0.2%)  1272 (0.2%)  
Household 29296 (5%)  29296 (5%)  
Others 
 
1194 (0.2%)  1194 (0.2%)  
Marital status   Single 7291 (1.2%) 239756 
(40.6%) 
7291 (1.2%) 430225 
(72.8%) 
Married/Civil 108921 (18.4%)  108921 (18.4%)  
Widow/er 30459 (5.2%)  30459 (5.1%)  
Divorced 7446 (1.3%)  7446 (1.3%)  
Separated 2100 (0.3%)  2100 (0.4%)  
Partner 
uncategorised/other# 
195064 (33%)  4595 (0.8%)  
#Due to very small numbers in `Partner: other’ category the data are presented combined with `Partner: 
uncategorised’  
CPRD Clinical Practice Research Datalink HES Hospital Episodes Statistics
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S1 Fig- Timeliness of recording of living alone and residence: comparing data from Clinical Practice Research Datalink (CPRD) and Hospital 
Episodes Statistics (HES) with data obtained from CPRD, HES and family number 
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S2 Fig- Timeliness of recording of cohabitation and marital status: comparing data from Clinical Practice Research Datalink (CPRD) and Hospital 
Episodes Statistics (HES) with data obtained from CPRD, HES and family number 
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S3 Fig- Proportion of total study population (n=591,037) with recording of time-
varying social factors within 5 years of index date (01/01/2013) 
 
CPRD Clinical Practice Research Datalink HES Hospital Episodes Statistics FN family number 
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6.4 Determining immigration status in CPRD data 
As outlined previously in Chapter 4 (Section 4.3.4), I initially assessed immigration status 
based on medical codes for country of birth. To increase the assessment of immigration 
status, I expanded the code list to include “first language” codes to identify individuals born 
in countries where English was not the first language. This was done because the GPs were 
incentivised to record first language for all registered patients between 2008-2011.138, 139 
When immigration status was determined based only on country of birth medical codes, 
information was available for only 0.7% (n= 4187) of the study population (Table 6-1). The 
completeness of recording of immigration status increased to 1.6% (n= 9713) with the 
additional use of first language codes with country of birth codes (Table 6-1). As shown in 
Table 6-1, among the 9713 individuals with information on immigration status (using the 
wider definition comprising both country of birth and language codes), 7866 (81%) had a 
code for being an immigrant, while 19% (n=1847) had a code for being a non-immigrant. I 
considered that a GP was more likely to record that a patient was an immigrant than record 
that a patient was non-immigrant. Based on this assumption, as described in the published 
paper (Section 6.2), immigration status was considered as a binary variable for the entire 
study population: individuals with a country of birth code as immigrants or with first language 
code for languages other than English were categorised as immigrants while the rest of the 
study population was categorised as non-immigrants. Based on this binary categorisation 
and using the entire study population as denominator, of the total study population of 
591037 individuals: 7866 (1.3%) individuals were categorised as immigrants and the 
remaining 583171 (98.7%) individuals were categorised as non-immigrants.  
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Table 6-1 Ascertainment of immigration status in CPRD GOLD data based on country 
of birth and language codes 
Age group (study 
participants) 
Total number of 
individuals 
Immigration status 
information based on 
only country of birth 
codes N (row %) 
Immigration status 
information based on 
country of birth and 
language codes N (row %) 
65-70 years 183382 1333 (0.7) 2938 (1.6) 
70-75 years 131552 1001 (0.8) 2422 (1.8) 
75-80 years 109628 815 (0.7) 1982 (1.8) 
80-85 years 84473 562 (0.7) 1349 (1.6) 
85-90 years 51278 325 (0.6) 723 (1.4) 
>90 years 30724 151 (0.5) 299 (1) 
Total 591037 4187 (0.7)# 9713* (1.6) 
As described in text: # Of these 4187 individuals with available information: 2336 (55.8%) and 1851 (44.2%) were 
coded as immigrants and non-immigrants, respectively *Of these 9713 individuals with available information 7866 
individuals (81%) and 1847 (19%) were coded as immigrants and non-immigrants respectively 
 
As mentioned in the published paper (Section 6.2), the proportion of individuals identified as 
immigrants (1.3%) in the study was lower compared to the 2011 English Census data in 
which 9.9% individuals aged ≥65 years were recorded as non-UK born.152 The use of 
language codes could have preferentially captured data from immigrants who moved to the 
UK from non-English speaking countries but captured fewer individuals who migrated to the 
UK in early childhood if these individuals considered English as their first language. The 
language codes could have also under-ascertained individuals born in countries other than 
UK where English is the first language such as the Republic of Ireland, United States of 
America, Canada or Australia, and those who registered with their GPs after 2011 when 
incentivisation for first language recording was withdrawn. The effect of under ascertainment 
of immigration status on its association with zoster disease burden and zoster vaccine 
uptake are further discussed in Chapters 7 and 8.  
6.5 Family number  
The use of family number (discussed in detail in Chapter 4: Section 4.3) contributed to the 
availability of data for living alone, cohabitation and marital status.  This is illustrated in the 
supplementary material to the published paper (S4 Table): in comparison to data available 
from CPRD (excluding family number) and/or HES, the additional use of family number 
increased the completeness of recording for living alone (29% versus 70%), cohabitation 
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(22% versus 60%) and marital status (27% versus 59%). However, data obtained from using 
family number was less timely compared to the information obtained from using CPRD 
GOLD and HES data without family number. This is because it is unclear how often the 
family number is updated with changes in patient’s address as discussed previously in 
Section 4.4.3. After including information from family number for determining whether 
individuals were living alone, their cohabitation status and marital status, 20.3%, 11.7% and 
13.5% respectively of individuals with available data had this information recorded within 5 
years of the index date (S1 and S2 Fig. supplementary material to the published paper). 
These proportions were lower compared to those obtained from using only CPRD GOLD 
(without family number) and HES data: 34.7%, 16.8% and 19.5% of individuals with 
available data for living alone, cohabitation status and marital status respectively had 
information recorded within 5 years of the index date.  
The assessment of care home residence after including information from the family number 
resulted in ~5.6% of the total study population (n=591037) being defined as care home 
residents (S5 table supplementary material to the published paper). This proportion was 
higher compared to the proportion (4.9%) residing in care home, obtained from utilising only 
CPRD GOLD and HES data (i.e. not using information from family number). The latter data 
(4.9%) were more comparable (Figure 3 published paper Section 6.2) to the 2011 English 
census data, which reported 3.2% individuals aged ≥65 years residing in care home.147 
Therefore, ascertainment of care home residence was based on information obtained from 
using only CPRD and HES data. 
6.6 Chapter summary 
This chapter presented the application of methodology for ascertainment of socio-
demographic factors in linked EHR, developed as a part of this thesis and detailed in 
Chapter 4. This included an assessment of completeness of recording of socio-
demographic factors, their representativeness, timeliness of recordings and additional 
information gained from linkages, which was the second objective of this thesis (Section 
1.5.2). In the next two chapters: Chapters 7 and 8, I describe the results of applying these 
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methods to assess the association of socio-demographic factors with zoster incidence and 
zoster vaccine uptake, respectively.  
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 Chapter 7. A cohort study to investigate the role of 
social determinants related to the burden of herpes 
zoster: a vaccine preventable disease 
7.1 Introduction 
This chapter forms the second of the three chapters included in the Results section of this 
thesis. The methodology for determining the recording of socio-demographic factors in the 
linked electronic data (Chapter 4) was applied in a cohort study conducted to assess 
inequalities in zoster disease burden amongst older individuals in England, which is the third 
objective of this thesis. The details of this work, published in the British Journal of 
Dermatology are presented in the next section. The paper is followed by the supplementary 
material (Section 7.3) to the published paper and results of further investigation into the 
possible impact of missing data on the findings of the paper (Section 7.4). 
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7.2 Paper 3: Inequalities in zoster disease burden: a population-based 
cohort study to identify social determinants using linked data from 
the UK Clinical Practice Research Datalink 
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Summary
Background Zoster vaccination was introduced in England in 2013, where tackling
health inequalities is a statutory requirement. However, specific population
groups with higher zoster burden remain largely unidentified.
Objectives To evaluate health inequalities in zoster disease burden prior to zoster
vaccine introduction in England.
Methods This population-based cohort study used anonymized U.K. primary care
data linked to hospitalization and deprivation data. Individuals aged ≥ 65 years
without prior zoster history (N = 862 470) were followed from 1 September
2003 to 31 August 2013. Poisson regression was used to obtain adjusted rate
ratios (ARRs) for the association of sociodemographic factors (ethnicity, immi-
gration status, individuals’ area-level deprivation, care home residence, living
arrangements) with first zoster episode. Possible mediation by comorbidities and
immunosuppressive medications was also assessed.
Results There were 37 014 first zoster episodes, with an incidence of 879 [95%
confidence interval (CI) 870–888] per 1000 person-years at risk. In multivari-
able analyses, factors associated with higher zoster rates included care home resi-
dence (10% higher vs. those not in care homes), being a woman (16% higher
vs. men), nonimmigrants (~30% higher than immigrants) and white ethnicity
(for example, twice the rate compared with those of black ethnicity). Zoster inci-
dence decreased slightly with increasing deprivation (ARR most vs. least deprived
096 (95% CI 092–099) and among those living alone (ARR 096, 95% CI
094–098). Mediating variables made little difference to the ARR of social factors
but were themselves associated with increased zoster burden (ARR varied from
111 to 384).
Conclusions The burden of zoster was higher in specific sociodemographic groups.
Further study is needed to ascertain whether these individuals are attending for
zoster vaccination.
What’s already known about this topic?
• Monitoring and reducing health inequalities is a statutory requirement in the U.K.
• Incidence of herpes zoster is known to be higher among individuals with certain
comorbidities and those taking immunosuppressive treatment.
• In contrast, little is known about the social determinants of zoster, which may con-
tribute to the inequality of zoster disease burden in England.
What does this study add?
• Older individuals at higher risk of zoster included women, those in care homes,
those of white ethnicity and nonimmigrants.
© 2018 The Authors British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2018) 1
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• Individuals with certain comorbidities and taking immunosuppressive therapies
were at appreciable increased risk of zoster, but this explained little of the
increased risk in the specific demographic and social groups.
• The findings should inform possible future use of the inactivated zoster vaccine
among those at higher risk, including care home residents.
Herpes zoster is associated with appreciable morbidity, and
postherpetic neuralgia (PHN, its commonest complication)
can be an incapacitating condition.1,2 Zoster can be precipi-
tated by immunosenescence or suppression of cell-mediated
immunity, and incidence increases with age, with rates vary-
ing from 6–8 per 1000 person-years to 8–12 per 1000 per-
son-years among those aged 60 and 80 years, respectively.1–5
Antiviral medications may limit zoster symptoms but their
effect on PHN remains uncertain.6 A single-dose vaccine that
is effective in preventing zoster and PHN was introduced in
the U.K. in 2013, targeting individuals aged 70–79 years.7–10
The effect of sociodemographic factors on zoster incidence
has not been extensively investigated. Older individuals and
those of white ethnicity have been shown to be at higher risk
of zoster.4,11,12 The association with other sociodemographic
factors such as sex, country of birth, marital status and socio-
economic status has been inconclusive.3–5,12–14 The unequal
distribution of zoster between social groups could potentially
be exacerbated by differential uptake of zoster vaccination,
resulting in even higher disease burden among some older
individuals. Identifying social groups at higher zoster risk is
therefore essential for planning preventative interventions to
mitigate inequalities of zoster burden and promote healthy
ageing across the population.
In England, zoster incidence trends are monitored using
general practice data to assess the impact of the vaccination
programme, but apart from sex no other social factors are
being evaluated.15 We have shown that some of these factors
can be ascertained using routinely collected electronic health
records such as the Clinical Practice Research Datalink
(CPRD),16 one of the world’s largest anonymized primary care
data sources.17
The aim of this cohort study was to determine the associa-
tion of sociodemographic factors with zoster incidence in Eng-
land using linked CPRD data in the period immediately before
zoster vaccine introduction, to inform suitable targeted vacci-
nation strategies.
Patients and methods
Data sources
This study used anonymized CPRD data linked to hospitaliza-
tion and deprivation data. CPRD provides quality-assured clini-
cal, lifestyle, demographic and administrative data, for a
representative sample of ~7% of the U.K. population.17–19 The
validity of recorded diagnoses within the database is generally
high.18 In England, CPRD provides linkages at an individual level
with other data, including hospitalization [Hospital Episode
Statistics (HES)] and deprivation data, for ~75% of practices.17,18
The deprivation data were based on a patient’s area of residence
and/or practice location [Index of Multiple Deprivation (IMD): a
composite small area-level score].17,18
Study population and follow-up
This cohort study spanned the 10-year period (1 September
2003 to 31 August 2013) prior to zoster vaccine introduction.
The study population comprised patients aged ≥ 65 years who
were registered with a CPRD practice in England during the
study period and eligible for linkage. Patients with zoster or
PHN codes prior to start of follow-up, or whose first zoster
code during follow-up was PHN, were identified in CPRD and
HES [using Read codes for CPRD and International Classifica-
tion of Disease (ICD) 10th revision codes for HES,
Appendix S1] and excluded.
Follow-up started on the latest of the following: study start
date (1 September 2003); 1 year after current registration date
(to avoid retrospective recording of past zoster in first few
months of new registration);20 the date the practice met
CPRD’s quality criteria;18 or individuals’ 65th birthday. Fol-
low-up ended on the earliest of the following: study end date
(31 August 2013); zoster date; transfer-out date; last collec-
tion date from the practice; or date of death.
Outcome
Incident zoster cases were defined as the first diagnostic code
for zoster during follow-up, using both CPRD and HES data
(Appendix S1; see Supporting Information). In the HES data,
patients with zoster codes in either the primary or the sec-
ondary diagnosis fields were included, and the hospital epi-
sode start date was used as the date of zoster.
Exposures
A conceptual framework (Appendix S2), based on the World
Health Organization’s Commission on Social Determinants of
Health framework, was hypothesized for the association of
individual-level sociodemographic factors with zoster inci-
dence.21 These factors included immigration status, religion,
ethnicity, deprivation, care home residence, marital status,
cohabitation (individuals living as a couple) and living alone.
The latter three factors provided overlapping information
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about an individual’s living arrangements. The code lists and
details of how these factors were identified in linked CPRD
data are provided in Appendices S3 and S4. The following fac-
tors were categorized as binary variables: being an immigrant
to the U.K., care home residence, cohabitation and living
alone. Marital status had six categories: single, married, wid-
owed, divorced, separated, and uncategorized/other partner.
Religion and ethnicity had eight (Christian, Buddhist, Hindu,
Jewish, Muslim, Sikh, other and no religion) and five (white,
south Asian, black, other and mixed) categories, respectively.
Social factors that changed with time such as marital status,
cohabitation, living alone and care home residence were time-
updated over the study period.
IMD data were available at both individual- and practice-
small area-level as quintiles [1 (least deprived) to 5 (most
deprived)]; individuals with missing IMD data were assigned
their practice’s IMD quintile.
Other variables
Based on previous data22 and the U.K. Green Book10 guidance
for immunosuppressive conditions considered to be a con-
traindication to live zoster vaccination, certain predisposing
conditions and immunosuppressive medications were postu-
lated as mediators between sociodemographic factors and zoster
incidence (Appendix S2). Conditions identified in either CPRD
or HES (Appendix S3) that were considered immunosuppressive
from the time of recorded diagnosis included rheumatoid
arthritis, systemic lupus erythematosus, inflammatory bowel
disease, diabetes mellitus, chronic kidney disease, chronic
obstructive pulmonary disease, asthma, human immunodefi-
ciency virus infection, other cellular immune deficiency and
solid organ transplant. Individuals with haematopoietic stem
cell transplant, leukaemia, lymphoma, myeloma and other
plasma cell dyscrasias were considered to be immunosuppressed
for 24 months following each record.22 Information on
immunosuppressive medications was extracted using previously
described methodology.22 Details for identifying immunosup-
pressive conditions and treatments in these data are provided in
Appendices S4–5. All putative mediating variables were catego-
rized as binary variables. Age was categorized in 5-yearly bands
from 65 to 84 years, with a final category of ≥ 85 years. The
study period was divided into five approximately equal cate-
gories to observe any temporal changes in zoster incidence.
Analyses
For all sociodemographic factors, the person-time at risk,
number of first zoster cases and missing values were tabulated.
Zoster incidence rates for each factor were obtained by divid-
ing the number of zoster cases by the person-time at risk. The
demographic characteristics of individuals with a past history
of zoster excluded from the study were compared with indi-
viduals included in the study.
Poisson regression was used to estimate incidence of the first
zoster episode and 95% confidence intervals (CI). Hypothesis
testing was conducted using likelihood ratio tests unless other-
wise stated. Age, sex and calendar period were considered as a
priori confounders; age and sex were also considered as risk
factors in their own right. The effect estimates for all explana-
tory and hypothesized mediating variables were first examined
after adjusting for the three a priori confounders in a mini-
mally adjusted model. A hierarchical approach to causal mod-
elling, based on the hypothesized causal framework between
the factors of interest, was then adopted for multivariable anal-
yses (Appendix S6).23 The first multivariable model included
the a priori confounders, ethnicity and immigration status
(model 1); patient-level IMD was then added (model 2), fol-
lowed by care home residence and living alone status (model
3). The potential mediating effects of comorbidities and thera-
peutic agents were examined in models 4 and 5, respectively.
Collinearity between closely related factors (for example living
arrangements) was assessed by comparing measures of effect
and log standard errors of the coefficient in minimally adjusted
and multivariable models. For multivariable models, individu-
als with complete covariate data were analysed. Data were anal-
ysed using the Stata 14 software package (StataCorp, College
Station, TX, U.S.A.).
Ethics
The protocol for this research was approved by the Indepen-
dent Scientific Advisory Committee (ISAC) for Medicines and
Healthcare products Regulatory Agency Database Research
(protocol number 16_168) and made available to the journal
and reviewers during peer review. The study was also
approved by the Observational/Interventions Research Ethics
Committee of the London School of Hygiene and Tropical
Medicine (Reference: 11910).
Results
The cohort initially included 931 830 individuals (Fig. 1)
from 385 practices across England, of which 69 360 were
excluded because of a prior history of zoster. The demo-
graphic characteristics of patients with and without a prior
zoster history (excluded and included, respectively, in the
study) are presented in Appendix S7. Those with a previous
history of zoster were likely to be older at the start of the
study (1 September 2003), women, nonimmigrants and indi-
viduals of white ethnicity, but were similar to included indi-
viduals with respect to IMD quintiles.
The median follow-up time for the eligible study cohort
(N = 862 470) was 433 [interquartile range (IQR)182–807]
years. More than half of the eligible study population were
women and were aged 65–69 years at the start of follow-up
(Table S1; see Supporting Information). Data were missing for
four variables: religion (98% missing), marital status (47%
missing), ethnicity (175% missing) and sex (< 001% missing)
(Table S1). For < 01% of the study population (n = 849), the
missing values of patient-level IMD were replaced by practice-
level IMD (Table S1).
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In total, 37 014 individuals experienced a first zoster epi-
sode during follow-up, the median age at zoster was
757 years (IQR 702–818 years) and the incidence was
879 (95% CI 870–888) per 1000 person-years at risk
(Table S1). The unadjusted zoster rates for all sociodemo-
graphic factors and mediating variables are presented in
Table S1.
A decision was made to drop the two variables with appre-
ciable missing data (religion and marital status) from further
analyses. Ethnicity and sex were retained in the analysis but
individuals with missing data were dropped. The complete
case analysis included 711 590 patients, after dropping partic-
ipants with missing data on ethnicity (n = 150 878) and/or
sex (n = 2) (Fig. 1). Demographic characteristics of individu-
als with and without missing ethnicity data are provided in
Appendix S8. Those without ethnicity data were similar to
those included in the analysis with only slightly lower zoster
incidence and marginally fewer comorbidities (Appendix S8).
In the minimally adjusted model (adjusted for age, sex and
calendar period, Table S2), zoster rates increased linearly with
age, the adjusted rate ratios (ARRs) in the oldest age groups
(aged ≥ 85 years) being 40% higher than for those aged 65–-
69 years. There was little evidence of changing incidence over
the study period. For the sociodemographic factors of interest,
men, those who were of non-white ethnicity, immigrants,
those living in more deprived areas (at the practice or patient-
level) and those living alone had lower rates of zoster, with
reduced rates of between 5% (for moderate deprivation at the
patient-level) to 53% (for black ethnicity) (all P-values
< 0001). Care home residents had higher zoster incidence
(ARR 112, 95% CI 106–118) than non-care home residents.
As expected, most of the comorbidities and all immunosup-
pressive treatments were associated with higher zoster inci-
dence (Table S2).
After adjusting for immigration status in addition to the
a priori confounders (model 1), the effect of ethnicity was
Patients aged ≥ 65 years during study period 01/09/2003-31/08/2013 registered with a CPRD 
practice and meeting the data quality assessment criteria
N = 931 830
Total patients included in the study  
N = 862 470
Patients with zoster code prior to start of follow-upa or with a 
first zoster code during follow up recorded as PHN
N = 69 360
Multivariable analyses: complete case analysis with non-missing data for all exposure variables 
(except for religion and marital statusb) 
N = 711 590
Patients with missing data for ethnicity and /or gender excluded 
N = 150 880
[Ethnicity (n = 150878), gender (n = 1) and both ethnicity and 
gender (n = 1)]
Fig 1. Study participants flow chart. aFollow-up started on the latest of the following: study start date (1 September 2003); 1 year after current
registration date; the date the practice met CPRD’s quality criteria; or individuals’ 65th birthday. Follow-up ended on the earliest of the following:
study end date (31 August 2013); zoster date; transfer-out date; last collection date from the practice; or date of death. bBoth these variables were
excluded from the analyses. CPRD, Clinical Practice Research Datalink; PHN, post-herpetic neuralgia.
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almost unchanged, with each non-white ethnic group remain-
ing at lower risk of zoster [ranging from a 15% reduced rate
(other ethnicity) to a 51% reduced rate (black ethnicity),
Table S2]. In contrast, the effect estimate for immigration status
was slightly attenuated after additionally adjusting for ethnicity,
although immigrants remained at 23% lower risk of zoster.
Practice- and patient-level deprivation were closely correlated,
as were living alone and cohabitation status; thus, only patient-
level IMD was added to model 2 and living alone to model 3.
There were no appreciable changes in the effect estimates for
each factor with successive adjustment (Table S2). Those living
in a care home had about a 10% higher rate of zoster, and those
living alone a reduced rate of 4% (model 3, Table S2). None of
the factors appeared to be mediated by comorbidities or
immunosuppressive therapies (models 4 and 5, Table S2).
When analyses were repeated for those with missing ethni-
city data, effect estimates in the minimally adjusted analysis
were all in the same direction of the main analysis
(Appendix S9). In further sensitivity analyses, restriction to
those of white ethnicity also showed no differences to the
main analysis (Appendix S10). Substitution of practice- for
patient-level IMD (Appendix S11) and cohabitation instead of
living alone (Appendix S12) also did not change the findings.
Discussion
In this large population-based cohort study, sociodemographic
factors independently associated with higher zoster risk
included age, female sex, white ethnicity and care home resi-
dence. There was little evidence of increased incidence among
minority ethnic groups, those living alone or living in
deprived areas. As in previous studies, increasing age, specific
comorbidities and immunosuppressive treatments were associ-
ated with higher zoster incidence.
This study used one of the world’s largest quality-assured pri-
mary care databases, linked to hospitalization and social depriva-
tion data, and provided data for a wide range of social factors,
including potential mediating variables for zoster risk. These
results could be potentially generalizable to older individuals
without prior history of zoster from countries with universal
access to health care as in the U.K. Ascertainment of social factors
using routinely collected electronic health records was achieved
by using detailed coding algorithms and rigorous methodology.
Causal modelling based on a predefined conceptual framework
ensured quantification of robust effect estimates.
The limitations associated with use of routinely collected
data included potential misclassification of both exposure and
outcome. Time-varying exposures such as living alone may be
misclassified in these data if not updated in a timely manner
in general practitioner records. Similarly, for binary variables,
the assumption that absence of a code implies absence of the
characteristic may not be true. However, the methods used in
this study are based on our previously developed methodology
for ascertainment of social factors among older individuals
using linked CPRD data, which found prevalence of factors
such as ethnicity, living alone, cohabitation and care home
residence comparable with the 2011 English Census, whereas
being an immigrant was under-represented in these data.16 In
the U.K., zoster is mainly diagnosed clinically;22 however, a
clinical diagnosis of zoster in primary care is reported to have
a high (91%) positive predictive value among older individu-
als.24 Any misclassification of exposure or outcome is likely to
be nondifferential, tending to bias effect estimates towards the
null. Thus, the actual effect estimates may be even larger than
observed here.
Differential zoster ascertainment in different social groups is
a consideration. For example, it is possible that those living
alone or in more deprived areas may not seek care for zoster.
Those seeking ongoing care for their comorbidities may have
a higher opportunity of zoster diagnosis, although we found
no mediating effect of comorbidities for any of the social fac-
tors examined. A previous U.S. study reported that 95% of
older individuals were likely to consult for zoster, irrespective
of sociodemographic characteristics such as income or marital
status.25 Unavailability of factors such as education, income
and social class, and poor recording of religion (2%) and mar-
ital status (~50%) in these data precluded the assessment of
their association with zoster in this study. Finally, excluding
individuals with missing ethnicity data could have biased our
results, but further multivariable and sensitivity analyses
showed no evidence for this.
The rates in this study are comparable with previously
reported zoster rates of 6–8 per 1000 person-years and 8–12
per 1000 person-years among individuals aged 60 and
80 years, respectively.2 However, the overall incidence of first
zoster episodes in this study of individuals aged ≥ 65 years
was slightly higher than a U.K.-based study of only immuno-
competent individuals that reported zoster rates of 596 (aged
65–69 years) to 622 (aged ≥ 85 years) per 1000 person-
years.26
Increasing age and female sex are both known to be associ-
ated with higher zoster incidence owing to age- and
sex-related immune differences and possible differences in
health-seeking behaviour.2–4 The finding of lower zoster dis-
ease burden among individuals of non-white ethnicity seen in
this study has been previously reported.4,11–14 This effect of
lower zoster incidence among individuals of non-white ethni-
city could be explained by persisting immunity to zoster in
later years because of late-onset varicella in individuals born
in the Caribbean or tropical countries,3,14,27,28 although
immigrants represent a heterogeneous group in terms of their
country of origin and age of arrival in the U.K. There was lit-
tle evidence of collinearity between ethnicity and immigration
status, and the finding of lower zoster incidence among those
of non-white ethnicity, independent of immigration status,
could perhaps be explained by social mixing patterns in
extended families leading to varicella contacts and boosting of
zoster immunity among older individuals.29 It is also possible
that zoster might be underdiagnosed if individuals of non-white
ethnicity who developed zoster were less likely to consult or less
likely to be diagnosed, but it seems implausible in view of the
large effect seen. The association of care home residence with
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higher zoster incidence was noted independent of age and
comorbidities. The effect of malnutrition on immune function
could also play an important role; previous research has sug-
gested that nearly one in three care home residents could be at
risk of malnutrition.30–32 The association of higher zoster inci-
dence with certain comorbidities and taking immunosuppres-
sive treatment has been previously reported.2,3,5,22,33 Similarly,
as reported previously, we also did not find any evidence of an
association of diabetes with zoster disease burden.22 The associ-
ation of social support, cohabitation or being married with zos-
ter incidence is conflicting: some studies have reported no
association with being married,5,12,14 individuals with a confi-
dant having lower12 or no effect14 on zoster incidence, whereas
another study reported higher zoster risk among individuals not
cohabiting.4 The unexpected finding of an independent associa-
tion of living alone and lower patient-level IMD with lower
incidence of first zoster episode could perhaps be because of a
higher occurrence of zoster among these social groups before
the age of 65 years and thus their exclusion from the current
study. However, there was no evidence for any appreciable dif-
ferences in patient-level IMD scores when the characteristics of
individuals with/without prior zoster history were compared.
In conclusion, this large population-based cohort study has
identified social factors associated with zoster incidence among
an older population in the U.K. Typically, older patients with
higher level of deprivation, those of non-white ethnicity,
immigrants and those living alone are at greater risk of infec-
tious diseases; interestingly, our study found these groups were
at lower risk of zoster. However, care home residence was asso-
ciated with higher zoster burden and it may be worth consider-
ing targeted vaccination of this group. Further research on the
risk of PHN in these social groups would also help inform vac-
cination policy. It will be interesting to determine in future
studies whether these social groups with higher zoster inci-
dence come forward for zoster vaccination.
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Table S1 Baseline characteristics of the study cohort (N = 862 470 outcome n =37 014) 
Characteristics Total N 
 (column %*) 
Outcome N 
(row %*) 
Person-years 
(1000) 
Zoster incidence per 
1,000 person-years at 
risk (95% CI) 
Overall 862,470 37,014 (4.3%) 4210.5 8.79 (8.70–8.88) 
Time-constant exposure variables     
Age at start of follow-
up (years) 
 
65-69 442499 (51.3%) 15979 (3.6%) 2051 7.79 (7.67-7.91) 
70-74 136151 (15.8%) 7842 (5.8%) 856.6 9.15 (8.95-9.36) 
75-79 112302 (13%) 6358 (5.7%) 632.9 10.05 (9.80-10.30) 
80-84 89827 (10.4%) 4292 (4.8%) 420.7 10.20 (9.90-10.51) 
85 & above 81691 (9.5%) 2543 (3.1%) 249.3 10.20 (9.81-10.60) 
Sex  Male 389,264 (45.1%) 14771 (3.8%) 1873.7 7.88 (7.76-8.01) 
Female 473,204 (54.9%) 22243 (4.7%) 2336.8 9.52 (9.39-9.64) 
Missing 2 (0.0002%) 0 - - 
Ethnicity  White 684870 (79.4%) 31789 (4.6%) 3454.5 
 
9.20 (9.10-9.30) 
South Asian 12273 (1.4%) 322 (2.6%) 52.1 6.18 (5.54-6.90) 
Black 7176 (0.8%) 128 (1.8%) 30.5 4.19 (3.53-4.99) 
Other 5850 (0.7%) 178 (3%) 24.1 7.39 (6.38-8.56) 
Mixed 1422 (0.2%) 42 (3%) 6.2 6.75 (4.99-9.14) 
Missing 150879 (17.5%) 4555 (3%) - - 
Religion  Christian 14705 (1.7%) 660 (4.5%) 68.7 9.60 (8.90-10.36) 
Buddhist 47 (0%) 1 (2.1%) 0.2 5.96 (0.84-42.30) 
Hindu 428 (0.1%) 16 (3.7%) 2.1 7.69 (4.71-12.55) 
Jewish 344 (0%) 8 (2.3%) 1.7 4.79 (2.40-9.59) 
Muslim 681 (0.1%) 9 (1.3%) 2.9 3.16 (1.64-6.07) 
Sikh 136 (0%) 2 (1.5%) 0.5 4.06 (1.01-16.23) 
Other 27 (0%) 0 (0%) 0.1 - 
No religion 1085 (0.1%) 51 (4.7%) 4.4 11.59 (8.81-15.24) 
Missing 845017 (98%) 36267 (4.3%) - - 
Immigration status Not immigrant 853123 (98.9%) 36785 (4.3%) 
 
4170.6 8.82 (8.73-8.91) 
Immigrant 9347 (1.1%) 229 (2.4%) 
 
39.9 5.74 (5.04-6.53) 
Patient-level IMD~ 1 (least deprived) 201684 (23.4%) 9141 (4.5%) 
 
1011.5 
 
9.04 (8.85-9.22) 
2 220924 (25.6%) 9790 (4.4%) 
 
1095.6 
 
8.94 (8.76-9.11) 
3 181648 (21.1%) 7671 (4.2%) 
 
881 8.71 (8.51-8.90) 
4 158865 (18.4%) 6485 (4.1%) 
 
758.8 8.55 (8.34-8.76) 
5 (most deprived) 99349 (11.5%) 3927 (4%) 
 
463.7 8.47 (8.21-8.74) 
Practice-level IMD 1 (least deprived) 129174 (15%) 6101 (4.7%) 
 
649.7 9.39 (9.16-9.63) 
2 197749 (22.9%) 8420 (4.3%) 
 
972 8.66 (8.48-8.85) 
3 195727 (22.7%) 8491 (4.3%) 
 
935.5 9.08 (8.89-9.27) 
4 185751 (21.5%) 7649 (4.1%) 
 
896.2 8.53 (8.35-8.73) 
5 (most deprived) 154069 (17.9%) 6353 (4.1%) 757.2 8.39 (8.19-8.60) 
Time-varying exposure variables     
Age acquired during 
the study (years) 
65-69 - 8907 1227.4 7.26 (7.11-7.41) 
70-74 - 8488 1006.6 8.43 (8.25-8.61) 
75-79 - 7934 827.5 9.59 (9.38-9.80) 
80-84 - 6147 613.5 10.02 (9.77-10.27) 
85 & above - 5538 535.5 10.34 (10.07-10.62) 
 
Living alone  No - 24865 2767.5 8.98 (8.87-9.1) 
Yes - 12149 1443.1 8.42 (8.27-8.57)  
     
Contd. 
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Characteristics Total N 
 (column %*) 
Outcome N 
(row %*) 
Person-years 
(1000) 
Zoster incidence per 
1,000 person-years at 
risk (95% CI) 
Marital status Single - 402 46.2 8.69 (7.88-9.59) 
Married/Civil - 7126 768.4 9.27 (9.06-9.49) 
Widow/er - 2730 265.1 10.30 (9.92-10.69) 
Divorced - 332 39.5 8.41 (7.55-9.37) 
Separated - 111 11.2 9.87 (8.20-11.89) 
Partner 
uncategorized/ 
other 
- 10471 1169.1 
 
8.96 (8.79-9.13) 
Missing 407609 (47.3%) 15842 (3.9%) - - 
Cohabiting  No - 18855 2215.9 8.51 (8.39-8.63) 
Yes - 18159 1994.6 9.1 (8.97-9.24) 
Care home  No - 35494 4071.7 8.72 (8.63-8.81) 
Yes - 1520 138.8 10.95 (10.41-11.51) 
Calendar period 
 
 2003-2005 - 8357 958.9 8.72 (8.53-8.90) 
 2006-2007 - 7611 849 8.96 (8.77-9.17) 
 2008-2009 - 7752 872.6 8.88 (8.69-9.08) 
 2010-2011 - 7528 853.2 8.82 (8.63-9.02) 
 2012-2013 - 5766 676.9 8.52 (8.30-8.74) 
Comorbidities and medications     
Rheumatoid arthritis No - 35724 4114.6 8.68 (8.59-8.77) 
Yes - 1290 95.9 13.45 (12.74-14.2) 
Systemic lupus 
Erythematosus 
No - 36923 4204.5 8.78 (8.69-8.87) 
Yes - 91 6.1 15.05 (12.26-18.49) 
Inflammatory bowel 
disease 
No - 36417 4158.6 8.76 (8.67-8.85) 
Yes - 597 52 11.49 (10.6-12.45) 
Diabetes mellitus No - 31335 3584.9 8.74 (8.64-8.84) 
Yes - 5679 625.7 9.08 (8.84-9.32) 
Chronic kidney 
disease 
No - 30563 3590.2 8.51 (8.42-8.61) 
Yes - 6451 620.3 10.4 (10.15-10.66) 
COPD/ asthma No - 29365 3504.1 8.38 (8.28-8.48) 
Yes - 7649 706.4 10.83 (10.59-11.07) 
Human 
Immunodeficiency 
virus infection 
No - 37008 4210 8.79 (8.7-8.88) 
Yes - 6 0.5 12.26 (5.51-27.29) 
Cellular immune 
deficiency 
No - 36932 4204.2 8.78 (8.7-8.87) 
Yes - 82 6.3 12.97 (10.44-16.1) 
Solid organ transplant No - 36949 4206.4 8.78 (8.69-8.87) 
Yes - 65 4.2 15.66 (12.28-19.97) 
Bone marrow/ stem 
cell transplant 
No - 36997 4210.3 8.79 (8.7-8.88) 
Yes - 17 0.2 79.01 (49.12-127.1) 
Lymphoma, myeloma, 
other plasma cell 
dyscrasias and 
leukaemia 
No - 36535 4191.4 8.72 (8.63-8.81) 
Yes - 479 19.1 25.03 (22.88-27.37) 
Cancer 
chemotherapeutic 
agents/ cancer 
radiotherapy 
No - 36256 4164.3 8.71 (8.62-8.8) 
Yes - 758 46.2 16.41 (15.28-17.62) 
Oral corticosteroids No - 36655 4192.6 8.74 (8.65-8.83) 
Yes - 359 17.9 20.02 (18.05-22.2) 
Other 
immunosuppressant 
drugs#  
No - 36673 4191.8 8.75 (8.66-8.84) 
Yes - 341 18.7 18.2 (16.36-20.23) 
*percentage presented for time-constant variables ~849 (0.1%) missing values for patient-level IMD replaced by practice IMD; 
#includes azathioprine, biological therapy, methotrexate, 6-mercaptopurine, other immunosuppressants such as tacrolimus, 
sirolimus, and other disease-modifying antirheumatic drugs: ciclosporin, mycophenolate, leflunomide.  
Table S2 Multivariable analysis: social factors associated with zoster disease incidence (complete case analysis; individuals with missing data for ethnicity and 
sex excluded) (N = 711 590, outcome n =32 459)   
Exposures  Minimally 
adjusted for age, 
sex and calendar 
period 
RR (95% CI) 
P-value* 
(PT) 
 
Model 1: 
additionally 
adjusted for 
immigration 
status & ethnicity 
RR (95% CI) 
P-value* 
(PT) 
Model 2: 
additionally 
adjusted for 
patient-level IMD 
RR (95% CI)  
P-value* 
(PT) 
Model 3: 
additionally 
adjusted for care 
home residence & 
living alone  
RR (95% CI) 
P-value* 
(PT) 
Model 4: 
additionally 
adjusted for 
comorbidities 
RR (95% CI) 
P-value* 
(PT) 
Model 5: 
additionally 
adjusted for 
immuno-
suppressive 
therapies  
RR (95% CI) 
P-value* 
(PT) 
Age acquired during 
the study(years) 
65-69 1  1  1  1  1  1 <0.0001 
70-74   1.16 (1.12-1.20) <0.0001 1.16 (1.12-1.20) <0.0001 1.16 (1.12-1.20) <0.0001 1.16 (1.12-1.20) <0.0001 1.15 (1.11-1.18) <0.0001 1.15 (1.11-1.18)  
75-79   1.29 (1.25-1.34) (<0.0001) 1.29 (1.25-1.33) (<0.0001) 1.29 (1.25-1.33) (<0.0001) 1.29 (1.25-1.33) (<0.0001) 1.26 (1.22-1.31) (<0.0001) 1.27 (1.22-1.31) (<0.0001) 
80-84  1.36 (1.31-1.41)  1.35 (1.31-1.40)  1.35 (1.31-1.40)  1.35 (1.30-1.40)  1.32 (1.27-1.36)  1.32 (1.28-1.37)  
85 & above 1.40 (1.35-1.45)  1.38 (1.34-1.44)  1.39 (1.34-1.44)  1.38 (1.33-1.43)  1.35 (1.30-1.40)  1.36 (1.31-1.41)  
Sex Male 0.85 (0.84-0.87) <0.0001 0.85 (0.84-0.87) <0.0001 0.85 (0.84-0.87) <0.0001 0.86 (0.84-0.87) <0.0001 0.86 (0.84-0.88) <0.0001 0.86 (0.84-0.88) <0.0001 
Female 1  1  1  1  1  1  
Ethnicity White 1  1  1  1  1  1  
South Asian 0.70 (0.63-0.79) <0.0001 0.76 (0.67-0.85) <0.0001 0.76 (0.68-0.85) <0.0001 0.76 (0.68-0.85) <0.0001 0.75 (0.67-0.84) <0.0001 0.75 (0.67-0.84) <0.0001 
Black 0.47 (0.40-0.56)  0.49 (0.41-0.58)  0.49 (0.41-0.59)  0.49 (0.41-0.59)  0.49 (0.42-0.59)  0.50 (0.42-0.59)  
Other 0.83 (0.71-0.96)  0.85 (0.74-0.99)  0.86 (0.74-0.99)  0.85 (0.74-0.99)  0.86 (0.75-1.00)  0.87 (0.75-1.00)  
Mixed 0.77 (0.57-1.04)  0.78 (0.58-1.06)  0.78 (0.58-1.06)  0.78 (0.58-1.06)  0.78 (0.58-1.06)  0.79 (0.58-1.06)  
Immigration status Not immigrant 1  1  1  1  1  1  
Immigrant 0.65 (0.57-0.74) <0.0001 0.77 (0.67-0.88) 0.0001 0.77 (0.67-0.88) 0.0001 0.77 (0.67-0.88) 0.0001 0.77 (0.67-0.89) 0.0002 0.77 (0.67-0.89) 0.0002 
Patient-level IMD~ 1 (least deprived) 1  Not in model - 1  1  1  1  
2 0.98 (0.95-1.01) 0.0006   0.98 (0.95-1.01) 0.01 0.98 (0.95-1.01) 0.02 0.98 (0.95-1.01) 0.0003 0.98 (0.95-1.01) 0.0005 
3 0.95 (0.92-0.98)    0.95 (0.92-0.99)  0.95 (0.92-0.99)  0.95 (0.92-0.98)  0.95 (0.92-0.98)  
4 0.94 (0.91-0.98)    0.95 (0.92-0.99)  0.96 (0.92-0.99)  0.94 (0.91-0.98)  0.94 (0.91-0.98)  
5 (most deprived) 0.93 (0.90-0.97)    0.95 (0.92-0.99)  0.96 (0.92-0.99)  0.93 (0.89-0.97)  0.93 (0.89-0.97)  
Practice-level IMD 1 (least deprived) 1  Not in model - Not in model - Not in model - Not in model - Not in model - 
2 0.92 (0.88-0.95) <0.0001           
3 0.96 (0.93-1.00)            
4 0.91 (0.88-0.94)            
5 (most deprived) 0.90 (0.86-0.93)            
Calendar period 2003-2005 1  1  1  1  1  1  
 2006-2007 1.03 (0.99-1.06) 0.14 1.03 (0.99-1.06) 0.18 1.03 (0.99-1.06) 0.19 1.03 (0.99-1.06) 0.18 1.01 (0.98-1.04) 0.007 1.01 (0.98-1.04) 0.001 
 2008-2009 1.02 (0.99-1.06)  1.03 (0.99-1.06)  1.03 (0.99-1.06)  1.02 (0.99-1.06)  0.99 (0.96-1.03)  0.99 (0.96-1.03)  
 2010-2011 1.01 (0.98-1.05)  1.02 (0.99-1.05)  1.02 (0.98-1.05)  1.01 (0.98-1.05)  0.98 (0.94-1.01)  0.97 (0.94-1.01)  
 2012-2013 0.99 (0.95-1.02)  0.99 (0.96-1.03)  0.99 (0.96-1.03)  0.99 (0.95-1.02)  0.95 (0.91-0.98)  0.94 (0.91-0.97)  
Care home residence No 1  Not in model - Not in model - 1  1  1  
Yes 1.12 (1.06-1.18) 0.0001     1.10 (1.04-1.17) 0.0007 1.09 (1.03-1.15) 0.004 1.09 (1.03-1.15) 0.004 
 
Living alone 
No 1  Not in model - Not in model - 1  1  1  
Yes 0.95 (0.93-0.97) <0.0001     0.96 (0.94-0.98) 0.0006 0.96 (0.94-0.98) 0.001 0.96 (0.94-0.99) 0.002 
Cohabitation No 1  Not in model - Not in model - Not in model - Not in model - Not in model - 
 Yes 1.07 (1.05-1.09) <0.0001           
Rheumatoid arthritis No 1  Not in model - Not in model - Not in model - 1  1  
Yes 1.45 (1.37-1.54) <0.0001       1.40 (1.32-1.49) <0.0001 1.34 (1.26-1.42) <0.0001 
Systemic lupus 
Erythematosus 
No 1  Not in model - Not in model - Not in model - 1  1  
Yes 1.67 (1.35-2.07) <0.0001       1.53 (1.24-1.89) 0.0003 1.45 (1.17-1.80) 0.001 
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Exposures  Minimally 
adjusted for age, 
sex and calendar 
period 
RR (95% CI) 
P-value* 
(PT) 
 
Model 1: 
additionally 
adjusted for 
immigration 
status & ethnicity 
RR (95% CI) 
P-value* 
(PT) 
Model 2: 
additionally 
adjusted for 
patient-level IMD 
RR (95% CI)  
P-value* 
(PT) 
Model 3: 
additionally 
adjusted for care 
home residence & 
living alone  
RR (95% CI) 
P-value* 
(PT) 
Model 4: 
additionally 
adjusted for 
comorbidities 
RR (95% CI) 
P-value* 
(PT) 
Model 5: 
additionally 
adjusted for 
immuno-
suppressive 
therapies  
RR (95% CI) 
P-value* 
(PT) 
Inflammatory bowel 
disease 
No 1  Not in model - Not in model - Not in model - 1  1  
Yes 1.29 (1.18-1.40) <0.0001       1.25 (1.15-1.36) <0.0001 1.19 (1.10-1.30) 0.0001 
Diabetes mellitus No 1  Not in model - Not in model - Not in model - 1  1  
Yes 1.02 (0.99-1.05) 0.21       1.01 (0.98-1.04) 0.48 1.01 (0.98-1.04) 0.52 
Chronic kidney disease No 1  Not in model - Not in model - Not in model - 1  1  
Yes 1.13 (1.10-1.17) <0.0001       1.11 (1.08-1.15) <0.0001 1.11 (1.07-1.14) <0.0001 
COPD/ asthma No 1  Not in model - Not in model - Not in model - 1  1  
Yes 1.26 (1.23-1.30) <0.0001       1.25 (1.22-1.29) <0.0001 1.24 (1.21-1.27) <0.0001 
HIV No 1  Not in model - Not in model - Not in model - 1  1  
Yes 1.80 (0.81-4.01) 0.19       1.93 (0.87-4.29) 0.15 1.94 (0.87-4.31) 0.14 
Cellular immune 
deficiency 
No 1  Not in model - Not in model - Not in model - 1  1  
Yes 1.41 (1.13-1.77) 0.004       1.15 (0.91-1.43) 0.25 1.04 (0.83-1.31) 0.71 
Solid organ transplant No 1  Not in model - Not in model - Not in model - 1  1  
Yes 1.95 (1.53-2.48) <0.0001       1.81 (1.42-2.31) <0.0001 1.43 (1.12-1.84) 0.008 
Bone marrow/ stem 
cell transplant 
No 1  Not in model - Not in model - Not in model - 1  1  
Yes 10.31 (6.41-16.59) <0.0001       4.53 (2.80-7.35) <0.0001 3.84 (2.37-6.24) <0.0001 
Lymphoma, myeloma, 
other plasma cell 
dyscrasias & 
leukaemia 
No 1  Not in model - Not in model - Not in model - 1  1  
Yes 2.83 (2.58-3.10) <0.0001       2.68 (2.44-2.94) <0.0001 2.36 (2.14-2.60) <0.0001 
Cancer 
chemotherapeutic 
agents/ radiotherapy 
No 1  Not in model - Not in model - Not in model - Not in model - 1  
Yes 1.86 (1.73-2.00) <0.0001         1.55 (1.43-1.67) <0.0001 
Oral corticosteroids No 1  Not in model - Not in model - Not in model - Not in model - 1  
Yes 2.32 (2.09-2.58) <0.0001         2.00 (1.80-2.23) <0.0001 
Other immuno-
suppressant drugs# 
excluding oral 
corticosteroids 
No 1  Not in model - Not in model - Not in model - Not in model - 1  
Yes 2.09 (1.87-2.33) <0.0001         1.63 (1.45-1.83) <0.0001 
RR, rate ratios; CI, confidence interval; PT, P-value for trend; IMD, index of multiple deprivation. ~ 668 (0.09%) missing values replaced by practice IMD; COPD, chronic obstructive pulmonary disease; HIV, Human 
Immunodeficiency virus infection; *likelihood ratio test #azathioprine, biological therapy, methotrexate, 6-mercaptopurine, other immunosuppressants such as tacrolimus, sirolimus, other disease-modifying antirheumatic 
drugs e.g.: ciclosporin, mycophenolate, leflunomide. 
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Appendix S1 Codelist: zoster 
Codelist is available in this thesis as Appendix 3. 
Appendix S2 Conceptual hierarchical framework for the association of social factors 
with zoster disease burden 
 
Appendix S3 Code lists: social factors, comorbidities and medications 
Codelists are available in this thesis as Appendices 4-10 and13-17. 
Appendix S4 Identification of exposures, comorbidities and medications in Clinical 
Practice Research Datalink and Hospital Episode Statistics 
These are described in thesis Chapters 4 and 5. 
Appendix S5 Immunosuppressive medications and conditions: defining periods of 
immunosuppression 
These are described in thesis Chapter 5.
Level 4: Co-morbidities^ 
Level 2: Deprivation 
Level 3: Marital status, cohabitation, living alone, care home 
residence 
Level 1: Ethnicity, immigration status, religion 
Level 5: Immunosuppressive medications~ 
Outcome: Zoster 1st episode 
A priori 
confounders 
  
Age 
^included rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, diabetes 
mellitus, chronic kidney disease, chronic obstructive pulmonary disease or asthma, HIV infection, other 
cellular immune deficiency, leukemia, lymphoma, myeloma, other plasma cell dyscrasias, haematopoietic 
stem cell transplant & solid organ transplant  ~included immune-suppressive doses of oral/injectable 
corticosteroids, other immune-suppressants drugs (e.g. azathioprine, biological therapy, methotrexate) and 
cancer chemo/radiotherapy 
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Appendix 6 Inclusion of explanatory variables in causal modelling based on hierarchical framework 
(Based on1) 
 
Model Explanatory variable Interpretation 
Adjusted for a 
priori 
confounders 
All variables adjusted for a priori confounders: age, sex and 
calendar period 
Effect estimate of each variable adjusted for a priori confounders 
Model-1* Ethnicity and immigration status with a priori confounders Effects of ethnicity and immigration status adjusted for a priori confounders and each other 
Model-2* Model-1+IMD Effects of ethnicity and immigration status not mediated via IMD & adjusted for a priori 
confounders and each other 
Effects of IMD adjusted for other variables in the model and a priori confounders* 
Model-3* Model-2 + living alone+ care home residence Effects of ethnicity and immigration status not mediated via living alone and care home 
residence, adjusted for other variables in the model and a priori confounders*  
Effect of IMD not mediated via living alone and care home residence, adjusted for other 
variables in the model and a priori confounders*  
Effect of living alone+ and care home residence adjusted for other variables in the model 
and a priori confounders*  
Model-4* Model-3 + co-morbidities~ Effect of ethnicity and immigration status, IMD, living alone and care home residence not 
mediated via co-morbidities* 
Effect of co-morbidities adjusted for other variables in the model and a priori confounders*  
Model-5* Model-4 + medications# Effect of ethnicity and immigration status, IMD, living alone, care home residence and co-
morbidities not mediated via medications* 
Effect of medication adjusted for other variables in the model and a priori confounders*  
*all variables in the model adjusted for each other and a priori confounders: age, sex and calendar period 
 IMD index of multiple deprivation ~co-morbidities included systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, chronic obstructive pulmonary disease, asthma, chronic 
kidney disease, diabetes, HIV, cellular immune deficiency, acute and chronic leukemia, lymphoma, myeloma and other haematological malignancies including plasma cell dyscrasias, solid organ 
transplant and bone marrow transplant # steroids (oral or injectable), radiotherapy and chemotherapy, biological therapy, disease modifying anti-rheumatic drugs (DMARDs): azathioprine, 
methotrexate, and other DMARDs), other immunosuppressive drugs such as tacrolimus 
 
Reference: 1. Victora CG, Huttly SR, Fuchs SC, Olinto MT. The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. Int J Epidemiol. 1997 Feb;26(1):224-7 
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Appendix S7 Comparison of patients excluded due to prior history of zoster and 
patients included in the study 
Characteristics Excluded individuals 
from  study due to 
prior history of zoster 
N=69360 
Included in study 
N=862470 
Median age in years at start of the study date 
(01/09/2003) (interquartile range) 
 
70.2 (61.2-79.2) 68.2 (61.2-76.2) 
Sex  Male 27,296 (39.4%) 389,264 (45.1%) 
 Female 42,064 (60.6) 473,204 (54.9%) 
 Missing - 2 (0.0002%) 
Patient-level IMD~+ 1 (least deprived) 16542 (23.9%) 201684 (23.4%) 
 2 17933 (25.8%) 220924 (25.6%) 
 3 14705 (21.2%) 181648 (21.1%) 
 4 12200 (17.6%) 158865 (18.4%) 
 5 (most deprived) 7980 (11.5%) 99349 (11.5%) 
Immigration status Not immigrant 68916 (99.4%) 853123 (98.9%) 
 Immigrant 444 (0.6%) 9347 (1.1%) 
Ethnicity  White 58022 (83.6%) 684870 (79.4%) 
 South Asian 597 (0.9%) 12273 (1.4%) 
 Black 213 (0.3%) 7176 (0.8%) 
 Other 385 (0.6%) 5850 (0.7%) 
 Mixed 72 (0.1%) 1422 (0.2%) 
 Missing 10071 (14.5%) 150879 (17.5%) 
IMD index of multiple deprivation ~ for excluded group 42 (0.06%) missing values replaced by practice IMD + for 
included group 849 (0.1%) missing values replaced by practice IMD 
  
Appendix S8 Baseline characteristics of patients excluded from analysis due to missing data for ethnicity and included 
in complete case analysis 
 Patients excluded from complete case analysis*  
N=150,878 outcome=4555 (3%) Incidence per 1,000 
pyr (95%CI) 7.08 (6.88-7.29) 
Median age (years) at start of follow-up (IQR)      
68.2 (65-77.2) 
Median age (years)  at current registration date (IQR) 
54.5 (40.7-65.2) 
Patients included in complete case analysis 
N=711,590, outcome=32,459 (4.6%) Incidence 
per 1,000 pyr (95%CI)= 9.09 (9.0-9.20) 
Median age (years)at start of follow-up (IQR) 
69.6 (65-77.8) 
Median age (years)  at current registration date 
(IQR) 57.8 (43.6-67.7) 
Total (column 
%) 
No outcome (row 
%) 
With outcome 
(row %) 
Total (column 
%) 
No outcome 
(row %) 
With 
outcome 
(row %) 
Age at start of follow-
up (years) 
65-69 83822 (55.6%) 81529 (97.3%) 2293 (2.7%) 358677 (50.4%) 344991 (96.2%) 13686 (3.8%) 
70-74 20483 (13.6%) 19610 (95.7%) 873 (4.3%) 115668 (16.3%) 108699 (94%) 6969 (6%) 
75-79 15803 (10.5%) 15173 (96%) 630 (4%) 96499 (13.6%) 90771 (94.1%) 5728 (5.9%) 
80-84 13997 (9.3%) 13568 (96.9%) 429 (3.1%) 75828 (10.7%) 71965 (94.9%) 3863 (5.1%) 
85 & above 16773 (11.1%) 16443 (98%) 330 (2%) 64918 (9.1%) 62705 (96.6%) 2213 (3.4%) 
Sex  Male 69563 (46.1%) 67808 (97.5%) 1755 (2.5%) 319701 (44.9%) 306685 (95.9%) 13016 (4.1%) 
Female 81315 (53.9%) 78515 (96.6%) 2800 (3.4%) 391889 (55.1%) 372446 (95%) 19443 (5%) 
Ethnicity White Missing - - 684869 (96.2%) 653080 (95.4%) 31789 (4.6%) 
South Asian Missing - - 12273 (1.7%) 11951 (97.4%) 322 (2.6%) 
Black Missing - - 7176 (1%) 7048 (98.2%) 128 (1.8%) 
Other Missing - - 5850 (0.8%) 5672 (97%) 178 (3%) 
Mixed Missing - - 1422 (0.2%) 1380 (97%) 42 (3%) 
Immigration status Not immigrant 150493 (99.7%) 145943 (97%) 4550 (3%) 702628 (98.7%) 670393 (95.4%) 32235 (4.6%) 
Immigrant 385 (0.3%) 380 (98.7%) 5 (1.3%) 8962 (1.3%) 8738 (97.5%) 224 (2.5%) 
Patient-level IMD~+ 1 (least deprived) 43002 (28.5%) 
 
41528 (96.6%) 1474 (3.4%) 158682 (22.3%) 151015 (95.2%) 7667 (4.8%) 
2 38525 (25.5%) 37304 (96.8%) 1221 (3.2%) 182399 (25.6%) 173830 (95.3%) 8569 (4.7%) 
3 30681 (20.3%) 29743 (96.9%) 938 (3.1%) 150966 (21.2%) 144233 (95.5%) 6733 (4.5%) 
4 24951 (16.5%) 24334 (97.5%) 617 (2.5%) 133913 (18.8%) 128045 (95.6%) 5868 (4.4%) 
5 (most deprived) 13719 (9.1%) 13414 (97.8%) 305 (2.2%) 85630 (12%) 82008 (95.8%) 3622 (4.2%) 
Practice-level IMD 1 (least deprived) 27600 (18.3%) 26611 (96.4%) 989 (3.6%) 101574 (14.3%) 96462 (95%) 5112 (5%) 
2 34219 (22.7%) 33174 (96.9%) 1045 (3.1%) 163530 (23%) 156155 (95.5%) 7375 (4.5%) 
3 36234 (24%) 35084 (96.8%) 1150 (3.2%) 159492 (22.4%) 152151 (95.4%) 7341 (4.6%) 
4 30206 (20%) 29429 (97.4%) 777 (2.6%) 155544 (21.9%) 148672 (95.6%) 6872 (4.4%) 
5 (most deprived) 22619 (15%) 22025 (97.4%) 594 (2.6%) 131450 (18.5%) 125691 (95.6%) 5759 (4.4%) 
Lived alone^  No 94153 (62.4%) 91134 (96.8%) 3019 (3.2%) 469693 (66%) 447925 (95.4%) 21768 (4.6%) 
Yes 56725 (37.6%) 55189 (97.3%) 1536 (2.7%) 241897 (34%) 231206 (95.6%) 10691 (4.4%) 
Cohabiting^  No 86967 (57.6%) 84630 (97.3%) 2337 (2.7%) 384524 (54%) 368040 (95.7%) 16484 (4.3%) 
Yes 63911 (42.4%) 61693 (96.5%) 2218 (3.5%) 327066 (46%) 311091 (95.1%) 15975 (4.9%) 
Care home^  No 142765 (94.6%) 138370 (96.9%) 4395 (3.1%) 653967 (91.9%) 622930 (95.3%) 31037 (4.7%) 
Yes 8113 (5.4%) 7953 (98%) 160 (2%) 57623 (8.1%) 56201 (97.5%) 1422 (2.5%) 
Rheumatoid arthritis^ No 148501 (98.4%) 144047 (97%) 4454 (3%) 689035 (96.8%) 657765 (95.5%) 31270 (4.5%) 
Yes 2377 (1.6%) 2276 (95.8%) 101 (4.2%) 22555 (3.2%) 21366 (94.7%) 1189 (5.3%) 
Systemic Lupus 
Erythematosus^ 
No 150712 (99.9%) 146163 (97%) 4549 (3%) 710274 (99.8%) 677900 (95.4%) 32374 (4.6%) 
Yes 166 (0.1%) 160 (96.4%) 6 (3.6%) 1316 (0.2%) 1231 (93.5%) 85 (6.5%) 
Inflammatory bowel 
disease^ 
No 149776 (99.3%) 145268 (97%) 4508 (3%) 700505 (98.4%) 668596 (95.4%) 31909 (4.6%) 
Yes 1102 (0.7%) 1055 (95.7%) 47 (4.3%) 11085 (1.6%) 10535 (95%) 550 (5%) 
Diabetes mellitus^ No 133054 (88.2%) 129003 (97%) 4051 (3%) 578619 (81.3%) 551335 (95.3%) 27284 (4.7%) 
Yes 17824 (11.8%) 17320 (97.2%) 504 (2.8%) 132971 (18.7%) 127796 (96.1%) 5175 (3.9%) 
Chronic kidney 
disease^ 
No 131782 (87.3%) 127735 (96.9%) 4047 (3.1%) 542165 (76.2%) 515649 (95.1%) 26516 (4.9%) 
Yes 19096 (12.7%) 18588 (97.3%) 508 (2.7%) 169425 (23.8%) 163482 (96.5%) 5943 (3.5%) 
COPD/ asthma^ No 131132 (86.9%) 127240 (97%) 3892 (3%) 557917 (78.4%) 532444 (95.4%) 25473 (4.6%) 
Yes 19746 (13.1%) 19083 (96.6%) 663 (3.4%) 153673 (21.6%) 146687 (95.5%) 6986 (4.5%) 
HIV infection^ No 150860 (100%) 146305 (97%) 4555 (3%) 711457 (100%) 679004 (95.4%) 32453 (4.6%) 
Yes 18 (0%) 18 (100%) 0 (0%) 133 (0%) 127 (95.5%) 6 (4.5%) 
Cellular immune 
deficiency^ 
No 150631 (99.8%) 146081 (97%) 4550 (3%) 708715 (99.6%) 676333 (95.4%) 32382 (4.6%) 
Yes 247 (0.2%) 242 (98%) 5 (2%) 2875 (0.4%) 2798 (97.3%) 77 (2.7%) 
Solid organ 
transplant^ 
No 150795 (99.9%) 146240 (97%) 4555 (3%) 710593 (99.9%) 678199 (95.4%) 32394 (4.6%) 
Yes 83 (0.1%) 83 (100%) 0 (0%) 997 (0.1%) 932 (93.5%) 65 (6.5%) 
Bone marrow/ stem 
cell  transplant^ 
No 150871 (100%) 146317 (97%) 4554 (3%) 711397 (100%) 678960 (95.4%) 32437 (4.6%) 
Yes 7 (0%) 6 (85.7%) 1 (14.3%) 193 (0%) 171 (88.6%) 22 (11.4%) 
Leukemia and other 
disorders$^ 
No 149762 (99.3%) 145246 (97%) 4516 (3%) 701044 (98.5%) 669161 (95.5%) 31883 (4.5%) 
Yes 1116 (0.7%) 1077 (96.5%) 39 (3.5%) 10546 (1.5%) 9970 (94.5%) 576 (5.5%) 
Cancer CT/ RT^ No 147571 (97.8%) 143105 (97%) 4466 (3%) 667658 (93.8%) 636619 (95.4%) 31039 (4.6%) 
Yes 3307 (2.2%) 3218 (97.3%) 89 (2.7%) 43932 (6.2%) 42512 (96.8%) 1420 (3.2%) 
Oral corticosteroids^ No 149154 (98.9%) 144665 (97%) 4489 (3%) 694275 (97.6%) 662784 (95.5%) 31491 (4.5%) 
Yes 1724 (1.1%) 1658 (96.2%) 66 (3.8%) 17315 (2.4%) 16347 (94.4%) 968 (5.6%) 
Other immuno-
suppressant drugs^#  
No 150274 (99.6%) 145745 (97%) 4529 (3%) 704364 (99%) 672362 (95.5%) 32002 (4.5%) 
Yes 604 (0.4%) 578 (95.7%) 26 (4.3%) 7226 (1%) 6769 (93.7%) 457 (6.3%) 
pyr person-years at risk CI confidence interval *one patients with missing gender information excluded from analysis IQR interquartile range IMD index of multiple 
deprivation ~for excluded group 181 (0.1%) missing values replaced by practice IMD +for included group 668 (0.09%) missing values replaced by practice IMD ^ Ever had, 
$ includes lymphoma, myeloma, other plasma cell dyscrasias  CT chemotherapy  RT radiotherapy  # includes azathioprine, biological therapy, methotrexate, 6-
mercaptopurine, other immunosuppressant such as tacrolimus, sirolimus, and other disease-modifying antirheumatic drugs: ciclosporin, mycophenolate, leflunomide 
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Appendix S9 Multivariable analysis: Social factors associated with zoster disease incidence amongst patients excluded from analysis due to 
missing data for ethnicity (N= 150878, outcome= 4555)$ 
Exposures  Minimally 
adjusted for age, 
gender and 
calendar period 
RR (95% CI) 
P 
value* 
Model additionally 
adjusted for 
immigration status 
& patient-level IMD  
P value* Model additionally 
adjusted for care 
home residence & 
living alone  
RR (95% CI) 
P value* Model 
additionally 
adjusted for 
co-morbidities 
^ RR (95% CI) 
P value* Model additionally 
adjusted for 
immuno-suppressive 
therapies+ 
RR (95% CI) 
P value* 
Age acquired 
during the 
study(years) 
65-69 1  1  1  1  1  
70-74   1.10 (1.02-1.19) <0.0001 1.10 (1.02-1.19) <0.0001 1.10 (1.02-1.19) <0.0001 1.09 (1.00-1.18) <0.0001 1.08 (1.00-1.18) <0.0001 
75-79   1.33 (1.23-1.45)  1.34 (1.23-1.45)  1.33 (1.23-1.45)  1.29 (1.19-1.41)  1.29 (1.19-1.41)  
80-84  1.23 (1.11-1.35)  1.24 (1.12-1.36)  1.23 (1.12-1.36)  1.18 (1.07-1.30)  1.18 (1.07-1.30)  
85  & above 1.19 (1.08-1.31)  1.20 (1.09-1.33)  1.19 (1.08-1.31)  1.15 (1.04-1.27)  1.15 (1.04-1.27)  
Gender Male 0.80 (0.75-0.85) <0.0001 0.80 (0.75-0.85) <0.0001 0.81 (0.76-0.86) <0.0001 0.81 (0.76-0.86) <0.0001 0.81 (0.76-0.86) <0.0001 
Female 1  1  1  1  1  
Immigration 
status 
Not immigrant 1  1  1  1  1  
Immigrant 0.52 (0.22-1.26) 0.11 0.54 (0.23-1.31) 0.13 0.54 (0.22-1.30) 0.13 0.53 (0.22-1.29) 0.12 0.54 (0.22-1.29) 0.12 
Patient-level IMD~ 1 (least deprived) 1  1  1  1  1  
2 0.96 (0.89-1.04) <0.0001 0.96 (0.89-1.04) <0.0001 0.97 (0.90-1.04) <0.0001 0.97 (0.90-1.04) <0.0001 0.97 (0.90-1.04) <0.0001 
3 0.95 (0.88-1.03)  0.95 (0.88-1.03)  0.96 (0.88-1.04)  0.95 (0.88-1.03)  0.95 (0.88-1.03)  
4 0.79 (0.72-0.86)  0.79 (0.72-0.86)  0.80 (0.73-0.88)  0.79 (0.72-0.87)  0.79 (0.72-0.87)  
5 (most deprived) 0.74 (0.66-0.84)  0.75 (0.66-0.84)  0.76 (0.67-0.86)  0.75 (0.66-0.85)  0.75 (0.66-0.85)  
Practice-level IMD 1 (least deprived) 1  Not in model - Not in model - Not in model - Not in model - 
2 0.91 (0.83-0.99) <0.0001         
3 0.92 (0.85-1.01)          
4 0.81 (0.73-0.89)          
5 (most deprived) 0.78 (0.70-0.86)          
Calendar period 2003-2005 1  1  1  1  1  
 2006-2007 1.01 (0.92-1.10) 0.63 1.00 (0.92-1.09) 0.53 1.00 (0.91-1.08) 0.49 0.98 (0.90-1.07) 0.19 0.99 (0.91-1.07) 0.22 
 2008-2009 0.95 (0.87-1.04)  0.94 (0.86-1.03)  0.94 (0.86-1.02)  0.92 (0.84-1.00)  0.92 (0.84-1.01)  
 2010-2011 0.99 (0.91-1.08)  0.98 (0.90-1.07)  0.98 (0.90-1.07)  0.95 (0.87-1.04)  0.96 (0.88-1.05)  
 2012-2013 0.95 (0.87-1.05)  0.94 (0.86-1.04)  0.94 (0.85-1.03)  0.91 (0.83-1.00)  0.91 (0.83-1.01)  
Care home 
residence 
No 1  Not in model - 1  1  1  
Yes 1.31 (1.11-1.54) 0.002   1.24 (1.05-1.46) 0.02 1.20 (1.02-1.42) 0.03 1.20 (1.02-1.42) 0.03 
Living alone No 1  Not in model - 1  1  1  
Yes 0.85 (0.80-0.90) <0.0001   0.87 (0.82-0.93) <0.0001 0.88 (0.82-0.93) <0.0001 0.88 (0.83-0.94) <0.0001 
Cohabitation No 1  Not in model - Not in model# - Not in model# - Not in model# - 
 Yes 1.18 (1.12-1.25) <0.0001         
$one patients with missing gender information excluded from analysis RR rate ratios CI confidence interval IMD index of multiple deprivation ~for excluded group 181 (0.1%) missing values replaced by practice IMD *likelihood 
ratio test # multicollinearity issue  ^included rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease or asthma, HIV 
infection, other cellular immune deficiency, leukemia, lymphoma, myeloma, other plasma cell dyscrasias, haematopoietic stem cell transplant & solid organ transplant  +included immunosuppressive doses of oral/injectable 
corticosteroids, other immunosuppressants drugs (e.g. azathioprine, biological therapy, methotrexate) and cancer chemo/radiotherapy 
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Appendix S10 Multivariable analysis: Social factors associated with zoster disease incidence restricted to patients of White ethnicity (N= 684869 
outcome= 31789) 
Exposures  Minimally 
adjusted for 
age, gender & 
calendar period  
RR (95% CI) 
P value* 
(PT) 
Model adjusted 
for age, gender, 
calendar period, 
immigration & 
IMD RR (95% CI) 
P value* 
(PT) 
Model additionally 
adjusted for care 
home residence & 
living alone  
RR (95% CI) 
P value* 
(PT) 
Model  
additionally 
adjusted for co-
morbidites^  
RR (95% CI) 
P value* 
(PT) 
Model 4 
additionally 
adjusted for IS 
therapies~  
RR (95% CI) 
P value* 
(PT) 
Age acquired 
during the 
study(years) 
65-69 1  1  1  1  1  
70-74   1.16 (1.12-1.20) <0.0001 1.16 (1.12-1.20) <0.0001 1.16 (1.12-1.20) <0.0001 1.15 (1.11-1.18) <0.0001 1.15 (1.11-1.18) <0.0001 
75-79   1.29 (1.25-1.34) (<0.0001) 1.29 (1.25-1.34) (<0.0001) 1.29 (1.25-1.34) (<0.0001) 1.27 (1.23-1.31) (<0.0001) 1.27 (1.23-1.31) (<0.0001) 
80-84  1.35 (1.30-1.40)  1.35 (1.30-1.40)  1.35 (1.30-1.40)  1.32 (1.27-1.36)  1.32 (1.27-1.37)  
85  & above 1.38 (1.34-1.44)  1.39 (1.34-1.44)  1.38 (1.33-1.43)  1.35 (1.30-1.40)  1.36 (1.31-1.41)  
Gender Male 0.85 (0.83-0.87) <0.0001 0.85 (0.83-0.87) <0.0001 0.85 (0.83-0.87) <0.0001 0.85 (0.84-0.87) <0.0001 0.85 (0.83-0.87) <0.0001 
Female 1  1  1  1  1  
Immigration status Not immigrant 1  1  1  1  1  
Immigrant 0.74 (0.61-0.90) 0.002 0.75 (0.62-0.91) 0.002 0.75 (0.62-0.90) 0.002 0.75 (0.62-0.91) 0.002 0.75 (0.62-0.91) 0.002 
Patient level IMD~ 1 (least deprived) 1  1  1  1  1  
2 0.98 (0.95-1.01) 0.02 0.98 (0.95-1.01) 0.02 0.98 (0.95-1.01) 0.04 0.98 (0.95-1.01) 0.0006 0.98 (0.95-1.01) 0.0009 
3 0.96 (0.92-0.99)  0.96 (0.92-0.99)  0.96 (0.93-0.99)  0.95 (0.92-0.98)  0.95 (0.92-0.98)  
4 0.95 (0.92-0.99)  0.95 (0.92-0.99)  0.96 (0.92-0.99)  0.94 (0.91-0.98)  0.94 (0.91-0.98)  
5 (most deprived) 0.95 (0.92-0.99)  0.96 (0.92-0.99)  0.96 (0.92-1.00)  0.93 (0.90-0.97)  0.93 (0.90-0.97)  
Practice-level IMD 1 (least deprived) 1  Not in model - Not in model - Not in model - Not in model - 
2 0.92 (0.88-0.95) <0.0001         
3 0.97 (0.93-1.00)          
4 0.92 (0.89-0.95)          
5 (most deprived) 0.90 (0.87-0.94)          
Calendar period 2003-2005 1  1  1  1  1  
 2006-2007 1.03 (1.00-1.07) 0.13 1.03 (1.00-1.07) 0.13 1.03 (1.00-1.06) 0.13 1.01 (0.98-1.05) 0.005 1.01 (0.98-1.05) 0.0008 
 2008-2009 1.03 (1.00-1.06)  1.03 (1.00-1.06)  1.03 (0.99-1.06)  1.00 (0.96-1.03)  0.99 (0.96-1.03)  
 2010-2011 1.02 (0.98-1.05)  1.02 (0.98-1.05)  1.01 (0.98-1.05)  0.98 (0.94-1.01)  0.97 (0.94-1.01)  
 2012-2013 0.99 (0.96-1.03)  0.99 (0.96-1.03)  0.99 (0.95-1.02)  0.95 (0.91-0.98)  0.94 (0.91-0.98)  
Care home 
residence 
No 1  Not in model - 1  1  1  
Yes 1.11 (1.05-1.18) 0.0002   1.10 (1.04-1.16) 0.001 1.08 (1.02-1.15) 0.007 1.08 (1.02-1.15) 0.006 
Living alone No 1  Not in model - 1  1  1  
Yes 0.95 (0.93-0.98) 0.0001   0.96 (0.94-0.98) 0.001 0.96 (0.94-0.99) 0.002 0.96 (0.94-0.99) 0.002 
Cohabitation No 1  Not in model - Not in model # - Not in model # - Not in model # - 
 Yes 1.06 (1.03-1.08) <0.0001         
RR rate ratios CI confidence interval PT P value for trend IMD index of multiple deprivation ~ 648 patients (0.09%) missing values replaced by practice IMD *likelihood ratio test IS immunosuppressive # multicollinearity issue  
^included rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease or asthma, HIV infection, other cellular immune 
deficiency, leukemia, lymphoma, myeloma, other plasma cell dyscrasias, haematopoietic stem cell transplant & solid organ transplant  ~included immunosuppressive doses of oral/injectable corticosteroids, other 
immunosuppressants drugs (e.g. azathioprine, biological therapy, methotrexate) and cancer chemo/radiotherapy  
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Appendix S11 Sensitivity analysis: Multivariable analysis including practice-level IMD 
Exposures  Model adjusted for age, gender, 
calendar period, immigration 
status, ethnicity and practice-
level IMD RR(95%CI) 
P value* Model 2 additionally 
adjusted for care home 
residence & living alone 
RR (95% CI) 
P value* Model 3 additionally 
adjusted for co-
morbidities^ 
RR (95% CI) 
P value* Model 4 additionally 
adjusted for IS 
therapies~ 
RR (95% CI) 
P value* 
Age acquired 
during the 
study(years) 
65-69 1  1  1  1  
70-74   1.16 (1.12-1.20) <0.0001 1.16 (1.12-1.20) <0.0001 1.15 (1.11-1.18) <0.0001 1.15 (1.11-1.18) <0.0001 
75-79   1.29 (1.25-1.33)  1.29 (1.25-1.33)  1.26 (1.22-1.31)  1.26 (1.22-1.31)  
80-84  1.35 (1.30-1.40)  1.35 (1.30-1.39)  1.32 (1.27-1.36)  1.32 (1.27-1.37)  
85  & above 1.38 (1.33-1.43)  1.37 (1.32-1.42)  1.35 (1.30-1.40)  1.36 (1.31-1.41)  
Gender Male 0.85 (0.84-0.87) <0.0001 0.86 (0.84-0.87) <0.0001 0.86 (0.84-0.88) <0.0001 0.86 (0.84-0.88) <0.0001 
Female 1  1  1  1  
Ethnicity White 1  1  1  1  
 South Asian 0.76 (0.68-0.85) <0.0001 0.76 (0.67-0.85) <0.0001 0.75 (0.67-0.84) <0.0001 0.75 (0.67-0.84) <0.0001 
 Black 0.49 (0.41-0.59)  0.49 (0.41-0.59)  0.49 (0.41-0.59)  0.49 (0.42-0.59)  
 Other 0.85 (0.74-0.99)  0.85 (0.73-0.99)  0.86 (0.74-1.00)  0.86 (0.74-1.00)  
 Mixed 0.78 (0.58-1.06)  0.78 (0.58-1.06)  0.78 (0.58-1.06)  0.78 (0.58-1.06)  
Immigration 
status 
Not immigrant 1  1  1  1  
Immigrant 0.77 (0.67-0.89) 0.0002 0.77 (0.67-0.89) 0.0002 0.77 (0.67-0.89) 0.0002 0.77 (0.67-0.89) 0.0002 
Patient level IMD~ 1 (least deprived) Not in model  Not in model - Not in model - Not in model - 
2         
3         
4         
5 (most deprived)         
Practice-level IMD 1 (least deprived) 1  1  1  1  
2 0.92 (0.88-0.95) <0.0001 0.92 (0.89-0.95) <0.0001 0.92 (0.89-0.95) <0.0001 0.92 (0.89-0.95) <0.0001 
3 0.97 (0.93-1.00)  0.97 (0.93-1.00)  0.97 (0.93-1.00)  0.97 (0.93-1.00)  
4 0.92 (0.88-0.95)  0.92 (0.89-0.95)  0.91 (0.88-0.95)  0.92 (0.88-0.95)  
5 (most deprived) 0.90 (0.87-0.94)  0.91 (0.87-0.94)  0.90 (0.86-0.93)  0.90 (0.86-0.93)  
Calendar period 2003-2005 1  1  1  1  
 2006-2007 1.03 (0.99-1.06) 0.18 1.03 (0.99-1.06) 0.17 1.01 (0.98-1.04) 0.007 1.01 (0.98-1.04) 0.0013 
 2008-2009 1.03 (0.99-1.06)  1.02 (0.99-1.06)  0.99 (0.96-1.03)  0.99 (0.96-1.03)  
 2010-2011 1.02 (0.98-1.05)  1.01 (0.98-1.05)  0.98 (0.94-1.01)  0.97 (0.94-1.01)  
 2012-2013 0.99 (0.96-1.03)  0.99 (0.95-1.02)  0.95 (0.91-0.98)  0.94 (0.91-0.97)  
Care home 
residence 
No Not in model - 1  1  1  
Yes   1.10 (1.04-1.16) 0.0008 1.08 (1.02-1.15) 0.005 1.08 (1.03-1.15) 0.005 
Living alone No Not in model - 1  1  1  
Yes   0.96 (0.94-0.98) 0.0007 0.96 (0.94-0.98) 0.001 0.96 (0.94-0.99) 0.001 
Cohabitation No Not in model - Not in model # - Not in model # - Not in model # - 
 Yes         
RR rate ratios CI confidence interval IMD index of multiple deprivation ~ 668 patients (0.09%) missing values replaced by practice IMD *likelihood ratio test IS immunosuppressive # multicollinearity issue  ^included rheumatoid 
arthritis, systemic lupus erythematosus, inflammatory bowel disease, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease or asthma, HIV infection, other cellular immune deficiency, leukemia, 
lymphoma, myeloma, other plasma cell dyscrasias, haematopoietic stem cell transplant & solid organ transplant  ~included immunosuppressive doses of oral/injectable corticosteroids, other immunosuppressant drugs (e.g. 
azathioprine, biological therapy, methotrexate) and cancer chemo/radiotherapy 
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Appendix S12 Sensitivity analysis: Multivariable analysis including cohabitation 
Exposures  Model adjusted for age, gender, 
ethnicity, immigration, 
deprivation, care home residence 
& cohabitation RR (95% CI) 
P value* Model additionally 
adjusted for co-
morbidities^ 
RR (95% CI) 
P value* Model additionally 
adjusted for immuno-
suppressive therapy~ 
RR (95% CI) 
P value* 
Age acquired during the 
study(years) 
65-69 1  1  1  
70-74   1.16 (1.12-1.19) <0.0001 1.15 (1.11-1.18) <0.0001 1.15 (1.11-1.18) <0.0001 
75-79   1.29 (1.24-1.33)  1.26 (1.22-1.30)  1.26 (1.22-1.30)  
80-84  1.35 (1.30-1.39)  1.32 (1.27-1.36)  1.32 (1.28-1.37)  
85  & above 1.38 (1.33-1.43)  1.36 (1.31-1.41)  1.37 (1.32-1.42)  
Gender Male 0.85 (0.83-0.87) <0.0001 0.86 (0.84-0.87) <0.0001 0.85 (0.84-0.87) <0.0001 
Female 1  1  1  
Ethnicity White 1  1  1  
 South Asian 0.77 (0.68-0.86) <0.0001 0.76 (0.68-0.85) <0.0001 0.76 (0.68-0.85) <0.0001 
 Black 0.50 (0.42-0.59)  0.50 (0.42-0.59)  0.50 (0.42-0.60)  
 Other 0.86 (0.74-1.00)  0.87 (0.75-1.01)  0.87 (0.75-1.01)  
 Mixed 0.79 (0.58-1.07)  0.79 (0.58-1.07)  0.79 (0.59-1.07)  
Immigration status Not immigrant 1  1  1  
Immigrant 0.77 (0.67-0.89) 0.0001 0.77 (0.67-0.89) 0.0002 0.78 (0.67-0.89) 0.0002 
Patient level IMD~ 1 (least deprived) 1  1  1  
2 0.98 (0.95-1.01) 0.04 0.98 (0.95-1.01) 0.0009 0.98 (0.95-1.01) 0.001 
3 0.96 (0.93-0.99)  0.95 (0.92-0.98)  0.95 (0.92-0.98)  
4 0.96 (0.93-0.99)  0.95 (0.91-0.98)  0.95 (0.91-0.98)  
5 (most deprived) 0.96 (0.92-1.00)  0.93 (0.90-0.97)  0.94 (0.90-0.97)  
Practice-level IMD 1 (least deprived) Not in model - Not in model - Not in model - 
2       
3       
4       
5 (most deprived)       
Calendar period 2003-2005 1  1  1  
 2006-2007 1.03 (0.99-1.06) 0.18 1.01 (0.98-1.04) 0.006 1.01 (0.98-1.04) 0.001 
 2008-2009 1.02 (0.99-1.06)  0.99 (0.96-1.03)  0.99 (0.96-1.02)  
 2010-2011 1.01 (0.98-1.05)  0.98 (0.94-1.01)  0.97 (0.94-1.01)  
 2012-2013 0.99 (0.95-1.02)  0.95 (0.91-0.98)  0.94 (0.90-0.97)  
Care home residence No 1  1  1  
Yes 1.13 (1.07-1.19) <0.0001 1.11 (1.05-1.17) 0.0002 1.11 (1.05-1.17) 0.0002 
Living alone No Not in model # - Not in model # - Not in model # - 
Yes       
Cohabitation No 1  1  1  
 Yes 1.06 (1.04-1.08) <0.0001 1.06 (1.04-1.08) <0.0001 1.06 (1.04-1.08) <0.0001 
 
RR rate ratios CI confidence interval IMD index of multiple deprivation ~ 668 patients (0.09%) missing values replaced by practice IMD *likelihood ratio test # multicollinearity issue  ^included rheumatoid arthritis, systemic lupus 
erythematosus, inflammatory bowel disease, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease or asthma, HIV infection, other cellular immune deficiency, leukemia, lymphoma, myeloma, other 
plasma cell dyscrasias, haematopoietic stem cell transplant & solid organ transplant  ~included immunosuppressive doses of oral/injectable corticosteroids, other immunosuppressant drugs (e.g. azathioprine, biological 
therapy, methotrexate) and cancer chemo/radiotherapy 
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7.4 Further investigation of the likely impact of missing data 
The use of a complete case analysis (Section 7.2) after excluding 17.5% (N=150880) of the 
study participants who had missing ethnicity (n=150878), missing gender (n=1) or missing 
both ethnicity and gender data (n=1) (study flow chart: Figure 1 submitted paper), could 
have biased the effect estimates. To assess the impact of missing data, I conducted some 
additional analyses, described in next section. 
7.4.1 Additional analyses to assess the impact of missing data 
Additional analyses include those that were presented in the Appendices of the paper 
(Sections 7.2 and 7.3) and those conducted subsequently.  Together, these extended 
analyses comprised: 
(1) A comparison of the baseline characteristics of patients included and excluded 
(owing to missing ethnicity data) from the complete case analysis was conducted. 
The reasons for start and end follow-up between the two groups were also 
compared. 
(2) As the group excluded from the main analyses had missing data for ethnicity, fully 
adjusted multivariable models (adjusted for other socio-demographic factors 
including ethnicity) could not be compared between the excluded group and the 
individuals included in the primary analyses. However, it was feasible to compare 
the association of socio-demographic factors except ethnicity with zoster disease 
incidence in minimally adjusted analyses (adjusted for age, gender and calendar 
period) between the two groups.  
(3) Minimally adjusted analyses for the entire study population (N=862468), excluding 
only the two patients with missing gender data, and comparing the results to the 
minimally adjusted analysis for the individuals who were included in the complete 
case analysis. 
7.4.2 Results of additional analyses  
Results of the three additional analyses conducted are summarised below. 
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(1) Individuals excluded from the complete case analysis because of missing ethnicity 
data (n=150878) had a slightly lower rate of zoster (7.08 (95%CI: 6.88-7.29) per 
1000 person-years) compared to the participants included in the main analysis with 
zoster incidence rate of 9.09 (95%CI 9.0-9.20) per 1000 person-years (Table 7-1). 
 
Table 7-1 Comparison of zoster incidence between total study population, individuals 
included and excluded from the complete case analysis 
 
 
The baseline characteristics of patients included in the complete case analyses and 
excluded from these analyses owing to missing ethnicity data are also provided in 
Appendix 8 (Section 7.3).  Patients included in the analysis were slightly older at 
their current registration date with their GP: median age 57.8 years (IQR: 43.6-67.7 
years) compared to 54.5 Years (IQR: 40.7-65.2 years) for excluded patients. 
Participants excluded from the analysis were also more likely to be from the two 
extreme age groups at the start of follow-up (65-69 years: 56% versus 50%; ≥85 
years: 11% versus 9%), from the least deprived patient-level IMD (~29% versus 
22%) and slightly more likely to be living alone (~38% versus 34%). Excluded 
patients were less likely to have co-morbidities such as diabetes, chronic kidney 
disease, and COPD/asthma. In the excluded group, individuals were also less likely 
to be recorded as an immigrant (0.3% versus 1.3%) or to be residing in care home 
(~5% versus 8%). When, in further analyses, the criteria used for start and end of 
follow-up were compared for the two groups (Table 7-2), individuals included in the 
analysis were more likely to have joined the practice recently compared to the 
excluded group (entering the study one year after they registered with the practice), 
 Zoster incidence per 1000 person-years at risk (95% 
confidence interval) 
Total study population 
N=862470 
Outcome=37014 
8.79 (8.70-8.88) 
Patients included in complete case analysis 
N=711590 
Outcome=32459 
9.09 (9.0-9.20) 
Patients excluded from complete case analysis 
N=150878 
Outcome=4555 
7.08 (6.88-7.29) 
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perhaps explaining the better capture of ethnicity data in the included group. 
Individuals with missing ethnicity data were more likely to end follow-up because 
they had transferred out of the practice (22% compared to 15% of those with non-
missing ethnicity data). 
Table 7-2 Criteria for start and end of follow-up for patients excluded from complete 
case analysis due to missing data for ethnicity and for patients included in complete 
case analyses 
 Criterion Patients excluded from 
complete case analysis 
due to missing ethnicity 
data 
N=150,878$ 
Patients included in 
complete case analysis 
N=711590 
Start of follow up Study start date 74929 (49.7%) 332016 (46.7%) 
Age=65 years 56719 (37.6%) 223064 (31.4%) 
CRD+1 year  13168 (8.7%) 124071 (17.4%) 
UTS date 6062 (4%) 32434 (4.6%) 
CRD+1 year & UTS date - 4 (0*%) 
CRD+1 year & study start 
date 
- 1 (0*%) 
End of follow-up End of study 59526 (39.5%) 327202 (46%) 
Transfer out date 33723 (22.4%) 105846 (14.9%) 
Death 26312 (17.4%) 121909 (17.1%) 
Last collection date from 
practice 
20439 (13.6%) 100628 (14.1%) 
Death and transfer out 
date 
6323 (4.2%) 23519 (3.3%) 
Outcome date 4555 (3%) 32456 (4.6%) 
Death and end of study 
date 
- 26 (0*%) 
Outcome date and end of 
study date 
- 2 (0*%) 
Transfer out date and end 
of study date 
- 1 (0*%) 
Last collection date from 
practice and outcome date 
- 1 (0*%) 
$one patient with missing both gender & ethnicity information excluded from analysis CRD current registration date 
UTS up to standard date * rounded to one decimal point 
 
(2) Complete case analyses for the association of socio-demographic factors with 
zoster disease incidence amongst patients with missing ethnicity data are presented 
in Appendix 9 of the published paper and a comparison of minimally adjusted 
analyses restricted to individuals with missing ethnicity data and those included in 
the complete case analyses are reproduced in Table 7-3. Overall, the effect 
estimates were in the same direction as those from the main analysis. Amongst the 
excluded group, the effect estimate for care home residence was greater than that in 
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the complete case analysis (RR: 1.31 versus 1.12), although the 95% CI 
overlapped.  In contrast, there was evidence from the non-overlapping confidence 
intervals that the effect of living alone was stronger in the excluded group (RR: 0.85 
versus 0.95). Some other differences included: there was no evidence of linear trend 
of increasing zoster incidence with age, and there was no evidence for the 
association of immigration status on zoster incidence (RR: 0.52 (95%CI: 0.22-1.26) 
in the excluded group compared to the main analysis (RR: 0.65 (95%CI: 0.57-0.74)). 
Amongst the excluded individuals there was a strong inverse gradient of decreasing 
zoster risk with increasing deprivation, with the most deprived individuals in the 
excluded groups having a lower zoster risk than those in the complete case analysis 
(RR: 0.74 versus 0.93).  
(3) The comparison of the minimally adjusted analysis for the entire study population 
with the minimally adjusted model of the complete case analysis is also presented in 
Table 7-3 (final two columns). There were no appreciable differences in the effect 
estimates between these two groups for any of the factors examined. 
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Table 7-3 Socio-demographic factors associated with zoster burden in the minimally adjusted model: comparison of  individuals excluded due to 
missing ethnicity data, those included in complete case analysis and total study population  
Exposures  Individuals excluded due to missing ethnicity 
data N=150878$ Outcome=4555 
Patient included in complete case analysis 
N=711,590 Outcome=32,459 
Total study population 
N=862,468# Outcome=37,014 
Minimally adjusted for age, gender and 
calendar period 
RR (95% CI) 
P value*  Minimally adjusted for age, gender 
and calendar period 
RR (95% CI) 
P value* 
(PT) 
 
Minimally adjusted for age, gender 
and calendar period 
RR (95% CI) 
P value* 
(PT)) 
 
Age acquired during 
the study(years) 
65-69 1  1  1  
70-74   1.10 (1.02-1.19) <0.0001 1.16 (1.12-1.20) <0.0001 1.16 (1.12-1.19) <0.0001 
75-79   1.33 (1.23-1.45)  1.29 (1.25-1.34) (<0.0001) 1.31 (1.27-1.35) (<0.0001) 
80-84  1.23 (1.11-1.35)  1.36 (1.31-1.41)  1.36 (1.32-1.41)  
85  & above 1.19 (1.08-1.31)  1.40 (1.35-1.45)  1.38 (1.34-1.43)  
Gender Male 0.80 (0.75-0.85) <0.0001 0.85 (0.84-0.87) <0.0001 0.85 (0.83-0.87) <0.0001 
Female 1  1  1  
Calendar period 2003-2005 1  1  1  
 2006-2007 1.01 (0.92-1.10) 0.63 1.03 (0.99-1.06) 0.14 1.03 (1.00-1.06) 0.11 
 2008-2009 0.95 (0.87-1.04)  1.02 (0.99-1.06)  1.02 (0.99-1.05)  
 2010-2011 0.99 (0.91-1.08)  1.01 (0.98-1.05)  1.02 (0.99-1.05)  
 2012-2013 0.95 (0.87-1.05)  0.99 (0.95-1.02)  0.99 (0.96-1.02)  
Immigration status Not immigrant 1  1  1  
Immigrant 0.52 (0.22-1.26) 0.11 0.65 (0.57-0.74) <0.0001 0.66 (0.58-0.75) <0.0001 
Patient-level IMD 1 (least deprived) 1  1  1  
2 0.96 (0.89-1.04) <0.0001 0.98 (0.95-1.01) 0.0006 0.98 (0.96-1.01) <0.0001 
3 0.95 (0.88-1.03)  0.95 (0.92-0.98)  0.96 (0.93-0.99)  
4 0.79 (0.72-0.86)  0.94 (0.91-0.98)  0.94 (0.91-0.97)  
5 (most deprived) 0.74 (0.66-0.84)  0.93 (0.90-0.97)  0.93 (0.89-0.96)  
Practice-level IMD 1 (least deprived) 1  1  1  
2 0.91 (0.83-0.99) <0.0001 0.92 (0.88-0.95) <0.0001 0.92 (0.89-0.95) <0.0001 
3 0.92 (0.85-1.01)  0.96 (0.93-1.00)  0.96 (0.93-0.99)  
4 0.81 (0.73-0.89)  0.91 (0.88-0.94)  0.91 (0.88-0.94)  
5 (most deprived) 0.78 (0.70-0.86)  0.90 (0.86-0.93)  0.89 (0.86-0.93)  
Care home residence No 1  1  1  
Yes 1.31 (1.11-1.54) 0.002 1.12 (1.06-1.18) 0.0001 1.14 (1.08-1.20) <0.0001 
Living alone No 1  1  1  
Yes 0.85 (0.80-0.90) <0.0001 0.95 (0.93-0.97) <0.0001 0.93 (0.91-0.95) <0.0001 
Cohabitation No 1  1  1  
 Yes 1.18 (1.12-1.25) <0.0001 1.07 (1.05-1.09) <0.0001 1.09 (1.06-1.11) <0.0001 
$one patient with missing both gender & ethnicity information excluded from analysis # 2 patients with missing gender data excluded RR rate ratios CI confidence interval *likelihood ratio test PT P value for trend  IMD index of 
multiple deprivation 
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7.4.3 Conclusions from additional analyses to assess the impact of missing 
data 
The socio-demographic characteristics of the individuals excluded (due to missing ethnicity 
data) and included in the complete case analysis were described. The minimally adjusted 
effect estimates for zoster incidence from the main analysis were also compared to (1) a 
minimally adjusted model restricted to individuals with missing ethnicity data and (2) a 
minimally adjusted model for the entire study population. Although it was not possible to 
compare the results of the fully adjusted RRs in those included and excluded from analyses 
(due to missing ethnicity data for those excluded), the results of minimally adjusted analyses 
suggested that the effect estimates for excluded individuals were generally in the same 
direction to that of main analysis. The lack of evidence for the effect of immigration status in 
the excluded group could be due to lack of power to detect an effect - the number of 
individuals identified as immigrants in excluded group who experienced a zoster episode 
during the follow-up period was relatively small (n=5; supplementary material to the 
published paper: Appendix 8). It is also feasible that excluded patients with missing ethnicity 
data might also have lower capture of immigration status recording. There was also no 
strong evidence of a difference in the effect of care home in the excluded and included 
groups on zoster incidence. However the effect of living alone in the excluded and included 
group, although in same direction of lower risk, had non-overlapping 95% confidence 
intervals indicating a difference between the two groups with regards to this factor.  In 
contrast, the comparison of effect estimates from minimally adjusted analysis between those 
included in the complete case analysis and those in the total study population were all very 
similar, including the estimate for living alone.  
Those excluded had a lower prevalence of co-morbidities, and therefore the lack of 
recording of ethnicity in the excluded group may have been due to less GP visits. Given that 
those with co-morbidities are higher risk for zoster,46 this might explain the higher zoster 
incidence recorded amongst the individuals included in the main analysis (Table 7-1). 
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As stated earlier it was not possible to compare fully adjusted models amongst those 
included and excluded from the analyses owing to missing ethnicity data in the excluded 
group. However, the effect estimates from the multivariable model (Model 3 in Table 2 of the 
published paper - adjusted for age, gender, ethnicity, immigration status, patient-level 
deprivation, care home residence and living alone) in the main analysis were largely similar 
to those of the minimally adjusted model. Therefore, based on the comparison of the 
minimally adjusted models, if those with missing ethnicity data could have been included in 
the main analyses, the effect of social factors such as care home residence are likely to 
have been similar to the main analysis; and there was no obvious evidence that missing 
data had biased the effect estimate for care home residence.  For the effect of living alone 
and those residing in most deprived areas, it is possible that the complete case analyses 
might have underestimated the lower zoster risk in these social groups.  
7.5 Chapter summary 
This chapter described the application of the methodology developed (thesis objective 2) for 
ascertaining socio-demographic factors in linked electronic health data by assessing the 
socio-demographic determinants of zoster disease burden in England. In the next chapter 
(Chapter 8), a further application of this methodology for the assessment of zoster 
vaccination inequalities in England is described to assess whether specific socio-
demographic groups with higher zoster burden are coming forward for zoster vaccination. 
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 Chapter 8. A cohort study to investigate the role of 
social determinants and uptake of zoster vaccine 
8.1 Introduction 
This chapter is the last of the three chapters comprising the Results section of this thesis. 
Similar to the previous two Results chapters (Chapter 6 and 7), this chapter is presented in 
journal paper format and details the work conducted to meet the fourth and the final 
objective of this thesis: to determine the association of socio-demographic factors with 
zoster vaccine uptake in England.  
 The paper is followed by supplementary material (Section 8.3) to the submitted paper. The 
results of further investigation into the possible impact of missing data on the findings of the 
paper, the details of inadvertent zoster vaccination amongst immunosuppressed individuals 
(a secondary objective in the published paper) and potential misclassification of individuals 
eligible for zoster vaccination due to the lack of availability of month of birth in CPRD 
(Section 3.5.3) are described in Sections 8.4, 8.5 and 8.6, respectively. Finally, as 
introduced previously in Section 1.3.4, I identify different socio-demographic groups with 
potential double inequalities in Section 8.7. 
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Abstract 
Objective 
To quantify inequalities in zoster vaccine uptake by determining its association with socio-
demographic factors: age, gender, ethnicity, immigration status, deprivation, care home 
residence and living arrangements.   
Method  
This population-based cohort study utilised anonymised primary care electronic health 
records (Clinical Practice Research Datalink) linked to deprivation and hospitalisation data. 
Data from 35,333 individuals from 277 general practices in England and eligible for zoster 
vaccination during the two-year period (2013-2015) after vaccine introduction were 
analysed. Logistic regression was to obtain adjusted odds ratios (aOR) for the association of 
socio-demographic factors with zoster vaccine uptake for adults aged 70 years (main target 
group) and adults aged 79 years (catch-up group). 
Results 
Amongst those eligible for vaccination, 52.4% (n=18,499) received the vaccine. Socio-
demographic factors independently associated with lower zoster vaccine uptake in 
multivariable analyses were: being older (catch-up group: aged 79 years) aOR=0.89 (95% 
confidence interval (CI):0.85-0.93), care home residence (aOR=0.64 (95%CI: 0.57-0.73)) 
and living alone (aOR=0.85 (95%CI: 0.81-0.90)).  Uptake decreased with increasing levels 
of deprivation (p-value for trend<0.0001; aOR most deprived versus least deprived 
areas=0.69 (95%CI: 0.64-0.75)). Uptake was also lower amongst those of non-White 
ethnicities (for example, Black versus White ethnicity: aOR=0.61 (95%CI: 0.49-0.75)) but 
was not lower among immigrants after adjusting for ethnicity. Lower uptake was also seen 
amongst females in the catch-up group.  
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Conclusions 
Inequalities in zoster vaccine uptake exist in England; with lower uptake among those of 
non-White ethnicities, and among those living alone, in a care home and in more deprived 
areas. Tailored interventions to increase uptake in these social groups should assist in 
realising the aim of mitigating vaccination inequalities. As care home residents are also at 
higher risk of zoster, improving the uptake of zoster vaccination in this group will also 
mitigate inequalities in zoster burden. 
Introduction 
Zoster is caused by reactivation of latent varicella-zoster virus infection and mainly affects 
older individuals. It is characterised by a painful dermatomal rash which may be followed by 
persisting pain called post-herpetic neuralgia (PHN).[1] Amongst individuals aged ≥70 years 
in England and Wales, an estimated ~53,000 cases of zoster occur annually of which ~27% 
develop post-herpetic neuralgia.[2] To reduce zoster disease burden, the UK introduced a 
national zoster vaccination programme (using a live vaccine) in 2013, targeting individuals 
aged 70 years, with a catch-up programme targeting older age groups.[3-5] The programme 
comprises vaccine administration to individuals aged 70 years on 1 September of the 
corresponding year (the routine cohort). For the catch-up programme, the vaccine was 
gradually rolled out in 2013/14 to individuals aged 79 years on 1 September 2013, and in 
2014/15 to those aged 78 and 79 years on 1 September 2014.[6, 7] Additionally, eligible 
individuals who missed the vaccine in previous years were given the opportunity to get 
vaccinated in subsequent years. At introduction, uptake of the programme was around 
~62% in the routine cohort but has decreased to ~55% in 2015-2016.[8] The reasons cited 
for this decline include difficulties experienced by general practice personnel who were busy 
with seasonal influenza vaccination, challenges in identifying individuals eligible for 
vaccination, insufficient follow-up of unvaccinated individuals and a potential decline in 
vaccine knowledge amongst the eligible cohort.[6-8]   
Monitoring and reducing inequalities in healthcare services or interventions is a statutory 
requirement in the UK.[9] Inequalities in vaccine uptake, resulting in higher disease burden 
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in specific population groups, are well described.[10-13] Our 2017 systematic review and 
meta-analysis investigated vaccine uptake amongst individuals aged ≥65 years in Europe 
and reported lower seasonal influenza vaccine uptake amongst individuals living alone, 
those residing in more deprived areas and amongst immigrants.[12] Currently the national 
zoster post-vaccination surveillance in England comprises collection of aggregated general 
practice level data with information only on gender and limited ethnicity data.[8] The national 
zoster vaccine uptake for England was found generally to be higher amongst males, 
particularly in  the  catch-up cohort.[8] The aggregated national zoster uptake data were also 
utilised in a 2017 study, which reported lower zoster vaccine uptake in deprived areas and 
amongst most non-White ethnic groups.[14]  However in this study, deprivation was 
assessed as an ecological factor and individuals were assigned ethnicity and vaccination 
status derived from the proportions reported only at an aggregated general practice 
level.[14]  
Ascertainment of the socio-demographic determinants of zoster vaccine uptake can provide 
important information to public health professionals to address vaccination-related 
inequalities and reduce zoster disease burden. We have recently shown that routinely 
collected clinical and administrative information in the form of anonymised linked electronic 
health records are a useful resource to examine some of these socio-demographic factors, 
and these data can be used to supplement the routine surveillance data.[15]  
The primary objective of this study was therefore to identify the socio-demographic 
determinants, relevant at an individual level, of zoster vaccine uptake in England, using one 
of the world’s largest databases of general practice electronic health records: the Clinical 
Practice Research Datalink (CPRD),[16]  with an overarching aim of mitigating vaccination 
inequalities amongst older individuals. The nine socio-demographic factors of interest 
included: age, gender, ethnicity, immigration status, deprivation (patient- and practice-level), 
marital status, cohabitation, living alone and care home residence. As a secondary objective, 
we also ascertained inadvertent zoster vaccination of individuals whilst they were 
immunosuppressed, to quantify possible violations of the inclusion criteria. 
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Methods 
Data source 
The CPRD provides quality-assured anonymised primary care patients’ clinical, 
administrative and lifestyle data representative of and covering ~7% of the UK 
population.[16, 17] Additionally, CPRD data from ~75% general practices in England can be 
linked at an individual level to hospitalisation (Hospital Episode Statistics, HES) data,[18] 
which provides information on all admissions to NHS hospitals, and at lower layer super 
output area (LSOA) level (which covers a population of 1000-3000)[19] to deprivation data 
(Index of Multiple deprivation (IMD) score).[19, 20] The validity of various diagnoses 
recorded in CPRD was reported as high in a systematic review spanning a 21-year study 
period.[21]  
Study population 
This 2-year cohort study from England spanned the period from 01/09/2013 to 31/08/2015, 
the first two years after the zoster vaccine was introduced.  To maintain patient anonymity, 
CPRD data provide only year of birth for adult patients. This posed a problem in how to 
identify individuals who were eligible for zoster vaccination, which is determined by their age 
on a specific date. The common convention of using the mid-year (1st July) to assign study 
participants’ day and month of birth would wrongly classify some individuals as eligible for 
zoster vaccination. Importantly, the resulting unvaccinated group would comprise a mixture 
of individuals with possibly differing social factors: a) those eligible for vaccination who 
chose not to be vaccinated and b) those ineligible on the grounds of age, thus potentially 
resulting in biased effect estimates. To address this, we selected all individuals born in 1943 
(or 1934 for catch-up cohort), who would have been eligible for vaccination at some point 
during the 2-year follow-up period as follows: those born in January-August 1943 would be 
eligible for the vaccine in 2013/14 or in 2014/15 if born September-December 1943; and 
determined vaccine uptake for the 2-year study period. The study population therefore 
comprised individuals born in 1943 (the routine cohort) and in 1934 (the catch-up cohort), 
who were alive and registered on 01/09/2013 (the start of the national programme) with a 
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CPRD general practice that had agreed to linkage to HES and IMD data and that met 
CPRD’s quality assurance criteria.[20] Start of follow up was on 01/09/2013 and a minimum 
of five months of follow-up was required from then (i.e. from September until the end of 
January, coinciding with the main part of the seasonal influenza vaccination season),[22] to 
ensure that individuals had sufficient opportunity to receive zoster vaccination. Individuals 
who had any immunosuppressive conditions or therapies at the start of follow up, that were 
contraindications to receiving the live zoster vaccine,[4] were excluded from analyses of the 
socio-demographic determinants of vaccine uptake but included in descriptive analyses of 
inadvertent zoster vaccinations amongst immunosuppressed individuals. All individuals with 
zoster vaccine codes prior to the start of national programme and start of the study 
(01/09/2013) were also excluded.[23, 24] End of follow-up was defined as the earliest of: (a) 
the end of the study (31/08/2015), (b) individuals’ transfer out date from the practice, (c) 
individuals’ date of death, or (d) the date data were last collected from the practice.[20] 
Defining the outcome 
Zoster vaccination was determined in five different data files in CPRD: using product codes 
in patients’ therapy files, immunisation codes in their immunisation files and Read codes (S1 
Table) in their clinical, referral and test files.[20] Additional immunisation and Read codes 
provided further information on whether the vaccine was advised, refused or administered. 
When vaccination data appeared in more than one file, we used an algorithm to assign 
vaccination date for each individual and handle conflicting information; details are provided 
in the S1 Text and S1 Fig. 
Exposure variables 
The socio-demographic factors of interest were identified based on our previously developed 
methodology of using CPRD linked to HES and IMD data.[15] The factors of interest, in 
addition to age and gender, included ethnicity, immigration status, care home residence, 
marital status, cohabitation (defined as two individuals living as a couple) and living alone; 
code lists are provided in S2 Table. The latter three social factors provided complementary 
information about an individual’s living arrangements. Religion was not examined as our 
previous work has shown it to be poorly recorded in CPRD data (<3% of older 
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individuals).[15] For binary socio-demographic variables, individuals without relevant codes 
were considered not to have that characteristic. Ethnicity (five categories: White, South 
Asian, Black, Others and Mixed) and immigration status (binary) were defined as factors that 
did not vary with time. Time-varying factors included marital status (six categories: single, 
widow, married, divorced, separated, partner uncategorised/other), cohabitation, living alone 
and care home residence (binary variables). All the time-varying factors were determined at 
the start of follow up, with any changes by the end of the 2-year follow-up period quantified 
and described. Deprivation data (IMD quintile at LSOA level: 2015) for patient- and practice-
level were both available. Practice-level IMD quintiles were used if individual-level data were 
unavailable.  
Other variables 
At the initiation of the zoster vaccination programme, GPs were encouraged to co-administer 
zoster with seasonal influenza vaccine (SIV).[25] We therefore investigated the concurrent 
administration of zoster vaccine with SIV. This was achieved by identifying specific product 
codes, immunisation type codes and Read codes in CPRD (S3 Table) during the SIV 
campaign season (September-March)[26] of 2013/14 and 2014/15. Individuals who received 
SIV or/and zoster vaccine were quantified. 
We also identified, throughout the study period, individuals who had immunosuppressive 
conditions or treatments that were contraindications to receipt of zoster vaccine.  This was 
done to identify those who were eligible to receive the live zoster vaccine for the main 
analysis, and to describe the extent of inadvertent administration of zoster vaccine to those 
with contraindications.  The immunosuppressive conditions and drugs included were those 
listed in the UK Green Book; code lists (S2 Table) and algorithms used to identify these are 
described in the S4 Table.[4]  
A past history of zoster was also ascertained using zoster or PHN codes from both CPRD 
and HES (S5 Table) occurring before the start of follow-up (01/09/2013), or a first zoster 
code of PHN occurring during follow-up. 
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Analyses 
A complete case analysis using multivariable logistic regression was used to determine the 
association of socio-demographic factors with zoster vaccine uptake, using adjusted odds 
ratios (aOR) with 95% confidence intervals (CI). Logistic regression models were chosen to 
address the problem of potential misclassification of individuals for vaccine eligibility based 
on their date of birth and therefore the lack of information on person-time at risk for 
vaccination. The exposure and outcome characteristics of individuals excluded from 
complete case primary analysis because of missing data were described. 
Gender and being a part of the routine or catch-up cohort (born in 1943 and 1934, 
respectively) were considered to be a priori confounders of the socio-demographic factors of 
interest, as well as potential determinants of zoster vaccine uptake. An existing conceptual 
framework [27] was adapted to postulate the hierarchical inter-relationships between distal 
and proximate social factors with the outcome (S6 Table).[28] Using this framework, socio-
demographic factors were added sequentially, as long as data sparsity or multicollinearity 
were not encountered. Standard errors of the coefficients were compared in successive 
analyses to assess multicollinearity between socio-demographic factors. Likelihood ratio 
tests were conducted for hypothesis testing unless otherwise indicated. Linear trends, if 
appropriate, were also examined for ordered categorical variables such as patient- and 
practice-level IMD. Differences in the effects of social factors in the two age groups (routine 
and catch-up) were investigated by adding interaction terms to the models. 
In sensitivity analyses, we repeated multivariable analyses: 1) restricted to individuals who 
were followed up for the entire study period of two years; 2) adding the social factors that 
had been excluded due to multicollinearity issues; 3) replacing the status of the time-varying 
factors to that ascertained at the end of follow-up instead of at the start of follow-up, and 4) 
including past history of zoster in the final multivariable model as a potential mediator of 
some of the socio-demographic factors. 
Additionally, inadvertent zoster vaccination amongst individuals with immunosuppressive 
conditions or therapies was also described. 
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Data were analysed using Stata 14 (StataCorp, College Station, TX, USA). 
Ethics 
Approval was sought and obtained from the Observational/Interventions Research Ethics 
Committee of the London School of Hygiene and Tropical Medicine (Reference: 11910) and 
from the Independent Scientific Advisory Committee (ISAC) of the Medicines and Healthcare 
products Regulatory Agency (reference:16_168). The ISAC protocol was made available to 
the reviewers of this paper.  
 
Results 
A total of 39,120 individuals born in 1943 or 1934 and with no evidence of prior zoster 
vaccination were registered with a CPRD practice, which had consented to linkages, on 
01/09/2013 (Fig1). After excluding those who had contraindications to zoster vaccine at the 
start of follow-up or less than 5 months follow-up, 35,333 individuals from 277 practices were 
considered for the primary analysis (Fig 1). 
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Fig.1 Zoster vaccine uptake study flow chart 
251 
 
Primary analysis 
A slight majority of the participants in the primary analysis (Table 1) were female. A higher 
proportion was born in the year 1943 (the main target group), were from a White ethnic 
background, and were cohabiting (living as a couple) and/or not living alone. Data for marital 
status were missing for ~37% participants (Table 1) and practice-level IMD was used to 
replace the missing patient-level IMD for 0.07% (n=26) participants. A past history of zoster 
was present for ~11% of participants (Table 1). 
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Table 1.Baseline characteristics of the study population: comparison of individuals 
with minimum follow-up of 5 months and 24 months 
 
Variables  
 
Primary analysisa N= 35333 from 
277 practices, vaccine 
uptake=18499 (52.4%) 
Sensitivity analysisb N= 21137 from 
178 practices, vaccine uptake=12173 
(57.6%) 
 
 
Total (column %) Received zoster 
vaccine (row %) 
Total (column %) Received zoster 
vaccine (row %) 
Gender Male 16633 (47.1%) 8859 (53.3%) 9829 (46.5%) 5763 (58.6%) 
Female 18700 (52.9%) 9640 (51.6%) 11308 (53.5%) 6410 (56.7%) 
Year of birth 1943 21458 (60.7%) 11452 (53.4%) 13011 (61.6%) 7580 (58.3%) 
1934 13875 (39.3%) 7047 (50.8%) 8126 (38.4%) 4593 (56.5%) 
Immigration 
status 
Not immigrant 34821 (98.6%) 18270 (52.5%) 20891 (98.8%) 12052 (57.7%) 
Immigrant 512 (1.4%) 229 (44.7%) 246 (1.2%) 121 (49.2%) 
Ethnicity White 30052 (85.1%) 16244 (54.1%) 18044 (85.4%) 10709 (59.3%) 
South Asian 669 (1.9%) 304 (45.4%) 269 (1.3%) 136 (50.6%) 
Black 380 (1.1%) 147 (38.7%) 172 (0.8%) 89 (51.7%) 
Other 262 (0.7%) 107 (40.8%) 138 (0.7%) 68 (49.3%) 
Mixed 86 (0.2%) 36 (41.9%) 46 (0.2%) 25 (54.3%) 
Missing 3884 (11%) 1661 (42.8%) 2468 (11.7%) 1146 (46.4%) 
Patient-level 
IMD~# 
Least deprived 9313 (26.4%) 5230 (56.2%) 5521 (26.1%) 3429 (62.1%) 
2 8692 (24.6%) 4670 (53.7%) 5096 (24.1%) 2959 (58.1%) 
3 7520 (21.3%) 3884 (51.6%) 4644 (22%) 2645 (57%) 
4 5828 (16.5%) 2890 (49.6%) 3595 (17%) 1950 (54.2%) 
Most deprived 3980 (11.3%) 1825 (45.9%) 2281 (10.8%) 1190 (52.2%) 
Practice-level 
IMD 
Least deprived 6184 (17.5%) 3479 (56.3%) 3190 (15.1%) 1922 (60.3%) 
2 7979 (22.6%) 3952 (49.5%) 4994 (23.6%) 2711 (54.3%) 
3 7407 (21%) 3849 (52%) 4157 (19.7%) 2464 (59.3%) 
4 6455 (18.3%) 3488 (54%) 4040 (19.1%) 2321 (57.5%) 
Most deprived 7308 (20.7%) 3731 (51.1%) 4756 (22.5%) 2755 (57.9%) 
Care home* No 34133 (96.6%) 17976 (52.7%) 20509 (97%) 11851 (57.8%) 
Yes 1200 (3.4%) 523 (43.6%) 628 (3%) 322 (51.3%) 
Living alone* No 25525 (72.2%) 13738 (53.8%) 15419 (72.9%) 9122 (59.2%) 
Yes 9808 (27.8%) 4761 (48.5%) 5718 (27.1%) 3051 (53.4%) 
Cohabiting* No 15352 (43.4%) 7316 (47.7%) 8899 (42.1%) 4691 (52.7%) 
Yes 19981 (56.6%) 11183 (56%) 12238 (57.9%) 7482 (61.1%) 
Marital status* Single 497 (1.4%) 232 (46.7%) 295 (1.4%) 148 (50.2%) 
Married/Civil 6495 (18.4%) 3502 (53.9%) 3959 (18.7%) 2372 (59.9%) 
Widow/er 1537 (4.4%) 800 (52%) 872 (4.1%) 508 (58.3%) 
Divorced 516 (1.5%) 246 (47.7%) 304 (1.4%) 163 (53.6%) 
Separated 143 (0.4%) 64 (44.8%) 93 (0.4%) 50 (53.8%) 
Partner other/ 
uncategorised 
13091 (37.1%) 7465 (57%) 8028 (38%) 4969 (61.9%) 
Missing 13054 (36.9%) 6190 (47.4%) 7586 (35.9%) 3963 (52.2%) 
History of zoster* No 31319 (88.6%) 16286 (52%) 18732 (88.6%) 10721 (57.2%) 
Yes 4014 (11.4%) 2213 (55.1%) 2405 (11.4%) 1452 (60.4%) 
aThose with immunosuppressing condition at start of follow-up excluded with minimum follow-up >=5 months  IMD 
index of multiple deprivation ~ 26 and #2 patients with missing patient-level IMD were replaced with practice-level 
IMD for primary and secondary analyses respectively bThose with immunosuppressing condition at start of follow-up 
excluded with minimum follow-up >=24 months *at start of follow-up 
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Fig.2 Zoster and seasonal influenza vaccine uptake amongst study participants 
Received both zoster & SIV 
N=17,527 (49.6%) 
Received only zoster 
vaccine N=972 (2.8%) 
Received only SIV 
N=10,665 (30.2%) 
Received neither zoster or 
SIV N=6169 (17.5%) 
Individuals with follow-up ≥5 months
#
 N=35333 (100%) 
Received both zoster & 
SIV on same date  
N=6455 (36.8%*) 
Received both zoster & 
SIV but on different date 
N= 11,072 (63.2%*) 
#
Individuals with immunosuppressing condition at start of follow-up excluded and had minimum follow-up of ≥5 months 
SIV seasonal influenza vaccine 
*denominator=17,527 
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Of the total participants considered for the primary analysis, zoster vaccine was 
administered to 18,499 (52.4%) individuals. Uptake amongst the main target group (those 
born in 1943) was ~53% compared to ~51% amongst the catch-up cohort (individuals born 
in 1934). Nearly half (n=17,527) of the participants received both zoster vaccine and SIV 
(Fig 2); of these, only ~37% (n=6455) got both vaccines on same date (Fig 2), however the 
majority (~87%, n=16,066) received zoster vaccination during the influenza campaign period 
(September-March)[26] of 2013/2014 and 2014/2015. Amongst ~80% (n=28,192) of the 
participants who received SIV, ~73% (n=20,685) received SIV in both the 2013/2014 and 
2014/2015 campaign periods while 22.4% (N=6,323) received SIV only in 2013/2014, and 
4.2% (N=1,184) only in 2014/2015 season (data not shown).  
A decision was made to drop marital status from the multivariable analyses, due to a large 
proportion of individuals with missing data for this variable. Thus, in the subsequent 
complete case analysis, only patients with missing ethnicity data were excluded.  This 
resulted in a final study population of 31,449 individuals, amongst whom the zoster vaccine 
uptake was 53.5% (Fig 1). Comparison of individuals included (n=31,449) and excluded 
(n=3884) from the complete case analysis due to missing ethnicity data is available in S7 
Table. Briefly, excluded individuals were more likely to be in the main target cohort, and to 
be from less deprived patient- and practice-level areas, and were less likely to be care home 
residents, to have evidence that they were an immigrant or to have past history of zoster. 
The excluded group was also less likely to be vaccinated for zoster. 
Time-varying exposures at the start and end of follow-up remained largely unchanged for 
~99% individuals included in the complete case analysis (S8 Table). 
a) Minimally adjusted model  
In the analysis adjusted for a priori confounders (gender and year of birth), there was strong 
evidence of an association between higher zoster vaccine uptake and male gender, with 
uptake 10% higher compared to females (Table 2). There was also evidence of  lower 
vaccine uptake amongst the catch-up cohort, immigrants, those of non-White ethnicity, care 
home residents, those living alone and those not cohabiting, with reduced odds of between 
12% (being in the catch-up cohort) to 46% (Black ethnicity) (all p values <0.001, Table 2)). 
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There was also strong evidence for a linear trend (p for trend <0.0001) for decreasing 
vaccine uptake with increasing patient-level deprivation (IMD) score, the most deprived 
group having 34% lower odds of uptake compared to the least deprived group. Non-linear 
decreases in uptake were seen for practices in more deprived areas (Table 2).  
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Table 2.Multivariable analyses- social factors associated with zoster vaccine uptake complete case analysis: Individuals with minimum 
follow-up of 5 monthsa  
 
 
 
Minimally adjusted 
for year of birth & 
gender OR (95% CI) 
P value~ 
(PT) 
Model 1 additionally 
adjusted for 
immigration status & 
ethnicity OR (95% CI) 
P 
value~ 
Model 2 additionally 
adjusted for patient-
level IMD OR (95% 
CI) 
P value~ 
(PT) 
Model 3 adjusted for 
all variables unless 
indicated OR (95% CI) 
P value~ 
(PT) 
Gender Male 1.10 (1.05-1.15) 0.0001 1.09 (1.05-1.14) 0.0001 1.09 (1.04-1.14) 0.0001 1.08 (1.04-1.13) 0.0005 
Female 1  1  1  1  
Year of birth 1943 (main target group) 1  1  1  1  
1934 (catch-up cohort) 0.88 (0.84-0.92) <0.0001 0.88 (0.84-0.92) <0.0001 0.87 (0.84-0.91) <0.0001 0.89 (0.85-0.93) <0.0001 
Immigration status Not immigrant 1  1  1  1  
Immigrant 0.71 (0.59-0.85) 0.0002 0.91 (0.75-1.11) 0.36 0.94 (0.77-1.15) 0.55 0.94 (0.77-1.14) 0.52 
Ethnicity White 1  1  1  1  
South Asian 0.70 (0.60-0.82) <0.0001 0.73 (0.61-0.86) <0.0001 0.73 (0.62-0.86) <0.0001 0.72 (0.61-0.85) <0.0001 
Black 0.54 (0.44-0.67)  0.55 (0.44-0.67)  0.61 (0.49-0.75)  0.61 (0.49-0.75)  
Other 0.58 (0.45-0.75)  0.59 (0.46-0.76)  0.60 (0.47-0.77)  0.61 (0.47-0.78)  
Mixed 0.61 (0.40-0.94)  0.61 (0.40-0.94)  0.63 (0.41-0.96)  0.62 (0.40-0.96)  
Patient-level IMD# Least deprived 1  Not in model  1  1  
2 0.92 (0.86-0.98) <0.0001    0.92 (0.86-0.98) <0.0001 0.92 (0.87-0.98) <0.0001 
3 0.85 (0.79-0.90) (<0.0001)   0.85 (0.80-0.91) (<0.0001) 0.86 (0.81-0.92) (<0.0001) 
4 0.77 (0.72-0.83)    0.78 (0.73-0.84)  0.80 (0.74-0.86)  
Most deprived 0.66 (0.61-0.71)    0.67 (0.62-0.73)  0.69 (0.64-0.75)  
Practice-level IMD Least deprived 1  Not in model  Not in model#  Not in model#  
2 0.76 (0.71-0.82) <0.0001       
3 0.86 (0.80-0.93)        
4 0.94 (0.87-1.01)        
Most deprived 0.81 (0.75-0.87)        
Care home* No 1  Not in model  Not in model  1  
Yes 0.66 (0.58-0.74)  <0.0001     0.64 (0.57-0.73) <0.0001 
Living alone* Not living alone 1  Not in model  Not in model  1  
Yes living alone 0.85 (0.81-0.89) <0.0001     0.85 (0.81-0.90) <0.0001 
Cohabiting* No 0.73 (0.70-0.77) <0.0001 Not in model  Not in model  Not in model#  
Yes 1        
aThose with immunosuppressing condition at start of follow-up excluded (Number of patients=31449 vaccine uptake= 16,838 (53.5%)) OR odds ratio CI confidence interval ~ likelihood 
ratio test PT P value for trend IMD index of multiple deprivation # 19 patients with missing patient-level IMD were replaced with practice-level IMD  *at start of follow-up # excluded due to 
multicollinearity issues 
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b) Multivariable analyses 
After additionally adjusting the minimally adjusted model for immigration status and ethnicity 
(Multivariable Model 1, Table 2), no appreciable changes in effect estimates were observed, 
except lower uptake amongst immigrants was no longer apparent after adjustment for 
ethnicity, with no evidence of collinearity between the two variables. As patient- and 
practice-level IMD were considered to be correlated, and as social factors relevant at an 
individual level were more of interest, only patient-level IMD was added to Model 2. No 
noticeable changes in effect estimates between Model 1 and Model 2 were observed, and 
the strong evidence of linear trend of lower uptake with increasing deprivation score seen in 
minimally adjusted analysis was still evident (p<0.001) in this model. Similarly, living alone 
status and cohabitation were closely correlated, and so living alone was added to the final 
multivariable model (Model 3), along with care home residence. Again, the previously 
observed associations of lower uptake with living alone and residing in care home persisted 
in this model; individuals living alone and those residing in care home had 15% and 36% 
decreased odds of uptake, respectively (Table 2). The effect estimates for other variables 
were unchanged. 
There was evidence that the effect of male gender, patient-level IMD and care home 
residence varied with age (Table 3). Analyses showed that the increase in vaccine uptake 
among males was restricted to the catch-up cohort, and that the effects of care home status 
and (to a lesser extent) increasing deprivation on lower vaccine uptake were more marked in 
the catch-up cohort compared to the routine cohort.  
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Table 3 Interaction between age and social factors  
 Gender Total  
N (column %) 
Zoster 
vaccinations N 
(row %) 
Stratum-specific adjusted# 
OR for zoster vaccination  
(95%CI) 
P-value for 
interaction* 
Main target group Males 9059 (48.4%) 4977 (54.9%) 1.00 (0.95-1.06) 
 
<0.0001 
 Females 9677 (51.6%) 5303 (54.8%) 1  
Catch-up cohort Males 5786 (45.5%) 3156 (54.5%) 1.22 (1.13-1.31) 
 
 
 Females 6927 (54.5%) 3402 (49.1%) 1  
  Immigration 
status 
Total  
N (column %) 
Zoster 
vaccinations N 
(row %) 
 
Stratum-specific adjusted# 
OR for zoster vaccination  
(95%CI) 
P-value for 
interaction* 
Main target group Not immigrant 18432 (98.4%) 10139 (55%) 1 0.93 
 Immigrant 304 (1.6%) 141 (46.4%) 0.93 (0.73-1.19)  
Catch-up cohort Not immigrant 12527 (98.5%) 6478 (51.7%) 1  
 Immigrant 186 (1.5%) 80 (43%) 0.95 (0.70-1.29) 
 
 
       Ethnicity Total  
N (column %) 
Zoster 
vaccinations N 
(row %) 
 
Stratum-specific adjusted# 
OR for zoster vaccination  
(95%CI) 
P-value for 
interaction* 
Main target group White 17878 (95.4%) 9907 (55.4%) 1 0.73 
 South Asian 423 (2.3%) 202 (47.8%) 0.75 (0.61-0.91)  
 Black 211 (1.1%) 79 (37.4%) 0.55 (0.41-0.72)  
 Other 170 (0.9%) 69 (40.6%) 0.57 (0.42-0.78)  
 Mixed 54 (0.3%) 23 (42.6%) 0.61 (0.35-1.05)  
Catch-up cohort White 12174 (95.8%) 6337 (52.1%) 1  
 South Asian 246 (1.9%) 102 (41.5%) 0.68 (0.52-0.89)  
 Black 169 (1.3%) 68 (40.2%) 0.70 (0.51-0.96)  
 Other 92 (0.7%) 38 (41.3%) 0.67 (0.44-1.03)  
 Mixed 32 (0.3%) 13 (40.6%) 0.64 (0.32-1.31)  
       Patient-level 
IMD 
Total  
N (column %) 
Zoster 
vaccinations N 
(row %) 
 
Stratum-specific adjusted# 
OR for zoster vaccination  
(95%CI) 
P-value for 
interaction* 
Main target group Least deprived 4781 (25.5%) 2766 (57.9%) 1 0.07 
 2 4514 (24.1%) 2520 (55.8%) 0.93 (0.85-1.00)  
 3 4033 (21.5%) 2226 (55.2%) 0.91 (0.83-0.99)  
 4 3160 (16.9%) 1658 (52.5%) 0.83 (0.76-0.91)  
 Most deprived 2248 (12%) 1110 (49.4%) 0.75 (0.68-0.83)  
Catch-up cohort Least deprived 3261 (25.7%) 1837 (56.3%) 1  
 2 3208 (25.2%) 1732 (54%) 0.92 (0.83-1.01)  
 3 2677 (21.1%) 1342 (50.1%) 0.80 (0.72-0.88)  
 4 2119 (16.7%) 1024 (48.3%) 0.76 (0.68-0.84)  
 Most deprived 1448 (11.4%) 623 (43%) 0.62 (0.55-0.70)  
       Care home 
residence 
Total  
N (column %) 
Zoster 
vaccinations N 
(row %) 
 
Stratum-specific adjusted# 
OR for zoster vaccination  
(95%CI) 
P-value for 
interaction* 
Main target group No 18217 (97.2%) 10021 (55%) 1 0.0008 
 Yes 519 (2.8%) 259 (49.9%) 0.80 (0.67-0.95)  
Catch-up cohort No 12097 (95.2%) 6328 (52.3%) 1  
 Yes 616 (4.8%) 230 (37.3%) 0.53 (0.45-0.63)  
       Living alone Total  
N (column %) 
Zoster 
vaccinations N 
(row %) 
 
Stratum-specific adjusted# 
OR for zoster vaccination  
(95%CI) 
P-value for 
interaction* 
Main target group Not living alone 14005 (74.7%) 7860 (56.1%) 1 0.22 
 Yes living 
alone 
4731 (25.3%) 2420 (51.2%) 0.83 (0.78-0.89)  
Catch-up cohort Not living alone 8791 (69.1%) 4618 (52.5%) 1  
 Yes living 
alone 
3922 (30.9%) 1940 (49.5%) 0.89 (0.82-0.96)  
# Final Model 3 from Table 2 (Number of patients=31449 vaccine uptake= 16,838 (53.5%)) OR odds ratio CI 
confidence interval *likelihood ratio test 
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Sensitivity analyses  
There were no appreciable differences between the baseline characteristics of individuals 
with follow-up for the entire 2-year study period and those included in primary analysis 
(follow-up period of ≥5 months) (Table 1). The results of multivariable analyses for those 
with longer follow up were similar to those from primary analysis except there was some 
attenuation in the association of ethnicity with vaccine uptake; individuals of Other ethnicities 
had 31% reduced odds (versus 39% in primary analysis) of uptake compared to those of 
White ethnicity in this model (Table 4). 
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Table 4 Sensitivity analyses: Social factors associated with zoster vaccine uptake complete case analysis (Model 3)  
Variables  Primary analysis 
N=31,449 vaccine 
uptake: n=16,838 
Sensitivity analysisa 
N=18,669 vaccine 
uptake: n=11027 
Sensitivity analysisb 
N=31,449 vaccine 
uptake: n=16,838 
Sensitivity analysisc 
N=31,449 vaccine 
uptake: n=16,838 
Sensitivity analysisd 
N=31,130 vaccine 
uptake: n=16,707 
Sensitivity analysise 
N=31,449 vaccine 
uptake: n=16,838 
Sensitivity analysisf 
N=31,449 vaccine 
uptake: n=16,838 
 
 
OR (95% CI) P value~ 
(PT) 
OR (95% CI) P value~ 
(PT) 
OR 
(95% CI) 
P value~ 
(PT) 
OR 
(95% CI) 
P value~ 
(PT) 
OR (95% CI) P value~ 
(PT) 
OR 
(95% CI) 
P value~ 
(PT) 
OR 
(95% CI) 
P value~ 
(PT) 
Gender Male 1.08 
(1.04-1.13) 
0.0005 1.10 (1.03-
1.16) 
0.003 1.07 
(1.02-1.12) 
0.003 1.08 
(1.04-1.13) 
0.0005 1.09 
(1.04-1.14) 
0.0003 1.08 
(1.04-1.13) 
 
0.0005 
 
1.09 
(1.04-1.14) 
0.0003 
Female 1  1  1  1  1  1  1  
Year of 
birth 
1943  1  1  1  1  1  1  1  
1934  0.89 
(0.85-0.93) 
<0.0001 0.92 
(0.86-0.98) 
0.006 0.89 
(0.85-0.93) 
<0.0001 0.89 
(0.85-0.93) 
<0.0001 0.89 
(0.85-0.93) 
<0.0001 0.89 
(0.85-0.94) 
 
<0.0001 0.89 
(0.85-0.93) 
<0.0001 
Immigrant No 1  1  1  1  1  1  1  
Yes 0.94 
(0.77-1.14) 
0.52 0.82 
(0.62-1.08) 
0.16 0.94 
(0.77-1.15) 
0.56 0.92 
(0.75-1.12) 
0.4 0.96 
(0.79-1.18) 
0.72 0.93 
(0.77-1.14) 
 
0.51 0.94 
(0.77-1.15) 
0.54 
Ethnicity White 1  1  1  1  1  1  1  
South 
Asian 
0.72 
(0.61-0.85) 
<0.0001 0.73 
(0.57-0.94) 
0.03 0.76 
(0.64-0.89) 
<0.0001 0.71 
(0.60-0.84) 
<0.0001 0.73 
(0.62-0.86) 
<0.0001 0.72 
(0.61-0.85) 
<0.0001 0.72 
(0.61-0.86) 
<0.0001 
Black 0.61 
 (0.49-0.75) 
 0.85 
(0.62-1.15) 
 0.64 
(0.52-0.79) 
 0.55 
(0.45-0.68) 
 0.59 
(0.48-0.74) 
 0.61 
(0.49-0.75) 
 0.62 
(0.50-0.76) 
 
Other 0.61 
(0.47-0.78) 
 0.69 
(0.49-0.97) 
 0.62 
(0.48-0.79) 
 0.60 
(0.47-0.78) 
 0.62 
(0.48-0.80) 
 0.60 
(0.47-0.78) 
 0.61 
(0.47-0.78) 
 
Mixed 0.62 
(0.40-0.96) 
 0.84 
(0.47-1.50) 
 0.63 
(0.41-0.98) 
 0.61 
(0.40-0.93) 
 0.58 
(0.38-0.91) 
 0.62 
(0.40-0.96) 
 0.63 
(0.41-0.96) 
 
Patient-
level IMD 
Least 
deprived 
1  1  1  Not in 
model# 
 1  1  1  
2 0.92 
(0.87-0.98) 
<0.0001 
 
0.84 
(0.77-0.92) 
<0.0001 
 
0.93 
(0.87-0.99) 
<0.0001   0.94 
(0.88-1.00) 
<0.0001 
 
0.92 
(0.87-0.98) 
<0.0001 0.92 
(0.87-0.98) 
<0.0001 
 
3 0.86 
(0.81-0.92) 
(<0.0001) 0.81 
(0.74-0.88) 
(<0.0001) 0.87 
(0.81-0.92) 
(<0.0001)   0.86 
(0.81-0.92) 
(<0.0001) 0.86 
(0.81-0.92) 
(<0.0001) 0.86 
(0.81-0.92) 
(<0.0001) 
4 0.80 
 (0.74-0.86) 
 0.74 
(0.67-0.81) 
 0.81 
(0.76-0.87) 
   0.80 
(0.75-0.86) 
 0.80 
(0.75-0.86) 
 0.80 
(0.74-0.86) 
 
Most 
deprived 
0.69 
(0.64-0.75) 
 0.67 
(0.60-0.75) 
 0.72 
(0.66-0.78) 
   0.69 
(0.64-0.75) 
 0.70 
(0.65-0.76) 
 0.69 
(0.64-0.75) Contd. 
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Variables  Primary analysis 
N=31,449 vaccine 
uptake: n=16,838 
Sensitivity analysisa 
N=18,669 vaccine 
uptake: n=11027 
Sensitivity analysisb 
N=31,449 vaccine 
uptake: n=16,838 
Sensitivity analysisc 
N=31,449 vaccine 
uptake: n=16,838 
Sensitivity analysisd 
N=31,130 vaccine 
uptake: n=16,707 
Sensitivity analysise 
N=31,449 vaccine 
uptake: n=16,838 
Sensitivity analysisf 
N=31,449 vaccine 
uptake: n=16,838 
 
 
OR (95% CI) P value~ 
(PT) 
OR (95% CI) P value~ 
(PT) 
OR 
(95% CI) 
P value~ 
(PT) 
OR 
(95% CI) 
P value~ 
(PT) 
OR (95% CI) P value~ 
(PT) 
OR 
(95% CI) 
P value~ 
(PT) 
OR 
(95% CI) 
P value~ 
(PT) 
Practice-
level IMD 
Least 
deprived 
Not in 
model# 
 Not in 
model# 
 Not in 
model# 
 1  Not in 
model# 
 Not in 
model# 
 Not in 
model# 
 
2       0.77 
(0.72-0.83) 
<0.0001       
3       0.87 
(0.81-0.94) 
       
4       0.97 
(0.90-1.04) 
       
Most 
deprived 
      0.83 
(0.77-0.90) 
       
Care 
home* 
No 1  1  1  1  1  1  1  
Yes 0.64 
(0.57-0.73) 
<0.0001 0.68 
(0.58-0.80) 
<0.0001 0.69 
(0.61-0.78) 
<0.0001 0.63 
(0.56-0.71) 
<0.0001 0.64 
(0.57-0.73) 
<0.0001 0.63 
(0.57-0.70) 
 
<0.0001 0.64 
(0.57-0.72) 
<0.0001 
Living 
alone* 
Not 
living 
alone 
1  1  Not in 
model# 
 1  1  1  1  
Yes 
living 
alone 
0.85 
 (0.81-0.90) 
<0.0001 0.84 
(0.79-0.90) 
<0.0001   0.83 
(0.79-0.88) 
<0.0001 0.86 
(0.82-0.91) 
<0.0001 0.85 
(0.81-0.89) 
 
<0.0001 0.86 
(0.81-0.90) 
<0.0001 
Cohabiting
* 
No Not in 
model# 
 Not in 
model# 
 1  Not in 
model# 
 Not in 
model# 
 Not in 
model# 
 Not in 
model# 
 
Yes     1.30 
(1.25-1.36) 
<0.0001         
History of 
zoster*  
No Not in model  Not in model  Not in 
model 
 Not in 
model 
 Not in model  Not in 
model 
 1  
Yes             1.12 
(1.04-1.20) 
0.002 
OR odds ratio CI confidence interval PT P value for trend ~ likelihood ratio test a restricted to individuals with follow-up of 24 months b Including cohabitation instead of living alone in 
multivariable analysis c Including practice level IMD instead of patient level IMD  d Excluding patients with immunosuppressing condition at end of follow-up (n=1835) instead of at start of 
follow-up and excluding those with follow-up <5months e Care home status at end of follow-up f includes history of zoster in the model *determined at start of follow-up IMD index of 
multiple deprivation # excluded due to multicollinearity issues
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Substitution of cohabitation status instead of living alone, practice-level IMD instead of 
patient-level IMD, excluding individuals with immunosuppressive conditions at the end as 
opposed to start of follow-up (S9 Table) and determining care home status at the end 
instead of start of follow-up (Table 4: sensitivity analyses) did not change the findings. 
Individuals with a past history of zoster had 12% higher odds of uptake (Table 4), but 
inclusion of past zoster in the multivariable model made little difference to the other effect 
estimates. 
To assess the impact of excluding individuals from the complete case analysis, a further 
exploratory analysis was conducted, by re-running the minimally adjusted analysis for the 
entire study population (N=35,333) with follow-up ≥5 months including those with missing 
data on ethnicity (S10 Table). Comparing the minimally adjusted model with that of primary 
analysis revealed no noticeable differences in effect estimates. 
Inadvertent zoster vaccinations 
Of the 19,330 in the total study population who received vaccination (Fig 1), 3% (n=596) 
received zoster vaccine whilst immunosuppressed.[4] Of these 596 patients, 28 (4.7%) 
patients had more than one immunosuppressive condition at the time of vaccination. The 
maximum number of immunosuppressive conditions at time of vaccination was three. The 
most common immunosuppressive condition (n=445) during which the patients received 
zoster vaccine was cancer chemotherapy or radiotherapy, followed by patients taking other 
immunosuppressive medications (n=69), patients with leukemia, lymphoma, myeloma, other 
plasma cell dyscrasias (n=49), treatment with immunosuppressive dose of oral corticosteroid 
(n=28), cellular immune deficiency (n=25), solid organ transplant (n=9) and HIV (n=1). None 
of the patients received zoster vaccination during the immunosuppressive phase of a stem 
cell or bone marrow transplant. 
Discussion 
To the best of our knowledge, this is the first study to quantify the inequalities in the uptake 
of zoster vaccine, administered in a national vaccination programme, using anonymised 
electronic health records.  This large 2-year population based study from England  revealed 
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that lower zoster vaccine uptake was independently associated with being a part of the 
catch-up cohort, non-White ethnicity,  residing in a care home, living alone, and not 
cohabiting (living as a couple). A graded inverse association of patient-level deprivation with 
vaccine uptake was also observed. Lower uptake was also seen amongst females in the 
catch-up cohort, and the effects of care home residence and deprivation were more marked 
among the older catch-up group.   
Strengths and limitations 
Strengths of the study include the large sample size, and linkages to hospitalisation data 
which provided additional information about socio-demographic factors as well as zoster 
vaccine contraindications. Multivariable analysis, using a hierarchical causal modelling 
approach, enabled appropriate interpretation of effect estimates. The NHS zoster 
vaccination programme is administered via general practice only and thus capture of 
vaccination is likely to be good. Additionally, our previous methodological study investigating 
ascertainment of socio-demographic factors in linked CPRD data showed that the 
distribution of factors such as ethnicity, not living alone, cohabitation and care home 
residence for individuals aged ≥65 years was comparable to the distribution in the 2011 
English Census.[15] 
The study limitations include potential misclassification of both socio-demographic factors 
and the zoster vaccination recording, despite our previous study showing good capture of 
socio-demographic factors in CPRD data.[15]  If this misclassification was non-differential, 
this may have underestimated the effect estimates in this study. An additional issue is that 
some individuals may have changed exposure status over time. Ideally, person-time at risk 
to estimate vaccination rates would have been preferable but unavailability of complete 
dates of birth in CPRD precluded this ascertainment.   However, factors ascertained at start 
of follow-up remained unchanged for ~99% individuals at the end of follow-up and sensitivity 
analyses to assess the impact of the time-varying factors reassuringly revealed similar 
results to the primary analysis. There was also potential for bias resulting from the complete 
case analysis (owing to missing ethnicity information) which led to exclusion of data from 
11% of the study population. Further assessment of this revealed that effect estimates from 
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the minimally adjusted models for individuals for the entire study population (after dropping 
ethnicity) had no appreciable differences to those obtained from the complete case analysis. 
Lack of recording of marital status prevented investigation of its association with zoster 
vaccine uptake, but other closely related variables for living arrangements such as 
cohabitation and living alone were available.  
Comparison with other studies 
Our finding of higher uptake in the main target group compared to the catch-up cohort 
reflects the findings from the national annual zoster vaccine coverage data for England over 
the same time period, and vaccine coverage among the individuals in our study who were 
followed up for the entire study duration (and thus had fuller capture of uptake of 
vaccination) is comparable to the coverage estimates in the national data.[6, 7] Higher 
uptake amongst males in the catch-up cohort observed in this study also was shown in the 
national data for 2013-2015 for reasons that are currently unexplained.[6, 7] This is in 
contrast to findings from North America that have reported a higher zoster vaccine uptake 
amongst females.[29-31] The majority of zoster vaccinations (87%) in this study occurred 
during the influenza season, suggesting that opportunistic targeting of the eligible population 
for zoster vaccine during SIV programme might have played a role. The national annual  
zoster vaccination data also supports this finding.[6, 7] Our finding of a linear relationship 
between increasing level of deprivation and lower zoster vaccine uptake also confirms the 
earlier analyses of the national data, which found a similar trend but was restricted to 
examining deprivation at the general practice-level;[14]  studies from the US and Canada 
have also reported the lower zoster vaccine amongst individuals with lower income.[30-32] 
Higher zoster vaccine uptake amongst individuals of White ethnicity, as seen here, has been 
reported from other zoster vaccine studies from high income countries.[14, 30, 32-35]  
Several of our findings are novel with respect to zoster vaccine uptake. These include lower 
uptake among individuals who were living alone or not cohabiting; this echoes studies 
showing lower uptake of seasonal influenza vaccine among those living alone in older 
European populations.[12] Our finding that immigration status was not independently 
associated with zoster vaccine uptake after adjusting for ethnicity is in contrast with previous 
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findings of lower uptake among immigrant populations for seasonal influenza and 
pneumococcal vaccine in Spain and Israel, although none of these studies adjusted 
additionally for ethnicity.[36-43]  The lower uptake of zoster vaccine among care home 
residents adds to a number of studies investigating uptake of other vaccines such as 
influenza and pneumococcal vaccines which have reported higher and lower uptake 
respectively, amongst care home residents.[44-48]  
Interpretation of findings and implications 
This study demonstrates that in a public funded healthcare system, vaccination inequalities 
exist during a crucial period of programme initiation, and identifies socio-demographic 
groups that could be targeted with tailored interventions to increase zoster vaccine uptake. 
Of particular interest is the finding of lower uptake among care home residents; we have 
shown recently that individuals in care homes are at higher risk of developing zoster,[49] and 
so are a group with possible double health inequity (of both zoster burden and zoster 
vaccine uptake).  Lower vaccine uptake among these residents could be due to lack of 
awareness amongst care home staff about the newly introduced programme and issues 
around getting consent. The reasons cited for differential (higher or lower) uptake of other 
vaccines among care home residents have included presence of vaccination polices in care 
homes, staff awareness, vaccination consent from the residents, location and care home 
ownership (public versus private).[44, 47, 48] The potential double health inequity amongst 
care home residents highlights a need for more rigorous targeting of these individuals to 
mitigate health inequality.  
Similarly, targeting of older individuals who live alone may be needed to encourage zoster 
vaccination. Individuals cohabiting or living with their relatives may be more motivated by 
their social networks to get vaccinated. Secondly, higher disease awareness amongst these 
individuals, by witnessing the debilitating effect of zoster in their relatives, may also increase 
uptake. This was examined in a US study that reported higher zoster vaccine uptake 
amongst individuals in the three months after occurrence of zoster in their partners, 
reflecting a short term effect of disease awareness.[49]  However, our finding that 
adjustment for a past personal history of zoster made little difference to effect estimates of 
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social factors suggests that social networks may have a longer-lasting effect on encouraging 
vaccine uptake in older individuals, or that the occurrence of zoster in partners versus self 
may have a different effect on uptake.  The lower uptake of vaccine among those of non-
White ethnicity, but the attenuation of this association after restricting to individuals with 
longer follow up, suggests that there might be delay in uptake amongst some ethnic groups. 
There may be a lack of zoster disease awareness among some ethnic groups because of 
lower lifetime risk of zoster, which may be due to genetic causes, social mixing patterns that 
limit contacts with varicella and thus boosting of varicella-zoster virus immunity, and late 
onset of varicella among those born overseas.[33, 49, 50] Alternatively, the lower uptake 
may reflect existing healthcare inequalities. The lack of association of immigration status 
with zoster vaccine uptake after adjusting for ethnicity could be due to confounding by 
ethnicity, or simply to lack of power to detect an effect - the number of individuals identified 
as immigrants in the study population was relatively small (1.4%; n=512) of which zoster 
vaccine uptake was observed amongst only 229 individuals.  It is also feasible that in 
England, where national zoster vaccination programme is available free-of-charge, 
vaccination inequalities were not observed for older immigrant populations.   
Conclusions 
This population-based cohort study provides evidence of inequalities in zoster vaccine 
uptake in the period immediately after the introduction of a national vaccination programme, 
identifying a wide range of socio-demographic determinants of uptake of zoster vaccine.  
This work should encourage effective planning and implementation of specific interventions 
to target these socio-demographic groups to mitigate vaccination inequalities amongst older 
individuals. Factors that are currently poorly recorded in routinely collected data, such as 
religion, education and income, should inform policy drivers such as the sustainability and 
transformation partnerships to incentivise better recording of these factors and/or facilitate 
other data linkages for comprehensive knowledge and future interventions to improve overall 
health and wellbeing of older populations. As care home residents are both less likely to 
receive zoster vaccine and are at higher risk of zoster, improving the uptake of zoster 
vaccination in this group will also mitigate inequalities in zoster burden.  
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8.3 Supplementary material to the submitted paper 
S1 Table Code list: zoster vaccine 
Codelist is available in this thesis as Appendix 12 
S2 Table Code list social factors and immunosuppressive conditions 
Codelists are available in this thesis as Appendices 4-10 and 14-17  
S3 Table Code list seasonal influenza vaccine 
Codelist is available in this thesis as Appendix 19 
S4 Table Dose and duration criteria for immunosuppressive conditions/therapies 
These are described in Chapter 5 of this thesis 
S5 Table Zoster and post-herpetic neuralgia codes 
Codelist is available in this thesis as Appendix 3 
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S6 Table Hierarchical conceptual framework and interpretation of effect estimates 
(based on [1]) 
Hierarchical 
models 
Explanatory variables Interpretation of effect estimates 
`Minimally’ 
adjusted 
model  
Each explanatory variable 
adjusted in-turn for a priori 
confounders: year of birth 
and gender 
Effect estimate of each variable adjusted 
for a priori confounders. 
 
Model-1*^ Ethnicity +immigration status^ 
with a priori confounders 
Effects of ethnicity and immigration status 
adjusted for each other and a priori 
confounders 
 
Model-2* Model-1+ patient-level 
deprivation# 
1) (i) Effects of  ethnicity  and immigration 
status not mediated via deprivation and 
adjusted for each other and a priori 
confounders  
(ii) Effect of patient-level deprivation 
adjusted for a priori confounders, ethnicity 
and immigration status 
 
Model-3* Model-2 + rest of the 
explanatory variables~  
(i) Effect of ethnicity and immigration 
status not mediated via deprivation and 
other explanatory variables~ * 
(ii) Effect of deprivation not mediated via  
other explanatory variables~* 
(iii) Effect of other explanatory variables~ * 
 
*all variables in the model adjusted for each other and a priori confounders: year of birth and sex ^ethnicity and 
immigration status examined for multicollinearity # patient-level and practice-level deprivation were considered to be 
correlated therefore only patient-level deprivation used ~ care home residence, living alone status and cohabitation 
status (living alone and cohabitation examined for multicollinearity) 
 
1. Victora CG, Huttly SR, Fuchs SC, Olinto MT. The role of conceptual frameworks in 
epidemiological analysis: a hierarchical approach. Int J Epidemiol. 1997;26(1):224-7. 
PubMed PMID: 9126524.
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S7 Table Baseline characteristics of patients excluded from primary complete case analysis due to missing ethnicity and those included in 
analysis with complete covariate data 
Variables 
 
 
Excluded from complete case analysis1 due to missing data on 
ethnicity N=3884, vaccine uptake=1661 (42.8%) 
Age (years) at current registration date: median (IQR) 48.9 (36.4-58.2), 
mean (range) 46.3 (0-79) 
Included in complete case analysis1 
N=31449, vaccine uptake=16,838 (53.5%) 
Age (years) at current registration date: median (IQR) 52.9 (40.4-62.8), 
mean (range) 50 (0-79) 
 
 
Total (column %) Not received zoster 
vaccine (row %) 
Received zoster 
vaccine (row %) 
Total (column %) Not received zoster 
vaccine (row %) 
Received zoster 
vaccine (row %) 
Gender Male 1788 (46%) 1062 (59.4%) 726 (40.6%) 14845 (47.2%) 6712 (45.2%) 8133 (54.8%) 
Female 2096 (54%) 1161 (55.4%) 935 (44.6%) 16604 (52.8%) 7899 (47.6%) 8705 (52.4%) 
Year of birth 1943 (main target group) 2722 (70.1%) 1550 (56.9%) 1172 (43.1%) 18736 (59.6%) 8456 (45.1%) 10280 (54.9%) 
1934 (catch-up cohort) 1162 (29.9%) 673 (57.9%) 489 (42.1%) 12713 (40.4%) 6155 (48.4%) 6558 (51.6%) 
Immigration status Not immigrant 3862 (99.4%) 2209 (57.2%) 1653 (42.8%) 30959 (98.4%) 14342 (46.3%) 16617 (53.7%) 
Immigrant 22 (0.6%) 14 (63.6%) 8 (36.4%) 490 (1.6%) 269 (54.9%) 221 (45.1%) 
Patient level IMD Least deprived 1271 (32.7%) 644 (50.7%) 627 (49.3%) 8042 (25.6%) 3439 (42.8%) 4603 (57.2%) 
2 970 (25%) 552 (56.9%) 418 (43.1%) 7722 (24.6%) 3470 (44.9%) 4252 (55.1%) 
3 810 (20.9%) 494 (61%) 316 (39%) 6710 (21.3%) 3142 (46.8%) 3568 (53.2%) 
4 549 (14.1%) 341 (62.1%) 208 (37.9%) 5279 (16.8%) 2597 (49.2%) 2682 (50.8%) 
Most deprived 284 (7.3%) 192 (67.6%) 92 (32.4%) 3696 (11.8%) 1963 (53.1%) 1733 (46.9%) 
Practice level IMD Least deprived 976 (25.1%) 476 (48.8%) 500 (51.2%) 5208 (16.6%) 2229 (42.8%) 2979 (57.2%) 
2 868 (22.3%) 514 (59.2%) 354 (40.8%) 7111 (22.6%) 3513 (49.4%) 3598 (50.6%) 
3 844 (21.7%) 510 (60.4%) 334 (39.6%) 6563 (20.9%) 3048 (46.4%) 3515 (53.6%) 
4 559 (14.4%) 350 (62.6%) 209 (37.4%) 5896 (18.7%) 2617 (44.4%) 3279 (55.6%) 
Most deprived 637 (16.4%) 373 (58.6%) 264 (41.4%) 6671 (21.2%) 3204 (48%) 3467 (52%) 
Care home* No 3819 (98.3%) 2192 (57.4%) 1627 (42.6%) 30314 (96.4%) 13965 (46.1%) 16349 (53.9%) 
Yes 65 (1.7%) 31 (47.7%) 34 (52.3%) 1135 (3.6%) 646 (56.9%) 489 (43.1%) 
Living alone* Not living alone 2729 (70.3%) 1469 (53.8%) 1260 (46.2%) 22796 (72.5%) 10318 (45.3%) 12478 (54.7%) 
Yes living alone 1155 (29.7%) 754 (65.3%) 401 (34.7%) 8653 (27.5%) 4293 (49.6%) 4360 (50.4%) 
Cohabiting* No 1754 (45.2%) 1103 (62.9%) 651 (37.1%) 13598 (43.2%) 6933 (51%) 6665 (49%) 
Yes 2130 (54.8%) 1120 (52.6%) 1010 (47.4%) 17851 (56.8%) 7678 (43%) 10173 (57%) 
History of zoster* 
 
No 3524 (90.7%) 2037 (57.8%) 1487 (42.2%) 27795 (88.4%) 12996 (46.8%) 14799 (53.2%) 
Yes 360 (9.3%) 186 (51.7%) 174 (48.3%) 3654 (11.6%) 1615 (44.2%) 2039 (55.8%) 
1 Those with immune-suppressing condition at start of follow-up excluded with minimum follow-up >=5 months IQR interquartile range IMD index of multiple deprivation * at start of follow-up 
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S8 Table Changes in time varying factors at start and end follow-up 
Variables Patients with 
information 
available N (%) 
Patients with same 
information at start and end 
of follow-up N (%) 
Patients with different 
exposure information at 
start and end of follow-up N 
(%) 
 
Living alone 31449 (100%) 31427 (99.9%) 22 (0.1%) 
Cohabiting 31449 (100%) 31439 (99.97%) 10 (0.03%) 
Care home 31449 (100%) 31080 (98.8%) 369 (1.2%) 
Marital status 19930 (63.3%) 19895 (99.8%) 35 (0.2%) 
 
S9 Table Changes in immunosuppressive therapy/ condition during follow-up 
Out of the total study population N=39120, 2818 individuals had record(s) of 
immunosuppressive condition/therapy during follow-up. An individual might have >1 
condition at a given time; similarly one individual may be immunosuppressed at different 
time points during the follow-up. Number of individuals with immunosuppressive condition/ 
therapy record at start of follow-up was N=1494, at end of follow-up was N=1835. Individuals 
with a code(s) during the middle of the follow-up and not at the start or end of the follow-up 
was 377.  
 
Immunosuppressive 
therapy or condition 
Total number* of patients with one or more immunosuppressive condition(s) 
or taking immunosuppressive therapy (therapies) at any time during follow-up: 
N=2818 (Total study population=39120) 
Total number 
of individuals 
with the 
condition* 
Patients with 
condition at 
start of follow-
up & not at 
end-follow-up 
N (row%) 
Patients with 
condition at end 
of follow-up & 
not at start of 
follow-up N 
(row%) 
Patients with 
condition at 
both start & 
end of follow-
up N (row%) 
Patients with 
condition only 
during middle 
of follow-up 
not at start or 
end of follow-
up N (row%) 
Oral corticosteroids 194 46 (23.7%) 45 (23.2%) 26 (13.4%) 77 (39.7%) 
Other immune- suppressive 
drugs~ 
317 48 (15.1%) 51 (16.1%) 195 (61.5%) 23 (7.3%) 
Lymphoma, myeloma, 
other plasma cell 
dyscrasias &  leukemia 
399 75 (18.8%) 166 (41.6%) 158 (39.6%) 0 (0%) 
Stem cell transplant, bone 
marrow transplant 
12 5 (41.7%) 5 (41.7%) 2 (16.7%) 0 (0%) 
Cancer radio/chemotherapy 2082 525 (25.2%) 788 (37.8%) 446 (21.4%) 323 (15.5%) 
Solid organ transplant 60 0 (0%) 6 (10%) 54 (90%) 0 (0%) 
Cellular immune deficiency 132 0 (0%) 57 (43.2%) 75 (56.8%) 0 (0%) 
HIV 15 0 (0%) 0 (0%) 15 (100%) 0 (0%) 
*an individual may have >1 condition/therapy at a given time ~includes azathioprine, biological therapy, methotrexate, 6-
mercaptopurine, other immunosuppressant such as tacrolimus, sirolimus, and other disease-modifying antirheumatic drugs: 
ciclosporin, mycophenolate, leflunomide 
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S10 Table Social factors associated with zoster vaccine uptake: primary complete 
case analysis excluding ethnicity 
 
Number of patients=35,333 vaccine uptake=18,499  
Variables 
 
Minimally adjusted for 
year of birth & gender 
OR (95% CI) 
P value~ 
(PT) 
Gender Male 1.07 (1.02-1.11) 0.002 
Female 1  
Year of birth 1943 (main target group) 1  
1934 (catch-up cohort) 0.90 (0.87-0.94) <0.0001 
Immigration 
status 
Not immigrant 1  
Immigrant 0.73 (0.62-0.88) 0.0005 
Patient-level 
IMD$ 
Least deprived 1  
2 0.91 (0.86-0.96) <0.0001  
3 0.83 (0.78-0.89) (<0.0001) 
4 0.77 (0.72-0.82)  
Most deprived 0.66 (0.61-0.71)  
Practice-level 
IMD 
Least deprived 1  
2 0.76 (0.71-0.82) <0.0001 
3 0.84 (0.79-0.90)  
4 0.92 (0.85-0.98)  
Most deprived 0.81 (0.76-0.87)  
Care home* No 1  
Yes 0.71 (0.63-0.79) <0.0001 
Living alone* Not living alone 1  
Yes living alone 0.82 (0.78-0.86) <0.0001 
Cohabiting* No 0.72 (0.69-0.75) <0.0001 
Yes 1  
OR odds ratio CI confidence interval PT P value for trend ~ likelihood ratio test IMD index of multiple deprivation $26 
patients with missing patient-level IMD were replaced with practice-level IMD *at start of follow-up  
 
 
S1 Text Details of determining zoster vaccination status 
This is described in Section 5.2.2. 
S1 Fig Decision flow chart for ascertaining zoster vaccine status 
Please see Figure 5-1 of this thesis. 
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8.4 Further investigation of the likely impact of missing data 
Individuals with complete covariate data were included in multivariable analysis, and this led 
to the exclusion of 3884 (11%) study participants with missing ethnicity data (study flow 
chart: Figure 1 submitted paper Section 8.2). As with the analyses of zoster burden 
presented in Chapter 7, the complete case analyses of the socio-demographic determinants 
of zoster vaccine uptake could have resulted in biased effect estimates.  To assess the 
impact of missing data, I utilised the same approach as for the zoster disease burden 
analyses and conducted three additional analyses, which are described in the next section. 
8.4.1 Additional analyses to assess the impact of missing data 
Although the analyses were briefly discussed in the submitted paper, they are reported in 
detail here. These three analyses included: 
(1) The baseline characteristics of patients included and excluded from complete case 
analysis were compared. The start of follow-up for all study participants was on the 
same date (01/09/2013; the start of the national zoster vaccination programme), but 
the reasons for end of follow-up in the two groups were also compared. 
(2) Comparison of minimally adjusted analyses (adjusted for age and gender) between 
those included and excluded from the complete case analyses. 
(3) As described above (2), minimally adjusted analyses for the association of all socio-
demographic factors except ethnicity (the variable with missing data) with zoster 
vaccine uptake for the entire study population were also compared with the 
minimally adjusted estimates from the primary analysis. 
8.4.2 Results of additional analyses  
A comparison of the baseline characteristics of the individuals excluded and included in 
complete case analysis is shown in Section 8.3 (Supplementary material: S7 Table of the 
submitted paper). Individuals excluded from analyses were less likely to be vaccinated (43% 
versus ~54% in the included group); they were also more likely (70% versus 60%) to be 
from the main target group (those aged 70 years) and were slightly younger at the time of 
registration with their GP (median age 48.9 years versus 52.9 years for the included group). 
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Excluded individuals were also more likely to be from less-deprived practice- and patient-
level IMD, less likely to be care home residents (1.7% versus 3.6%) or to be recorded as an 
immigrant (0.6% versus 1.6%). The reasons for individuals’ end of follow-up are shown in 
Table 8-1.  The main differences between the two groups was that the individuals excluded 
from the study were less likely to die during the follow-up (0.6% versus 2.9% in the included 
group).They were also more likely to end follow-up at the study end date of 31/08/2015 (64% 
versus 59% of those included in the main analysis). 
 
Table 8-1 Reasons for end of follow-up for patients excluded (due to missing ethnicity 
data) and included in complete case analysis 
 Reason Patients excluded from complete 
case analysis due to missing 
data on ethnicity N=3884 
Patients included in 
complete case analysis 
N=31449 
End of 
follow-up* 
End of study 2468 (63.5%) 18667 (59.4%) 
Last collection date from 
practice 
1229 (31.6%) 10588 (33.7%) 
Transfer out date 160 (4.1%) 1132 (3.6%) 
Death date 22 (0.6%) 897 (2.9%) 
Transfer out date and death 
date 
5 (0.1%) 163 (0.5%) 
End of study and death date - 2 (0%) 
* All study participants started follow-up at the start of national zoster vaccination programme: 01/09/2013 
 
A comparison of the minimally adjusted models for the association of socio-demographic 
factors with zoster vaccine uptake for both analyses (2) and (3) is provided in Table 8-2. The 
minimally adjusted effect estimates for deprivation, living alone and cohabitation from the 
excluded and included groups were in same direction (Table 8-2). There was some evidence 
that the lower uptake amongst those living alone (OR:0.62 (95%CI: 0.54-0.71)) in the 
excluded group was more marked compared to those included in the analysis (OR:0.85 
(95%CI: 0.81-0.89)).The main differences between the excluded and the included groups 
were for male gender, care home residence and immigration status. The odds of uptake 
were lower (OR: 0.85 (95%CI: 0.74-0.96)) amongst males in the excluded group versus the 
slightly higher uptake (OR: 1.10 (95%CI: 1.05-1.15)) amongst males in included group 
(Table 8-2). There was no evidence for the association of care home residence with zoster 
vaccination (OR: 1.46 (95%CI: 0.89-2.39)) in the excluded group compared to lower odds of 
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vaccine uptake in the included group (OR: 0.66 (95%CI: 0.58-0.74)); however, the former 
analysis was based on only 65 individuals residing in a care home. Although the point 
estimates were very similar, there was also no evidence for an association of immigration 
status (OR: 0.76 (95%CI: 0.32-1.83) in the excluded compared to those included in analyses 
(OR: 0.71 (95%CI: 0.59-0.85)); as with care home residence, this latter analysis was based 
on only 22 individuals coded as being an immigrant. 
In contrast, the minimally adjusted effect estimates for the entire study population were 
largely similar for all socio-demographic factors of interest to those from complete case 
analyses (Table 8-2).  
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Table 8-2 Socio-demographic factors associated with zoster vaccine uptake in minimally adjusted model: comparison of individuals excluded due 
to missing ethnicity data, those included in complete case analysis and total study population  
Exposures Individuals excluded due to missing ethnicity 
data N=3884, uptake=1661 (42.8%)  
Individuals included in primary complete 
case analysis N=31449 uptake=16, 838 
(53.5%) 
Total study population N=35,333 
uptake=18,499 (52.4%) 
Minimally adjusted for age & 
gender OR (95% CI)  
P value~ 
(PT) 
Minimally adjusted for age 
& gender OR (95% CI) 
P value~ 
(PT) 
Minimally adjusted for age 
& gender OR (95% CI) 
P value~ 
(PT) 
Gender Male 0.85 (0.74-0.96) 0.01 1.10 (1.05-1.15) 0.0001 1.07 (1.02-1.11) 0.002 
 Female 1  1  1  
Year of birth 1943 (main target group) 1  1  1  
 1934 (catch-up cohort) 0.95 (0.83-1.09) 0.48 0.88 (0.84-0.92) <0.0001 0.90 (0.87-0.94) <0.0001 
Immigration Not immigrant 1  1  1  
 Immigrant 0.76 (0.32-1.83) 0.5 0.71 (0.59-0.85) 0.0002 0.73 (0.62-0.88) 0.0005 
Patient-level IMD Least deprived 1  1  1  
 2 0.78 (0.66-0.92) <0.0001 
(<0.0001) 
0.92 (0.86-0.98) <0.0001 
(<0.0001) 
0.91 (0.86-0.96) <0.0001 
(<0.0001) 
 3 0.65 (0.55-0.78)  0.85 (0.79-0.90)  0.83 (0.78-0.89)  
 4 0.62 (0.51-0.77)  0.77 (0.72-0.83)  0.77 (0.72-0.82)  
 Most deprived 0.49 (0.37-0.64)  0.66 (0.61-0.71)  0.66 (0.61-0.71)  
Practice-level 
IMD 
Least deprived 1  1  1  
 2 0.65 (0.54-0.78) <0.0001 0.76 (0.71-0.82) <0.0001 0.76 (0.71-0.82) <0.0001 
 3 0.62 (0.51-0.74)  0.86 (0.80-0.93)  0.84 (0.79-0.90)  
 4 0.56 (0.45-0.69)  0.94 (0.87-1.01)  0.92 (0.85-0.98)  
 Most deprived 0.67 (0.55-0.82)  0.81 (0.75-0.87)  0.81 (0.76-0.87)  
Care home* No 1  1  1  
 Yes 1.46 (0.89-2.39) 0.13 0.66 (0.58-0.74)  <0.0001 0.71 (0.63-0.79) <0.0001 
Living alone* Not living alone 1  1  1  
 Yes living alone 0.62 (0.54-0.71) <0.0001 0.85 (0.81-0.89) <0.0001 0.82 (0.78-0.86) 
 
<0.0001 
Cohabiting* No 0.65 (0.57-0.74) <0.0001 0.73 (0.70-0.77) <0.0001 0.72 (0.69-0.75) <0.0001 
 Yes 1  1  1  
OR odds ratio CI confidence interval PT P value for trend ~ likelihood ratio test IMD index of multiple deprivation *at start of follow-up  
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8.4.3 Conclusions from additional analyses to assess the impact of missing 
data 
As mentioned in Section 8.4.1, owing to missing ethnicity data it was only possible to 
compare effect estimates adjusted for gender and age between the total study population 
and the groups excluded and included in the complete case analyses. Within the complete 
case analyses (Table 2 of the submitted paper, Section 8.2), the estimates for all socio-
demographic factors (except for immigration status) remained largely unchanged from 
minimally adjusted estimates to those from the multivariable model (Model 3: adjusted for 
age, gender, ethnicity, immigration, deprivation, care home residence and living alone). 
Further adjustment for other socio-demographic factors in the analyses for the excluded 
individuals, has this been possible, would not have altered appreciably the effect estimates 
reported in the minimally adjusted model for these individuals (other than immigration 
status). The minimally adjusted model including all (excluded and included) individuals 
provides effect estimates that are likely to be similar to those that could have been obtained 
in a fully adjusted model (data permitting).  
In the excluded group, there was no evidence for the effect of immigration status, unlike the 
included group, though the point estimates were very similar. However, this could have been 
due to lack of power and perhaps due to poorer capture of immigration status amongst these 
individuals who were missing ethnicity data. It was also not feasible to adjust the effect of 
immigration on uptake for ethnicity, which in the main analysis suggested that the effect of 
being an immigrant was confounded by ethnicity.  Similarly, the differences in the minimally 
adjusted estimates for care home residence amongst the two groups could be explained due 
of lack of power in the excluded group. For the total study population, on the other hand, 
there were no appreciable changes in the minimally adjusted effect estimates for these 
factors compared to those observed in the complete case analyses. 
The effect of gender (with lower odds of uptake amongst men) on vaccine uptake in the 
minimally adjusted analysis for the excluded group is interesting. As described in the 
submitted paper (Section 8.2) the effect of gender on vaccination in the routine and catch-
up cohort was examined by adding an interaction term to the main analyses (Table 4 of the 
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submitted paper, Section 8.2), the results of which are reproduced below as Table 8-3 for 
comparative purposes. In the main analysis, there was strong evidence that the effect of 
gender was different in the two age groups, with higher vaccine uptake amongst males 
being restricted to the catch-up cohort.  
Table 8-3 Interaction between age and gender: complete case primary analysis 
 Gender Total  
N (column %) 
Zoster 
vaccinations N 
(row %) 
Stratum-specific 
adjusted# OR for zoster 
vaccination (95%CI) 
 
P-value for 
interaction* 
Main target 
group 
Males 9059 (48.4%) 4977 (54.9%) 1.00 (0.95-1.06) 
 
<0.0001 
 Females 9677 (51.6%) 5303 (54.8%) 1  
Catch-up cohort Males 5786 (45.5%) 3156 (54.5%) 1.22 (1.13-1.31) 
 
 
 Females 6927 (54.5%) 3402 (49.1%) 1  
# Final Model 3 from Table 2 of the paper (Section 8.2) OR odds ratio CI confidence interval *likelihood ratio test 
 
As mentioned in Section 8.4.2, the excluded group contained a higher proportion of 
individuals belonging to the routine cohort (70% versus 59.6% in the included group). When 
further stratified by gender, the majority of excluded males were also from the routine cohort 
(1305/1788, 73%). Similar to the main analysis, I examined the effect of gender in the 
excluded cohort stratified by age by adding an interaction term to the minimally adjusted 
analysis (Table 8-4). 
Table 8-4 Interaction between age and gender amongst individuals excluded from 
analysis 
  
Total N (column %) Zoster 
vaccination N 
(row %) 
Stratum-specific OR for 
vaccine uptake 
P value of 
interaction 
Main target 
group 
Males 1305 (33.6) 530 (40.6) 0.83 (0.71-0.96) 0.56 
 
Females 1417 (36.5) 642 (45.3) 1 
 
Catch-up 
cohort 
Males 483 (12.4) 196 (40.6) 0.90 (0.71-1.14) 
 
 
Females 679 (17.5) 293 (43.2) 1 
 
Total 
 
3884 (100) 1661 (42.8) 
  
 
As shown in Table 8-3, in the main analysis, there was no evidence for an effect of gender 
on uptake in the routine cohort.  However, amongst the excluded individuals, the stratified 
analysis (Table 8-4) revealed a lower uptake amongst men compared to women in the 
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younger (routine) group with little evidence of an effect of gender in the catch-up cohort, 
although assessment of the latter was limited by small numbers. As the excluded individuals 
included a higher proportion (73%) of males from the routine cohort (Table 8-4), this may 
have explained why, overall, there was no increased odds of vaccination among males in 
the excluded group, if the effect of increased uptake in older males was being diluted by a 
higher proportion of younger males. It is also possible that males excluded from the 
analyses because of missing ethnicity data could comprise those with low health-seeking 
behaviour, who were possibly less likely to come forward for vaccination. However, for the 
total study population, in keeping with the findings for other socio-demographic factors, there 
was no appreciable difference for the effect of gender in the minimally adjusted analysis to 
that observed in the complete case analyses. Moreover, the national surveillance data for 
2013-2015, which captured coverage data from almost all practices in England, also found 
increased uptake amongst men in the catch-up cohort but very similar uptake among males 
versus females in the routine cohort.68, 69 This is in keeping with the findings of my primary 
complete case analysis. 
8.5 Inadvertent zoster vaccination amongst immunosuppressed 
individuals 
As discussed in previously in Section 1.2.6, currently only live zoster vaccine is available in 
the UK, which is contraindicated for those with immunosuppressive conditions or taking 
immunosuppressive therapies. A secondary objective of this cohort study (Section 8.2) was 
to assess inadvertent zoster vaccination amongst immunosuppressed individuals to quantify 
the magnitude of possible violations of the UK zoster vaccination guidelines.60 
The methods to identify individuals who had an immunosuppressive condition/therapy that is 
a contraindication for the live zoster vaccine were described in Chapter 5 (Sections 5.3.2 
and 5.3.3). Inadvertent zoster vaccination was discussed briefly in the submitted journal 
paper (Section 8.2). Details about the number and the type of immunosuppressive 
conditions/therapy at the time zoster vaccination are provided here. The rationale for this 
further characterisation was that this information could be useful in increasing awareness of 
primary care healthcare providers about contraindications to zoster vaccination.  
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Of the 19,330 individuals in the total study population who received vaccination, 3% (n=596) 
received zoster vaccine whilst they were immunosuppressed. Of these 596 individuals, the 
majority (95%; n=568) had only one immunosuppressive condition and/or therapy at the time 
of vaccination (Table 8-5). Amongst individuals with single immunosuppressive condition/ 
therapy, the commonest condition was a recent receipt of cancer radiotherapy or 
chemotherapy (n=425; 75% of the total) followed by use of other non-steroid 
immunosuppressive drugs (n=56; 10%). 
 
Table 8-5 Individuals with one immunosuppressive condition at the time zoster 
vaccination 
Immunosuppressive condition/ therapy Number of 
individuals with 
zoster vaccinations 
Cancer radio/chemotherapy 
425 (74.8%) 
Other immunosuppressive drugs 
56 (9.9%) 
Haematological malignancies 
37 (6.5%) 
Oral steroid (immunosuppressive doses) 
25 (4.4%) 
Cellular immune deficiency 
20 (3.5%) 
Solid organ transplant 
4 (0.7%) 
HIV 
1 (0.2%) 
Total 568 (100%) 
 
A further 26 individuals (4% of the total 596) had two immunosuppressive conditions and/or 
therapy at the time of vaccination, most of these individuals (n=18; 69% of the total) were 
also those who had recently received cancer chemotherapy or radiotherapy (Table 8-6).  
Table 8-6 Individuals with two immunosuppressive conditions at the time zoster 
vaccination 
Immunosuppressive condition/ therapy Number of 
individuals with 
zoster 
vaccinations 
Cancer radio/chemotherapy & haematological malignancies 
9 (34.6%) 
Cancer radio/chemotherapy & other immunosuppressive drugs 
5 (19.2%) 
Cancer radio/chemotherapy & oral steroids 
3 (11.5%) 
Cellular immune deficiency & other immunosuppressive drugs 
3 (11.5%) 
Solid organ transplant & other immunosuppressive drugs 
3 (11.5%) 
Cellular immune deficiency & haematological malignancies 
2 (7.7%) 
Cancer radio/chemotherapy & solid organ transplant 
1 (3.8%) 
Total 26 (100%) 
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Only two individuals (0.3% of the total 596) had three immunosuppressive conditions (Table 
8-7). This indicates that the presence of more than one immunosuppressive conditions at 
the time zoster vaccination was less likely to lead to the breach of vaccination guidelines. 
The possibility of misclassification of immunosuppressive status resulting in overestimation 
of violations of vaccine policy is discussed in Chapter 9. 
 
Table 8-7 Individuals with three immunosuppressive conditions at the time zoster 
vaccination 
Immunosuppressive condition/ therapy Number of 
individuals with 
zoster 
vaccinations 
Cancer radio/chemotherapy & other immunosuppressive drugs & solid organ transplant 1 (50%) 
Cancer radio/chemotherapy & other immunosuppressive drugs & haematological 
malignancies 
1 (50%) 
Total 2 (100%) 
 
8.6 Potential misclassification of individuals eligible for zoster 
vaccination 
As the month of birth for adults was unavailable in CPRD (Section 3.5.3), individuals born in 
1943 (or 1934 for the catch-up cohort), who would have been eligible for the vaccine in 
2013/14 (if born between January-August) or in 2014/15 (if born between September-
December) were selected (Figures 3-9 and 3-10). For the primary analysis individuals 
included in the study were required to have a minimum follow-up of 5 months, while 
individuals who completed the follow-up for the entire study period i.e. 24 months were 
included in the secondary analysis (Figure 1 of the submitted paper, Section 8.2). It is 
possible that some individuals born between September- December (Figures 3-9 and 3-10) 
were only followed up for the first 5 months of the study period (September 2013- January 
2014). These individuals would not have been eligible for zoster vaccination during the 
period (2013/14) that they contributed data for primary analysis. Inclusion of these ineligible 
individuals would have biased the ORs towards null. I examined this in a secondary analysis 
of individuals who were followed-up for the entire study period i.e. 24 months (Table 4 of the 
submitted paper, Section 8.2). The results of multivariable analyses were similar to those of 
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the primary analysis except the lower odds of uptake amongst non-White ethnicities were 
attenuated. This may indicate that the effect estimates from the primary analysis perhaps 
better capture early adopters of vaccination and that specific socio-demographic groups may 
come forward later. It is therefore important to repeat the analysis of vaccine uptake as the 
campaign continues to observe temporal changes in the inequalities of vaccine uptake 
identified in the first two years of the vaccination programme. 
8.7 Double inequalities 
Having completed investigations of socio-demographic determinants of both zoster disease 
burden and zoster vaccine uptake, it was possible to identify individuals from specific socio-
demographic groups who were “doubly disadvantaged” (Section 1.3.4) i.e. at increased risk 
of developing zoster and also having lower zoster vaccine uptake. The two such groups 
identified (Table 8-8) included individuals residing in care homes and older females (Table 8-
3). These individuals could be specifically targeted with more personalised interventions to 
reduce vaccination inequalities. This is discussed further in Section 9.4. 
 
Table 8-8 Strength of association of social determinants with zoster disease burden 
and vaccine uptake 
Social determinants First zoster episode 
2003-2013 
aIRR (95% CI) 
 
Zoster vaccine 
uptake 2013-2015 
aOR (95% CI) 
Evidence for 
double 
inequality~ 
Gender: Females versus males 1.17 (1.14-1.20)  0.92 (0.88-0.97) Yes 
Care home residence: Care home 
residence versus non-residence 
1.10 (1.04-1.17) 0.64 (0.57- 0.73) Yes 
Ethnicity: Black ethnicity versus 
White 
0.49 (0.41-0.59) 0.61 (0.49-0.75) No 
Immigration: Immigrant versus non-
immigrant: 
0.77 (0.67-0.88) 0.94 (0.77-1.14) No 
Deprivation: Most deprived versus 
least deprived 
0.96 (0.92-0.99) 0.69 (0.64-0.75) No 
Living alone: Living alone versus not 
living alone 
0.96 (0.94-0.98) 0.85 (0.81-0.90) No 
aIRR adjusted incidence risk ratio aOR adjusted odds ratio CI confidence interval ~ higher disease burden and 
lower vaccine uptake 
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8.8 Chapter summary 
This chapter comprises a report of the social determinants of zoster vaccine uptake amongst 
older individuals in England and formed the last chapter of the Results section. In the last 
chapter of this thesis, Chapter 9, I discuss the overall findings from studies carried out in 
this thesis, and give an overview of the strengths and limitations of this work. The implication 
for future research and public health are also described. 
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 Chapter 9. Overall discussion & conclusions 
The first section of this chapter briefly recapitulates the overall aims and objectives of the 
thesis, provides a synopsis of the main results and discussion points from the more detailed 
description presented under the Results section and also describes the overall strengths and 
limitations of this work. The second section of this chapter explores the implications of this 
work for public health and future research. 
9.1 Recapitulation of the aims and objectives of the thesis 
The overall aim of this thesis was to assess inequalities in vaccine-preventable disease 
burden and vaccine uptake in older individuals using routinely collected EHR and to 
contribute towards achieving the goal of health equality. The objectives of this thesis (Table 
1-2) were: to identify from the existing literature which socio-demographic factors were 
associated with vaccine uptake amongst older individuals (objective 1); to develop 
methodology for the ascertainment of socio-demographic factors and to assess their 
recording in the linked UK EHR of older individuals (objective 2), and then using the linked 
EHR to describe socio-demographic factors associated with zoster disease incidence 
(objective 3) and zoster vaccine uptake in England (objective 4). 
9.2 Summary of main findings 
9.2.1 Which socio-demographic factors are associated with uptake of 
routinely administered vaccines amongst older individuals in Europe? 
What was previously known? 
A previous review described associations of social factors such as socio-economic level, 
education, marital status, urban or rural area of residence and ethnicity with uptake of a 
single vaccine: seasonal influenza vaccine.156 No overall effect estimates for the 
associations with vaccine uptake, or assessment of between-study heterogeneity, were 
provided.  
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What does this thesis add? 
The comprehensive systematic review (published paper: Chapter 2) conducted to meet the 
first objective of this thesis, examined the association of uptake of all routinely administered 
vaccines amongst older individuals with a wide range of socio-demographic factors: living 
alone, religion, immigration status, residence (rural/ urban), marital status, education, 
income, vaccination costs, social class and area-level deprivation. This was also the first 
review to quantify the association of these factors with vaccine uptake, using meta-analysis. 
Furthermore, a detailed quality assessment of the published literature and exploration of the 
reasons for between-study heterogeneity using meta-regression were conducted. The 
review identified 35 eligible studies, which quantified the association of socio-demographic 
factors with seasonal influenza, pneumococcal, zoster and pandemic influenza vaccination. 
One key factor identified in this review to be associated with seasonal influenza vaccine 
uptake was living alone, which is emerging as a broader determinant of healthy ageing.15, 157 
Higher seasonal influenza vaccine uptake was observed amongst individuals not living alone 
while lower uptake of this vaccine was observed amongst individuals from more deprived 
areas and immigrants.  The studies included in the review had low risk of bias due to 
exposure or outcome misclassification, but had a higher risk of confounding bias. However, 
multivariable meta-regression analysis undertaken to investigate between-study 
heterogeneity for the effect of education (a social factor with sufficient studies to conduct 
meta-regression) with seasonal influenza vaccine uptake indicated that heterogeneity in 
study findings was partly explained by vaccination costs and by confounding bias.  
9.2.2 To develop methodology for ascertainment of socio-demographic 
factors and to assess their availability in EHR amongst older 
individuals  
What was previously known? 
Methodologies to improve ascertainment of social determinants of health in EHR are 
required to allow utilisation of these databases for researching health inequalities on an 
290 
 
ongoing basis and to also provide insights into improving data quality. The quality and 
completeness of recording for one social factor, ethnicity, had been assessed in linked 
CPRD data.137 However, data for the completeness of recording of ethnicity specifically for 
older individuals were unavailable and this previous evaluation was conducted mainly during 
the period when general practitioners were incentivised to record ethnicity. Some other 
studies have utilised EHR in the UK to assess time-varying factors such as residence in a 
care home and cohabitation.136, 141, 143, 144 However, these studies did not did not report the 
timeliness or representativeness of recording of these factors and did not utilise primary care 
data linked to hospitalisation data. 
What does this thesis add? 
Methodology was developed for assessing the recording of socio-demographic factors, 
which could potentially be determinants of health inequality, including disease burden and 
health care interventions.  In addition to ethnicity and small area-level deprivation, six other 
socio-demographic factors were assessed: religion, immigration status, marital status, place 
of residence, living alone and cohabitation (living as a couple). The quality of recording of 
these factors was evaluated using four pre-set standards: completeness, 
representativeness, timeliness (when appropriate) and the contribution made by linkages to 
EHR in addition to primary care data. The completeness of recording for these factors varied 
considerably from 2.6% (for religion) to 79.4% for ethnicity. The recording of ethnicity, care 
home residence, and living arrangements (living alone and cohabitation) was comparable to 
the 2011 English Census data. Despite using country of birth and “first language” codes, the 
number of individuals coded as immigrants was under-ascertained in these data compared 
to the 2011 English Census (as detailed in Chapter 6). Timeliness (recording within the last 
five years of date of interest) for time-varying factors ranged from ~35% to ~60%. Linkages 
to other datasets improved the availability of ethnicity data from ~55% in CPRD to ~79% 
using both CPRD and HES; while deprivation data were only available as linkage.  
This thesis demonstrated that linked CPRD data can be successfully utilised for 
ascertainment of socio-demographic factors. Based on the analyses reported in Chapter 6, 
ethnicity, care home residence, living arrangements (living alone and cohabitation) and 
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deprivation can be assessed in these data as potential socio-demographic determinants of 
inequalities amongst older individuals. Some factors, such as religion and marital status, 
were found to be poorly captured in these data. GP incentivisation plays an important role in 
completeness of these records as was exemplified by the recording of ethnicity. 
Incentivisation of GPs for recording of other socio-demographic factors and linkages with 
other data sources may help to improve the completeness of these data. 
9.2.3 Health inequalities and social determinants of zoster disease burden 
What is already known on this topic? 
The zoster vaccination programme was introduced in September 2013 in the UK. To make a 
comprehensive assessment of the impact of zoster vaccination on zoster disease burden, 
studies to identify any disparities in zoster burden in the pre-vaccination period are required. 
Although certain co-morbidities and immunosuppressive therapies are known to be 
associated with high risk of zoster, the social determinants for zoster disease burden in 
England, which may contribute to inequalities, are not well known. 
What this study adds 
Inequalities in zoster disease burden were seen amongst individuals aged ≥65 years in 
England during the ten-year period prior to vaccine introduction (2003-2013). In multivariable 
analyses, older individuals identified at a higher risk of zoster burden included females (16% 
higher rate compared to males), non-immigrants (~30% higher rate than immigrants) and 
White ethnicity (for example, twice the rate compared to those of Black ethnicity). Individuals 
residing in a care home were also at a 10% higher risk of zoster. Individuals living in the 
most deprived areas compared to least deprived were at a slightly (4%) lower zoster risk, as 
were the older individuals living alone versus those not living alone. Adjusting for certain co-
morbidities, immunosuppressive conditions and therapeutic agents (potential mediators of 
the effect of socio-demographic factors on zoster risk) made little difference to the effect 
estimates for any of the socio-demographic factors but were themselves associated with 
appreciable increased risk of zoster. Identification of the social determinants of zoster 
disease burden in the pre-zoster vaccination era amongst older individuals revealed an 
interesting picture. As anticipated, older age, female gender and care home residence were 
associated with a higher zoster disease burden. However, individuals with a higher level of 
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deprivation, non-White ethnicity, immigrants and individuals living alone were at a lower risk 
of a first zoster episode, although these social groups are usually considered to be at higher 
risk for infectious diseases. The associations of older age, female gender, care home 
residence, White ethnicity, and being a non-immigrant with higher zoster incidence are 
biologically plausible, as discussed in Chapter 7, and the appreciably increased risks of 
zoster among individuals with immunosuppressive conditions or therapies have been shown 
in previous research. The slight decreased risk of zoster associated with both living alone 
and living in the most deprived areas was a surprising finding and one which is difficult to 
explain. It is feasible that these individuals might have had zoster episodes before the age of 
65 years that were poorly captured in the historical GP data when these individuals 
registered with a new GP.  
9.2.4 Health inequalities and social determinants of zoster vaccine uptake 
What is already known on this topic? 
The national zoster immunisation programme was introduced in England on 1 September 
2013, which targeted individuals aged 70 years (routine cohort) with a catch-up cohort of older 
individuals aged ≤79 years. Vaccine uptake during first year of introduction (2013-2014) was 
~61% and gradually reduced to ~55% (2015-2016). The national data provide coverage 
information using aggregated GP data for gender with limited ethnicity data and coverage by 
deprivation at the general practice level (as an ecological factor). Uptake was reported to be 
lower amongst females for the period 2013-2015, and for individuals of most non-White 
ethnicities and those registered with general practices in more deprived areas (2014-2015). 
What this study adds 
In multivariable analyses, 36% lower zoster vaccine uptake was observed amongst individuals 
residing in care homes, 15% lower uptake amongst individuals living alone and 11% lower 
uptake amongst those in the catch-up cohort. In contrast to the national data, which utilised 
aggregated GP data, this study reported the association of social factors such as ethnicity and 
deprivation at an individual level. Lower vaccine uptake was observed amongst individuals of 
non-White ethnicity (for example, individuals of Black ethnicity had 39% lower uptake 
compared to individuals of White ethnicity)- confirming the findings of the previous analysis of 
national data. Conversely, immigration status was not associated with zoster vaccine uptake 
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after adjusting for ethnicity. Unlike the analysis of the national surveillance data that provided 
information on deprivation at the general practice level, this study  found decreasing vaccine 
uptake with increasing patient-level deprivation (p value for trend <0.0001) with 31% lower 
uptake amongst the most deprived patient-level IMD versus the least deprived IMD. Higher 
uptake (22%) was also observed for males in the catch-up cohort. Using the results of zoster 
burden analysis, it was possible to identify individuals with double inequalities (lower uptake 
and higher disease burden); two such groups identified included individuals residing in care 
homes and older females. 
Inadvertent zoster vaccination amongst individuals whilst they were immunosuppressed was 
observed for ~3% of the study population. This finding should be useful for increasing 
awareness amongst health care professionals about contraindications to the administration of 
this live vaccine. 
 
9.3 Strengths and limitations 
The strengths and weaknesses of the systematic review and of the three studies conducted 
to meet the other objectives of this thesis were comprehensively discussed in the specific 
chapters: Chapter 2 and Chapters 6-8, respectively. Here an overview of the strengths and 
limitations of this thesis are presented. 
9.3.1 Strengths 
9.3.1.1 Large primary care database linked to other data sources 
All three studies conducted to meet the study objectives utilised a primary care database: 
CPRD, which is one the world’s largest quality-assured databases and is broadly 
representative of the UK population. The large sample sizes of these studies were feasible 
owing to this large database, allowing reduction of random error with more accurate 
estimation of effect estimates. The use of CPRD also allowed for a good capture of zoster 
vaccination data, as the NHS zoster vaccination programme is delivered via primary care. 
There was sufficient power to study the association of multiple exposures with the outcome 
of interest and to include hypothesized mediating variables in the statistical models.  
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Using primary care data linked to hospitalisation data facilitated and improved assessment 
of socio-demographic factors, incident zoster (the outcome in the zoster burden analysis), 
co-morbidities and other covariates of interest. Similarly, linkage to deprivation data provided 
small area-level deprivation status for the study participants. The availability of long-term 
data for participants also allowed the exposure and co-morbidities to be time-updated.   
9.3.1.2 Conceptual frameworks and ascertainment of socio-demographic factors  
Pre-defined conceptual frameworks were used in all three observational studies and the 
systematic review, which facilitated the study of the inter-relationships between the main 
exposures, hypothesized mediating variables and the outcomes of interest. These 
frameworks were an adaptation of the conceptual framework proposed by the WHO’s 
Commission on Social Determinants of Health, which assesses the complex association of 
social determinants of health with health inequalities.4 Use of these pre-specified 
frameworks allowed hierarchical causal modelling, adjustment for confounding variables and 
appropriate interpretation of effect estimates. 
The details of the methodology developed to identify socio-demographic factors amongst 
older individuals in EHR were provided in Chapter 6. This methodology provides a resource 
for the research community for the assessment of inequalities amongst older individuals for 
different conditions and interventions. The development of code lists for socio-demographic 
factors utilised in this thesis was an iterative process that also utilised the hospitalisation 
data. This involved extensive use of codes across data sources including innovative use of 
“first language” codes to help identify immigration status. Time updating these factors, when 
appropriate, to minimise exposure misclassification and the comparison of recording of the 
socio-demographic factors in EHR with the standard national data (Census data) provided 
reassurance about the representativeness of some of these data.   
9.3.1.3 Study designs and analyses  
Suitable study designs, feasible in routinely collected data, were chosen to address the 
study objectives appropriately. To identify the social determinants of zoster disease burden 
and zoster vaccine uptake (objectives 3 and 4, respectively) cohort studies were used. Use 
of a cohort study design for identifying inequalities in zoster disease burden permitted the 
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assessment of incidence rates and incidence rate ratios. Similarly, a cross-sectional study 
design, which is an efficient way to assess the prevalence of social factors’ recording in the 
EHR (objective 2), was also utilised.  
The use of meta-analyses in the systematic review (Chapter 2) made it feasible to quantify 
the association of socio-demographic factors with vaccine uptake amongst older individuals 
and provided summary effect estimates (objective 1). For the zoster burden and vaccine 
uptake analyses, exposures of interest were mutually adjusted in multivariable analyses, for 
example inclusion of both ethnicity and immigration status in the models estimated the 
association of these two factors with the outcome of interest independent of each other. 
However, for other closely related socio-demographic factors, for example living alone and 
cohabitation (living as a couple), where collinearity issues precluded the simultaneous 
inclusion of these factors, sensitivity analyses with these individual factors allowed the 
ascertainment of their association with the outcome. It was also possible to study numerous 
hypothesized mediating variables (co-morbidities and immunosuppressive 
conditions/therapies in the burden study) and other covariates of interest (seasonal influenza 
vaccine uptake and past history of zoster) in the uptake study. Although unavailability of 
complete date of birth in the EHR (discussed in Chapter 3) precluded the estimation of 
person-time at risk for the vaccine uptake analyses, sensitivity analyses allowed for the 
ascertainment of time varying factors at both the start and end of the follow-up of the study.  
9.3.2 Limitations 
9.3.2.1 Information bias and misclassification  
The possibility of both non-differential and differential misclassification of the socio-
demographic factors and of the zoster episode or vaccination, and the implications of any 
misclassification, were discussed in detail in Chapters 6-8. Misclassification of exposures, 
outcomes and other covariates may occur in a number of ways in routinely collected EHR. 
This may occur due to coding errors, incomplete capture of some factors by healthcare 
personnel or may also be due to misdiagnoses of zoster or co-morbidities. It is also possible 
to misclassify time-varying factors if they are not updated in a timely way in these data. 
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Misclassification of the binary variables may also occur if the assumption that absence of 
codes indicate absence of those characteristics is incorrect. 
 If the misclassification of these factors was non-differential with respect to vaccine uptake or 
zoster incidence, this may have underestimated the effect estimates in this study. Although 
not investigated specifically for zoster, in general the validity of diagnostic codes in CPRD is 
reported to have a high positive predictive value;118 also as mentioned in the Introduction 
(Section 1.2.4) the positive predictive for the clinical diagnosis of zoster is reported to be 
high (91%-100%).50, 51 The use of these primary care data also maximises the ascertainment 
of zoster vaccination which is delivered through primary care. 
I will now highlight specific issues, previously discussed in Chapters 6-8, which are pertinent 
to the analyses conducted in this thesis. 
In the zoster burden analysis, ascertainment bias was feasible if zoster episodes were 
differentially assessed amongst individuals who might not come forward for clinical care, 
such as individuals from areas that are more deprived or those living alone. This differential 
misclassification could have led to underestimation of the zoster disease effect estimates in 
this thesis.  It is also feasible that some milder cases of zoster are not captured in these data 
and the association reported in this thesis are applicable to zoster cases severe enough to 
warrant a GP consultation. However, a previous US study has shown that older individuals 
with zoster are likely to seek medical advice irrespective of their social circumstances, 
minimising the possibility of differential misclassification.85 For both the zoster burden and 
vaccine uptake study, it was possible that individuals coming forward with zoster symptoms 
or for vaccination might be more likely to have their socio-demographic factors recorded, 
biasing the effect estimates for a factor for which an absence of code was treated as the 
absence of the characteristics (immigration status) or resulting in missing data and exclusion 
of the individual from multivariable analyses. Although in this thesis the recording of factors 
such as ethnicity, care home residence and living arrangements in the linked CPRD data 
were comparable to the prevalence recorded in the 2011 English Census data, factors such 
as immigration status, religion and marital status appeared to be under-ascertained. The 
effect of marital status could not be assessed for both burden and uptake analyses due to 
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missing data but results were available for other two closely related factors: living alone and 
cohabitation. 
 The association of immigration with burden of zoster (aRR 0.77 (0.67-0.88) versus non-
immigrants) could be biased due to under-ascertainment of immigration status in these data. 
However, if such misclassification was non-differential with respect to zoster risk, this would 
not explain the protective effect. I also tried to capture immigration status using the “first 
language” codes (as described in Section 6.4), which were included as GPs were 
incentivised to record first language spoken for all registered patients between 2008-
2011.138, 139 This could have led to preferential capture of immigrants who moved from non-
English speaking countries, a heterogeneous group, with varying age of acquiring primary 
infection and zoster risk. For the zoster vaccine uptake study, the lower odds of vaccine 
uptake in the minimally adjusted model amongst immigrants was attenuated after adjusting 
for other variables including ethnicity. As with the burden analyses, the lower uptake 
amongst immigrants observed in the minimally adjusted model could not be explained if the 
misclassification of immigration status was non-differential with respect to uptake. The 
attenuation after adjusting for ethnicity may have been due to confounding of the effect of 
immigration status by ethnicity, although the inability to detect an effect due to lack of power 
is also a possibility as there were only 1.4% (n=514) individuals were coded as immigrants 
for the primary analysis (Table 1 submitted paper Section 8.2).   
For defining the immunosuppressive period, I included a period of three months prior to the 
appearance of first code for immunosuppressive therapies in CPRD to account for coding 
delays based on the assumptions that these therapies were initiated in hospitals. This 
assumption may be incorrect for some individuals prescribed high doses of oral 
corticosteroids for conditions such as chronic obstructive pulmonary disease, which may be 
initiated by GPs. I could have therefore overestimated the proportion of individuals who were 
vaccinated during a period of immunosuppression. For the burden analyses, for which 
immunosuppressive agents were considered as potential mediators between socio-
demographic factors and zoster incidence, this misclassification could have resulted in 
attenuation of any mediating effect of immunosuppression on zoster incidence. Conversely, 
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for other immunosuppressive therapies given entirely in secondary care such as cancer 
radiotherapy, I might have underestimated periods of immunosuppression. 
Another limitation of using these data was the potential misclassification of individuals 
eligible for zoster vaccination due to unavailability of month of birth for adults. As detailed 
earlier in Section 8.6, it was possible that effect estimates in the primary analyses were 
underestimated due to the potential inclusion of some individuals born in the later part of 
2013-2014 and only followed-up for the first 5 months of the study period (September 2013- 
January 2014) who would not have been eligible for vaccination in 2013-2014. However, the 
secondary analysis of individuals who were followed-up for the entire study period (24 
months) revealed similar results to the primary analysis except that the lower uptake 
amongst non-White ethnicities was attenuated. Similarly, the person-time at risk for 
vaccination could not be ascertained due to the lack of availability of date of birth. As 
person-time at risk for vaccination could not be determined, to determine study participants 
eligible to receive the live zoster vaccine and to ascertain the status of other time-varying 
factors of interest, I chose the option of using immunosuppressive status and time-varying 
social factors at the start of follow-up. I chose this option based on the assumption that in 
this older group of individuals the changes in their sociodemographic and immune status 
was likely to small during the two-year study period. This assumption might not have been 
correct for some factors such as living alone or cohabitation or some individuals might have 
initiated immunosuppressive treatment during follow-up. Therefore, to assess the impact of 
misclassification resulting from these variables not being time updated during the 2-year 
study period, I reassessed effect estimates in sensitivity analyses based on the status of 
these factors at the end of follow-up (Table 3, submitted paper Section 8.2) . These 
sensitivity analyses did not reveal any appreciable differences from the main analysis.  
For defining individuals eligible for zoster vaccination, the other option that I could have used 
to reduce misclassification of immunosuppressive status was to exclude all individuals with 
immunosuppressive conditions/therapies code at any time during the follow-up to determine 
the number of people eligible for vaccination. As shown in S9 Table (supplementary material 
to the published paper, Section 8.3) out of the total study population (N=39120), 2818 
(7.2%) individuals had one or more code(s) for immunosuppressive condition(s) at some 
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time point during the follow-up. Of these 2818 participants, 1494 and 1835 individuals had 
one or more of these codes at start or end of follow-up, respectively. The number of 
individuals who had code(s) for these conditions only during the middle of follow-up was very 
small (n= 377).  
9.3.2.2 Selection bias and missing data  
The study population selected for all the studies conducted to meet this thesis’s objectives 
were derived from the CPRD, which is largely representative of the UK population.114 
Although all individuals meeting the eligibility criteria were included in the cohort studies 
(inequalities in zoster incidence and zoster vaccine uptake) conducted in this thesis, 
selection bias could have resulted by excluding individuals with missing data. Complete case 
analyses were used for the two cohort studies after excluding participants with missing data 
for ethnicity. This led to inclusion of ~83% (n=711,590) and ~89% (n=31,449) of study 
population in the primary analysis for the zoster burden study (objective 3, Chapter 7) and 
the zoster vaccine uptake study (objective 4, Chapter 8), respectively. The additional 
analyses conducted to assess the impact of missing data and the conclusions from these 
analyses were detailed for both burden and uptake cohort studies in Sections 7.4 and 8.4, 
respectively. Here I discuss some salient features of these analyses.  
For the burden analyses, it is feasible that complete case analyses might have under-
estimated the effect of living alone on zoster disease burden. Amongst the excluded group 
with missing ethnicity data, the minimally adjusted model (adjusted for age, gender and time) 
(Section 7.4.2) for the effect of living alone on zoster incidence revealed a slightly larger 
protective effect (aRR 0.85 (95%CI: 0.80-0.90) compared to the similar model from the 
complete case analyses (aRR 0.95 (95%CI: 0.93-0.97) and that from the total study 
population (aRR 0.93 (95%CI: 0.91-0.95).  
Similarly, in the zoster vaccine uptake study (as detailed in Section 8.4), there was evidence 
for lower uptake amongst men in the minimally adjusted model (adjusted for age) (Table 8-2, 
Section 8.4.2) in the group excluded from analyses due to missing ethnicity data. The effect 
of gender between the routine and catch-up cohort was assessed by adding an interaction 
term to the primary analysis (Table 8-3) which revealed that the higher uptake was confined 
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to men from the catch-up cohort with no effect in the routine cohort. The excluded group 
largely consisted of younger individuals from the routine cohort (70% versus 60% in the 
included group). The excluded group also had higher proportion (73%) of men from the 
routine cohort, who had lower uptake compared to women (Table 8-4). However, the finding 
of higher zoster vaccine uptake amongst older men (catch-up cohort) in the main analysis in 
this thesis also echoes the findings of the national surveillance data, which did not suffer 
from missing data as discussed previously in Section 8.4.3. 
Apart from the complete case analyses for dealing with missing data, I could have utilised 
multiple imputation. Imputing missing values is appropriate if the data are missing at 
random. However, I did not use this technique as the assumption of missing at random 
might not have been valid in these analyses, for example, lack of ethnicity recording could 
possibly be due to less health seeking behaviour with less contact with health services and 
thus less opportunity for vaccination. As an alternative to multiple imputation, I conducted 
series of sensitivity analyses to examine the effect of missing data on effect estimates. 
Finally, the association of factors such as religion and marital status with zoster incidence 
and vaccine uptake could not be examined owing to missing data. As mentioned before, it 
was feasible to look at the association of other factors closely related to marital status: 
cohabitation and living alone in both these analyses.  
9.3.2.3 Other factors 
The association of vaccine uptake with other social factors relevant at an individual level, 
identified in the WHO’s CSDH conceptual framework (Section 1.1.1), that were examined in 
the systematic review (Chapter 2) included education, income and social class. These 
social factors could not be assessed in the zoster vaccine uptake and burden analyses due 
to their unavailability in the linked CPRD data. 
Similarly, I could not examine the association of mediating behavioural factors (cultural 
factors, knowledge, beliefs and attitudes) with vaccination inequalities, as they were 
unavailable in these data.  These factors are likely to play a role in vaccine uptake in older 
populations, as has been shown for influenza vaccination.156, 158 Identification of these 
factors would have provided a more comprehensive picture about the social determinants of 
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vaccination inequalities and would allow better implementation of specific interventions. This 
would have also provided a better understanding of lower uptake amongst certain socio-
demographic groups such as care home residence or individuals living alone. For care 
homes, mediating factors at both individual- and care-home level need exploration. Co-
morbidities could also be potential mediators of the association between social 
characteristics and vaccine uptake or burden of disease. I examined certain co-morbidities, 
identified as risk factors for zoster in a previous study, as possible mediators for the 
association between socio-demographic factors with zoster burden, but they did not appear 
to explain the associations that were seen. Unlike influenza vaccine, there are currently no 
recommended clinical risk groups for targeting with the live zoster vaccine that would prompt 
GPs to offer the vaccine to individuals with specific co-morbidities. It is possible that, as 
individuals with co-morbidities are more likely to have repeated contacts with their GPs, this 
may have provided a window of opportunity for vaccinations.  However, this seems unlikely 
to explain some of the associations seen, such as the higher uptake in males compared to 
females in the catch-up cohort.   
9.3.2.4 Confounding 
Adjusted effect estimates could have residual confounding from misclassification of social 
factors that were acting as confounders of other factors- for example, as observed for the 
zoster vaccine uptake analyses, the association of immigration status (lower odds of uptake 
amongst immigrants) with zoster vaccine uptake observed in the minimally adjusted analysis 
(adjusted for age and gender, Section 8.2, Table 2) was attenuated after adjusting for 
ethnicity. It is therefore feasible that association observed between immigration and uptake 
could potentially have residual confounding if ethnicity was misclassified. Residual 
confounding could have also occurred from unmeasured social factors such as religion, 
education, or an individual’s income. 
9.3.2.5 Reverse causality 
In the zoster disease burden study, it is possible that some exposures might have resulted 
from the outcome, for example if individuals develop PHN, this may affect their social life, 
ability to work and eventually determine their socio-economic status. However, in this thesis 
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first zoster episode was defined as the outcome of interest and individuals with a past history 
of zoster were excluded from the analyses. Secondly, this may also be less likely in view of 
the study population consisting of older individuals, many of whom would have already 
retired from work. 
9.3.2.6 External validity  
The demographic group of interest for the aims and objectives of this thesis was the older 
UK population and therefore all studies conducted in this thesis incorporated older age as an 
eligibility criterion. In this thesis, the social determinants of the burden of a first zoster 
episode and zoster vaccine uptake were ascertained for individuals from England. The 
results are potentially generalizable to older individuals from countries with universal 
healthcare access and a national zoster vaccination programme as seen in the UK. The 
generalisability of equity-related outcomes is more likely if there is a biological basis for the 
association, as seen here for the burden analyses. For vaccine uptake, although knowledge 
and behavioural factors play a role, the findings from the vaccine uptake study are in 
keeping with the results from the systematic review (Chapter 2) which presented summary 
estimates for the association of socio-demographic factors with vaccine uptake in Europe. 
Therefore, the results of the uptake study are likely to be generalizable to other high income 
countries offering a national zoster vaccination programme via primary care with vaccination 
provided free-of-charge. 
9.4 Implications for public health and policy makers 
The rationale for using the socio-demographic factors identified from the systematic review 
of factors associated with vaccine uptake was to establish the role of double inequalities 
(9.4.1) i.e. are the factors associated with lower vaccine uptake also associated with higher 
disease burden? It could be argued that another systematic review examining socio-
demographic factors associated with vaccine-preventable disease burden could also have 
been undertaken. However, this thesis utilised the WHO’s comprehensive conceptual 
framework for the social determinants of health,4 and gathered all social factors information 
available in the CPRD data relevant for older individuals for the burden analyses.   
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The vaccination inequalities found to be present in England within the first two years of the 
introduction of the zoster immunisation programme should help public health professionals 
to target specific groups amongst older individuals to mitigate vaccination inequality, 
promote healthy ageing and ultimately contribute towards a higher and an equitable healthy 
life expectancy (1.1.2). 
Some social factors were poorly captured in the EHR and their association with zoster 
burden and vaccination could not be assessed in this thesis. Incentivisation of health care 
professional for recoding these factors play a role in completeness of recordings as was 
shown for ethnicity recording this thesis and a prior study.137 This could guide policy makers 
such as the sustainability and transformation partnerships to incentivise primary care 
providers for better recording of these factors and to also facilitate other data linkages for 
improving the health of older individuals by monitoring and striving towards health equality. 
9.4.1 The role of double inequalities 
As described in Section 8.7, the findings from this thesis should also help healthcare 
providers in identifying specific social groups with double inequalities (Table 8-8) i.e. 
individuals residing in care homes and older females. Specific interventions directed towards 
these groups can be implemented to reduce vaccination inequalities. 
9.5 Implications for future research 
9.5.1 Using electronic health records and future linkages 
This thesis provided the association of socio-demographic factors with first zoster episodes. 
Understanding about the social determinants of zoster could be further improved by also 
ascertaining the social determinants of PHN, an important sequela of zoster. This study 
question would be also helpful in informing the national zoster vaccination policy.  
Another important contribution of this thesis is the development of methodology for 
ascertainment of socio-demographic factors using EHR. The methodology could be also 
adapted for use in other countries using EHR and could be potentially extrapolated for use in 
younger age groups, pregnant women and other individuals in clinical risk groups. Identifying 
the social determinants of vaccine uptake amongst these population groups will also 
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enhance the understanding and provide a broad overview of health inequalities in the UK for 
appropriate interventions. The statistical methods developed as a part of thesis will be 
available to other researchers using CPRD and HES data and studying other conditions 
amongst older individuals.  These methods offer a significant opportunity in developing 
automated surveillance processes for generating ongoing cycle of inequality assessment i.e. 
identifying socio-demographic factors for vaccine preventable diseases, other chronic 
conditions and interventions. This should contribute towards achieving health equalities.  
The feasibility of future data linkages between primary care data, social care data and 
census data could be explored with appropriate data permissions. Such linkages will not 
only enhance the availability of biological factors but other social, behavioural and 
psychological factors that could not be examined in this thesis. The establishment of a 
national health and bioinformatics institute by the Medical Research council, Health Data 
Research UK to harness different data and research expertise available in the UK  is a 
positive step in this direction.159 
9.5.2 Other research questions  
The association of social factors such as education, social class and income with zoster 
disease burden and vaccine uptake could be also examined in future research using primary 
data collection.  The reasons for lower uptake amongst certain socio-demographic groups 
such as care home residents need further exploration for factors relevant at an individual 
level (for example, knowledge and attitudes towards vaccination) and at the care home-level 
(for example, attitudes of staff, vaccination policy implementation). Additionally, as discussed 
in Section 8.6, the social determinants of zoster vaccine uptake should be re-assessed as 
the vaccination programme continues to observe whether vaccination inequalities seen in 
the first two years of programme change.  
9.6 Personal development 
Conducting different studies as a part of this thesis has been an eventful journey. I found the 
systematic review and meta-analysis to be one of the most challenging task of this thesis. 
The diversity of study designs and finding an effective and meaningful way to summarise the 
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evidence so they made sense to the readers was an iterative process. This has helped me 
to develop necessary skills of project management, to conduct meta-analyses and quality 
assessments. Using routinely collected data for conducting three different observational 
studies not only improved my understanding of these data but has made me aware of some 
of the challenges in study design specific to these data sources.   
My data management skills, ability to use Stata® software, applying the principles of 
epidemiology that I learned during my MSc course to conduct well-designed studies and 
dealing with uncertainty have definitely improved during the course of this thesis. Presenting 
the findings of this research in various conferences and writing peer-reviewed papers have 
also improved my communication skills. Another difficult but an important lesson that I 
learned during this doctorate was from my two doctorate supervisors: “how to see the wood 
for the trees”, an expression used on numerous occasions in our meetings. 
These skills will undoubtedly help in my future career in Public Health and Medical 
Microbiology. 
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Appendix 1 2017-updated review: summary of the studies identified 
First Author  SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used 
for the SD) 
Effect estimates of vaccine 
uptake (estimates are odds 
ratios (95% confidence 
interval) unless specified 
Effect estimates adjusted for the following 
confounders 
Cross-sectional studies     
Bocquier92 Income 
 
SIV Income (individual level based on education class and income) (6)   
 Living arrangements  lowest level (0-1) 1 (adjusted risk ratio) Gender, age, living with a partner, type of 
residence area, and for whether the respondent 
answered him/herself or not. (Note effect 
estimates from model 1 which was not adjusted for 
chronic diseases) 
 Area of residence  2 1.01 (0.96-1.06)  
   3 1.05 (1.00-1.11) 
   4 1.08 (1.01-1.15) 
   5 1.05 (0.97-1.14) 
   highest level 6 1.06 (0.97-1.15) 
   Living arrangements (2)  
   Living with partner No  1 (adjusted risk ratio) 
   Living with partner Yes 1.10 (1.06-1.14) 
   Area of residence (2)  
   Rural 1 (adjusted risk ratio) 
   Urban 0.99 (0.96-1.03) 
 
Dominguez93 Education SIV Education (2)  Unadjusted 
 Relationship status  No/primary education 
 
1  
 Living arrangements  Secondary or higher 0.84 (0.61–1.16) (cOR)  
   Relationship status (4)   
   Married/Cohabiting 1 (aOR) Gender marital status living alone, number of GP 
visits, alcohol intake, influenza vaccine in last 3 
seasons, past pneumococcal vaccine uptake, level 
of dependence 
   Single 0.55 (0.31–0.98) 
   Widowed 1.10 (0.77–1.58) 
   Separated/Divorced 0.87 (0.36–2.11) 
   Living arrangements (2)   
   Lives alone 1 (aOR) 
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First Author  SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used 
for the SD) 
Effect estimates of vaccine 
uptake (estimates are odds 
ratios (95% confidence 
interval) unless specified 
Effect estimates adjusted for the following 
confounders 
   Lives with cohabitant 1.35 (0.88–2.07) 
Dominguez94 Education PV Education (3)  Unadjusted 
 Relationship status  No education 1 (cOR)  
 Living arrangements  Primary education 0.86 (0.60- 1.22)   
   Secondary or higher 0.66 (0.44-0.98)  
   Relationship status (4)   
   Married/Cohabiting 1(cOR)  
   Single 0.83 (0.46-1.51)  
   Widowed 0.97 (0.70-1.35)   
   Separated/Divorced 1.98 (0.47-8.26)   
   Living arrangements (2)   
   Lives alone 1(cOR)  
   Lives with cohabitant 1.16 (0.79-1.70)   
Fabiani95 COB SIV COB (2)  Sex, age, area of residence, educational level, 
occupational status, household composition, 
economic resources, and health services utilization 
index 
   Native 1 (aOR) 
   Immigrants 0.81 (0.68-0.97) 
Ganczak97 Area of residence SIV Area of residence (2)   
 Education  Rural 1 (aOR) Age, residence, co-morbidity, influenza vaccine 
information, family member vaccinated and 
willingness for vaccination  Income  Urban 7.69 (1.18-100) 
 Living arrangements  Education (2)   
   primary & secondary 1 (cOR) Unadjusted 
   vocational & university 1.21 (0.70-2.09)  
   Income (self-assessed) (2)   
   high 0.96 (0.55-1.69)  
   low 1 (cOR)  
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First Author  SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used 
for the SD) 
Effect estimates of vaccine 
uptake (estimates are odds 
ratios (95% confidence 
interval) unless specified 
Effect estimates adjusted for the following 
confounders 
   Living arrangements (2)   
   Not living alone 0.58 (0.33-1.02)  
   Living alone 1 (cOR)  
Gorska-
Ciebiada98 
Area of residence SIV Area of residence (2)   
Income  Rural 1 (cOR) Unadjusted 
 Relationship status  Urban 2.06 (1.31-3.24)  
 Education  Income (3)   
   High ((>2000 pln/person) 5.34 (2.38- 12.02) Income, comorbidity, health professional 
recommendation, anti-hyperglycemic medications 
   Medium Not reported 
   Low (<1000 pln/person) 1 
   Relationship status (2)   
   Single 0.99 (0.52-1.86) 
 
 
   Married 1 (cOR) Unadjusted 
   Education (4)   
   Primary 1 (cOR)  
   Secondary 1.54 (0.48-4.93)  
   Technical 1.43 (0.41-4.94)  
   University 3.18 (0.86-11.79)  
  PV Area of residence (2)   
   Rural 1 (cOR) Unadjusted as estimated from raw data 
   Urban 2.22 (0.63-7.87)  
   Income (3)    
   High (>2000 pln/person) 1.48 (0.36-6.07)  
   Medium (1000-2000 pln/person) 1.25 (0.33-4.80)  
   Low (<1000 pln/person) 1 (cOR)  
319 
 
First Author  SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used 
for the SD) 
Effect estimates of vaccine 
uptake (estimates are odds 
ratios (95% confidence 
interval) unless specified 
Effect estimates adjusted for the following 
confounders 
   Relationship status (2)    
   Single 1.28 (0.50-3.29)  
   Married 1 (cOR)  
   Education (4)    
   Primary 1 (cOR)  
   Secondary 1.11 (0.23-5.40)  
   Technical 1.15 (0.21-6.20)  
   University 0.36 (0.03-4.21)  
Hellfritzsch99 Relationship status SIV Relationship status (2)  Adjusted prevalence ratio of being married 
amongst vaccinated vs being married amongst 
unvaccinated=1.07(1.03–1.11); Adjusted 
prevalence ratio of being Alone/divorced/widowed 
amongst vaccinated vs being married amongst 
unvaccinated 0.83 (0.74–0.92) (adjusted for age 
and gender) 
 Education  Married/living with partner 1 (cOR) from raw data 
 Area of residence  Alone/divorced/widowed 0.87 (0.75-1.01) 
 Income  Education level beyond primary school (7)   No difference reported in adjuste  (ag  and
gender) prevalence ratios for education, residence 
and income    None 1 (cOR) from raw data 
   Skilled worker 1.19 (0.86-1.65)  
   Very short (courses) 0.98 (0.83-1.15)  
   Short (< 3 years) 0.82 (0.63-1.06)  
   Medium (3-4 years) 0.91 (0.72-1.14)  
   Long (>4 years) 1.17 (0.84-1.65)  
   Other 0.97 (0.73-1.28)  
   Area of residence (4)    
   Urban 1.15 (0.97-1.36)  
   Small town 1.06 (0.86-1.31)  
   Rural 1 (cOR) from raw data  
   Other 0.25 (0.06-1.10)  
   Annual household income (6)    
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First Author  SD examined  vaccine Definitions and categorisation of SD 
(Numbers in brackets indicate the number of categories used 
for the SD) 
Effect estimates of vaccine 
uptake (estimates are odds 
ratios (95% confidence 
interval) unless specified 
Effect estimates adjusted for the following 
confounders 
   <99,000 Danish Kroner/annum 1 (cOR) from raw data  
   100,000–149,000 Danish Kroner /annum 0.89 (0.64-1.25)  
   150,000–249,000 Danish Kroner /annum 1.07 (0.79-1.46)  
   250,000–374,000 Danish Kroner /annum 0.88 (0.63-1.22)  
   375,000–524,000 Danish Kroner /annum 0.72 (0.49-1.05)  
   >525,000 Danish Kroner /annum 1.01 (0.65-1.56)  
Ward82 Area-level SES HZ Area-level SES for GP practice (5)   
   Quintile 1 - least deprived 1 (cOR) from raw data  
   Quintile 2 0.90 (0.87-0.93) Unadjusted  
   Quintile 3 0.87 (0.84-0.90)  
   Quintile 4 0.73 (0.71-0.76)  
   Quintile 5- most deprived 0.66 (0.64-0.68)  
Cohort study      
Gallini96 Area-level SES SIV Area-level SES of individual’s municipality (3)   
   Lowest quartile 1.00 (0.96-1.04) adjusted risk 
ratio 
Age, gender, deprivation, co-morbidities and 
health resource use    2nd and 3rd quartile 1 
   Highest quartile 1.02 (0.97- 1.06)  
SD social determinants SIV seasonal influenza vaccine COB country of birth PV pneumococcal vaccine HZ herpes zoster SES socio-economic status CI confidence interval aOR adjusted odds ratio 
cOR unadjusted odds ratio pln Polish złoty 
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Appendix 2 Quality assessment details: 2017-updated review 
First author Selection bias  Outcome 
misclassification 
SD number 
Examined 
Which SD Exposure bias  Confounding bias Missing data bias Overadjustment 
Bocquier92 Low risk response 
rate 76.6% 
Low risk : Self-
reported SIV 
vaccine in last 12 
months  
3 Income/ wealth 
Living 
arrangements 
Residence 
Based on 3 variables 
education, income 
and occupation 
(interview self-
reported): Low risk 
 All 3 SD: Low risk as adjusted for 
year, gender, living with partner, 
area of residence 
Low risk: 0.5%  
missing data 
Low risk: as model 
without chronic 
disease provided 
Dominguez93 Unclear risk : 
response rate not 
available 
Low risk : from 
recent records  SIV  
vaccinations  
3 Education Self-reported and 
records: low risk 
Education: High risk as unadjusted  Low risk Low risk: as model 
without chronic 
disease provided 
    Marital status  Living arrangements and marital 
status adjusted for each other and 
unadjusted for any other level 1 
variable (adjusted for  gender marital 
status living alone, number of GP 
visits, alcohol intake, influenza 
vaccine in last 3 seasons, past 
pneumococcal vaccine uptake, level 
of dependence ) 
Unclear risk as 
not reported 
 
    Living 
arrangements 
    
Dominguez94 Unclear risk : 
response rate not 
available 
Low risk : from PV 
vaccination records 
3 Education Self-reported and 
records: low risk 
High risk as unadjusted  Low risk 0.5% 
missing 
Low risk: as 
unadjusted 
    Marital status   Low risk 0.6% 
missing 
 
    Living 
arrangements 
  Low risk 0.3% 
missing 
 
Fabiani95 Low risk: 82.5% 
overall response 
rate age specific 
response rate not 
available but as 
overall response 
rate is high so low 
risk 
Low risk : Self-
reported SIV 
vaccine in preceding 
season  
1 Country of birth (self-reported): Low 
risk 
Low risk adjusted for sex, age, area 
of residence, educational level, 
occupational status, household 
composition, economic resources, 
and health services utilization index 
Low risk none 
missing 
Low risk 
Ganczak97 Low risk: 92% 
response rate 
Low risk : Self-
reported SIV 
vaccine in preceding 
season  
4 Place of  
residence 
(self-reported): Low 
risk 
Residence: High risk as unadjusted 
for gender or another level 1 variable 
Low risk none 
missing 
High risk as 
adjusted for co-
morbidity 
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First author Selection bias  Outcome 
misclassification 
SD number 
Examined 
Which SD Exposure bias  Confounding bias Missing data bias Overadjustment 
    Education  Education: High risk as unadjusted   Low risk as 
unadjusted 
    Income  Income: High risk as unadjusted    
    Living 
arrangement 
 Living arrangements: High risk as 
unadjusted  
  
Gorska-Ciebiada98 Unclear risk: 
response rate not 
reported 
Low risk : Self-
reported SIV 
vaccine in preceding 
season & ever had 
PV vaccine 
4 Place of  
residence 
(self-reported): Low 
risk for both SIV & 
PV 
 SIV place of residence, education 
and marital status: High risk as 
unadjusted  
SIV income high risk as unadjusted 
for any other level 1 variable 
PV all 4 SD high risk as unadjusted 
Low risk none 
missing 
Low risk for both 
SIV & PV 
    Education    Low risk for both 
SIV & PV 
    Income    High risk as 
adjusted for co-
morbidity for SIV but 
low risk for PV 
    Marital status    Low risk for both 
SIV & PV 
Hellfritzsch99 Unclear risk: age 
specific response 
rate not reported 
(overall response 
rate=69%) 
Low risk :  SIV 
vaccine from 
records within 6 
months of 
answering 
questionnaire 
4 Place of  
residence 
(self-reported): Low 
risk 
 High risk as unadjusted  Low risk  Low risk as 
unadjusted 
    Education     
    Marital status     
    Income   High risk a 
missing for 35% 
 
Ward82 Low risk Low risk :  zoster  
vaccine from 
records  
1 Area-level SES Low risk records High risk as unadjusted  Low risk Low risk as not 
adjusted for co-
morbidity 
Gallini96 Low risk >70% were 
followed-up 
Low risk: recent 
records SIV 
vaccination 
1 Area-level SES Area SES (from 
records date not 
reported): Unclear 
risk 
Area SES: High risk as unadjusted 
for any level 1 variable (adjusted for 
age and gender, deprivation co-
morbidities, health resource use) 
Low risk: SD 
data available 
for all 
individuals 
High risk 
SD social determinants SIV seasonal influenza vaccine PV pneumococcal vaccine HZ herpes zoster SES socio-economic status 
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Appendix 3 Appendix Codelists: zoster and post herpetic neuralgia 
1. Zoster  
CPRD 
Medical code Read term 
390 Herpes zoster 
516 Shingles 
7331 Ramsey Hunt Syndrome 
8936 Ophthalmic herpes zoster infection 
14718 Herpes zoster with ophthalmic complication 
14793 Herpes zoster otitis externa 
18918 Herpes zoster ophthalmicus 
21069 Herpes zoster with unspecified complication 
21471 Herpes zoster NOS 
25320 Herpes zoster with dermatitis of eyelid 
27403 Geniculate herpes zoster 
27546 Herpes zoster with keratoconjunctivitis 
31681 Herpes zoster - otitis externa 
33810 Herpes zoster with other ophthalmic complication 
38531 Herpes zoster with other specified complication NOS 
39692 Polyneuropathy in herpes zoster 
43235 Herpes zoster with other specified complication 
44944 Herpes zoster with meningitis 
47375 Zoster encephalitis 
50537 Herpes zoster with other CNS complications 
51692 Encephalitis due to herpes zoster 
52126 Herpes zoster with other central nervous system complication 
52319 Disseminated zoster 
55940 Herpes zoster iridocyclitis 
57895 Herpes zoster meningitis 
62558 Infective otitis externa due to herpes zoster 
63739 Herpes zoster with other CNS complication NOS 
69405 Herpes zoster encephalitis 
70197 [X]Zoster without complications 
71464 Meningitis due to herpes zoster virus 
105157 Hutchinson's sign - herpes zoster involving nose tip 
HES 
ICD code ICD description 
B02 Herpes zoster 
B02.0 Zoster encephalitis 
B02.1 Zoster meningitus 
B02.3 Zoster ocular disease 
B02.7 Disseminated zoster 
B02.8 Zoster with other complications 
B02.9 Zoster without complications 
2. History of zoster codes (Post herpetic neuralgia) 
CPRD 
Medical code Read term 
1598 Post-herpetic neuralgia 
7584 Post-herpetic trigeminal neuralgia 
10223 Postherpetic neuralgia 
17180 Postzoster neuralgia 
31709 Postherpetic polyneuropathy 
11498 Postherpetic trigeminal neuralgia 
HES 
ICD code ICD description 
G53.0 Postherpectic neuralgia 
B02.2 Zoster with other nervous system involvement    
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Appendix 4 Codelist: ethnicity 
Medcode Readcode Readterm 
10196 9S...00 Ethnic groups (1991 census) 
22467 9S1..00 White 
12446 9S10.00 White British 
24837 9S11.00 White Irish 
12444 9S12.00 Other white ethnic group 
26467 9S13.00 White Scottish 
26310 9S14.00 Other white British ethnic group 
12632 9S2..00 Black Caribbean 
12778 9S3..00 Black African 
24339 9S4..00 Black, other, non-mixed origin 
12452 9S41.00 Black British 
57435 9S42.00 Black Caribbean/W.I./Guyana 
47950 9S42.11 Black Caribbean 
47997 9S42.12 Black West Indian 
32100 9S42.13 Black Guyana 
41329 9S43.00 Black N African/Arab/Iranian 
46812 9S43.11 Black North African 
57752 9S43.12 Black Arab 
50286 9S43.13 Black Iranian 
35412 9S44.00 Black - other African country 
47965 9S45.00 Black E Afric Asia/Indo-Caribb 
57753 9S45.11 Black East African Asian 
57763 9S45.12 Black Indo-Caribbean 
48005 9S46.00 Black Indian sub-continent 
35350 9S47.00 Black - other Asian 
26312 9S48.00 Black Black - other 
25676 9S5..00 Black - other, mixed 
25623 9S51.00 Other Black - Black/White orig 
32165 9S52.00 Other Black - Black/Asian orig 
12482 9S6..00 Indian 
24690 9S7..00 Pakistani 
24740 9S8..00 Bangladeshi 
24272 9S9..00 Chinese 
30280 9SA..00 Other ethnic non-mixed (NMO) 
32110 9SA1.00 Brit. ethnic minor. spec.(NMO) 
57764 9SA2.00 Brit. ethnic minor. unsp (NMO) 
54593 9SA3.00 Caribbean I./W.I./Guyana (NMO) 
57094 9SA3.11 Caribbean Island (NMO) 
57075 9SA3.12 West Indian (NMO) 
93144 9SA3.13 Guyana (NMO) 
24962 9SA4.00 N African Arab/Iranian (NMO) 
47285 9SA4.11 North African Arab (NMO) 
25082 9SA4.12 Iranian (NMO) 
47969 9SA5.00 Other African countries (NMO) 
38097 9SA6.00 E Afric Asian/Indo-Carib (NMO) 
46818 9SA6.11 East African Asian (NMO) 
99316 9SA6.12 Indo-Caribbean (NMO) 
39696 9SA7.00 Indian sub-continent (NMO) 
26379 9SA8.00 Other Asian (NMO) 
24270 9SA9.00 Irish (NMO) 
45947 9SAA.00 Greek/Greek Cypriot (NMO) 
45955 9SAA.11 Greek (NMO) 
47949 9SAA.12 Greek Cypriot (NMO) 
32066 9SAB.00 Turkish/Turkish Cypriot (NMO) 
32126 9SAB.11 Turkish (NMO) 
32069 9SAB.12 Turkish Cypriot (NMO) 
12633 9SAC.00 Other European (NMO) 
41214 9SAD.00 Other ethnic NEC (NMO) 
12696 9SB..00 Other ethnic, mixed origin 
47401 9SB1.00 Other ethnic, Black/White orig 
32401 9SB2.00 Other ethnic, Asian/White orig 
35459 9SB3.00 Other ethnic, mixed white orig 
32420 9SB4.00 Other ethnic, other mixed orig 
32425 9SB5.00 Black Caribbean and White 
32443 9SB6.00 Black African and White 
25411 9SC..00 Vietnamese 
12429 9SD..00 Ethnic group not given - patient refused 
24340 9SE..00 Ethnic group not recorded 
32136 9SG..00 Other black ethnic group 
12668 9SH..00 Other Asian ethnic group 
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Medcode Readcode Readterm 
47601 9SI..00 Irish traveller 
12757 9SJ..00 Other ethnic group 
45199 9SZ..00 Ethnic groups (census) NOS 
23955 9T...00 Ethnicity and other related nationality data 
45008 9T1..00 New Zealand ethnic groups 
57286 9T11.00 New Zealand European 
85509 9T11.11 Pakeha 
85505 9T12.00 Other European in New Zealand 
32479 9T13.00 New Zealand Maori 
64610 9T14.00 Samoan 
89910 9T15.00 Cook Island Maori 
60837 9T16.00 Tongan 
55584 9T17.00 Niuean 
25434 9T18.00 Tokelauan 
64609 9T19.00 Fijian 
46752 9T1A.00 Other Pacific ethnic group 
46649 9T1B.00 South East Asian 
12718 9T1C.00 Chinese 
25920 9T1D.00 Indian 
32396 9T1E.00 Other Asian 
96789 9T1Y.00 Other New Zealand ethnic group 
71425 9T1Z.00 New Zealand ethnic group NOS 
32781 9T2..00 Traveller - gypsy 
94487 9T3..00 Yemeni 
12435 9i...00 Ethnic category - 2001 census 
12351 9i0..00 British or mixed British - ethnic category 2001 census 
98111 9i00.00 White British - ethnic category 2001 census 
12532 9i1..00 Irish - ethnic category 2001 census 
98213 9i10.00 White Irish - ethnic category 2001 census 
12421 9i2..00 Other White background - ethnic category 2001 census 
12352 9i20.00 English - ethnic category 2001 census 
12436 9i21.00 Scottish - ethnic category 2001 census 
12681 9i22.00 Welsh - ethnic category 2001 census 
28887 9i23.00 Cornish - ethnic category 2001 census 
42294 9i24.00 Northern Irish - ethnic category 2001 census 
40102 9i25.00 Ulster Scots - ethnic category 2001 census 
32778 9i26.00 Cypriot (part not stated) - ethnic category 2001 census 
12355 9i27.00 Greek - ethnic category 2001 census 
12769 9i28.00 Greek Cypriot - ethnic category 2001 census 
12746 9i29.00 Turkish - ethnic category 2001 census 
32413 9i2A.00 Turkish Cypriot - ethnic category 2001 census 
12412 9i2B.00 Italian - ethnic category 2001 census 
55223 9i2C.00 Irish Traveller - ethnic category 2001 census 
55113 9i2D.00 Traveller - ethnic category 2001 census 
42290 9i2E.00 Gypsy/Romany - ethnic category 2001 census 
12467 9i2F.00 Polish - ethnic category 2001 census 
12433 9i2G.00 Baltic Estonian/Latvian/Lithuanian - ethn categ 2001 census 
28973 9i2H.00 Commonwealth (Russian) Indep States - ethn categ 2001 census 
26341 9i2J.00 Kosovan - ethnic category 2001 census 
25422 9i2K.00 Albanian - ethnic category 2001 census 
46956 9i2L.00 Bosnian - ethnic category 2001 census 
28866 9i2M.00 Croatian - ethnic category 2001 census 
47074 9i2N.00 Serbian - ethnic category 2001 census 
28936 9i2P.00 Other republics former Yugoslavia - ethnic categ 2001 census 
26391 9i2Q.00 Mixed Irish and other White - ethnic category 2001 census 
12402 9i2R.00 Oth White European/European unsp/Mixed European 2001 census 
28900 9i2S.00 Other mixed White - ethnic category 2001 census 
12591 9i2T.00 Other White or White unspecified ethnic category 2001 census 
12742 9i3..00 White and Black Caribbean - ethnic category 2001 census 
12437 9i4..00 White and Black African - ethnic category 2001 census 
12638 9i5..00 White and Asian - ethnic category 2001 census 
12873 9i6..00 Other Mixed background - ethnic category 2001 census 
12795 9i60.00 Black and Asian - ethnic category 2001 census 
49940 9i61.00 Black and Chinese - ethnic category 2001 census 
40110 9i62.00 Black and White - ethnic category 2001 census 
12706 9i63.00 Chinese and White - ethnic category 2001 census 
47005 9i64.00 Asian and Chinese - ethnic category 2001 census 
32408 9i65.00 Other Mixed or Mixed unspecified ethnic category 2001 census 
12414 9i7..00 Indian or British Indian - ethnic category 2001 census 
12460 9i8..00 Pakistani or British Pakistani - ethnic category 2001 census 
28888 9i9..00 Bangladeshi or British Bangladeshi - ethn categ 2001 census 
12513 9iA..00 Other Asian background - ethnic category 2001 census 
26392 9iA1.00 Punjabi - ethnic category 2001 census 
64133 9iA2.00 Kashmiri - ethnic category 2001 census 
47077 9iA3.00 East African Asian - ethnic category 2001 census 
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Medcode Readcode Readterm 
12608 9iA4.00 Sri Lankan - ethnic category 2001 census 
12760 9iA5.00 Tamil - ethnic category 2001 census 
12887 9iA6.00 Sinhalese - ethnic category 2001 census 
32399 9iA7.00 Caribbean Asian - ethnic category 2001 census 
12653 9iA8.00 British Asian - ethnic category 2001 census 
46056 9iA9.00 Mixed Asian - ethnic category 2001 census 
28935 9iAA.00 Other Asian or Asian unspecified ethnic category 2001 census 
12432 9iB..00 Caribbean - ethnic category 2001 census 
12350 9iC..00 African - ethnic category 2001 census 
32389 9iD..00 Other Black background - ethnic category 2001 census 
12443 9iD0.00 Somali - ethnic category 2001 census 
32886 9iD1.00 Nigerian - ethnic category 2001 census 
40097 9iD2.00 Black British - ethnic category 2001 census 
40096 9iD3.00 Mixed Black - ethnic category 2001 census 
46047 9iD4.00 Other Black or Black unspecified ethnic category 2001 census 
12468 9iE..00 Chinese - ethnic category 2001 census 
12434 9iF..00 Other - ethnic category 2001 census 
12719 9iF0.00 Vietnamese - ethnic category 2001 census 
12473 9iF1.00 Japanese - ethnic category 2001 census 
12420 9iF2.00 Filipino - ethnic category 2001 census 
12730 9iF3.00 Malaysian - ethnic category 2001 census 
63872 9iF4.00 Buddhist - ethnic category 2001 census 
56127 9iF5.00 Hindu - ethnic category 2001 census 
46063 9iF6.00 Jewish - ethnic category 2001 census 
47091 9iF7.00 Muslim - ethnic category 2001 census 
49658 9iF8.00 Sikh - ethnic category 2001 census 
46059 9iF9.00 Arab - ethnic category 2001 census 
47028 9iFA.00 North African - ethnic category 2001 census 
28909 9iFB.00 Mid East (excl Israeli, Iranian & Arab) - eth cat 2001 cens 
46964 9iFC.00 Israeli - ethnic category 2001 census 
25937 9iFD.00 Iranian - ethnic category 2001 census 
45964 9iFE.00 Kurdish - ethnic category 2001 census 
25451 9iFF.00 Moroccan - ethnic category 2001 census 
26246 9iFG.00 Latin American - ethnic category 2001 census 
12756 9iFH.00 South and Central American - ethnic category 2001 census 
32382 9iFJ.00 Mauritian/Seychellois/Maldivian/St Helena eth cat 2001census 
26455 9iFK.00 Any other group - ethnic category 2001 census 
12459 9iG..00 Ethnic category not stated - 2001 census 
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Appendix 5 Codelist: country of birth, immigration status and language codes 
Medcode Readcode Readterm 
4114 13ZC.00 Immigrant 
8929 ZV70314 [V]Immigration medical 
9144 13Z6800 Speaks English poorly 
9292 133L.00 Immigrant 
9627 13ZN.00 Asylum seeker 
11552 13e..00 Country of birth (Asian) 
12458 13gf.00 Born in South Africa 
12713 13eG.00 Born in Iraq 
22294 13lZ.00 Main spoken language Turkish 
23523 13Z6000 English as a second language 
24295 13Z6500 Language Punjabi 
24296 13Z6300 Language Hindi 
24403 13ZB.00 Refugee 
24691 13Z6600 Language Urdu 
24712 13Z6200 Language Gujurati 
24741 13Z6100 Language Bengali 
24881 13lC.00 Main spoken language Polish 
25007 13eH.00 Born in Israel 
25008 13go.00 Born in Zimbabwe 
25092 13eY.00 Born in Philippines 
25133 13gi.00 Born in Tanzania 
25256 13dl.00 Born in Yugoslavia 
25410 13b0.00 Vietnamese language 
25423 13lS.00 Main spoken language Albanian 
25472 13l2.00 Main spoken language Cantonese 
25609 13lx.00 Main spoken language Thai 
25616 13lp.00 Main spoken language Malayalam 
25632 ZV70516 [V]Refugee health examination 
25664 13gC.00 Born in Congo 
25665 13l5.00 Main spoken language French 
25730 13dM.00 Born in Kosovo 
25752 13dC.00 Born in England 
25802 13l1.00 Main spoken language Bengali 
25829 13lE.00 Main spoken language Punjabi 
25995 13eW.00 Born in Pakistan 
26078 13lP.00 Main spoken language Shona 
26196 13Z6400 Language Pashtu 
26247 13lH.00 Main spoken language Spanish 
26334 13eo.00 Born in Vietnam 
26335 13lb.00 Main spoken language Vietnamese 
26337 13l0.00 Main spoken language Arabic 
26361 13lL.00 Main spoken language Urdu 
26426 13eF.00 Born in Iran 
26463 13dA.00 Born in Czech Republic 
26464 13l3.00 Main spoken language Czech 
28301 13dP.00 Born in Lithuania 
28529 13eg.00 Born in Syria 
30224 13gY.00 Born in Niger 
30606 13f5.00 Born in Canada 
30800 13d..00 Country of birth (European) 
32053 13f..00 Country of birth (American) 
32055 13d0.00 Born in Albania 
32058 13e8.00 Born in China 
32060 13e0.00 Born in Afghanistan 
32061 13h0.00 Born in Australia 
32062 13jC.00 Born in Trinidad and Tobago 
32065 13db.00 Born in Scotland 
32067 13gJ.00 Born in Ghana 
32068 13gl.00 Born in Uganda 
32070 13eI.00 Born in Japan 
32072 13fL.00 Born in USA 
32074 13h1.00 Born in New Zealand 
32075 13f3.00 Born in Brazil 
32076 13j6.00 Born in Jamaica 
32079 13g0.00 Born in Algeria 
32080 13dH.00 Born in Greece 
32081 13dF.00 Born in France 
32082 13eD.00 Born in India 
32085 13dG.00 Born in Germany 
32089 13j2.00 Born in Barbados 
32090 13fN.00 Born in Venezuela 
32094 13dW.00 Born in Poland 
32097 13de.00 Born in Spain 
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Medcode Readcode Readterm 
32098 13df.00 Born in Sweden 
32099 13gM.00 Born in Ivory Coast 
32102 13g..00 Country of birth (African) 
32103 13di.00 Born in Ukraine 
32105 13dk.00 Born in Wales 
32108 13gV.00 Born in Morocco 
32111 13gZ.00 Born in Nigeria 
32112 13gN.00 Born in Kenya 
32113 13dK.00 Born in Ireland 
32114 13ek.00 Born in Turkey 
32115 13gS.00 Born in Malawi 
32116 13dL.00 Born in Italy 
32117 13dU.00 Born in Northern Ireland 
32119 13dc.00 Born in Slovakia 
32120 13fB.00 Born in Grenada 
32125 13e3.00 Born in Bangladesh 
32127 13eb.00 Born in Russia 
32128 13eM.00 Born in Kyrgyzstan 
32131 13j9.00 Born in St. Lucia 
32135 13ej.00 Born in Thailand 
32139 13dD.00 Born in Estonia 
32140 13gU.00 Born in Mauritius 
32144 13ec.00 Born in Saudi Arabia 
32150 13dh.00 Born in The Netherlands 
32157 13ed.00 Born in Singapore 
32158 13gG.00 Born in Ethiopia 
32160 13dX.00 Born in Portugal 
32162 13gW.00 Born in Mozambique 
32166 13fJ.00 Born in Peru 
32167 13g5.00 Born in Burundi 
32168 13gn.00 Born in Zambia 
32169 13d7.00 Born in Bulgaria 
32171 13eP.00 Born in Malaysia 
32173 13dE.00 Born in Finland 
32186 13dB.00 Born in Denmark 
32189 13ge.00 Born in Somalia 
32190 13d9.00 Born in Cyprus 
32197 13gd.00 Born in Sierra Leone 
32201 13fF.00 Born in Mexico 
32202 13e7.00 Born in Chechnya 
32207 13gI.00 Born in Gambia 
32217 13eT.00 Born in Nepal 
32220 13eC.00 Born in Hong Kong 
32233 13gX.00 Born in Namibia 
32237 13gP.00 Born in Liberia 
32242 13dN.00 Born in Latvia 
32245 13ef.00 Born in Sri Lanka 
32254 13e6.00 Born in Burma 
32255 13g7.00 Born in Cameroon 
32260 13g1.00 Born in Angola 
32273 13e2.00 Born in Bahrain 
32293 13k4.00 Born in Seychelles 
32301 13j0.00 Born in Antigua and Barbuda 
32303 13f7.00 Born in Columbia 
32304 13jB.00 Born in Togo 
32309 13gc.00 Born in Senegal 
32311 13f9.00 Born in Ecuador 
32313 13d2.00 Born in Austria 
32325 13f0.00 Born in Argentina 
32331 13ga.00 Born in Rwanda 
32333 13gE.00 Born in Egypt 
32342 13f4.00 Born in British Guyana 
32345 13dZ.00 Born in Romania 
32347 13gL.00 Born in Guinea Republic 
32352 13d4.00 Born in Belgium 
32361 13e1.00 Born in Armenia 
32369 13j4.00 Born in Dominican Republic 
32390 13eh.00 Born in Taiwan 
32397 13d6.00 Born in Bosnia - Herzegovnia 
32417 13k..00 Country of birth (Pacific) 
32427 13lF.00 Main spoken language Russian 
32456 13lG.00 Main spoken language Somali 
32688 13dI.00 Born in Hungary 
32728 13lD.00 Main spoken language Portuguese 
32741 13gk.00 Born in Tunisia 
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32776 13lB.00 Main spoken language Mandarin 
32807 13dg.00 Born in Switzerland 
36794 13gg.00 Born in Sudan 
36852 13lW.00 Main spoken language Japanese 
36862 13lt.00 Main spoken language Serbian 
36980 13lQ.00 Main spoken language Italian 
37197 13gR.00 Born in Madagascar 
38075 13fD.00 Born in Guyana 
38117 13gA.00 Born in Chad 
39974 13dS.00 Born in Moldavia 
41209 13gm.00 Born in Zaire 
41210 13d8.00 Born in Croatia 
41211 13eO.00 Born in Lebanon 
41213 13dV.00 Born in Norway 
41217 13eL.00 Born in Kuwait 
41228 13ee.00 Born in South Korea 
41230 13f2.00 Born in Bolivia 
41233 13d5.00 Born in Belorussia 
41280 13fE.00 Born in Honduras 
41289 13eE.00 Born in Indonesia 
41290 13j3.00 Born in Cuba 
41291 13f6.00 Born in Chile 
41292 13eK.00 Born in Kazakhstan 
41297 13eX.00 Born in Palestine 
41302 13el.00 Born in Turkmenistan 
41304 13dd.00 Born in Slovenia 
41311 13eJ.00 Born in Jordan 
41312 13dJ.00 Born in Iceland 
41316 13g3.00 Born in Botswana 
41318 13g2.00 Born in Benin 
41327 13h..00 Country of birth (Australasian) 
41337 13d3.00 Born in Azerbaijan 
41341 13gQ.00 Born in Libya 
41344 13ep.00 Born in Yemen 
41350 13gh.00 Born in Swaziland 
41351 13eS.00 Born in Mongolia 
41354 13e9.00 Born in Democratic People's Republic of Korea 
41356 13ea.00 Born in Republic of Korea 
41357 13dY.00 Born in Republic of Ireland 
41364 13dR.00 Born in Malta 
41365 13gK.00 Born in Guinea Bissau 
41367 13fM.00 Born in Uruguay 
41372 13em.00 Born in United Arab Emirates 
41399 13fI.00 Born in Paraguay 
41402 13en.00 Born in Uzbekistan 
42635 13k0.00 Born in Fiji 
42639 13eZ.00 Born in Qatar 
46014 13lN.00 Main spoken language Kurdish 
46029 13l8.00 Main spoken language Hindi 
46325 13lY.00 Main spoken language Lithuanian 
46861 13lK.00 Main spoken language Tamil 
46973 13ln.00 Main spoken language Lingala 
46974 13lV.00 Main spoken language Greek 
47007 13li.00 Main spoken language French Creole 
47029 13lO.00 Main spoken language Farsi 
47073 133Q.00 Family reunion immigrant 
47399 13n2.00 Reads Punjabi 
47400 13n9.00 Reads Cantonese 
47402 13n0.00 Reads Arabic 
47404 13n7.00 Reads Urdu 
47559 13k6.00 Born in Tonga 
47627 13lJ.00 Main spoken language Sylheti 
47628 13ld.00 Main spoken language Amharic 
47630 13lR.00 Main spoken language German 
47631 13lw.00 Main spoken language Tagalog 
47641 13lI.00 Main spoken language Swahili 
47643 13lu.00 Main spoken language Sinhala 
47644 13ly.00 Main spoken language Tigrinya 
47646 13lm.00 Main spoken language Igbo 
48002 13l6.00 Main spoken language Gujerati 
48029 6951.00 Immigration examination 
48297 13k5.00 Born in Solomon Islands 
49402 13eB.00 Born in Georgia 
49907 13j..00 Country of birth (Atlantic) 
51778 13eV.00 Born in Oman 
330 
 
Medcode Readcode Readterm 
52200 13b4.00 Mirpuri language 
52204 13nD.00 Reads Hindi 
52209 13n8.00 Reads Bengali 
54409 13lM.00 Main spoken language Yoruba 
54410 13lT.00 Main spoken language Croatian 
54413 13lc.00 Main spoken language Akan 
54414 13lf.00 Main spoken language Dutch 
54415 13lX.00 Main spoken language Korean 
54416 13l9.00 Main spoken language Iba 
54417 13lv.00 Main spoken language Swedish 
56879 13lh.00 Main spoken language Flemish 
57186 13eA.00 Born in East Timor 
57189 13k7.00 Born in Tuvalu 
57341 13nE.00 Reads Chinese 
57343 13n5.00 Reads Spanish 
57345 13n1.00 Reads Portuguese 
57462 13b3.00 Creole language 
57755 13ll.00 Main spoken language Hebrew 
57758 13lq.00 Main spoken language Norwegian 
58192 13j5.00 Born in Haiti 
58193 13l7.00 Main spoken language Hausa 
58525 13nC.00 Reads French 
58527 13g4.00 Born in Burkina Faso 
58528 13n3.00 Reads Russian 
58531 13n4.00 Reads Somali 
58533 13j1.00 Born in Bahamas 
58537 13nF.00 Reads Polish 
58552 13nA.00 Reads Czech 
58643 13lr.00 Main spoken language Pashto 
59657 13gH.00 Born in Gabon 
62298 13e5.00 Born in Brunei 
63923 13fH.00 Born in Panama 
63927 13gj.00 Born in The Gambia 
63932 13sA.00 English as a second language 
63943 13fA.00 Born in El Salvador 
64120 13k3.00 Born in Papua New Guinea 
64391 13lj.00 Main spoken language Gaelic 
64948 13ls.00 Main spoken language Patois 
64949 13gp.00 Born in Eritrea 
64984 13f8.00 Born in Costa Rica 
65310 13eR.00 Born in Mali 
65503 69D8.00 Exam. of refugee 
66551 13jA.00 Born in St. Vincent 
66553 13j8.00 Born in St. Kitts and Nevis 
66560 13eU.00 Born in North Korea 
66564 13nW.00 Reads Greek 
66565 13nR.00 Reads Italian 
66685 13la.00 Main spoken language Ukrainian 
66826 13n6.00 Reads Tamil 
68778 13nS.00 Reads German 
68866 13gD.00 Born in Djibouti 
69131 13dQ.00 Born in Luxembourg 
69135 13j7.00 Born in Puerto Rico 
69139 13lg.00 Main spoken language Ethiopian 
69143 13gT.00 Born in Mauritania 
69153 13lo.00 Main spoken language Luganda 
69426 13fK.00 Born in Suriname 
69431 13eN.00 Born in Laos 
69560 13g8.00 Born in Cape Verde Islands 
69806 13fC.00 Born in Guatemala 
71190 13dT.00 Born in Monaco 
72379 13lA.00 Main spoken language Kutchi 
74892 13fG.00 Born in Nicaragua 
90860 13nH.00 Reads Farsi 
90868 13nG.00 Reads Lithuanian 
91328 13eQ.00 Born in Maldives 
91419 13nY.00 Reads Turkish 
91420 13nQ.00 Reads Kurdish 
91422 13lk.00 Main spoken language Hakka 
91423 13nJ.00 Reads Chinese - Traditional 
93443 13nc.00 Reads Pashto 
93444 13nf.00 Reads Tigrinya 
93462 13nK.00 Reads Gujarati 
93569 13nX.00 Reads Japanese 
93697 13gO.00 Born in Lesotho 
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93893 13nh.00 Reads Burmese 
93923 13gF.00 Born in Equatorial Guinea 
93935 13d1.00 Born in Andorra 
94050 13f1.00 Born in Belize 
94072 13ng.00 Reads Bulgarian 
94906 13Zd.00 Failed asylum seeker 
95590 13nM.00 Reads Chinese - Simplified 
95593 13nV.00 Reads Croatian 
95708 13dO.00 Born in Liechtenstein 
95775 13nZ.00 Reads Vietnamese 
95897 13u0.00 Main spoken language Bulgarian 
95940 13ur.00 Main spoken language Latvian 
95968 13lT.11 Main spoken language Serbo-Croatian 
95969 13lt.11 Main spoken language Serbo-Croatian 
95970 13lO.11 Main spoken language Persian 
95974 13lu.11 Main spoken language Sinhalese 
95978 13w1.00 Main spoken language Nepali 
95985 13nm.00 Reads Malay 
96041 13ua.00 Main spoken language Hungarian 
96146 13uh.00 Main spoken language Irish 
96147 13lE.11 Main spoken language Panjabi 
96148 13u5.00 Main spoken language Afrikaans 
96152 13u1.00 Main spoken language Romanian 
96163 13wL.00 Main spoken language Telugu 
96223 13wR.00 Main spoken language Twi 
96230 13wG.00 Main spoken language Slovenian 
96240 13wD.00 Main spoken language Sindhi 
96267 13ux.00 Main spoken language Marathi 
96268 13uj.00 Main spoken language Kannada 
96289 13uN.00 Main spoken language Danish 
96290 13u6.00 Main spoken language Armenian 
96295 13t..00 Born in British overseas territory 
96296 13na.00 Reads Amharic 
96317 13w5.00 Main spoken language Quechua 
96370 13uv.00 Main spoken language Maltese 
96376 13uu.00 Main spoken language Malay 
96485 13le.00 Main spoken language Brawa 
96558 13wM.00 Main spoken language Tibetan 
96559 13uG.00 Main spoken language Burmese 
96560 13uT.00 Main spoken language Finnish 
96611 13us.00 Main spoken language Macedonian 
96634 13wN.00 Main spoken language Tongan 
96636 13g6.00 Born in Cambodia 
96784 13wT.00 Main spoken language Uzbek 
96805 13nj.00 Reads Indonesian 
96824 13dm.00 Born in former Yugoslav Republic of Macedonia 
96857 13u2.00 Main spoken language Oromo 
96858 13w2.00 Main spoken language Occitan 
96868 13u4.00 Main spoken language Afar 
96873 13wa.00 Main spoken language Zulu 
96877 13w..00 Supplemental main language spoken 
96928 13uQ.00 Main spoken language Estonian 
97015 13uk.00 Main spoken language Kashmiri 
97038 13uz.00 Main spoken language Mongolian 
97039 13wW.00 Main spoken language Wolof 
97041 13wQ.00 Main spoken language Turkmen 
97083 13u9.00 Main spoken language Azerbaijani 
97131 13wH.00 Main spoken language Sundanese 
97136 13no.00 Reads Ndebele 
97212 13uX.00 Main spoken language Georgian 
97273 13wX.00 Main spoken language Xhosa 
97274 13uc.00 Main spoken language Indonesian 
97297 13w3.00 Main spoken language Oriya 
97298 9NUC.11 Persian language interpreter needed 
97390 13e4.00 Born in Bhutan 
97439 13wB.00 Main spoken language Southern Sotho 
97440 13w6.00 Main spoken language Romansh 
97574 13uB.00 Main spoken language Basque 
97595 13ul.00 Main spoken language Kazakh 
97612 13v..00 Born French overseas region department collectivity territor 
97644 9NUz.00 Bulgarian language interpreter needed 
97685 13wP.00 Main spoken language Tsonga 
97789 13uP.00 Main spoken language Esperanto 
97997 13uK.00 Main spoken language Catalan 
98038 13t1.00 Born in Bermuda 
332 
 
Medcode Readcode Readterm 
98062 9Nmm.00 Burmese language interpreter needed 
98070 13uZ.00 Main spoken language Guarani 
98132 13up.00 Main spoken language Lao 
98194 13um.00 Main spoken language Kinyarwanda 
98215 13uy.00 Main spoken language Moldavian 
98228 13nN.00 Reads Swahili 
98229 13nn.00 Reads Mongolian 
98255 13uw.00 Main spoken language Maori 
98285 13w4.00 Main spoken language Filipino 
98369 13nP.00 Reads Yoruba 
98510 13uY.00 Main spoken language Kalaallisut 
98530 13da.00 Born in San Marino 
98604 13ub.00 Main spoken language Icelandic 
98762 13u8.00 Main spoken language Aymara 
98809 9NmQ.00 Hungarian language interpreter needed 
98841 9NUy.00 Romanian language interpreter needed 
98942 13nb.00 Reads Lingala 
99119 13dj.00 Born in Vatican City 
99258 13g9.00 Born in Central African Republic 
99431 13jD.00 Born in Dominica 
99712 13wS.00 Main spoken language Uighur 
99740 13nd.00 Reads Serbian 
99794 9Nn1.00 Tsonga language interpreter needed 
100007 13ei.00 Born in Tajikistan 
100010 13nT.00 Reads Albanian 
100011 13ui.00 Main spoken language Javanese 
100013 13uL.00 Main spoken language Slovak 
100438 9NmA.00 Macedonian language interpreter needed 
100517 13dn.00 Born in Serbia 
100707 13uR.00 Main spoken language Faeroese 
100714 13uS.00 Main spoken language Fijian 
100716 13ug.00 Main spoken language Inuktitut 
100743 13uW.00 Main spoken language Galician 
100759 9Nn7.00 Slovenian language interpreter needed 
100813 9NmM.00 Interlingue language interpreter needed 
100828 13uH.00 Main spoken language Belarusian 
100949 13uD.00 Main spoken language Bihari 
101038 13wb.00 Main spoken language Konkani 
101158 13gB.00 Born in Comoros Islands 
101189 13uJ.00 Main spoken language Central Khmer 
101220 13wA.00 Main spoken language Dari 
101284 9NnK.00 Nepali language interpreter needed 
101591 13gb.00 Born in Sao Tome and Principe 
101614 9Nn4.00 Telugu language interpreter needed 
101620 13ut.00 Main spoken language Malagasy 
101659 13ud.00 Main spoken language Interlingua 
101761 13l9.11 Main spoken language Iban 
101788 13uM.00 Main spoken language Corsican 
101814 9NUc.11 Punjabi language interpreter needed 
102007 13uY.11 Main spoken language Greenlandic 
102127 13uC.00 Main spoken language Dzongkha 
102128 13uF.00 Main spoken language Breton 
102129 13ue.00 Main spoken language Interlingue 
102184 13u3.00 Main spoken language Abkhazian 
102218 13u7.00 Main spoken language Assamese 
102259 13uA.00 Main spoken language Bashkir 
102877 13wC.00 Main spoken language Tswana 
103200 13uV.00 Main spoken language Frisian 
103219 13w7.00 Main spoken language Samoan 
103364 13v0.00 Born in Martinique 
103965 13k9.00 Born in Western Samoa 
104071 13uq.00 Main spoken language Bamun 
104123 13Zw.00 Has United Kingdom student visa 
104284 13ni.00 Reads Chechen 
104635 9NmC.00 Latvian language interpreter needed 
104678 9Nmx.00 Oromo language interpreter needed 
104886 13wE.00 Main spoken language Ndebele 
104901 9Nm6.00 Brawa language interpreter needed 
104983 13t2.00 Born in Anguilla 
105079 9Nmd.00 Catalan language interpreter needed 
105153 133A000 International student 
105523 13wV.00 Main spoken language Tetum 
105529 13wc.00 Main spoken language Aragonese 
105608 13nk.00 Reads Kinyarwanda 
105923 13t0.00 Born in Montserrat 
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105960 13wJ.00 Main spoken language Tajik 
107687 133A011 Overseas student 
108184 9Nn6.00 Turkmen language interpreter needed 
108271 13jE.00 Born in Aruba 
108936 13v7.00 Born in Guadeloupe 
109092 13ds.00 Born in Jersey 
109093 13dr.00 Born in Guernsey 
109226 13eq.00 Born in Christmas Island 
109260 13dq.00 Born in Republic of Moldova 
109276 13t5.00 Born in St Helena, Ascension and Tristan da Cunha 
109457 13do.00 Born in Montenegro 
109458 13jG.00 Born in Saint Vincent and the Grenadines 
109489 9NmE.00 Kinyarwanda language interpreter needed 
109727 13t3.00 Born in British Virgin Islands 
109791 13kB.00 Born in American Samoa 
109898 13dp.00 Born in Belarus 
109992 13gq.00 Born in Democratic Republic of Congo 
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Appendix 6 Codelist: religion 
Medcode Readcode Readterm 
2053 1357 Jehovah's Witness 
12477 1355 Jewish 
12622 135Y.00 Spiritualist 
12685 1358 Hindu 
19559 135D.00 Religion, none 
24263 1351 Church of England 
24268 1352 Roman Catholic 
24273 135S.00 Buddhist 
24297 135B.00 Sikh 
24341 1359 Islam 
24669 135A.00 Christian 
25594 135F.00 Baptist 
25996 1359.11 Muslim 
29954 1356 Christian Scientist 
31044 135J.00 Church of Scotland 
31585 135N.00 Plymouth Brethren 
39701 135M.00 Society of Friends 
39751 135G.00 Methodist 
39839 1354 Atheist 
46063 9iF6.00 Jewish - ethnic category 2001 Census 
47091 9iF7.00 Muslim - ethnic category 2001 Census 
47329 135W.00 Salvation Army 
47959 135K.00 Pentecostal 
47961 135L.00 Evangelical 
47962 135C.00 Mixed religion 
47968 135P.00 Agnostic 
47971 1351.11 Anglican 
47972 135I.00 Presbyterian 
47998 135d.00 Orthodox Christian 
47999 135V.00 Jainism 
48000 135H.00 United Reform Church 
49658 9iF8.00 Sikh - ethnic category 2001 Census 
50229 135T.00 Rastafarian 
52201 135O.00 Christadelphian 
56127 9iF5.00 Hindu - ethnic category 2001 Census 
57757 1353 Nonconformist 
58665 1359100 Sunni muslim 
63872 9iF4.00 Buddhist - ethnic category 2001 Census 
64041 1359000 Shiite muslim 
64056 135b.00 Pagan 
64057 135c.00 Mormon 
64058 135a.00 Moravian religion 
92227 135X.00 Eastern Catholic 
99738 13zA.00 Protestant 
100125 13zp.00 Church of England, follower of religion 
100433 13z2.00 Armenian Orthodox 
100435 13yH.00 Follower of Goddess tradition 
100497 13yX.00 Mennonite 
100522 13zJ.00 Church of Scotland, follower of religion 
100526 13yc.00 Seventh Day Adventist 
100536 13z6.00 Scottish Episcopalian 
100713 13yQ.00 Pure Land Buddhist 
100794 13zC.00 French Protestant 
100867 135l.00 African religion, follower of religion 
100951 135m.00 Yoruba, follower of religion 
101115 13zG.00 Lutheran 
101118 13yB.00 Ancestral worship 
101144 135z.00 New age practitioner 
101384 13zi.00 Orthodox Jew 
101650 135i.00 Baha'i 
101828 13z5.00 Ukrainian Catholic 
101837 13yP.00 Zen Buddhist 
101856 13z3.00 Greek Orthodox 
101905 13y8.00 Black magic 
102123 135x.00 Native American religion, follower of religion 
102124 13z9.00 Catholic: non Roman Catholic 
102238 13yi.00 Judaic Christian 
102253 135v.00 Radha Soami 
102459 13zE.00 Follower of United Reformed Church 
102498 13yD.00 Wiccan 
102646 135e.00 Shinto 
102697 13yy.00 Romanian Orthodox 
102902 13zF.00 Quaker 
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102956 13za.00 Sanatana Dharma 
102991 13zd.00 Shakti Hindu 
103060 135j.00 Druze 
103225 135t.00 Satanist 
103376 13y5.00 Chondogyo 
103692 13ys.00 Russian Orthodox 
103742 13yH.11 Goddess 
103845 13y3.00 Humanist 
103929 13zD.00 Free Church of Scotland 
104111 13z1.00 Bulgarian Orthodox 
104329 135v.11 Sant Mat 
104723 13zH.00 Congregationalist 
104737 13zl.00 Ashkenazi Jew 
104893 13yl.00 Christian Existentialist 
104965 13ze.00 Smarta Hindu 
105120 135w.00 Pantheist 
105407 13y4.00 Deist 
105517 13yF.00 Occultist 
105548 13y1.00 Kabbalist 
105874 135q.00 Taoist 
106119 135p.00 Unitarian Universalist 
106797 13yt.00 Ethiopian Orthodox Tewahedo 
107174 135Z.11 Rastafarian 
107288 13yh.00 Messianic Jew 
107636 13zP.00 Reformed Christian 
107810 13yv.00 Ukrainian Orthodox 
107871 13yG.00 Heathen 
107962 13zh.00 Reform Jew 
108011 135k.00 Ahmadi 
108014 13ym.00 Celtic Christian 
108015 13yj.00 Christian Spiritualist 
108066 13yZ.00 Free Church 
108225 13yC.00 Zoroastrian 
108497 13zg.00 Arya Samaj Hindu 
108571 13yn.00 Celtic Orthodox Christian 
109080 13yN.00 Mahayana Buddhist 
109590 13z8.00 Church in Wales 
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Appendix 7 Codelist: residence 
Medcode Readcode Readterm 
1123 13HQ.00 In prison 
2562 13D..11 Homeless 
6855 9491.00 Patient died at home 
6859 9N1F.00 Seen in warden sup home 
6991 9493.00 Patient died in nursing home 
7101 9N1F.12 Seen in old people's home 
7653 9N1G.00 Seen in nursing home 
10120 9N1C.00 Seen in own home 
10993 ZLG4.00 Discharge to nursing home 
11419 13F7200 Lives in an old peoples home 
11504 ZU33200 Lives with daughter 
11949 13F4.00 Warden attended 
12798 ZU33600 Lives with father 
12807 ZU33100 Lives with children 
13355 13F1.00 Independant housing, not alone 
13357 13F3.00 Lives alone -no help available 
13358 13FH.00 Lives with relatives 
13359 13F6100 Lives in a nursing home 
13360 13F6.00 Nursing/other home 
13361 13F4.11 Lives in warden controlled accommodation 
13562 ZV70317 [V]Old age home admission medical 
15691 13F3100 Lives alone needs housekeeper 
15700 13JS.00 Works away from home 
15840 13F7100 Lives in a welfare home 
17279 13FH000 Elderly relative lives with family 
18291 13EC.00 House in poor repair 
19610 13FJ.00 Independent housing, lives alone 
21280 13F5200 Resident in part III accomodation 
22503 ZU33300 Lives with son 
24494 ZV60600 [V]Institution resident 
24756 13KD.00 Owner-occupier 
24815 13K8.00 House rented from council 
24816 Z177C00 Residential care 
24828 Z177F00 Nursing home care 
24910 13KA.00 House rented-private landlord 
24956 13FK.00 Lives in a residential home 
25143 13K6.00 Houseowner - no mortgage 
25452 13D2.00 Homeless single person 
26177 8He0.00 Referral to intermediate care - hospital at home 
26720 13FB.00 Living in lodgings 
26812 9494.00 Patient died in resid.inst.NOS 
27360 13F5100 Part III accomodation arranged 
27425 13F5.00 Part III accommodation 
27936 8HE6.00 Delayed discharge to nursing home 
27968 13F7.00 Residential institution 
28448 ZU33500 Lives with mother 
28773 ZV60700 [V]Sheltered housing 
30200 ZV60611 [V]Boarding school resident 
30807 13F4000 Resident in sheltered accommodation 
31385 13F8100 Long stay hospital inpatient 
31678 13EF.00 Divorced couple sharing house 
31951 13F9.00 Living in hostel 
32448 13EH100 Harrassment by landlord 
32753 13D3.11 Tramp 
32774 13D1.00 Homeless family 
33006 1311.11 Homemaker 
33153 1312.00 House husband 
33994 ZW63200 Staying with carer 
34506 13FL.00 Living rough 
34794 13F9.11 Living in sheltered accomodatn 
35040 ZLG5.00 Discharge to sheltered housing 
35172 9N1E.00 Seen in warden sup flat 
35187 9N1D.00 Seen in warden sup house 
35279 9N1H.00 Seen in Elderly Mentaly Infirm home 
35716 13FA.00 Living in B&B accommodation 
36096 13F5.11 Part 3 accomodation 
36730 Z37C.00 Provision of special residential school 
36809 ZU33.00 Lives with family 
36905 ZLG5100 Discharge to warden controlled accommodation 
36968 ZU33400 Lives with parents 
37829 U195100 [X]Victim of volcanic eruption occurrn in resident instit'n 
39311 9492.00 Patient died in part 3 accom. 
39685 13K7.00 Houseowner with mortgage 
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40822 ZU33700 Lives with grandparents 
41188 13FC.11 Lives in a bedsit 
41388 13D5.00 Vagrant 
41986 699Z.00 Exam. for institution NOS 
42191 ZLG3.00 Discharge to residential home 
42533 ZU26100 Number of dependants in household 
42654 ZU35.00 Lives with companion 
43057 13FG.00 Squatter 
43393 ZU33800 Lives with grandfather 
43709 ZV70H00 [V]Examination for admission to residential institutions 
43911 ZU33900 Lives with grandmother 
43915 ZLG4100 Discharge to private nursing home 
44053 699..00 Examination for institution 
45650 T704.00 Place of occurrence of accident/poisoning, residential house 
46222 T774.00 Place of occurrence of accident/poisoning, old people's home 
46303 U10z100 [X]Unspecified fall, occurrence in residential institution 
46588 13K9.00 House rented from housing ass. 
46642 9b79.00 Other residential care homes managed by local authority 
47577 ZW63100 Living with carer 
47591 13FS.00 Long stay hospital inpatient 
47609 T77..00 Place of accident or poisoning, residential institution 
47685 ZV6y200 [V]Other boarder in health-care facility 
48549 ZLG3100 Discharge to private residential home 
48733 U198100 [X]Victim of flood, occurrence in residential institution 
48805 U120100 [X]Hit struck kick twist bit/scratch anoth pers resid instit 
48932 U125100 [X]Bitten/struck by oth mammal occurrn in resident instit'n 
49138 ZV63212 [V]Delayed discharge - nursing home vacancy awaited 
49210 U101100 [X]Fall same level from slip trip + stumb occ resid instit 
49681 13FX.00 Lives in care home 
50206 8O0A.00 Provision of special residential school 
50792 9N1F.11 Seen in Part 3 accomodation 
51193 ZU32.00 Lives with friends 
51495 13FC.00 Living in bedsitter 
51851 U104100 [X]Fall whle carried/supported oth persons occ resid instit 
52249 13FQ.00 Lives on council site 
52466 U10A100 [X]Fall on + from stair + step occurrnce resident instit'n 
52682 6992.00 Prison medical examination 
52881 U291.00 [X]Intent self harm by sharp object occ resident instit'n 
53140 Z177D00 Local authority residential care 
53600 U12A100 [X]Contct wth plant thorn+spine+sharp leave occ resid instit 
54260 U3F1.00 [X]Assault by blunt object occurrn in resident institution 
54735 13EC.11 Slum housing 
54948 ZLG5200 Discharge to part III accommodation 
55276 ZU37.00 Lives in a community 
56326 U3K1.00 [X]Assault by bodily force occurrn in residential institut'n 
56969 T77z.00 Accident/poisoning occurred in residential institution NOS 
57438 ZU32100 Lives with friend 
59330 T776.00 Place of occurrence of accident or poisoning, prison 
59523 13D3.12 Vagabond 
59548 13FT.00 Lives in an old peoples home 
59653 6991.00 Geriatric home admission exam. 
60404 U221.00 [X]Intent self harm by drowning/submersn occ resid instit'n 
60684 U2A1.00 [X]Intent self harm by blunt object occ resident instit'n 
61385 9b1C.00 Hospice - independent 
62522 U3z1.00 [X]Assault by unspecified means occurrn resident institut'n 
64410 U211.00 [X]Intent self harm by hangng strangult/suffoct resid instit 
65445 13FP.00 Lives on private site 
66122 13F5111 Part 3 accomodation arranged 
66599 U152100 [X]Exposure to unspecif electric current occ resid instit'n 
66656 U128100 [X]Bitten/struck by crocodil/alligatr occ in resid instit'n 
66922 U108100 [X]Fall involv other furniture occurrn resident institut'n 
67112 9k6..00 Homeless - enhanced services administration 
67187 13FM.00 Sleeping in night shelter 
67586 U241.00 [X]Int self harm rifl s'gun/lrg frarm disch occ resid instit 
67903 U105100 [X]Fall involvng wheelchair occurrence residential instit'n 
67930 13FG.11 Illegal tennant 
68005 13FV.00 Lives in a welfare home 
69028 ZLG3200 Discharge to part III residential home 
69762 U106100 [X]Fall involving bed occurrence in residential institution 
70021 ZU36.00 Lives as companion 
70848 13FW.00 Living in temporary housing 
71663 ZU37200 Lives in boarding school 
72474 U10J100 [X]Other fall on same level, occurrnce in resident instit'n 
72716 U143100 [X]Inhalation of gastric contents occurrn resident instit'n 
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72838 13FR.00 Lives on unofficial site 
73083 9b0Y.00 Nursing home visit note 
73101 U3L1.00 [X]Sexual assault by bodily force occurrn resident instit'n 
73177 ZLG6100 Discharge to long stay hospital 
73321 9b1P.00 Nursing home 
87882 U2y1.00 [X]Intent self harm by oth specif means occ resid instit'n 
90547 ZU34.00 Lives with lodger 
91941 U11Q100 [X]Foreign body enter into/thr eye/natrl orif, resid instit 
92265 U197100 [X]Victim of cataclysmic storm occurrn in resident instit'n 
92315 U3y1.00 [X]Assault by oth specif means occurrn resident institution 
93837 U2C1.00 [X]Int self harm jump/lying befr mov obje occ resid instit'n 
93865 U11H100 [X]Explosn+ruptur of pressr tyre pipe/hose occ resid instit 
93998 9b0i.00 Residential home visit note 
94070 8O24.00 Provision of continuing care in nursing home 
95555 ZU37300 Lives in a commune 
95661 U116100 [X]Contact wth knife sword/dagger occurrn in resid instit'n 
95880 13It.00 Lives with grandmother 
96605 9k60.00 Homeless - enhanced service completed 
96663 U112100 [X]Strikng against/struck by other object occ in resid inst 
97138 13Is.00 Lives with grandfather 
97757 13D7.00 Sofa surfer - person of no fixed abode 
99091 U122100 [X]Crush push/step on by crowd/humn stampede occ resid inst 
99110 U10F100 [X]Fall from cliff, occurrence in residential institution 
99120 U193100 [X]Victim of lightning, occurrn in residential institution 
99148 9b7A.00 Other residential care home man voluntary/private agents 
99453 U156100 [X]Expos unspecif type of radiatn occurrn resident instit'n 
99598 U114100 [X]Contact with lifting+transmissn dev NEC occ resid instit 
99907 ZV60011 [V]Hobo 
100246 ZVu5700 [X]Other boarder in health care facility 
100389 U321.00 [X]Assault by pesticides occurrn in residential institution 
100710 U10D100 [X]Fall from out of/thro buildng/struct occ resid instit'n 
101003 9NFR.00 Home visit request by residential institution 
101078 949D.00 Patient died in care home 
101400 13Zr.00 Lives with immunocompromised person 
102230 M270100 Nursing home acquired pressure ulcer 
102493 8Ht..00 Admission to nursing home 
103138 U3E1.00 [X]Assault by sharp object occurrn in resident institution 
103285 9b70.00 Client's or patient's home 
103461 133c.00 Hospital at home patient 
103510 ZV60014 [V]Tramp 
103553 ZU37100 Lives in a school community 
104962 13D8.00 Length of time homeless 
105063 U127100 [X]Bittn/stung by nven insct+oth nven arthrop occ resid inst 
106027 13KD.11 Lives in own home 
106285 U126100 [X]Contact wth marine animal occurrn in resident institut'n 
106972 13IZ000 Lives with adoptive parents 
107072 U144100 [X]Inhal+ingest food caus obst resp tract occ resid instit'n 
107393 9Ngr.00 Under care of homeless advocacy service 
107733 13IZ200 Lives with biological parents 
107757 9NFW.00 Care home visit 
107809 918F200 Lives with carer 
107927 U1B4100 [X]Lack of water, occurrence in residential institution 
108702 13D6.00 Lives in squat 
109437 TD17200 Accident due to fall from burning convalescent home 
109673 13IZ100 Lives with biological parent and step parent 
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Appendix 8 Codelist: cohabitation 
Medcode Readcode Readterm 
333 13H4200 Marital conflict 
723 13H4.12 Marital stress 
954 13H4100 Marital breakdown 
1349 13H4.00 Marital problems 
1540 13H4212 Marital disharmony 
1580 1332.11 Remarried 
3321 SN56300 Battered wife 
3394 13W9.00 Single parent family 
3483 13HD.00 Violent spouse 
3551 13H4211 Marital discord 
3719 13L6.00 Spouse unwell 
3988 1332.00 Married 
4565 6741.00 Marital counselling 
4925 1333.13 Wife left home 
5055 1333.12 Husband left home 
7419 1332.12 Newly wed 
7869 13H1.00 Marriage 
8470 13IL100 Wife pregnant 
9551 ZV61100 [V]Marital problems 
9612 1311.00 Housewife 
10330 13L3.11 Alcoholic spouse 
11103 1331.11 Single - unmarried 
13001 6123.00 No partner at present 
15115 13HH.15 Looks after chronically sick spouse 
15313 13H4300 Maladjustment to married life 
15404 13L3.13 Husband alcoholic 
15777 13HV311 Spouse committed infidelity 
15824 13L1.11 Disabled spouse 
15950 13H5.12 Spouse returned home 
16262 13H6.11 Unmarried parent 
16315 133G.00 Common-law husband 
16344 8C81.12 Artificial insemin by husband 
16552 13HH.13 Looks after chronically sick husband 
17538 13IL300 Wife alive 
20079 13H6.00 Single parent 
20149 13HH.16 Looks after chronically sick wife 
21346 8C92.00 Spouse reassured 
21433 13HV313 Husband committed adultery 
21860 13IL.00 Health of spouse 
21925 13HV400 Seven year itch - marital 
23385 13FD100 Spouse cannot care for patient 
23508 SN56400 Battered husband 
23514 13HT114 Wife unable to cope 
23974 13IL200 Wife well 
24769 13I7100 Husband in prison 
25149 13W9011 Single parent family - mother 
25452 13D2.00 Homeless single person 
25503 1336.00 Cohabiting 
27385 1333.11 Separated from cohabitee 
29543 13H5.00 Marital reconciliation 
29544 13H4.11 Marital trouble 
30597 ZV26500 [V]Artificial insemination from husband 
30950 13H4213 Row with wife 
31678 13EF.00 Divorced couple sharing house 
32984 1F81.00 Spouse cooks food 
33001 131..11 Occupation of husband 
33153 1312.00 House husband 
34771 13HV.00 Extra-marital problems 
36077 131..00 Occupation of spouse 
36333 ZLB4.00 Seen by marriage guidance counsellor 
37113 U3M0.00 [X]Neglect and abandonment, by spouse or partner 
37265 1331.00 Single 
37551 13HVZ00 Extra-marital problems NOS 
38325 13H5.11 Cohabitee returned 
39292 131..12 Occupation of wife 
39474 9NA8.00 Cohabitee made appointment 
39651 13HV300 Spouse committed adultery 
39879 13HV314 Oil rig wives syndrome 
41203 13L1200 Spouse is handicapped 
42321 13H4311 Spouse unsympathetic 
42386 133H.00 Common-law wife 
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42398 13I7200 Spouse arrested 
42400 13HV312 Wife committed adultery 
42402 13WE.00 Spouse works away from home 
42428 1333.14 Cohabitee left home 
50149 13W7000 Crime against spouse 
54096 131Z.00 Occupation of spouse NOS 
54816 13H4312 Spouse inattentive 
59817 9d31.00 Husband 
59829 9d32.00 Wife 
60723 918j.00 Partner is informal carer 
63118 1276.11 Spouse haemophiliac 
88373 133S.00 Married/civil partner 
95101 9d30.00 Spouse 
98130 9d33.00 Cohabitee 
104879 133e.00 Common law partnership 
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Appendix 9 Codelist: marital status 
Medcode Readcode Readterm 
207 13M1.00 Death of spouse 
333 13H4200 Marital conflict 
723 13H4.12 Marital stress 
838 13H3000 Divorce proceedings 
954 13H4100 Marital breakdown 
1328 6124.00 Partner had vasectomy 
1349 13H4.00 Marital problems 
1522 1334.00 Divorced 
1540 13H4212 Marital disharmony 
1580 1332.11 Remarried 
2093 13H2.00 Separation 
2159 13H3100 Divorce proceedings pending 
3111 13HP100 Girlfriend relationship problem 
3321 SN56300 Battered wife 
3394 13W9.00 Single parent family 
3483 13HD.00 Violent spouse 
3551 13H4211 Marital discord 
3719 13L6.00 Spouse unwell 
3988 1332.00 Married 
4204 1333.00 Separated 
4312 1335.00 Widowed 
4531 13HP000 Boyfriend relationship problem 
4565 6741.00 Marital counselling 
4925 1333.13 Wife left home 
5055 1333.12 Husband left home 
6056 13H3.00 Divorce 
6104 13HP.00 Relationship problems 
7419 1332.12 Newly wed 
7869 13H1.00 Marriage 
8470 13IL100 Wife pregnant 
9112 13HX.00 New relationship 
9551 ZV61100 [V]Marital problems 
9612 1311.00 Housewife 
9910 13H3.11 Divorce problems 
10330 13L3.11 Alcoholic spouse 
11103 1331.11 Single - unmarried 
11251 13MG.00 Death of wife 
12076 ZU14111 Husband died 
12325 ZU14100 Death of husband 
13001 6123.00 No partner at present 
15020 13HG.11 Spouse left home 
15115 13HH.15 Looks after chronically sick spouse 
15313 13H4300 Maladjustment to married life 
15404 13L3.13 Husband alcoholic 
15527 133C.00 Widower 
15777 13HV311 Spouse committed infidelity 
15824 13L1.11 Disabled spouse 
15950 13H5.12 Spouse returned home 
16262 13H6.11 Unmarried parent 
16315 133G.00 Common-law husband 
16344 8C81.12 Artificial insemin by husband 
16552 13HH.13 Looks after chronically sick husband 
17538 13IL300 Wife alive 
17802 13MH.00 Husband died 
20079 13H6.00 Single parent 
20149 13HH.16 Looks after chronically sick wife 
20217 13HM.11 Legal problem with separation 
20313 13HM.12 Legal problem with divorce 
20536 13HV100 Affair ended 
21346 8C92.00 Spouse reassured 
21433 13HV313 Husband committed adultery 
21860 13IL.00 Health of spouse 
21925 13HV400 Seven year itch - marital 
22336 13L6.11 Has infirm partner 
22909 13JK.13 Partnership problems 
22934 6124.11 Partner sterilised 
23385 13FD100 Spouse cannot care for patient 
23409 13HV000 Affair started 
23445 13HV200 Affair unsatisfactory 
23508 SN56400 Battered husband 
23514 13HT114 Wife unable to cope 
23858 ZV61011 [V]Divorce 
23974 13IL200 Wife well 
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24055 13HG.00 Broken with partner 
24769 13I7100 Husband in prison 
25097 13MI.00 Death of husband 
25149 13W9011 Single parent family - mother 
25452 13D2.00 Homeless single person 
25503 1336.00 Cohabiting 
27385 1333.11 Separated from cohabitee 
27434 13HV011 Lover taken 
27572 13HE.00 Engaged 
28440 13MF.00 Death of partner 
28484 U3N0.00 [X]Other maltreatment syndromes, by spouse or partner 
29543 13H5.00 Marital reconciliation 
29544 13H4.11 Marital trouble 
30597 ZV26500 [V]Artificial insemination from husband 
30950 13H4213 Row with wife 
31495 8H7I.00 Refer to partner 
31678 13EF.00 Divorced couple sharing house 
32451 67M..00 Informing partner 
32984 1F81.00 Spouse cooks food 
33000 13Q..12 Widows pensions 
33001 131..11 Occupation of husband 
33153 1312.00 House husband 
33188 13ID.00 Partner unemployed 
34771 13HV.00 Extra-marital problems 
36077 131..00 Occupation of spouse 
36333 ZLB4.00 Seen by marriage guidance counsellor 
36947 13L7.00 Partner dying 
37113 U3M0.00 [X]Neglect and abandonment, by spouse or partner 
37265 1331.00 Single 
37551 13HVZ00 Extra-marital problems NOS 
38325 13H5.11 Cohabitee returned 
39292 131..12 Occupation of wife 
39474 9NA8.00 Cohabitee made appointment 
39651 13HV300 Spouse committed adultery 
39879 13HV314 Oil rig wives syndrome 
40493 13HF.00 Broken engagement 
40866 13Q..00 Widows benefits 
41203 13L1200 Spouse is handicapped 
42321 13H4311 Spouse unsympathetic 
42386 133H.00 Common-law wife 
42390 13I7300 Boyfriend arrested 
42398 13I7200 Spouse arrested 
42400 13HV312 Wife committed adultery 
42402 13WE.00 Spouse works away from home 
42428 1333.14 Cohabitee left home 
45005 1AZ5.00 Fertility problems in partner 
45010 13Q3.00 Widows pension 
47411 13I2.00 Partner stops work 
49666 1AZ4.00 Low sperm count in partner 
50149 13W7000 Crime against spouse 
50485 13HY.00 First relationship 
54096 131Z.00 Occupation of spouse NOS 
54816 13H4312 Spouse inattentive 
56178 13HV012 Mistress taken 
59817 9d31.00 Husband 
59829 9d32.00 Wife 
60723 918j.00 Partner is informal carer 
60821 13QZ.00 Widows benefits NOS 
61291 1A85.00 Breast lump detected by partner 
61509 13Q..11 Widows allowances 
63118 1276.11 Spouse haemophiliac 
68095 13I7400 Girlfriend arrested 
88373 133S.00 Married/civil partner 
91652 7E0A300 Intrauterine insemination superovulation partner sperm 
94044 133V.00 Widowed/surviving civil partner 
94917 13Ir.00 Partner pregnant 
95101 9d30.00 Spouse 
96856 133T.00 Divorced/person whose civil partnership has been dissolved 
97076 6127.00 Partner had tubal ligation 
98130 9d33.00 Cohabitee 
98610 13Q5.00 War widows pension 
98818 13Q1.00 Widows allowance 
99328 13I1.00 Partner begins work 
100785 68b9.00 Anten screen, partner tested and no genetic risk identified 
101900 13I4.00 Partner works after retirement 
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102413 133b.00 Partner in relationship 
104879 133e.00 Common law partnership 
104936 U3P0.00 [X]Maltreatment, by spouse or partner 
109323 13I3.00 Partner retires 
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Appendix 10 Codelist: living alone 
Medcode Readcode Readterm 
464 13HT115 Domestic problems 
1123 13HQ.00 In prison 
1650 13HT100 Stress at home 
2562 13D..11 Homeless 
2955 1B1K.12 Lives alone 
11504 ZU33200 Lives with daughter 
12798 ZU33600 Lives with father 
12807 ZU33100 Lives with children 
13355 13F1.00 Independant housing, not alone 
13356 13F2.00 Lives alone - help available 
13357 13F3.00 Lives alone -no help available 
13358 13FH.00 Lives with relatives 
15416 13F7300 Lives in a childrens home 
15691 13F3100 Lives alone needs housekeeper 
15700 13JS.00 Works away from home 
15840 13F7100 Lives in a welfare home 
17279 13FH000 Elderly relative lives with family 
19610 13FJ.00 Independent housing, lives alone 
20155 13HT113 Home unsettled 
21405 13F7400 Admitted to a children's home 
22249 ZU3..11 Lives with 
22336 13L6.11 Has infirm partner 
22503 ZU33300 Lives with son 
23575 13FD.00 No carers, though not alone 
25167 ZU31.00 Lives alone 
25452 13D2.00 Homeless single person 
25715 8He1.00 Referral to intermediate care - community rehabilitation 
26177 8He0.00 Referral to intermediate care - hospital at home 
28448 ZU33500 Lives with mother 
30200 ZV60611 [V]Boarding school resident 
30965 13E6.00 Overcrowded in house 
31385 13F8100 Long stay hospital inpatient 
31678 13EF.00 Divorced couple sharing house 
32753 13D3.11 Tramp 
32774 13D1.00 Homeless family 
32882 8He..00 Referral to intermediate care 
33006 1311.11 Homemaker 
33994 ZW63200 Staying with carer 
34506 13FL.00 Living rough 
36418 ZV60300 [V]Person living alone 
36730 Z37C.00 Provision of special residential school 
36809 ZU33.00 Lives with family 
36947 13L7.00 Partner dying 
36968 ZU33400 Lives with parents 
40822 ZU33700 Lives with grandparents 
41388 13D5.00 Vagrant 
42533 ZU26100 Number of dependants in household 
42654 ZU35.00 Lives with companion 
43393 ZU33800 Lives with grandfather 
43911 ZU33900 Lives with grandmother 
47577 ZW63100 Living with carer 
47591 13FS.00 Long stay hospital inpatient 
49138 ZV63212 [V]Delayed discharge - nursing home vacancy awaited 
50111 13HH.11 Cares for mentally handicapped dependent 
50206 8O0A.00 Provision of special residential school 
50994 13HH.18 Looks after physically handicapped dependent 
51193 ZU32.00 Lives with friends 
52682 6992.00 Prison medical examination 
53343 ZU3..12 LW - Lives with 
55276 ZU37.00 Lives in a community 
57438 ZU32100 Lives with friend 
59330 T776.00 Place of occurrence of accident or poisoning, prison 
59523 13D3.12 Vagabond 
61385 9b1C.00 Hospice - independent 
66549 13EA.00 Multiple occupancy 
67112 9k6..00 Homeless - enhanced services administration 
67187 13FM.00 Sleeping in night shelter 
68005 13FV.00 Lives in a welfare home 
70021 ZU36.00 Lives as companion 
71339 0A82.00 Companion 
71663 ZU37200 Lives in boarding school 
73177 ZLG6100 Discharge to long stay hospital 
86390 13FY.00 Lives in a children's unit 
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90547 ZU34.00 Lives with lodger 
94886 13Il.00 Subject to interim supervision order under Children Act 1989 
95555 ZU37300 Lives in a commune 
95880 13It.00 Lives with grandmother 
96605 9k60.00 Homeless - enhanced service completed 
97138 13Is.00 Lives with grandfather 
99907 ZV60011 [V]Hobo 
101400 13Zr.00 Lives with immunocompromised person 
101582 9b0t.00 Children's home visit note 
103510 ZV60014 [V]Tramp 
103553 ZU37100 Lives in a school community 
104962 13D8.00 Length of time homeless 
106972 13IZ000 Lives with adoptive parents 
107393 9Ngr.00 Under care of homeless advocacy service 
107733 13IZ200 Lives with biological parents 
107809 918F200 Lives with carer 
109673 13IZ100 Lives with biological parent and step parent 
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Appendix 11 Codelist: partner uncategorised 
Medcode Read code Read term 
1328 6124.00 Partner had vasectomy 
6104 13HP.00 Relationship problems 
9112 13HX.00 New relationship 
20536 13HV100 Affair ended 
22336 13L6.11 Has infirm partner 
22909 13JK.13 Partnership problems 
22934 6124.11 Partner sterilised 
23409 13HV000 Affair started 
23445 13HV200 Affair unsatisfactory 
25503 1336.00 Cohabiting 
27434 13HV011 Lover taken 
28484 U3N0.00 [X]Other maltreatment syndromes, by spouse or partner 
31495 8H7I.00 Refer to partner 
32451 67M..00 Informing partner 
33188 13ID.00 Partner unemployed 
36947 13L7.00 Partner dying 
37113 U3M0.00 [X]Neglect and abandonment, by spouse or partner 
38325 13H5.11 Cohabitee returned 
39474 9NA8.00 Cohabitee made appointment 
45005 1AZ5.00 Fertility problems in partner 
47411 13I2.00 Partner stops work 
49666 1AZ4.00 Low sperm count in partner 
50485 13HY.00 First relationship 
56178 13HV012 Mistress taken 
60723 918j.00 Partner is informal carer 
61291 1A85.00 Breast lump detected by partner 
91652 7E0A300 Intrauterine insemination superovulation partner sperm 
94917 13Ir.00 Partner pregnant 
97076 6127.00 Partner had tubal ligation 
98130 9d33.00 Cohabitee 
99328 13I1.00 Partner begins work 
100785 68b9.00 Anten screen, partner tested and no genetic risk identified 
101900 13I4.00 Partner works after retirement 
102413 133b.00 Partner in relationship 
104936 U3P0.00 [X]Maltreatment, by spouse or partner 
109323 13I3.00 Partner retires 
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Appendix 12 Codelist: zoster vaccine 
Medcode Read code Read term 
106904 65FY.00 Herpes zoster vaccination 
106593 65FY.11 Shingles vaccination 
107067 65FY000 Herpes zoster vaccination given by other health care provide 
106948 68Nv.00 No consent for herpes zoster vaccination 
106946 8I2r.00 Herpes zoster vaccination contraindicated 
106947 8IEl.00 Herpes zoster vaccination declined 
107061 9Nig.00 Did not attend herpes zoster vaccination 
108895 U60K600 [X]Herpes zoster vacc caus adverse effects therapeutic use 
 
prodcode Productname 
47327 Zostavax vaccine powder and solvent for suspension for injection 0.65ml pre-filled syringes (sanofi 
pasteur MSD Ltd) 
48314 Shingles (Herpes Zoster) vaccine (live) powder and solvent for suspension for injection 0.65ml pre-
filled syringes 
 
immtype Description  
88 Shingles 
91 Shingles OHP 
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Appendix 13 Codelist: chronic conditions 
1. Systemic lupus erythematosus 
A) CPRD 
 
medcode readcode readterm 
4125 M154.00 Lupus erythematosus 
7522 M154z00 Lupus erythematosus NOS 
7871 N000.00 Systemic lupus erythematosus 
11920 N000400 Systemic lupus erythematosus with pericarditis 
20007 N000000 Disseminated lupus erythematosus 
22205 K01x411 Lupus nephritis 
29519 N000300 Systemic lupus erythematosus with organ or sys involv 
31564 H57y400 Lung disease with systemic lupus erythematosus 
33449 M154000 Lupus erythematosus chronicus 
36942 N000200 Drug-induced systemic lupus erythematosus 
40797 M154200 Lupus erythematosus migrans 
42719 N000z00 Systemic lupus erythematosus NOS 
44095 F371000 Polyneuropathy in disseminated lupus erythematosus 
45726 ZRq9.00 Systemic lupus erythematosus disease activity index 
47047 ZR2l.11 BILAG - British isles lupus assessment group score 
47672 K01x400 Nephrotic syndrome in systemic lupus erythematosus 
51798 ZRq8.00 Systemic lupus activity measure 
57675 N000100 Libman-Sacks disease 
58706 Nyu4300 [X]Other forms of systemic lupus erythematosus 
63283 ZRq9.11 SLEDAI-Sys lup ery dis act ind 
63955 M154600 Lupus erythematosus unguium mutilans 
65391 M154300 Lupus erythematosus nodularis 
101433 N000600 Cerebral lupus 
106086 ZRq8.11 SLAM - Systemic lupus activity measure 
108072 F396100 Myopathy due to disseminated lupus erythematosus 
 
 
B) Hospital Episodes Statistics 
 
ICD 10 DESCRIPTION 
M32 Systemic lupus erythematosus 
M32.0 Drug-induced systemic lupus erythematosus 
M32.1 Systemic lupus erythematosus with organ or system involvement 
M32.8 Other forms of systemic lupus erythematosus 
M32.9 Systemic lupus erythematosus, unspecified 
 
2. Rheumatoid arthritis 
A) CPRD 
medcode readcode readterm 
844 N040.00 Rheumatoid arthritis 
4186 N043.00 Juvenile rheumatoid arthritis - Still's disease 
5723 N042200 Rheumatoid nodule 
6916 N040P00 Seronegative rheumatoid arthritis 
8350 N040T00 Flare of rheumatoid arthritis 
9707 N047.00 Seropositive errosive rheumatoid arthritis 
9954 H570.00 Rheumatoid lung 
12019 N04X.00 Seropositive rheumatoid arthritis, unspecified 
17412 66H..13 Rheumatoid arthrit. monitoring 
18155 N040Q00 Rheumatoid bursitis 
21358 N040200 Rheumatoid arthritis of shoulder 
21533 N043200 Pauciarticular juvenile rheumatoid arthritis 
23552 N041.00 Felty's syndrome 
23834 N005.00 Adult Still's Disease 
27557 N043z00 Juvenile rheumatoid arthritis NOS 
28853 N04y012 Fibrosing alveolitis associated with rheumatoid arthritis 
30548 N040N00 Rheumatoid vasculitis 
31054 N040S00 Rheumatoid arthritis - multiple joint 
31209 F396400 Myopathy due to rheumatoid arthritis 
31360 N045500 Juvenile rheumatoid arthritis 
31724 N04y000 Rheumatoid lung 
32001 N04y200 Adult-onset Still's disease 
33264 2G27.00 O/E-hands-rheumatoid spindling 
36276 N043300 Monarticular juvenile rheumatoid arthritis 
37431 N042z00 Rheumatoid arthropathy + visceral/systemic involvement NOS 
41941 N040900 Rheumatoid arthritis of PIP joint of finger 
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medcode readcode readterm 
42299 N040800 Rheumatoid arthritis of MCP joint 
42719 N000z00 Systemic lupus erythematosus NOS 
43816 G5yA.00 Rheumatoid carditis 
44203 N040100 Other rheumatoid arthritis of spine 
44743 N040000 Rheumatoid arthritis of cervical spine 
46436 N042100 Rheumatoid lung disease 
47831 N043100 Acute polyarticular juvenile rheumatoid arthritis 
48832 N040700 Rheumatoid arthritis of wrist 
49067 N040B00 Rheumatoid arthritis of hip 
49227 N042.00 Other rheumatoid arthropathy + visceral/systemic involvement 
49787 G5y8.00 Rheumatoid myocarditis 
50644 N043000 Juvenile rheumatoid arthropathy unspecified 
50863 N040D00 Rheumatoid arthritis of knee 
51238 N040K00 Rheumatoid arthritis of 1st MTP joint 
51239 N040F00 Rheumatoid arthritis of ankle 
53621 N040R00 Rheumatoid nodule 
56202 Nyu1G00 [X]Seropositive rheumatoid arthritis, unspecified 
56838 N04y011 Caplan's syndrome 
59738 N040500 Rheumatoid arthritis of elbow 
62401 F371200 Polyneuropathy in rheumatoid arthritis 
63198 N040A00 Rheumatoid arthritis of DIP joint of finger 
63365 N040600 Rheumatoid arthritis of distal radio-ulnar joint 
70221 Nyu1200 [X]Other specified rheumatoid arthritis 
70658 N040H00 Rheumatoid arthritis of talonavicular joint 
71784 N040J00 Rheumatoid arthritis of other tarsal joint 
73619 N040G00 Rheumatoid arthritis of subtalar joint 
93715 Nyu1100 [X]Other seropositive rheumatoid arthritis 
99414 N040L00 Rheumatoid arthritis of lesser MTP joint 
100776 N040C00 Rheumatoid arthritis of sacro-iliac joint 
100914 N040400 Rheumatoid arthritis of acromioclavicular joint 
102088 7P20300 Delivery of rehabilitation for rheumatoid arthritis 
103829 38DZ000 Disease activity score 28 joint in rheumatoid arthritis 
105507 66HB000 Rheumatoid arthritis annual review 
106092 9hR1.00 Except rheumatoid arthritis qual indicator: informed dissent 
106093 9hR..00 Exception reporting: rheumatoid arthritis quality indicators 
106118 9hR0.00 Except rheumatoid arthritis quality indicator: pt unsuitable 
106440 Nyu1000 [X]Rheumatoid arthritis+involvement/other organs or systems 
107112 N040M00 Rheumatoid arthritis of IP joint of toe 
107340 9mM..00 Rheumatoid arthritis monitoring invitation 
107435 9mM0.00 Rheumatoid arthritis monitoring invitation first letter 
107575 9mM1.00 Rheumatoid arthritis monitoring invitation second letter 
107606 9mM3.00 Rheumatoid arthritis monitoring verbal invitation 
107676 9mM2.00 Rheumatoid arthritis monitoring invitation third letter 
107791 N040E00 Rheumatoid arthritis of tibio-fibular joint 
107797 9mM4.00 Rheumatoid arthritis monitoring telephone invitation 
107963 N040300 Rheumatoid arthritis of sternoclavicular joint 
 
B) Hospital Episodes Statistics 
ICD 10 DESCRIPTION 
J99.0 Rheumatoid lung disease 
M05 Seropositive rheumatoid arthritis 
M05.0 Felty's syndrome 
M05.00 Felty's syndrome 
M05.01 Felty's syndrome 
M05.02 Felty's syndrome 
M05.03 Felty's syndrome 
M05.04 Felty's syndrome 
M05.05 Felty's syndrome 
M05.06 Felty's syndrome 
M05.07 Felty's syndrome 
M05.08 Felty's syndrome 
M05.09 Felty's syndrome 
M05.1 Rheumatoid lung disease 
M05.10 Rheumatoid lung disease 
M05.11 Rheumatoid lung disease 
M05.12 Rheumatoid lung disease 
M05.13 Rheumatoid lung disease 
M05.14 Rheumatoid lung disease 
M05.15 Rheumatoid lung disease 
M05.16 Rheumatoid lung disease 
M05.17 Rheumatoid lung disease 
M05.18 Rheumatoid lung disease 
M05.19 Rheumatoid lung disease 
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M05.2 Rheumatoid vasculitis 
M05.20 Rheumatoid vasculitis 
M05.21 Rheumatoid vasculitis 
M05.22 Rheumatoid vasculitis 
M05.23 Rheumatoid vasculitis 
M05.24 Rheumatoid vasculitis 
M05.25 Rheumatoid vasculitis 
M05.26 Rheumatoid vasculitis 
M05.27 Rheumatoid vasculitis 
M05.28 Rheumatoid vasculitis 
M05.29 Rheumatoid vasculitis 
M05.3 Rheumatoid arthritis with involvement of other organs and systems 
M05.30 Rheumatoid arthritis with involvement of other organs and systems 
M05.31 Rheumatoid arthritis with involvement of other organs and systems 
M05.32 Rheumatoid arthritis with involvement of other organs and systems 
M05.33 Rheumatoid arthritis with involvement of other organs and systems 
M05.34 Rheumatoid arthritis with involvement of other organs and systems 
M05.35 Rheumatoid arthritis with involvement of other organs and systems 
M05.36 Rheumatoid arthritis with involvement of other organs and systems 
M05.37 Rheumatoid arthritis with involvement of other organs and systems 
M05.38 Rheumatoid arthritis with involvement of other organs and systems 
M05.39 Rheumatoid arthritis with involvement of other organs and systems 
M05.8 Other seropositive rheumatoid arthritis 
M05.80 Other seropositive rheumatoid arthritis 
M05.81 Other seropositive rheumatoid arthritis 
M05.82 Other seropositive rheumatoid arthritis 
M05.83 Other seropositive rheumatoid arthritis 
M05.84 Other seropositive rheumatoid arthritis 
M05.85 Other seropositive rheumatoid arthritis 
M05.86 Other seropositive rheumatoid arthritis 
M05.87 Other seropositive rheumatoid arthritis 
M05.88 Other seropositive rheumatoid arthritis 
M05.89 Other seropositive rheumatoid arthritis 
M05.9 Seropositive rheumatoid arthritis, unspecified 
M05.90 Seropositive rheumatoid arthritis, unspecified 
M05.91 Seropositive rheumatoid arthritis, unspecified 
M05.92 Seropositive rheumatoid arthritis, unspecified 
M05.93 Seropositive rheumatoid arthritis, unspecified 
M05.94 Seropositive rheumatoid arthritis, unspecified 
M05.95 Seropositive rheumatoid arthritis, unspecified 
M05.96 Seropositive rheumatoid arthritis, unspecified 
M05.97 Seropositive rheumatoid arthritis, unspecified 
M05.98 Seropositive rheumatoid arthritis, unspecified 
M05.99 Seropositive rheumatoid arthritis, unspecified 
M06 Other rheumatoid arthritis 
M06.0 Seronegative rheumatoid arthritis 
M06.00 Seronegative rheumatoid arthritis 
M06.01 Seronegative rheumatoid arthritis 
M06.02 Seronegative rheumatoid arthritis 
M06.03 Seronegative rheumatoid arthritis 
M06.04 Seronegative rheumatoid arthritis 
M06.05 Seronegative rheumatoid arthritis 
M06.06 Seronegative rheumatoid arthritis 
M06.07 Seronegative rheumatoid arthritis 
M06.08 Seronegative rheumatoid arthritis 
M06.09 Seronegative rheumatoid arthritis 
M06.1 Adult-onset Still's disease 
M06.10 Adult-onset Still's disease 
M06.11 Adult-onset Still's disease 
M06.12 Adult-onset Still's disease 
M06.13 Adult-onset Still's disease 
M06.14 Adult-onset Still's disease 
M06.15 Adult-onset Still's disease 
M06.16 Adult-onset Still's disease 
M06.17 Adult-onset Still's disease 
M06.18 Adult-onset Still's disease 
M06.19 Adult-onset Still's disease 
M06.2 Rheumatoid bursitis 
M06.20 Rheumatoid bursitis 
M06.21 Rheumatoid bursitis 
M06.22 Rheumatoid bursitis 
M06.23 Rheumatoid bursitis 
M06.24 Rheumatoid bursitis 
M06.25 Rheumatoid bursitis 
M06.26 Rheumatoid bursitis 
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M06.27 Rheumatoid bursitis 
M06.28 Rheumatoid bursitis 
M06.29 Rheumatoid bursitis 
M06.3 Rheumatoid nodule 
M06.30 Rheumatoid nodule 
M06.31 Rheumatoid nodule 
M06.32 Rheumatoid nodule 
M06.33 Rheumatoid nodule 
M06.34 Rheumatoid nodule 
M06.35 Rheumatoid nodule 
M06.36 Rheumatoid nodule 
M06.37 Rheumatoid nodule 
M06.38 Rheumatoid nodule 
M06.39 Rheumatoid nodule 
M06.8 Other specified rheumatoid arthritis 
M06.80 Other specified rheumatoid arthritis 
M06.81 Other specified rheumatoid arthritis 
M06.82 Other specified rheumatoid arthritis 
M06.83 Other specified rheumatoid arthritis 
M06.84 Other specified rheumatoid arthritis 
M06.85 Other specified rheumatoid arthritis 
M06.86 Other specified rheumatoid arthritis 
M06.87 Other specified rheumatoid arthritis 
M06.88 Other specified rheumatoid arthritis 
M06.89 Other specified rheumatoid arthritis 
M06.9 Rheumatoid arthritis, unspecified 
M06.90 Rheumatoid arthritis, unspecified 
M06.91 Rheumatoid arthritis, unspecified 
M06.92 Rheumatoid arthritis, unspecified 
M06.93 Rheumatoid arthritis, unspecified 
M06.94 Rheumatoid arthritis, unspecified 
M06.95 Rheumatoid arthritis, unspecified 
M06.96 Rheumatoid arthritis, unspecified 
M06.97 Rheumatoid arthritis, unspecified 
M06.98 Rheumatoid arthritis, unspecified 
M06.99 Rheumatoid arthritis, unspecified 
M08.0 Juvenile rheumatoid arthritis 
M08.00 Juvenile rheumatoid arthritis 
M08.01 Juvenile rheumatoid arthritis 
M08.02 Juvenile rheumatoid arthritis 
M08.03 Juvenile rheumatoid arthritis 
M08.04 Juvenile rheumatoid arthritis 
M08.05 Juvenile rheumatoid arthritis 
M08.06 Juvenile rheumatoid arthritis 
M08.07 Juvenile rheumatoid arthritis 
M08.08 Juvenile rheumatoid arthritis 
M08.09 Juvenile rheumatoid arthritis 
 
3. Inflammatory bowel disease 
A) CPRD 
medcode readcode readterm 
593 J40..11 Crohn's disease 
704 J410100 Ulcerative colitis 
1784 J41..12 Ulcerative colitis and/or proctitis 
1796 J4...12 Inflammatory bowel disease 
5133 J41..00 Idiopathic proctocolitis 
5749 14C4.11 H/O: ulcerative colitis 
6538 J401z11 Crohn's colitis 
6650 J410.00 Ulcerative proctocolitis 
8347 J410300 Ulcerative proctitis 
9359 J400z00 Crohn's disease of the small bowel NOS 
11119 ZR3S.11 CDAI - Crohn's disease activity index 
11286 J40..00 Regional enteritis - Crohn's disease 
11337 ZR3S.00 Crohn's disease activity index 
12575 N045300 Juvenile arthritis in Crohn's disease 
15207 J41z.00 Idiopathic proctocolitis NOS 
15773 J402.00 Regional ileocolitis 
17641 N031000 Arthropathy in ulcerative colitis 
20480 N031100 Arthropathy in Crohn's disease 
20688 J401z00 Crohn's disease of the large bowel NOS 
22516 J410400 Exacerbation of ulcerative colitis 
24550 J41y.00 Other idiopathic proctocolitis 
24858 J410200 Ulcerative rectosigmoiditis 
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28476 J400200 Crohn's disease of the terminal ileum 
29616 J08z900 Orofacial Crohn's disease 
30433 J411.00 Ulcerative (chronic) enterocolitis 
33456 J410z00 Ulcerative proctocolitis NOS 
36913 J400500 Exacerbation of Crohn's disease of small intestine 
39037 J401200 Exacerbation of Crohn's disease of large intestine 
39278 J400400 Crohn's disease of the ileum NOS 
42822 J412.00 Ulcerative (chronic) ileocolitis 
43090 J41yz00 Other idiopathic proctocolitis NOS 
44426 J401.00 Regional enteritis of the large bowel 
48732 J410000 Ulcerative ileocolitis 
51576 J400.00 Regional enteritis of the small bowel 
51578 J40..12 Granulomatous enteritis 
52449 J40z.00 Regional enteritis NOS 
53743 Jyu4100 [X]Other ulcerative colitis 
59994 J40z.11 Crohn's disease NOS 
62628 J401000 Regional enteritis of the colon 
63036 J400100 Regional enteritis of the jejunum 
64773 J401100 Regional enteritis of the rectum 
66238 J400300 Crohn's disease of the ileum unspecified 
69959 Jyu4000 [X]Other Crohn's disease 
71083 N045400 Juvenile arthritis in ulcerative colitis 
71945 J400000 Regional enteritis of the duodenum 
104259 J413.00 Ulcerative pancolitis 
107313 8Cc5.00 Management of inflammatory bowel disease 
110283 8Cc5.11 Management of IBD (inflammatory bowel disease) 
 
B) Hospital Episodes Statistics 
ICD 10 DESCRIPTION 
K50 Crohn's disease [regional enteritis] 
K50.0 Crohn's disease of small intestine 
K50.1 Crohn's disease of large intestine 
K50.8 Other Crohn's disease 
K50.9 Crohn's disease, unspecified 
K51 Ulcerative colitis 
K51.0 Ulcerative (chronic) pancolitis 
K51.2 Ulcerative (chronic) proctitis 
K51.3 Ulcerative (chronic) rectosigmoiditis 
K51.4 Inflammatory polyps 
K51.5 Left sided colitis 
K51.8 Other ulcerative colitis 
K51.9 Ulcerative colitis, unspecified 
M07.4 Arthropathy in Crohn's disease [regional enteritis] 
M07.40 Arthropathy in Crohn's disease [regional enteritis] 
M07.41 Arthropathy in Crohn's disease [regional enteritis] 
M07.42 Arthropathy in Crohn's disease [regional enteritis] 
M07.43 Arthropathy in Crohn's disease [regional enteritis] 
M07.44 Arthropathy in Crohn's disease [regional enteritis] 
M07.45 Arthropathy in Crohn's disease [regional enteritis] 
M07.46 Arthropathy in Crohn's disease [regional enteritis] 
M07.47 Arthropathy in Crohn's disease [regional enteritis] 
M07.48 Arthropathy in Crohn's disease [regional enteritis] 
M07.49 Arthropathy in Crohn's disease [regional enteritis] 
M07.5 Arthropathy in ulcerative colitis 
M07.50 Arthropathy in ulcerative colitis 
M07.51 Arthropathy in ulcerative colitis 
M07.52 Arthropathy in ulcerative colitis 
M07.53 Arthropathy in ulcerative colitis 
M07.54 Arthropathy in ulcerative colitis 
M07.55 Arthropathy in ulcerative colitis 
M07.56 Arthropathy in ulcerative colitis 
M07.57 Arthropathy in ulcerative colitis 
M07.58 Arthropathy in ulcerative colitis 
M07.59 Arthropathy in ulcerative colitis 
M09.1 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.10 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.11 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.12 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.13 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.14 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.15 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.16 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.17 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.18 Juvenile arthritis in Crohn's disease [regional enteritis] 
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M09.19 Juvenile arthritis in Crohn's disease [regional enteritis] 
M09.2 Juvenile arthritis in ulcerative colitis 
M09.20 Juvenile arthritis in ulcerative colitis 
M09.21 Juvenile arthritis in ulcerative colitis 
M09.22 Juvenile arthritis in ulcerative colitis 
M09.23 Juvenile arthritis in ulcerative colitis 
M09.24 Juvenile arthritis in ulcerative colitis 
M09.25 Juvenile arthritis in ulcerative colitis 
M09.26 Juvenile arthritis in ulcerative colitis 
M09.27 Juvenile arthritis in ulcerative colitis 
M09.28 Juvenile arthritis in ulcerative colitis 
M09.29 Juvenile arthritis in ulcerative colitis 
 
4. Chronic obstructive pulmonary disease and asthma 
A) CPRD 
medcode readcode readterm 
78 H33..00 Asthma 
81 663..11 Asthma monitoring 
185 H333.00 Acute exacerbation of asthma 
232 H33z100 Asthma attack 
233 H33z011 Severe asthma attack 
719 14B4.00 H/O: asthma 
794 H32..00 Emphysema 
998 H3...11 Chronic obstructive airways disease 
1001 H3...00 Chronic obstructive pulmonary disease 
1208 H330.12 Childhood asthma 
1446 H312200 Acute exacerbation of chronic obstructive airways disease 
1555 H33..11 Bronchial asthma 
2290 H330.11 Allergic asthma 
3018 663V100 Mild asthma 
3243 H31..00 Chronic bronchitis 
3366 663V300 Severe asthma 
3458 663V000 Occasional asthma 
3665 H331.11 Late onset asthma 
4084 663K.00 Airways obstructn irreversible 
4442 H33z.00 Asthma unspecified 
4606 H33zz11 Exercise induced asthma 
4892 H33z000 Status asthmaticus NOS 
5267 H331.00 Intrinsic asthma 
5627 H330011 Hay fever with asthma 
5710 H3z..00 Chronic obstructive airways disease NOS 
5798 H312000 Chronic asthmatic bronchitis 
5909 H312011 Chronic wheezy bronchitis 
6707 H330111 Extrinsic asthma with asthma attack 
7058 8H2P.00 Emergency admission, asthma 
7146 H330.00 Extrinsic (atopic) asthma 
7191 663P.00 Asthma limiting activities 
7229 663W.00 Asthma prophylactic medication used 
7378 663U.00 Asthma management plan given 
7416 663N.00 Asthma disturbing sleep 
7731 H330.14 Pollen asthma 
7884 H3y1.00 Chron obstruct pulmonary dis wth acute exacerbation, unspec 
8335 H33z111 Asthma attack NOS 
8355 9OJA.11 Asthma monitored 
9018 663y.00 Number of asthma exacerbations in past year 
9520 66YB.00 Chronic obstructive pulmonary disease monitoring 
9552 66Y5.00 Change in asthma management plan 
9663 66Y9.00 Step up change in asthma management plan 
9876 H38..00 Severe chronic obstructive pulmonary disease 
10043 66YJ.00 Asthma annual review 
10274 8B3j.00 Asthma medication review 
10487 663j.00 Asthma - currently active 
10802 H37..00 Moderate chronic obstructive pulmonary disease 
10863 H36..00 Mild chronic obstructive pulmonary disease 
10980 H322.00 Centrilobular emphysema 
10996 2126200 Asthma resolved 
11019 8H2R.00 Admit COPD emergency 
11022 178..00 Asthma trigger 
11150 H311.00 Mucopurulent chronic bronchitis 
11287 66YM.00 Chronic obstructive pulmonary disease annual review 
11370 1O2..00 Asthma confirmed 
11839 212G.00 Asthma resolved 
12166 H3y..00 Other specified chronic obstructive airways disease 
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medcode readcode readterm 
12987 H33z200 Late-onset asthma 
13064 663V.00 Asthma severity 
13065 663V200 Moderate asthma 
13066 663h.00 Asthma - currently dormant 
13173 663O.00 Asthma not disturbing sleep 
13174 663Q.00 Asthma not limiting activities 
13175 663N200 Asthma disturbs sleep frequently 
14777 H330000 Extrinsic asthma without status asthmaticus 
14798 H312100 Emphysematous bronchitis 
15157 H31z.00 Chronic bronchitis NOS 
15248 H330.13 Hay fever with asthma 
15626 H310000 Chronic catarrhal bronchitis 
16070 H33zz00 Asthma NOS 
16410 H32yz00 Other emphysema NOS 
16667 8795 Asthma control step 2 
16785 8794 Asthma control step 1 
18141 66YE.00 Asthma monitoring due 
18223 66YA.00 Step down change in asthma management plan 
18224 8796 Asthma control step 3 
18323 H331111 Intrinsic asthma with asthma attack 
18476 66YL.11 COPD follow-up 
18501 66YI.00 COPD self-management plan given 
18621 66YL.00 Chronic obstructive pulmonary disease follow-up 
18792 9Oi..00 Chronic obstructive pulmonary disease monitoring admin 
19003 66Ye.00 Emergency COPD admission since last appointment 
19106 66Yd.00 COPD accident and emergency attendance since last visit 
19167 66YQ.00 Asthma monitoring by nurse 
19519 663p.00 Asthma treatment compliance unsatisfactory 
19520 663n.00 Asthma treatment compliance satisfactory 
19539 9OJA.00 Asthma monitoring check done 
20860 8798 Asthma control step 5 
20886 8797 Asthma control step 4 
21061 H3y0.00 Chronic obstruct pulmonary dis with acute lower resp infectn 
21232 H33zz12 Allergic asthma NEC 
22752 173c.00 Occupational asthma 
22905 H581.00 Interstitial emphysema 
23492 H320z00 Chronic bullous emphysema NOS 
24248 H313.00 Mixed simple and mucopurulent chronic bronchitis 
24479 663d.00 Emergency asthma admission since last appointment 
24506 8791 Further asthma - drug prevent. 
24884 663u.00 Asthma causes daytime symptoms 1 to 2 times per week 
25181 663e.00 Asthma restricts exercise 
25603 H310.00 Simple chronic bronchitis 
25791 8CR0.00 Asthma clinical management plan 
25796 H332.00 Mixed asthma 
26018 66YS.00 Chronic obstructive pulmonary disease monitoring by nurse 
26306 H320.00 Chronic bullous emphysema 
26501 663s.00 Asthma never causes daytime symptoms 
26503 663v.00 Asthma causes daytime symptoms most days 
26504 663f.00 Asthma never restricts exercise 
26506 6.63E+102 Asthma severely restricts exercise 
26861 663 Asthma sometimes restricts exercise 
27819 H312.00 Obstructive chronic bronchitis 
27926 H330100 Extrinsic asthma with status asthmaticus 
28743 66Yf.00 Number of COPD exacerbations in past year 
28755 9Oi0.00 Chronic obstructive pulmonary disease monitoring 1st letter 
29325 H331000 Intrinsic asthma without status asthmaticus 
29645 8793 Asthma control step 0 
30458 66YR.00 Asthma monitoring by doctor 
30815 663N000 Asthma causing night waking 
31167 66YP.00 Asthma night-time symptoms 
31225 663t.00 Asthma causes daytime symptoms 1 to 2 times per month 
32727 H33z.11 Hyperreactive airways disease 
33450 H32z.00 Emphysema NOS 
34202 9Oi1.00 Chronic obstructive pulmonary disease monitoring 2nd letter 
34215 9Oi2.00 Chronic obstructive pulmonary disease monitoring 3rd letter 
37247 H3z..11 Chronic obstructive pulmonary disease NOS 
37371 66YD.00 Chronic obstructive pulmonary disease monitoring due 
37959 H311100 Fetid chronic bronchitis 
38074 9Oi4.00 Chronic obstructive pulmonary disease monitor phone invite 
38143 663O000 Asthma never disturbs sleep 
38144 663w.00 Asthma limits walking up hills or stairs 
38145 663x.00 Asthma limits walking on the flat 
38146 663N100 Asthma disturbs sleep weekly 
39570 663r.00 Asthma causes night symptoms 1 to 2 times per month 
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medcode readcode readterm 
40159 H311000 Purulent chronic bronchitis 
40788 H32y.00 Other emphysema 
40823 H334.00 Brittle asthma 
40864 U60F615 [X] Adverse reaction to theophylline - asthma 
41017 1780 Aspirin induced asthma 
41020 66YC.00 Absent from work or school due to asthma 
42258 9Oi3.00 Chronic obstructive pulmonary disease monitoring verb invite 
42313 679V.00 Health education - chronic obstructive pulmonary disease 
42824 663q.00 Asthma daytime symptoms 
44525 H312z00 Obstructive chronic bronchitis NOS 
45073 H331z00 Intrinsic asthma NOS 
45089 H31y100 Chronic tracheobronchitis 
45770 66Yg.00 Chronic obstructive pulmonary disease disturbs sleep 
45771 66Yh.00 Chronic obstructive pulmonary disease does not disturb sleep 
45777 8CR1.00 Chronic obstructive pulmonary disease clini management plan 
45782 H330z00 Extrinsic asthma NOS 
45998 66YT.00 Chronic obstructive pulmonary disease monitoring by doctor 
46036 66Yi.00 Multiple COPD emergency hospital admissions 
46529 9OJ1.00 Attends asthma monitoring 
46578 H321.00 Panlobular emphysema 
47337 663m.00 Asthma accident and emergency attendance since last visit 
47684 H47y000 Detergent asthma 
47993 66YZ.00 Does not have asthma management plan 
48591 TJF7300 Adverse reaction to theophylline (asthma) 
54893 H582.00 Compensatory emphysema 
56860 H320000 Segmental bullous emphysema 
58196 H331100 Intrinsic asthma with status asthmaticus 
59263 H32y111 Acute interstitial emphysema 
60188 H320200 Giant bullous emphysema 
61118 H310z00 Simple chronic bronchitis NOS 
61513 H311z00 Mucopurulent chronic bronchitis NOS 
63479 H32y200 MacLeod's unilateral emphysema 
64721 H464000 Chronic emphysema due to chemical fumes 
65733 Hyu3100 [X]Other specified chronic obstructive pulmonary disease 
66043 H31y.00 Other chronic bronchitis 
66058 Hyu3000 [X]Other emphysema 
67040 H3y..11 Other specified chronic obstructive pulmonary disease 
68066 H31yz00 Other chronic bronchitis NOS 
68662 H320100 Zonal bullous emphysema 
70787 H32y100 Atrophic (senile) emphysema 
73522 173d.00 Work aggravated asthma 
92955 H32y000 Acute vesicular emphysema 
93568 H39..00 Very severe chronic obstructive pulmonary disease 
96931 14OX.00 At risk of chronic obstructive pulmonary diseas exacerbation 
98283 9kf2.00 COPD structured smoking assessment declined - enh serv admin 
98284 9kf1.00 Refer COPD structured smoking assessment - enhanc serv admin 
99536 H320300 Bullous emphysema with collapse 
99793 8CMA000 Patient has a written asthma personal action plan 
99948 9kf0.00 COPD patient unsuitable for pulmonary rehab - enh serv admin 
100509 9NNX.00 Under care of asthma specialist nurse 
101042 8BMW.00 Issue of chronic obstructive pulmonary disease rescue pack 
102170 66Yp.00 Asthma review using Roy Colleg of Physicians three questions 
102209 38DV.00 Mini asthma quality of life questionnaire 
102301 1787 Asthma trigger - seasonal 
102341 1781 Asthma trigger - pollen 
102395 66Yr.00 Asthma causes symptoms most nights 
102400 66Yq.00 Asthma causes night time symptoms 1 to 2 times per week 
102449 1789 Asthma trigger - respiratory infection 
102685 66YB000 Chronic obstructive pulmonary disease 3 monthly review 
102713 663P000 Asthma limits activities 1 to 2 times per month 
102888 663P100 Asthma limits activities 1 to 2 times per week 
102952 1783 Asthma trigger - warm air 
103007 66YB100 Chronic obstructive pulmonary disease 6 monthly review 
103321 1786 Asthma trigger - animals 
103400 9kf1.11 Referred for COPD structured smoking assessment 
103494 14B3.12 History of chronic obstructive pulmonary disease 
103558 8CeD.00 Preferred place of care for next exacerbation of COPD 
103612 66Ys.00 Asthma never causes night symptoms 
103678 8BMa000 Chronic obstructiv pulmonary disease medication optimisation 
103758 8Hkw.00 Referral to COPD community nursing team 
103760 9kf2.11 COPD structured smoking assessment declined 
103813 1788.00 Asthma trigger - cold air 
103864 9kf0.11 COPD patient unsuitable for pulmonary rehabilitation 
103944 178A.00 Asthma trigger - airborne dust 
103945 1785.00 Asthma trigger - damp 
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103952 1784.00 Asthma trigger - emotion 
103955 1782.00 Asthma trigger - tobacco smoke 
103998 663P200 Asthma limits activities most days 
104117 661M300 COPD self-management plan agreed 
104169 661N300 COPD self-management plan review 
104265 9e03.00 GP OOH service notified of COPD care plan 
104481 8CMV.00 Has chronic obstructive pulmonary disease care plan 
104608 H3A..00 End stage chronic obstructive airways disease 
104710 9NgP.11 On COPD (chr obstruc pulmonary disease) supportv cre pathway 
104985 9NgP.00 On chronic obstructive pulmonary disease supprtv cre pathway 
104998 8I61000 Chronic obstructve pulmonry disease rescue pack not indicatd 
105420 661N100 Asthma self-management plan review 
105457 8CMW500 Chronic obstructive pulmonary disease care pathway 
105674 661M100 Asthma self-management plan agreed 
106637 9Nk7000 Seen in chronic obstructive pulmonary disease clinic 
106805 H335.00 Chronic asthma with fixed airflow obstruction 
106945 8IEZ.00 Chronic obstructive pulmonary disease rescue pack declined 
107167 66Yu.00 Number days absent from school due to asthma in past 6 month 
107877 8IEy.00 Chronic obstructive pulmon dis wr self managem plan declined 
108475 66Yz000 Asthma management plan declined 
108586 66Yz100 Chronic obstruct pulmonary disease management plan declined 
108599 38QM.00 Childhood Asthma Control Test 
108912 9OJB.00 Asthma monitorng invit SMS (short message servce) txt messge 
109468 9OJC.00 Asthma monitoring invitation email 
109683 2126F00 Chronic obstructive pulmonary disease resolved 
109774 66YB200 Telehealth chronic obstructive pulmonary disease monitoring 
109958 H3B..00 Asthma-chronic obstructive pulmonary disease overlap syndrom 
109996 66Yz500 Telehealth asthma monitoring 
110339 9OJB000 Asthma monitoring SMS text message 1st invitation 
110345 38B8.00 Severe asthma exacerbation risk assessment 
110406 14Ok000 At risk of severe asthma exacerbation 
110533 9OJB100 Asthma monitoring SMS text message 2nd invitation 
 
B) Hospital Episodes Statistics 
ICD10 DESCRIPTION 
J41 Simple and mucopurulent chronic bronchitis 
J41.0 Simple chronic bronchitis 
J41.1 Mucopurulent chronic bronchitis 
J41.8 Mixed simple and mucopurulent chronic bronchitis 
J42 Unspecified chronic bronchitis 
J43 Emphysema 
J43.0 MacLeod syndrome 
J43.1 Panlobular emphysema 
J43.2 Centrilobular emphysema 
J43.8 Other emphysema 
J43.9 Emphysema, unspecified 
J44 Other chronic obstructive pulmonary disease 
J44.0 Chronic obstructive pulmonary disease with acute lower respiratory infection 
J44.1 Chronic obstructive pulmonary disease with acute exacerbation, unspecified 
J44.8 Other specified chronic obstructive pulmonary disease 
J44.9 Chronic obstructive pulmonary disease, unspecified 
J45 Asthma 
J45.0 Predominantly allergic asthma 
J45.1 Nonallergic asthma 
J45.8 Mixed asthma 
J45.9 Asthma, unspecified 
J46 Status asthmaticus 
 
5. Diabetes 
A) CPRD 
medcode readcode readterm 
506 C100112 Non-insulin dependent diabetes mellitus 
711 C10..00 Diabetes mellitus 
758 C10F.00 Type 2 diabetes mellitus 
1038 C100011 Insulin dependent diabetes mellitus 
1323 F420.00 Diabetic retinopathy 
1407 C10FJ00 Insulin treated Type 2 diabetes mellitus 
1549 C10E.00 Type 1 diabetes mellitus 
1647 C108.00 Insulin dependent diabetes mellitus 
1682 C101.00 Diabetes mellitus with ketoacidosis 
1684 66A4.00 Diabetic on oral treatment 
2340 F381311 Diabetic amyotrophy 
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2342 F372.12 Diabetic neuropathy 
2378 66AJ.00 Diabetic - poor control 
2471 K01x100 Nephrotic syndrome in diabetes mellitus 
2475 C104.11 Diabetic nephropathy 
2478 66AJ100 Brittle diabetes 
2986 F420200 Preproliferative diabetic retinopathy 
3286 F420100 Proliferative diabetic retinopathy 
3837 F420400 Diabetic maculopathy 
4513 C109.00 Non-insulin dependent diabetes mellitus 
5002 F372.11 Diabetic polyneuropathy 
5884 C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
6125 66AS.00 Diabetic annual review 
6430 9NM0.00 Attending diabetes clinic 
6509 C108700 Insulin dependent diabetes mellitus with retinopathy 
6791 C108800 Insulin dependant diabetes mellitus - poor control 
7045 14F4.00 H/O: Admission in last year for diabetes foot problem 
7059 8H2J.00 Admit diabetic emergency 
7069 F420000 Background diabetic retinopathy 
7328 M037200 Cellulitis in diabetic foot 
7563 66A3.00 Diabetic on diet only 
7795 C106.12 Diabetes mellitus with neuropathy 
8403 C109700 Non-insulin dependant diabetes mellitus - poor control 
8836 66AR.00 Diabetes management plan given 
8842 66A5.00 Diabetic on insulin 
9013 66AJ.11 Unstable diabetes 
9835 2BBL.00 O/E - diabetic maculopathy present both eyes 
9881 M271200 Mixed diabetic ulcer - foot 
9958 42W..00 Hb. A1C - diabetic control 
9974 9N1v.00 Seen in diabetic eye clinic 
10098 C10yy00 Other specified diabetes mellitus with other spec comps 
10099 F420300 Advanced diabetic maculopathy 
10418 C10ED00 Type 1 diabetes mellitus with nephropathy 
10642 ZC2C800 Dietary advice for diabetes mellitus 
10659 F464000 Diabetic cataract 
10692 C10EM00 Type 1 diabetes mellitus with ketoacidosis 
10755 F420600 Non proliferative diabetic retinopathy 
10824 9N1i.00 Seen in diabetic foot clinic 
10977 66Ac.00 Diabetic peripheral neuropathy screening 
11018 8HBG.00 Diabetic retinopathy 12 month review 
11047 66AH000 Conversion to insulin 
11094 9NND.00 Under care of diabetic foot screener 
11129 2BBQ.00 O/E - left eye background diabetic retinopathy 
11433 2BBP.00 O/E - right eye background diabetic retinopathy 
11471 8B3l.00 Diabetes medication review 
11599 7276 Pan retinal photocoagulation for diabetes 
11626 F420z00 Diabetic retinopathy NOS 
11663 M271100 Neuropathic diabetic ulcer - foot 
11677 8H7r.00 Refer to diabetic foot screener 
12213 8BL2.00 Patient on maximal tolerated therapy for diabetes 
12247 8I6G.00 Diabetic foot examination not indicated 
12262 8I3X.00 Diabetic retinopathy screening refused 
12307 66AU.00 Diabetes care by hospital only 
12455 C10E.11 Type I diabetes mellitus 
12506 66AP.00 Diabetes: practice programme 
12640 C10FC00 Type 2 diabetes mellitus with nephropathy 
12675 66AQ.00 Diabetes: shared care programme 
12736 C10F500 Type 2 diabetes mellitus with gangrene 
13071 66AI.00 Diabetic - good control 
13078 13AC.00 Diabetic weight reducing diet 
13097 2BBT.00 O/E - right eye proliferative diabetic retinopathy 
13099 2BBR.00 O/E - right eye preproliferative diabetic retinopathy 
13101 2BBV.00 O/E - left eye proliferative diabetic retinopathy 
13102 2BBW.00 O/E - right eye diabetic maculopathy 
13103 2BBS.00 O/E - left eye preproliferative diabetic retinopathy 
13108 2BBX.00 O/E - left eye diabetic maculopathy 
13279 C104y00 Other specified diabetes mellitus with renal complications 
14049 42WZ.00 Hb. A1C - diabetic control NOS 
14050 42c..00 HbA1 - diabetic control 
14803 C100100 Diabetes mellitus, adult onset, no mention of complication 
14889 C100111 Maturity onset diabetes 
15690 C103.00 Diabetes mellitus with ketoacidotic coma 
16230 C106.00 Diabetes mellitus with neurological manifestation 
16490 66AH.00 Diabetic treatment changed 
16491 C106.13 Diabetes mellitus with polyneuropathy 
16502 C104.00 Diabetes mellitus with renal manifestation 
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16881 ZV65312 [V]Dietary counselling in diabetes mellitus 
17067 F171100 Autonomic neuropathy due to diabetes 
17095 2G5A.00 O/E - Right diabetic foot at risk 
17236 14P3.00 H/O: insulin therapy 
17247 F35z000 Diabetic mononeuritis NOS 
17262 C109600 Non-insulin-dependent diabetes mellitus with retinopathy 
17313 F440700 Diabetic iritis 
17545 C108F11 Type I diabetes mellitus with diabetic cataract 
17817 7L19800 Subcutaneous injection of insulin 
17858 C108.12 Type 1 diabetes mellitus 
17859 C109.12 Type 2 diabetes mellitus 
17869 66AL.00 Diabetic-uncooperative patient 
17886 66AM.00 Diabetic - follow-up default 
18056 2G5C.00 Foot abnormality - diabetes related 
18142 N030000 Diabetic cheiroarthropathy 
18143 C109G11 Type II diabetes mellitus with arthropathy 
18167 66AT.00 Annual diabetic blood test 
18209 C109012 Type 2 diabetes mellitus with renal complications 
18219 C109.13 Type II diabetes mellitus 
18230 C108J12 Type 1 diabetes mellitus with neuropathic arthropathy 
18264 C109J12 Insulin treated Type II diabetes mellitus 
18278 C109J00 Insulin treated Type 2 diabetes mellitus 
18311 68A7.00 Diabetic retinopathy screening 
18387 C10E700 Type 1 diabetes mellitus with retinopathy 
18390 C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
18425 C10FB00 Type 2 diabetes mellitus with polyneuropathy 
18496 C10F600 Type 2 diabetes mellitus with retinopathy 
18505 C108.11 IDDM-Insulin dependent diabetes mellitus 
18642 C10EH00 Type 1 diabetes mellitus with arthropathy 
18662 8HBH.00 Diabetic retinopathy 6 month review 
18683 C10E500 Type 1 diabetes mellitus with ulcer 
18747 8I6F.00 Diabetic retinopathy screening not indicated 
18777 C10F000 Type 2 diabetes mellitus with renal complications 
18824 8I3W.00 Diabetic foot examination declined 
19381 8HTk.00 Referral to diabetic eye clinic 
19739 68A9.00 Diabetic retinopathy screening offered 
20696 66AA.11 Injection sites - diabetic 
21482 C102.00 Diabetes mellitus with hyperosmolar coma 
21983 C108012 Type 1 diabetes mellitus with renal complications 
22023 66AJz00 Diabetic - poor control NOS 
22573 C106z00 Diabetes mellitus NOS with neurological manifestation 
22823 66Ab.00 Diabetic foot examination 
22871 C10EP00 Type 1 diabetes mellitus with exudative maculopathy 
22884 C10F.11 Type II diabetes mellitus 
22967 2BBF.00 Retinal abnormality - diabetes related 
23479 C350011 Bronzed diabetes 
24327 M271000 Ischaemic ulcer diabetic foot 
24363 8A13.00 Diabetic stabilisation 
24423 C108.13 Type I diabetes mellitus 
24458 C109711 Type II diabetes mellitus - poor control 
24490 C100000 Diabetes mellitus, juvenile type, no mention of complication 
24571 F372200 Asymptomatic diabetic neuropathy 
24693 C109G00 Non-insulin dependent diabetes mellitus with arthropathy 
24694 C108B00 Insulin dependent diabetes mellitus with mononeuropathy 
24836 C109C12 Type 2 diabetes mellitus with nephropathy 
25041 ZC2CA00 Dietary advice for type II diabetes 
25591 C10FQ00 Type 2 diabetes mellitus with exudative maculopathy 
25627 C10F700 Type 2 diabetes mellitus - poor control 
26054 C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
26664 2G5B.00 O/E - Left diabetic foot at risk 
26666 2G5E.00 O/E - Right diabetic foot at low risk 
26667 2G5I.00 O/E - Left diabetic foot at low risk 
26855 C108400 Unstable insulin dependant diabetes mellitus 
27891 N030100 Diabetic Charcot arthropathy 
27921 2G51000 Foot abnormality - diabetes related 
28769 66AV.00 Diabetic on insulin and oral treatment 
28856 8CP2.00 Transition of diabetes care options discussed 
28873 66Ai.00 Diabetic 6 month review 
29041 66AN.00 Date diabetic treatment start 
29979 C109900 Non-insulin-dependent diabetes mellitus without complication 
30247 TJ23000 Adverse reaction to insulins 
30294 C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
30323 C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
30477 F420700 High risk proliferative diabetic retinopathy 
30648 9N4p.00 Did not attend diabetic retinopathy clinic 
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31053 R054300 [D]Widespread diabetic foot gangrene 
31156 2G5J.00 O/E - Left diabetic foot at moderate risk 
31157 2G5F.00 O/E - Right diabetic foot at moderate risk 
31171 2G5G.00 O/E - Right diabetic foot at high risk 
31172 2G5K.00 O/E - Left diabetic foot at high risk 
31310 C108900 Insulin dependant diabetes maturity onset 
31790 F372.00 Polyneuropathy in diabetes 
32359 ZRbH.00 Perceived control of insulin-dependent diabetes 
32403 C107.11 Diabetes mellitus with gangrene 
32556 C107.12 Diabetes with gangrene 
32627 C10FN00 Type 2 diabetes mellitus with ketoacidosis 
33254 C105.00 Diabetes mellitus with ophthalmic manifestation 
33343 C10y.00 Diabetes mellitus with other specified manifestation 
33807 C107200 Diabetes mellitus, adult with gangrene 
34152 G73y000 Diabetic peripheral angiopathy 
34268 C10F200 Type 2 diabetes mellitus with neurological complications 
34283 C105z00 Diabetes mellitus NOS with ophthalmic manifestation 
34450 C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
34528 3882 Diabetes well being questionnaire 
34912 C109400 Non-insulin dependent diabetes mellitus with ulcer 
35105 C104100 Diabetes mellitus, adult onset, with renal manifestation 
35107 C104z00 Diabetes mellitis with nephropathy NOS 
35116 2G5L.00 O/E - Left diabetic foot - ulcerated 
35288 C10E800 Type 1 diabetes mellitus - poor control 
35316 2G5H.00 O/E - Right diabetic foot - ulcerated 
35321 8H3O.00 Non-urgent diabetic admission 
35383 9OLD.00 Diabetic patient unsuitable for digital retinal photography 
35385 C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
35399 C107.00 Diabetes mellitus with peripheral circulatory disorder 
35785 F372100 Chronic painful diabetic neuropathy 
36633 C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
36695 C10D.00 Diabetes mellitus autosomal dominant type 2 
36798 7L10000 Continuous subcutaneous infusion of insulin 
37315 F3y0.00 Diabetic mononeuropathy 
37648 C109J11 Insulin treated non-insulin dependent diabetes mellitus 
37806 C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
38076 M21yC00 Insulin lipohypertrophy 
38130 ZRB6.00 Diabetes wellbeing questionnaire 
38161 C108711 Type I diabetes mellitus with retinopathy 
38617 C101y00 Other specified diabetes mellitus with ketoacidosis 
38986 C100.00 Diabetes mellitus with no mention of complication 
39070 C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma 
39317 C106100 Diabetes mellitus, adult onset, + neurological manifestation 
39420 F381300 Myasthenic syndrome due to diabetic amyotrophy 
39809 C108J00 Insulin dependent diab mell with neuropathic arthropathy 
40023 C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma 
40401 C109500 Non-insulin dependent diabetes mellitus with gangrene 
40682 C10E900 Type 1 diabetes mellitus maturity onset 
40837 C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
40962 C109H00 Non-insulin dependent d m with neuropathic arthropathy 
41049 C108712 Type 1 diabetes mellitus with retinopathy 
41389 C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation 
41686 Cyu2000 [X]Other specified diabetes mellitus 
41716 C108C00 Insulin dependent diabetes mellitus with polyneuropathy 
42505 C101z00 Diabetes mellitus NOS with ketoacidosis 
42567 C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma 
42729 C108E11 Type I diabetes mellitus with hypoglycaemic coma 
42762 C109612 Type 2 diabetes mellitus with retinopathy 
42831 C10E200 Type 1 diabetes mellitus with neurological complications 
43139 C102100 Diabetes mellitus, adult onset, with hyperosmolar coma 
43227 C10F311 Type II diabetes mellitus with multiple complications 
43453 C10C.00 Diabetes mellitus autosomal dominant 
43493 M21yC11 Insulin site lipohypertrophy 
43785 C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma 
43857 C10M.00 Lipoatrophic diabetes mellitus 
43921 C10E400 Unstable type 1 diabetes mellitus 
43951 66AK.00 Diabetic - cooperative patient 
44033 F345000 Diabetic mononeuritis multiplex 
44260 C108F00 Insulin dependent diabetes mellitus with diabetic cataract 
44312 9M10.00 Informed dissent for diabetes national audit 
44440 C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma 
44443 C108500 Insulin dependent diabetes mellitus with ulcer 
44779 C109E12 Type 2 diabetes mellitus with diabetic cataract 
44982 C10FE00 Type 2 diabetes mellitus with diabetic cataract 
45276 C10E312 Insulin dependent diabetes mellitus with multiple complicat 
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45467 C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy 
45491 C10z.00 Diabetes mellitus with unspecified complication 
45499 K01x111 Kimmelstiel - Wilson disease 
45913 C109712 Type 2 diabetes mellitus - poor control 
45914 C108812 Type 1 diabetes mellitus - poor control 
45919 C109212 Type 2 diabetes mellitus with neurological complications 
46150 C109512 Type 2 diabetes mellitus with gangrene 
46290 C108y00 Other specified diabetes mellitus with multiple comps 
46301 C10EC00 Type 1 diabetes mellitus with polyneuropathy 
46624 C10C.11 Maturity onset diabetes in youth 
46850 C108811 Type I diabetes mellitus - poor control 
46917 C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
46963 C108000 Insulin-dependent diabetes mellitus with renal complications 
47032 8CS0.00 Diabetes care plan agreed 
47058 8Hg4.00 Discharged from care of diabetes specialist nurse 
47315 C10F711 Type II diabetes mellitus - poor control 
47321 C10F100 Type 2 diabetes mellitus with ophthalmic complications 
47328 2BBk.00 O/E - right eye stable treated prolif diabetic retinopathy 
47341 8A12.00 Diabetic crisis monitoring 
47370 8HLE.00 Diabetology D.V. done 
47377 C105y00 Other specified diabetes mellitus with ophthalmic complicatn 
47409 C109B11 Type II diabetes mellitus with polyneuropathy 
47582 C10E000 Type 1 diabetes mellitus with renal complications 
47584 F420500 Advanced diabetic retinal disease 
47649 C10E100 Type 1 diabetes mellitus with ophthalmic complications 
47650 C10E300 Type 1 diabetes mellitus with multiple complications 
47816 C109H11 Type II diabetes mellitus with neuropathic arthropathy 
47954 C10F900 Type 2 diabetes mellitus without complication 
48078 F372000 Acute painful diabetic neuropathy 
48192 C109E11 Type II diabetes mellitus with diabetic cataract 
48310 ZV6DA00 [V]Admitted for commencement of insulin 
49074 C10F400 Type 2 diabetes mellitus with ulcer 
49146 C108211 Type I diabetes mellitus with neurological complications 
49276 C108100 Insulin-dependent diabetes mellitus with ophthalmic comps 
49554 C10EF00 Type 1 diabetes mellitus with diabetic cataract 
49640 2G5W.00 O/E - left chronic diabetic foot ulcer 
49655 C10F611 Type II diabetes mellitus with retinopathy 
49869 C109G12 Type 2 diabetes mellitus with arthropathy 
49884 6761 Diabetic pre-pregnancy counselling 
49949 C10E411 Unstable type I diabetes mellitus 
50175 66AW.00 Diabetic foot risk assessment 
50225 C109011 Type II diabetes mellitus with renal complications 
50429 C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps 
50527 C10FB11 Type II diabetes mellitus with polyneuropathy 
50609 L180600 Pre-existing diabetes mellitus, non-insulin-dependent 
50813 C109A11 Type II diabetes mellitus with mononeuropathy 
50960 L180500 Pre-existing diabetes mellitus, insulin-dependent 
50972 C100z00 Diabetes mellitus NOS with no mention of complication 
51261 C10E.12 Insulin dependent diabetes mellitus 
51697 C10G.00 Secondary pancreatic diabetes mellitus 
51756 C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
51939 ZV6DB00 [V]Admitted for conversion to insulin 
51957 C108511 Type I diabetes mellitus with ulcer 
52041 2BBl.00 O/E - left eye stable treated prolif diabetic retinopathy 
52104 C108300 Insulin dependent diabetes mellitus with multiple complicatn 
52212 Cyu2.00 [X]Diabetes mellitus 
52237 9360 Patient held diabetic record issued 
52283 C108200 Insulin-dependent diabetes mellitus with neurological comps 
52303 C109000 Non-insulin-dependent diabetes mellitus with renal comps 
52630 2BBo.00 O/E - sight threatening diabetic retinopathy 
53200 C101000 Diabetes mellitus, juvenile type, with ketoacidosis 
53238 66AG.00 Diabetic drug side effects 
53392 C10F911 Type II diabetes mellitus without complication 
53630 C110.11 Insulin coma 
53634 R054200 [D]Gangrene of toe in diabetic 
54008 C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy 
54212 C109F00 Non-insulin-dependent d m with peripheral angiopath 
54600 C10E412 Unstable insulin dependent diabetes mellitus 
54601 9NN8.00 Under care of diabetologist 
54856 C101100 Diabetes mellitus, adult onset, with ketoacidosis 
54899 C109F11 Type II diabetes mellitus with peripheral angiopathy 
55075 C109411 Type II diabetes mellitus with ulcer 
55239 C10EQ00 Type 1 diabetes mellitus with gastroparesis 
55431 L180X00 Pre-existing diabetes mellitus, unspecified 
55842 C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
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56268 C109D11 Type II diabetes mellitus with hypoglycaemic coma 
56448 C108A00 Insulin-dependent diabetes without complication 
57278 C10F011 Type II diabetes mellitus with renal complications 
57333 N030011 Diabetic cheiropathy 
57389 93C4.00 Patient consent given for addition to diabetic register 
57621 C108D00 Insulin dependent diabetes mellitus with nephropathy 
57723 8HHy.00 Referral to diabetic register 
58133 ZLD7500 Discharge by diabetic liaison nurse 
58159 8I3k.00 Insulin therapy declined 
58604 C109611 Type II diabetes mellitus with retinopathy 
59253 C10FG00 Type 2 diabetes mellitus with arthropathy 
59288 C103y00 Other specified diabetes mellitus with coma 
59365 C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
59725 C109111 Type II diabetes mellitus with ophthalmic complications 
59903 C106.11 Diabetic amyotrophy 
59991 C10D.11 Maturity onset diabetes in youth type 2 
60107 C108411 Unstable type I diabetes mellitus 
60208 C108J11 Type I diabetes mellitus with neuropathic arthropathy 
60499 C108600 Insulin dependent diabetes mellitus with gangrene 
60699 C109F12 Type 2 diabetes mellitus with peripheral angiopathy 
60796 C10FL11 Type II diabetes mellitus with persistent proteinuria 
61021 68AB.00 Diabetic digital retinopathy screening offered 
61071 C109D12 Type 2 diabetes mellitus with hypoglycaemic coma 
61210 TJ23z00 Adverse reaction to insulins and antidiabetic agents NOS 
61344 C108011 Type I diabetes mellitus with renal complications 
61461 9M00.00 Informed consent for diabetes national audit 
61520 C110000 Iatrogenic hyperinsulinism 
61523 C106y00 Other specified diabetes mellitus with neurological comps 
61557 8HKE.00 Diabetology D.V. requested 
61670 889A.00 Diab mellit insulin-glucose infus acute myocardial infarct 
61829 C108212 Type 1 diabetes mellitus with neurological complications 
62107 C109511 Type II diabetes mellitus with gangrene 
62146 C109300 Non-insulin-dependent diabetes mellitus with multiple comps 
62209 C10EM11 Type I diabetes mellitus with ketoacidosis 
62352 C108H11 Type I diabetes mellitus with arthropathy 
62384 2G5V.00 O/E - right chronic diabetic foot ulcer 
62613 C10EA11 Type I diabetes mellitus without complication 
62674 C10FA00 Type 2 diabetes mellitus with mononeuropathy 
63017 C108911 Type I diabetes mellitus maturity onset 
63357 C107100 Diabetes mellitus, adult, + peripheral circulatory disorder 
63364 U602312 [X] Adverse reaction to insulins 
63371 C10y100 Diabetes mellitus, adult, + other specified manifestation 
63412 8CR2.00 Diabetes clinical management plan 
63690 C10FR00 Type 2 diabetes mellitus with gastroparesis 
63762 C10z100 Diabetes mellitus, adult onset, + unspecified complication 
64142 8Hl1.00 Referral for diabetic retinopathy screening 
64283 C10zy00 Other specified diabetes mellitus with unspecified comps 
64357 C10zz00 Diabetes mellitus NOS with unspecified complication 
64446 C108G00 Insulin dependent diab mell with peripheral angiopathy 
64449 C108z00 Unspecified diabetes mellitus with multiple complications 
64571 C109C11 Type II diabetes mellitus with nephropathy 
64668 C10FJ11 Insulin treated Type II diabetes mellitus 
65025 C107z00 Diabetes mellitus NOS with peripheral circulatory disorder 
65062 C103z00 Diabetes mellitus NOS with ketoacidotic coma 
65267 C10F300 Type 2 diabetes mellitus with multiple complications 
65463 F420800 High risk non proliferative diabetic retinopathy 
65616 C108H00 Insulin dependent diabetes mellitus with arthropathy 
65684 U602311 [X] Adverse reaction to insulins and antidiabetic agents 
65704 C109412 Type 2 diabetes mellitus with ulcer 
66145 C10EN11 Type I diabetes mellitus with ketoacidotic coma 
66274 66Ah.00 Insulin needles changed for each injection 
66872 C108D11 Type I diabetes mellitus with nephropathy 
66965 C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
67853 C106000 Diabetes mellitus, juvenile, + neurological manifestation 
67905 C109211 Type II diabetes mellitus with neurological complications 
68105 C10EB00 Type 1 diabetes mellitus with mononeuropathy 
68390 C108512 Type 1 diabetes mellitus with ulcer 
68546 ZRB4.00 Diabetes clinic satisfaction questionnaire 
68792 C10z000 Diabetes mellitus, juvenile type, + unspecified complication 
68818 ZRB5.11 DTSQ - Diabetes treatment satisfaction questionnaire 
68843 C103100 Diabetes mellitus, adult onset, with ketoacidotic coma 
68928 TJ23.00 Adverse reaction to insulins and antidiabetic agents 
69043 ZC2C900 Dietary advice for type I diabetes 
69152 66Aj.00 Insulin needles changed less than once a day 
69278 C109E00 Non-insulin depend diabetes mellitus with diabetic cataract 
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69676 C10EA00 Type 1 diabetes mellitus without complication 
69748 C105000 Diabetes mellitus, juvenile type, + ophthalmic manifestation 
69993 C10E600 Type 1 diabetes mellitus with gangrene 
70316 C109112 Type 2 diabetes mellitus with ophthalmic complications 
70448 C107000 Diabetes mellitus, juvenile +peripheral circulatory disorder 
70766 C108E12 Type 1 diabetes mellitus with hypoglycaemic coma 
70821 C10yz00 Diabetes mellitus NOS with other specified manifestation 
72320 C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy 
72333 8HME.00 Listed for Diabetology admissn 
72345 C102z00 Diabetes mellitus NOS with hyperosmolar coma 
72702 C10E812 Insulin dependent diabetes mellitus - poor control 
83485 66Am.00 Insulin dose changed 
83532 66Ao.00 Diabetes type 2 review 
85660 66An.00 Diabetes type 1 review 
85991 C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
90301 66Ag.00 Insulin needles changed daily 
91164 ZRB4.11 CSQ - Diabetes clinic satisfaction questionnaire 
91646 C10F411 Type II diabetes mellitus with ulcer 
91942 C10E311 Type I diabetes mellitus with multiple complications 
91943 C10EC11 Type I diabetes mellitus with polyneuropathy 
93380 C10N100 Cystic fibrosis related diabetes mellitus 
93390 9OLH.00 Attended DAFNE diabetes structured education programme 
93468 C10EG00 Type 1 diabetes mellitus with peripheral angiopathy 
93491 9OLJ.00 DAFNE diabetes structured education programme completed 
93631 9OLL.00 XPERT diabetes structured education programme completed 
93704 8Hj3.00 Referral to DAFNE diabetes structured education programme 
93727 C10FE11 Type II diabetes mellitus with diabetic cataract 
93870 8Hj5.00 Referral to XPERT diabetes structured education programme 
93875 C10E712 Insulin dependent diabetes mellitus with retinopathy 
93878 C10E511 Type I diabetes mellitus with ulcer 
93922 C104000 Diabetes mellitus, juvenile type, with renal manifestation 
94011 9OLG.00 Attended XPERT diabetes structured education programme 
94699 ZRB5.00 Diabetes treatment satisfaction questionnaire 
94955 9NiE.00 Did not attend XPERT diabetes structured education programme 
94956 8I84.00 Did not complete XPERT diabetes structured education program 
95343 C10E711 Type I diabetes mellitus with retinopathy 
95351 C10FA11 Type II diabetes mellitus with mononeuropathy 
95636 C10ER00 Latent autoimmune diabetes mellitus in adult 
95992 C108A11 Type I diabetes mellitus without complication 
95994 66Aq.00 Diabetic foot screen 
96010 66Ap.00 Insulin treatment initiated 
96143 9kL..00 Insulin initiation - enhanced services administration 
96235 C10E911 Type I diabetes mellitus maturity onset 
96506 C10G000 Secondary pancreatic diabetes mellitus without complication 
97446 C108912 Type 1 diabetes mellitus maturity onset 
97474 C108412 Unstable type 1 diabetes mellitus 
97809 8I82.00 Did not complete DAFNE diabetes structured education program 
97824 ZRB6.11 DWBQ - Diabetes wellbeing questionnaire 
97849 C10E912 Insulin dependent diabetes maturity onset 
97894 C10EP11 Type I diabetes mellitus with exudative maculopathy 
98071 C10E112 Insulin-dependent diabetes mellitus with ophthalmic comps 
98392 C10C.12 Maturity onset diabetes in youth type 1 
98616 C10F211 Type II diabetes mellitus with neurological complications 
98704 C10E512 Insulin dependent diabetes mellitus with ulcer 
98723 C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
98954 3883 Diabetes treatment satisfaction questionnaire 
99231 C108B11 Type I diabetes mellitus with mononeuropathy 
99277 9NiC.00 Did not attend DAFNE diabetes structured education programme 
99311 C10E111 Type I diabetes mellitus with ophthalmic complications 
99628 Kyu0300 [X]Glomerular disorders in diabetes mellitus 
99716 C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma 
99719 C10EA12 Insulin-dependent diabetes without complication 
100033 U60231E [X] Adverse reaction to insulins and antidiabetic agents NOS 
100292 Cyu2300 [X]Unspecified diabetes mellitus with renal complications 
100770 C10EF12 Insulin dependent diabetes mellitus with diabetic cataract 
100964 C10F111 Type II diabetes mellitus with ophthalmic complications 
101311 C10EC12 Insulin dependent diabetes mellitus with polyneuropathy 
101735 C10E212 Insulin-dependent diabetes mellitus with neurological comps 
101881 2BBr.00 Impaired vision due to diabetic retinopathy 
102112 C10E611 Type I diabetes mellitus with gangrene 
102163 C10ED12 Insulin dependent diabetes mellitus with nephropathy 
102201 C10FC11 Type II diabetes mellitus with nephropathy 
102434 66Au.00 Diabetic erectile dysfunction review 
102490 66Av.00 Diabetic assessment of erectile dysfunction 
102611 66At111 Type 2 diabetic dietary review 
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102620 C10EL11 Type I diabetes mellitus with persistent microalbuminuria 
102704 66At000 Type I diabetic dietary review 
102740 C108112 Type 1 diabetes mellitus with ophthalmic complications 
102768 9NiZ.00 Did not attend diabetes foot screening 
102946 C10E012 Insulin-dependent diabetes mellitus with renal complications 
103743 8IE2.00 Diabetes care plan declined 
103902 C10FG11 Type II diabetes mellitus with arthropathy 
103935 1IA..00 No evidence of diabetic nephropathy 
104254 7L10011 Subcutaneous infusion with insulin pump 
104287 8Hlc.00 Referral to community diabetes service 
104323 C10F511 Type II diabetes mellitus with gangrene 
104374 67D8.00 Provision of diabetes clinical summary 
104453 66At011 Type 1 diabetic dietary review 
104639 C10FF11 Type II diabetes mellitus with peripheral angiopathy 
105207 8HTE100 Referral to community diabetes clinic 
105302 K08yA00 Proteinuric diabetic nephropathy 
105337 C10E811 Type I diabetes mellitus - poor control 
105446 679c.00 Insulin administration education 
105585 8CMW700 Diabetes clinical pathway 
105740 2G5d.00 O/E - Left diabetic foot at increased risk 
105741 2G5e.00 O/E - Right diabetic foot at increased risk 
105784 C109912 Type 2 diabetes mellitus without complication 
105937 8IEQ.00 Referral to community diabetes specialist nurse declined 
106061 C10FP11 Type II diabetes mellitus with ketoacidotic coma 
106218 9m0A.00 Declined diabetic retinopathy screening 
106269 9m0..00 Diabetic retinopathy screening administrative status 
106327 9m04.00 Excluded from diabetic retinopathy screening 
106328 9m07.00 Excluded diabetc retinop screen as under care ophthalmolgist 
106329 9m08.00 Excluded from diabetic retinopathy screening as blind 
106332 9m00.00 Eligible for diabetic retinopathy screening 
106350 9m05.00 Excluded from diabetic retinopathy screening as moved away 
106351 9m09.00 Excluded from diabetic retinop screen as no longer diabetic 
106352 9m06.00 Excluded from diabetic retinopathy screening as deceased 
106360 K27y700 Erectile dysfunction due to diabetes mellitus 
106441 9m01.00 Ineligible for diabetic retinopathy screening 
106445 9m0E.00 Excluded from diabetic retinopathy screen physical disorder 
106528 C10FN11 Type II diabetes mellitus with ketoacidosis 
106679 8OA3.00 Provision of written information about diabetes and driving 
106722 9Oy0300 Diabetic foot screening invitation second letter 
106723 9Oy0200 Diabetic foot screening invitation first letter 
106738 9Oy0000 Diabetic foot screening invitation 
106778 9m0C.00 Excluded frm diabetic retinopathy screen as terminal illness 
106953 8IEa.00 Referral to DAFNE diabetes structured educn prog declined 
107331 66AH100 Conversion to insulin in secondary care 
107361 679L200 Education about diabetes and driving 
107414 8I94.00 Diabetes structured education programme not available 
107423 661N400 Diabetes self-management plan review 
107464 66AS000 Diabetes Year of Care annual review 
107508 66AH200 Conversion to insulin by diabetes specialist nurse 
107597 9m0D.00 Excluded from diabetic retinopthy screen as learn disability 
107603 C10P.00 Diabetes mellitus in remission 
107701 C10FK11 Hyperosmolar non-ketotic state in type II diabetes mellitus 
107739 679L211 Advice about diabetes and driving 
107793 9Oy0400 Diabetic foot screening invitation third letter 
107824 C10P100 Type II diabetes mellitus in remission 
107881 K08yA11 Clinical diabetic nephropathy 
108005 C109312 Type 2 diabetes mellitus with multiple complications 
108007 C108311 Type I diabetes mellitus with multiple complications 
108360 C10P000 Type I diabetes mellitus in remission 
108634 9NJy.00 In-house diabetic foot screening 
108655 8BAp.00 Insulin passport not checked 
108724 C10EQ11 Type I diabetes mellitus with gastroparesis 
108890 679L300 Diabetic foot care education 
108993 661M400 Diabetes self-management plan agreed 
109051 C10E612 Insulin dependent diabetes mellitus with gangrene 
109103 C109911 Type II diabetes mellitus without complication 
109197 C10FH11 Type II diabetes mellitus with neuropathic arthropathy 
109520 9m03.00 Eligibility permanently inactive for diabetic retinop screen 
109521 9m02.00 Eligibility temporarily inactive for diabetic retinop screen 
109628 C10P011 Type 1 diabetes mellitus in remission 
109643 66o1.00 Enquiry about diabetic erectile dysfunction declined 
109700 66AH300 Conversion to non-insulin injectable medication 
109760 1M8..00 Diabetic peripheral neuropathic pain 
109806 8Hgd.00 Discharge from secondary care diabetes service 
109837 C10E011 Type I diabetes mellitus with renal complications 
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109865 C109B12 Type 2 diabetes mellitus with polyneuropathy 
109878 ZC2C911 Diet advice for insulin-dependent diabetes 
110344 66o2.00 Diabetic on non-insulin injectable medication 
110379 66o5.00 Diabetic on oral treatment and glucagon-like peptide 1 
110393 13B1000 Diabetic carbohydrate counting diet 
110400 C108F12 Type 1 diabetes mellitus with diabetic cataract 
110409 679l.00 Diabetic injection administration education 
110611 C10P111 Type 2 diabetes mellitus in remission 
110997 C10y000 Diabetes mellitus, juvenile, + other specified manifestation 
111106 C108A12 Type 1 diabetes mellitus without complication 
 
B) Hospital Episodes Statistics 
ICD 10 DESCRIPTION 
E10 Type 1 diabetes mellitus 
E10.0 Type 1 diabetes mellitus 
E10.1 Type 1 diabetes mellitus 
E10.2 Type 1 diabetes mellitus 
E10.3 Type 1 diabetes mellitus 
E10.4 Type 1 diabetes mellitus 
E10.5 Type 1 diabetes mellitus 
E10.6 Type 1 diabetes mellitus 
E10.7 Type 1 diabetes mellitus 
E10.8 Type 1 diabetes mellitus 
E10.9 Type 1 diabetes mellitus 
E11 Type 2 diabetes mellitus 
E11.0 Type 2 diabetes mellitus 
E11.1 Type 2 diabetes mellitus 
E11.2 Type 2 diabetes mellitus 
E11.3 Type 2 diabetes mellitus 
E11.4 Type 2 diabetes mellitus 
E11.5 Type 2 diabetes mellitus 
E11.6 Type 2 diabetes mellitus 
E11.7 Type 2 diabetes mellitus 
E11.8 Type 2 diabetes mellitus 
E11.9 Type 2 diabetes mellitus 
E13 Other specified diabetes mellitus 
E13.0 Other specified diabetes mellitus 
E13.1 Other specified diabetes mellitus 
E13.2 Other specified diabetes mellitus 
E13.3 Other specified diabetes mellitus 
E13.4 Other specified diabetes mellitus 
E13.5 Other specified diabetes mellitus 
E13.6 Other specified diabetes mellitus 
E13.7 Other specified diabetes mellitus 
E13.8 Other specified diabetes mellitus 
E13.9 Other specified diabetes mellitus 
E14 Unspecified diabetes mellitus 
E14.0 Unspecified diabetes mellitus 
E14.1 Unspecified diabetes mellitus 
E14.2 Unspecified diabetes mellitus 
E14.3 Unspecified diabetes mellitus 
E14.4 Unspecified diabetes mellitus 
E14.5 Unspecified diabetes mellitus 
E14.6 Unspecified diabetes mellitus 
E14.7 Unspecified diabetes mellitus 
E14.8 Unspecified diabetes mellitus 
E14.9 Unspecified diabetes mellitus 
G59.0 Diabetic mononeuropathy 
G63.2 Diabetic polyneuropathy 
H28.0 Diabetic cataract 
H36.0 Diabetic retinopathy 
M14.2 Diabetic arthropathy 
N08.3 Glomerular disorders in diabetes mellitus 
O24.0 Diabetes mellitus in pregnancy: Pre-existing type 1 diabetes mellitus 
O24.1 Diabetes mellitus in pregnancy: Pre-existing type 2 diabetes mellitus 
O24.3 Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, unspecified 
 
6. Chronic kidney disease 
A) CPRD 
medcode readcode readterm 
512 K05..00 Chronic renal failure 
1803 K011.00 Nephrotic syndrome with membranous glomerulonephritis 
365 
 
medcode readcode readterm 
2088 K00..00 Acute glomerulonephritis 
2471 K01x100 Nephrotic syndrome in diabetes mellitus 
2475 C104.11 Diabetic nephropathy 
2773 K0...00 Nephritis  nephrosis and nephrotic syndrome 
2994 7L1A100 Peritoneal dialysis 
2995 G760.00 Acquired arteriovenous fistula 
2996 7L1A200 Haemodialysis NEC 
2999 K01..00 Nephrotic syndrome 
3205 7A60100 Creation of arteriovenous fistula NEC 
4480 K07z.00 Renal sclerosis NOS 
4668 G22..00 Hypertensive renal disease 
4669 K02y200 Chronic focal glomerulonephritis 
4850 K03..11 Nephritis and nephropathy unspecified 
5182 K03z.00 Unspecified glomerulonephritis NOS 
5291 K031.00 Membranous nephritis unspecified 
5417 K00..11 Acute nephritis 
6712 K050.00 End stage renal failure 
7190 K072.00 Glomerulosclerosis 
7804 K02..00 Chronic glomerulonephritis 
8037 7L1B000 Insertion of ambulatory peritoneal dialysis catheter 
8330 K0D..00 End-stage renal disease 
8607 K0C0.00 Analgesic nephropathy 
8668 K0A..00 Glomerular disease 
8828 14D1.00 H/O: nephritis 
8919 K08..00 Impaired renal function disorder 
9379 K08y500 Acute interstitial nephritis 
9765 7A61400 Ligation of acquired arteriovenous fistula 
9840 K010.00 Nephrotic syndrome with proliferative glomerulonephritis 
10081 K05..11 Chronic uraemia 
10418 C10ED00 Type 1 diabetes mellitus with nephropathy 
10636 J624.00 Hepatorenal syndrome 
10647 K02..11 Nephritis - chronic 
10809 K021.00 Chronic membranous glomerulonephritis 
11553 SP08300 Kidney transplant failure and rejection 
11773 7L1A.11 Dialysis for renal failure 
11873 K03..12 Nephropathy  unspecified 
11875 K02..12 Nephropathy - chronic 
12465 K032.00 Membranoproliferative nephritis unspecified 
12479 1Z13.00 Chronic kidney disease stage 4 
12566 1Z12.00 Chronic kidney disease stage 3 
12585 1Z14.00 Chronic kidney disease stage 5 
12586 1Z11.00 Chronic kidney disease stage 2 
12640 C10FC00 Type 2 diabetes mellitus with nephropathy 
12720 1Z1..00 Chronic renal impairment 
13279 C104y00 Other specified diabetes mellitus with renal complications 
15097 K02z.00 Chronic glomerulonephritis NOS 
15106 G22z.00 Hypertensive renal disease NOS 
15780 K0z..00 Nephritis  nephrosis and nephrotic syndrome NOS 
16008 K030.00 Proliferative nephritis unspecified 
16465 K190X00 Persistent proteinuria  
16502 C104.00 Diabetes mellitus with renal manifestation 
16929 D215.00 Anaemia secondary to renal failure 
17253 8L50.00 Renal transplant planned 
17365 K01B.00 Nephrotic syndrome  diffuse crescentic glomerulonephritis 
17434 G22..11 Nephrosclerosis 
18209 C109012 Type 2 diabetes mellitus with renal complications 
18390 C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
18777 C10F000 Type 2 diabetes mellitus with renal complications 
18779 7A61100 Repair of acquired arteriovenous fistula 
19316 K016.00 Nephrotic syndrome  diffuse membranous glomerulonephritis 
20027 K00y000 Acute glomerulonephritis in diseases EC 
20073 7L1A000 Renal dialysis 
20074 K00..12 Bright's disease 
20129 K00z.00 Acute glomerulonephritis NOS 
20196 14V2.00 H/O: renal dialysis 
20516 K13yz11 Salt-losing nephritis 
21297 K0A3.00 Chronic nephritic syndrome 
21423 K032600 Berger's IgA or IgG nephropathy 
21687 C345.00 Gout due to impairment of renal function 
21837 G232.00 Hypertensive heart&renal dis wth (congestive) heart failure 
21947 K017.00 Nephrotic syn difus mesangial prolifertiv glomerulonephritis 
21983 C108012 Type 1 diabetes mellitus with renal complications 
21989 K019.00 Nephrotic syn diffuse mesangiocapillary glomerulonephritis 
22205 K01x411 Lupus nephritis 
22252 ZV45100 [V]Renal dialysis status 
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medcode readcode readterm 
22852 K015.00 Nephrotic syndrome  focal and segmental glomerular lesions 
22897 D310100 Henoch-Schonlein nephritis 
23773 7L1B100 Removal of ambulatory peritoneal dialysis catheter 
23913 K014.00 Nephrotic syndrome  minor glomerular abnormality 
23990 K03T.00 Tubulo-interstit nephritis  not specif as acute or chron 
24151 7A60.00 Arteriovenous shunt 
24384 K032400 Familial glomerulonephritis in Alport's syndrome 
24736 K0C..00 Drug/heavy-metal-induced tubulo-interstitial and tub conditn 
24836 C109C12 Type 2 diabetes mellitus with nephropathy 
25394 D215000 Anaemia secondary to chronic renal failure 
25521 7A60112 Creation of brachial-cephalic fistula 
25980 K08z.00 Impaired renal function disorder NOS 
26054 C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
26220 K07..00 Renal sclerosis unspecified 
26862 7B06300 Exploration of renal transplant 
27335 K03y000 Other nephritis and nephrosis in diseases EC 
27427 K01z.00 Nephrotic syndrome NOS 
28158 TB11.00 Kidney dialysis with complication  without blame 
28269 7A60111 Creation of radial-cephalic fistula 
28684 G233.00 Hypertensive heart and renal disease with renal failure 
29013 1Z10.00 Chronic kidney disease stage 1 
29384 K000.00 Acute proliferative glomerulonephritis 
29634 K013.00 Nephrotic syndrome with minimal change glomerulonephritis 
29638 K080.00 Renal osteodystrophy 
30294 C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
30301 K03X.00 Unsp nephrit synd  diff mesang prolif glomerulonephritis 
30323 C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
30709 7L1C000 Insertion of temporary peritoneal dialysis catheter 
30756 7L1A500 Continuous ambulatory peritoneal dialysis 
31478 7A60300 Removal of infected arteriovenous shunt 
31549 7L1A.00 Compensation for renal failure 
31581 K0A0.00 Acute nephritic syndrome 
32423 G222.00 Hypertensive renal disease with renal failure 
33580 K03..00 Nephritis and nephropathy unspecified 
34637 K080z00 Renal osteodystrophy NOS 
34648 K080100 Renal dwarfism 
34669 K03y200 Other interstitial nephritis 
34998 K020.00 Chronic proliferative glomerulonephritis 
35065 K03y.00 Other nephritis and nephrosis unspecified 
35105 C104100 Diabetes mellitus  adult onset  with renal manifestation 
35107 C104z00 Diabetes mellitus with nephropathy NOS 
35921 TA22.00 Failure of sterile precautions during perfusion 
36125 K03U.00 Unspecif nephr synd  diff concentric glomerulonephritis 
36205 K0A5.00 Hereditary nephropathy not elsewhere classified 
36342 K032y13 Mesangioproliferative glomerulonephritis NEC 
36442 7L1B.11 Placement ambulatory dialysis apparatus - compens renal fail 
38572 K104.00 Xanthogranulomatous pyelonephritis 
39649 G220.00 Malignant hypertensive renal disease 
39840 K08y.00 Other impaired renal function disorder 
40349 K013.11 Lipoid nephrosis 
40413 K0A3100 Chronic nephritic syndrm focal+segmental glomerular lesions 
41013 K08y300 Renal function impairment with growth failure 
41148 K0B4000 Renal tubulo-interstitial disorder in SLE 
41159 K0C1.00 Nephropathy induced by other drugs meds and biologl substncs 
41239 K0A5100 Hereditary nephropathy NEC focal+segmnt glomerular lesion 
41285 K0A1200 Rapid progres neph syn diffuse membranous glomerulonephritis 
41676 K034.00 Renal cortical necrosis unspecified 
41881 K032y14 Mesangiocapillary glomerulonephritis NEC 
42632 PD12.00 Medullary cystic disease 
43611 K0A4.00 Isolated proteinuria with specified morphological lesion 
43935 G221.00 Benign hypertensive renal disease 
44055 K03yz00 Other nephritis and nephrosis NOS 
44270 K0A5200 Hereditry nephropathy NEC difus membran glomerulnephritis 
44422 14V2.11 H/O: kidney dialysis 
44541 K0A2600 Recurrent and persistent haematuria  dense deposit disease 
44804 K0A4100 Isolatd proteinur/specifd morphlgcl les foc+seg glom lesn 
45499 K01x111 Kimmelstiel - Wilson disease 
45523 K0B..00 Renal tubulo-interstitial disorders in diseases EC 
45867 K035.00 Renal medullary necrosis unspecified 
45904 K0B2.00 Ren tub-interst disordr/blood dis+disordr inv immune mech 
46145 ZV56011 [V]Aftercare involving renal dialysis NOS 
46963 C108000 Insulin-dependent diabetes mellitus with renal complications 
47135 PD12100 Medullary cystic disease  adult type 
47582 C10E000 Type 1 diabetes mellitus with renal complications 
47672 K01x400 Nephrotic syndrome in systemic lupus erythematosus 
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medcode readcode readterm 
47838 K00yz00 Other acute glomerulonephritis NOS 
47922 K01x000 Nephrotic syndrome in amyloidosis 
48022 7L1Ay00 Other specified compensation for renal failure 
48057 K0B5.00 Renal tubulo-interstitial disordrs in transplant rejectn 
48261 K00y200 Acute focal nephritis 
48475 K08yz11 Renal acidaemia 
49150 K0y..00 Other specified nephritis  nephrosis or nephrotic syndrome 
49642 K0A2300 Recur+persist haemuria df mesangial prolif glomerulnephritis 
50200 K0A1600 Rapid progressive nephritic syndrome  dense deposit disease 
50225 C109011 Type II diabetes mellitus with renal complications 
50305 K032y11 Hypocomplementaemic persistent glomerulonephritis NEC 
50472 K018.00 Nephrotic syn difus endocapilary proliftv glomerulonephritis 
50728 K080200 Renal infantilism 
50804 K08yz00 Other impaired renal function disorder NOS 
50893 K0C4.00 Toxic nephropathy not elsewhere classified 
51039 7B01200 Bilateral nephrectomy 
51113 K0A5000 Hereditary nephropathy NEC minor glomerular abnormality 
52303 C109000 Non-insulin-dependent diabetes mellitus with renal comps 
52969 C341.00 Gouty nephropathy 
53852 K05..12 End stage renal failure 
53940 Kyu2100 [X]Other chronic renal failure 
54312 K0A0500 Acute neph syn  diffuse mesangiocapillary glomerulonephritis 
54844 U612200 [X]Failure sterile precautions dur kidney dialys/other perf 
55100 K00y300 Acute diffuse nephritis 
55389 K0A0300 Acut neph syn  diffuse mesangial prolifrative glomnephritis 
55548 K0A7.00 Glom disordr in blood diseas+disordr invlvg imun mechansm 
56760 7L1B.00 Placement ambulatory apparatus compensation renal failure 
56893 K0A3300 Chron neph syn difus mesangial prolifrtiv glomerulonephritis 
56939 K08y000 Hypokalaemic nephropathy 
56987 K01A.00 Nephrotic syndrome  dense deposit disease 
57072 K032500 Other familial glomerulonephritis 
57168 K0A3200 Chron nephritic syndrom difuse membranous glomerulonephritis 
57278 C10F011 Type II diabetes mellitus with renal complications 
57621 C108D00 Insulin dependent diabetes mellitus with nephropathy 
57784 K0C2.00 Nephropathy induced by unspec drug medicament or biol subs 
57926 K013.12 Steroid sensitive nephrotic syndrome 
57987 G234.00 Hyperten heart&renal dis+both(congestv)heart and renal fail 
58060 K0A1300 Rpd prog neph syn df mesangial prolifratv glomerulonephritis 
58164 K033.00 Rapidly progressive nephritis unspecified 
58618 7A60z00 Arteriovenous shunt NOS 
58671 K0A5300 Heredtry nephrpthy NEC difus mesangial prolif glomnephrit 
58750 K01x300 Nephrotic syndrome in polyarteritis nodosa 
59194 7L1By00 Placement ambulatory apparatus- compensate renal failure OS 
59365 C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
59992 K0A4W00 Isolated proteinuria  with unspecified morpholog changes 
60128 K03V.00 Unspecified nephritic syndrome  dense deposit disease 
60198 K0A3600 Chronic nephritic syndrome  dense deposit disease 
60302 7A60600 Creation of graft fistula for dialysis 
60484 K0A2500 Recur+persist hmuria df mesangiocapilary glomerulonephritis 
60743 ZV56.00 [V]Aftercare involving intermittent dialysis 
60796 C10FL11 Type II diabetes mellitus with persistent proteinuria 
60856 K0A2700 Recur+persist haematuria difus crescentic glomerulonephritis 
60857 K0A3700 Chronic nephritic syn diffuse crescentic glomerulonephritis 
60960 K02y.00 Other chronic glomerulonephritis 
61145 C341z00 Gouty nephropathy NOS 
61317 K0A2200 Recur+persist haematuria difus membranous glomerulonephritis 
61344 C108011 Type I diabetes mellitus with renal complications 
61494 K022.00 Chronic membranoproliferative glomerulonephritis 
61811 K0A4500 Isoltd prteinur+specfd morph les df mesangiocap glomnephr 
61814 K0A0700 Acute nephrotic syndrm diffuse crescentic glomerulonephritis 
62320 K0A1700 Rapid progres nephritic syn df crescentic glomerulonephritis 
62520 K03W.00 Unsp nephrit synd  diff endocap prolif glomerulonephritis 
62868 K032300 Anaphylactoid glomerulonephritis 
62980 K0A5X00 Hereditary nephropathy  unspecif morphological changes 
63000 G231.00 Benign hypertensive heart and renal disease 
63063 7A60000 Insertion of arteriovenous prosthesis 
63190 7A60200 Attention to arteriovenous shunt 
63305 7A60500 Thrombectomy of arteriovenous fistula 
63466 G23..00 Hypertensive heart and renal disease 
63599 K00y.00 Other acute glomerulonephritis 
63615 K02yz00 Other chronic glomerulonephritis NOS 
63786 K01w.00 Congenital nephrotic syndrome 
64030 Kyu5G00 [X]Persistent proteinuria  unspecified 
64571 C109C11 Type II diabetes mellitus with nephropathy 
64636 7L1Az00 Compensation for renal failure NOS 
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medcode readcode readterm 
64828 7L1A600 Peritoneal dialysis NEC 
65064 K023.00 Chronic rapidly progressive glomerulonephritis 
65089 7L1Cz00 Placement other apparatus- compensate for renal failure NOS 
65398 7A60y00 Other specified arteriovenous shunt 
65400 K02y300 Chronic diffuse glomerulonephritis 
66062 K080300 Renal rickets 
66136 K0A0100 Acute nephritic syndrome focal+segmental glomerular lesions 
66503 K0A0200 Acute nephritic syn  diffuse membranous glomerulonephritis 
66505 K0A3000 Chronic nephritic syndrome  minor glomerular abnormality 
66613 K0A4300 Isoltd prteinur/spcfd morph lesn df mesngl prolf glomneph 
66714 TB11.11 Renal dialysis with complication  without blame 
66872 C108D11 Type I diabetes mellitus with nephropathy 
67193 K032y00 Nephritis unsp+OS membranoprolif glomerulonephritis lesion 
67197 A786.00 Haemorrhagic nephrosonephritis 
67232 G230.00 Malignant hypertensive heart and renal disease 
67261 K0B4.00 Ren tub-interstitl disordr/systemc connectv tiss disorder 
67460 K001.00 Acute nephritis with lesions of necrotising glomerulitis 
67995 K032000 Focal membranoproliferative glomerulonephritis 
68112 C373600 Nephropathic amyloidosis 
68364 K0A2100 Recur+persist haematuria  focal+segmental glomerular lesions 
68659 G23z.00 Hypertensive heart and renal disease NOS 
69266 TA22000 Failure of sterile precautions during kidney dialysis 
69427 TA02z00 Accid cut puncture perf h'ge - perfusion NOS 
69760 ZVu3G00 [X]Other dialysis 
71124 7L1A300 Haemofiltration 
71174 K0A1.00 Rapidly progressive nephritic syndrome 
71709 Kyu0900 [X]Unsp nephrit synd  diff mesang prolif glomerulonephritis 
71964 K0A4200 Isolatd proteinur/specfd morphlgcl les df membrn glomneph 
72303 K01w000 Finnish nephrosis syndrome 
72478 Kyu1400 [X]Nephropathy induced by other drugs+biological substances 
73026 K0A3500 Chronic neph syn difus mesangiocapillary glomerulonephritis 
83513 7L1C.00 Placement other apparatus for compensation for renal failure 
85659 K0A2800 IgA nephropathy 
85991 C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
88597 7L1A400 Automated peritoneal dialysis 
89332 9Ot5.00 Predicted stage chronic kidney disease 
90952 7B0F100 Pre-transplantation of kidney work-up  recipient 
91738 K0A5600 Hereditary nephropathy NEC  dense deposit disease 
93922 C104000 Diabetes mellitus  juvenile type  with renal manifestation 
94261 K00y100 Acute exudative nephritis 
94350 K032z00 Nephritis unsp+membranoprolif glomerulonephritis lesion NOS 
94373 K01y.00 Nephrotic syndrome with other pathological kidney lesions 
94789 1Z17.00 Chronic kidney disease stage 1 with proteinuria 
94793 1Z1B.00 Chronic kidney disease stage 3 with proteinuria 
94842 Kyu1.00 [X]Renal tubulo-interstitial diseases 
94965 1Z15.00 Chronic kidney disease stage 3A 
95121 1Z1A.00 Chronic kidney disease stage 2 without proteinuria 
95122 1Z1H.00 Chronic kidney disease stage 4 with proteinuria 
95123 1Z1C.00 Chronic kidney disease stage 3 without proteinuria 
95145 1Z1B.11 CKD stage 3 with proteinuria 
95146 1Z19.00 Chronic kidney disease stage 2 with proteinuria 
95175 1Z1E.00 Chronic kidney disease stage 3A without proteinuria 
95176 1Z1E.11 CKD stage 3A without proteinuria 
95177 1Z1G.00 Chronic kidney disease stage 3B without proteinuria 
95178 1Z1F.00 Chronic kidney disease stage 3B with proteinuria 
95179 1Z16.00 Chronic kidney disease stage 3B 
95180 1Z1F.11 CKD stage 3B with proteinuria 
95188 1Z1C.11 CKD stage 3 without proteinuria 
95405 1Z1L.00 Chronic kidney disease stage 5 without proteinuria 
95406 1Z1J.00 Chronic kidney disease stage 4 without proteinuria 
95408 1Z1D.00 Chronic kidney disease stage 3A with proteinuria 
95508 1Z1K.00 Chronic kidney disease stage 5 with proteinuria 
95546 K0A2000 Recurrent+persistnt haematuria minor glomerular abnormality 
95571 1Z1D.11 CKD stage 3A with proteinuria 
95572 1Z18.00 Chronic kidney disease stage 1 without proteinuria 
96131 7A60400 Banding of arteriovenous fistula 
96184 TA02000 Accid cut puncture perf h'ge - kidney dialysis 
96347 7A61900 Ligation of arteriovenous dialysis fistula 
96819 Kyu4000 [X]Other disorders resulting/impaired renal tubular function 
97388 K032y15 Mixed membranous and proliferative glomerulonephritis NEC 
97587 1Z1J.11 CKD stage 4 without proteinuria 
97683 1Z1L.11 CKD stage 5 without proteinuria 
97734 K0A1100 Rapid progres nephritic syn focal+segmental glomerulr lesion 
97758 K02y000 Chronic glomerulonephritis + diseases EC 
97978 1Z1A.11 CKD stage 2 without proteinuria 
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97979 1Z19.11 CKD stage 2 with proteinuria 
97980 1Z17.11 CKD stage 1 with proteinuria 
99139 K0B6.00 Balkan nephropathy 
99160 1Z1K.11 CKD stage 5 with proteinuria 
99312 1Z1H.11 CKD stage 4 with proteinuria 
99628 Kyu0300 [X]Glomerular disorders in diabetes mellitus 
99644 K012.00 Nephrotic syndrome+membranoproliferative glomerulonephritis 
99685 K0A0600 Acute nephritic syndrome  dense deposit disease 
100205 K0E..00 Acute-on-chronic renal failure 
100235 7A61111 Ligation of acquired arteriovenous fistula 
100292 Cyu2300 [X]Unspecified diabetes mellitus with renal complications 
100558 K0A0000 Acute nephritic syndrome  minor glomerular abnormality 
100633 1Z1G.11 CKD stage 3B without proteinuria 
100693 Kyu1C00 [X]Renal tubulo-interstitial disorders/transplant rejection 
101358 K0A0400 Ac neph syn difus endocaplry prolifrative glomerulonephritis 
101453 Kyu1000 [X]Other chronic tubulo-interstitial nephritis 
101572 K0A4X00 Isolated proteinuria  with oth specif morpholog changes 
101756 7L1A011 Thomas intravascular shunt for dialysis 
102163 C10ED12 Insulin dependent diabetes mellitus with nephropathy 
102201 C10FC11 Type II diabetes mellitus with nephropathy 
102620 C10EL11 Type I diabetes mellitus with persistent microalbuminuria 
102946 C10E012 Insulin-dependent diabetes mellitus with renal complications 
102947 K13yB00 Ischaemic nephropathy 
103176 K13yA00 Dent's disease 
103532 K0A5500 [X]Heredtry nephrpthy NEC difus mesangiocapilry glomneph 
103757 Kyu1E00 [X]Tubulo-interstit nephritis, not specif as acute or chron 
104201 SP08H00 Acute rejection of renal transplant 
104586 7L1B200 Flushing of peritoneal dialysis catheter 
104619 K053.00 Chronic kidney disease stage 3 
104630 SP08G00 Acute rejection of renal transplant - grade III 
104905 SP08D00 Acute-on-chronic rejection of renal transplant 
104960 SP08E00 Acute rejection of renal transplant - grade I 
104963 K054.00 Chronic kidney disease stage 4 
104981 K05..13 Chronic kidney disease 
105151 K055.00 Chronic kidney disease stage 5 
105302 K08yA00 Proteinuric diabetic nephropathy 
105383 K052.00 Chronic kidney disease stage 2 
105392 K051.00 Chronic kidney disease stage 1 
105436 SP0G.00 Anaphylactoid reaction due to haemodialysis 
105680 K0C6.00 Chronic lithium nephrotoxicity 
105723 K000100 Crescentic glomerulonephritis 
105742 G72D200 Aneurysm of anastomotic site of dialysis AV fistula 
105760 G72C.00 Ruptured aneurysm of dialysis vascular access 
105794 PD12012 Autosomal recessive medullary cystic disease 
105811 SP08R00 Renal transplant rejection 
105859 K0A8.00 Rapidly progressive glomerulonephritis 
105976 K0H..00 Acute scleroderma renal crisis 
106058 C372400 Urate nephropathy 
106213 C372411 Uric acid nephropathy 
106620 SP08J00 Chronic rejection of renal transplant 
106720 Gy21.00 Thrombosis of dialysis arteriovenous fistula 
106975 Gy51.00 Haemorrhage of dialysis arteriovenous fistula 
107000 SP08F00 Acute rejection of renal transplant - grade II 
107027 K0G..00 Sickle cell nephropathy 
107082 Gy31.00 Occlusion of dialysis arteriovenous fistula 
107188 G72D.00 Aneurysm of dialysis arteriovenous fistula 
107216 Kyu0F00 [X]Hereditary nephropathy, unspecif morphological changes 
107220 G72D100 Aneurysm of needle site of dialysis arteriovenous fistula 
107260 Gy41.00 Infection of dialysis arteriovenous fistula 
107382 K0J0.00 Renal involvement in scleroderma 
107719 7A61A00 Ligation of arteriovenous dialysis graft 
107746 Gy1..00 Stenosis of dialysis vascular access 
107771 K06..12 Kidney failure unspecified 
107814 K032200 Focal glomerulon + focal recurr macroscop glomerulonephritis 
107881 K08yA11 Clinical diabetic nephropathy 
107900 SP0E.00 Disorders associated with peritoneal dialysis 
108116 Gy3..00 Occlusion of dialysis vascular access 
108213 Gy40.00 Infection of dialysis arteriovenous graft 
108423 Gy60.00 Rupture of dialysis arteriovenous graft 
108591 K01w100 Drash syndrome 
108699 Gy10.00 Stenosis of dialysis arteriovenous graft 
108711 K000111 CGN - Crescentic glomerulonephritis 
108759 Gy5..00 Haemorrhage of dialysis vascular access 
108766 661M200 Chronic kidney disease self-management plan agreed 
108785 SP0F.00 Haemodialysis first use syndrome 
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108816 K01x.00 Nephrotic syndrome in diseases EC 
108922 K01w112 Wilms' tumour + nephrotic syndrome + pseudohermaphroditism 
109106 PD12200 Nephronophthisis - medullary cystic disease 
109135 Gy30.00 Occlusion of dialysis arteriovenous graft 
109657 1Z1Y.00 CKD with GFR category G3b & albuminuria category A2 
109750 2126E00 Chronic kidney disease resolved 
109804 1Z1T.00 CKD with GFR category G3a & albuminuria category A1 
109805 1Z1V.00 CKD with GFR category G3a & albuminuria category A2 
109809 Gy2..00 Thrombosis of dialysis vascular access 
109837 C10E011 Type I diabetes mellitus with renal complications 
109884 SP0H.00 Disorder associated with dialysis 
109905 1Z1W.00 CKD with GFR category G3a & albuminuria category A3 
109945 K0A1400 Rapid progres neph syn df endocapilary prolifv glomnephritis 
109963 1Z1X.00 CKD with GFR category G3b & albuminuria category A1 
109980 1Z1a.00 CKD with GFR category G4 & albuminuria category A1 
109981 1Z1e.00 CKD with GFR category G5 & albuminuria category A2 
109990 1Z1Z.00 CKD with GFR category G3b & albuminuria category A3 
110003 1Z1N.00 CKD with GFR category G1 & albuminuria category A2 
110033 1Z1M.00 CKD with GFR category G1 & albuminuria category A1 
110051 Gy4..00 Infection of dialysis vascular access 
110072 Z919200 Washing back through haemodialysis lines 
110095 G72D000 Aneurysm of superficialised artery of dialysis AV fistula 
110108 1Z1R.00 CKD with GFR category G2 & albuminuria category A2 
110133 1Z1d.00 CKD with GFR category G5 & albuminuria category A1 
110208 PD12211 Autosomal dominant medullary cystic disease 
110251 1Z1S.00 CKD with GFR category G2 & albuminuria category A3 
110269 1Z1Q.00 CKD with GFR category G2 & albuminuria category A1 
110467 1Z1f.00 CKD with GFR category G5 & albuminuria category A3 
110484 1Z1P.00 CKD with GFR category G1 & albuminuria category A3 
110626 1Z1c.00 CKD with GFR category G4 & albuminuria category A3 
110749 K01w200 Congenital nephrotic syndrome with focal glomerulosclerosis 
111022 1Z18.11 CKD stage 1 without proteinuria 
111029 K032y12 Lobular glomerulonephritis NEC 
111103 SP0E100 Thrombus in peritoneal dialysis catheter 
 
B) Hospital Episodes Statistics 
ICD 
10 
DESCRIPTION MODIFIER_4 
E10.2 Type 1 diabetes mellitus With renal complications 
E11.2 Type 2 diabetes mellitus With renal complications 
E12.2 Malnutrition-related diabetes mellitus With renal complications 
E13.2 Other specified diabetes mellitus With renal complications 
E14.2 Unspecified diabetes mellitus With renal complications 
I12 Hypertensive renal disease 
 
I12.0 Hypertensive renal disease with renal failure 
 
I12.9 Hypertensive renal disease without renal failure 
 
I13 Hypertensive heart and renal disease 
 
I13.0 Hypertensive heart and renal disease with (congestive) 
heart failure 
 
I13.1 Hypertensive heart and renal disease with renal failure 
 
I13.2 Hypertensive heart and renal disease with both 
(congestive) heart failure and renal failure 
 
I13.9 Hypertensive heart and renal disease, unspecified 
 
N00 Acute nephritic syndrome 
 
N00.0 Acute nephritic syndrome Minor glomerular abnormality 
N00.1 Acute nephritic syndrome Focal and segmental glomerular lesions 
N00.2 Acute nephritic syndrome Diffuse membranous glomerulonephritis 
N00.3 Acute nephritic syndrome Diffuse mesangial proliferative glomerulonephritis 
N00.4 Acute nephritic syndrome Diffuse endocapillary proliferative 
glomerulonephritis 
N00.5 Acute nephritic syndrome Diffuse mesangiocapillary glomerulonephritis 
N00.6 Acute nephritic syndrome Dense deposit disease 
N00.7 Acute nephritic syndrome Diffuse crescentic glomerulonephritis 
N00.8 Acute nephritic syndrome Other 
N00.9 Acute nephritic syndrome Unspecified 
N01 Rapidly progressive nephritic syndrome 
 
N01.0 Rapidly progressive nephritic syndrome Minor glomerular abnormality 
N01.1 Rapidly progressive nephritic syndrome Focal and segmental glomerular lesions 
N01.2 Rapidly progressive nephritic syndrome Diffuse membranous glomerulonephritis 
N01.3 Rapidly progressive nephritic syndrome Diffuse mesangial proliferative glomerulonephritis 
N01.4 Rapidly progressive nephritic syndrome Diffuse endocapillary proliferative 
glomerulonephritis 
N01.5 Rapidly progressive nephritic syndrome Diffuse mesangiocapillary glomerulonephritis 
N01.6 Rapidly progressive nephritic syndrome Dense deposit disease 
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N01.7 Rapidly progressive nephritic syndrome Diffuse crescentic glomerulonephritis 
N01.8 Rapidly progressive nephritic syndrome Other 
N01.9 Rapidly progressive nephritic syndrome Unspecified 
N02 Recurrent and persistent haematuria 
 
N02.0 Recurrent and persistent haematuria Minor glomerular abnormality 
N02.1 Recurrent and persistent haematuria Focal and segmental glomerular lesions 
N02.2 Recurrent and persistent haematuria Diffuse membranous glomerulonephritis 
N02.3 Recurrent and persistent haematuria Diffuse mesangial proliferative glomerulonephritis 
N02.4 Recurrent and persistent haematuria Diffuse endocapillary proliferative 
glomerulonephritis 
N02.5 Recurrent and persistent haematuria Diffuse mesangiocapillary glomerulonephritis 
N02.6 Recurrent and persistent haematuria Dense deposit disease 
N02.7 Recurrent and persistent haematuria Diffuse crescentic glomerulonephritis 
N02.8 Recurrent and persistent haematuria Other 
N02.9 Recurrent and persistent haematuria Unspecified 
N03 Chronic nephritic syndrome 
 
N03.0 Chronic nephritic syndrome Minor glomerular abnormality 
N03.1 Chronic nephritic syndrome Focal and segmental glomerular lesions 
N03.2 Chronic nephritic syndrome Diffuse membranous glomerulonephritis 
N03.3 Chronic nephritic syndrome Diffuse mesangial proliferative glomerulonephritis 
N03.4 Chronic nephritic syndrome Diffuse endocapillary proliferative 
glomerulonephritis 
N03.5 Chronic nephritic syndrome Diffuse mesangiocapillary glomerulonephritis 
N03.6 Chronic nephritic syndrome Dense deposit disease 
N03.7 Chronic nephritic syndrome Diffuse crescentic glomerulonephritis 
N03.8 Chronic nephritic syndrome Other 
N03.9 Chronic nephritic syndrome Unspecified 
N04 Nephrotic syndrome 
 
N04.0 Nephrotic syndrome Minor glomerular abnormality 
N04.1 Nephrotic syndrome Focal and segmental glomerular lesions 
N04.2 Nephrotic syndrome Diffuse membranous glomerulonephritis 
N04.3 Nephrotic syndrome Diffuse mesangial proliferative glomerulonephritis 
N04.4 Nephrotic syndrome Diffuse endocapillary proliferative 
glomerulonephritis 
N04.5 Nephrotic syndrome Diffuse mesangiocapillary glomerulonephritis 
N04.6 Nephrotic syndrome Dense deposit disease 
N04.7 Nephrotic syndrome Diffuse crescentic glomerulonephritis 
N04.8 Nephrotic syndrome Other 
N04.9 Nephrotic syndrome Unspecified 
N05 Unspecified nephritic syndrome 
 
N05.0 Unspecified nephritic syndrome Minor glomerular abnormality 
N05.1 Unspecified nephritic syndrome Focal and segmental glomerular lesions 
N05.2 Unspecified nephritic syndrome Diffuse membranous glomerulonephritis 
N05.3 Unspecified nephritic syndrome Diffuse mesangial proliferative glomerulonephritis 
N05.4 Unspecified nephritic syndrome Diffuse endocapillary proliferative 
glomerulonephritis 
N05.5 Unspecified nephritic syndrome Diffuse mesangiocapillary glomerulonephritis 
N05.6 Unspecified nephritic syndrome Dense deposit disease 
N05.7 Unspecified nephritic syndrome Diffuse crescentic glomerulonephritis 
N05.8 Unspecified nephritic syndrome Other 
N05.9 Unspecified nephritic syndrome Unspecified 
N06 Isolated proteinuria with specified morphological lesion 
 
N06.0 Isolated proteinuria with specified morphological lesion Minor glomerular abnormality 
N06.1 Isolated proteinuria with specified morphological lesion Focal and segmental glomerular lesions 
N06.2 Isolated proteinuria with specified morphological lesion Diffuse membranous glomerulonephritis 
N06.3 Isolated proteinuria with specified morphological lesion Diffuse mesangial proliferative glomerulonephritis 
N06.4 Isolated proteinuria with specified morphological lesion Diffuse endocapillary proliferative 
glomerulonephritis 
N06.5 Isolated proteinuria with specified morphological lesion Diffuse mesangiocapillary glomerulonephritis 
N06.6 Isolated proteinuria with specified morphological lesion Dense deposit disease 
N06.7 Isolated proteinuria with specified morphological lesion Diffuse crescentic glomerulonephritis 
N06.8 Isolated proteinuria with specified morphological lesion Other 
N06.9 Isolated proteinuria with specified morphological lesion Unspecified 
N07 Hereditary nephropathy, not elsewhere classified 
 
N07.0 Hereditary nephropathy, not elsewhere classified Minor glomerular abnormality 
N07.1 Hereditary nephropathy, not elsewhere classified Focal and segmental glomerular lesions 
N07.2 Hereditary nephropathy, not elsewhere classified Diffuse membranous glomerulonephritis 
N07.3 Hereditary nephropathy, not elsewhere classified Diffuse mesangial proliferative glomerulonephritis 
N07.4 Hereditary nephropathy, not elsewhere classified Diffuse endocapillary proliferative 
glomerulonephritis 
N07.5 Hereditary nephropathy, not elsewhere classified Diffuse mesangiocapillary glomerulonephritis 
N07.6 Hereditary nephropathy, not elsewhere classified Dense deposit disease 
N07.7 Hereditary nephropathy, not elsewhere classified Diffuse crescentic glomerulonephritis 
N07.8 Hereditary nephropathy, not elsewhere classified Other 
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N07.9 Hereditary nephropathy, not elsewhere classified Unspecified 
N08 Glomerular disorders in diseases classified elsewhere 
 
N08.0 Glomerular disorders in infectious and parasitic diseases 
classified elsewhere 
 
N08.1 Glomerular disorders in neoplastic diseases 
 
N08.2 Glomerular disorders in blood diseases and disorders 
involving the immune mechanism 
 
N08.3 Glomerular disorders in diabetes mellitus 
 
N08.4 Glomerular disorders in other endocrine, nutritional and 
metabolic diseases 
 
N08.5 Glomerular disorders in systemic connective tissue 
disorders 
 
N08.8 Glomerular disorders in other diseases classified 
elsewhere 
 
N11 Chronic tubulo-interstitial nephritis 
 
N11.0 Nonobstructive reflux-associated chronic pyelonephritis 
 
N11.1 Chronic obstructive pyelonephritis 
 
N11.8 Other chronic tubulo-interstitial nephritis 
 
N11.9 Chronic tubulo-interstitial nephritis, unspecified 
 
N12 Tubulo-interstitial nephritis, not specified as acute or 
chronic 
 
N15.0 Balkan nephropathy 
 
N16.2 Renal tubulo-interstitial disorders in blood diseases and 
disorders involving the immune mechanism 
 
N16.3 Renal tubulo-interstitial disorders in metabolic diseases 
 
N16.4 Renal tubulo-interstitial disorders in systemic connective 
tissue disorders 
 
N16.5 Renal tubulo-interstitial disorders in transplant rejection 
 
N16.8 Renal tubulo-interstitial disorders in other diseases 
classified elsewhere 
 
N18 Chronic kidney disease 
 
N18.1 Chronic kidney disease, stage 1 
 
N18.2 Chronic kidney disease, stage 2 
 
N18.3 Chronic kidney disease, stage 3 
 
N18.4 Chronic kidney disease, stage 4 
 
N18.5 Chronic kidney disease, stage 5 
 
N18.9 Chronic kidney disease, unspecified 
 
N19 Unspecified kidney failure 
 
N25 Disorders resulting from impaired renal tubular function 
 
N25.0 Renal osteodystrophy 
 
N25.1 Nephrogenic diabetes insipidus 
 
N25.8 Other disorders resulting from impaired renal tubular 
function 
 
N25.9 Disorder resulting from impaired renal tubular function, 
unspecified 
 
T86.1 Kidney transplant failure and rejection 
 
Y84.1 Kidney dialysis 
 
Z49 Care involving dialysis 
 
Z49.0 Preparatory care for dialysis 
 
Z49.1 Extracorporeal dialysis 
 
Z49.2 Other dialysis 
 
Z99.2 Dependence on renal dialysis 
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Appendix 14 Codelist: Haematopoietic and lymphoid tissue malignancies including 
haematopoietic stem cell transplant 
1. Bone marrow/ stem cell  transplant 
A) CPRD 
medcode readcode readterm 
1392 7K1Q.11 Bone marrow transplant 
15406 7K1Q100 Allograft of bone marrow NEC 
18628 7K1Q200 Transfusion of stem cells 
21021 7K1Q.00 Graft of bone marrow 
22728 SP08700 Acute graft-versus-host disease 
25695 SP08800 Chronic graft-versus-host disease 
28232 7L14400 Peripheral blood stem cell graft 
52943 SP08200 Bone-marrow transplant rejection 
54420 7L14411 Second stage peripheral stem cell infusion 
63236 7L17311 First stage peripheral stem cell infusion 
70870 7K1Qz00 Graft of bone marrow NOS 
72436 7K1Qy00 Other specified graft of bone marrow 
85492 7K1Q300 Allograft of bone marrow from sibling donor 
86063 7L14500 Autologous peripheral blood stem cell transplant 
89920 7L14700 Allogeneic peripheral blood stem cell transplant 
95840 7K1Q400 Allograft of bone marrow from matched unrelated donor 
98608 7K1Q600 Allograft of bone marrow from unmatched unrelated donor 
100912 7K1Q500 Allograft of bone marrow from haploidentical donor 
110109 7L14600 Syngeneic peripheral blood stem cell transplant 
 
B) Hospital Episodes Statistics 
ICD10 DESCRIPTION 
T86.0 Bone-marrow transplant rejection 
 
C) Office of Population Censuses and Surveys (OPCS) version 4 codes 
Opcs Description_other Description 
W341 Graft of bone marrow Autograft of bone marrow 
W342 Graft of bone marrow Allograft of bone marrow nec 
W343 Graft of bone marrow Allograft of bone marrow from sibling donor 
W344 Graft of bone marrow Allograft of bone marrow from matched unrelated donor 
W345 Graft of bone marrow Allograft of bone marrow from haploidentical donor 
W346 Graft of bone marrow Allograft of bone marrow from unmatched unrelated 
donor 
W348 Graft of bone marrow Other specified 
W349 Graft of bone marrow Unspecified 
W991 Graft of cord blood stem cells to bone marrow Allograft of cord blood stem cells to bone marrow 
W998 Graft of cord blood stem cells to bone marrow Other specified 
W999 Graft of cord blood stem cells to bone marrow Unspecified 
X334 Other blood transfusion Autologous peripheral blood stem cell transplant 
X335 Other blood transfusion Syngeneic peripheral blood stem cell transplant 
X336 Other blood transfusion Allogeneic peripheral blood stem cell transplant 
 
2. Lymphoma, myeloma, other plasma cell dyscrasias & leukemia 
A) CPRD 
medcode readcode readterm 
102688 ByuD400 [X]Other malignant immunoproliferative diseases 
102688 ByuD400 [X]Other malignant immunoproliferative diseases 
1481 B600.00 Reticulosarcoma 
1483 BBg1.11 [M]Lymphoma NOS 
2462 B61..00 Hodgkin's disease 
3371 BBg2.11 [M]Non Hodgkins lymphoma 
3604 B627.00 Non - Hodgkin's lymphoma 
3672 BBn0.12 [M]MYELOMA NOS 
3710 BBB1.00 [M]Adenolymphoma 
4072 B680.00 Acute leukaemia NOS 
4222 B64..11 Lymphatic leukaemia 
4250 B68z.00 Leukaemia NOS 
4251 B640.00 Acute lymphoid leukaemia 
4413 B650.00 Acute myeloid leukaemia 
4637 BBr..00 [M]Leukaemias 
4870 B625.11 HISTIOCYTOSIS X (ACUTE, PROGRESSIVE) 
4944 B630.00 MULTIPLE MYELOMA 
5137 B624.11 Leukaemic reticuloendotheliosis 
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5179 B620.00 Nodular lymphoma (Brill - Symmers disease) 
5915 BBrA400 [M]Hairy cell leukaemia 
6316 BBr0100 [M]Acute leukaemia NOS 
7176 B65..00 Myeloid leukaemia 
7940 ByuDF11 [X]Non-Hodgkin's lymphoma NOS 
8625 B641.00 Chronic lymphoid leukaemia 
8649 ByuDF00 [X]Non-Hodgkin's lymphoma, unspecified type 
9172 BBmK.00 [M]WALDENSTROM'S MACROGLOBULINAEMIA 
9673 BBs5.00 [M]Chronic lymphoproliferative disease 
10411 C333000 WALDENSTROM'S MACROGLOBULINAEMIA 
10726 B651.00 Chronic myeloid leukaemia 
12006 B621.00 Mycosis fungoides 
12146 BBr2000 [M]Lymphoid leukaemia NOS 
12323 B6...00 MALIGNANT NEOPLASM OF LYMPHATIC AND HAEMOPOIETIC TISSUE 
12335 B62y.00 Malignant lymphoma NOS 
12464 B62x200 Peripheral T-cell lymphoma 
15027 B62yz00 Malignant lymphoma NOS 
15036 B626.00 MALIGNANT MAST CELL TUMOURS 
15211 B630.12 MYELOMATOSIS 
15504 B62y800 Malignant lymphoma NOS of lymph nodes of multiple sites 
16416 B681.00 Chronic leukaemia NOS 
16460 BBg2.00 [M]Malignant lymphoma, non Hodgkin's type 
16774 BBmD.00 [M] Cutaneous lymphoma 
17177 1429 H/O: * leukaemia 
17178 BBg..00 [M]Lymphomas, NOS or diffuse 
17182 B627C11 Follicular lymphoma NOS 
17460 B627700 Diffuse non-Hodgkin's lymphoblastic (diffuse) lymphoma 
17887 B62x.00 Malignant lymphoma otherwise specified 
18383 BBmH.00 [M] Large cell lymphoma 
18744 BBn0.11 [M]MULTIPLE MYELOMA 
19028 B630100 SOLITARY MYELOMA 
19140 B614800 Hodgkin's nodular sclerosis of lymph nodes of multiple sites 
19372 B64..00 Lymphoid leukaemia 
19974 B660.00 Acute monocytic leukaemia 
20437 BBk..00 [M]Lymphomas, nodular or follicular 
20440 B69..00 Myelomonocytic leukaemia 
20635 BBr2011 [M]Lymphatic leukaemia 
20710 BBj..00 [M]Hodgkin's disease 
21329 B630200 PLASMACYTOMA NOS 
21402 B602.00 Burkitt's lymphoma 
21463 BBgC.11 [M]Lymphocytic lymphoma NOS 
21549 B627C00 Follicular non-Hodgkin's lymphoma 
22050 B691.00 Chronic myelomonocytic leukaemia 
22071 BBr0111 [M]Blast cell leukaemia 
22158 B630000 Malignant plasma cell neoplasm, extramedullary plasmacytoma 
23711 BBg1000 [M]Malignant lymphoma, diffuse NOS 
25191 B68..00 Leukaemia of unspecified cell type 
26135 BBm6.00 [M] ALPHA HEAVY CHAIN DISEASE 
27330 B624.00 Leukaemic reticuloendotheliosis 
27340 B670.11 Di Guglielmo's disease 
27416 B601.00 Lymphosarcoma 
27458 B661.00 Chronic monocytic leukaemia 
27520 B651z00 Chronic myeloid leukaemia NOS 
27664 B65y100 Acute promyelocytic leukaemia 
27790 B641.11 Chronic lymphatic leukaemia 
27965 BBv2.00 [M]AngiocentricT-cell lymphoma 
28276 B675.00 ACUTE MYELOFIBROSIS 
28639 B627000 Follicular non-Hodgkin's small cleaved cell lymphoma 
29178 B614.00 Hodgkin's disease, nodular sclerosis 
29335 BBr2700 [M]Adult T-cell leukaemia/lymphoma 
29876 B613z00 Hodgkin's, lymphocytic-histiocytic predominance NOS 
30632 B67z.00 Other specified leukaemia NOS 
30646 B6y..00 MALIGNANT NEOPLASM LYMPHATIC OR HAEMATOPOIETIC TISSUE OS 
31324 B626800 MAST CELL MALIGNANCY OF LYMPH NODES OF MULTIPLE SITES 
31492 BBm9.00 [M] Monocytoid B-cell lymphoma 
31537 BBj1100 [M]Hodgkin,s disease, lymphocytic predominance, nodular 
31576 B627B00 Other types of follicular non-Hodgkin's lymphoma 
31586 B64y100 Prolymphocytic leukaemia 
31671 BBn0.00 [M]PLASMA CELL MYELOMA 
31701 B651.11 Chronic granulocytic leukaemia 
31726 BBgM.00 [M]Malignant lymphoma, small cleaved cell, diffuse 
31741 BBj6200 [M]Hodgkin,s disease, nodular sclerosis, lymphocytic deplet 
31749 BBv0.00 [M]Monocytoid B-cell lymphoma 
31750 BBr0300 [M]Chronic leukaemia NOS 
31794 B627W00 Unspecified B-cell non-Hodgkin's lymphoma 
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32240 4M22.00 Lymphoma stage III 
33333 B62..00 OTHER MALIGNANT NEOPLASM OF LYMPHOID AND HISTIOCYTIC TISSUE 
33344 B65z.00 Myeloid leukaemia NOS 
33869 BBgR.00 [M]Malignant lymphoma, large cell, diffuse NOS 
34089 B62y400 Malignant lymphoma NOS of lymph nodes of axilla and arm 
34352 BBgG.12 [M]Lymphoblastic lymphoma NOS 
34692 B68y.00 Other leukaemia of unspecified cell type 
34926 B625.00 LETTERER-SIWE DISEASE 
35014 B622.00 Sezary's disease 
35697 BBr6.00 [M]Myeloid leukaemias 
35875 B66..00 Monocytic leukaemia 
36114 BBg1.00 [M]Malignant lymphoma NOS 
36693 ZV10600 [V]Personal history of leukaemia 
37112 B6...11 MALIGNANT NEOPLASM OF HISTIOCYTIC TISSUE 
37182 B63..00 Multiple myeloma and immunoproliferative neoplasms 
37272 B67..00 Other specified leukaemia 
37410 BBr2100 [M]Acute lymphoid leukaemia 
37461 B64y200 Adult T-cell leukaemia 
37487 BBrA700 [M]Acute myelofibrosis 
37723 BBr6011 [M]Granulocytic leukaemia NOS 
38005 B621z00 Mycosis fungoides NOS 
38321 B936.12 PLASMACYTOMA NOS 
38331 B64yz00 Other lymphoid leukaemia NOS 
38914 B64z.00 Lymphoid leukaemia NOS 
38939 B613.00 Hodgkin's disease, lymphocytic-histiocytic predominance 
39187 B631.00 Plasma cell leukaemia 
39490 BBn0.14 [M]PLASMACYTIC MYELOMA 
39798 B627X00 Diffuse non-Hodgkin's lymphoma, unspecified 
39883 BBk5.00 [M]Malig lymp, follicular centre cell, cleaved, follicular 
39906 BBgE.00 [M]Malignant lymphoma, centrocytic 
40420 BBr0.00 [M]Leukaemias unspecified 
40508 BBj6000 [M]Hodgkin,s disease, nodular sclerosis, lymphocytic predom 
40513 BBkz.00 [M]Lymphoma, nodular or follicular NOS 
40561 ZV10711 [V]Personal history of Hodgkin's disease 
40740 ByuD.00 [X]Malignant neoplasms of lymphoid, haematopoietic and rela 
40766 BBm5.00 [M] Peripheral T-cell lymphoma NOS 
40991 4M2..00 Lymphoma staging system 
41369 B60..00 Lymphosarcoma and reticulosarcoma 
41500 BBr2300 [M]Chronic lymphoid leukaemia 
41734 BBr0000 [M]Leukaemia NOS 
41754 BBg7.00 [M]Malignant lymphoma, lymphoplasmacytoid type 
41841 BBgB.00 [M]Malignant lymphoma, follicular centre cell NOS 
42198 BBj6.00 [M]Hodgkin's disease, nodular sclerosis NOS 
42297 BBrz.00 [M]Leukaemia NOS 
42461 B61zz00 Hodgkin's disease NOS 
42539 B670.00 Acute erythraemia and erythroleukaemia 
42579 B62y300 Malignant lymphoma NOS of intra-abdominal lymph nodes 
42769 BBjz.00 [M]Hodgkin's disease NOS 
43312 B936.11 MYELOMA - SOLITARY 
43415 ByuD000 [X]Other Hodgkin's disease 
43450 B63z.00 Immunoproliferative neoplasm or myeloma NOS 
43459 BBn..00 [M]Plasma cell tumours 
43552 B630.11 KAHLER'S DISEASE 
44196 B611.00 Hodgkin's granuloma 
44267 B623.00 MALIGNANT HISTIOCYTOSIS 
44318 B62xX00 Oth and unspecif peripheral & cutaneous T-cell lymphomas 
44617 A789600 HIV disease resulting in Burkitt's lymphoma 
45264 B620100 Nodular lymphoma of lymph nodes of head, face and neck 
45768 BBm3.12 [M]ACUTE PROGRESSIVE HISTIOCYTOSIS X 
46042 B630300 LAMBDA LIGHT CHAIN MYELOMA 
46048 BBr2500 [M]Prolymphocytic leukaemia 
46263 BBr6700 [M]Acute myelomonocytic leukaemia 
46444 BBr4.00 [M]Erythroleukaemias 
46877 BBgL.00 [M]Malignant lymphoma, small lymphocytic NOS 
46931 BBg4.00 [M]Malignant lymphoma, stem cell type 
46967 BBl..00 [M]Mycosis fungoides 
47204 B625z00 LETTERER-SIWE DISEASE NOS 
47330 BBm2.00 [M]HISTIOCYTIC MEDULLARY RETICULOSIS 
48049 BBr6800 [M]Chronic myelomonocytic leukaemia 
48155 BBr2.00 [M]Lymphoid leukaemias 
48253 BBg8.00 [M]Malignant lymphoma, immunoblastic type 
49131 BBg0.00 [M]Lymphomatous tumour, benign 
49253 BBk0.13 [M]Giant follicular lymphoma 
49262 B627200 Follicular non-Hodgkin's large cell lymphoma 
49301 B6z..00 MALIGNANT NEOPLASM LYMPHATIC OR HAEMATOPOIETIC TISSUE NOS 
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49327 BBrA500 [M]Acute megakaryoblastic leukaemia 
49530 BBmC.00 [M] T-gamma lymphoproliferative disease 
49605 B615.00 Hodgkin's disease, mixed cellularity 
49725 B64y.00 Other lymphoid leukaemia 
49825 BBh0.11 [M]RETICULUM CELL SARCOMA NOS 
50668 B627300 Diffuse non-Hodgkin's small cell (diffuse) lymphoma 
50695 B627500 Diffuse non-Hodgkin mixed sml & lge cell (diffuse) lymphoma 
50696 B62y100 Malignant lymphoma NOS of lymph nodes of head, face and neck 
50858 B674.00 ACUTE PANMYELOSIS 
50928 BBr2600 [M]Burkitt's cell leukaemia 
51285 BBj2.00 [M]Hodgkin's disease, mixed cellularity 
51680 BBgV.00 [M]Malignant lymphoma, small cell, noncleaved, diffuse 
51852 BBgD.00 [M]Malig lymphoma, lymphocytic, intermediate different NOS 
51895 BBgz.00 [M]Lymphoma, diffuse or NOS 
52327 B653000 Chloroma 
52591 BBgG.13 [M]Lymphoblastoma NOS 
52593 BBmE.00 [M] GAMMA HEAVY CHAIN DISEASE 
52942 BBr6300 [M]Chronic myeloid leukaemia 
52946 4C53.00 BONE MARROW: MYELOMA CELLS 
53397 B61z.00 Hodgkin's disease NOS 
53477 ZV67811 [V]Follow-up examination after chemotherapy for leukaemia 
53551 B627600 Diffuse non-Hodgkin's immunoblastic (diffuse) lymphoma 
53647 BBn0.13 [M]MYELOMATOSIS 
54083 B625800 LETTERER-SIWE DISEASE OF LYMPH NODES OF MULTIPLE SITES 
54190 BBm8.00 [M] Angioimmunoblastic lymphadenopathy 
54585 BBr6100 [M]Acute myeloid leukaemia 
54793 B682.00 Subacute leukaemia NOS 
55303 B614100 Hodgkin's nodular sclerosis of head, face and neck 
56041 BBj1.00 [M]Hodgkin's disease, lymphocytic predominance 
57225 B614000 Hodgkin's disease, nodular sclerosis of unspecified site 
57316 BBr6600 [M]Acute promyelocytic leukaemia 
57427 B62y000 Malignant lymphoma NOS of unspecified site 
57544 BBm4.00 [M]True histiocytic lymphoma 
57671 B672.00 Megakaryocytic leukaemia 
57713 BBr8.00 [M]Eosinophilic leukaemias 
57737 B62x100 Lymphoepithelioid lymphoma 
58015 BBgQ.00 [M]Malignant lymphomatous polyposis 
58082 B620800 Nodular lymphoma of lymph nodes of multiple sites 
58684 B615200 Hodgkin's mixed cellularity of intrathoracic lymph nodes 
58871 B623z00 MALIGNANT HISTIOCYTOSIS NOS 
58953 BBk8.00 [M]Malig lymp,follicular centre cell,noncleaved,follicular 
58962 B62x500 Malignant immunoproliferative small intestinal disease 
59115 B602100 Burkitt's lymphoma of lymph nodes of head, face and neck 
59593 BBm3.00 [M]LETTERER - SIWE DISEASE 
59663 B936.00 Neoplasm of uncertain behaviour of plasma cells 
59755 B61z200 Hodgkin's disease NOS of intrathoracic lymph nodes 
59778 B61z100 Hodgkin's disease NOS of lymph nodes of head, face and neck 
59929 BBr0z00 [M]Leukaemia unspecified, NOS 
60092 B62y700 Malignant lymphoma NOS of spleen 
60242 B600000 Reticulosarcoma of unspecified site 
60275 BBgJ.00 [M]Malignant lymphoma, centroblastic type NOS 
60433 N330900 OSTEOPOROSIS IN MULTIPLE MYELOMATOSIS 
60504 BBgC.12 [M]Lymphocytic lymphosarcoma NOS 
60918 4M20.00 Lymphoma stage I 
61146 BBmF.00 [M] Angiocentric immunoproliferative lesion 
61149 B614300 Hodgkin's nodular sclerosis of intra-abdominal lymph nodes 
61251 BBgN.00 [M]Malign lymphoma,lymphocytic,intermediate differn, diffuse 
61500 B690.00 Acute myelomonocytic leukaemia 
61662 B61z000 Hodgkin's disease NOS, unspecified site 
61693 ByuD600 [X]Other myeloid leukaemia 
61997 BBj0.00 [M]Hodgkin's disease NOS 
62330 BBr6z00 [M]Other myeloid leukaemia NOS 
62380 B601200 Lymphosarcoma of intrathoracic lymph nodes 
62437 B62x400 Malignant reticulosis 
63054 B614z00 Hodgkin's disease, nodular sclerosis NOS 
63105 B62y500 Malignant lymphoma NOS of lymph node inguinal region and leg 
63239 BBm1.00 [M]MALIGNANT HISTIOCYTOSIS 
63375 ByuDE00 [X]Unspecified B-cell non-Hodgkin's lymphoma 
63475 B652.00 Subacute myeloid leukaemia 
63570 BBr0113 [M]Stem cell leukaemia 
63625 B616400 Hodgkin's lymphocytic depletion lymph nodes axilla and arm 
63699 BBk0.00 [M]Malignant lymphoma, nodular NOS 
63723 B601z00 Lymphosarcoma NOS 
63864 BBn2.00 [M]PLASMACYTOMA NOS 
63973 BBm0.00 [M]Microglioma 
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63994 BBgS.00 [M]Malignant lymphoma, large cell, cleaved, diffuse 
64036 B612.00 Hodgkin's sarcoma 
64068 BBnz.00 [M]Plasma cell tumour NOS 
64336 ByuD300 [X]Other specified types of non-Hodgkin's lymphoma 
64343 BBj6100 [M]Hodgkin,s disease, nodular sclerosis, mixed cellularity 
64427 B62z100 UNSPEC MALIG NEOP LYMPHOID/HISTIOCYTIC LYMPH NODE 
HEAD/NECK 
64515 ByuDC00 [X]Diffuse non-Hodgkin's lymphoma, unspecified 
64567 B63y.00 Other immunoproliferative neoplasms 
64618 BBr3.00 [M]Plasma cell leukaemias 
64670 B601300 Lymphosarcoma of intra-abdominal lymph nodes 
64947 BBk0.11 [M]Brill - Symmers' disease 
64963 BBr0112 [M]Blastic leukaemia 
65122 B624000 Leukaemic reticuloendotheliosis of unspecified sites 
65123 B624300 Leukaemic reticuloend of intra-abdominal lymph nodes 
65165 ByuD900 [X]Other leukaemia of unspecified cell type 
65180 B627800 Diffuse non-Hodgkin's lymphoma undifferentiated (diffuse) 
65434 B62z.00 MALIGNANT NEOPLASMS OF LYMPHOID AND HISTIOCYTIC TISSUE NOS 
65483 B614400 Hodgkin's nodular sclerosis of lymph nodes of axilla and arm 
65489 B610.00 Hodgkin's paragranuloma 
65584 BBj1000 [M]Hodgkin,s disease, lymphocytic predominance, diffuse 
65642 B623300 MALIGNANT HISTIOCYTOSIS OF INTRA-ABDOMINAL LYMPH NODES 
65701 B620z00 Nodular lymphoma NOS 
65721 B673.00 Mast cell leukaemia 
65777 B672.11 Thrombocytic leukaemia 
66089 B65yz00 Other myeloid leukaemia NOS 
66327 B620000 Nodular lymphoma of unspecified site 
66367 A789700 HIV dis resulting oth types of non-Hodgkin's lymphoma 
66603 BBgK.00 [M]Malig lymphoma, follicular centre cell, non-cleaved NOS 
66694 BBr6311 [M]Naegeli-type monocytic leukaemia 
67029 ByuD500 [X]Other lymphoid leukaemia 
67339 BBp2.00 [M]MALIGNANT MASTOCYTOSIS 
67506 B614200 Hodgkin's nodular sclerosis of intrathoracic lymph nodes 
67518 ByuD100 [X]Other types of follicular non-Hodgkin's lymphoma 
67700 B66..12 Monoblastic leukaemia 
67703 B616.00 Hodgkin's disease, lymphocytic depletion 
68039 B612400 Hodgkin's sarcoma of lymph nodes of axilla and upper limb 
68330 B613100 Hodgkin's, lymphocytic-histiocytic pred of head, face, neck 
68353 BBmJ.00 [M] Angioendotheliomatosis 
68964 BBgA.00 [M]Malignant lymphoma, centroblastic-centrocytic, diffuse 
69299 BBrA111 [M]Thrombocytic leukaemia 
69301 BBg5.00 [M]Malignant lymphoma, convoluted cell type NOS 
69497 B623000 MALIGNANT HISTIOCYTOSIS OF UNSPECIFIED SITE 
69767 AyuC600 [X]HIV disease resulting in other non-Hodgkin's lymphoma 
69980 BBgC.00 [M]Malignant lymphoma, lymphocytic, well differentiated NOS 
70374 B600300 Reticulosarcoma of intra-abdominal lymph nodes 
70509 B627D00 Diffuse non-Hodgkin's centroblastic lymphoma 
70716 B62zz11 Immunoproliferative neoplasm 
70724 B653.00 Myeloid sarcoma 
70740 BBm1.11 [M]Malignant reticulosis 
70842 B627100 Follicular non-Hodg mixed sml cleavd & lge cell lymphoma 
70935 BBr4000 [M]Erythroleukaemia 
71031 B600100 Reticulosarcoma of lymph nodes of head, face and neck 
71117 BBg3.00 [M]Malignant lymphoma, undifferentiated cell type NOS 
71142 B613000 Hodgkin's, lymphocytic-histiocytic predominance unspec site 
71238 B601100 Lymphosarcoma of lymph nodes of head, face and neck 
71262 B62y600 Malignant lymphoma NOS of intrapelvic lymph nodes 
71304 B602z00 Burkitt's lymphoma NOS 
71377 BBr8000 [M]Eosinophilic leukaemia 
71609 B62z500 UNSPEC MALIG NEOP LYMPHOID/HISTIOCYTIC NODES INGUINAL/LEG 
71619 BBgT.00 [M]Malignant lymphoma, large cell, noncleaved, diffuse 
71625 B601000 Lymphosarcoma of unspecified site 
71652 BBgP.00 [M]Malignant lymphoma, mixed small and large cell, diffuse 
71672 4M23.00 Lymphoma stage IV 
71850 BBr6000 [M]Myeloid leukaemia NOS 
72179 BBr0200 [M]Subacute leukaemia NOS 
72196 BBgG.00 [M]Malignant lymphoma, lymphocytic, poorly different NOS 
72197 B67y000 Lymphosarcoma cell leukaemia 
72222 BBrA100 [M]Megakaryocytic leukaemia 
72310 BBr0400 [M]Aleukaemic leukaemia NOS 
72433 BBh0.00 [M]Reticulosarcoma NOS 
72500 ByuDB00 [X]Mal neoplasm/lymphoid,haematopoietic+related tissu,unspcf 
72714 B621500 Mycosis fungoides of lymph nodes of inguinal region and leg 
72725 B62y200 Malignant lymphoma NOS of intrathoracic lymph nodes 
72774 B642.00 Subacute lymphoid leukaemia 
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medcode readcode readterm 
73066 BBrA.00 [M]Miscellaneous leukaemias 
73088 BBr9000 [M]Monocytic leukaemia NOS 
73135 BBn2.12 [M]SOLITARY MYELOMA 
73532 B613300 Hodgkin's, lymphocytic-histiocytic pred intra-abdominal node 
73777 B624z00 Leukaemic reticuloendotheliosis NOS 
87335 B624.12 Hairy cell leukaemia 
89230 BBj9.00 [M]Hodgkin's granuloma 
89329 ByuD800 [X]Other specified leukaemias 
89657 B626z00 MALIGNANT MAST CELL TUMOUR NOS 
89762 ByuD700 [X]Other monocytic leukaemia 
90201 B62x000 T-zone lymphoma 
91674 B621300 Mycosis fungoides of intra-abdominal lymph nodes 
91900 B61z400 Hodgkin's disease NOS of lymph nodes of axilla and arm 
92068 B620300 Nodular lymphoma of intra-abdominal lymph nodes 
92245 B613200 Hodgkin's, lymphocytic-histiocytic pred intrathoracic nodes 
92380 B602500 Burkitt's lymphoma of lymph nodes of inguinal region and leg 
93342 B66z.00 Monocytic leukaemia NOS 
93384 B62z200 UNSPEC MALIG NEOP LYMPHOID/HISTIOCYTIC OF INTRATHORACIC 
NODE 
93951 B613500 Hodgkin's, lymphocytic-histiocytic pred inguinal and leg 
94005 B615z00 Hodgkin's disease, mixed cellularity NOS 
94174 B67y.00 Other and unspecified leukaemia 
94239 BBp1.00 [M]MAST CELL SARCOMA 
94279 B61z700 Hodgkin's disease NOS of spleen 
94407 B615100 Hodgkin's mixed cellularity of lymph nodes head, face, neck 
94415 B623100 MALIGNANT HISTIOCYTOSIS OF LYMPH NODES HEAD, FACE AND NECK 
94597 ZV10611 [V]Personal history of lymphoid leukaemia 
94935 4M21.00 Lymphoma stage II 
94995 B620500 Nodular lymphoma of lymph nodes of inguinal region and leg 
95012 B621800 Mycosis fungoides of lymph nodes of multiple sites 
95049 B616000 Hodgkin's lymphocytic depletion of unspecified site 
95058 B600700 Reticulosarcoma of spleen 
95338 B613600 Hodgkin's, lymphocytic-histiocytic pred intrapelvic nodes 
95464 BBl0.00 [M]Mycosis fungoides 
95545 B627911 Maltoma 
95630 B62x600 True histiocytic lymphoma 
95715 B627900 Mucosa-associated lymphoma 
95792 B62zz00 LYMPHOID AND HISTIOCYTIC MALIGNANCY NOS 
95949 B621000 Mycosis fungoides of unspecified site 
96183 BBj4.00 [M]Hodgkin's disease,lymphocytic depletion,diffuse fibrosis 
96379 B621400 Mycosis fungoides of lymph nodes of axilla and upper limb 
96893 BBrA300 [M]Myeloid sarcoma 
97577 B602300 Burkitt's lymphoma of intra-abdominal lymph nodes 
97746 B61z800 Hodgkin's disease NOS of lymph nodes of multiple sites 
97756 BBl1.00 [M]Sezary's disease 
97852 BBk7.00 [M]Malignant lymphoma, centroblastic type, follicular 
97863 B615000 Hodgkin's disease, mixed cellularity of unspecified site 
98009 BBrA312 [M]Granulocytic sarcoma 
98596 ByuD200 [X]Other types of diffuse non-Hodgkin's lymphoma 
98840 B610300 Hodgkin's paragranuloma of intra-abdominal lymph nodes 
98909 B611100 Hodgkin's granuloma of lymph nodes of head, face and neck 
98961 BBk2.00 [M]Malignant lymphoma, centroblastic-centrocytic, follicular 
99012 B61z500 Hodgkin's disease NOS of lymph nodes inguinal region and leg 
99015 B66y.00 Other monocytic leukaemia 
99067 C333200 GAMMA HEAVY CHAIN DISEASE 
99200 BBj7.00 [M]Hodgkin's disease, nodular sclerosis, cellular phase 
99240 B600z00 Reticulosarcoma NOS 
99413 B67yz00 Other and unspecified leukaemia NOS 
99655 BBg6.00 [M]Lymphosarcoma NOS 
99695 BBlz.00 [M]Mycosis fungoides NOS 
99702 BBn3.00 [M]Plasma cell tumour, malignant 
99847 SP08A00 Post-transplant lymphoproliferative disorder 
99887 B60y.00 Other specified reticulosarcoma or lymphosarcoma 
99951 B60z.00 Reticulosarcoma or lymphosarcoma NOS 
100006 B602200 Burkitt's lymphoma of intrathoracic lymph nodes 
100352 B601500 Lymphosarcoma of lymph nodes of inguinal region and leg 
100423 B610100 Hodgkin's paragranuloma of lymph nodes of head, face, neck 
100532 B622z00 Sezary's disease NOS 
100544 BBh2.00 [M]Reticulosarcoma, nodular 
100615 B626500 Mast cell malignancy of lymph nodes inguinal region and leg 
100786 B651000 Chronic eosinophilic leukaemia 
100927 BBr4z00 [M]Erythroleukaemia NOS 
101114 B627A00 Diffuse non-Hodgkin's large cell lymphoma 
101271 BBs1.00 [M]Acute panmyelosis 
101429 BBj0.11 [M]Lymphogranuloma, malignant 
379 
 
medcode readcode readterm 
101465 B62z800 Unspec malig neop lymphoid/histiocytic of multiple sites 
101530 B616z00 Hodgkin's disease, lymphocytic depletion NOS 
101606 B662.00 Subacute monocytic leukaemia 
101715 B616700 Hodgkin's disease, lymphocytic depletion of spleen 
102158 B625200 Letterer-Siwe disease of intrathoracic lymph nodes 
102164 BBn2.11 [M]Monostotic myeloma 
102594 B627E00 Diffuse large B-cell lymphoma 
102715 B625000 Letterer-Siwe disease of unspecified sites 
102764 BBrA600 [M]Acute panmyelosis 
102783 B651200 Chronic neutrophilic leukaemia 
103245 B601700 Lymphosarcoma of spleen 
103353 B62z300 Unspec malig neop lymphoid/histiocytic intra-abdominal nodes 
103645 B66yz00 Other monocytic leukaemia NOS 
103900 B626000 Mast cell malignancy of unspecified site 
104152 B628.00 Follicular lymphoma 
104291 B61..11 Hodgkin lymphoma 
104325 B640000 B-cell acute lymphoblastic leukaemia 
104328 B641000 B-cell chronic lymphocytic leukaemia 
104386 B62F000 Small cell B-cell lymphoma 
104391 B627.11 Non-Hodgkin lymphoma 
104412 B62F200 Lymphoblastic (diffuse) lymphoma 
104418 B630400 Solitary plasmacytoma 
104475 B692.00 Subacute myelomonocytic leukaemia 
104484 B61C.00 Other classical Hodgkin lymphoma 
104620 B62F100 Mantle cell lymphoma 
104743 B613800 Hodgkin's, lymphocytic-histiocytic pred of multiple sites 
104788 B654.00 Acute myeloblastic leukaemia 
104790 B601800 Lymphosarcoma of lymph nodes of multiple sites 
104862 B62E300 Cutaneous T-cell lymphoma 
104895 B617.00 Nodular lymphocyte predominant Hodgkin lymphoma 
104934 B62Ew00 Other mature T/NK-cell lymphoma 
104939 B64y500 Adult T-cell lymphoma/leukaemia (HTLV-1-associated) 
105020 B628300 Follicular lymphoma grade 3a 
105025 ByuDA00 [X]Oth spcf mal neoplsm/lymphoid,haematopoietic+rltd tissue 
105038 B627G00 Mediastinal (thymic) large B-cell lymphoma 
105069 B693.00 Juvenile myelomonocytic leukaemia 
105083 B62D.00 Histiocytic sarcoma 
105085 B62E.00 T/NK-cell lymphoma 
105095 B628100 Follicular lymphoma grade 2 
105203 B620200 Nodular lymphoma of intrathoracic lymph nodes 
105286 B62EA00 Primary cutaneous CD30-positive T-cell proliferations 
105335 B62A.00 Sarcoma of dendritic cells 
105375 B62E800 Blastic NK-cell lymphoma 
105472 B614700 Hodgkin's disease, nodular sclerosis of spleen 
105559 B62E100 Anaplastic large cell lymphoma, ALK-positive 
105636 B62E900 Angioimmunoblastic T-cell lymphoma 
105709 B62E600 Enteropathy-associated T-cell lymphoma 
105762 B62C.00 Unifocal Langerhans-cell histiocytosis 
105792 B629.00 Multifocal multisystemic dissem Langerhans-cell histiocytosi 
105841 B618.00 Nodular sclerosis classical Hodgkin lymphoma 
105889 B628000 Follicular lymphoma grade 1 
105925 B62E700 Subcutaneous panniculitic T-cell lymphoma 
105955 B62E200 Anaplastic large cell lymphoma, ALK-negative 
105957 B651100 Chronic myeloid leukaemia, BCR/ABL positive 
105966 B627F00 Extranod marg zone B-cell lymphom mucosa-assoc lymphoid tiss 
106063 B628700 Other types of follicular lymphoma 
106137 BBh..00 [M]Reticulosarcomas 
106197 BBr7000 [M]Basophilic leukaemia 
106349 B61z.11 Hodgkin lymphoma NOS 
106483 BBr6200 [M]Subacute myeloid leukaemia 
106597 B61B.00 Lymphocyte-rich classical Hodgkin lymphoma 
106867 B62F.11 Non-follicular lymphoma 
106884 B62F.00 Nonfollicular lymphoma 
106911 B613700 Hodgkin's, lymphocytic-histiocytic predominance of spleen 
106924 B641200 Clinical stage B chronic lymphocytic leukaemia 
106969 B628500 Diffuse follicle centre lymphoma 
106970 BBk3.00 [M]Malig lymphoma, lymphocytic, well differentiated,nodular 
107017 B641011 Chronic lymphocytic leukaemia of B-cell type 
107032 B616800 Hodgkin's lymphocytic depletion lymph nodes multiple sites 
107052 B641100 Clinical stage A chronic lymphocytic leukaemia 
107163 B641300 Clinical stage C chronic lymphocytic leukaemia 
107166 B628200 Follicular lymphoma grade 3 
107236 B651300 Atypical chronic myeloid leukaemia, BCR/ABL negative 
107638 B62z400 Unspec malig neop lymphoid/histiocytic lymph node axilla/arm 
107643 B64y400 T-cell prolymphocytic leukaemia 
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107773 BBr8z00 [M]Eosinophilic leukaemia NOS 
107804 B61z300 Hodgkin's disease NOS of intra-abdominal lymph nodes 
107949 B62E500 Hepatosplenic T-cell lymphoma 
107973 B628400 Follicular lymphoma grade 3b 
108037 B62z000 Unspec malig neop lymphoid/histiocytic of unspecified site 
108102 C333300 Heavy chain disease 
108182 B627400 Diffuse non-Hodgkin's small cleaved cell (diffuse) lymphoma 
108235 C333011 Waldenstrom macroglobulinaemia 
108316 BBrAz00 [M]Miscellaneous leukaemia NOS 
108424 B663.00 Acute monoblastic leukaemia 
108656 B64y300 B-cell prolymphocytic leukaemia 
108715 B66..11 Histiocytic leukaemia 
108719 B628600 Cutaneous follicle centre lymphoma 
108775 B619.00 Mixed cellularity classical Hodgkin lymphoma 
108886 B615500 Hodgkin's mixed cellularity of lymph nodes inguinal and leg 
108964 BBr6900 [M]Juvenile myelomonocytic leukaemia 
109342 B62z600 Unspec malig neop lymphoid/histiocytic of intrapelvic nodes 
109714 ByuDD00 [X]Oth and unspecif peripheral & cutaneous T-cell lymphomas 
109780 B62E400 Extranodal NK/T-cell lymphoma, nasal type 
110058 ZV10613 [V]Personal history of myeloid leukaemia 
110191 B62B.00 Multifocal and unisystemic Langerhans-cell histiocytosis 
110349 BBr3z00 [M]Plasma cell leukaemia NOS 
110563 B616500 Hodgkin's lymphocytic depletion lymph nodes inguinal and leg 
110838 B676.00 Acute erythroid leukaemia 
110903 B623800 Malignant histiocytosis of lymph nodes of multiple sites 
111040 D401.12 Lipochrome histiocytosis - familial 
111113 BBj3.00 [M]Hodgkin's disease, lymphocytic depletion NOS 
 
B) Hospital Episodes Statistics 
ICD10 DESCRIPTION 
B21.1 HIV disease resulting in Burkitt lymphoma 
B21.2 HIV disease resulting in other types of non-Hodgkin lymphoma 
B21.3 HIV disease resulting in other malignant neoplasms of lymphoid, haematopoietic and related 
tissue 
C81 Hodgkin lymphoma 
C81.0 Nodular lymphocyte predominant Hodgkin lymphoma 
C81.1 Nodular sclerosis (classical) Hodgkin lymphoma 
C81.2 Mixed cellularity (classical) Hodgkin lymphoma 
C81.3 Lymphocyte depleted (classical) Hodgkin lymphoma 
C81.4 Lymphocyte-rich (classical) Hodgkin lymphoma 
C81.7 Other (classical) Hodgkin lymphoma 
C81.9 Hodgkin lymphoma, unspecified 
C82 Follicular lymphoma 
C82.0 Follicular lymphoma grade I 
C82.1 Follicular lymphoma grade II 
C82.2 Follicular lymphoma grade III, unspecified 
C82.3 Follicular lymphoma grade IIIa 
C82.4 Follicular lymphoma grade IIIb 
C82.5 Diffuse follicle centre lymphoma 
C82.6 Cutaneous follicle centre lymphoma 
C82.7 Other types of follicular lymphoma 
C82.9 Follicular lymphoma, unspecified 
C83 Non-follicular lymphoma 
C83.0 Small cell B-cell lymphoma 
C83.1 Mantle cell lymphoma 
C83.2 Diffuse non-Hodgkin mixed sml & lge cell (diffuse) lymphoma 
C83.3 Diffuse large B-cell lymphoma 
C83.4 Diffuse non-Hodgkin's immunoblastic (diffuse) lymphoma 
C83.5 Lymphoblastic (diffuse) lymphoma 
C83.6 Diffuse non-Hodgkin's lymphoma undifferentiated (diffuse) 
C83.7 Burkitt lymphoma 
C83.8 Other non-follicular lymphoma 
C83.9 Non-follicular (diffuse) lymphoma, unspecified 
C84 Mature T/NK-cell lymphomas 
C84.0 Mycosis fungoides 
C84.1 S├®zary disease 
C84.2 Peripheral and cutaneous T-cell lymphomas, T-zone lymphoma 
C84.3 Periph & cutan T-cell lymphomas, lymphoepithelioid lymphoma 
C84.4 Peripheral T-cell lymphoma, not elsewhere classified 
C84.5 Other mature T/NK-cell lymphomas 
C84.6 Anaplastic large cell lymphoma, ALK-positive 
C84.7 Anaplastic large cell lymphoma, ALK-negative 
C84.8 Cutaneous T-cell lymphoma, unspecified 
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C84.9 Mature T/NK-cell lymphoma, unspecified 
C85 Other and unspecified types of non-Hodgkin lymphoma 
C85.0 Oth & unspec types of non-Hodgkin's lymphoma, lymphosarcoma 
C85.1 B-cell lymphoma, unspecified 
C85.2 Mediastinal (thymic) large B-cell lymphoma 
C85.7 Other specified types of non-Hodgkin lymphoma 
C85.9 Non-Hodgkin lymphoma, unspecified 
C86 Other specified types of T/NK-cell lymphoma 
C86.0 Extranodal NK/T-cell lymphoma, nasal type 
C86.1 Hepatosplenic T-cell lymphoma 
C86.2 Enteropathy-type (intestinal) T-cell lymphoma 
C86.3 Subcutaneous panniculitis-like T-cell lymphoma 
C86.4 Blastic NK-cell lymphoma 
C86.5 Angioimmunoblastic T-cell lymphoma 
C86.6 Primary cutaneous CD30-positive T-cell proliferations 
C88 Malignant immunoproliferative diseases 
C88.0 Waldenstr├Âm macroglobulinaemia 
C88.1 Alpha heavy chain disease 
C88.2 Other heavy chain disease 
C88.3 Immunoproliferative small intestinal disease 
C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-
lymphoma] 
C88.7 Other malignant immunoproliferative diseases 
C88.9 Malignant immunoproliferative disease, unspecified 
C90 Multiple myeloma and malignant plasma cell neoplasms 
C90.0 Multiple myeloma 
C90.1 Plasma cell leukaemia 
C90.2 Extramedullary plasmacytoma 
C90.3 Solitary plasmacytoma 
C91 Lymphoid leukaemia 
C91.0 Acute lymphoblastic leukaemia [ALL] 
C91.1 Chronic lymphocytic leukaemia of B-cell type 
C91.2 Subacute lymphocytic leukaemia 
C91.3 Prolymphocytic leukaemia of B-cell type 
C91.4 Hairy-cell leukaemia 
C91.5 Adult T-cell lymphoma/leukaemia [HTLV-1-associated] 
C91.6 Prolymphocytic leukaemia of T-cell type 
C91.7 Other lymphoid leukaemia 
C91.8 Mature B-cell leukaemia Burkitt-type 
C91.9 Lymphoid leukaemia, unspecified 
C92 Myeloid leukaemia 
C92.0 Acute myeloblastic leukaemia [AML] 
C92.1 Chronic myeloid leukaemia [CML], BCR/ABL-positive 
C92.2 Atypical chronic myeloid leukaemia, BCR/ABL-negative 
C92.3 Myeloid sarcoma 
C92.4 Acute promyelocytic leukaemia [PML] 
C92.5 Acute myelomonocytic leukaemia 
C92.6 Acute myeloid leukaemia with 11q23-abnormality 
C92.7 Other myeloid leukaemia 
C92.8 Acute myeloid leukaemia with multilineage dysplasia 
C92.9 Myeloid leukaemia, unspecified 
C93 Monocytic leukaemia 
C93.0 Acute monoblastic/monocytic leukaemia 
C93.1 Chronic myelomonocytic leukaemia 
C93.2 Subacute monocytic leukaemia 
C93.3 Juvenile myelomonocytic leukaemia 
C93.7 Other monocytic leukaemia 
C93.9 Monocytic leukaemia, unspecified 
C94 Other leukaemias of specified cell type 
C94.0 Acute erythroid leukaemia 
C94.1 Chronic erythraemia 
C94.2 Acute megakaryoblastic leukaemia 
C94.3 Mast cell leukaemia 
C94.4 Acute panmyelosis with myelofibrosis 
C94.5 Acute myelofibrosis 
C94.6 Myelodysplastic and myeloproliferative disease, not elsewhere classified 
C94.7 Other specified leukaemias 
C95 Leukaemia of unspecified cell type 
C95.0 Acute leukaemia of unspecified cell type 
C95.1 Chronic leukaemia of unspecified cell type 
C95.2 Subacute leukaemia unsp cell type 
C95.7 Other leukaemia of unspecified cell type 
C95.9 Leukaemia, unspecified 
C96 Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue 
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C96.0 Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis [Letterer-Siwe 
disease] 
C96.1 Malignant histiocytosis 
C96.2 Malignant mast cell tumour 
C96.3 True histiocyt lymphoma 
C96.4 Sarcoma of dendritic cells (accessory cells) 
C96.5 Multifocal and unisystemic Langerhans-cell histiocytosis 
C96.6 Unifocal Langerhans-cell histiocytosis 
C96.7 Other specified malignant neoplasms of lymphoid, haematopoietic and related tissue 
C96.8 Histiocytic sarcoma 
C96.9 Malignant neoplasm of lymphoid, haematopoietic and related tissue, unspecified 
Z85.6 Personal history of leukaemia 
Z85.7 Personal history of other malignant neoplasms of lymphoid, haematopoietic and related tissues 
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Appendix 15 Codelist: HIV, other cellular immune deficiency and solid organ 
transplant 
1. HIV 
A) CPRD 
medcode readcode readterm 
2835 43C3.11 HIV positive 
8281 A789A00 HIV disease resulting in wasting syndrome 
9130 A788.11 Human immunodeficiency virus infection 
23763 65QA.00 AIDS carrier 
23770 A788.00 Acquired immune deficiency syndrome 
23951 A789200 HIV disease resulting in candidiasis 
24872 ZV01A00 [V]Asymptomatic human immunodeficency virus infection status 
27053 4J34.00 HIV viral load 
27641 A789300 HIV disease resulting in Pneumocystis carinii pneumonia 
27853 A789500 HIV disease resulting in Kaposi's sarcoma 
33943 65VE.00 Notification of AIDS 
36294 A788z00 Acquired human immunodeficiency virus infection syndrome NOS 
37006 A789000 HIV disease resulting in mycobacterial infection 
41185 Eu02400 [X]Dementia in human immunodef virus [HIV] disease 
43537 43j7.00 HIV 1 nucleic acid detection 
44288 R109.00 [D]Laboratory evidence of human immunodeficiency virus [HIV] 
44303 A789.00 Human immunodef virus resulting in other disease 
44617 A789600 HIV disease resulting in Burkitt's lymphoma 
47632 A788U00 HIV disease result/haematological+immunologic abnorms,NEC 
50076 A789400 HIV disease resulting in multiple infections 
51708 A789X00 HIV dis reslt/oth mal neopl/lymph,h'matopoetc+reltd tissu 
53636 A788400 Human immunodeficiency virus with neurological disease 
58857 A788000 Acute human immunodeficiency virus infection 
58859 A788100 Asymptomatic human immunodeficiency virus infection 
62854 AyuC.00 [X]Human immunodeficiency virus disease 
62891 A788y00 Human immunodeficiency virus with other clinical findings 
65117 A789900 HIV disease resulting in lymphoid interstitial pneumonitis 
66367 A789700 HIV dis resulting oth types of non-Hodgkin's lymphoma 
66368 A789100 HIV disease resulting in cytomegaloviral disease 
67575 A788W00 HIV disease resulting in unspecified malignant neoplasm 
69766 A788200 HIV infection with persistent generalised lymphadenopathy 
69767 AyuC600 [X]HIV disease resulting in other non-Hodgkin's lymphoma 
70528 A788500 Human immunodeficiency virus with secondary infection 
70869 A788300 Human immunodeficiency virus with constitutional disease 
71450 A788X00 HIV disease resulting/unspcf infectious+parasitic disease 
93642 43w3.00 Human immunodeficiency virus RNA/DNA ratio 
96751 AyuCB00 [X]HIV disease result/haematological+immunologic abnorms,NEC 
96902 4J3F.00 Human immunodeficiency virus viral load by log rank 
100769 AyuCD00 [X]Unspecified human immunodeficiency virus [HIV] disease 
101191 66j0.00 Human immunodeficiency virus annual review 
101836 A788600 Human immunodeficiency virus with secondary cancers 
102117 AyuC300 [X]HIV disease resulting in multiple infections 
102252 AyuCC00 [X]HIV disease resulting in other specified conditions 
104134 AyuC400 [X]HIV disease resulting/other infectious+parasitic diseases 
104466 L179.00 HIV disease complicating pregnancy childbirth puerperium 
104717 A789311 HIV disease resulting in Pneumocystis jirovecii pneumonia 
105040 9kl..00 HIV pos gen health check serv declind - enhanc service admin 
105324 A789800 HIV disease resulting in multiple malignant neoplasms 
107594 9Nt1000 Seen by community HIV (human immunodeficiency virus) nurse 
107807 AyuC100 [X]HIV disease resulting in other viral infections 
108054 A789511 HIV disease resulting in Kaposi sarcoma 
108385 9mN..00 Human immunodeficiency virus infection monitoring invitation 
108631 8Hle.00 Referral to community HIV nurse specialist 
109327 9mN0.00 HIV infection monitoring telephone invitation 
109513 4J3N.00 Human immunodeficiency virus drug resistance test 
110374 4J3P.00 Human immunodeficiency virus type 1 subtype identification 
 
B) Hospital Episodes Statistics 
ICD 10 DESCRIPTION 
B20 Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases 
B20.0 HIV disease resulting in mycobacterial infection 
B20.1 HIV disease resulting in other bacterial infections 
B20.2 HIV disease resulting in cytomegaloviral disease 
B20.3 HIV disease resulting in other viral infections 
B20.4 HIV disease resulting in candidiasis 
B20.5 HIV disease resulting in other mycoses 
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B20.6 HIV disease resulting in Pneumocystis jirovecii pneumonia 
B20.7 HIV disease resulting in multiple infections 
B20.8 HIV disease resulting in other infectious and parasitic diseases 
B20.9 HIV disease resulting in unspecified infectious or parasitic disease 
B21 Human immunodeficiency virus [HIV] disease resulting in malignant neoplasms 
B21.0 HIV disease resulting in Kaposi sarcoma 
B21.1 HIV disease resulting in Burkitt lymphoma 
B21.2 HIV disease resulting in other types of non-Hodgkin lymphoma 
B21.3 HIV disease resulting in other malignant neoplasms of lymphoid, haematopoietic and related 
tissue 
B21.7 HIV disease resulting in multiple malignant neoplasms 
B21.8 HIV disease resulting in other malignant neoplasms 
B21.9 HIV disease resulting in unspecified malignant neoplasm 
B22 Human immunodeficiency virus [HIV] disease resulting in other specified diseases 
B22.0 HIV disease resulting in encephalopathy 
B22.1 HIV disease resulting in lymphoid interstitial pneumonitis 
B22.2 HIV disease resulting in wasting syndrome 
B22.7 HIV disease resulting in multiple diseases classified elsewhere 
B23 Human immunodeficiency virus [HIV] disease resulting in other conditions 
B23.0 Acute HIV infection syndrome 
B23.1 HIV disease resulting in (persistent) generalized lymphadenopathy 
B23.2 HIV disease resulting in haematological and immunological abnormalities, not elsewhere 
classified 
B23.8 HIV disease resulting in other specified conditions 
B24 Unspecified human immunodeficiency virus [HIV] disease 
F02.4 Dementia in human immunodeficiency virus [HIV] disease 
O98.7 Human immunodeficiency virus [HIV] disease complicating pregnancy, childbirth and the 
puerperium 
R75 Laboratory evidence of human immunodeficiency virus [HIV] 
Z21 Asymptomatic human immunodeficiency virus [HIV] infection status 
 
2. Cellular immune deficiency 
A) CPRD 
medcode readcode readterm 
938 D201600 Pancytopenia NOS 
5823 D201500 Pancytopenia - acquired 
10955 C391100 Di George syndrome 
15422 D20..00 Aplastic anaemia 
15658 D201.00 Acquired aplastic anaemia 
16108 D201000 Aplastic anaemia due to chronic disease 
16903 F14y011 Louis - Bar syndrome 
21723 D201z00 Acquired aplastic anaemia NOS 
31275 D201611 Pancytopenia with malformation 
31322 C391200 Wiskott - Aldrich syndrome 
31491 D200211 Pancytopenia-dysmelia 
31541 C392300 Severe combined immunodefiency with reticular dysgenesis 
37539 D2...00 Aplastic and other anaemias 
41142 D204.00 Idiopathic aplastic anaemia 
42394 D401.11 Job's syndrome 
42439 C391211 Thrombocytopenic eczema with immunodeficiency 
43166 D201100 Aplastic anaemia due to drugs 
48035 C391011 T-lymphocyte deficiency 
48293 C392100 Severe combined immunodeficiency 
48307 C391.00 Deficiencies of cell-mediated immunity 
48879 J637.00 Hepatic veno-occlusive disease 
49530 BBmC.00 [M] T-gamma lymphoproliferative disease 
49542 C392500 Severe combined immunodef with low or normal B-cell numbers 
50526 C392800 Major histocompatibility complex class I deficiency 
50665 C391000 Predominantly T-cell immuno-deficiency NOS 
57552 C30yy11 Adenosine-deaminase deficiency 
57859 D201200 Aplastic anaemia due to infection 
60758 C391012 Cellular immunity syndrome 
61326 D201612 Pancytopenia with pancreatitis 
62236 C392.00 Combined immunity deficiency 
62328 C392z00 Combined immunity deficiency NOS 
66073 C392400 Severe combined immunodef with low T- and B-cell numbers 
66239 D201400 Aplastic anaemia due to toxic cause 
68087 D20z.00 Aplastic anaemia NOS 
69027 D200.00 Constitutional aplastic anaemia 
69061 D200011 Constitutional aplastic anaemia without malformation 
69379 D200y00 Other specified constitutional aplastic anaemia 
70128 D201311 Radiation aplastic anaemia 
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medcode readcode readterm 
72804 C392600 Adenosine deaminase deficiency 
73583 F14y000 Ataxia-telangiectasia 
93936 C392700 Purine nucleoside phosphorylase deficiency 
94120 C392111 Swiss type agammaglobulinaemia 
102848 D200200 Constitutional aplastic anaemia with malformation 
103977 C392900 Major histocompatibility complex class II deficiency 
 
B) Hospital Episodes Statistics 
ICD10 DESCRIPTION 
D61 Other aplastic anaemias 
D61.0 Constitutional aplastic anaemia 
D61.1 Drug-induced aplastic anaemia 
D61.2 Aplastic anaemia due to other external agents 
D61.3 Idiopathic aplastic anaemia 
D61.8 Other specified aplastic anaemias 
D61.9 Aplastic anaemia, unspecified 
D81 Combined immunodeficiencies 
D81.0 Severe combined immunodeficiency [SCID] with reticular dysgenesis 
D81.1 Severe combined immunodeficiency [SCID] with low T- and B-cell numbers 
D81.2 Severe combined immunodeficiency [SCID] with low or normal B-cell numbers 
D81.3 Adenosine deaminase [ADA] deficiency 
D81.4 Nezelof syndrome 
D81.5 Purine nucleoside phosphorylase [PNP] deficiency 
D81.6 Major histocompatibility complex class I deficiency 
D81.7 Major histocompatibility complex class II deficiency 
D81.8 Other combined immunodeficiencies 
D81.9 Combined immunodeficiency, unspecified 
D82 Immunodeficiency associated with other major defects 
D82.0 Wiskott-Aldrich syndrome 
D82.1 Di George syndrome 
D82.2 Immunodeficiency with short-limbed stature 
D82.3 Immunodeficiency following hereditary defective response to Epstein-Barr virus 
D82.4 Hyperimmunoglobulin E [IgE] syndrome 
D82.8 Immunodeficiency associated with other specified major defects 
D82.9 Immunodeficiency associated with major defect, unspecified 
D83 Common variable immunodeficiency 
D83.0 Common variable immunodeficiency with predominant abnormalities of B-cell numbers and 
function 
D83.1 Common variable immunodeficiency with predominant immunoregulatory T-cell disorders 
D83.2 Common variable immunodeficiency with autoantibodies to B- or T-cells 
D83.8 Other common variable immunodeficiencies 
D83.9 Common variable immunodeficiency, unspecified 
D84.0 Lymphocyte function antigen-1 [LFA-1] defect 
G11.3 Cerebellar ataxia with defective DNA repair 
D47.1 Chronic myeloproliferative disease 
 
3. Solid organ transplant 
A) CPRD 
medcode readcode readterm 
242 7901000 Allotransplantation of heart NEC 
250 7900.00 Transplantation of heart and lung 
2124 8HBB.00 Transplant follow-up 
2997 7B00.00 Transplantation of kidney 
4405 7800.00 Transplantation of liver 
4438 7901.00 Other transplantation of heart 
5504 7B00z00 Transplantation of kidney NOS 
5911 ZV42000 [V]Kidney transplanted 
6692 SP08600 Liver transplant failure and rejection 
9026 ZV42700 [V]Liver transplanted 
9384 ZV42100 [V]Heart transplanted 
10394 ZV42600 [V]Lung transplanted 
10461 7450.00 Transplantation of lung 
11113 SP08100 Transplanted organ rejection 
11553 SP08300 Kidney transplant failure and rejection 
11745 7B00100 Transplantation of kidney from live donor 
18774 TB00111 Renal transplant with complication, without blame 
22653 ZV42.00 [V]Transplanted organ or tissue 
24361 7B00200 Transplantation of kidney from cadaver 
25896 SP08z00 Transplanted organ complication NOS 
26862 7B06300 Exploration of renal transplant 
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medcode readcode readterm 
27319 7800z00 Transplantation of liver NOS 
27679 SP08500 Heart-lung transplant failure and rejection 
29831 SP08000 Transplanted organ failure 
30052 SP...18 Transplant complications 
31997 TB00200 Liver transplant with complication, without blame 
32025 7800000 Orthotopic transplantation of liver 
35368 7830.00 Transplantation of pancreas 
37198 14S8.00 H/O: liver recipient 
38011 7450z00 Transplantation of lung NOS 
41495 7901z00 Other transplantation of heart NOS 
44077 ZV42y12 [V]Pancreas transplanted 
44893 SP08.00 Transplanted organ complication 
47033 ZLEQJ00 Discharge from transplant surgery service 
47484 SP08400 Heart transplant failure and rejection 
47495 14SZ.00 H/O:tissue/organ recipient NOS 
48057 K0B5.00 Renal tubulo-interstitial disordrs in transplant rejectn 
48121 7B01500 Transplant nephrectomy 
49028 14S2.00 H/O: kidney recipient 
50226 SyuKK00 [X]Failure & rejection of other transplanted organ & tissue 
53626 7900000 Allotransplantation of heart and lung 
54990 TB00100 Kidney transplant with complication, without blame 
55151 7B00000 Autotransplant of kidney 
56993 7830100 Transplantation of whole pancreas 
57403 14S..00 H/O: tissue/organ recipient 
59394 14S3.00 H/O: heart recipient 
59610 8C31.00 Transplant immunosuppression 
60955 7830300 Transplantation of islets of Langerhans 
61073 7900z00 Transplantation of heart and lung NOS 
64438 TB00000 Heart transplant with complication, without blame 
65772 14S9.00 H/O: lung recipient 
66456 ZV42y00 [V]Other specified transplanted organ or tissue 
66705 7B00111 Allotransplantation of kidney from live donor 
67499 7830z00 Transplantation of pancreas NOS 
69147 ZLD4K00 Discharge by transplant surgeon 
69194 7800200 Replacement of previous liver transplant 
69734 7901y00 Other specified other transplantation of heart 
70712 SP08011 Det.ren.func.after ren.transpl 
70874 7B00y00 Other specified transplantation of kidney 
71422 7800100 Heterotopic transplantation of liver 
72004 7B01511 Excision of rejected transplanted kidney 
72092 ZV42z00 [V]Unspecified transplanted organ or tissue 
72939 7901100 Xenotransplantation of heart 
73743 7450y00 Other specified transplantation of lung 
89445 7800111 Auxillary liver transplant 
89924 7B00300 Allotransplantation of kidney from cadaver, heart-beating 
90952 7B0F100 Pre-transplantation of kidney work-up, recipient 
93366 7B0F.00 Interventions associated with transplantation of kidney 
93713 7450100 Single lung transplant 
93751 ZV42y11 [V]Intestine transplanted 
93844 7901500 Revision of transplantation of heart NEC 
94964 7B0F400 Post-transplantation of kidney examination, live donor 
96095 7B0F200 Pre-transplantation of kidney work-up, live donor 
96129 7831200 Excision of transplanted pancreas 
96133 7B00400 Allotransplantation kidney from cadaver, heart non-beating 
96423 ZV42.11 [V]Transplanted organ 
96578 7450000 Double lung transplant 
97157 7800500 Orthotopic transplantation of liver NEC 
98364 7B00211 Allotransplantation of kidney from cadaver 
99250 7800y00 Other specified transplantation of liver 
99847 SP08A00 Post-transplant lymphoproliferative disorder 
100073 7800112 Piggy back liver transplant 
100621 764C.00 Transplantation of ileum 
100693 Kyu1C00 [X]Renal tubulo-interstitial disorders/transplant rejection 
101231 7830200 Transplantation of tail of pancreas 
102998 7125.00 Transplantation of thymus gland 
103429 7B0F300 Post-transplantation of kidney examination, recipient 
103649 9b8K.00 Transplantation surgery 
104049 7B0Fz00 Interventions associated with transplantation of kidney NOS 
104050 7B0Fy00 OS interventions associated with transplantation of kidney 
104201 SP08H00 Acute rejection of renal transplant 
104630 SP08G00 Acute rejection of renal transplant - grade III 
104905 SP08D00 Acute-on-chronic rejection of renal transplant 
104960 SP08E00 Acute rejection of renal transplant - grade I 
105328 7B00212 Cadaveric renal transplant 
105506 7800400 Orthotopic transplantation of whole liver 
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medcode readcode readterm 
105724 SP08N00 Unexplained episode of renal transplant dysfunction 
105787 7B00600 Xenograft renal transplant 
105811 SP08R00 Renal transplant rejection 
106015 7842000 Transplantation of spleen 
106301 SP08P00 Stenosis of vein of transplanted kidney 
106620 SP08J00 Chronic rejection of renal transplant 
106866 SP08W00 Vascular complication of renal transplant 
107000 SP08F00 Acute rejection of renal transplant - grade II 
107416 7901300 Piggyback transplantation of heart 
107752 SP08T00 Urological complication of renal transplant 
108330 SP08900 Complication of transplanted lung 
108437 SP08V00 Very mild acute rejection of renal transplant 
108705 SP08V11 Borderline changes of acute rejection 
109304 9b8B200 Cardiothoracic transplantation 
109455 7B00500 Allotransplantation of kidney from cadaver NEC 
110789 761N.00 Transplantation of stomach 
 
B) Hospital Episodes Statistics 
ICD10 DESCRIPTION 
T86.1 Kidney transplant failure and rejection 
T86.2 Heart transplant failure and rejection 
T86.3 Heart-lung transplant failure and rejection 
T86.4 Liver transplant failure and rejection 
Z94.0 Kidney transplant status 
Z94.1 Heart transplant status 
Z94.2 Lung transplant status 
Z94.3 Heart and lungs transplant status 
Z94.4 Liver transplant status 
 
C) Office of Population Censuses and Surveys (OPCS) version 4 codes 
Opcs Description_other Description 
B171 Transplantation of thymus gland Allotransplantation of thymus gland 
B178 Transplantation of thymus gland Other specified 
B179 Transplantation of thymus gland Unspecified 
E531 Transplantation of lung Double lung transplant 
E532 Transplantation of lung Single lung transplant 
E533 Transplantation of lung Single lobe lung transplant 
E538 Transplantation of lung Other specified 
E539 Transplantation of lung Unspecified 
G681 Transplantation of ileum Allotransplantation of ileum 
G688 Transplantation of ileum Other specified 
G689 Transplantation of ileum Unspecified 
J011 Transplantation of liver Orthotopic transplantation of liver nec 
J012 Transplantation of liver Heterotopic transplantation of liver 
J013 Transplantation of liver Replacement of previous liver transplant 
J014 Transplantation of liver Transplantation of liver cells 
J015 Transplantation of liver Orthotopic transplantation of whole liver 
J018 Transplantation of liver Other specified 
J019 Transplantation of liver Unspecified 
J541 Transplantation of pancreas Transplantation of pancreas and duodenum 
J542 Transplantation of pancreas Transplantation of whole pancreas 
J543 Transplantation of pancreas Transplantation of tail of pancreas 
J544 Transplantation of pancreas Transplantation of islet of langerhans 
J545 Transplantation of pancreas Renewal of transplanted pancreatic tissue 
J548 Transplantation of pancreas Other specified 
J549 Transplantation of pancreas Unspecified 
J553 Total excision of pancreas Excision of transplanted pancreas 
J721 Other operations on spleen Transplantation of spleen 
K011 Transplantation of heart and lung Allotransplantation of heart and lung 
K012 Transplantation of heart and lung Revision of transplantation of heart and lung 
K018 Transplantation of heart and lung Other specified 
K019 Transplantation of heart and lung Unspecified 
K021 Other transplantation of heart Allotransplantation of heart nec 
K022 Other transplantation of heart Xenotransplantation of heart 
K023 Other transplantation of heart Implantation of prosthetic heart 
K024 Other transplantation of heart Piggyback transplantation of heart 
K025 Other transplantation of heart Revision of implantation of prosthetic heart 
K026 Other transplantation of heart Revision of transplantation of heart nec 
K028 Other transplantation of heart Other specified 
388 
 
Opcs Description_other Description 
K029 Other transplantation of heart Unspecified 
M011 Transplantation of kidney Autotransplantation of kidney 
M012 Transplantation of kidney Allotransplantation of kidney from live donor 
M013 Transplantation of kidney Allotransplantation of kidney from cadaver nec 
M014 Transplantation of kidney Allotransplantation of kidney from cadaver heart 
beating M015 Transplantation of kidney Allotransplantation of kidney from cadaver heart non-
beating M018 Transplantation of kidney Other specified 
M019 Transplantation of kidney Unspecified 
M026 Total excision of kidney Excision of rejected transplanted kidney 
M084 Other open operations on kidney Exploration of transplanted kidney 
M174 Interventions associated with transplantation of 
kidney 
Post-transplantation of kidney examination - recipient 
M178 Interventions associated with transplantation of 
kidney 
Other specified 
M179 Interventions associated with transplantation of 
kidney 
Unspecified 
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Appendix 16 Codelist: Chemotherapy and radiotherapy 
 
Radiotherapy and chemotherapy 
A) CPRD 
medcode readcode readterm 
320 7M37100 Radiotherapy NEC 
783 8BAD.00 CHEMOTHERAPY 
1009 8HB6.00 Radiotherapy follow-up 
1482 59...00 External radiotherapy 
3622 5A11.00 Thyroid gland ablat - irradiat 
5019 8BAD000 CANCER CHEMOTHERAPY 
5404 7M0P.00 Introduction removable radioactive material into organ NOC 
5527 ZV58000 [V]Radiotherapy session 
9706 5154.00 Radiotherapy completed 
10346 9N0D.00 Seen in radiotherapy clinic 
10542 5A16.00 Radioactive drug therapy 
10776 5A...11 Radiotherapy - internal 
10932 8H67.00 Referred for radiotherapy 
10950 ZL93100 Seen by radiotherapist 
14887 8BA5.00 ORAL CHEMOTHERAPY 
15362 7E0C000 Introduction of radioactive substance into uterine cavity 
15386 7L16100 INTRAVENOUS CHEMOTHERAPY 
16662 ZV66100 [V]Convalescence after radiotherapy 
16771 59...11 X-ray therapy -external 
16935 515..00 Progress of radiotherapy 
18079 8HB7.00 CHEMOTHERAPY FOLLOW-UP 
18675 8BAK.00 POST-OPERARTIVE CHEMOTHERAPY 
18715 5AB..00 Stereotactic radiotherapy 
18832 8BAa.00 DATE CHEMOTHERAPY COMPLETED 
18904 ZV67100 [V]Radiotherapy follow-up 
19467 8BAJ.00 PRE-OPERATIVE CHEMOTHERAPY 
20282 7M0Py00 Introduction removable radioactive material to organ NOC OS 
20336 7272200 Radiotherapy to lesion of retina 
20381 ZV58100 [V]MAINTENANCE CHEMOTHERAPY 
20443 ZV67200 [V]CHEMOTHERAPY FOLLOW-UP 
21318 8BA5.11 Oral cytotoxic drug therapy 
22472 59Z..00 External radiotherapy NOS 
22490 8BAL.00 COMBINED PRE-OPERATIVE CHEMOTHERAPY AND RADIOTHERAPY 
23589 7M0Pz00 Introduction removable radioactive material to organ NOC NOS 
25479 ZV67800 [V]FOLLOW-UP EXAMIN AFTER CHEMOTHERAPY FOR MALIGN NEOPLASM 
25490 ZLD2400 Discharge by radiotherapist 
26149 8CV1.00 CHEMOTHERAPY STARTED 
28071 7L10200 CONTINUOUS INFUSION OF CHEMOTHERAPY 
28427 7D03400 Implantation of radioactive substance into vulva 
28712 8J01.00 Iodine seed radiotherapy 
28809 8BAM.00 COMBINED POST-OPERATIVE CHEMOTHERAPY AND RADIOTHERAPY 
29285 5149.00 Radiotherapy-tumour palliation 
29301 514Z.00 Radiotherapy purpose - NOS 
29679 5146.00 Radiotherapy - post-op.control 
30264 7L19300 SUBCUTANEOUS CHEMOTHERAPY 
30547 ZV67700 [V]Follow-up exam after radiotherapy for malignant neoplasm 
30942 9N1yC00 Seen in radiotherapy clinic 
31489 ZV58800 [V]CHEMOTHERAPY SESSION FOR NEOPLASM 
31527 514..00 Purpose of radiotherapy 
31804 TB12100 Radiotherapy procedure with complication, without blame 
32478 ZL13100 Under care of radiotherapist 
35597 5147.00 Radiotherapy for analgesia 
35609 ZV66200 [V]CONVALESCENCE AFTER CHEMOTHERAPY 
36225 5A4..11 Radium needles 
36489 7M0B200 Radiofrequency controlled thermal destruction of organ NOC 
36810 5AC..00 Strontium 89 therapy 
36981 5155.00 Awaiting radiotherapy 
37123 7L18200 INTRAMUSCULAR CHEMOTHERAPY 
38466 5151.00 Radiotherapy started 
38662 7M0P000 Introduction of radioactive caesium into organ NOC 
38773 5A...00 Other nuclear therapy 
39951 5A9..00 Selectron therapy 
40070 7101100 Implantation of radioactive substance into pituitary gland 
40310 D400312 Neutropenia due to irradiation 
40490 7046200 INTRATHECAL CHEMOTHERAPY 
41044 8J...00 Radiotherapy treatment groups 
42351 591..00 X-ray beam therapy 
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medcode readcode readterm 
42671 5A8..00 Other radiotherapy misc. 
43261 5144.00 Radiotherapy - pre-op. control 
44148 5914.11 Deep X-ray therapy 
44831 5153.00 Radiotherapy stopped 
45087 8H3L.00 Non-urgent radiotherapy admisn 
45099 515Z.00 Radiotherapy progress NOS 
46028 8BAY.00 DATE CHEMOTHERAPY STOPPED 
46824 8H2G.00 Admit radiotherapy emergency 
48991 5136.00 X-ray metastasis control 
49760 U603318 [X] Adverse reaction to mitomycin 
50731 7H2C000 Introduction of radioactive substance into peritoneal cavity 
51781 ZVu3L00 [X]OTHER CHEMOTHERAPY 
51787 5975.00 EXT.BEAM + CHEMOTHERAPY 
51959 8BAI.00 AMBULATORY CHEMOTHERAPY 
52108 8F83.00 Convalescence after radiother. 
53180 5A46.00 Radioth.: temp. pelvic implant 
53477 ZV67811 [V]FOLLOW-UP EXAMINATION AFTER CHEMOTHERAPY FOR LEUKAEMIA 
54828 7D15400 Implantation of radioactive substance into vagina 
54919 5A8Z.00 Other radiotherapy NOS 
55261 5152.00 Radiotherapy changed 
55828 5145.00 Radiotherapy -intra-op.control 
55832 5143.00 Radioth. for lymphat.irradiat. 
55836 5148.00 Radiotherapy for inflammation 
57591 591Z.00 X-ray beam therapy NOS 
58036 7220100 Radiotherapy to lacrimal gland 
59684 7M0c.00 Radiotherapy procedures 
59796 5914.00 Deep X-ray therapy 150-400 Kv 
59890 5913.00 Half deep therapy 60-150 Kv 
60076 5141.00 Radioth.for immunosuppression 
60091 5912.00 Superfic.X-ray therapy 10-60Kv 
60674 7052200 Radiotherapy to lesion of peripheral nerve 
60682 ZV6B100 [V]FOLLOW-UP EXAM AFTER CHEMOTHERAPY FOR OTHER CONDITIONS 
61955 5AA..00 Iridium wire therapy 
62202 8J00.00 High dose brachytherapy 
62864 5A73.00 Radio-chemo.: oral route 
62951 5A15.00 Bone tumour/metast.irradiat. 
64143 597Z.00 Combined radiotherapy NOS 
64801 5A3..00 Intern.radioth-permanent seeds 
64997 7L1d.00 DELIVERY OF CHEMOTHERAPY FOR NEOPLASM 
65739 5A53.00 Preload radioth.- nose 
67248 5A12.00 Thyroid tumour/metast irradiat 
68344 7244400 Radiotherapy to lesion of cornea 
68423 7L1Z.00 Radiotherapy delivery 
69165 594..00 Heavy particle therapy 
69387 5974.00 EXT.BEAM-SURGERY+CHEMOTHERAPY 
69877 5A3Z.00 Radioth.: permanent seeds NOS 
69979 5AZ..00 Other nuclear therapy NOS 
70128 D201311 Radiation aplastic anaemia 
70246 5A1..00 Internal metabolic radiotherap 
70290 5A7..00 RADIOMIMETIC CHEMOTHERAPY 
70386 TA32.00 Overdose of radiation in therapy 
70445 7M0cy00 Other specified radiotherapy procedures 
70478 5A4..00 Radioth.: temporary implant 
70549 5142.00 Radioth. for haemopo. irradiat 
71008 7809400 Percutaneous radiofrequency ablation of lesion of liver 
71098 592Z.00 High-energy beam therapy NOS 
71598 5A45.00 Radioth.: temp. abdom. implant 
71599 5A1Z.00 Internal metabolic radioth.NOS 
71837 U603300 [X]OTHER ANTINEOPLAST DRUGS CAUS ADVERSE EFF IN THERAP USE 
71926 5134.00 X-ray # reduction control 
72850 5971.00 Extern.beam+intern.radiotherap 
72978 597..00 Combined radiotherapy 
73171 5A64.00 Afterload radioth.-fem.genital 
73172 5A7Z.00 RADIO-CHEMOTHERAPY NOS 
73173 5A13.00 Bone marrow suppres.-irradiat. 
73300 5922.00 Betatron photon therapy 
73462 5917.00 Intracavitary X-ray therapy 
73692 5A4Z.00 Radioth.:temporary implant NOS 
85984 5941.00 Proton therapy 
86329 7L1Z400 Oral delivery of radiotherapy for thyroid ablation 
87860 7M0P300 Intro radioactive substance org interstit brachytherapy NOC 
88367 7B0A800 Percutaneous radiofrequency ablation of lesion of kidney 
88762 5135.00 Radiological tumour control 
88889 7M0Q300 Radioactive seed implantation NOC 
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medcode readcode readterm 
89452 7L1b.00 PROCUREMENT DRUGS FOR CHEMOTHERAPY FOR NEOPLASM IN BANDS 
1-5 
90743 7L1e.00 DELIVERY OF ORAL CHEMOTHERAPY FOR NEOPLASM 
91433 7B3CB00 Radioactive seed implantation into prostate 
91694 7L1Z300 Delivery of a fraction of external beam radiotherapy NEC 
91778 7L1d000 Del comp chemo neo inc prolong infusion treat first attend 
91891 7L1Zz00 Radiotherapy delivery NOS 
91918 7272700 External beam radiotherapy to lesion of retina 
92174 7454400 Percutaneous radiofrequency ablation of lesion of lung 
92956 7L1Z011 Delivery of a fraction of total body irradiation 
92999 5A27.00 Radioth.: infuse organ cavity 
93607 5A81.00 Give radiosensitising drug 
93669 7L1Y.00 Radiotherapy preparation 
94305 596..00 Short dis.+contact radiotherap 
94306 593..00 Fast-electron therapy 
94431 7L1ez00 DELIVERY OF ORAL CHEMOTHERAPY FOR NEOPLASM NOS 
94478 5A42.00 Radioth:temp.head/neck implant 
94479 5973.00 Ext.beam-surg.+post-op.radioth 
94617 5A62.00 Afterload radioth.- upper GIT 
94760 U603316 [X] Adverse reaction to chlorambucil 
94764 7L1Y000 Preparation for total body irradiation 
95009 7L1Z100 Delivery of a fraction of intracavitary radiotherapy 
95066 5961.00 Radium contact therapy 
95098 5A33.00 Radioth.: seeds into cavity 
95126 7L1Zy00 Other specified radiotherapy delivery 
95424 7L1dz00 DELIVERY OF CHEMOTHERAPY FOR NEOPLASM NOS 
95693 7L1Xy00 Other specified radiotherapy volume definition 
95851 U603311 [X] ADVERSE REACTION TO ANTINEOPLASTIC ANTIBIOTICS 
95890 5962.00 Beta source contact therapy 
96310 7L1dy00 OTHER SPECIFIED DELIVERY OF CHEMOTHERAPY FOR NEOPLASM 
96446 U613200 [X]Overdose of radiation given during therapy 
96458 7L1Z000 Delivery of a fraction of total body irradiation (TBI) 
96467 5942.00 Deuteron therapy 
96535 7B3BC00 Endoscopic radiofrequency ablation of lesion of prostate 
97097 5131.00 Radiological pre-op. control 
97106 5A28.00 Radioth.: infiltrate tissue 
97154 5137.00 X-ray radiotherapy control 
97253 7K1V700 Percutaneous radiofrequency ablation of lesion of bone 
97412 7M0P400 Intro radioactive substance into organ for brachytherapy NOC 
98358 7L1h000 Preparation for intensity modulated radiation therapy 
98625 U603100 [X]ANTINEOPLAST ANTIMETABS CAUS ADVERSE EFF IN THERAP USE 
98750 Z9KG500 Brachytherapy monitoring 
98826 5A58.00 Preload radioth-female genital 
98828 592..00 High-energy beam therapy 
98829 5921.00 Linear-accelerator photon ther 
98830 593Z.00 Fast-electron therapy NOS 
98882 5A74.00 Radio-chemo.: I-V route 
98902 7M0c500 Superficial or orthovoltage treatment for radiotherapy 
98940 7L1i.00 Preparation for brachytherapy 
99327 5963.00 Mould technique gamma/beta 
99469 56B5.00 Image: field control:radiother 
100382 5A21.00 Radioth.: infuse - skull/brain 
100390 7M0P500 Intro non-remov radioact subst into organ for brachyther NOC 
100396 7L1Z500 Delivery of a fraction of intraluminal brachytherapy 
100724 5A2Z.00 Intern. unsealed radioth. NOS 
100725 5A26.00 Radioth:infuse-urinary bladder 
100758 5953.00 Comb.tele+int.dist.curietherap 
100832 5133.00 Radiological post-op. control 
100901 7M0c400 Megavoltage treatment for simple radiotherapy 
100942 U60331B [X] Adverse reaction to estramustine phosphate 
101203 Z1Q1.11 Administering radionuclide 
101391 7809300 Selective internal radiotherapy microspheres lesion of liver 
101436 U603314 [X] Adverse reaction to bleomycin 
101693 8CRC.00 Cancer chemotherapy management plan 
102671 5A59.00 Preload radioth-urinary system 
102672 5A14.00 Polycythaemia irradiation 
102823 782M600 Percutaneous brachytherapy of lesion of bile duct 
103302 U603200 [X]Antineoplast natural prod caus adverse eff in therap use 
103372 5A2..00 Intern.radioth-unsealed source 
103413 7L1i100 Preparation for intracavitary brachytherapy 
103525 7L1Z200 Delivery of a fraction of interstitial radiotherapy 
103600 U603118 [X] Adverse reaction to carboplatin 
103872 7M0l.00 Support for preparation for radiotherapy 
103957 7B3CA00 Transurethral radiofrequency needle ablation of prostate 
104000 7L1h400 Prep for simple radioth with imaging and simple calculation 
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medcode readcode readterm 
104099 7M0c300 Megavoltage treatment for complex radiotherapy 
104142 8BAl.00 Neoadjuvant chemotherapy 
105128 596Z.00 Short dist/contact radioth NOS 
105129 5A57.00 Preload radioth.- resp.organs 
105323 7M0c000 Delivery fraction complex radiotherapy megavoltage machine 
105336 7L1d400 Electrochemotherapy 
105610 7M0ly00 Other specified support for preparation for radiotherapy 
105864 ZV1C300 [V]Personal history of chemotherapy for neoplastic disease 
106149 5933.00 Positron therapy 
106334 5A22.00 Radioth.: infuse - head/neck 
107069 7L1Yz00 Radiotherapy preparation NOS 
107130 5A77.00 Radio-chem.: into cavity 
107133 595..00 Gamma-ray+int.dist.curietherap 
107175 5A51.00 Preload radioth.- orbit 
107418 5A17.00 Combined internal radiotherapy 
107525 7L1iz00 Preparation for brachytherapy NOS 
107734 7L1d200 Deliver simple parenteral chemother neoplas first attendance 
107914 U60331D [X] Adverse reaction to antineoplastic antibiotics NOS 
108138 7L2..00 Radiotherapy 
108140 7L1hz00 Preparation for external beam radiotherapy NOS 
108202 7M0c200 Delivery fraction radiotherapy superficial orthovoltage mach 
108561 7Q0J.00 Other chemotherapy drugs 
109592 5932.00 Betatron electron therapy 
110074 7M0p000 High dose rate brachytherapy 
110894 SL07.00 Antineoplastic antibiotic poisoning 
 
B) Hospital Episodes Statistics 
ICD 10  DESCRIPTION 
Z08.1 Follow-up examination after radiotherapy for malignant neoplasm 
Z08.2 Follow-up examination after chemotherapy for malignant neoplasm 
Z09.1 Follow-up examination after radiotherapy for other conditions 
Z09.2 Follow-up examination after chemotherapy for other conditions 
Z51.0 Radiotherapy session 
Z51.1 Chemotherapy session for neoplasm 
Z51.2 Other chemotherapy 
Z54.1 Convalescence following radiotherapy 
Z54.2 Convalescence following chemotherapy 
Z29.2 Other prophylactic chemotherapy 
Z92.6 Personal history of chemotherapy for neoplastic disease 
 
C) Office of Population Censuses and Surveys (OPCS) version 4 codes 
Opcs Description_other Description 
B022 Destruction of pituitary gland Implantation of radioactive substance into pituitary gland 
C242 Operations on lacrimal gland Radiotherapy to lacrimal gland 
C823 Destruction of lesion of retina External beam radiotherapy to lesion of retina 
J123 Other therapeutic percutaneous operations on liver Selective internal radiotherapy with microspheres to lesion 
M706 Other operations on outlet of male bladder Radioactive seed implantation into prostate 
M712 Other operations on prostate Implantation of radioactive substance into prostate 
P064 Extirpation of lesion of vulva Implantation of radioactive substance into vulva 
P205 Extirpation of lesion of vagina Implantation of radioactive substance into vagina 
Q151 Introduction of other substance into uterine cavity Introduction of radioactive substance into uterine cavity 
T133 Introduction of substance into pleural cavity Introduction of cytotoxic substance into pleural cavity 
T481 Other operations on peritoneum Introduction of radioactive substance into peritoneal cavity 
T482 Other operations on peritoneum Introduction of cytotoxic substance into peritoneal cavity 
X352 Other intravenous injection Intravenous chemotherapy 
X373 Intramuscular injection Intramuscular chemotherapy 
X384 Subcutaneous injection Subcutaneous chemotherapy 
X651 Radiotherapy delivery Delivery of a fraction of total body irradiation 
X652 Radiotherapy delivery Delivery of a fraction of intracavitary radiotherapy 
X653 Radiotherapy delivery Delivery of a fraction of interstitial radiotherapy 
X654 Radiotherapy delivery Delivery of a fraction of external beam radiotherapy nec 
X655 Radiotherapy delivery Oral delivery of radiotherapy for thyroid ablation 
X656 Radiotherapy delivery Delivery of a fraction of intraluminal brachytherapy 
X658 Radiotherapy delivery Other specified 
X659 Radiotherapy delivery Unspecified 
X671 Preparation for external beam radiotherapy Preparation for intensity modulated radiation therapy 
X672 Preparation for external beam radiotherapy Preparation for total body irradiation 
X673 Preparation for external beam radiotherapy Preparation for hemi body irradiation 
X674 Preparation for external beam radiotherapy Preparation for simple radiotherapy imaging and dosimetry 
X675 Preparation for external beam radiotherapy Preparation for simple radioth imaging simple calculation 
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Opcs Description_other Description 
X676 Preparation for external beam radiotherapy Preparation for superficial radiotherapy simple calculation 
X677 Preparation for external beam radiotherapy Preparation for complex conformal radiotherapy 
X678 Preparation for external beam radiotherapy Other specified 
X679 Preparation for external beam radiotherapy Unspecified 
X721 Delivery of chemotherapy for neoplasm Del. Of complex chemo./neoplasm/prolonged infusional 
treat. 
X722 Delivery of chemotherapy for neoplasm Del. Of complex parental chemo./neoplasm first 
attendance 
X723 Delivery of chemotherapy for neoplasm Del. Of simple parental chemo./neoplasm first attendance 
X724 Delivery of chemotherapy for neoplasm Del. Of subsequent element of cycle of chemo. For 
neoplasm 
X728 Delivery of chemotherapy for neoplasm Other specified 
X729 Delivery of chemotherapy for neoplasm Unspecified 
X731 Delivery of oral chemotherapy for neoplasm Delivery of exclusively oral chemotherapy for neoplasm 
X738 Delivery of oral chemotherapy for neoplasm Other specified 
X739 Delivery of oral chemotherapy for neoplasm Unspecified 
Y351 Introduction of removable radioactive material into 
org 
Introduction of radioactive caesium into organ noc 
Y352 Introduction of removable radioactive material into 
org 
Introduction of iridium wire into organ noc 
Y353 Introduction of removable radioactive material into 
org 
Introduction of radium into organ noc 
Y354 Introduction of removable radioactive material into 
org 
Introduction of radioactive substance organ brachytherap 
noc 
Y358 Introduction of removable radioactive material into 
org 
Other specified 
Y359 Introduction of removable radioactive material into 
org 
Unspecified 
Y363 Introduction of non-removable material into organ 
noc 
Radioactive seed implantation noc 
Y364 Introduction of non-removable material into organ 
noc 
Introduction non-rem radioact substance organ for brach 
noc 
Y911 External beam radiotherapy Megavoltage treatment for complex radiotherapy 
Y912 External beam radiotherapy Megavoltage treatment for simple radiotherapy 
Y913 External beam radiotherapy Superficial or orthovoltage treatment for radiotherapy 
Y914 External beam radiotherapy Megavoltage treatment for adaptive radiotherapy 
Y918 External beam radiotherapy Other specified 
Y919 External beam radiotherapy Unspecified 
Y921 Support for preparation for radiotherapy Technical support for preparation for radiotherapy 
Y928 Support for preparation for radiotherapy Other specified 
Y929 Support for preparation for radiotherapy Unspecified 
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Appendix 17 Codelist: steroids and other immunosuppressive drugs 
1. Oral corticosteroids 
Prodcode Product name Drug substance 
name 
Substance 
strength 
Formulation 
44 prednisolone enteric coated tablets 5mg  prednisolone 5mg enteric coated tablets 
95 prednisolone tablets 5mg  prednisolone 5mg tablets 
186 dexamethasone elixir 0.5mg/5ml  dexamethasone 0.5mg/5ml elixir 
229 cortisone acetate tablets 25mg  cortisone acetate 25mg tablets 
557 prednisolone enteric coated tablets 2.5mg  prednisolone 2.5mg enteric coated tablets 
578 prednisolone tablets 1mg  prednisolone 1mg tablets 
955 prednisolone sodium phosphate soluble 
tablet 5mg  
prednisolone 
sodium phosphate 
5mg soluble tablet 
1063 PREDNESOL tablets 5mg [SOVEREIGN] prednisolone 
sodium phosphate 
5mg tablets 
1280 dexamethasone tablets 2mg  dexamethasone 2mg tablets 
1380 ENTOCORT CR modified release capsules 
3mg [ASTRAZENEC] 
budesonide 3mg modified release 
capsules 
1709 hydrocortisone pellets 2.5 mg loz 
   
1971 BETNESOL tablets 0.5mg [FOCUS] betamethasone 
sodium phosphate 
0.5mg tablets 
2044 prednisone 2.5 mg tab 
   
2130 methylprednisolone tablets 4mg  methylprednisolone 4mg tablets 
2368 prednisolone tablets 2.5mg  prednisolone 2.5mg tablets 
2390 prednisolone e/c 1 mg tab 
   
2704 prednisolone tablets 25mg  prednisolone 25mg tablets 
2799 prednisolone 10 mg tab 
   
2949 prednisone tablets 5mg  prednisone 5mg tablets 
3059 prednisolone 50 mg tab 
   
3345 SINTISONE tablets [PHARMACIA] prednisolone 
steaglate 
 
tablets 
3418 hydrocortisone tablets 10mg  hydrocortisone 10mg tablets 
3557 prednisone tablets 1mg  prednisone 1mg tablets 
3898 budesonide modified release capsules 3mg  budesonide 3mg modified release 
capsules 
3969 dexamethasone 8 mg tab 
   
3992 deflazacort tablets 6mg  deflazacort 6mg tablets 
4535 hydrocortisone tablets 20mg  hydrocortisone 20mg tablets 
4779 dexamethasone tablets 0.5mg  dexamethasone 0.5mg tablets 
4943 dexamethasone sugar free oral solution 
2mg/5ml  
dexamethasone 
sodium phosphate 
2mg/5ml sugar free oral solution 
5157 dexamethasone oral solution 2mg/5ml  dexamethasone 2mg/5ml oral solution 
5490 DELTACORTRIL ENTERIC tablets 5mg 
[ALLIANCE] 
prednisolone 5mg tablets 
5913 DELTACORTRIL ENTERIC tablets 2.5mg 
[ALLIANCE] 
prednisolone 2.5mg tablets 
6095 budesonide capsules 3mg  budesonide 3mg capsules 
6098 HYDROCORTONE tablets 10mg [M S D] hydrocortisone 10mg tablets 
7286 betamethasone sodium phosphate soluble 
tablet 500micrograms  
betamethasone 
sodium phosphate 
500micrograms soluble tablet 
7548 cortisone acetate capsules 5mg  cortisone acetate 5mg capsules 
7584 prednisolone 4 mg tab 
   
7710 prednisolone 15 mg tab 
   
7934 prednisone 30 mg tab 
   
8261 MEDRONE tablets 16mg [PHARMACIA] methylprednisolone 16mg tablets 
9375 deflazacort tablets 1mg  deflazacort 1mg tablets 
9727 prednisolone tablets 50mg  prednisolone 50mg tablets 
9994 DECADRON tablets 0.5mg [M S D] dexamethasone 0.5mg tablets 
10552 methylprednisolone tablets 16mg  methylprednisolone 16mg tablets 
10574 cortisone acetate tablets 5mg  cortisone acetate 5mg tablets 
10683 MEDRONE tablets 2mg [PHARMACIA] methylprednisolone 2mg tablets 
10684 methylprednisolone tablets 2mg  methylprednisolone 2mg tablets 
10754 HYDROCORTISTAB tablets 20mg 
[WAYMADE] 
hydrocortisone 20mg tablets 
10864 betamethasone tablets 500micrograms  betamethasone 500micrograms tablets 
11149 BETNELAN tablets 0.5mg [FOCUS] betamethasone 0.5mg tablets 
12398 CORTELAN tablets 25mg [GLAXO] cortisone acetate 25mg tablets 
12400 CORTISYL tablets 25mg [AVENTIS] cortisone acetate 25mg tablets 
13043 HYDROCORTONE tablets 20mg [M S D] hydrocortisone 20mg tablets 
13522 prednisolone 2 mg tab 
   
13615 prednisone 10 mg tab 
   
14076 hydrocortisone sugar free oral suspension 
5mg/5ml  
hydrocortisone 5mg/5ml sugar free oral 
suspension 
14172 methylprednisolone tablets 100mg  methylprednisolone 100mg tablets 
15471 hydrocortisone 25 mg tab 
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Prodcode Product name Drug substance 
name 
Substance 
strength 
Formulation 
15555 MEDRONE tablets 4mg [PHARMACIA] methylprednisolone 4mg tablets 
15617 LEDERCORT tablets 4mg [WYETH PHAR] triamcinolone 4mg tablets 
16525 BUDENOFALK capsules 3mg [DR FALK] budesonide 3mg capsules 
16724 prednisone 50 mg tab 
   
17101 dexamethasone 750 mcg tab 
   
17410 deflazacort tablets 30mg  deflazacort 30mg tablets 
18042 MEDRONE tablets 100mg [PHARMACIA] methylprednisolone 100mg tablets 
18637 CORTISTAB tablets 25mg [WAYMADE] cortisone acetate 25mg tablets 
18955 hydrocortisone 4.5 mg loz 
   
19141 PREDNISOLONE soluble tablet 5mg 
[SOVEREIGN] 
prednisolone 
sodium phosphate 
5mg soluble tablet 
19908 triamcinolone tablets 2mg  triamcinolone 2mg tablets 
20095 PRECORTISYL FORTE tablets 25mg 
[AVENTIS] 
prednisolone 25mg tablets 
20577 CALCORT tablets 6mg [SHIRE] deflazacort 6mg tablets 
20670 prednisolone e/c 
   
20731 hydrocortisone pellets 
   
21218 DEXSOL oral solution 2mg/5ml 
[ROSEMONT] 
dexamethasone 
sodium phosphate 
2mg/5ml oral solution 
21417 PREDNISOLONE tablets 5mg 
[HILLCROSS] 
prednisolone 5mg tablets 
21465 betamethasone .1 mg tab 
   
21833 DECORTISYL tablets 5mg [ROUSSEL] prednisone 5mg tablets 
21903 ORADEXON-ORGANON tablets 2mg 
[ORGANON] 
dexamethasone 2mg tablets 
22555 CALCORT tablets 1mg [SHIRE] deflazacort 1mg tablets 
22827 betamethasone .1 mg pel 
   
23111 triamcinolone tablets 4mg  triamcinolone 4mg tablets 
23210 CORTISTAB tablets 5mg [WAYMADE] cortisone acetate 5mg tablets 
23512 PRECORTISYL tablets 5mg 
[HOECHSTMAR] 
prednisolone 5mg tablets 
23788 cortisone acetate 2.5 mg tab 
   
24014 LEDERCORT tablets 2mg [WYETH PHAR] triamcinolone 2mg tablets 
24716 prednisolone e/c 
   
25272 PRECORTISYL tablets 1mg 
[HOECHSTMAR] 
prednisolone 1mg tablets 
27083 betamethasone valerate .1 mg tab 
   
27720 hydrocortisone 
   
27889 prednisolone 
   
27959 prednisolone 
   
27962 DELTASTAB tablets 1mg [WAYMADE] prednisolone 1mg tablets 
28375 PREDNISOLONE enteric coated tablets 
2.5mg [HILLCROSS] 
prednisolone 2.5mg enteric coated tablets 
28376 PREDNISOLONE enteric coated tablets 
2.5mg [BIOREX] 
prednisolone 2.5mg enteric coated tablets 
28615 methylprednisolone l/a 4 mg cap 
   
28859 DELTASTAB tablets 5mg [WAYMADE] prednisolone 5mg tablets 
29112 CALCORT tablets 30mg [SHIRE] deflazacort 30mg tablets 
29322 betamethasone loz 
   
29333 PREDNISOLONE tablets 5mg [ACTAVIS] prednisolone 5mg tablets 
30390 deltastab 2 mg tab 
   
30971 decortisyl 25 mg tab 
   
31327 prednisolone steaglate tablets 6.65mg  prednisolone 
steaglate 
6.65mg tablets 
31532 PREDNISOLONE enteric coated tablets 
5mg [HILLCROSS] 
prednisolone 5mg enteric coated tablets 
32803 PREDNISOLONE enteric coated tablets 
5mg [ACTAVIS] 
prednisolone 5mg enteric coated tablets 
32835 PREDNISOLONE tablets 5mg 
[WOCKHARDT] 
prednisolone 5mg tablets 
33639 cortisone acetate msd 25 mg tab 
   
33691 PREDNISOLONE enteric coated tablets 
5mg [BIOREX] 
prednisolone 5mg enteric coated tablets 
33988 PREDNISOLONE tablets 5mg [CO-
PHARMA] 
prednisolone 5mg tablets 
33990 PREDNISOLONE tablets 5mg [IVAX] prednisolone 5mg tablets 
34109 prednisolone enteric coated tablets 5mg  prednisolone 5mg enteric coated tablets 
34393 PREDNISOLONE enteric coated tablets 
5mg [TEVA] 
prednisolone 5mg enteric coated tablets 
34404 PREDNISOLONE tablets 1mg [ACTAVIS] prednisolone 1mg tablets 
34452 PREDNISOLONE tablets 1mg 
[HILLCROSS] 
prednisolone 1mg tablets 
34461 PREDNISOLONE enteric coated tablets 
2.5mg [ACTAVIS] 
prednisolone 2.5mg enteric coated tablets 
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Prodcode Product name Drug substance 
name 
Substance 
strength 
Formulation 
34631 PREDNISOLONE tablets 1mg [CO-
PHARMA] 
prednisolone 1mg tablets 
34660 PREDNISOLONE tablets 1mg [KENT] prednisolone 1mg tablets 
34748 PREDNISOLONE tablets 1mg [TEVA] prednisolone 1mg tablets 
34781 PREDNISOLONE tablets 5mg [KENT] prednisolone 5mg tablets 
34801 DEXAMETHASONE elixir 0.5mg/5ml 
[ROSEMONT] 
dexamethasone 0.5mg/5ml elixir 
34880 DEXAMETHASONE tablets 2mg 
[ORGANON] 
dexamethasone 2mg tablets 
34914 PREDNISOLONE tablets 1mg 
[CELLTECH] 
prednisolone 1mg tablets 
34915 DEXAMETHASONE tablets 0.5mg 
[ORGANON] 
dexamethasone 0.5mg tablets 
34978 PREDNISOLONE tablets 1mg 
[WOCKHARDT] 
prednisolone 1mg tablets 
36055 DEXAMETHASONE tablets 2mg 
[HILLCROSS] 
dexamethasone 2mg tablets 
36686 cortisone acetate msd 5 mg tab 
   
37203 beclometasone gastro-resistant modified 
release tablets 5mg  
beclometasone 
dipropionate 
5mg gastro-resistant modified 
release tablets 
38022 hydrocortisone oral suspension 10mg/5ml  hydrocortisone 10mg/5ml oral suspension 
38054 hydrocortisone tablets  hydrocortisone 
 
tablets 
38407 prednisolone (roi) tablets 20mg  prednisolone 20mg tablets 
39067 CLIPPER gastro-resistant modified release 
tablets 5mg [CHIESI] 
beclometasone 
dipropionate 
5mg gastro-resistant modified 
release tablets 
41335 CALCORT tablets 6mg [SANOFI/AVE] deflazacort 6mg tablets 
41515 PREDNISOLONE tablets 5mg [TEVA] prednisolone 5mg tablets 
41745 PREDNISOLONE tablets 25mg 
[WINTHROP] 
prednisolone 25mg tablets 
43544 PREDNISONE tablets 5mg [KNOLL] prednisone 5mg tablets 
44380 prednisone modified release tablet 1mg  prednisone 1mg modified release tablet 
44723 prednisone modified release tablet 5mg  prednisone 5mg modified release tablet 
44802 LODOTRA modified release tablet 5mg 
[NAPPPHARM] 
prednisone 5mg modified release tablet 
44803 LODOTRA modified release tablet 2mg 
[NAPPPHARM] 
prednisone 2mg modified release tablet 
45234 dexamethasone capsules  dexamethasone 
 
capsules 
45302 PREDNISOLONE tablets 5mg [BIOREX] prednisolone 5mg tablets 
46711 prednisone modified release tablet 2mg  prednisone 2mg modified release tablet 
47142 Prednisolone 5mg Soluble tablet 
(Amdipharm Plc) 
Prednisolone 
sodium phosphate 
5mg Soluble tablet 
47225 Budesonide 9mg gastro-resistant granules 
sachets 
Budesonide 9mg Gastro-resistant 
granules 
48088 Budenofalk 9mg gastro-resistant granules 
sachets (Dr. Falk Pharma UK Ltd) 
Budesonide 9mg Gastro-resistant 
granules 
50225 Betnesol 500microgram soluble tablets 
(Waymade Healthcare Plc) 
Betamethasone 
sodium phosphate 
500microgram Soluble tablet 
51722 Hydrocortisone 5mg/5ml oral suspension Hydrocortisone 1mg/1ml Oral suspension 
51753 Prednisolone 1mg tablets (Co-Pharma Ltd) Prednisolone 1mg Tablet 
51824 Hydrocortisone 5mg/5ml oral suspension 
sugar free 
Hydrocortisone 1mg/1ml Oral suspension 
51849 Hydrocortisone 1mg/5ml oral suspension 
   
51871 Hydrocortisone 2mg capsules 
   
51872 Hydrocortisone 2.5mg capsules Hydrocortisone 2.5mg Capsule 
51997 Budesonide 9mg gastro-resistant granules 
sachets 
Budesonide 9mg Gastro-resistant 
granules 
52053 Hydrocortisone 3mg/5ml oral suspension 
   
52396 Dexamethasone 1mg/5ml oral solution Dexamethasone 200microgram/1ml Oral solution 
53143 Cortisone 25mg tablets (A A H 
Pharmaceuticals Ltd) 
Cortisone acetate 25mg Tablet 
53207 Dexamethasone tablets Dexamethasone 
  
53313 Prednisolone 20mg/5ml oral suspension Prednisolone 4mg/1ml Oral suspension 
53336 Prednisolone 25mg tablets (A A H 
Pharmaceuticals Ltd) 
Prednisolone 25mg Tablet 
53705 Cortisone acetate 5mg Capsule 
(Martindale Pharmaceuticals Ltd) 
Cortisone acetate 5mg Capsule 
53953 Hydrocortisone 5mg modified-release 
tablets 
   
54118 Prednisolone 25mg/5ml oral suspension Prednisolone 5mg/1ml Oral suspension 
54432 Lodotra 1mg modified-release tablets 
(Napp Pharmaceuticals Ltd) 
Prednisone 1mg Modified-release tablet 
54434 Prednisolone 2.5mg/5ml oral suspension Prednisolone 500microgram/1ml Oral suspension 
54793 Dexamethasone 2mg/5ml oral suspension Dexamethasone 400microgram/1ml Oral suspension 
54794 Hydrocortisone 20mg modified-release 
tablets 
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55024 Prednisolone 5mg/5ml oral solution Prednisolone 1mg/1ml Oral solution 
55401 Dexamethasone 500microgram tablets (A 
A H Pharmaceuticals Ltd) 
Dexamethasone 500microgram Tablet 
55480 Prednisolone 2.5mg gastro-resistant 
tablets (Alliance Pharmaceuticals Ltd) 
Prednisolone 2.5mg Gastro-resistant tablet 
56144 Budenofalk 9mg gastro-resistant granules 
sachets (Dr. Falk Pharma UK Ltd) 
Budesonide 9mg Gastro-resistant 
granules 
56319 Hydrocortisone 2.5mg muco-adhesive 
buccal tablets sugar free (A A H 
Pharmaceuticals Ltd) 
Hydrocortisone 
sodium succinate 
2.5mg Muco-adhesive buccal 
tablet 
56347 Dexamethasone 5mg/5ml oral solution Dexamethasone 1mg/1ml Oral solution 
56443 Dexamethasone 10mg/5ml oral solution 
   
56891 Prednisolone 1mg tablets (Waymade 
Healthcare Plc) 
Prednisolone 1mg Tablet 
57931 Hydrocortisone 20mg tablets (Teva UK Ltd) Hydrocortisone 20mg Tablet 
58000 Prednisolone 5mg tablets (Almus 
Pharmaceuticals Ltd) 
Prednisolone 5mg Tablet 
58061 Prednisone 50mg tablets Prednisone 50mg Tablet 
58234 Prednisolone 10mg/5ml oral solution Prednisolone 2mg/1ml Oral solution 
58369 Prednisolone 5mg tablets (Boston 
Healthcare Ltd) 
Prednisolone 5mg Tablet 
58384 Prednisolone 1mg tablets (Almus 
Pharmaceuticals Ltd) 
Prednisolone 1mg Tablet 
58474 Dexamethasone 2mg/5ml oral solution 
sugar free (A A H Pharmaceuticals Ltd) 
Dexamethasone 
sodium phosphate 
400microgram/1ml Oral solution 
58592 Plenadren 20mg modified-release tablets 
(Shire Pharmaceuticals Ltd) 
   
58987 Prednisolone 5mg gastro-resistant tablets 
(Phoenix Healthcare Distribution Ltd) 
Prednisolone 5mg Gastro-resistant tablet 
59229 Dilacort 5mg gastro-resistant tablets 
(Auden McKenzie (Pharma Division) Ltd) 
Prednisolone 5mg Gastro-resistant tablet 
59283 Dilacort 2.5mg gastro-resistant tablets 
(Auden McKenzie (Pharma Division) Ltd) 
Prednisolone 2.5mg Gastro-resistant tablet 
59338 Prednisolone 1mg/5ml oral solution Prednisolone 200microgram/1ml Oral solution 
59418 Plenadren 5mg modified-release tablets 
(Shire Pharmaceuticals Ltd) 
   
59912 Prednisolone 5mg gastro-resistant tablets 
(Waymade Healthcare Plc) 
Prednisolone 5mg Gastro-resistant tablet 
60064 Dexamethasone 10mg/5ml oral solution 
sugar free 
   
60120 Dexamethasone 2mg tablets (Alliance 
Healthcare (Distribution) Ltd) 
Dexamethasone 2mg Tablet 
60421 Prednisolone 5mg tablets (Co-Pharma Ltd) Prednisolone 5mg Tablet 
60946 Entocort CR 3mg capsules (Waymade 
Healthcare Plc) 
Budesonide 3mg Modified-release 
capsule 
61132 Prednisolone 1mg tablets (Boston 
Healthcare Ltd) 
Prednisolone 1mg Tablet 
61162 Prednisolone 5mg tablets (Waymade 
Healthcare Plc) 
Prednisolone 5mg Tablet 
61689 Prednisolone 5mg soluble tablets (A A H 
Pharmaceuticals Ltd) 
Prednisolone 
sodium phosphate 
5mg Soluble tablet 
61791 Hydrocortisone 2.5mg muco-adhesive 
buccal tablets sugar free (Waymade 
Healthcare Plc) 
Hydrocortisone 
sodium succinate 
2.5mg Muco-adhesive buccal 
tablet 
62656 Prednisone 5mg Tablet (Hillcross 
Pharmaceuticals Ltd) 
Prednisone 5mg Tablet 
62909 Dexamethasone 2mg tablets (A A H 
Pharmaceuticals Ltd) 
Dexamethasone 2mg Tablet 
63066 Prednisolone 2.5mg tablets Prednisolone 2.5mg Tablet 
63082 Prednisolone 20mg tablets 
   
63138 Hydrocortisone 5mg/5ml oral solution 
   
63172 Prednisolone 10mg tablets 
   
63214 Prednisolone 5mg soluble tablets (Alliance 
Healthcare (Distribution) Ltd) 
Prednisolone 
sodium phosphate 
5mg Soluble tablet 
63549 Prednisolone 1mg/ml oral solution (Logixx 
Pharma Solutions Ltd) 
Prednisolone 1mg/1ml Oral solution 
63791 Prednisolone 5mg/5ml oral solution unit 
dose 
   
63893 Budesonide 9mg modified-release tablets Budesonide 9mg Modified-release tablet 
64007 Pevanti 10mg tablets (AMCo) Prednisolone 10mg Tablet 
64008 Pevanti 2.5mg tablets (AMCo) Prednisolone 2.5mg Tablet 
64009 Pevanti 20mg tablets (AMCo) 
   
64050 Martapan 2mg/5ml oral solution 
(Martindale Pharmaceuticals Ltd) 
Dexamethasone 
sodium phosphate 
400microgram/1ml Oral solution 
64059 Hydrocortisone 2.5mg/5ml oral suspension Hydrocortisone 500microgram/1ml Oral suspension 
64128 Pevanti 5mg tablets (AMCo) Prednisolone 5mg Tablet 
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64221 Prednisolone 5mg/5ml oral suspension Prednisolone 1mg/1ml Oral suspension 
64235 Betamethasone 500microgram soluble 
tablets sugar free (Alliance Healthcare 
(Distribution) Ltd) 
Betamethasone 
sodium phosphate 
500microgram Soluble tablet 
64416 Prednisolone 10mg/ml oral solution sugar 
free 
   
64557 Cortiment 9mg modified-release tablets 
(Ferring Pharmaceuticals Ltd) 
Budesonide 9mg Modified-release tablet 
64747 Dexamethasone 2mg/5ml oral solution 
   
64766 Dexamethasone 20mg/5ml oral solution 
sugar free 
Dexamethasone 
sodium phosphate 
4mg/1ml Oral solution 
64787 Hydrocortisone 10mg tablets (Almus 
Pharmaceuticals Ltd) 
Hydrocortisone 10mg Tablet 
65020 Prednisolone 25mg/5ml oral solution 
   
65626 Prednisolone 10mg/5ml oral suspension Prednisolone 2mg/1ml Oral suspension 
65984 Hydrocortisone 10mg tablets (Actavis UK 
Ltd) 
Hydrocortisone 10mg Tablet 
66015 Prednisolone Dompe 5mg/5ml oral solution 
unit dose (Logixx Pharma Solutions Ltd) 
   
66200 Dexamethasone 2mg soluble tablets sugar 
free 
   
66287 Dexamethasone 8mg soluble tablets sugar 
free 
   
66327 Hydrocortisone 20mg tablets (Actavis UK 
Ltd) 
Hydrocortisone 20mg Tablet 
66524 Dexamethasone 4mg soluble tablets sugar 
free 
Dexamethasone 
sodium phosphate 
4mg Soluble tablet 
     
66550 Prednisolone 5mg gastro-resistant tablets 
(Alliance Healthcare (Distribution) Ltd) 
Prednisolone 5mg Gastro-resistant tablet 
66556 Hydrocortisone 2.5mg muco-adhesive 
buccal tablets sugar free (Sigma 
Pharmaceuticals Plc) 
Hydrocortisone 
sodium succinate 
2.5mg Muco-adhesive buccal 
tablet 
66645 Prednisolone 5mg/5ml oral solution unit 
dose (Logixx Pharma Solutions Ltd) 
   
66666 Hydrocortisone 10mg tablets (Teva UK Ltd) Hydrocortisone 10mg Tablet 
66724 Dexamethasone 10mg capsules 
   
66914 Prednisolone 1mg gastro-resistant tablets 
   
 
2. Other immunosuppressant drugs* excluding oral corticosteroids  
 
Prodcode Product name Drug substance name Substance strength Formulation 
12339 AZAMUNE tablets 50mg [PENN] azathioprine 50mg tablets 
6882 adalimumab injection 40mg  adalimumab 40mg injection 
65339 Azapress 50mg tablets (Ennogen Pharma Ltd) Azathioprine 50mg Tablet 
55773 Azathioprine 10mg/5ml oral suspension Azathioprine 2mg/1ml Oral suspension 
53869 Azathioprine 20mg/5ml oral solution Azathioprine 4mg/1ml Oral solution 
54982 Azathioprine 20mg/5ml oral suspension Azathioprine 4mg/1ml Oral suspension 
63121 Azathioprine 25mg tablets (Alliance 
Healthcare (Distribution) Ltd) 
Azathioprine 25mg Tablet 
59006 Azathioprine 25mg tablets (Kent 
Pharmaceuticals Ltd) 
Azathioprine 25mg Tablet 
66003 Azathioprine 25mg tablets (Mawdsley-Brooks 
& Company Ltd) 
Azathioprine 25mg Tablet 
53956 Azathioprine 50mg tablets (Almus 
Pharmaceuticals Ltd) 
Azathioprine 50mg Tablet 
53797 Azathioprine 50mg tablets (Arrow Generics 
Ltd) 
Azathioprine 50mg Tablet 
58654 Azathioprine 50mg tablets (Sandoz Ltd) Azathioprine 50mg Tablet 
61160 Azathioprine 50mg tablets (Tillomed 
Laboratories Ltd) 
Azathioprine 50mg Tablet 
23850 HUMIRA injection 40mg [ABBOTT] adalimumab 40mg injection 
65735 Aflibercept 2mg/50microlitres solution for 
injection vials 
Aflibercept 40mg/1ml Solution for injection 
60484 Eylea 2mg/50microlitres solution for injection 
vials (Bayer Plc) 
Aflibercept 40mg/1ml Solution for injection 
51181 Azathioprine 60mg/5ml oral solution Azathioprine 12mg/1ml Oral solution 
770 azathioprine capsules  azathioprine 
 
capsules 
42273 alemtuzumab concentrate for solution for 
infusion 30mg/1ml  
alemtuzumab 30mg/1ml concentrate for 
solution for infusion 
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55815 MabCampath 30mg/1ml concentrate for 
solution for infusion vials (Genzyme 
Therapeutics Ltd) 
Alemtuzumab 30mg/1ml Solution for infusion 
39115 azathioprine capsules 10mg  azathioprine 10mg capsules 
270 azathioprine injection 50mg/vial  azathioprine 50mg/vial injection 
55858 Azathioprine oral solution Azathioprine 
  
22982 azathioprine oral solution 50mg/5ml  azathioprine 50mg/5ml oral solution 
31598 MABCAMPATH concentrate for solution for 
infusion 10mg/ml [SCHERING] 
alemtuzumab 10mg/ml concentrate for 
solution for infusion 
36792 azathioprine oral solution 50mg/ml  azathioprine 50mg/ml oral solution 
35518 azathioprine oral suspension 50mg/5ml  azathioprine 50mg/5ml oral suspension 
13320 azathioprine tablets 10mg  azathioprine 10mg tablets 
451 azathioprine tablets 25mg  azathioprine 25mg tablets 
34816 AZATHIOPRINE tablets 25mg [GEN (UK)] azathioprine 25mg tablets 
32101 AZATHIOPRINE tablets 25mg [HILLCROSS] azathioprine 25mg tablets 
571 azathioprine tablets 50mg  azathioprine 50mg tablets 
43562 AZATHIOPRINE tablets 50mg [ACTAVIS] azathioprine 50mg tablets 
41670 AZATHIOPRINE tablets 50mg [CP PHARM] azathioprine 50mg tablets 
34451 AZATHIOPRINE tablets 50mg [GEN (UK)] azathioprine 50mg tablets 
34687 AZATHIOPRINE tablets 50mg [HILLCROSS] azathioprine 50mg tablets 
29340 AZATHIOPRINE tablets 50mg [IVAX] azathioprine 50mg tablets 
31215 AZATHIOPRINE tablets 50mg [KENT] azathioprine 50mg tablets 
41620 AZATHIOPRINE tablets 50mg [TEVA] azathioprine 50mg tablets 
26261 BERKAPRINE tablets 50mg [RORER] azathioprine 50mg tablets 
21899 IMMUNOPRIN tablets 50mg [ASHBOURNE] azathioprine 50mg tablets 
14395 IMURAN injection 50mg/vial [ASPEN EURO] azathioprine 50mg/vial injection 
30495 IMURAN tablets 10mg [WELLCOME] azathioprine 10mg tablets 
43077 IMURAN tablets 25mg [ASPEN EURO] azathioprine 25mg tablets 
671 IMURAN tablets 25mg [WELLCOME] azathioprine 25mg tablets 
42988 IMURAN tablets 50mg [ASPEN EURO] azathioprine 50mg tablets 
1899 IMURAN tablets 50mg [WELLCOME] azathioprine 50mg tablets 
19072 OPRISINE tablets 50mg [OPUS] azathioprine 50mg tablets 
3874 busulfan tablets 2mg  busulfan 2mg tablets 
22204 busulfan tablets 500micrograms  busulfan 500micrograms tablets 
26301 MYLERAN tablets 2mg [WELLCOME] busulfan 2mg tablets 
32412 MYLERAN tablets 500micrograms 
[WELLCOME] 
busulfan 500micrograms tablets 
65607 Capecitabine 150mg tablets (A A H 
Pharmaceuticals Ltd) 
Capecitabine 150mg Tablet 
7340 capecitabine tablets 150mg  capecitabine 150mg tablets 
7341 capecitabine tablets 500mg  capecitabine 500mg tablets 
33127 XELODA tablets 150mg [ROCHE] capecitabine 150mg tablets 
18063 XELODA tablets 500mg [ROCHE] capecitabine 500mg tablets 
61065 Carboplatin 450mg/45ml solution for infusion 
vials 
Carboplatin 10mg/1ml Solution for infusion 
10328 carboplatin concentrate for solution for 
infusion 10mg/ml  
carboplatin 10mg/ml concentrate for 
solution for infusion 
40781 carboplatin concentrate for solution for 
infusion 150mg/15ml  
carboplatin 150mg/15ml concentrate for 
solution for infusion 
35855 carboplatin concentrate for solution for 
infusion 50mg/5ml  
carboplatin 50mg/5ml concentrate for 
solution for infusion 
39450 carboplatin concentrate for solution for 
infusion 600mg/60ml  
carboplatin 600mg/60ml concentrate for 
solution for infusion 
24096 carboplatin injection 150mg  carboplatin 150mg injection 
36726 anakinra injection 100mg/0.67ml  anakinra 100mg/0.67ml injection 
32418 KINERET injection 100mg/0.67ml [SWED 
ORPH] 
anakinra 100mg/0.67ml injection 
42696 THYMOGLOBULINE powder for solution for 
infusion 25mg [GENZYME] 
antithymocyte 
immunoglobulin 
(rabbit) 
25mg powder for solution 
for infusion 
18236 carboplatin injection 50mg/vial  carboplatin 50mg/vial injection 
64626 Otezla 30mg tablets (Celgene Ltd) Apremilast 30mg Tablet 
37915 basiliximab powder for solution for infusion 
10mg  
basiliximab 10mg powder for solution 
for infusion 
40632 basiliximab powder for solution for infusion 
20mg  
basiliximab 20mg powder for solution 
for infusion 
41963 PARAPLATIN concentrate for solution for 
infusion 10mg/ml [BRISTOL] 
carboplatin 10mg/ml concentrate for 
solution for infusion 
37542 PARAPLATIN injection 150mg [BRISTOL] carboplatin 150mg injection 
41281 carmustine implant 7.7mg  carmustine 7.7mg implant 
5600 chlorambucil tablets 2mg  chlorambucil 2mg tablets 
8665 chlorambucil tablets 5mg  chlorambucil 5mg tablets 
16838 LEUKERAN tablets 2mg [WELLCOME] chlorambucil 2mg tablets 
61351 Simulect 10mg powder and solvent for 
solution for injection vials (Novartis 
Pharmaceuticals UK Ltd) 
Basiliximab 10mg Powder and solvent 
for solution for 
injection 
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26315 LEUKERAN tablets 5mg [WELLCOME] chlorambucil 5mg tablets 
28709 chlormethine injection 10mg  chlormethine 
hydrochloride 
10mg injection 
26119 CHLORMETHINE injection 10mg/ml 
[SOVEREIGN] 
chlormethine 
hydrochloride 
10mg/ml injection 
47102 Capimune 50mg capsules (Generics (UK) Ltd) Ciclosporin 50mg Capsule 
46395 CAPIMUNE capsules 100mg [GEN (UK)] ciclosporin 100mg capsules 
46637 CAPIMUNE capsules 25mg [GEN (UK)] ciclosporin 25mg capsules 
63798 Ciclosporin 100mg capsules (A A H 
Pharmaceuticals Ltd) 
Ciclosporin 100mg Capsule 
59250 Ciclosporin 100mg capsules (Colorama 
Pharmaceuticals Ltd) 
Ciclosporin 100mg Capsule 
54975 Ciclosporin 100mg capsules (Cubic 
Pharmaceuticals Ltd) 
Ciclosporin 100mg Capsule 
65639 Ciclosporin 100mg capsules (J M McGill Ltd) Ciclosporin 100mg Capsule 
48556 Ciclosporin 100mg capsules (Phoenix 
Healthcare Distribution Ltd) 
Ciclosporin 100mg Capsule 
54134 Ciclosporin 100mg capsules (Sigma 
Pharmaceuticals Plc) 
Ciclosporin 100mg Capsule 
55116 Ciclosporin 25mg capsules (Cubic 
Pharmaceuticals Ltd) 
Ciclosporin 25mg Capsule 
62051 Ciclosporin 25mg capsules (Niche Pharma 
Ltd) 
Ciclosporin 25mg Capsule 
48763 Ciclosporin 25mg capsules (Phoenix 
Healthcare Distribution Ltd) 
Ciclosporin 25mg Capsule 
52743 Ciclosporin 25mg capsules (Sigma 
Pharmaceuticals Plc) 
Ciclosporin 25mg Capsule 
59249 Ciclosporin 50mg capsules (Colorama 
Pharmaceuticals Ltd) 
Ciclosporin 50mg Capsule 
54974 Ciclosporin 50mg capsules (Cubic 
Pharmaceuticals Ltd) 
Ciclosporin 50mg Capsule 
48798 Ciclosporin 50mg capsules (Phoenix 
Healthcare Distribution Ltd) 
Ciclosporin 50mg Capsule 
54867 Ciclosporin 50mg capsules (Sigma 
Pharmaceuticals Plc) 
Ciclosporin 50mg Capsule 
3896 ciclosporin capsules 100mg  ciclosporin 100mg capsules 
16035 ciclosporin capsules 10mg  ciclosporin 10mg capsules 
32614 SIMULECT powder for solution for infusion 
20mg [NOVARTIS] 
basiliximab 20mg powder for solution 
for infusion 
2838 ciclosporin capsules 25mg  ciclosporin 25mg capsules 
25740 AVASTIN concentrate for solution for infusion 
100mg/4ml [ROCHE] 
bevacizumab 100mg/4ml concentrate for 
solution for infusion 
2837 ciclosporin capsules 50mg  ciclosporin 50mg capsules 
42924 ciclosporin concentrate for solution for infusion 
250mg/5ml  
ciclosporin 250mg/5ml concentrate for 
solution for infusion 
38056 ciclosporin concentrate for solution for infusion 
50mg/1ml  
ciclosporin 50mg/1ml concentrate for 
solution for infusion 
19370 ciclosporin concentrate for solution for infusion 
50mg/ml  
ciclosporin 50mg/ml concentrate for 
solution for infusion 
1626 ciclosporin oral solution 100mg/ml  ciclosporin 100mg/ml oral solution 
42449 DEXIMUNE capsules 100mg [DEXCEL] ciclosporin 100mg capsules 
42637 DEXIMUNE capsules 25mg [DEXCEL] ciclosporin 25mg capsules 
42448 DEXIMUNE capsules 50mg [DEXCEL] ciclosporin 50mg capsules 
52615 Neoral 100mg capsules (Sigma 
Pharmaceuticals Plc) 
Ciclosporin 100mg Capsule 
49958 Neoral 25mg capsules (Doncaster 
Pharmaceuticals Ltd) 
Ciclosporin 25mg Capsule 
53175 Neoral 25mg capsules (Mawdsley-Brooks & 
Company Ltd) 
Ciclosporin 25mg Capsule 
53176 Neoral 50mg capsules (Doncaster 
Pharmaceuticals Ltd) 
Ciclosporin 50mg Capsule 
973 NEORAL capsules 100mg [NOVARTIS] ciclosporin 100mg capsules 
16137 NEORAL capsules 10mg [NOVARTIS] ciclosporin 10mg capsules 
972 NEORAL capsules 25mg [NOVARTIS] ciclosporin 25mg capsules 
4231 NEORAL capsules 50mg [NOVARTIS] ciclosporin 50mg capsules 
1905 NEORAL oral solution 100mg/ml [NOVARTIS] ciclosporin 100mg/ml oral solution 
13556 SANDIMMUN capsules 100mg [NOVARTIS] ciclosporin 100mg capsules 
3920 SANDIMMUN capsules 25mg [NOVARTIS] ciclosporin 25mg capsules 
15596 SANDIMMUN capsules 50mg [NOVARTIS] ciclosporin 50mg capsules 
26790 SANDIMMUN concentrate for solution for 
infusion 50mg/ml [NOVARTIS] 
ciclosporin 50mg/ml concentrate for 
solution for infusion 
13494 SANDIMMUN sugar free solution 100mg/ml 
[NOVARTIS] 
ciclosporin 100mg/ml sugar free solution 
64857 Vanquoral 100mg capsules (Teva UK Ltd) Ciclosporin 100mg Capsule 
66785 Vanquoral 10mg capsules (Teva UK Ltd) Ciclosporin 10mg Capsule 
66473 Vanquoral 25mg capsules (Teva UK Ltd) Ciclosporin 25mg Capsule 
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64858 Vanquoral 50mg capsules (Teva UK Ltd) Ciclosporin 50mg Capsule 
38145 bevacizumab concentrate for solution for 
infusion 100mg/4ml  
bevacizumab 100mg/4ml concentrate for 
solution for infusion 
48068 Cisplatin 100mg/100ml solution for infusion 
vials 
Cisplatin 1mg/1ml Solution for infusion 
38453 cisplatin concentrate for solution for infusion 
10mg/10ml  
cisplatin 10mg/10ml concentrate for 
solution for infusion 
32824 cisplatin concentrate for solution for infusion 
1mg/ml  
cisplatin 1mg/ml concentrate for 
solution for infusion 
44388 cisplatin concentrate for solution for infusion 
50mg/50ml  
cisplatin 50mg/50ml concentrate for 
solution for infusion 
28324 cisplatin powder 25mg/vial  cisplatin 25mg/vial powder 
38185 cisplatin powder for concentrate for solution 
for infusion 50mg  
cisplatin 50mg powder for 
concentrate for 
solution for infusion 
40454 cladribine injection 10mg/5ml  cladribine 10mg/5ml injection 
38081 ERWINASE powder for solution for injection 
10000 units/vial [OPI] 
crisantaspase 10000 units/vial powder for solution 
for injection 
47752 Cyclophosphamide 25mg tablets Cyclophosphamide 25mg Tablet 
26322 cyclophosphamide injection 100mg  cyclophosphamide 100mg injection 
26066 cyclophosphamide injection 200mg  cyclophosphamide 200mg injection 
29840 cyclophosphamide powder for solution for 
injection 1000mg  
cyclophosphamide 1000mg powder for solution 
for injection 
16105 cyclophosphamide powder for solution for 
injection 500mg  
cyclophosphamide 500mg powder for solution 
for injection 
3984 cyclophosphamide tablets 10mg  cyclophosphamide 10mg tablets 
3985 cyclophosphamide tablets 50mg  cyclophosphamide 50mg tablets 
34728 CYCLOPHOSPHAMIDE tablets 50mg 
[PHARMACIA] 
cyclophosphamide 50mg tablets 
44309 ENDOXANA injection 1000mg [BAXTER 
ONC] 
cyclophosphamide 1000mg injection 
44273 ENDOXANA injection 200mg [BAXTER ONC] cyclophosphamide 200mg injection 
31193 ENDOXANA tablets 10mg [BAXTER ONC] cyclophosphamide 10mg tablets 
10729 ENDOXANA tablets 50mg [BAXTER ONC] cyclophosphamide 50mg tablets 
44740 bortezomib powder for solution for injection 
3.5mg  
bortezomib 3.5mg powder for solution 
for injection 
41266 cytarabine injection solution 1g/10ml  cytarabine 1g/10ml injection solution 
40732 VELCADE powder for solution for injection 
3.5mg [ORTHO BIO] 
bortezomib 3.5mg powder for solution 
for injection 
45647 canakinumab powder for solution for injection 
150mg  
canakinumab 150mg powder for solution 
for injection 
44100 certolizumab pegol injection solution 
200mg/1ml  
certolizumab pegol 200mg/1ml injection solution 
43703 CIMZIA injection solution 200mg/1ml [UCB] certolizumab pegol 200mg/1ml injection solution 
19335 CYTOSAR injection 500mg [PHARMACIA] cytarabine 500mg injection 
66380 DepoCyte 50mg/5ml suspension for injection 
vials (Napp Pharmaceuticals Ltd) 
Cytarabine 10mg/1ml Suspension for 
injection 
18238 dacarbazine powder for solution for injection 
100mg  
dacarbazine citrate 100mg powder for solution 
for injection 
28682 dacarbazine powder for solution for injection 
200mg  
dacarbazine citrate 200mg powder for solution 
for injection 
32204 DTIC-DOME injection 100mg/vial [BAYER] dacarbazine citrate 100mg/vial injection 
58496 Cosmegen Lyovac 500microgram powder for 
solution for injection vials (Orphan Europe 
(UK) Ltd) 
Dactinomycin 500microgram Powder for solution 
for injection 
27071 dactinomycin powder for solution for injection 
500micrograms  
dactinomycin 500micrograms powder for solution 
for injection 
11003 CERUBIDIN powder for concentrate for 
solution for injection 20mg/vial [RHONE] 
daunorubicin 20mg/vial powder for 
concentrate for 
solution for injection 
43805 daunorubicin powder for concentrate for 
solution for injection 20mg/vial  
daunorubicin 20mg/vial powder for 
concentrate for 
solution for injection 
52396 Dexamethasone 1mg/5ml oral solution Dexamethasone 200microgram/1ml Oral solution 
13952 DECADRON injection 4mg/ml [MSD 
MORSON] 
dexamethasone 
sodium phosphate 
4mg/ml injection 
26454 DECADRON injection 4mg/ml [MSD 
MORSON] 
dexamethasone 
sodium phosphate 
4mg/ml injection 
21668 DECADRON SHOCK PAK 20mg/ml [M S D] dexamethasone 
sodium phosphate 
20mg/ml SHOCK PAK 
31948 DEXAMETHASONE injection 4mg/ml 
[MAYNE] 
dexamethasone 
sodium phosphate 
4mg/ml injection 
34083 DEXAMETHASONE injection 5mg/ml 
[ORGANON] 
dexamethasone 
sodium phosphate 
5mg/ml injection 
19259 dexamethasone injection 8mg/2ml  dexamethasone 
sodium phosphate 
8mg/2ml injection 
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26300 dexamethasone shock treatment pack 
20mg/ml  
dexamethasone 
sodium phosphate 
20mg/ml shock treatment 
pack 
28215 dexamethasone sodium phosphate injection 
120mg/5ml  
dexamethasone 
sodium phosphate 
120mg/5ml injection 
4233 dexamethasone sodium phosphate injection 
4mg/ml  
dexamethasone 
sodium phosphate 
4mg/ml injection 
13972 dexamethasone sodium phosphate injection 
5mg/ml  
dexamethasone 
sodium phosphate 
5mg/ml injection 
11334 dexamethasone sodium phosphate IV 
injection 4mg/ml  
dexamethasone 
sodium phosphate 
4mg/ml IV injection 
47755 Docetaxel 160mg/16ml solution for infusion 
vials 
Docetaxel 160mg/16ml Concentrate For 
Solution For 
Infusion 
36831 docetaxel concentrate for dilution for infusion 
solution 20mg/0.5ml  
docetaxel 20mg/0.5ml concentrate for 
dilution for infusion 
solution 
38999 docetaxel concentrate for dilution for infusion 
solution 80mg/2ml  
docetaxel 80mg/2ml concentrate for 
dilution for infusion 
solution 
33560 docetaxel concentrate for intravenous infusion 
40mg/ml  
docetaxel 40mg/ml concentrate for 
intravenous infusion 
44425 docetaxel concentrate for solution for infusion 
20mg/1ml  
docetaxel 20mg/1ml concentrate for 
solution for infusion 
23849 TAXOTERE concentrate for intravenous 
infusion 40mg/ml [AVENTIS] 
docetaxel 40mg/ml concentrate for 
intravenous infusion 
36552 TAXOTERE concentrate for solution for 
infusion 20mg/0.5ml [AVENTIS] 
docetaxel 20mg/0.5ml concentrate for 
solution for infusion 
44087 TAXOTERE concentrate for solution for 
infusion 20mg/1ml [AVENTIS] 
docetaxel 20mg/1ml concentrate for 
solution for infusion 
26680 ADRIAMYCIN injection 10mg/vial 
[PHARMACIA] 
doxorubicin 
hydrochloride 
10mg/vial injection 
27469 ADRIAMYCIN injection 50mg/vial 
[PHARMACIA] 
doxorubicin 
hydrochloride 
50mg/vial injection 
42817 daclizumab concentrate for solution for 
infusion 25mg/5ml  
daclizumab 25mg/5ml concentrate for 
solution for infusion 
42390 dasatinib tablets 100mg  dasatinib 100mg tablets 
37238 dasatinib tablets 20mg  dasatinib 20mg tablets 
36062 dasatinib tablets 50mg  dasatinib 50mg tablets 
36957 dasatinib tablets 70mg  dasatinib 70mg tablets 
66774 Benepali 50mg/1ml solution for injection pre-
filled syringes (Biogen Idec Ltd) 
Etanercept 50mg/1ml Solution for injection 
61373 Enbrel 50mg/1ml solution for injection pre-
filled MyClic pen (Pfizer Ltd) 
Etanercept 50mg/1ml Solution for injection 
37784 CAELYX concentrate for solution for infusion 
20mg/10ml [JANSSEN] 
doxorubicin 
hydrochloride 
20mg/10ml concentrate for 
solution for infusion 
24997 CAELYX concentrate for solution for infusion 
2mg/ml [SCHERING-P] 
doxorubicin 
hydrochloride 
2mg/ml concentrate for 
solution for infusion 
40250 CAELYX concentrate for solution for infusion 
50mg/25ml [JANSSEN] 
doxorubicin 
hydrochloride 
50mg/25ml concentrate for 
solution for infusion 
37942 doxorubicin citrate liposomal complex powder 
for concentrate for solution for infusion 50mg  
doxorubicin 
hydrochloride 
50mg powder for 
concentrate for 
solution for infusion 
55271 Doxorubicin encapsulated in liposomes 
2mg/ml concentrate solution for infusion 
Doxorubicin 
Hydrochloride 
  
39307 doxorubicin injection 10mg/5ml  doxorubicin 
hydrochloride 
10mg/5ml injection 
45026 doxorubicin injection 200mg/100ml  doxorubicin 
hydrochloride 
200mg/100ml injection 
26947 doxorubicin injection 2mg/ml  doxorubicin 
hydrochloride 
2mg/ml injection 
30836 doxorubicin powder for solution for injection 
10mg  
doxorubicin 
hydrochloride 
10mg powder for solution 
for injection 
33878 MYOCET powder for concentrate for solution 
for infusion 50mg [CEPHALON] 
doxorubicin 
hydrochloride 
50mg powder for 
concentrate for 
solution for infusion 
56410 Caelyx 50mg/25ml concentrate for solution for 
infusion vials (Janssen-Cilag Ltd) 
Doxorubicin 
hydrochloride 
liposomal pegylated 
2mg/1ml Solution for infusion 
31539 epirubicin hydrochloride injection (powder) 
20mg  
epirubicin 
hydrochloride 
20mg injection (powder) 
39387 epirubicin hydrochloride injection 100mg/50ml  epirubicin 
hydrochloride 
100mg/50ml injection 
40251 epirubicin hydrochloride injection 
200mg/100ml  
epirubicin 
hydrochloride 
200mg/100ml injection 
29652 epirubicin hydrochloride injection 2mg/ml  epirubicin 
hydrochloride 
2mg/ml injection 
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40816 epirubicin hydrochloride injection 50mg/25ml  epirubicin 
hydrochloride 
50mg/25ml injection 
49856 Enbrel 50mg/1ml solution for injection pre-
filled syringes (Pfizer Ltd) 
Etanercept 50mg/1ml Solution for injection 
41058 ENBREL FOR PAEDIATRIC USE powder for 
solution for injection 25mg [PFIZER] 
etanercept 25mg powder for solution 
for injection 
35419 ENBREL injection solution 25mg [PFIZER] etanercept 25mg injection solution 
36556 ENBREL injection solution 50mg [PFIZER] etanercept 50mg injection solution 
14886 ENBREL powder for solution for injection 
25mg [PFIZER] 
etanercept 25mg powder for solution 
for injection 
19257 ENBREL powder for solution for injection 
50mg [WYETH PHAR] 
etanercept 50mg powder for solution 
for injection 
47843 Etanercept 10mg powder and solvent for 
solution for injection vials 
Etanercept 10mg Powder For 
Solution For 
Injection 
28325 epirubicin hydrochloride powder for solution 
for injection 50mg  
epirubicin 
hydrochloride 
50mg powder for solution 
for injection 
28889 PHARMORUBICIN injection solution 2mg/ml 
[PHARMACIA] 
epirubicin 
hydrochloride 
2mg/ml injection solution 
43639 PHARMORUBICIN powder for solution for 
injection 50mg [PHARMACIA] 
epirubicin 
hydrochloride 
50mg powder for solution 
for injection 
62759 Eribulin 880micrograms/2ml solution for 
injection vials 
Eribulin .44mg/1ml Solution for injection 
13604 ESTRACYT capsules 140mg [PHARMACIA] estramustine sodium 
phosphate 
140mg capsules 
13735 estramustine phosphate capsules 140mg  estramustine sodium 
phosphate 
140mg capsules 
50998 Etanercept 50mg/1ml solution for injection 
pre-filled syringes 
Etanercept 50mg/1ml Solution for injection 
36008 etanercept injection solution 25mg  etanercept 25mg injection solution 
35126 etanercept injection solution 50mg  etanercept 50mg injection solution 
36263 EPOSIN concentrate for solution for infusion 
20mg/ml [MEDAC UK] 
etoposide 20mg/ml concentrate for 
solution for infusion 
48177 Etoposide 100mg/5ml solution for infusion 
vials 
Etoposide 20mg/1ml Solution for infusion 
63011 Etoposide 500mg/25ml solution for infusion 
vials 
Etoposide 20mg/1ml Solution for infusion 
18751 etoposide capsules 100mg  etoposide 100mg capsules 
8756 etoposide capsules 50mg  etoposide 50mg capsules 
31115 etoposide concentrate for solution for infusion 
20mg/ml  
etoposide 20mg/ml concentrate for 
solution for infusion 
37375 VEPESID capsules 100mg [BRISTOL] etoposide 100mg capsules 
29761 VEPESID capsules 50mg [BRISTOL] etoposide 50mg capsules 
44387 etoposide phosphate lyophilised powder for 
injection 100mg  
etoposide phosphate 100mg lyophilised powder 
for injection 
29743 FLUDARA ORAL tablets 10mg [GENZYME] fludarabine phosphate 10mg tablets 
24681 fludarabine powder for solution for injection 
50mg  
fludarabine phosphate 50mg powder for solution 
for injection 
18476 fludarabine tablets 10mg  fludarabine phosphate 10mg tablets 
18070 Fluorouracil 250mg capsules Fluorouracil 250mg Capsule 
15921 etanercept powder for solution for injection 
25mg  
etanercept 25mg powder for solution 
for injection 
26387 etanercept powder for solution for injection 
50mg  
etanercept 50mg powder for solution 
for injection 
43781 AFINITOR tablets 10mg [NOVARTIS] everolimus 10mg tablets 
65378 Everolimus 500microgram tablets Everolimus 500microgram Tablet 
46070 everolimus tablets 5mg  everolimus 5mg tablets 
47398 Golimumab 50mg/0.5ml solution for injection 
pre-filled syringes 
Golimumab 100mg/1ml Solution for injection 
46370 golimumab pre-filled pen injection solution 
50mg  
golimumab 50mg injection solution 
18070 fluorouracil capsules 250mg  fluorouracil 250mg capsules 
19556 FLUORO-URACIL capsules 250mg 
[CAMBRIDGE] 
fluorouracil 250mg capsules 
39388 fluorouracil injection 1g/20ml  fluorouracil 1g/20ml injection 
20229 FLUORO-URACIL injection 25mg/ml 
[CAMBRIDGE] 
fluorouracil 25mg/ml injection 
36575 fluorouracil injection 50mg/ml  fluorouracil 50mg/ml injection 
58240 Fluorouracil 2.5g/100ml solution for infusion 
vials 
Fluorouracil sodium 25mg/1ml Solution for infusion 
55091 Fluorouracil 500mg/10ml solution for injection 
vials 
Fluorouracil sodium 50mg/1ml Solution for injection 
40780 gemcitabine powder for solution for infusion 
1g/vial  
gemcitabine 
hydrochloride 
1g/vial powder for solution 
for infusion 
33418 gemcitabine powder for solution for infusion 
200mg/vial  
gemcitabine 
hydrochloride 
200mg/vial powder for solution 
for infusion 
6884 HYDREA capsules 500mg [SQUIBB] hydroxycarbamide 500mg capsules 
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47127 Hydroxycarbamide 100mg tablets Hydroxycarbamide 100mg Film Coated Tablets 
50565 Hydroxycarbamide 300mg capsules Hydroxycarbamide 300mg Capsule 
59007 Hydroxycarbamide 500mg capsules (A A H 
Pharmaceuticals Ltd) 
Hydroxycarbamide 500mg Capsule 
66728 Idelalisib 100mg tablets Idelalisib 100mg Tablet 
65085 Zydelig 100mg tablets (Gilead Sciences 
International Ltd) 
Idelalisib 100mg Tablet 
6333 hydroxycarbamide capsules 500mg  hydroxycarbamide 500mg capsules 
21295 GLIVEC capsules 100mg [NOVARTIS] imatinib mesilate 100mg capsules 
33823 GLIVEC tablets 100mg [NOVARTIS] imatinib mesilate 100mg tablets 
28800 GLIVEC tablets 400mg [NOVARTIS] imatinib mesilate 400mg tablets 
33330 HYDROXYCARBAMIDE capsules 500mg 
[MEDAC UK] 
hydroxycarbamide 500mg capsules 
39548 hydroxycarbamide film coated tablets 1000mg  hydroxycarbamide 1000mg film coated tablets 
38319 hydroxycarbamide oral solution 500mg/5ml  hydroxycarbamide 500mg/5ml oral solution 
3873 hydroxyurea capsules 500mg  hydroxycarbamide 500mg capsules 
65463 Siklos 1000mg tablets (Nordic Pharma Ltd) Hydroxycarbamide 1gram Tablet 
31339 idarubicin hydrochloride capsules 10mg  idarubicin 
hydrochloride 
10mg capsules 
31984 idarubicin hydrochloride capsules 5mg  idarubicin 
hydrochloride 
5mg capsules 
43168 ifosfamide injection 2g/vial  ifosfamide 2g/vial injection 
21286 imatinib capsules 100mg  imatinib mesilate 100mg capsules 
29229 imatinib tablets 100mg  imatinib mesilate 100mg tablets 
21318 imatinib tablets 400mg  imatinib mesilate 400mg tablets 
64636 Inflectra 100mg powder for concentrate for 
solution for infusion vials (Hospira UK Ltd) 
Infliximab 100mg Powder for solution 
for infusion 
40983 irinotecan hydrochloride concentrate for 
solution for infusion 40mg/2ml  
irinotecan 
hydrochloride 
40mg/2ml concentrate for 
solution for infusion 
59339 Irinotecan 40mg/2ml concentrate for solution 
for infusion vials (Hospira UK Ltd) 
Irinotecan 
hydrochloride 
trihydrate 
20mg/1ml Solution for infusion 
16822 infliximab powder for concentrate for solution 
for infusion 100mg  
infliximab 100mg powder for 
concentrate for 
solution for infusion 
18460 ARAVA tablets 100mg [AVENTIS] leflunomide 100mg tablets 
16522 ARAVA tablets 10mg [AVENTIS] leflunomide 10mg tablets 
17642 ARAVA tablets 20mg [AVENTIS] leflunomide 20mg tablets 
48217 Leflunomide 10mg tablets (medac UK) Leflunomide 10mg Tablet 
62993 Leflunomide 20mg tablets (Sandoz Ltd) Leflunomide 20mg Tablet 
4970 leflunomide tablets 100mg  leflunomide 100mg tablets 
4971 leflunomide tablets 10mg  leflunomide 10mg tablets 
6934 leflunomide tablets 20mg  leflunomide 20mg tablets 
60630 Lenalidomide 2.5mg capsules Lenalidomide 2.5mg Capsule 
44529 lenalidomide capsules 10mg  lenalidomide 10mg capsules 
46205 lenalidomide capsules 15mg  lenalidomide 15mg capsules 
40626 lenalidomide capsules 25mg  lenalidomide 25mg capsules 
42056 lenalidomide capsules 5mg  lenalidomide 5mg capsules 
58227 Revlimid 10mg capsules (Celgene Ltd) Lenalidomide 10mg Capsule 
56818 Revlimid 15mg capsules (Celgene Ltd) Lenalidomide 15mg Capsule 
41139 REVLIMID capsules 25mg [CELGENE] lenalidomide 25mg capsules 
22392 REMICADE powder for concentrate for 
solution for infusion 100mg [SCHERING-P] 
infliximab 100mg powder for 
concentrate for 
solution for infusion 
58862 Ipilimumab 200mg/40ml solution for infusion 
vials 
Ipilimumab 5mg/1ml Solution for infusion 
25848 CCNU capsules 10mg [LUNDBECK] lomustine 10mg capsules 
8404 CCNU capsules 40mg [LUNDBECK] lomustine 40mg capsules 
12067 lomustine capsules 40mg  lomustine 40mg capsules 
30014 MITHRACIN injection 2.5mg/vial [PFIZER] mannitol/sodium 
phosphate/plicamycin 
2.5mg/vial injection 
31494 mithramycin injection 2.5mg/vial  mannitol/sodium 
phosphate/plicamycin 
2.5mg/vial injection 
26343 ALKERAN tablets 2mg [WELLCOME] melphalan 2mg tablets 
23270 ALKERAN tablets 5mg [WELLCOME] melphalan 5mg tablets 
16929 melphalan tablets 2mg  melphalan 2mg tablets 
12150 melphalan tablets 5mg  melphalan 5mg tablets 
26580 melphalan injection 100mg/vial  melphalan 
hydrochloride 
100mg/vial injection 
37099 melphalan powder for solution for injection 
50mg  
melphalan 
hydrochloride 
50mg powder for solution 
for injection 
57239 Mercaptopurine 20mg/ml oral suspension Mercaptopurine 20mg/1ml Oral suspension 
56753 Mercaptopurine 25mg tablets Mercaptopurine 25mg Tablet 
55772 Mercaptopurine 25mg/5ml oral suspension Mercaptopurine 5mg/1ml Oral suspension 
61545 Mercaptopurine 50mg tablets (Aspen Pharma 
Trading Ltd) 
Mercaptopurine 50mg Tablet 
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52333 Mercaptopurine 75mg/5ml oral suspension Mercaptopurine 15mg/1ml Oral suspension 
19982 mercaptopurine capsules 10mg  mercaptopurine 10mg capsules 
47369 Mercaptopurine Oral solution Mercaptopurine 
 
Oral Liquid 
32972 mercaptopurine tablets 10mg  mercaptopurine 10mg tablets 
3450 mercaptopurine tablets 50mg  mercaptopurine 50mg tablets 
29675 PURI-NETHOL tablets 50mg [ALKOPHARMA] mercaptopurine 50mg tablets 
21753 MAXTREX tablets 10mg [PHARMACIA] methotrexate 10mg tablets 
13428 MAXTREX tablets 2.5mg [PHARMACIA] methotrexate 2.5mg tablets 
57441 Methotrexate 10mg tablets (A A H 
Pharmaceuticals Ltd) 
Methotrexate 10mg Tablet 
58885 Methotrexate 10mg tablets (Sigma 
Pharmaceuticals Plc) 
Methotrexate 10mg Tablet 
59538 Methotrexate 10mg tablets (Teva UK Ltd) Methotrexate 10mg Tablet 
57174 Methotrexate 10mg tablets (Waymade 
Healthcare Plc) 
Methotrexate 10mg Tablet 
61151 Methotrexate 10mg/0.2ml solution for injection 
pre-filled disposable devices 
Methotrexate 50mg/1ml Solution for injection 
56037 Methotrexate 2.5mg tablets (A A H 
Pharmaceuticals Ltd) 
Methotrexate 2.5mg Tablet 
51120 Methotrexate 2.5mg tablets (Alliance 
Healthcare (Distribution) Ltd) 
Methotrexate 2.5mg Tablet 
62833 Methotrexate 2.5mg tablets (DE 
Pharmaceuticals) 
Methotrexate 2.5mg Tablet 
60979 Methotrexate 2.5mg tablets (Morningside 
Healthcare Ltd) 
Methotrexate 2.5mg Tablet 
58303 Methotrexate 2.5mg tablets (Orion Pharma 
(UK) Ltd) 
Methotrexate 2.5mg Tablet 
49951 Methotrexate 2.5mg tablets (Sandoz Ltd) Methotrexate 2.5mg Tablet 
52606 Methotrexate 2.5mg tablets (Sigma 
Pharmaceuticals Plc) 
Methotrexate 2.5mg Tablet 
59685 Methotrexate 2.5mg tablets (Teva UK Ltd) Methotrexate 2.5mg Tablet 
53385 Methotrexate 2.5mg tablets (Waymade 
Healthcare Plc) 
Methotrexate 2.5mg Tablet 
61085 Methotrexate 2.5mg tablets (Waymade 
Healthcare Plc) 
Methotrexate 2.5mg Tablet 
61122 Methotrexate 25mg/0.5ml solution for injection 
pre-filled disposable devices 
Methotrexate 50mg/1ml Solution for injection 
59723 Methotrexate 7.5mg/5ml oral solution Methotrexate 1.5mg/1ml Oral solution 
40371 methotrexate injection 10mg/0.2ml  methotrexate 10mg/0.2ml injection 
32865 methotrexate injection 10mg/1ml  methotrexate 10mg/1ml injection 
46152 methotrexate injection 12.5mg/0.25ml  methotrexate 12.5mg/0.25ml injection 
40281 methotrexate injection 15mg/0.3ml  methotrexate 15mg/0.3ml injection 
27404 methotrexate injection 15mg/1.5ml  methotrexate 15mg/1.5ml injection 
46156 methotrexate injection 17.5mg/0.35ml  methotrexate 17.5mg/0.35ml injection 
40273 methotrexate injection 20mg/0.4ml  methotrexate 20mg/0.4ml injection 
45165 methotrexate injection 20mg/1ml  methotrexate 20mg/1ml injection 
26064 methotrexate injection 20mg/2ml  methotrexate 20mg/2ml injection 
46129 methotrexate injection 22.5mg/0.45ml  methotrexate 22.5mg/0.45ml injection 
40328 methotrexate injection 25mg/0.5ml  methotrexate 25mg/0.5ml injection 
45558 methotrexate injection 25mg/1.25ml  methotrexate 25mg/1.25ml injection 
24634 methotrexate injection 25mg/2.5ml  methotrexate 25mg/2.5ml injection 
44908 methotrexate injection 30mg/0.6ml  methotrexate 30mg/0.6ml injection 
46039 methotrexate injection 30mg/1.5ml  methotrexate 30mg/1.5ml injection 
40301 methotrexate injection 7.5mg/0.15ml  methotrexate 7.5mg/0.15ml injection 
35402 methotrexate injection 7.5mg/0.75ml  methotrexate 7.5mg/0.75ml injection 
36800 methotrexate oral solution 10mg/5ml  methotrexate 10mg/5ml oral solution 
36849 methotrexate oral suspension 10mg/5ml  methotrexate 10mg/5ml oral suspension 
28041 methotrexate oral suspension 12.5mg/5ml  methotrexate 12.5mg/5ml oral suspension 
35752 methotrexate oral suspension 7.5mg/5ml  methotrexate 7.5mg/5ml oral suspension 
18424 methotrexate sodium tablets 2.5mg  methotrexate 2.5mg tablets 
41585 METHOTREXATE SODIUM tablets 2.5mg 
[WYETH PHAR] 
methotrexate 2.5mg tablets 
17035 methotrexate suspension 2.5mg/5ml  methotrexate 2.5mg/5ml suspension 
877 methotrexate tablets 10mg  methotrexate 10mg tablets 
34929 METHOTREXATE tablets 10mg [HOSPIRA] methotrexate 10mg tablets 
823 methotrexate tablets 2.5mg  methotrexate 2.5mg tablets 
41104 METHOTREXATE tablets 2.5mg [CP 
PHARM] 
methotrexate 2.5mg tablets 
20951 METHOTREXATE tablets 2.5mg 
[GOLDSHIELD] 
methotrexate 2.5mg tablets 
32111 METHOTREXATE tablets 2.5mg [HOSPIRA] methotrexate 2.5mg tablets 
30780 METHOTREXATE tablets 2.5mg 
[PHARMACIA] 
methotrexate 2.5mg tablets 
40356 METOJECT injection 10mg/0.2ml [MEDAC 
UK] 
methotrexate 10mg/0.2ml injection 
37117 METOJECT injection 10mg/1ml [MEDAC UK] methotrexate 10mg/1ml injection 
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46098 METOJECT injection 12.5mg/0.25ml [MEDAC 
UK] 
methotrexate 12.5mg/0.25ml injection 
40284 METOJECT injection 15mg/0.3ml [MEDAC 
UK] 
methotrexate 15mg/0.3ml injection 
27400 METOJECT injection 15mg/1.5ml [MEDAC 
UK] 
methotrexate 15mg/1.5ml injection 
46265 METOJECT injection 17.5mg/0.35ml [MEDAC 
UK] 
methotrexate 17.5mg/0.35ml injection 
40292 METOJECT injection 20mg/0.4ml [MEDAC 
UK] 
methotrexate 20mg/0.4ml injection 
14348 METOJECT injection 20mg/2ml [MEDAC UK] methotrexate 20mg/2ml injection 
46197 METOJECT injection 22.5mg/0.45ml [MEDAC 
UK] 
methotrexate 22.5mg/0.45ml injection 
40293 METOJECT injection 25mg/0.5ml [MEDAC 
UK] 
methotrexate 25mg/0.5ml injection 
33601 METOJECT injection 25mg/2.5ml [MEDAC 
UK] 
methotrexate 25mg/2.5ml injection 
40280 METOJECT injection 7.5mg/0.15ml [MEDAC 
UK] 
methotrexate 7.5mg/0.15ml injection 
35865 METOJECT injection 7.5mg/0.75ml [MEDAC 
UK] 
methotrexate 7.5mg/0.75ml injection 
61050 Metoject PEN 10mg/0.2ml solution for 
injection pre-filled pen (medac UK) 
Methotrexate 50mg/1ml Solution for injection 
61171 Metoject PEN 15mg/0.3ml solution for 
injection pre-filled pen (medac UK) 
Methotrexate 50mg/1ml Solution for injection 
61181 Metoject PEN 17.5mg/0.35ml solution for 
injection pre-filled pen (medac UK) 
Methotrexate 50mg/1ml Solution for injection 
61180 Metoject PEN 20mg/0.4ml solution for 
injection pre-filled pen (medac UK) 
Methotrexate 50mg/1ml Solution for injection 
61169 Metoject PEN 25mg/0.5ml solution for 
injection pre-filled pen (medac UK) 
Methotrexate 50mg/1ml Solution for injection 
62421 Metoject PEN 27.5mg/0.55ml solution for 
injection pre-filled pen (medac UK) 
Methotrexate 50mg/1ml Solution for injection 
61488 Metoject PEN 30mg/0.6ml solution for 
injection pre-filled pen (medac UK) 
Methotrexate 50mg/1ml Solution for injection 
27342 MAXTREX injection 2.5mg/ml [PHARMACIA] methotrexate sodium 2.5mg/ml injection 
51667 Methotrexate 200mg/8ml solution for injection 
vials 
Methotrexate sodium 25mg/1ml Solution for injection 
65584 Methotrexate 2mg/ml oral solution sugar free Methotrexate sodium 2mg/1ml Oral solution 
51321 Methotrexate 50mg/2ml solution for injection 
vials 
Methotrexate sodium 25mg/1ml Solution for injection 
53696 Methotrexate 50mg/2ml solution for injection 
vials (A A H Pharmaceuticals Ltd) 
Methotrexate sodium 25mg/1ml Solution for injection 
49547 Methotrexate 5g/200ml solution for infusion 
vials 
Methotrexate sodium 25mg/1ml Solution for infusion 
36167 methotrexate injection 1000mg/10ml  methotrexate sodium 1000mg/10ml injection 
46407 methotrexate injection 1000mg/40ml  methotrexate sodium 1000mg/40ml injection 
12816 methotrexate injection 100mg/ml  methotrexate sodium 100mg/ml injection 
7337 methotrexate injection 10mg/0.4ml  methotrexate sodium 10mg/0.4ml injection 
7336 methotrexate injection 12.5mg/0.5ml  methotrexate sodium 12.5mg/0.5ml injection 
16540 methotrexate injection 15mg/0.6ml  methotrexate sodium 15mg/0.6ml injection 
18890 methotrexate injection 17.5mg/0.7ml  methotrexate sodium 17.5mg/0.7ml injection 
14347 methotrexate injection 20mg/0.8ml  methotrexate sodium 20mg/0.8ml injection 
34258 METHOTREXATE injection 20mg/0.8ml 
[CENT HOME] 
methotrexate sodium 20mg/0.8ml injection 
17672 methotrexate injection 22.5mg/0.9ml  methotrexate sodium 22.5mg/0.9ml injection 
16519 methotrexate injection 25mg/1ml  methotrexate sodium 25mg/1ml injection 
8583 methotrexate injection 25mg/ml  methotrexate sodium 25mg/ml injection 
27642 methotrexate injection 27.5mg/1.1ml  methotrexate sodium 27.5mg/1.1ml injection 
30703 methotrexate injection 30mg/1.2ml  methotrexate sodium 30mg/1.2ml injection 
41086 methotrexate injection 5000mg/50ml  methotrexate sodium 5000mg/50ml injection 
32229 methotrexate injection 500mg/20ml  methotrexate sodium 500mg/20ml injection 
24783 methotrexate injection 50mg/2ml  methotrexate sodium 50mg/2ml injection 
8327 methotrexate injection 50mg/3ml  methotrexate sodium 50mg/3ml injection 
30932 methotrexate injection 5mg/0.2ml  methotrexate sodium 5mg/0.2ml injection 
9528 methotrexate injection 5mg/2ml  methotrexate sodium 5mg/2ml injection 
16570 methotrexate injection 7.5mg/0.3ml  methotrexate sodium 7.5mg/0.3ml injection 
14748 methotrexate sodium injection 25mg/ml  methotrexate sodium 25mg/ml injection 
29069 methotrexate sterile powder 500mg/vial  methotrexate sodium 500mg/vial sterile powder 
57103 Metoject 27.5mg/0.55ml solution for injection 
pre-filled syringes (medac UK) 
Methotrexate sodium 50mg/1ml Solution for injection 
66487 Zlatal 12.5mg/0.5ml solution for injection pre-
filled syringes (Nordic Pharma Ltd) 
Methotrexate sodium 25mg/1ml Solution for injection 
37396 MYELOBROMOL tablets 125mg [DURBIN] mitobronitol 125mg tablets 
44478 LYSODREN tablets 500mg [LAB HRA] mitotane 500mg tablets 
35826 mitotane tablets 500mg  mitotane 500mg tablets 
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39366 mitoxantrone concentrate for solution for 
infusion 10mg/5ml  
mitoxantrone 
hydrochloride 
10mg/5ml concentrate for 
solution for infusion 
41267 mitoxantrone concentrate for solution for 
infusion 20mg/10ml  
mitoxantrone 
hydrochloride 
20mg/10ml concentrate for 
solution for infusion 
33174 mitoxantrone concentrate for solution for 
infusion 2mg/ml  
mitoxantrone 
hydrochloride 
2mg/ml concentrate for 
solution for infusion 
15405 NOVANTRONE concentrate for solution for 
infusion 2mg/ml [WYETH PHAR] 
mitoxantrone 
hydrochloride 
2mg/ml concentrate for 
solution for infusion 
45393 ARZIP tablets 500mg [WINTHROP] mycophenolate 
mofetil 
500mg tablets 
57593 CellCept 500mg tablets (Waymade 
Healthcare Plc) 
Mycophenolate 
mofetil 
500mg Tablet 
16919 CELLCEPT capsules 250mg [ROCHE] mycophenolate 
mofetil 
250mg capsules 
21732 CELLCEPT oral suspension 1g/5ml [ROCHE] mycophenolate 
mofetil 
1g/5ml oral suspension 
30581 CELLCEPT powder for concentrate for 
solution for infusion 500mg [ROCHE] 
mycophenolate 
mofetil 
500mg powder for 
concentrate for 
solution for infusion 
18804 CELLCEPT tablets 500mg [ROCHE] mycophenolate 
mofetil 
500mg tablets 
57272 Mycophenolate mofetil 125mg/5ml oral 
suspension 
Mycophenolate 
mofetil 
25mg/1ml Oral suspension 
60231 Mycophenolate mofetil 250mg capsules (A A 
H Pharmaceuticals Ltd) 
Mycophenolate 
mofetil 
250mg Capsule 
54317 Mycophenolate mofetil 250mg capsules 
(Sandoz Ltd) 
Mycophenolate 
mofetil 
250mg Capsule 
53255 Mycophenolate mofetil 250mg capsules 
(Sigma Pharmaceuticals Plc) 
Mycophenolate 
mofetil 
250mg Capsule 
58530 Mycophenolate mofetil 500mg tablets (Sigma 
Pharmaceuticals Plc) 
Mycophenolate 
mofetil 
500mg Tablet 
4438 mycophenolate mofetil capsules 250mg  mycophenolate 
mofetil 
250mg capsules 
16879 mycophenolate mofetil oral suspension 1g/5ml  mycophenolate 
mofetil 
1g/5ml oral suspension 
7077 mycophenolate mofetil powder for concentrate 
for solution for infusion 500mg  
mycophenolate 
mofetil 
500mg powder for 
concentrate for 
solution for infusion 
4230 mycophenolate mofetil tablets 500mg  mycophenolate 
mofetil 
500mg tablets 
50669 Mycophenolate motefil 500mg tablets (Sandoz 
Ltd) 
Mycophenolate 
mofetil 
500mg Tablet 
47746 Mycophenolate motefil 500mg tablets 
(Wockhardt UK Ltd) 
Mycophenolate 
mofetil 
500mg Tablet 
45489 MYFENAX capsules 250mg [TEVA] mycophenolate 
mofetil 
250mg capsules 
45043 MYFENAX tablets 500mg [TEVA] mycophenolate 
mofetil 
500mg tablets 
35301 mycophenolic acid gastro-resistant tablets 
180mg  
mycophenolate 
sodium 
180mg gastro-resistant 
tablets 
26097 mycophenolic acid gastro-resistant tablets 
360mg  
mycophenolate 
sodium 
360mg gastro-resistant 
tablets 
27290 MYFORTIC tablets 180mg [NOVARTIS] mycophenolate 
sodium 
180mg tablets 
27289 MYFORTIC tablets 360mg [NOVARTIS] mycophenolate 
sodium 
360mg tablets 
23832 ELOXATIN powder for concentrate for 
solution for infusion 100mg [SANOFI S] 
oxaliplatin 100mg powder for 
concentrate for 
solution for infusion 
50277 Oxaliplatin 100mg/20ml concentrate for 
solution for infusion vials (A A H 
Pharmaceuticals Ltd) 
Oxaliplatin 5mg/1ml Solution for infusion 
39895 oxaliplatin concentrate for solution for infusion 
100mg/20ml  
oxaliplatin 100mg/20ml concentrate for 
solution for infusion 
39553 oxaliplatin concentrate for solution for infusion 
50mg/10ml  
oxaliplatin 50mg/10ml concentrate for 
solution for infusion 
36714 oxaliplatin powder for concentrate for solution 
for infusion 100mg  
oxaliplatin 100mg powder for 
concentrate for 
solution for infusion 
27293 oxaliplatin powder for concentrate for solution 
for infusion 50mg  
oxaliplatin 50mg powder for 
concentrate for 
solution for infusion 
41191 natalizumab concentrate for solution for 
infusion 300mg/15ml  
natalizumab 300mg/15ml concentrate for 
solution for infusion 
47754 Paclitaxel 100mg/16.7ml solution for infusion 
vials 
Paclitaxel 6mg/1ml Solution for infusion 
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39919 paclitaxel albumin bound powder for 
suspension for infusion 100mg  
paclitaxel 100mg powder for 
suspension for 
infusion 
45147 paclitaxel concentrate for solution for infusion 
150mg/25ml  
paclitaxel 150mg/25ml concentrate for 
solution for infusion 
35854 paclitaxel concentrate for solution for infusion 
30mg/5ml  
paclitaxel 30mg/5ml concentrate for 
solution for infusion 
14381 paclitaxel concentrate for solution for infusion 
6mg/ml  
paclitaxel 6mg/ml concentrate for 
solution for infusion 
35384 TAXOL concentrate for solution for infusion 
30mg/5ml [BMS] 
paclitaxel 30mg/5ml concentrate for 
solution for infusion 
16173 TAXOL concentrate for solution for infusion 
6mg/ml [BMS] 
paclitaxel 6mg/ml concentrate for 
solution for infusion 
61366 Abraxane 100mg powder for suspension for 
infusion vials (Celgene Ltd) 
Paclitaxel albumin 100mg Powder for 
suspension for 
infusion 
37272 pemetrexed powder for concentrate for 
solution for infusion 500mg  
pemetrexed disodium 500mg powder for 
concentrate for 
solution for infusion 
43888 pentostatin powder for solution for injection 
10mg  
pentostatin 
(deoxycoformycin) 
10mg powder for solution 
for injection 
38254 TYSABRI concentrate for solution for infusion 
300mg/15ml [BIOGEN] 
natalizumab 300mg/15ml concentrate for 
solution for infusion 
45820 nilotinib capsules 150mg  nilotinib hydrochloride 
monohydrate 
150mg capsules 
28605 NATULAN capsules 50mg [CAMBRIDGE] procarbazine 
hydrochloride 
50mg capsules 
17186 procarbazine capsules 50mg  procarbazine 
hydrochloride 
50mg capsules 
38317 nilotinib capsules 200mg  nilotinib hydrochloride 
monohydrate 
200mg capsules 
39111 rituximab concentrate for intravenous infusion 
10mg/ml  
rituximab 10mg/ml concentrate for 
intravenous infusion 
44222 raltitrexed powder for concentrate for solution 
for infusion 2mg  
raltitrexed 2mg powder for 
concentrate for 
solution for infusion 
22640 razoxane tablets 125mg  razoxane 125mg tablets 
12066 RAZOXIN tablets 125mg [CAMBRIDGE] razoxane 125mg tablets 
33728 RAPAMUNE oral solution 1mg/ml [PFIZER] sirolimus 1mg/ml oral solution 
23289 RAPAMUNE tablets 1mg [PFIZER] sirolimus 1mg tablets 
28999 RAPAMUNE tablets 2mg [PFIZER] sirolimus 2mg tablets 
20097 sirolimus oral solution 1mg/ml  sirolimus 1mg/ml oral solution 
6600 sirolimus tablets 1mg  sirolimus 1mg tablets 
6484 sirolimus tablets 2mg  sirolimus 2mg tablets 
44783 sirolimus tablets 500 micrograms  sirolimus 500 micrograms tablets 
65704 Adoport 0.75mg capsules (Sandoz Ltd) Tacrolimus 750microgram Capsule 
63866 Adoport 2mg capsules (Sandoz Ltd) Tacrolimus 2mg Capsule 
44804 ADOPORT twice daily capsules 1mg 
[SANDOZ] 
tacrolimus 1mg twice daily capsules 
44640 ADOPORT twice daily capsules 500 
micrograms [SANDOZ] 
tacrolimus 500 micrograms twice daily capsules 
28490 rituximab concentrate for solution for infusion 
100mg/10ml  
rituximab 100mg/10ml concentrate for 
solution for infusion 
44641 ADOPORT twice daily capsules 5mg 
[SANDOZ] 
tacrolimus 5mg twice daily capsules 
37506 ADVAGRAF once daily modified release 
capsules 1mg [ASTELLAS] 
tacrolimus 1mg once daily modified 
release capsules 
40765 ADVAGRAF once daily modified release 
capsules 3mg [ASTELLAS] 
tacrolimus 3mg once daily modified 
release capsules 
39633 ADVAGRAF once daily modified release 
capsules 500 micrograms [ASTELLAS] 
tacrolimus 500 micrograms once daily modified 
release capsules 
38919 ADVAGRAF once daily modified release 
capsules 5mg [ASTELLAS] 
tacrolimus 5mg once daily modified 
release capsules 
46325 MODIGRAF granules for oral suspension 1mg 
[ASTELLAS] 
tacrolimus 1mg granules for oral 
suspension 
46324 MODIGRAF granules for oral suspension 
200micrograms [ASTELLAS] 
tacrolimus 200micrograms granules for oral 
suspension 
54198 Prograf 1mg capsules (Lexon (UK) Ltd) Tacrolimus 1mg Capsule 
3683 PROGRAF twice daily capsules 1mg 
[ASTELLAS] 
tacrolimus 1mg twice daily capsules 
5870 PROGRAF twice daily capsules 500 
micrograms [ASTELLAS] 
tacrolimus 500 micrograms twice daily capsules 
13271 PROGRAF twice daily capsules 5mg 
[ASTELLAS] 
tacrolimus 5mg twice daily capsules 
55066 Tacrolimus 2.5mg/5ml oral solution Tacrolimus 500microgram/1ml Oral solution 
63924 Tacrolimus 2mg capsules Tacrolimus 2mg Capsule 
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54048 Tacrolimus 500micrograms/5ml oral 
suspension 
Tacrolimus 100microgram/1ml Oral suspension 
63720 Tacrolimus 750microgram capsules Tacrolimus 750microgram Capsule 
36294 rituximab concentrate for solution for infusion 
500mg/50ml  
rituximab 500mg/50ml concentrate for 
solution for infusion 
33123 tacrolimus concentrate for solution for infusion 
5mg/1ml  
tacrolimus 5mg/1ml concentrate for 
solution for infusion 
43081 tacrolimus granules for oral suspension 1mg  tacrolimus 1mg granules for oral 
suspension 
43082 tacrolimus granules for oral suspension 
200micrograms  
tacrolimus 200micrograms granules for oral 
suspension 
40453 TORISEL concentrate for solution for infusion 
30mg/1.2ml [PFIZER] 
temsirolimus 30mg/1.2ml concentrate for 
solution for infusion 
62957 Tocilizumab 400mg/20ml solution for infusion 
vials 
Tocilizumab 20mg/1ml Solution for infusion 
46348 tocilizumab concentrate for solution for 
infusion 200mg/10ml  
tocilizumab 200mg/10ml concentrate for 
solution for infusion 
37985 tacrolimus once daily modified release 
capsules 1mg  
tacrolimus 1mg once daily modified 
release capsules 
40964 tacrolimus once daily modified release 
capsules 3mg  
tacrolimus 3mg once daily modified 
release capsules 
38113 tacrolimus once daily modified release 
capsules 500 micrograms  
tacrolimus 500 micrograms once daily modified 
release capsules 
38989 tacrolimus once daily modified release 
capsules 5mg  
tacrolimus 5mg once daily modified 
release capsules 
44926 tacrolimus oral suspension 2.5mg/5ml  tacrolimus 2.5mg/5ml oral suspension 
37155 tacrolimus suspension 1mg/ml  tacrolimus 1mg/ml suspension 
41502 tocilizumab concentrate for solution for 
infusion 80mg/4ml  
tocilizumab 80mg/4ml concentrate for 
solution for infusion 
64612 Apremilast 30mg tablets 
   
2839 tacrolimus twice daily capsules 1mg  tacrolimus 1mg twice daily capsules 
6495 tacrolimus twice daily capsules 500 
micrograms  
tacrolimus 500 micrograms twice daily capsules 
5089 tacrolimus twice daily capsules 5mg  tacrolimus 5mg twice daily capsules 
55010 Vivadex 5mg capsules (Dexcel-Pharma Ltd) Tacrolimus 5mg Capsule 
33519 UFTORAL capsules 224mg + 100mg [MERCK 
SER] 
tegafur/uracil 224mg + 100mg capsules 
33520 uracil with tegafur capsules 224mg + 100mg  tegafur/uracil 224mg + 100mg capsules 
55077 Temodal 100mg capsules (Merck Sharp & 
Dohme Ltd) 
Temozolomide 100mg Capsule 
35226 TEMODAL capsules 20mg [SCHERING-P] temozolomide 20mg capsules 
29700 TEMODAL capsules 250mg [SCHERING-P] temozolomide 250mg capsules 
33803 TEMODAL capsules 5mg [SCHERING-P] temozolomide 5mg capsules 
21249 temozolomide capsules 100mg  temozolomide 100mg capsules 
42372 temozolomide capsules 140mg  temozolomide 140mg capsules 
32490 temozolomide capsules 20mg  temozolomide 20mg capsules 
21250 temozolomide capsules 250mg  temozolomide 250mg capsules 
27922 temozolomide capsules 5mg  temozolomide 5mg capsules 
33385 thiotepa powder for solution for injection 15mg  thiotepa 15mg powder for solution 
for injection 
26502 LANVIS tablets 40mg [ALKOPHARMA] tioguanine 40mg tablets 
20094 tioguanine tablets 40mg  tioguanine 40mg tablets 
33227 HYCAMTIN powder for concentrate for 
solution for infusion 4mg [GLAXSK PHA] 
topotecan 
hydrochloride 
4mg powder for 
concentrate for 
solution for infusion 
47396 Topotecan 1mg capsules Topotecan 
hydrochloride 
1mg Capsule 
41960 topotecan powder for concentrate for solution 
for infusion 1mg  
topotecan 
hydrochloride 
1mg powder for 
concentrate for 
solution for infusion 
59362 Trabectedin 1mg powder for solution for 
infusion vials 
Trabectedin 1mg Powder for solution 
for infusion 
24448 treosulfan capsules 250mg  treosulfan 250mg capsules 
23871 TREOSULFAN capsules 250mg [FARILLON] treosulfan 250mg capsules 
32604 vinblastine sulphate injection 10mg/10ml  vinblastine sulphate 10mg/10ml injection 
31223 vinblastine sulphate injection 10mg/vial  vinblastine sulphate 10mg/vial injection 
42684 vinorelbine concentrate for solution for 
infusion 10mg/1ml  
vinorelbine 10mg/1ml concentrate for 
solution for infusion 
33171 vinorelbine injection solution 10mg/ml  vinorelbine 10mg/ml injection solution 
46838 Vinorelbine 80mg capsules Vinorelbine Tartrate 80mg Capsules 
32774 vinorelbine capsules 20mg  vinorelbine tartrate 20mg capsules 
60112 Erivedge 150mg capsules (Roche Products 
Ltd) 
Vismodegib 150mg Capsule 
65140 Vismodegib 150mg capsules Vismodegib 150mg Capsule 
59842 Azacitidine 100mg powder for suspension for 
injection vials 
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Prodcode Product name Drug substance name Substance strength Formulation 
3918 AZATHIOPRINE 10 MG TAB 
   
8776 AZATHIOPRINE 100 MG TAB 
   
15556 AZATHIOPRINE 125 MG TAB 
   
52921 Azathioprine 125mg/5ml oral suspension 
   
58142 Brentuximab vedotin 50mg powder for 
solution for infusion vials 
   
17206 AZATHIOPRINE 50 MG SUS 
   
66436 Cetuximab 500mg/100ml solution for infusion 
vials 
   
50494 Etanercept 50mg/1ml solution for injection 1ml 
pre-filled disposable devices 
   
58819 Herceptin 600mg/5ml solution for injection 
vials (Roche Products Ltd) 
   
20721 CCNU 
   
26806 DECADRON 2 MG TAB 
   
64427 Idelalisib 150mg tablets 
   
62157 Hydroxycarbamide 500mg/5ml oral 
suspension 
   
1901 IMURAN 10 MG TAB 
   
62007 Leflunomide 15mg tablets 
   
65629 Mercaptopurine 30mg capsules 
   
66583 Mercaptopurine 75mg tablets 
   
56041 Ipilimumab 50mg/10ml solution for infusion 
vials 
   
27579 METHOTREXATE 
   
61081 Methotrexate 12.5mg/0.25ml solution for 
injection pre-filled disposable devices 
   
61273 Methotrexate 15mg/0.3ml solution for injection 
pre-filled disposable devices 
   
61137 Methotrexate 17.5mg/0.35ml solution for 
injection pre-filled disposable devices 
   
61140 Methotrexate 20mg/0.4ml solution for injection 
pre-filled disposable devices 
   
61082 Methotrexate 22.5mg/0.45ml solution for 
injection pre-filled disposable devices 
   
65531 Otezla tablets treatment initiation pack 
(Celgene Ltd) 
   
21889 METHOTREXATE 25MG/1ML 
   
62753 Methotrexate 27.5mg/0.55ml solution for 
injection pre-filled syringes 
   
61796 Methotrexate 30mg/0.6ml solution for injection 
pre-filled disposable devices 
   
61172 Methotrexate 7.5mg/0.15ml solution for 
injection pre-filled disposable devices 
   
61211 Metoject PEN 12.5mg/0.25ml solution for 
injection pre-filled pen (medac UK) 
   
61419 Metoject PEN 22.5mg/0.45ml solution for 
injection pre-filled pen (medac UK) 
   
61178 Metoject PEN 7.5mg/0.15ml solution for 
injection pre-filled pen (medac UK) 
   
37395 MYELOBROMOL (NAMED PATIENT ONLY) 
125 MG TAB 
   
63210 Rapamune 0.5mg tablets (Pfizer Ltd) 
   
64152 Tacrolimus 1mg modified-release tablets 
   
26332 THIOTEPA 15 MG INJ 
   
62009 Trabectedin 250microgram powder for 
solution for infusion vials 
   
28726 TREOSULFAN LEO 
   
61908 Pertuzumab 420mg/14ml solution for infusion 
vials 
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Appendix 18 Completeness of recording of variables to identify dose and duration of 
immunosuppressive treatment before ‘hot decking’ technique* 
Data 
available 
from CPRD 
Zoster burden study (% complete 
data) 
Zoster vaccine uptake study (% 
complete data) 
Prescriptions 
for oral 
corticosteroids  
Prescriptions other 
immunosuppressive 
medications’ 
prescriptions 
Prescriptions 
oral 
corticosteroids 
Prescriptions other 
immunosuppressive 
medications 
Total 
quantitya 
99.3% 99.7% 99.6% 99.8% 
Dose in mg 100% 100% 100% 100% 
Numeric 
daily doseb 
55.3% 55% 82.2% 53.5% 
Number of 
packsc 
4.3% 4.2% 4.8% 3.1% 
Number of 
daysd 
5.6% 3.7% 5% 3% 
* Based on46 
a Total quantity of  the product entered by GP 
b Total number of tablets per day for particular prescription 
c Number of individual product packs prescribed for particular prescription 
d Number of total treatment days for that prescription 
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Appendix 19 Code list seasonal influenza vaccine 
medcode readcode readterm 
6 65E..00 Influenza vaccination 
10821 68NV.00 Influenza vacc consent given 
12336 ZV04800 [V]Influenza vaccination 
13025 U60K400 [X]Influenza vaccine causing adverse effects therapeutic use 
21123 ZV04811 [V]Flu - influenza vaccination 
49070 F034G00 Post influenza vaccination encephalitis 
94301 65E0.00 First pandemic influenza vaccination 
95092 65E1.00 Second pandemic influenza vaccination 
97941 65E2.00 Influenza vaccination given by other healthcare provider 
98047 68Nr.00 Consent given for pandemic influenza vaccination 
98183 65E9.00 PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given 
98184 65EA.00 PANDEMRIX - second influenza A (H1N1v) 2009 vaccination give 
98203 65EB.00 PANDEMRIX - 1st flu A (H1N1v) 2009 vac by othr hlth provider 
98217 65E3.00 1st pandemic influenza vacc give by other healthcare providr 
98234 65E5.00 CELVAPAN - first influenza A (H1N1v) 2009 vaccination given 
98302 65E6.00 CELVAPAN - second influenza A (H1N1v) 2009 vaccination given 
98303 65E8.00 CELVAPAN - 2nd flu A (H1N1v) 2009 vacc by othr hlth provider 
98304 65EC.00 PANDEMRIX - 2nd flu A (H1N1v) 2009 vac by othr hlth provider 
98306 65E4.00 2nd pandemic influenza vacc give by other healthcare providr 
98449 65E7.00 CELVAPAN - 1st flu A (H1N1v) 2009 vacc by othr hlth provider 
99801 68Nt.00 Consent given for influenza A subtype H1N1 vaccination 
104688 65ED.00 Seasonal influenza vaccination 
104958 68NV000 Consent given for seasonal influenza vaccination 
105077 65E2000 Seasonal influenza vaccin given by other healthcare provider 
105195 65ED000 Seasonal influenza vaccination given by pharmacist 
106994 65EE000 Administration of first intranasal influenza vaccination 
106995 65EE100 Administration of second intranasal influenza vaccination 
107156 65EE.00 Administration of intranasal influenza vaccination 
107297 65ED100 Administration of first intranasal seasonal influenza vacc 
107315 65E0000 Administration of first intranasal pandemic influenza vacc 
107352 65ED300 Administration of second intranasal seasonal influenza vacc 
107413 65E2100 First intranasal seasonal flu vacc gvn by othr hlthcare prov 
107573 65ED200 Seasonal influenza vaccination given while hospital inpt 
107646 65E1000 Administration of second intranasal pandemic influenza vacc 
107730 65E2200 Secnd intranasal seasonal flu vacc gvn by othr hlthcare prov 
108772 65E3000 First intranasal pndmc influenza vcc gvn othr hlthcare prvdr 
110182 65E2400 1st intramuscular seasonal influenza vacc given by other HCP 
110219 65E2300 2nd intramuscular seasonal influenza vacc given by other HCP 
110854 65ED400 Administration of first inactivated seasonal influenza vacc 
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prodcode productname 
398 Influenza inactivated split virion Vaccination (Aventis Pasteur MSD) 
639 Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes 
834 Begrivac vaccine suspension for injection 0.5ml pre-filled syringes (Novartis Vaccines and Diagnostics 
Ltd) 
922 Influenza inactivated surface antigen Vaccination 
1329 Fluvirin vaccine suspension for injection 0.5ml pre-filled syringes (Novartis Vaccines and Diagnostics 
Ltd) 
2139 Fluarix vaccine suspension for injection 0.5ml pre-filled syringes (GlaxoSmithKline UK Ltd) 
2552 Influvac Sub-unit vaccine suspension for injection 0.5ml pre-filled syringes (Abbott Healthcare 
Products Ltd) 
2601 Mfv-ject Vaccination (Aventis Pasteur MSD) 
7951 FLUVIRIN AQUEOUS ML VAC 
9710 Agrippal vaccine suspension for injection 0.5ml pre-filled syringes (Novartis Vaccines and Diagnostics 
Ltd) 
10030 Inflexal V vaccine suspension for injection 0.5ml pre-filled syringes (Janssen-Cilag Ltd) 
11824 Enzira vaccine suspension for injection 0.5ml pre-filled syringes (Pfizer Ltd) 
13595 Fluzone Vaccination (Aventis Pasteur MSD) 
16585 Viroflu vaccine suspension for injection 0.5ml pre-filled syringes (Janssen-Cilag Ltd) 
18612 Mastaflu vaccine suspension for injection 0.5ml pre-filled syringes (Masta Ltd) 
23251 FLUVIRIN PRE-FILLED SYRINGE 
24779 Influenza inactivated split virion Paediatric vaccination 
27407 Imuvac vaccine suspension for injection 0.5ml pre-filled syringes (Abbott Healthcare Products Ltd) 
30156 Invivac vaccine suspension for injection 0.5ml pre-filled syringes (Abbott Healthcare Products Ltd) 
30198 Influenza inactivated split virion Vaccination (sanofi pasteur MSD Ltd) 
32391 Influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes 
(Novartis Vaccines and Diagnostics Ltd) 
38421 Influenza inactivated split virion Vaccination (Evans Vaccines Ltd) 
40760 Influenza vaccine (split virion, inactivated) 15microgram strain suspension for injection 0.1ml pre-filled 
syringes 
40876 Influenza vaccine (split virion, inactivated) 9microgram strain suspension for injection 0.1ml pre-filled 
syringes 
41150 Pandemrix vaccine emulsion and suspension for emulsion for injection (GlaxoSmithKline UK Ltd) 
41168 Influenza H1N1 vaccine (split virion, inactivated, adjuvanted) emulsion and suspension for emulsion 
for injection 
41240 Influenza H1N1 vaccine (whole virion, Vero cell derived, inactivated) suspension for injection 
41925 Celvapan (H1N1) vaccine (whole virion, Vero cell derived, inactivated) suspension for injection (Baxter 
Healthcare Ltd) 
43825 Intanza 15microgram strain vaccine suspension for injection 0.1ml pre-filled syringes (sanofi pasteur 
MSD Ltd) 
43827 Intanza 9microgram strain vaccine suspension for injection 0.1ml pre-filled syringes (sanofi pasteur 
MSD Ltd) 
44759 INFLUENZA PRE-FILLED SYRINGE 
45661 Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Pfizer Ltd) 
47932 Fluenz vaccine nasal suspension 0.2ml unit dose (AstraZeneca UK Ltd) 
48085 Influenza inactivated split virion Vaccination (Chiron UK Ltd) 
48658 Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (sanofi 
pasteur MSD Ltd) 
48740 Influenza vaccine (surface antigen, inactivated) suspension for injection 0.5ml pre-filled syringes 
49716 Influenza vaccine (surface antigen, inactivated, virosome) suspension for injection 0.5ml pre-filled 
syringes 
51087 Optaflu vaccine suspension for injection 0.5ml pre-filled syringes (Novartis Vaccines and Diagnostics 
Ltd) 
51289 Influenza vaccine (live attenuated) nasal suspension 0.2ml unit dose 
54677 Preflucel vaccine suspension for injection 0.5ml pre-filled syringes (Baxter Healthcare Ltd) 
57140 Influenza vaccine (live attenuated) nasal suspension 0.2ml unit dose 
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57401 Influvac Desu vaccine suspension for injection 0.5ml pre-filled syringes (Abbott Healthcare Products 
Ltd) 
57678 Fluenz vaccine nasal suspension 0.2ml unit dose (AstraZeneca UK Ltd) 
57917 Fluarix Tetra vaccine suspension for injection 0.5ml pre-filled syringes (GlaxoSmithKline UK Ltd) 
61580 Influenza vaccine (split virion, inactivated) suspension for injection 0.25ml pre-filled syringes 
61792 Fluenz Tetra vaccine nasal suspension 0.2ml unit dose (AstraZeneca UK Ltd) 
61898 Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (A A H 
Pharmaceuticals Ltd) 
63690 Inflexal V suspension for injection 0.5ml pre-filled syringes (sanofi pasteur MSD Ltd) 
65205 FluMist Quadrivalent vaccine nasal suspension 0.2ml unit dose (AstraZeneca UK Ltd) 
 
Code Immunisation type 
4 FLU 
71 PFLUGEN 
72 PFLUGSK 
73 PFLUGSKO 
74 PFLUGS 
75 PFLUBAXO 
76 PFLUBAX 
78 PFLUGENO 
84 FLUSOHP 
85 FLUSPHARMA 
89 FLUSIN 
97 FLUSINOHP 
100 FLUSIMOHP 
 
 
